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Abstract 
 Xanthones are “privileged structures” from natural origin that are known for their 
great variety of biological activities. CEQUIMED-UP has focused for many years on the 
synthesis of prenylated xanthones and on evaluating its antitumor activity using different 
models. From the chemical library of prenylated xanthones of CEQUIMED-UP, a 
compound emerged as a very promising candidate, since it has shown to be able to inhibit 
the cell growth of several tumor cell lines, being particularly active in leukemia cell lines. 
This compound was coined as XP13 and was the launching platform for this work. 
 The objective of this work was to apply a multidimensional approach and to 
obtained XP13 analogues more potent and with a better pharmacokinetic profile. As a 
result, this work encompasses three different sections that were considered as a whole: 
the synthesis of analogues of XP13; the evaluation of the growth inhibition on four human 
tumor cell lines with the establishment of structure-activity relationship; and the prediction 
of the pharmacokinetic behavior using structural and physicochemical parameters 
determined in vitro and/or in silico.  
The main molecular modifications of XP13 comprised the introduction of a double 
bond in the fused ring to transform the fused 2,2-dimethyl-3,4-dihydropyran ring into a 2,2-
dimethylpyran ring, and also the change of the orientation of the fused ring along the 
different sides of the xanthone scaffold. Moreover, the importance of the phenolic OH of 
XP13 was evaluated by its removal or introduction of a methoxyl group, as well as by the 
changing of the relative position of this group along the xanthone scaffold. Lastly, 
analogues of XP13 with different functionalities on the unsubstituted aryl ring were also 
synthesized. 
The analogues of XP13 bearing a fused 2,2-dimethylpyran were synthesized either 
by total synthesis starting from an appropriate 2,2-dimethylbenzopyran and an ortho-
substituted carboxylic acid derivative, or by the cyclization of appropriate 1’,1’-dimethyl 
propargyl ether xanthones through an intramolecular hydroarylation catalyzed by a 
transition metal catalyst, namely platinum or gold. The analogues of XP13 bearing a fused 
2,2-dimethyl-3,4-dihydropyran ring were synthesized either by hydrogenation of the 
double bond of xanthones comprising a fused 2,2-dimethylpyran ring, by the reaction of a 
xanthone with prenyl bromide, by clay Montmorillonite K-10 catalysis and microwaves, or 
by total synthesis starting from the appropriated 2,2-dimethyl-3,4-dihydrobenzopyran. The 
xanthones that bear with substituents on the opposite side of the fused ring were 
synthesized by total synthesis (via benzophenone). This approach was also used for the 
development of a new route for the synthesis of XP13 which led to this compound in 
better yield than the reported in the literature. Besides the analogues of XP13, four 
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prenylated xanthones were also obtained from 1,2-dihydroxyxanthone. To sum up, 185 
compounds were synthesized including 38 analogues of XP13, being 31 described for the 
first time. 
The pharmacokinetic profile was evaluated by determining some physicochemical 
properties, namely lipophilicity, solubility and binding to albumin. The lipophilicity was 
determined using UV-Vis derivative spectroscopy in two membrane models, namely 
liposomes and micelles, and these two models were compared between each other. The 
micelles showed to have a high correlation with liposomes being an alternative to 
liposomes for the determination of lipophilicity. Moreover, a comparison of the lipophilicity 
determined by the two membrane models and calculated by three computational models 
was also made. A poor correlation between the membrane and computational models was 
observed. The solubility was determined by a thermodynamic assay and predicted by 
different in silico models, being observed a low solubility for the majority of the 
compounds. Finally, the binding dissociation constant between some of the compounds 
and albumin (bovine and human) was determined, being also proposed that there was a 
high probability that XP13 binds to the subdomain IIA of human serum albumin. 
A preview of the drug-likeness of the synthesized compounds was also made, 
based on several structural descriptors and physicochemical properties. All data were 
discussed and the obtained physicochemical parameter and the drug-likeness character 
of the synthesized compounds were justified by structural features of xanthones related to 
high planarity and symmetry. 
The growth inhibition of the synthesized compounds was determined on four 
human tumor cell lines, namely, MCF-7 (breast cancer), NCI-H460 (NSCLC), A375-C5 
(melanoma) and HL-60 (leukemia). Several compounds were more active than XP13, 
appearing some of them to exhibit selectivity towards the HL-60 tumor cell line. SAR was 
established for the compounds synthesized and the best candidates were selected based 
on the biological activity and pharmacokinetic behavior. 
 
Keywords: xanthones, drug-likeness, lipophilicity, solubility and antitumor.  
ǆŝ

Resumo 
As xantonas são “estruturas privilegiadas” de origem natural conhecidas pela 
grande variedade de atividades biológicas que apresentam. O CEQUIMED-UP tem vindo 
a sintetizar diversas xantonas preniladas e estudado a sua atividade antitumoral em 
diversos modelos. De entre a biblioteca de xantonas preniladas do CEQUIMED-UP, um 
composto emergiu como potencial candidato uma vez que inibiu o crescimento de 
diferentes linhas celulares tumorais humanas, principalmente leucémicas. Esse composto 
foi designado como XP13 sendo usado como ponto de partida neste trabalho. 
 O objetivo deste trabalho centra-se na aplicação de uma estratégia 
multidimensional que visa obter análogos da XP13 mais potentes e com um melhor perfil 
farmacocinético. Como tal, este trabalho foi dividido em três partes que foram 
consideradas como um todo: a síntese de análogos estruturais da XP13; a avaliação da 
inibição do crescimento celular em quatro linhas celulares tumorais humanas com o 
estabelecimento de relações de estrutura-atividade; e previsão do comportamento 
farmacocinético através do estudo de propriedades estruturais e físico-químicas 
determinadas in vitro e/ou in silico. 
 As principais modificações moleculares efetuadas na XP13 cingiram-se à 
introdução de uma ligação dupla no anel fundido 2,2-dimetil-3,4-di-hidropirano tornando-o 
num anel 2,2-dimetilpirano, assim como a alteração da sua orientação ao longo dos lados 
do esqueleto xantónico. Além disso, a importância do OH fenólico da XP13 foi estudado 
através da sua remoção ou modificação por um metoxilo, assim como pela sua colocação 
em diversas posições do esqueleto xantónico. Por fim, diversos análogos da XP13 
contendo substituintes no anel não substituído foram também sintetizados.  
 Os análogos da XP13 contendo um anel 2,2-dimetilpirano fundido foram 
sintetizados por síntese total partindo de um 2,2-dimetilbenzopirano e ácido carboxílico 
orto substituído apropriados, ou através da ciclização de uma xantona contendo o grupo 
1’,1’-dimetil propargílico por uma hidroarilação intramolecular catalisada por um metal de 
transição, nomeadamente platina ou ouro. Os análogos da XP13 contendo um anel 2,2-
dimetil-3,4-di-hidropirano fundido foram sintetizados por hidrogenação da ligação dupla 
de xantonas contendo um anel 2,2-dimetilpirano fundido, ou através da reação de 
xantonas com brometo de prenilo catalisado por argila Montmorillonite K-10 e micro-
ondas, ou por síntese total partindo de um 2,2-dimetil-3,4-di-hidropirano apropriado. As 
xantonas contendo substituintes no anel aromático não-substituído da XP13 foram 
obtidas por síntese total (via benzofenona). Este mesmo caminho sintético foi aplicado na 
síntese total da XP13 permitindo a obtenção desta substância com um rendimento 
superior ao descrito na literatura. Além dos análogos da XP13, quatro xantonas 
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preniladas foram sintetizadas a partir da 1,2-dihidroxixantona. Resumindo, 185 
substâncias foram sintetizadas incluindo 38 análogos da XP13 sendo que 31 destes 
análogos foram descritos pela primeira vez. 
 O perfile farmacocinético foi avaliado através da determinação de algumas 
propriedades físico-químicas, nomeadamente lipofilicidade, solubilidade e ligação à 
albumina. A lipofilicidade foi determinada usando espectroscopia derivativa do UV-Vis em 
dois modelos membranares, nomeadamente lipossomas e micelas, sendo posteriormente 
estes dois modelos comparados entre si. As micelas mostraram uma elevada correlação 
com os lipossomas provando que podem ser usados como um modelo alternativo aos 
lipossomas para a determinação da lipofilicidade. A comparação entre os dois modelos 
membranares e três programas para o cálculo da lipofilicidade foram também efetuados 
tendo-se observado uma pobre correlação entre eles. A solubilidade termodinâmica foi 
determinada para algumas substâncias e prevista para todas usando diversos modelos in 
silico, tendo-se observado uma baixa solubilidade para a grande maioria das substâncias. 
Por fim, a constante deligação de dissociação e outros parâmetros de ligação entre 
algumas das substâncias e a albumina (humana e bovina) foram determinados, tendo-se 
proposto que existe uma grande probabilidade que a XP13 se ligue ao subdomínio IIA da 
albumina sérica humana.  
A visualização da “drug-likeness” dos compostos sintetizados foi realizado 
baseado em descritores estruturais e propriedades físico-químicas. Todos os dados 
obtidos foram discutidos e os dados dos parâmetros físico-químicos e o caráter “drug-
like” dos compostos sintetizados foram justificados através das características estruturais 
das xantonas relacionadas com uma elevada planaridade e simetria. 
A inibição do crescimento celular das substâncias sintetizadas foi determinada em 
quatro linhas celulares tumorais humanas, nomeadamente, MCF-7 (cancro da mama), 
NCI-H460 (células não-pequenas de cancro do pulmão), A375-C5 (melanoma) e HL-60 
(leucemia). Diversas substâncias mostraram ser mais ativo que a XP13, sendo que 
algumas das substâncias aparentaram ser seletivas para a linha celular tumoral HL-60. 
Estudos de relação estrutura-atividade foram estabelecidas para as substâncias 
sintetizadas sendo selecionados posteriormente as substâncias mais promissoras 
considerando atividade biológica e as características farmacocinéticas.  
 
 
Palavras-chave: xantonas, drug-likeness, lipofilicidade, solubilidade e antitumoral. 
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CHAPTER 1 
Aims and Outline of the Thesis 
 
 
Aims 
 
The CEQUIMED-UP has been interested for many years in the search of new 
bioactive molecules and among the chemical library of CEQUIMED-UP, a molecule has 
shown a promising antitumor activity by the strong growth inhibition on several human 
tumor cell lines, being particularly active in leukemia cell lines. This molecule has given 
the code name XP13 and the aim of this thesis is to use this compound as a starting point 
for the search of more potent compounds and with a better pharmacokinetic profile using 
a multidimensional approach. 
This multidimensional optimization takes into account both pharmacodynamic and 
pharmacokinetic parameters and the objective is to obtain a promising compound(s) with 
desired combination of activity and ADME properties. So, new analogues of XP13 will be 
synthesized and their ability to inhibit the growth of four human tumor cell lines will be 
studied, as well as a set of structural and physicochemical properties related with ADME 
will be evaluated. 
The synthesis of analogues of XP13 and the study of the growth inhibition on four 
human tumor cell lines will allow the establishment of structure-activity relationship, and 
ŚĂƉƚĞƌϭ
Ϯ

the evaluation of the structural and physicochemical properties of the compounds 
synthesized will allow the prediction of any ADME-Tox liability in an early stage. The 
information gathered from the two areas will allow the ranking and prioritization of the 
most promising candidates. 
 
Specific Aims: 
• Synthesize analogues of XP13 in order to evaluate the importance that 
each portion of the scaffold has on the biological activity and on the 
physicochemical properties; 
• Develop a new and more versatile route for the synthesis of XP13; 
• Determine the lipophilicity of the xanthones synthesized using two 
membrane models, namely liposomes and micelles, and compare the two 
models between each other and with different computational programs; 
• Establish structure-lipophilicity relationship for the analogues of XP13 
synthesized;  
• Determine the thermodynamic solubility of the xanthones in water at pH = 
7.4 and relate the results obtained with structural properties; 
• Establish structure-solubility relationship; 
• Determine the binding dissociation constant of the analogues of XP13 for 
human and bovine serum albumin; 
• Establish structure-albumin binding relationship; 
• Predict the pharmacokinetic behavior of the analogues of XP13 
synthesized taking in consideration the structural and physicochemical 
properties determined experimentally and calculated; 
• Determine the growth inhibition on four tumor cell lines for all the analogues 
of XP13 synthesized and establish structure-activity relationship; 
• Rank and prioritize the compounds more promising taking in consideration 
the biological activity and the physicochemical properties. 
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Outline of the Thesis 
  
The thesis is organized in 6 chapters. 
The first chapter establishes the aims of the work focusing also on the organization 
of the thesis, giving a brief description of what will be referred in each chapter. 
 
The second chapter will deal with the theoretical background that supports the 
work developed and so is sub-divided in the different areas that comprise this thesis. One 
section will focus on the epidemiology and etiology of cancer and the different strategies 
that are used to treat this disease. Another section will refer the importance of natural 
products on drug discovery, particularly xanthones, referring the variety of biological 
activities and the different approaches to synthesize them. The last subsection will deal 
with the influence that structural and physicochemical properties have on the 
pharmacokinetic behavior of a compound, and how their determination allow the 
prediction of the ADME behavior. Since lipophilicity, solubility and binding to albumin were 
determined experimentally, these three properties will be referred more deeply and the 
different techniques used in their determination. 
 
The third chapter will focus on the results and discussion of the research work, 
being sub-divided in three sections which will deal with the synthesis of xanthones, the 
determination of physicochemical properties and the growth inhibitory activity.  
 
The fourth chapter will focus on the main conclusions and future work. 
 
The fifth chapter focuses on the experimental procedures, and is sub-divided in the 
different parts that compose this thesis. One section will refer the synthetic procedures 
used for the synthesis of the analogues of XP13. A second section will deal with the 
experimental procedures used for the determination of the physicochemical properties 
and the last section will refer the experimental procedure used for the determination of the 
growth inhibition on four human tumor cell lines. 
 
The Sixth section is the appendix where the review about the synthesis of 
xanthones and the curves of dose-response for the compounds tested can be consulted. 
 
The last pages concerns a table that gathers all the structural and physicochemical 
information of the compounds synthesized. 
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CHAPTER 2 
Introduction 
 
 
2.1 Cancer  
 
Cancer is a complex disease caused by a multistep process of sequential 
alterations in several genes. These alterations are usually somatic events, albeit germ-line 
mutations can predispose a person to heritable or familial cancer. The change in a single 
gene is seldom sufficient for the development of a malignant tumor [1].  
The accepted hallmarks of cancer cells, which were initially proposed in 2000 by 
Hanahan & Weinberg are: sustained antiproliferative signaling, resistance to cell death, 
capacity to evade growth suppressor, capacity to induce angiogenesis, invasion and 
metastasis, and replicative immortality [2]. Recently, these authors suggested two more 
emerging hallmarks: deregulation of cellular energetic and avoidance of immune 
destruction. Additionally, two characteristics facilitate acquisition of both all these 
hallmarks: i) genomic instability and ii) inflammation by innate immune cells [3].  
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2.1.1 Epidemiology 
 
 
According to WHO (data of 2004), cancer is the third cause of death in the world, 
just after cardiovascular and infectious
countries, cancer plays a higher role being the major cause of death for adults aged 15
years [4]. 
 
 
Figure 2.1 Main causes of deaths in the World (2004) distributed by leading causes and 
gender (Adapted from [4]). 
 
The cancer with higher incidence in the World is breast cancer according to the 
GLOBOCAN 2008, but the one that causes more 
breast, stomach and liver (Figure 2.
incidence in men is the prostate but the cancer with higher mortality is lung. In women, the 
cancer with higher incidence is breas
-parasitic diseases [4] (Figure 2.1). In high income 
deaths is lung cancer, followed by 
2) [5, 6]. In Portugal, the cancer that shows a higher 
t, being also the cancer with higher mortality 
-59 
 
[6]. 
 Leukemia is not one of the cancers with higher incidence, but has a low survival rate as it 
can be depicted from Figure 2.
than any other cancer [7]
 
 Figure 2.2 Cancer incidence and mortality in the World (Adapted from 
 
2.1.2 Treatment
 
Cancer is characterized by an unregulated proliferation of cells which can take 
place in different tissues and with different characteristics. 
on i) surgery through the removal of tumor cells; ii) radiotherapy to eliminate the tumor 
and surrounding cells; and iii) chemotherapy with anticancer agents. In spite of the 
improvement in surgery techniques, diagnosis, imagi
development of various new anti
death in the world [8]. 
 Considering the anticancer agents, the first generation of compounds were 
cytotoxic and non-selective and 
cancer cells replicate their DNA and divided more frequently than healthy cells 
These compounds include antimetabolites (
gemcitabine), genotoxic compounds (
2. The melanoma incidence is increasing at a faster rate 
. 
 
Cancer treatment focus mainly 
ng and radiotherapy, as well as the 
-cancer drugs, cancer is still one of the major causes of 
the underlying concept of these molecules was that 
e.g. methotrexate, 6
e.g. chlorambucil, cyclophosphamide
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[6]) 
[9, 10]. 
-mercaptopurine and 
, cisplatine, 
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doxorubicine) and compounds acting on structural proteins (e.g. paclitaxel, vincristine) 
[11-14]. In spite of being the base for most treatment regiments [15], the indiscriminate 
action of these compounds contributes to severe toxic effects, resulting in a low 
therapeutic index and narrow therapeutic window [16].  
Recently, there has been an important and significant progress in the study of the 
underlying cellular and molecular mechanisms involved in the development of cancers 
which lead to the identification of cancer-specific cellular targets [9]. The design of drugs 
that selectivity target these cancer-specific cellular processes have a clear advantage 
over the non-specific cytotoxic drugs since they exploit the differences between normal 
and cancer cells resulting in drugs with greater potency and lower toxicity [10]. Among the 
different classes of such anticancer agents are kinase inhibitors, proteosome inhibitors, 
anti-angiogenic compounds and hormonal agents [8-10, 17, 18]. These new classes of 
anticancer agents, named targeted therapeutics, comprise not only small molecules but 
also small proteins or antibodies [18]. Nonetheless, drug resistance often arises, both to 
the conventional cytotoxics and to the molecular targeted therapeutics. Therefore, there is 
a strong need to identify novel molecules to increase the resource of available drugs to 
fight this disease. 
 
2.1.3 In vitro assays for screening antitumor activity 
 
The in vitro assays for a rapid screening of antitumor activity usually consist on cell 
culture systems which use human (or other animal) tumor cell lines as models. These 
assays measure the ability that a given compound has to inhibit the growth or reduce the 
survival of such cancer cells in culture [19].  
The determination of the capacity of a compound to inhibit the growth and/or 
decrease the viability of tumor cell lines takes place under experimental conditions in 
which the cell lines are actively growing and under mitotic division. In such assays, the 
cells are usually cultured in a 96-well plate with or without the compound of interest at 
different concentrations, and the growth is measured indirectly by a colorimetric assay, 
being the intensity of the color directly proportional to the number of cells present [20, 21]. 
Therefore, after a specified time, the growth of a cancer cell line in the presence or 
absence of a compound gives information regarding its capacity to inhibit the cell 
proliferation (cell division) and/or increase cell death (reduce cell viability).  
There are two major techniques that are commonly used to rapidly assess the cell 
growth [20, 21]: i) techniques based on the mitochondrial metabolization of substrates by 
viable cells that give colored formazan products such as the 3-(4,5-dimethylthiazol-2-yl)-
 2,5-diphenyltetrazolium 
sulphophenyl)-2H-tetrazolium
techniques that use anionic
[24, 25], in which the dye is taken up by the cells and binds to the
proteins being the amount of dye dependent on the number of viable cells. Comparing the 
two techniques, the SRB assay is more sensitive, simpl
formazan-based assays giving also a better linearity, a good signal
stable end point [20]. The SRB assay is used in the National Cancer Institute (NCI) for the 
standard antitumor screening assays 
 
2.2 Natural products as a source of new drugs
 
Figure 2.3 Sources of small molecules approved from 1981 to 2010. (
drug; ND = derived from natural product;
by total synthesis but the pharmacophore is/was from a 
product mimic)(Adapted from 
  
 
The use of traditional medicinal, particularly plants, for the treatment of human 
illnesses dates back to the Egyptian civilization, about 2900 BCE, being 
still continues to be used currently in many places around the world 
drug discovery, Nature has been one of the most fruitful sources of drugs and lead 
compounds, and before 
bromide (MTT) [22] and the 2,3-bis(2
-5-carboxanilide sodium salt (XTT) 
 or cationic dyes, such as the sulforhodamine B (SRB) assay 
 amino acid residues of 
e and reproducible than the 
[20]. 
 NB = natural botanical; N = natural; 
natural product
[26]). 
the advent of high-throughput screening and
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-methoxy-4-nitro-5-
[23] assays; i) the 
-to-noise ratio and a 
 
 
S = totally synthetic 
S* = made 
; NM = natural 
a strategy that 
[27]. In the area of 
 post-genomic era, 
10 
 
about 80 % of the drugs in the market were either natural substances or inspired by a 
natural compound [28]. In spite of the number of drugs in the market that are either natural 
products or inspired by it has decreased in recent times, Na
of drugs as it can be depicted from 
were approved between 1981 and 2010, revealed that only 36 % are totally synthetic 
being all the other approved compounds either Natu
In this last group are included compounds that are obtained from semisynthetic 
modification of natural products (ND), the compounds that were obtained by total 
synthesis but the pharmacophore is/was a natural product 
obtained by mimic of a natural product, 
molecular skeletons around which a chemical library was created 
other compounds are in clinical trials for the treatment
cardiovascular, immunological and anticancer 
Particularly in the area of anticancer drugs, many compounds that are currently in 
the market and in clinical trials are from natural origin or derived from them 
as it can be depicted from Figure 2.4
anticancer agents in the last 30 years, only 20 % are totally synthetic being all the other 
based on natural products, which reveals the importance of natural products on this area 
[26].  
 
Figure 2.4 Sources of anticancer
totally synthetic drug; ND = derived from natural product;
natural; S* = made by total synthesis
product; NM = natural product mimic) (Adapted from 
Natural Products as a Source of 
ture is still an important source 
Figure 2.3. The analysis of the small molecules that 
ral Products or inspired by them 
and the compounds that were 
p.e. using natural privileged structures as 
[26]. In addition, many 
 of infectious diseases, neurological, 
[29]. 
[27
, from the small molecules that were approved as 
-small molecules approved from 1981 to 2010. (
 NB = natural botanical
 but the pharmacophore is/was from a 
new Drugs 
[26]. 
-33]. In fact, 
 
S = 
; N = 
natural 
[26]).
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2.2.1 Xanthones 
 
 
 
Figure 2.5 Xanthone Scaffold. 
 
Xanthones are a class of O-heterocycles bearing a dibenzo-Ȗ-pyrone scaffold 
(Figure 2.5) which can be found in Nature in higher plants, fungi and lichens [34-38]. The 
biosynthetic pathway leading to xanthones might occur by two processes: acetate 
polymalonic route and a mixed shikimate acetate pathway. In higher plants, the latter is 
more common and occurs through the condensation of two rings, one formed through the 
shikimic acid with a CO group attached, and the other from the acetate-polyketide route, 
to give a benzophenone which then cyclizes intramolecularly to give xanthones. The 
numbering of the xanthones isolated from plants takes in consideration the biosynthetic 
pathway and the ring A (Figure 2.5) refers to the shikimic acid pathway, and ring B 
(Figure 2.5) to the acetate pathway [36].  
The xanthones obtained from Nature are generally classified into 6 main groups: 
simple xanthones, xanthone glycosides, prenylated xanthones, xanthonolignoids, bis-
xanthones and miscellaneous [35], being the prenylated xanthones the most abundant 
[39]. 
 
The xanthones can also be obtained by chemical synthesis and several methods 
have been developed allowing the synthesis of xanthones with a great variety of 
substituents in all the positions of the xanthone scaffold [40-43]. 
 
The interest on this class of compounds arises from the great variety of biological 
activities reported which allow to consider this scaffold as a “privileged structure” and a 
good launching platform for the search of new bioactive molecules [44-47]. 
 
 
 
yĂŶƚŚŽŶĞƐ
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2.2.1.1 Biological Activity 
 
 The first report describing the pharmacological activity of xanthones dates back to 
1968 when diuretic and cardiotonic action of mangiferin was described for the first time 
[48]. Since then, many other biological activities and enzyme modulation have been 
reported for this class of compounds which have been extensively reviewed [36, 39, 44-
46, 49-54]. In Table 2.1 recent examples that illustrate the great variety of biological 
activities that have been described for this class of compounds are represented and in 
Table 2.2 the modulation of several enzymes by xanthones. 
 
Table 2.1 Recent examples of biological activities reported for xanthones. 
Biological Activity Reference 
Antitumor [55-59] 
Anti-allergic [60] 
Antimicrobial [61, 62] 
Anti-arrythmic [63] 
Antiplatelet/Anticoagulant [64-66] 
Anti-inflammatory [67] 
Anti-oxidant [68-70] 
CNS depressant [71] 
Hepatoprotective [72] 
Anti-diarrheal [73] 
 
Table 2.2 Recent examples of the modulation of enzyme systems by xanthones. 
Enzyme Reference 
Alpha-glucosidase [74-76] 
Neuraminidase [77, 78] 
Xanthine Oxidase [79] 
Cholesterol Acyltransferase [80] 
hCalmodulin [81] 
Topoisomerase II [82] 
Fatty acid synthase [83] 
Aromatase [84] 
Acetylcholinesterase [85] 
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 The antitumor activity is the biological activity more commonly reported for 
xanthones and in Figure 2.6 are represented key molecules that are known to exhibit 
potent antitumor activity.  
 
 
Figure 2.6 Xanthones with potent antitumor activity. 
 
Vadimezan or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) (Figure 2.6) is a 
xanthone derivative obtained by synthesis that has been studied as a vascular disrupting 
agent. Its mechanism of action has not been completely elucidated but it has 
demonstrated to be associated with an increase of the TNF-Į production [45, 46, 86, 87]. 
The Vadimezan is currently in Phase III clinical development by Novartis as a second line 
treatment for non-small cell lung cancer (NSCLC) and It was also in a Phase III clinical 
trial as a first line treatment for NSCLC but was discontinued in March 2010 [88]. 
 As it was state previously, the xanthones isolated from Nature could be classified 
into several families and among them, the most abundant are the prenylated xanthones. 
This family of xanthones comprises many compounds that have shown a great variety of 
biological activities, especially antitumor [39], being the gambogic acid and the Į-
mangostin two of the most potent compounds (Figure 2.6). 
The gambogic acid (Figure 2.6) is a representative compound of a sub-family of 
prenylated xanthones commonly referred as Garcinia or prenylated caged xanthones due 
to the presence of an uncommon 4-oxo-tricyclo[4.3.1.03.7]dec-8-en-2-one scaffold. The 
gambogic acid has shown to be a cytotoxic agent to many several tumor cell lines [45, 52, 
54] and its mechanism of action is not well understood being supposed to induce cell 
yĂŶƚŚŽŶĞƐ
ϭϰ

death through multiple mechanisms. Moreover, it has also shown an anti-angiogenic 
effect through the reduction of the vascular endothelial growth factor (VEGF) secretion 
and inhibition of the VEGF signal transduction [45, 52, 54, 89]. 
The Į-mangostin (Figure 2.6) demonstrated a strong growth inhibition in several 
tumor cell lines, being particularly selective for the leukemia cells. The antiproliferative 
effect was associated with apoptosis induction [44, 51, 90, 91]. Moreover, the Į-mangostin 
has also shown inhibit topoisomerases I and II [92] as well as aromatase [53, 93]. This 
compound has also shown an anti-angiogenic effect by inhibition of the phosphorylation of 
KDR tyrosine kinase [94].  
Other potent antitumor xanthone is psorospermin (Figure 2.6) which has shown a 
potent antitumor activity in leukemia cell lines and AIDS-related lymphoma being a 
topoisomerase II poison [45, 95, 96].  
 
 
 
Figure 2.7 The most promising compound of a chemical library of prenylated xanthones 
from CEQUIMED-UP. 
 
Considering the biological activity found for Natural prenylated xanthones, 
especially antitumor activity, CEQUIMED-UP designed and synthesized a chemical library 
of prenylated xanthones [97-100]. From them, a compound has shown to be particularly 
interesting [97, 98], a “hit” compound, which was called XP13 (12-hydroxy-2,2-dimethyl-
3,4-dihydropyrano[3,2-b]xanthen-6(2H)-one). This compound has a fused 2,2-dimethyl-
3,4-dihydropyran ring between 4a and 12a positions (Figure 2.7) of the xanthone ring and 
has shown a potent antiproliferative and apoptotic activity in leukemia cell lines. In 
addition, a computer screening using the structure of several anti- and pro-apoptotic 
proteins revealed that XP13 may block the binding of anti-apoptotic Bcl-xL to pro-apoptotic 
Bad and Bim [98]. XP13 has also shown an enhancement in the anti-estrogenic effect of 
4-hydroxytamoxifen in an estrogen-dependent (MCF-7) tumor cell line [97]. 
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2.2.1.2 Synthesis 
 
 The main methodologies that have been developed for the synthesis of xanthones 
can be consulted in the Appendix I, which is a review article regarding the synthesis of 
xanthones that has been submitted to the journal “Current Organic Chemistry”. 
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2.3 Drug-like Properties and Drug Discovery 
  
In the drug discovery field, the pathway that needs to be covered to turn a “hit” 
compound into a successful drug candidate is long, highly demanding and 
multidisciplinary [101]. The “hit” can be considered as a substance with a well defined 
structure and a given biological activity evaluated and related to a determined biological 
context [102-105]. The different approaches that can be followed to find a “hit” compound 
are extremely vast [106, 107], and after a “hit” compound has been found, it needs to be 
chemically modified in order to get a more promising compound [107-109]. This step 
should not only be focused solely on an increase of the biological activity since the risk of 
obtaining an extremely potent ligand that might not become a viable drug is very high. 
Accordingly, in this challenging process, the drug discovery program should be a 
multidimensional optimization, and as a result, an iterative process focusing on the 
increase of the potency and at the same time on the evaluation of the pharmacokinetic 
and toxicity parameters of the drug candidates, to assure that they have the potential to 
be developed as safe drug, and if possible, by oral route (Figure 2.8) [109-112]. 
 
 
Figure 2.8 Development of potential drug candidates with a balanced activity and ADME-
Tox using a multidimensional optimization strategy. (Adapted from [110]). 
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Poor pharmacokinetic properties were until the end of the 90’s responsible for the 
failure of more than 30 % of compounds entering clinical development [113]. The main 
reason for this high attrition rate was caused by the focus solely on the potency leaving 
the pharmacokinetic properties to a late stage in the drug discovery program, just before a 
candidate entered into drug development [110, 112, 114]. However, ten years later, the 
advances on preclinical ADME-Tox profiling and the evaluation in early stages of the drug 
discovery of pharmacokinetic in vitro and in vivo predictive models, led poor 
pharmacokinetic properties as responsible to less than 10 % of the drug failures [113]. 
Therefore, the evaluation of pharmacokinetic properties in an early stage of the drug 
discovery program has paid off and is now a well-established protocol in medicinal 
chemistry to predict and evaluate pharmacokinetic properties in parallel with biological 
activity during all the stages of drug discovery (Figure 2.9) [112, 114]. 
 
 
Figure 2.9 Iterative parallel optimization of the activity and property (Adapted from [115]). 
 
 
If we consider chemical space as all the possible organic compounds that can be 
synthesized, which for all purposes, is infinite being limited only by our imagination, the 
number of molecules that are capable of interacting with biological targets and at the 
same time have optimal ADME-Tox properties is limited (Figure 2.10) [116]. 
Consequently, to turn a “hit” compound into a more successful drug candidate, it needs to 
have what is normally called as drug-likeness in addition to a potent bioactivity. The drug-
like term was coined by Lipinski and it was referred to “compounds that have sufficiently 
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ADME properties and acceptable toxicity to survive through the completion of human 
Phase I clinical trials” [117].  
 
 
Figure 2.10 Pictorial representation of ADME-Tox and biological active space in the 
vastness of the chemical space (adapted from [116]). 
 
Other drug-like or drug-likeness definitions somewhat overlapping but far from 
identical [101] have also been proposed such as: 
 
• “Small molecules, similar to drugs with respect to calculated descriptors that 
are thought to capture synthetic feasibility, protein binding functionality, and 
favorable ADME and Tox properties” [118]. 
• “Physicochemical properties that improve probability of success in drug 
development by addressing issues of absorption and bioavailability…” [119]. 
• “A compound is drug-like if all its atoms or groups are situated in (molecular) 
environments to those of existing drugs” [120]. 
• If a compound have “sufficient functionality to potentially favorably interact with 
a receptor or enzyme, a relevant calculated or experimental molecular 
property profile…similar to that of known oral drugs, and likely to have 
acceptable ADME properties” [121]. 
• “Molecules which contain functional groups and/or have physical properties 
consistent with the majority of known drugs” [122].  
 
All in all, the drug-like or drug-likeness terms can be roughly defined as 
compounds that are: “orally bioavailable and relatively nontoxic in humans” [101]. The 
drug-likeness of a compound is ultimately evaluated by clinical data but since it is 
unaffordable to do so for all the compounds, the most common approach is to predict the 
drug-likeness by the determination of structural, physicochemical and biochemical 
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properties [112]. Therefore, an accurate profiling of drug-like properties allows the 
discrimination of drugs from non-drugs with a reliable amount of certainty. 
The profiling of the drug-likeness of a compound can be made at different levels, 
and as a compound progress through the drug discovery program, a deeper knowledge of 
its pharmacokinetic and toxicity behavior is known [112, 115]. In the first stages, the study 
focuses mainly on the determination of drug-like properties related to physicochemical 
properties, and more often, biochemical properties as well [110, 112, 114]. Most of the 
assays for the determination of the physicochemical properties bear on fast and reliable 
methods that can help to identify in an early stage any possible pharmacokinetic and 
toxicological limitation a compound might show. Only if the compound has shown no 
structural and physicochemical (or biochemical) liabilities, that other more complex drug-
like properties are evaluated [110, 112].  
Among the first drug-like properties to be evaluated in an early stage of a drug 
discovery project is the lipophilicity. This is undoubtedly the most important property which 
influences other physicochemical properties and several ADME-Tox parameters [112, 
123-126]. Another key drug-like property that is screened in an early phase is the solubility 
[114, 127, 128]. This physicochemical property is fundamental since the lack of solubility 
can affect not only the interpretation of biological assays but more importantly, the 
absorption of a molecule. Therefore, the sooner this property is evaluated, the sooner any 
liabilities regarding solubility are discarded [128]. The plasma protein binding is a property 
that is also commonly evaluated in an early stage of a drug discovery project since it 
influences the amount of compound that will be free in the bloodstream [129]. Other drug-
like properties such as pKa, permeability, metabolism and transport effect are also 
frequently evaluated in an early phase of the drug discovery program [114].  
 
2.3.1 Lipophilicity 
Lipophilicity represents the affinity of a molecule to a lipophilic environment and is 
commonly measured by the partition coefficient (Log P) of a solute in a single electrical 
form between two immiscible phases [130-133]. The two phases more commonly used 
are water and octanol, being the latter used as a surrogate of biological membranes [133]. 
 
ܮ݋݃ܲ ൌ ݈݋݃ ሾܿ݋݉݌݋ݑ݊݀ሿ௢௥௚௔௡௜௖ሾܿ݋݉݌݋ݑ݊݀ሿ௔௤௨௘௢௨௦ 
The Log P corresponds to the partition coefficient of a solute in the neutral form. 
However, for ionizable compounds, depending on the pH, part of the compounds might be 
ionized. In those cases, the distribution coefficient (Log D) can be used to represent the 
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portion of a solute that is in the ionic and neutral form at a specific pH. If at a given pH, the 
compound is only in the neutral form, the Log D will be equal to Log P [130-133]. If not 
stated otherwise, during this thesis, the Log P will be used to represent the partition 
coefficient of the neutral form between octanol and water and Log D will be used to 
represent the distribution coefficient at pH 7.4 between octanol and water as well.  
The lipophilicity is the net result of all the intermolecular forces that are involved in 
the partition between the solute and two phases. Using a linear solvation free-energy 
relationship, the lipophilicity can be factorized into two sets of terms: one relating to the 
hydrophobicity which takes in consideration the hydrophobic and dispersion forces; and 
other relating to the polar terms which accounts for the hydrogen bonds, and orientation 
and induction forces. In the isotropic models such as the octanol-water biphasic system, 
the lipophilicity measured fails to encode some crucial recognition forces that are known 
to take place in biochemistry and molecular pharmaceutics such as ionic bonds [130]. As 
a result, this methodology has some limitations especially for ionizable solutes. To 
overcome these limitations, other methods using artificial membranes have been 
developed mimicking to a better extent the biological membranes [130]. The lipophilicity 
can also be predicted using in silico programs [134]. All these methodologies will be 
described in the next section. 
 The lipophilicity has been correlated with many key drug-like properties including 
solubility [125, 135-139], permeability [125, 139, 140], plasma protein binding [125, 135, 
139], metabolism [140], CNS penetration [135, 141], volume of distribution [135] and 
clearance [135, 140] for example. A general guideline for a high oral bioavailability states 
that compounds with a moderate Log P (ranging from 0 to 3 as an example represented in 
Figure 2.11) are more likely to be orally bioavailable. Compounds with higher Log P will 
have lower solubility albeit good lipid bilayer permeability, and compounds with lower Log 
P will have a good solubility but poor lipid bilayer permeability [112].  
 
Figure 2.11 Hypothetical influence of Log P in oral bioavailability for a compound series 
(Adapted from [112]). 
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Molecules with high lipophilicity have also been correlated to an increase in the 
likelihood of toxicity by CyP 450 inhibition [125, 135, 139], hERG inhibition [135, 139] and 
promiscuity [125, 126, 142, 143], being also correlated with the drug potency [125]. 
Due to the role of the lipophilicity in influencing drug potency, pharmacokinetics 
and toxicity, the Log P is one of the first properties to be determined in silico and in vitro 
during the drug discovery program. In fact, some authors have referred to lipophilicity has 
the most important molecular property [125, 126]. The lipophilicity in the marketed oral 
drugs has changed less over time when compared with other properties which suggests 
that it is a crucial drug-like property and its control is essential for the development of a 
successful drug [126]. On the other hand, compounds from medicinal chemistry program 
of leading companies have increased in average 1.5 Log P units relatively to the marketed 
oral drugs which have been suggested to increase the risks of development attrition, 
being referred as one of the causes of the low productivity from pharmaceutical industries 
[126, 144-147]. 
 
2.3.1.1 Methodologies for measuring lipophilicity 
 
The IUPAC definition of lipophilicity refers that “lipophilicity represents the affinity 
of a molecule or a moiety for a lipophilic environment” [148] and is commonly determined 
by the partition coefficient between octanol and water. The “gold standard” technique for 
the determination of Log P and Log D is the shake-flask but many other alternatives have 
been developed throughout the time. These techniques are not only related to the 
experimental techniques per se but also with the use of other biphasic systems besides 
octanol-water. The lipophilicity methodologies can be sub-divided in two major areas: the 
determination of lipophilicity by experimental procedures and the calculation of lipophilicity 
using in silico models. 
 
2.3.1.1.1 Experimental lipophilicity methodologies 
Octanol-water methods 
 
 The work published by Hansch group was pioneering in expressing the lipophilicity 
through the octanol/water partition coefficient [149, 150]. Since then, many other groups 
have adopted this system of solvents and is now commonly accepted as the standard 
biphasic system for the assessment of lipophilicity. The main reasons for the high 
acceptance of this method for the estimation of the lipophilicity are [151, 152]:  
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• there is a large database of experimental results available;  
• the octanol is thought to have a membrane-like structure in contact with water;  
• the octanol has a low vapor pressure at room temperature, as well as a low 
UV absorption, making it suitable for the use in different experimental 
methodologies;  
• the octanol has an alcohol functional group allowing it to retain some of the 
hydrogen-bonding ability of water and also dissolve a significant amount of 
water; 
• there are many examples in the literature correlating the biological activity with 
Log P and Log D.  
 
The measurement of Log P and Log D in octanol-water is commonly determined 
through the shake-flask technique which is considered to be the standard methodology 
[112, 123, 124]. In the shake-flask technique, the solid compound is placed in a vial or 
flask and then measured volumes of octanol and water/buffer are added. The vial or flask 
is agitated between 24 to 72 hours and then the concentration for each of the phases is 
calculated using, for instance, HPLC [112]. This methodology is extremely laborious and 
as a result it has been scaled down to allow higher throughput [153, 154]. Nevertheless, 
the shake-flask has some serious limitations such as [155]:  
 
• during the experimental procedure extremely stable emulsions can be 
formed that cannot be separated;  
• for highly hydrophobic and hydrophilic compounds, it is hard to determine 
the lipophilicity by this methodology;  
• the concentration of the solute must be bellow the critical micelle 
concentration and aqueous solubility limit;  
• in the case of highly lipophilic compounds, the compounds can adhere to 
the surface of the vessel;  
• some compounds can act as surfactants and concentrate between the 
interface of the two solvents; and compounds must have high purity. 
 
An alternative to the shake-flask methodology is the determination of the Log P 
and Log D in octanol/water through a pH-metric technique [156, 157]. In this method, the 
compound is first titrated by the addition of acid or base to produce a titration curve. Then, 
another titration curve is made in the presence of 1-octanol. Depending on the partitioning 
between the two phases, it is observed a shift in the titration curve proportional to the 
ŚĂƉƚĞƌϮ
/ŶƚƌŽĚƵĐƚŝŽŶ
Ϯϯ

lipophilicity of the compound. This method has been automated and is available for 
purchase from Sirius Analytical Instruments [41] and Pion [158], being very popular in the 
pharmaceutical industries since it also allows the determination of the pKa [112]. The 
limitation of this last technique is that the sample molecules must be ionizable and have 
pKa in the measurable pH range [124]. 
  
Liquid chromatographic methods 
  
The different chromatographic techniques have been deeply studied throughout 
the time due to the capacity of separating compounds from a complex mixture of 
substances. If we assume that the temperature maintained constant, the separation is 
mainly determined by three aspects: the chemical structure of the solute, and the 
physicochemical properties of the mobile and stationary phases. In the case of liquid 
chromatography, there is the presence of a liquid mobile phase and liquid-like stationary 
phase. These two phases create an environment that is particular interesting for the 
measurement of the lipophilicity, since the interactions involved in the separation of a 
solute are similar to the interactions that guide the partition of a solute between two 
phases, such as octanol-water [159]. 
 The reverse-phase liquid-chromatography is usually employed in the assessment 
of lipophilicity in view of the fact that it is easier to immobilize a non-polar, viscous phase 
on the stationary phase than to use it as a liquid in the mobile phase. In the separation 
using reverse-phase liquid chromatography, there is a successive partitioning of the solute 
between a non-polar immobilized stationary phase and a polar mobile phase. Depending 
on the affinity of the solute for either of the phases, it will be retained more or less. 
Therefore, if a series of standards with known lipophilicity (determined by octanol-water) is 
tested, the retention will be different according to their lipophilicity. The plotting of the 
retention times and the lipophilicity will allow the establishment of a calibration curve for a 
given chromatographic system. Afterwards, the solute is tested and according to the 
retention time observed, the lipophilicity of the sample will be determined. The number of 
articles in the literature describing the determination of the lipophilicity through liquid 
chromatography is overwhelming and different chromatographic techniques have been 
employed including thin-layer chromatography (TLC) and high performance thin layer 
chromatography (HPTLC), high performance liquid chromatography (HPLC), counter-
current chromatography, micellar liquid chromatography and ion-pair chromatography 
[123, 155, 159, 160]. The first three techniques are more frequently employed and as 
result will be explained them in more in detail. 
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 The determination of the lipophilicity through reversed-phase TLC and HPTLC has 
shown a good correlation with the Log P determined by the shake-flask methodology 
[161]. In the reversed-phase TLC, the stationary phase used in the first published works 
used impregnated silica with different hydrophobic agents such as liquid paraffin [162] or 
silicone oil [163] or 1-octanol [164], to turn the plate into non-polar phase. Nowadays, the 
silica plates used in TLC and HPTLC had been gradually changing to octadecyl-silanized 
silica gel plates, since they are commercially available and the results obtained are more 
reproducible [155, 159, 161, 165]. The mobile phases employed here are aqueous with an 
organic modifier, usually methanol, acetone or acetonitrile [159]. This methodology is very 
simple and rapid and only needs a small amount of sample, allowing also the presence of 
impurities and the use of a larger lipophilic scale than the possible using shake-flask 
methodology [159]. However, there are some limitations with the use of highly etherified 
silica gel plates since it can only be used mobile phases with up to 40 % of water [155, 
165]. In addition, liquid compounds cannot be used here with exception of those with a 
very high boiling point [161]. 
 The determination of lipophilicity using reversed-phase HPLC has proved also to 
simulate octanol-water shake-flask technique and is a popular alternative to assess 
lipophilicity. As a matter of fact, it has been officially recommended by the OECD as an 
alternative methodology to the shake-flask for the assessment of the lipophilicity [166]. 
The stationary phases most widely used are C-18 and C-8 silanized silica gel column. In 
the determination of the lipophilicity using these columns, special attention must be given 
to the free silenols present because they interfere with the retention possibly due to the 
interaction with the solute. This is particularly serious in the case of basic compounds. As 
a result, the columns used for the assessment of the lipophilicity are either protected 
during the manufacture to hide the free silenols or a masking agent has to be added to the 
mobile phase. The mobile phases employed in this methodology are aqueous with the 
presence of an organic modifier such as acetonitrile, methanol or tetrahydrofuran [159, 
161]. Moreover, the determination can be done using either isocratic conditions or 
gradient conditions [165, 167]. This methodology have the same advantages of the RP-
TLC since it is fast, needing only a small amount of sample, it allows the presence of 
impurities and also allows the use of a larger lipophilic scale than the shake-flask 
technique, being amenable to automation. However, it is more expensive then the RP-
TLC methodologies, but it is much more accurate and reliable which can explain its 
popularity [160, 168]. The RP-HPLC methodology is a very useful tool for the 
determination of lipophilicity but in some cases it fails to correctly model the shake-flask 
method. For example, when there are differences in hydrogen-bonding interactions 
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between the two models, when the compounds and mobile phase interact with 
unprotected silanol groups present in the stationary phase and the pore size effect of the 
packed columns interfere with the interactions. In addition, there is poor reproducibility 
between different batches of the same type of column, even from the same manufacturer, 
and the pH that many silica-based columns can work is restrict limiting its applicability. 
Moreover, in the presence of highly lipophilic compounds, the elution times can be long, 
sometimes from 2 to 4 hours [159].  
 An alternative model to assess the octanol-water partition by HPLC uses pre-
coated-octanol columns or mobiles phases enriched with small amounts of 1-octanol. The 
former was first described by McCall [169] and was commercially available from Syrius 
Instrumental as a automated equipment for the assessment of lipophilicity [170]. This 
methodology showed good correlation with Log P determined by the shake-flask and 
reversed-phase HPLC but has some disadvantages since is time consuming to prepare 
the column and there is no guarantee that the characteristics of the column are 
maintained during its use, interfering with the reproducibility of the results. It is also not 
recommended for highly lipophilic compounds [159, 165]. The use of small quantities of 
octanol in the mobile phase has shown to be favorable for the assessment of the 
lipophilicity by HPLC since it is considered to give an octanol-like character to the 
chromatographic system [171-173]. This method is suitable for the estimation of 
lipophilicity for neutral and basic compounds but it is not recommendable for acids [159]. 
 All the methodologies for the assessment of lipophilicity described so far are either 
determined using octanol-water or estimated by comparison with standards determined by 
octanol-water methodology. In spite of being a very useful model being correlating with 
several biological properties, the octanol-water biphasic system is an isotropic model that 
mimics only to a limited extent the biological membranes. Therefore, the search for 
models that mimic the anisotropic environment and the similar type of interactions found in 
the biomembranes are getting more attention and several methodologies have been 
developed [130, 168, 174, 175]. One of the approaches developed for HPLC uses a 
stationary phase prepared from phospholipids covalently bonded to a propylamino-silica 
support material with the intend of mimicking the anisotropic environment found in the 
membranes. This kind of chromatography is commonly known as Immobilized Artificial 
Membrane (IAM) chromatography and is used frequently for the assessment of 
lipophilicity [160, 165, 167, 168, 174, 176, 177]. The phospholipid that is more frequently 
bonded to the propylamine residues is phosphatidylcholine which can be assembled in a 
single or double chain way [160, 165, 168, 174, 176]. The mobile phase is usually water 
with the presence of a buffer, usually PBS to mimic physiological conditions. For highly 
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lipophilic compounds, there is the need of the addition of an organic modifier such as 
methanol or acetonitrile which then needs to be extrapolated to 100 % aqueous phase 
[160, 168, 174, 176]. The compound partitioning is usually represented by the capacity 
factor calculated from the retention volume and the amount of immobilized lipids. The 
different capacity factors for a group of compounds can then be correlated with different 
biological properties, such as lipophilicity [176, 178, 179], gastro intestinal absorption in 
rats [180], permeability through Caco-2 layers [181], blood-brain barrier penetration [182, 
183] just no name a few examples. In the case of neutral compounds, the IAM has shown 
a good correlation with octanol-water model, but for ionizable compounds, especially for 
compounds with amines, there is a poor relationship [168, 174]. Moreover, the values are 
usually higher than the observed for the octanol-water possibly due to the interactions 
between the ionized compound and the phosphates from the stationary phase increasing 
the retention and therefore the lipophilicity [174]. In addition, this method has also been 
correlated with the lipophilicity determined using other biomembrane models such as 
liposomes being an alternative methodology to assess the lipophilicity for liposome/water 
models (which will be referred later) [176]. 
 In addition to IAM chromatography, immobilized liposomes have also been used to 
evaluate the lipophilicity, being referred in the literature as Immobilized Liposome 
Chromatography (ILC). In this case, the liposomes are not covalently bonded to silica but 
are adsorbed to gel beads. The liposome immobilized gel could either have a 
multilamellar or unilamellar structure (see next section) and these gel beads are packed 
into a HPLC column and capacity factors are calculated using an aqueous buffer eluent 
[130]. This capacity factors are then related with different biological properties including 
lipophilicity [178, 184]. 
 The use of electrokinetic chromatographic approaches is another alternative for 
the estimation of lipophilicity. In these techniques, a pseudo-stationary phase of either 
micelles or liposomes is used [130, 160]. Under electric conditions, the migration of the 
solute of interest and the micelles or liposomes, will be influenced by their partition. As a 
result, a retention factor can be determined relating the partition between the two phases 
derived from the migration time of an unretained solute (e.g. methanol), the retention time 
of the solute of interest and the retention time of the micelles or liposomes. This 
methodology has been related with Caco-2 cells [185], blood brain barrier [186] and skin 
permeability [187].  
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Figure 2.13 Classification of liposomes based on size and number of membrane bilayers. 
(Adapted from [188, 189]). 
 
Table 2.3 Characteristics for each class of liposomes.  
Type of Vesicles Abbreviation Diameter Size 
Number of Lipid 
Bilayers 
Small Unilamellar 
Vesicles 
SUVs 20-100 nm 1 
Large Unilamellar 
vesicles 
LUVs ≥ 100 nm 1 
Multilamellar 
Vesicles 
MLVs > 500 nm 5-20 
Oligolamellar 
Vesicles 
OVs 
(SOVs, LOVs, 
GOVs) 
100 nm - 1 μm 2-5 
Mulvesicular 
Vesicles 
MVs > 1 μm 
Multicompartmental 
structure 
 
  
There are a multitude of methods available for the formation of liposomes of 
different sizes and lamellarity [188, 190-192]. In Figure 2.14 are represented the main 
techniques used for the formation of liposomes but since it was only used the extrusion 
technique for the formation of LUVs, it will only be referred this technique. 
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Figure 2.14 Schematic representations of different techniques for the preparation of 
liposomes (Adapted from [188, 189]). 
 
The extrusion technique is used for the preparation of unilamellar liposomes of 
well-defined size. In this technique, the MLVs are forced to pass under pressure through 
filters of defined pores to generate a homogenous population of smaller vesicles with a 
mean value of diameter that reflects the diameter of the pore [193-196]. In order to pass 
through the filters of define diameter, the membrane of the MLVs is ruptured and after 
passing through the filter the resealing occurs. As a result, any solute that is trapped 
inside will leak out during the extrusion cycle. The vesicles need to be extruded five to ten 
times through each filter to get a homogenous population of liposomes of the desired size 
[193, 194].  
  
Liposome-water is a very attractive model as an alternative to the octanol-water for 
the assessment of lipophilicity since they are considered to represent a direct model for 
biological membranes [130, 152, 160, 168, 175]. As a matter of fact, liposomes have been 
shown to yield better correlations with pharmacokinetic behavior or biological activities 
when compared to the octanol-water model [197-200]. In contrast with isotropic solvents 
such as the octanol-water model, the artificial and biological membranes are anisotropic 
media and as a result, the evaluation of the lipophilicity on these models is sometimes 
referred as anisotropic lipophilicity [175]. In the liposome-water model, besides the 
hydrophobic and polar interactions which are also present in the isotropic models such as 
octanol-water, there is the possibility of ionic and electrostatic interactions between the 
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polar head of the phospholipids and the solute. In the octanol-water models, the ionic 
charges present are carried out by salt buffers, but since they do not have a specific 
location, they cannot contribute to the free energy transfer [168, 175]. Therefore, when 
using isotropic models for determining lipophilicity, they fail to encode some important 
recognition forces, especially ionic bonds which are particularly important when modeling 
the interaction of ionized molecules with biomembranes (Table 2.4). Since the majority of 
drugs are ionizable, this aspect must be taken into account in a model for the prediction of 
pharmacokinetic and pharmacodynamic properties [112].  
 
 
Table 2.4 Comparison between the intermolecular forces that influence molecular 
recognition in biochemical and pharmacological processes and the forces encoded in 
lipophilic parameter obtained by different methods (Adapted from [123]). 
Recognition Forces in 
Biochemistry and Molecular 
Pharmacology 
Lipophilicity 
Measured in 
liposome/water 
systems or IAM-HPLC 
Measured in liquid/liquid 
biphasic systems or 
RP-HPLC 
• Charge transfer and aryl/aryl 
stacking interactions 
  
• Ionic bonds 
Polarity 
 
• Ion-dipole bonds 
(permanent, induced) 
• Reinforced H-bonds 
• Normal H-bonds 
Polarity 
Van 
der 
Waals 
forces 
• Orientation forces 
(permanent dipole-
permanent dipole) 
• Induction forces 
(permanent dipole-
induced dipole) 
• Dispersion forces 
(instantaneous 
dipole-induced 
dipole) 
Hydrophobicity Hydrophobicity 
• Hydrophobic interactions 
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 There are several techniques available for assessing the distribution of a solute 
between a liposomic and an aqueous phase, and can be divided into two main areas: 
determination of the partition coefficients by physical separation of the aqueous and the 
lipidic phases and the determination of the partition coefficient without the need to 
separate the two phases [130, 152, 160, 168, 175, 201]. 
The determination of the partition coefficient of a solute between liposomes and 
water can be done by physical separation of the two phases followed by the quantification 
of the solute in either of the phases. The separation of the two phases has been 
accomplished through filtration [202, 203] or centrifugation [204-206], and then 
quantification could be done in the lipid retained in the filter or in the filtrate or supernant. 
However, not only the methodologies are very laborious and time-consuming but also 
have some limitations since the complete separation of the two phases is hard to obtain. 
The vesicle centrifugation and filtration are cumbersome processes and part of the lipid 
can still be present in the aqueous phase or part aqueous phase adsorb to the filters or 
pellets leading to an error in the quantification [201, 207]. Moreover, the centrifugation and 
filtration procedure may disturb the partition equilibrium [208]. 
  Due to the limitations of the separation techniques, several methodologies have 
been developed for the determination of the partition coefficient without the need to 
separate the two phases. One of the most popular methodologies is the equilibrium 
dialysis [209]. In this technique a liposomal suspension and an aqueous phase are placed 
in two compartments separated by a semi-permeable membrane which allows the 
passage of solute molecules but retains the liposomes. At time zero, a solution with the 
solute is placed in one of the compartments and a suspension of liposomes is placed on 
the other compartment. A time is given for the equilibrium between the two compartments 
to take place after which the solute’s concentration can be determined and a partition 
coefficient calculated [175, 201]. This technique is very laborious since it has to be tested 
at various concentrations and for each experiment only a single point is yield. As a result it 
is considered to be forbiddingly labor and cost-extensive for routine measurements [175]. 
Another alternative is to use the same approach used for the determination of the 
lipophilicity in octanol-water biphasic system by a pH-metric technology [210]. In this case, 
instead of the octanol phase, it is used the liposomes. The advantage of this methodology 
is the ability of measuring a broad range of log P values. However, this technique is 
limited to ionized compounds and the determination can suffer interference from the free 
fatty acids that can be present in the aqueous phase and the electrostatic and ionization 
forces of the phospholipids [175, 201].  
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In the two techniques described so far for the calculation of the partition coefficient 
without the separation of the two phases, the determination was made either by 
quantification or titration of the solute on aqueous phase. However, there is the possibility 
of analyzing the global system signal response originated the solute partition between the 
two phases, which if carried out at different liposome concentrations, a partition coefficient 
can be calculated. For example, UV-Vis spectrophotometry [201, 211], fluorescence 
spectroscopy [201, 211], NMR spectroscopy [212, 213], calorimetry [214] and EPR [215, 
216] methodologies have been applied for the calculation of the partition coefficient using 
this approach. The most common techniques are the UV-Vis and the fluorescence 
spectroscopic and since the former was used, it will be described in more detail. 
The UV-Vis technique is based on the change of an absorption parameter such as 
molar absorptivity (İ) or maximum wavelength (Ȝmax) of a solute when it permeates from 
the aqueous to the non polar media. However, it is only possible to calculate the partition 
coefficient as long as the change in the Ȝmax is in the order of 5-10 nm and/or a change in 
İ ≥ 10 %. As a matter of fact, batochromic deviations (Ȝmax for higher wavelengths) are 
indicative of a decrease on the polarity of the drug’s media which indicates the 
incorporation into the hydrophobic layer and hypsochromic (Ȝmax for lower wavelengths) 
the opposite [217].  
Considering the partition coefficient (Kp) (we will describe the partition between the 
membranes-water as Kp since the P and D refer to the octanol-water model) definition 
and experimental conditions under Lambert-Beer law, the absorbance (Abs) of a solution 
containing a given concentration of a solute distributed between the lipidic (l) and aqueous 
(w) phase, can be related with Kp by the following equation [218, 219]: 
                       
ܣܾݏ ൌ ܣܾݏ ൅ ሺܣܾݏ െ ܣܾݏሻܭሾܮሿܸ׎ͳ ൅ ܭሾܮሿܸ׎  
 
where, AbsT, AbsW and Absl are the total, aqueous and lipidic absorbance of the solute 
respectively, Kp is the partition coefficient (dimensionless), [L] the lipid concentration 
(mol.L-1) and Vø the lipid molar volume (L.mol-1). Albeit the equation seems very simple, 
its application is only limited to systems with low light scattering background signals such 
as micelles [201]. In the case of liposomes, this equation is not applicable due to the light 
scattering, particularly at wavelengths below 300 nm [218, 220]. Even with the subtraction 
for each lipid concentration of absorption spectra of liposome suspensions without the 
solute, the counterbalance of the sample and reference is always incomplete and as a 
result, it is usually difficult to obtain a flat and zero-level base line. In order to overcome 
the background interference caused by the light scattering, it is necessary to use 
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derivative spectrophotometry (in order to wavelength, Ȝ), which not only eliminates this 
problem but also leads to a better resolution of overlapping bands [218, 221]. Therefore, 
the use of derivative spectroscopy for the calculation of partition coefficient can be 
determined by the equation [211, 218]: 
ܦ ൌ ܦ ൅ ሺܦ െ ܦሻܭሾܮሿܸ׎ͳ ൅ ܭሾܮሿܸ׎  
   
Where, 
ܦ ൌ߲
௡ܣܾݏ
߲ߣ௡  
 
Accordingly, the partition coefficient could be calculated by fitting the derivative 
spectrometric data (D vs [L]) to the equation by a nonlinear regression method, being Dl 
and Kp the adjustable parameters. 
The determination of the partition coefficient of a solute between liposomes and 
water by derivative UV-Vis spectroscopy is a very useful methodology albeit being limited 
to compounds with high molar extinction coefficients and partition coefficients [207]. 
  
 
Another membrane model commonly used is micelles. Micelles are aggregates 
formed when amphiphilic molecules are placed in aqueous solution in a concentration 
above the critical micellar concentration. The aggregates are formed with the aim of 
decreasing the area of contact between the hydrocarbon chains and water. The critical 
micellar concentration is the concentration were a sudden transition in the physical 
properties of the amphiphilic molecule in aqueous solution takes place leading to the 
formation of micelles and is dependent on: the hydrophobicity of the hydrocarbon moiety; 
the type of polar head groups, the net charge of the polar head groups with the respective 
counter-ions as well as the type and concentration of the electrolytes present. Moreover, it 
is influenced by temperature and pressure [222]. 
 The micelles have usually between 50-200 monomers, with a hydrophobic core 
comprised of hydrocarbon chains, and a polar surface constituted from the hydrophilic 
groups (“head”) (Figure 2.15). Since the polar “head” groups are very close to each other, 
electrostatic repulsion is created opposing the micelization process. However, the 
surfactant counter-ion, if present in high concentration, is able to protect the charge of the 
aggregate by reducing the electrical potential and the repulsion between the polar heads 
of the monomers allowing the formation of micelles [222]. 
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experimental limitations, several chromatographic techniques have been developed using 
phospholipids, liposomes and micelles with the aim of creating an anisotropic medium 
similar to the one found in membrane models but with higher throughput, lower cost and 
higher lipophilic range. However, a comparative for all these chromatographic techniques 
need to be made so that the evaluation of the lipophilicity could be made with the broadest 
predictive capacity [130].  
 
2.3.1.1.2 In silico lipophilicity determination 
 
 The Log P and Log D prediction using software programs is undoubtedly a very 
useful tool in the drug discovery field. This is particularly imperative for the pharmaceutical 
industries which have chemical libraries of thousands of compounds and as a result it is 
prohibitive for them to evaluate the lipophilicity for all the compounds [134, 227]. 
Therefore, a quicker and cheaper alternative is to use computational programs that could 
predict with a high degree of accuracy the lipophilicity [112, 227]. However, the results 
obtained in silico must be reliable since the inaccuracy in the prediction of this property 
can mislead the selection of a compound during the drug discovery program, especially in 
the high throughput screening. There are numerous computational programs available for 
the prediction of this physicochemical property using different methods for the calculation, 
such as substructure-base methods [228] which cut the molecules into fragments 
(fragmental methods) or to single atoms (atom-based methods), and property-based 
methods [229] which uses descriptions of the entire molecule using empirical approaches, 
3D structure representation and topological descriptors [134]. As a result, the different 
programs use their own set of algorithms which mean that the prediction for the same 
molecules may vary from one program to the other [230]. In addition, the computational 
predictions are made by comparison with the log P obtained experimentally in the octanol-
water model. Therefore, the results predict the lipophilicity for this biphasic isotropic 
system and as far as we know, there are not any computational program developed taking 
in consideration the partition coefficient determined with membrane-water models.  
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2.3.2 Solubility 
 
Solubility is a property that is studied throughout drug discovery and development. 
The solubility is the maximum concentration reached for a compound in a solvent matrix 
and at equilibrium. The solubility is dependent on many factors which mean that there is 
not only a single value of solubility, but a value of solubility for specific conditions [112, 
127, 128]. The solubility is dependent on: 
 
• Structural properties of the compound: 
 Lipophilicity; 
 Size; 
 pKa; 
 Crystal lattice energy: determined by crystal stacking, melting point. 
• Physical state of the compound that is introduced in the solution: 
 Solid: amorphous, crystalline, polymorphic form; 
 Liquid: predissolved in solvent. 
• Composition and physical conditions of solvent(s): 
 Types of solvents; 
 Percentage of co-solvents; 
 Solution components; 
 pH; 
 Temperature. 
• Methods of measurement: 
 Equilibration time; 
 Separation techniques; 
 Detection. 
 
During the drug discovery stage, low solubility creates serious problems for in vitro 
and in vivo bioassays. For instance, in the in vitro bioassays, the insolubilization of a 
compound will lead to a lower concentration than targeted which may induce erroneous 
results and overlook of a possible valuable candidate. In the preclinical in vivo assays, the 
low solubility will affect the route of administration followed and the exposure levels [112, 
127, 128].  
In the case of drug development, the solubility is crucial to the dosage form used 
during clinical trials, e.g., salt forms, cocrystal forms, polymorphic forms, solvates and 
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hydrates. The solubility will also influence the development of analytical procedures and 
manufacturing strategies [112, 127, 128].  
Lipinski and collaborators evaluated the solubility of commercial drugs using a 
kinetic solubility assays and described that 87 % of the compounds had a solubility higher 
than 65 μg/mL, while only 7 % had a solubility lower than 20 μg/mL [117]. Therefore, a 
solubility of 65 μg/mL is considered to be the cut-off limit for a compound to be considered 
soluble. According to other authors, for compounds with average potency, a value of 100 
μM is sufficient for projecting oral absorption and for compounds not very potent, the 
solubility should be much higher (500-2000 μg/mL) [127]. 
Due to the importance of solubility in the drug discovery and development, several 
strategies can be followed to increase or overcome poor solubility. The strategies to 
increase the solubility include [112, 127, 128, 231, 232]: 
 
• modify the structure of the candidates to improve solubility, which include the 
introduction of either an ionizable or a hydrogen bonding or a polar group, 
decreasing the lipophilicity and molecular weight, disrupting the crystal 
packing and constructing a pro-drug; 
• increase in the dissolution rate by decreasing the size of the particles, the use 
of an oral solution, use of a formulation with surfactants and the preparation of 
a salt form: 
• the use of drug carriers such as liposomes. 
 
 
 
 
2.3.2.1 Methodologies for measuring solubility 
 
The methods for the determination of solubility are usually divided into two groups: 
thermodynamic/equilibrium solubility assays and kinetic solubility assays. The former can 
be used in all the phases of the drug discovery and development project and the latter is 
commonly used in the first steps of the drug discovery since it allows higher throughput 
[112, 127, 128, 233-235]. Besides these two methodologies, several in silico programs 
have also been developed for the determination of the solubility in different solvents [236-
238]. 
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2.3.2.1.1 Thermodynamic/Equilibrium solubility Assays 
 
In the thermodynamic assays, the solid compound is placed in a vessel and an 
aqueous solution is added to it, which means that the crystal-lattice energy must be 
overcome for dissolution to occur. Indeed, the solid compound is placed in excess and it is 
allowed to agitate between 24-72 hours at a controlled temperature until equilibrium is 
reached. The solution is filtered or centrifuged and the compound concentration is 
determined. This approach is referred as the “shake-flash” method and is considered to 
be the “gold-standard” solubility assay. The “shake-flask” method has been miniaturized 
and automated to allow higher throughput [112, 128, 239] which is important for 
pharmaceutical industries that have chemical libraries of thousands of compounds. In 
addition, a potentiometric method has been developed for the determination of the 
intrinsic solubility which has been automated and it is available commercially from Sirius-
Analytical [41] and Pion [158].  
Although several automated high throughput “shake-flask” and potentiometric 
methods are available, the number of assays that can be made per day is limited, 
especially when compared with the kinetic solubility assays. Moreover, these assays may 
require significant amounts of sample for highly soluble compounds which are usually not 
available in an early stage of the drug discovery stage [233], and the values may vary 
between amorphous and different crystal forms [112, 240]. Therefore, in the 
pharmaceutical industries, the use of this method is restricted to a few compounds of 
high-value in a later stage of the drug discovery project or in the pre-clinical stage [112, 
128, 234, 235, 240], where the solubility of the solid in difference matrices is needed, e.g., 
for animal dosing purposes [128].  
 
2.3.2.1.2 Kinetic Solubility Assays 
 
 In comparison with the thermodynamic/equilibrium solubility assays, in the kinetic 
solubility assays, small aliquots of different concentrated solutions of the compound 
(predissolved in an organic solvent such as DMSO or methanol, or for ionizable 
compounds in aqueous media by pH adjustment) are added to an aqueous matrix and 
analyzed for the presence of solute in solution or as a precipitate [112, 128, 233, 234]. In 
the former, a separation has to be performed to remove the insolubilized compound 
(filtration or centrifugation) and the supernatant is analyzed by a spectroscopic method; in 
the latter, no separation is required and a nephelometric, or other scattering light 
techniques, is performed to measure the compound insolubilization. In the kinetic solubility 
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assays, the compound is already dissolved and consequently, no crystal lattice energy 
needs to be overcome to dissolve the compound. Moreover, the solubility is not measured 
at equilibrium and is dependent on the time of the assay, on the type of co-solvent and its 
percentage in the final solution [112, 128, 233, 234, 240].  
 The kinetic solubility assays are the preferred methods in the pharmaceutical 
industries for the determination of the solubility in the early phases of the drug discovery 
project [112, 128]. Several automated high throughput methodologies are available 
commercially, allowing the determination of solubility in a reduced time and with the need 
of a small amount of sample (about 1 mg) [112, 128, 177, 233-235]. The kinetic solubility 
assays are usually determined using a sample solubilized in DMSO, and since this solvent 
is also used in the screening assays, the solubility determined in these experimental 
conditions gives an insight as whether or not the compound may be a false negative due 
to insolubilization in the bioassays, and also alert the teams to potential absorption 
liabilities [110, 112, 128]. 
 In general, the solubility determined by a kinetic assay tends to give higher values 
when compared with the thermodynamic assays. The presence of a co-solvent in the 
kinetic assay enhances the solubility in an aqueous matrix and for low-soluble 
compounds, there is the tendency to occur supersaturation due to a nonequilibrium state 
[112, 128, 233, 234, 240]. Accordingly, the percentage of the co-solvent in the final assay 
solution should be lowered to 1 % to minimize these effects. The equilibrium is time-
dependent and for long incubation times, the kinetic solubility assays tend to have an 
increase agreement with the solubility determined by a thermodynamic assay [128, 234]. 
  
2.3.2.1.3 In silico solubility methods 
 
The prediction of solubility using a computational model is a complex and 
challenging field in medicinal chemistry [236-238, 241-243]. The accuracy of a 
computational model depends greatly on the quality of the experimental data used and 
one of the most difficult tasks for the creation of a solubility computational model is to find 
a large high quality dataset collected in homogenous experimental conditions. Indeed, the 
values of solubility used in the computational models refer to thermodynamic solubility 
assays which may vary on the experimental technique, the pH of the assay, the 
electrolytes present in the solution and the crystal structure of the compounds, especially 
for poorly soluble compounds [236, 237, 241-244]. As with the Log P and Log D, there is 
the need to distinguish intrinsic solubility from the apparent solubility. The former refers to 
the solubility of unionized species and the latter to the solubility at a given pH for ionizable 
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compounds and can be used for the calculation of the intrinsic solubility if the pKa of the 
compound is known [241, 243]. Most in silico models predict the intrinsic solubility which is 
usually represented in its logarithmic form [242].  
The computational models developed for the determination of the solubility can be 
roughly divided into two main groups: those correlated with other experimentally 
determined properties and those not. In the former group, the experimentally determined 
properties that are most commonly used for the prediction of the solubility are the Log P 
and the melting point. In latter group are computational models that use Monte Carlo 
simulations and quantum-mechanical calculations, and models that use different 
molecular descriptors, which can be sub-divided into 1D, 2D or 3D methods depending on 
the molecular descriptors used [237, 238, 241-243]. In spite of several computational 
models available, the accuracy still remains low with large error units, especially for 
chemical diverse libraries [127, 237, 241, 243].  
 
The solubility is the maximum amount of a compound that can remain in solution at 
a certain volume of solvent, temperature and pressure, under equilibrium conditions. The 
equilibrium is a result of the net balancing of energy between the energy of the solvent 
and the solute interacting with themselves against the energy of solvent and solute 
interacting with each other [244]. Therefore, the solubility in water depends on two factors: 
the crystallinity of the solute and its ability to interact with water [245]. In fact, one of the 
most popular predictive models for the calculation of solubility, commonly referred as the 
General Solubility Equation (GSE): 
 
General Solubility Equation: 
Log S = –Log P – 0.01*(Mp – 25) + 0.5 
 
The GSE uses the experimental or calculated partition coefficient in octanol-water 
and the melting point (Mp) as variables, since the former relates directly to the affinity of 
the solute to water, and the latter to the crystal lattice and crystal packing energies of the 
solute [136, 246, 247]. Compounds with high melting point and low molecular weight have 
usually high rigidity, planarity and symmetry due to the crystal packing and ʌ-stacking 
interactions [245]. Moreover, the rigidity reduces the entropic contribution to the free 
energy of solvation decreasing even more the solubility [137, 248, 249]. From the analysis 
of the GSE, with an increase in either the lipophilicity or melting point, there is a decrease 
in the solubility, being the Log P more influential to the solubility than the melting point. 
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However, for compounds with a Log P between 2 and 4, the Mp influences greatly the 
solubility and may determine if a compound have a good or a poor solubility (Table 2.5). 
 
Table 2.5 Predicted solubility (Log S) as a function of Log P and Mp using the GSE 
(Adapted from [137]). 
 
Good solubility (> 200 µM/ > -3.7 Log S) 
 Intermediate solubility (30-200 µM/- 4.5 to -3.7 Log S) 
 Poorly Soluble (< 30 µM/ < -4.5 Log S) 
 
 Planarity and aromaticity have also been described as important factors 
influencing the solubility and the Mp [137, 139, 245, 248-251]. In a study for measuring 
complexity in a molecule using the fraction of hybridized-sp3 carbon (Fsp3), a relationship 
between this descriptor and solubility and Mp has been observed [251]. The Fsp3 is 
calculated by the ratio of the hybridized-sp3 carbons over the total number of carbons 
present in a molecule, being a low value of Fsp3 an indication of a high number of either 
sp2 or sp hybridized carbons. Therefore, a low value of Fsp3 is used as an indicator of a 
high level of planarity. From the analysis of a large database of compounds, it was 
observed that in average, the Fsp3 went up with an increase of solubility and went down 
with a decrease in the melting point. The trends can be visualized from the Table 2.6 
which links Mp and solubility with the Fsp3 [251]. The same relationship has been 
confirmed by other group that evaluated the influence of Fsp3 and other physicochemical 
properties on aqueous solubility and melting point [139] and it was concluded that the 
Fsp3 did not correlate with Log P and it was an important descriptor for solubility. In fact, 
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they considered that the Fsp3 influenced solubility as much as the Log P and that it should 
be taken into account during the drug discovery program [139]. 
 
Table 2.6 Variation of Fsp3 as a function of melting point and solubility. 
Mp (ºC) 25 75 125 175 225 275 325 375 
Fsp3 0.34 0.33 0.31 0.27 0.24 0.18 0.11 0.10 
 
Log S -12 -10 -8 -6 -4 -2 0 2 
Fsp3 0 0 0.07 0.31 0.42 0.38 0.56 0.67 
 
 Besides the GSE, other models for a fast prediction of solubility have been 
developed using the aromatic proportion (AP) as a variable influencing solubility. One of 
the models proposed an equation (named ESOL which states for Estimated SOLubility) 
for the prediction of solubility where besides the AP, the calculated Log P, molecular 
weight (MW) and number of rotatable bonds (RB) were also used as variables [138]. 
 
ESOL: 
Log (S) = 0.16 – 0.63cLogP – 0.0063MW + 0.0066RB – 0.74AP 
 
According to the authors, the fraction of aromatic carbons can be used as a 
measure of flexibility, which adding MW and number of RB, can be related to the Mp. This 
was described as an advantage when compared to the GSE since the Mp is frequently not 
determined in an early phase of the drug discovery program.  
In another model, the solubility was predicted using only the molecular weight and 
the AP (Figure 2.16) [252]. In this case, instead of a numeric value, the prediction of 
solubility was made in a qualitative manner using 30 μM as the cut-off limit. A 
classification tree was built using only the MW and AP as descriptors. As it can be 
depicted from the ESOL and the classification tree, a high value of AP have a deleterious 
effect on solubility, especially for molecules with a high molecular weight. 
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Figure 2.16 Classification tree for the prediction of solubility considering the MW and the 
AP. 
 
 For compounds with a similar value of Log P or Log D, the probability of a 
compound being soluble decrease with an increase in the number of aromatic rings [137, 
248]. In the case of the type or aromatic rings, it was observed that the carboaromatic 
rings have a more deleterious effect in the solubility than heteraromatic rings. Moreover, 
heteroaliphatic rings have shown to increase the solubility [250]. The lower solubility for a 
higher number of aromatic rings was explained by the increase in molecular rigidity, 
melting point and the capacity of ʌ-ʌ-stacking with an increase aromaticity inter alia.  
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2.3.3 Plasma Protein Binding (PPB) 
  
 A drug molecule when administered orally must pass through the intestinal barrier 
and reach the blood. However, to exert its biological effect, it still must be transported to 
the biological target and its efficacy will depend on the concentration of drug that is free 
(unbound) in the plasma. In fact, only the free drug molecules are able to cross the 
membrane barriers and be distributed to the different tissues. Thus, the concentration of 
unbound drug depends on the amount of compound that is bound to the plasmatic 
proteins, which is critically involved in the drug pharmacokinetics (Figure 2.17) [112, 253-
256].  
 
 
Figure 2.17 Protein Binding and drug distribution (Adapted from [253]). 
 
 The binding to plasmatic proteins have a crucial role in a compound 
pharmacokinetics and if a compound is highly or tightly bonded to plasmatic proteins, the 
effects will be [112, 254, 255]: 
 
• retained compound in plasma compartment; 
• restricted distribution to the target tissue (reduce the volume of distribution); 
• decreased metabolism, clearance and prolonged half-life; 
• limit brain penetration; 
• higher loading doses but lower maintenance doses. 
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The interaction of a compound with the plasmatic proteins is electrostatic and 
hydrophobic, being fast and reversible. Two plasmatic proteins are present in higher 
amount being the most responsible for the binding of drug molecules: albumin which in 
humans is referred to as human serum albumin (HSA) and α1-acid glycoprotein (AGP). 
Lipophilic compounds can also bind to other plasmatic proteins such as VHDL, HDL, LDL 
and VLDL. The HSA is the most abundant (60 % of the total plasma protein) present in a 
concentration ranging from 500 to 750 μM. The HSA binds strongly to organic anions but 
it can also bind to neutral and basic compounds. The AGP is present at lower 
concentrations and binds primarily to basic compounds [112, 255]. 
For compounds with high PPB, the reduction of the binding might be advisable and 
can be accomplished through structure modification. Compounds that are highly lipophilic, 
acidic and basic are known to bind strongly to plasmatic proteins and consequently, the 
reduction of the two physicochemical properties will lead to a lower binding [112, 254]. 
Other physicochemical property that has been correlated with PPB is polar surface area 
(PSA) and an increase of this property will lead to a lower PPB [112]. In addition, a high 
number of aromatic rings, especially carboaromatic rings, have been correlated with a 
high in vitro PPB and consequently, a reduction of the number of aromatic rings can lead 
to a reduction in PPB [248, 250]. 
 The determination of the PPB can be measured in vitro using human plasma or 
plasma from other species. Comparison of the free fractions among different species and 
using a wide range of compound concentrations is useful for the interpretation of the 
pharmacokinetic and pharmacodynamic results, and to also help in the prediction the 
properties of a drug candidate in humans [255]. Since the HSA and the AGP are the two 
most abundant proteins present in the blood stream, the determination of the binding to 
these two proteins is also useful [253]. 
 
2.3.3.1 Methodologies for measuring PPB 
 
No matter the administration route used to deliver the drug, once the drug is in the 
bloodstream, it will enter in contact with different constituents of the blood and interact 
with them. The drugs interact not only with red blood cells, leukocytes and platelets, but 
also with plasmatic proteins such as HSA, AGP, lipoproteins and globulins [112, 129]. The 
determination of the interaction of the drug with proteins of the blood is usually carried out 
in human plasma or serum [257]. However, it can also been determined in albumin or 
AGP which are the proteins present in higher quantities in the bloodstream, allowing a 
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deeper knowledge of the binding of the compound. In addition, several computational 
methods have been developed for the in silico prediction of this property. 
 
2.3.3.1.1 Assays in Plasma or Serum 
 
In order to evaluate most of the proteins present in the bloodstream, the interaction 
between a compound and the plasmatic proteins is carried out in human blood plasma or 
serum. The plasma is more commonly used than the serum since the latter lacks the 
clothing factors. The methods for the determination of the PPB, measure the binding of a 
compound to plasma proteins and also the unbound compound present in the aqueous 
phase. Therefore, it is not taking in consideration the percentage of compound that could 
be bond to the blood cells, such as red blood cells, leukocytes and platelets [112]. 
The technique considered the “gold standard” for measuring the PPB is the 
equilibrium dialysis which determines the concentration of the unbound compound after 
equilibrium between the compound and the plasmatic proteins have been reached. In 
spite of having been automated to allow higher throughput the number of samples that 
can be determined at a single run are limited [112, 255, 257]. The ultrafiltration is a fast 
and technically less challenging than the equilibrium dialysis and is frequently used in 
pharmaceutical industries for a fast determination of the PPB, since several automated 
high throughput are available commercially. This methodology have an important 
drawback since nonspecific binding to the filters and the walls of the collection chambers 
can take place leading to an underestimation of the concentration of the free compound 
[255]. The ultracentrifugation can be used instead to overcome this liability but have a big 
disadvantage since the equipment is expensive and the throughput is low. In addition to 
these methodologies, solid phase microextraction technique has also been used with 
success for the determination of the PPB [255]. All these methodologies rely on the 
determination of the concentration of the compound solubilized in the aqueous phase that 
is not bound to the plasmatic proteins. This methodology is very problematic for highly 
lipophilic compounds which are poorly soluble in water and have a high protein binding 
reaching very low concentrations in the aqueous phase. Therefore, many methodologies 
need to use very robust equipment such as LC-MS for the calculation of the concentration 
of the unbound compound [255, 257].   
 In an advanced stage of the drug discovery program, besides the determination of 
the PPB in human plasma or serum, it is also determined in plasma of different species. 
Moreover, the partition of a compound in red blood cells is also usually determined [255]. 
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2.3.3.1.2 Assays in a Plasmatic Protein 
 
 The blood is composed of different proteins being albumin and AGP the two 
plasmatic proteins found in higher amount in the bloodstream. The former is the most 
abundant (60 % of the total plasma proteins) and binds mainly to acidic compounds (but 
neutral and basic compounds as well) and the latter binds strongly to basic drugs (but 
neutral drugs can also be bound to it) [112, 129]. Since these two proteins are the two 
proteins must abundant in the bloodstream, the determination of the binding of a 
compound to plasmatic proteins is usually carried out in either/or both proteins [253]. 
 The data obtained from the PPB using plasma or serum gives information about 
the binding to all the plasmatic proteins without focusing on a particular protein. If instead 
of the plasma, a particular plasmatic protein is used, a deeper knowledge about the type 
of binding is withdrawn. However, the data obtained from a single plasmatic protein 
should be looked with cautious since the binding could be underestimated due to the 
possible interactions with other plasmatic proteins [255]. The methods developed for the 
determination of the binding of a compound can be roughly divided in two: the separative 
and non-separative methods [253].  
 
Separative Methods 
 
 The techniques used for the determination of the PPB using plasma and serum 
could also be applied here for the determination of the binding to a single plasmatic 
protein. Among them, the equilibrium dialysis, the ultracentrifugation and the ultrafiltration 
have been applied for the determination of the fraction of compound bound to a plasmatic 
protein. Moreover, liquid chromatographic techniques using either a stationary composed 
of immobilized plasmatic protein or size-exclusion chromatography have been applied for 
the determining the binding to albumin and AGP. Capillary electrophoresis and PAMPA 
have also been used for the determination of the binding of a compound to a plasmatic 
protein [253]. 
 
Non-separative Methods 
 
 The separative methods determine the fraction of compound bind to the plasmatic 
proteins not giving an understanding of the binding mechanism. On the other hand, the 
non-separative methods have the advantage of perform the determination of the binding 
in solution without disrupting the equilibrium and provide a better understanding of the 
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binding mechanism. These methods are based on the perturbation of the spectroscopic 
and energy levels of the ligand or the protein by the binding [253]. 
 The non-separative experimental techniques which can be used to study the 
binding mechanism are dependent on the kind of information wanted. Moreover, each 
method should be chosen considering the number of compounds since most of these 
techniques are time-consuming. The binding between the plasmatic protein and the ligand 
can be studied using different techniques such as UV-Vis, fluorescence, nuclear magnetic 
resonance, infrared, circular dichroism, optical rotator dispersion, isothermal titration 
calorimetry, differential scanning calorimetry and surface plasmon resonance [253]. 
 The evaluation of the binding of the compounds to a plasmatic protein was made 
using a spectroscopic technique and therefore it will be explained in more detail. 
The spectroscopic techniques are the most commonly used approaches for the 
calculation of a binding dissociation constant (Kd) between a ligand (L) and a receptor (R), 
being very useful for understanding the affinity of a compound to a biological target. The 
Kd is expressed in molarity and corresponds to the concentration where 50% of the ligand 
and receptor are bound, considering that the concentration of the ligand is in excess 
relatively to the receptor. For a specific set of conditions, equilibrium between the bound 
and unbound forms of the receptor is quantified in Kd values [258]: 
 
 
ܭ݀ ൌ  ሾܴሿሾܮሿሾܴܮሿ  
 
where, [RL] is the concentration of the complex receptor-ligand, and [R]f and [L]f are the 
receptor and ligand free concentrations. The smaller the Kd values, the tighter the 
bonding between a receptor and a ligand is. On the other end, for the association constant 
(Ka), the inverse is observed meaning that high Ka values correspond to a tighter bonding 
[258].  
The dissociation of a ligand-receptor complex takes place when the driving force of 
the dissociation is greater than the driving force leading to the binding, and Kd can be 
related to the Gibbs free energy by the following equation [258]: 
 
οܩ ൌ ܴܶሺܭ݀ሻ 
 
where, R is the gas constant and T the thermodynamic temperature. Albeit, the Kd can be 
estimated from kinetic studies, the binding phenomenon typically occurs in a short time 
scale which represent an experimental barrier for experimental measurements. Therefore, 
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the receptor-ligand (RL) interaction is usually studied after equilibrium between them has 
been reached. At equilibrium, the concentration of the RL complex is constant, thus the 
rates of complex association and dissociation are equal. The rates are given by the 
following kinetic equations [258]: 
݀ሾܴܮሿ
݀ݐ ൌ ݇ሾܴሿሾܮሿ 
െ݀ሾܴܮሿ
݀ݐ ൌ ݇ሾܴܮሿ 
 
where, kon is defined as the second-order rate constant for complex association and koff as 
the first-order rate constant for complex dissociation. At the equilibrium the rates must be 
equal [258]: 
 
݇ሾܴሿሾܮሿ ൌ ݇ሾܴܮሿ 
ሾܴܮሿ ൌ ݇݇ ሾܴሿሾܮሿ 
 
Considering that the kon/koff is equivalent to Ka: 
 
ሾܴܮሿ ൌ ܭܽሾܴሿሾܮሿ 
 
However, the equation is better expressed by the total receptor and ligand concentrations 
added, because in most cases, there is a great difficult in measuring the actual free 
concentrations. Therefore, If we consider that [R] = [RL] + [R]f and divide both sides of the 
equation by 1 + ([RL]/[R]f), it is obtained the following equation [258]: 
ሾܴሿ ൌ  ሾܴሿ
ͳ ൅ ሾܴܮሿሾܴሿ
 
 
where, [R] represents the total receptor concentration. Considering that Ka = [R]/[R]f[L]f: 
 
ሾܴܮሿ ൌ ܭܽሾܮሿ ሾܴሿͳ ൅ ܭሾܮሿ 
 
and knowing that Kd = 1/Ka, the equation is rearranged to: 
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If it is assumed that the concentration of the receptor is far less than the 
concentration of the ligand, the formation of the binary complex does not significantly 
decrease the concentration of the free ligand. Therefore, an approximation can be made 
and assume that the concentration of the free ligand is about the same as the total ligand 
concentration: [L]f § [L]. The previous equation can be written [258]: 
 
ሾܴܮሿ ൌ  ሾܴሿሾܮሿܭ݀ ൅ ሾܮሿ 
and: 
ሾܴܮሿ ൌ  ሾܴሿ
ͳ ൅ ܭ݀ሾܮሿ
 
  
This equation is named as Langmuir isotherm equation since it was first derived by 
Langmuir to describe the adsorption of gas molecules to a solid surface at constant 
temperature and pressure. It represents a square hyperbola which is typical of saturable 
binding in biochemical and chemical reactions. If the concentration of the total receptor in 
an experiment is not known, the use of a measurable signal associated to binding 
phenomena allows the construction of a binding isotherm that can be fitted into Langmuir 
isotherm equation written as [258]: 
ܻ ൌ ܻ
ͳ ൅ ܭ݀ሾܮሿ
 
 
where, Y is the signal measured experimentally. The Ymax (maximum measurable signal) 
and Kd can be obtained fitting a plot of Y versus ligand concentration using the previous 
equation. The Langmuir isotherm equation assumes that each receptor molecule have a 
single specific binding site for the ligand. However, in some cases, more than a binding 
site is present to where the ligand can bind. In the simplest case, the affinity of the ligand 
for all the binding sites is the same resulting in identical Kd, and the ligand binding to one 
site does not perturb the binding affinity of the other binding sites. In this case, the 
Langmuir isotherm can still be applied but the molarity of the specific binding sites for the 
ligand is n[R], where n is the number of specific binding sites that are available in the 
receptor molecule [258]: 
 
ሾܴܮሿ ൌ  ݊ሾܴሿ
ͳ ൅ ܭ݀ሾܮሿ
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Besides this simplest case, it is also possible that the binding of a ligand to a 
receptor can take place at more than one binding site where each binding site has a 
single independent Kd value (multiple non-equivalent binding sites). In this case, an 
individual binding isotherm can be constructed for each binding site. In either of the 
examples referred before, it was assumed that the different binding sites behaved 
independently from one another. However, this is not always true and in some cases the 
affinity of the ligand to one binding site on a receptor is modulated by the binding of a 
ligand molecule to other binding site. This kind of binding is designated as cooperative, 
and can be positive or negative if the binding of a ligand to one site increases or 
decreases the affinity of the ligand to the other site respectively [258].  
In addition to the Langmuir isotherm, other models have been developed for the 
determination of binding constants. One model consists on the use of a semi-logarithmic 
scale [258]: 
 
ܻ ൌ ܻ
ͳ ൅ ܭ݈݀݋݃ሾܮሿ
 
  
In this case, the isotherm has an “S” shape and the Kd is calculated by the visual 
observation of the midpoint of the curve. 
 In the previous equations, it was assumed that [L]f § [L]. However, if the ligand 
affinity to the receptor is very strong, the Kd could be close in magnitude to the 
concentration of the receptor. As a result, the [L]f is no longer similar to [L] and the 
Langmuir equation should not be applied in these cases with the risk of leading to errors 
in the Kd determination. Bearing this in mind, a new equation must be derived taking in 
consideration the depletion of the ligand and receptor concentrations once the RL 
complex is being formed [258]: 
 
ሾܴܮሿ ൌ  ሺሾܴሿ ൅ ሾܮሿ ൅ ܭሻ െඥሺሾܴሿ ൅ሾܮሿ ൅ ܭ݀ሻ
ʹ െ Ͷሾܴሿሾܮሿ
ʹ  
 
The quadratic equation described above is correct for any ligand-receptor binding 
interaction, albeit the Langmuir isotherm equation is easier and simpler to use when the 
ligand or receptor depletion is not significant [258]. 
 The Kd of the binding between some of the compounds synthesized and a 
plasmatic protein was determined using a fluorescence technique which is also widely 
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employed in other kinetic and protein stability studies [253]. The fluorescence technique is 
based on the light emission by a substance when it returns to the ground-state [259]. The 
fluorescence phenomenon is characterized by different parameters such as emission and 
excitation spectra, intensity and quantum yield and it is a very sensitive technique [259]. In 
order to be able to use the fluorescence technique, there is the need of the presence 
fluorophores which can be divided into two groups: intrinsic fluorophores for naturally 
fluorescent groups present in a sample or extrinsic fluorophores when a fluorescent 
molecule is added to a sample [259]. In the case of proteins, there are some aminoacids 
that can behave as intrinsic fluorophores allowing them to be used in fluorescence 
studies. The fluorescence aminoacids are tyrosine (Tyr), phenylalanine (Phe) and 
tryptophan (Trp), being the latter the stronger fluorophore [259]. However, all these 
aminoacids are not abundant in proteins and in the case of Trp, which is the dominating 
fluorophore [260, 261], is present at nearly 1 mole % in proteins [259, 262].  In the case of 
albumin, the human has one Trp residue and bovine 2 residues [263]. The Trp emission in 
proteins depends on the surrounding environment and changes in the emission spectra 
can be correlated with phenomena like conformational transitions, substrate binding, 
denaturation, protein folding and consequently  with  protein  structure [258, 259, 264]. 
The binding between the compounds synthesized and albumin was monitored by 
fluorescence quenching caused by the addition of increasing amounts of a compound to a 
solution of albumin which will be explained below. 
The fluorescence quenching corresponds to the decrease of the fluorescence 
intensity induced by the interaction of the quencher with the fluorophore [259]. The 
quenching process can be considered as collisional, static or a co-existence of both types. 
In the collisional quenching (also referred as dynamic quenching), it occurs a diffusion 
process of the quencher molecules to the fluorophore which must take place during the 
lifetime of the excited state. Upon contact, the fluorophore return to the ground state with 
the emission of a photon. In the static quenching, a ground state between the quencher 
molecules and the fluorophore is formed, which absorbs light and returns to the ground 
state without the emission of a photon. All in all, for quenching to take place, it requires 
molecular contact between the fluorophore and quencher species [259]. 
In order to determine the fluorescence quenching, the fluorescence intensities 
need to be corrected to eliminate the inner filter effect. The inner filter effect occurs when 
the compound used in the experiment absorbs at the wavelength of excitation of the 
fluorophore and decreases the real intensity of the exciting light beam resulting in a 
decrease of the measured fluorescence intensity. Therefore, the fluorescence intensities 
should be corrected and the following equation should be applied [259]: 
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where, Icorr is the corrected fluorescence intensity, I is the experimental fluorescence, AQ is 
the absorbance of the sample and AF is the absorbance of the sample. 
The determination of the dissociation constant can then be calculated using the 
Langmuir Isotherms, keeping the concentration of the plasmatic protein constant and 
varying the total compound concentration: 
 
ܳݑ݄݁݊ܿ݅݊݃ሺΨሻ ൌ  ܳ௠௔௫
ͳ ൅ ܭௗሾܮሿ
 
 
The percentage of quenching using the corrected fluorescence intensities are 
plotted as a function of the compound concentration, and the Kd and the quenching 
maximum (Qmax) are the adjustable parameters which can be calculated by a non-linear 
regression model through the Langmuir isotherm equation.  
The bonding could take place at more than one site, and in this case the equation 
used is: 
 
ܳݑ݄݁݊ܿ݅݊݃ሺΨሻ ൌ ݊ כ ܳ௠௔௫
ͳ ൅ ܭௗሾܮሿ
 
 
In the case of a strong, the equation to be used is the following, which need to take 
in consideration the concentration of the protein ([R]): 
 
ܳݑ݄݁݊ܿ݅݊݃ሺΨሻ ൌ ܥͳ ሺሾܴሿ ൅ ሾܮሿ ൅ ܭሻ െඥሺሾܴሿ ൅ሾܮሿ ൅ ܭሻ
ʹ െ Ͷሾܴሿሾܮሿ
ʹ  
 
Förster resonance energy transfer (FRET) 
 
 FRET is a non-radiative excitation energy transfer between a donor, the excited 
fluorophore, and an acceptor, a chromophore or a fluorophore that are separated by 
distances that exceed the sum of their Van der Waals radii. The FRET is frequently 
erroneously named as fluorescence-resonance energy since no fluorescence is involved. 
The energy is transferred through resonance, i.e., after the molecule is excited, an 
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oscillating electric field is generated that excites the electrons of an acceptor to its excited 
state. The acceptor after being excited can return to the fundamental state by different 
mechanisms including by a photon emission when the acceptor is a fluorophore, and if the 
acceptor is not fluorescent, by the interaction with the solvent. The FRET is a Coloumbic 
interaction being frequently referred as a dipole-dipole coupling since the FRET describes 
the energy that is transferred in terms of the interaction between the transition (dipole) 
moments in the very weak dipole-dipole coupling limit [259, 265]. 
 According to the Förster theory, the efficiency of the energy transfer (E) is 
dependable on: the distance (r) between the donor and acceptor (molecular distances in 
the range of 1-8 nm); the relative orientation between the donor and the acceptor 
transition dipoles (ț2), the quantum yield of the donor (ø) and the overlap of the 
fluorescence spectrum of the donor with the absorption spectra of the acceptor. The ț2 
can take values between 0 and 4, which for aligned transition dipoles (maximal energy 
transfer) the ț value is equal to 4. On the other hand, for dipoles orientated perpendicular 
to one another (minimum energy transfer) the ț2 is equal to 0. When the ț cannot be 
known, 2/3 is used as ț2 value [265].  
The FRET is defined as the ratio of the transfer rate to the sum of the rates of all 
deexcitation processes being given by [259]: 
ܧ ൌ ఛத ൅ ᐦ ൅ ƍ 
where, kƒ is the fluorescence decay ratio and k’ corresponds to the sum of the rates of all 
deexcitation processes. 
 Experimentally, the E can be calculated using either the relative quantum yields (or 
fluorescence intensities) or using the lifetimes of the donor in the presence and absence 
of the acceptor [259]: 
ܧிோா் ൌ ͳ െ
ܨௗ௔
ܨௗ  
or, 
ܧிோா் ൌ ͳ െ
߬ௗ௔
߬ௗ  
where, Fd is the donor fluorescence at a given wavelength in the absence of the acceptor, 
and Fda is the donor fluorescence intensity in the presence of the acceptor. The τd the 
donor lifetime in the absence of the acceptor and τda is the donor lifetime in the presence 
of the acceptor. 
The Förster theory shows that efficiency of the FRET varies as the inverse sixth 
power of the distance between the two molecules (r) through the following equation [265]: 
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where, R0 is the distance where the FRET is 50 %. The Ro is also referred to as the 
Förster radius. 
 The R0 is given by: 
 
ܴ଴ ൌ ቆ
ͻͲͲͲሺ݈݋݃ͳͲሻ݇ଶÞܬ
ͳʹͺߨହܰ݊ସ ቇ ൫݅݊%൯ 
 
Considering that N is the number of Avogadro, 
 
ܴ଴ ൌ ܿ݋݊ݏݐ ቆ
݇ଶÞܬ
݊ସ ቇ ൫݅݊%൯ 
 
where, ț2 is the orientation factor, ø the quantum yield of the donor in the absence of any 
transference, n the average refractive index of the medium in the wavelength range and J 
the it the spectral overlap integral which reflects the degree of overlap of the donor 
emission spectrum being given by [265]: 
 
ܬ ൌ ׬ ܨఒ
஽ሺߣሻߝ஺ሺߣሻߣସ݀ߣఒ
׬ ܨఒ஽ሺߣሻఒ
ሺ݅݊ܯିଵܿ݉ିଷሻ 
 
where, ܨఒ஽ is the normalized fluorescence intensity of the donor so [266], 
 
නܨఒ஽ሺߣሻ݀ߣ
ఒ
ൌ ͳ 
 
and ߝ஺ሺߣሻ is the molar extinction coefficient at a given Ȝ of the acceptor being expressed in 
M-1cm-1.  
 The R0 can be determined considering that ț2 is 2/3, the refractive index of the 
medium is n = 1.333 and the quantum yield of HSA ø = 0.118 [267]. Moreover, the 
determination of the R0 will then allow the calculation of the distance between the acceptor 
and the donor, r.  
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2.3.3.1.3 In silico PPB determination 
 
 Besides the different alternatives available for the experimental determination of 
PPB, several computational models have been developed for the in silico prediction of the 
PPB [112, 227, 268, 269]. The computational models can be divided in two groups 
depending on their ability to predict the whole bonding of a compound to plasmatic 
proteins or to a specific plasmatic protein such as human serum albumin [268, 270, 271]. 
Many computational models have been published using in-house and/or published data 
for the prediction of PPB [272, 273], and also several computational programs are 
available commercially using different descriptors and algorithms [112, 268, 269].  
 
  
 
 
  
ŚĂƉƚĞƌϮ
/ŶƚƌŽĚƵĐƚŝŽŶ
ϱϳ

2.3.4 Qualitative ADME-Tox profiling based on structural 
and physicochemical properties  
 
 
 
The profiling of the drug-likeness of a compound can be accomplished at different 
levels and one of the first approaches commonly followed in an initial stage of a drug 
discovery program is to evaluate structural and physicochemical properties since they 
ultimately influence the pharmacokinetic and toxicological behavior that a compound 
exhibit [112]. Indeed, the evaluation of structural and physicochemical properties intends 
to be a fast and cheap way of predicting the general drug-likeness of a compound and 
also to help shed light on any stringent ADME-Tox liabilities a compound might show, 
without the need to evaluate deeply all the pharmacokinetic and toxicological parameters 
[274]. Considering that all the orally administered drugs commercially available show 
some similar structural and physicochemical features that allow them to be orally 
available, Christopher Lipinski and collaborators proposed what is currently known as the 
“rule of five”, which allows a quick way of predicting the oral bioavailability of a compound 
[275]. The compliance of all the rules is not a guarantee that the compound is drug-like, 
but the failure of any of the rules decreases significantly the probability of being orally 
available [276, 277]. The “rule of five” states that in order to a compound to be orally 
available it should have [275, 276]:  
 
 
• Molecular Weight (MW)  500; 
• Log P  5; 
• H-bond Donors (HBD)  5; 
• H-bond acceptors (HBA)  10. 
 
 
These simple rules encode physicochemical properties concerning hydrogen 
bonding, size (molecular weight) and hydrophobicity (Log P) and relates them to the oral 
bioavailability [274]. Besides Lipinski, several groups have also evaluated different drug 
databases in the search of structural and physicochemical properties that allow the 
separation between drugs and non-drugs. In fact, a similar relation with the Lipinski “rule 
of five” was found by various groups [277-280] and some included extra descriptors such 
as functional groups [281], topological and flexibility descriptors (rotatable bonds [282] and 
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ring-count [283]), as well as other size (number of atoms [278], molecular refractivity 
[278], molecular volume [252]) and hydrogen bonding descriptors (polar surface area 
[282]) (see Table 2.7). In addition to these simple structural descriptors, more complex 
algorithms for the classification of the drug-likeness using atom types [284, 285], 
topological indices [286], fingerprints [287] and quantum chemical variables have also 
been described. The classification of the drug-likeness can be made in an all or nothing 
approach, such as the Lipinski “rule of five”, or in an index way derived from statistical 
distribution [288, 289]. Moreover, the algorithms can evaluate the cut-off limits at the same 
level, or use step-by-step decision tree algorithms [252]. In addition, other more complex 
algorithms such as neural network [285, 286, 288] and support vector machine [290, 291] 
have also been developed for the classification between drugs and non-drugs [274].  
 
Table 2.7 Overview of the guidelines for the prediction of general drug-likeness for oral 
bioavailability (Adapted from [274]). 
Descriptor Hutter Oprea Ghose Xu Veber Muegge 
MW > 230 - 160-480 - - - 
HBD > 0  2 -  5  12 - 
HBA > 0 2-9 -  10 - 
Log P - - -0.4 - 5.6 - - - 
Rotatable bonds 
(RB) > 0 2-8 - 3-35  10 - 
Number of rings > 0 1-4 - 1-7 - - 
Molecular 
refractivity 
> 40 - 40-130 - - - 
Number of 
atoms 
- - 20-70 10-50a - - 
Polar surface 
Area (PSA) - - - - < 140 Å
2
 - 
Functional 
groups 
> 0 - - - - 2-7 
Molecular 
Volume 
> 191 Å3 - - - - - 
Hutter index > 0 - - - - - 
aCount of non-hydrogen atoms only. 
  
 The guidelines most commonly used for a fast prediction of the general drug-
likeness are the Lipinski “rule of five” and “Veber rules”. The descriptors of Lipinski “rule of 
five”, with exception of the Log P, can be easily calculated from the structure. The Log P 
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commonly used in the Lipinski “rule of five” is calculated in silico but experimental Log P, if 
available, is a better choice since the computational Log P may vary significantly between 
programs (see previously in chapter 2.2.1.3). The descriptors of the “Veber rule” are also 
easily calculated from the structure and in the case of the polar surface area (PSA), 
different computational methods can be used. The PSA can be simply defined as part of 
the molecular surface that is polar, encoding optimal combination of H-bonding features, 
molecular polarity and solubility [292, 293]. The PSA can be expressed as dynamic PSA 
(dPSA), static PSA and topological PSA (tPSA) which takes in consideration the 
calculation method [293]. The dPSA is calculated using a Monte Carlo conformational 
search with following energy minimization [294]. The determination of the dPSA could be 
time-consuming explaining why is not so commonly used, especially in screening of large 
virtual libraries [293]. The static PSA uses instead only one conformer [295] which allows 
a much faster calculation being very dependable on the programs used for the 
determination of the most stable conformer [293]. In the case of tPSA, instead of using the 
a conformer, it uses different fragments of calculated 3D PSA allowing a fast 
determination of the PSA [296]. In fact, the tPSA have proved to have an excellent 
correlation with the dynamic PSA [296] and there are several web-based programs that 
allow a fast and accurate determination of this descriptor [292]. 
The evaluation of the rat bioavailability and Caco-2 assay of an in-house Abbot 
chemical library and comparison with different descriptors present in the “rule of five” and 
“Veber rules” allowed the development of A Bioavailability Score (ABS) that takes in 
consideration the ionization state [297]. The ABS gives a numerical score representing the 
probability that a compound has of experience a bioavailability in rat higher than 10 %, 
using different structural property combinations (Table 2.8).  
 
Table 2.8 A Bioavailability Score (ABS) represents the probability of a bioavailability 
higher than 10 % in rat using different molecular property combinations. 
ABS Charge at pH = 6.0 Other Property 
0.85 -1 PSA  75 Å2 
0.56 -1 or -2 75 < PSA < 150 Å2 
0.55 Not negative Pass rule of five 
0.17 Not negative Fail rule of five 
0.11 -1 or -2 PSA ≥ 150 Å2 
 
The rapid profiling of the drug-likeness using the “rule of five” or other general rules 
correspond only to the minimum criteria a compound must possess to be drug-like and not 
only there are some drugs that do not pass these criteria (e.g. natural products) but also it 
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is very easy for a compound to pass these general rules having no potential to become a 
drug [298]. Nevertheless, these rules are extremely useful, especially for virtual screening, 
high throughput screening and to help in the designing of combinatorial libraries with 
higher drug-like character [106, 299, 300]. 
 
 
The development of general rules for a rough prediction of the drug-likeness are 
created by finding common structural features found in drugs that are not present in other 
compounds. The classification is only expressed in qualitative terms and no information 
relating to the different ADME-Tox parameters is given. Along with these general rules 
that help to predict the overall drug-likeness, stricter and specific rules concerning only 
some of the bio-physicochemical parameters can also be found in the literature [135, 147, 
227, 241, 274, 298]. 
 
 
The evaluation of large databases in the search of trends correlating 
physicochemical properties and specific pharmacokinetic parameters led to some 
interesting results. A set of 30000 preclinical compounds profiled at GlaxoSmithKline 
correlating 12 physicochemical properties with 15 ADME-Tox assays were evaluated 
using principal component analysis [135]. The database evaluation led to the observation 
of some trends among several ADME-Tox parameters being Log P, MW and ionization 
state the physicochemical properties most useful for the prediction of potential ADME-Tox 
problems [135]. Based on molecular weight, Log P and ionization state it is possible to 
qualitatively predict ADME-Tox issues that might be experienced without the need to use 
complex computer simulations (Table 2.9). The examination of the table also allows 
taking prudent decisions regarding possible ADME-Tox problems that might arise with an 
increase in the lipophilicity, MW or introduction/removal of ionizable groups, which take 
place during the drug discovery. Moreover, the tables can also be used to assist in the 
guidance of a property-based drug design with the objective of overcoming any liabilities 
encountered for one or more ADME-Tox parameters [135, 147]. 
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Table 2.9 Relation between MW, cLog P and ionization state with different ADME-Tox 
parameters [135]. 
Neutral Molecules MW < 400 and cLog P < 4 MW > 400 and/or cLog > 4 
Solubility Average Lower 
Permeability Higher Average/Higher 
Bioavailability Average Lower 
Volume of distribution Average Average 
Plasma Protein Binding Average Higher 
CNS penetration Higher/Average Average/Lower 
Brain Tissue Binding Lower Higher 
P-gp Efflux Average Higher/Average 
In-vivo clearance Average Average 
hERG inhibition Lower Lower 
P450 inhibition 
Lower 2C9, 2C19, 2D6 and 
3A4 inhibition 
Higher 2C9, 2C19, and 3A4 
inhibition 
Higher 1A2 inhibition 
Lower 1A2 inhibition 
Average 2D6 inhibition 
 
Basic Molecules MW < 400 and cLog P < 4 MW > 400 and/or cLog > 4 
Solubility Higher/Average Lower 
Permeability Higher/Average Average 
Bioavailability Average Lower 
Volume of distribution Higher/Average Higher 
Plasma Protein Binding Lower Average 
CNS penetration Higher/Average Average/Lower 
Brain Tissue Binding Lower Higher 
P-gp Efflux Average Higher/Average 
In-vivo clearance Average Higher/Average 
hERG inhibition Average/Higher Higher 
P450 inhibition 
Lower 1A2, 2C9 and 2C9 
inhibition 
Average 2C9 and 2C19 
inhibition 
Average 2D6 and 3A4 
inhibition 
Lower 1A2 inhibition 
Higher 2D6 and 3A4 
inhibition 
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Acidic Molecules MW < 400 and cLog P < 4 MW > 400 and/or cLog > 4 
Solubility Higher Average/Higher 
Permeability Lower Average/Lower 
Bioavailability Average Average 
Volume of distribution Lower Lower 
Plasma Protein Binding Average/Higher Higher 
CNS penetration Lower Lower 
Brain Tissue Binding Lower Higher 
P-gp Efflux Lower Lower 
In-vivo clearance Average/Lower Average 
hERG inhibition Lower Lower 
P450 inhibition 
Lower 1A2, 2C9, 2C19, 2D6 
and 3A4 inhibition 
Lower 1A2, 2C19, 2D6 and 
3A4 inhibition 
Higher 2C9 inhibition 
 
Zwitterionic Molecules MW < 400 and cLog P < 4 MW > 400 and/or cLog > 4 
Solubility Higher Average/Higher 
Permeability Lower Lower/Average 
Bioavailability Lower Lower 
Volume of distribution Lower Average/Lower 
Plasma Protein Binding Average/Lower Higher 
CNS penetration Average/Lower Lower 
Brain Tissue Binding Lower Higher 
P-gp Efflux Average Average 
In-vivo clearance Average Average 
hERG inhibition Lower Average/Lower 
P450 inhibition 
Lower 1A2, 2C9, 2C19, 2D6 
and 3A4 inhibition 
Lower 1A2, 2C19 and 3A4 
inhibition 
Average 2C9 and 2D6 
inhibition 
 
Detrimental Impact 
 Modest Impact 
 Beneficial Impact 
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In another study, the relation between toxicity in animals and physicochemical 
properties was evaluated for a collection of Pfizer 245 pre-clinical candidates [143]. 
Among the physicochemical properties evaluated, the descriptors that were found to be 
more related with toxicity were tPSA and cLogP. The thresholds were 75 Å2 for the PSA 
and 3 for the cLog P. It was observed that for tPSA values lower than 75 Å2 and cLog P 
higher than 3, there is a six-fold increase in the probability of displaying in vivo toxicity 
when compared to compounds with a tPSA higher than 75 Å2 and cLog P lower than 3 
[143]. 
The relationship between permeability and physicochemical properties has been 
evaluated using an in-house chemical library of 9751 compounds of Astra-Zeneca [301]. 
The permeability was determined by the Caco-2 assay and the physicochemical 
parameters evaluated were Log D, cLog P, PSA, HBD, HBA, RB count and MW. It was 
observed a relation between poor permeability in Caco-2 cells and all the different 
physicochemical parameters evaluated with exception of the cLog P. However, the most 
discriminating properties were MW and the Log D allowing the establishment of a relation 
between high permeability and these two physicochemical properties (Table 2.10) [301].  
 
Table 2.10 Estimated of the lower limits of AZLog D required for a 50 % chance of having 
a good permeability in Caco-2 assay for a specific MW range. 
Molecular Weight AZLog D 
< 300 > 0.5 
300-350 > 1.1 
350-400 > 1.7 
400-450 > 3.1 
450-500 > 3.4 
> 500 > 4.5 
 
The analysis of a large database of 47018 compounds from Pfizer with the aim of 
searching for a relationship between Caco-2 permeability and in vitro clearance derived 
from human liver microsome assay with physicochemical properties [140]. The plotting of 
the compounds with good Caco-2 permeability and in vitro clearance using Log D and 
MW as variables, led to the observation of a triangular area, called Golden Triangle 
(Figure 2.18), where the potential to find a compound with good permeability and 
clearance was higher [140]. The Golden Triangle was defined by a base set at a 
molecular weight of 200 and a Log D range between -2 and 5, and the apex occurring at a 
molecular weight of 450 and Log D between 1 and 2 (Figure 2.18). From the analysis of 
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the Golden Triangle, it can be observed that as MW increases, the range of Log D that the 
compound should have decreases. 
 
 
Figure 2.18 Golden Triangle referring to the area where a good permeability and 
clearance have a better chance of being observed. 
 
 
Additional molecular descriptors related to aromaticity and molecular topology to 
complement the well establish Log P, Log D, MW, PSA, RBs, HBD, HBA and ionization 
state have been receiving an increasing attention [139, 147, 302]. Among the different 
descriptors, the aromatic ring count [137, 248-250], the fraction of sp3-hybridized carbon 
atoms (Fsp3) [139], aromatic atom count – sp3-hybridized carbon atoms [145, 251], chiral 
atom count [251] and fraction of the molecular framework (ƒMF) [139, 303] have been 
related to ADME-Tox parameters. 
A group of scientists from GlaxoSmithKline examined the influence that carbo- and 
hetero- aromatic rings as well as carboaliphatic and heteroaliphatic rings have on a 
compound developability [250]. The results from the study are summarized in Table 2.11 
and it can be observed that the carboaromatic rings have a detrimental effect in almost all 
the parameters evaluated with the exception of the CyP 450 1A2 inhibition. The 
heteroaromatic rings show a less detrimental effect than the carboaromatic, and in fact, 
they increase the solubility and decrease the lipophilicity. In the case of aliphatic rings, it 
was observed that the carboaliphatic rings have little influence and the heteroaliphatic 
rings with the exception of the hERG inhibition, have a beneficial effect in all the other 
parameters.  
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Table 2.11 Comparison of the effects that increasing ring count has on a compound 
developability considering the type of ringsa.  
 
Carbo-
Aromatics 
Hetero-
Aromatics 
Carbo-
Aliphatics 
Hetero-
Aliphatics 
CLNDSolubility -0.37 -0.10 -0.01 0.16 
CHILog D7.4 0.36 -0.17 0.06 -0.05 
HSA Binding 0.39 0.08 0.00 -0.29 
AGP Binding 0.43 0.04 -0.02 0.03 
CyP 3A4 inhibition 0.13 0.08 -0.02 0.08 
CyP 2C9 inhibition 0.26 0.12 0.01 -0.13 
CyP 2C19 inhibition 0.19 0.03 0.01 -0.14 
CyP 2D6 inhibition 0.06 -0.04 0.02 0.00 
CyP 1A2 inhibition -0.07 0.04 -0.03 -0.20 
hERG inhibition 0.18 0.02 -0.01 0.08 
aSpearman’s rank coefficient: ∆ > 0.3 – strong effect; ∆ < 0.3 – modest effect. 
Strong Detrimental Impact 
 Modest Detrimental Impact 
 No significant Impact 
 Modest Beneficial Impact 
 
The relationship between different structural and physicochemical properties with 
ADME-Tox parameters have been evaluated for a large data set of 86115 compounds 
from Astra Zeneca. The parameters evaluated were cLog P, molecular weight, ionized 
state,  Fsp3 and ƒMF which showed to be independent from each other [139]. The 
pharmacokinetic and toxicological properties evaluated were aqueous solubility, Caco-2 
permeability, plasma protein binding, hERG inhibition and CyP450 3A4 inhibition. The 
relationships between MW, cLog P and ionized state and the pharmacokinetic and 
toxicological properties were similar to the reported earlier by the analysis of a 
GlaxoSmithKline dataset (Table 2.4). Moreover, the Fsp3 and the ƒMF proved to be 
important molecular descriptors and were related to some of the properties determined 
experimentally. An increase of Fsp3 is related with an increase in solubility and a decrease 
in Caco-2 permeability and plasma protein binding (Table 2.12). The ƒMF is a descriptor of 
the molecular topology calculated by the ratio between the number of heavy atoms of the 
molecular framework and the total number of heavy atoms. This descriptor has shown to 
be correlated with solubility, Caco-2 permeability, plasma protein binding, hERG inhibition 
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and CyP450 3A4 inhibition. An increase in the ƒMF has been related to an increase in 
plasma protein binding, Caco-2 permeability, hERG inhibition and CyP450 3A4 inhibition, 
and a decrease in solubility (Table 2.5). 
 
Table 2.12 Influence of the Fsp3 and the ƒMF on several ADME-Tox assays [139]. 
 Fsp3 ƒMF 
Aqueous Solubility Fsp3 ↑, Log S ↑ ƒMF ↑, Log S ↓ 
Caco-2 permeability Fsp3 ↑, Log Papp ↓ ƒMF ↑, Log Papp ↑ 
Plasma Protein Binding Fsp3 ↑, fu ↑ ƒMF ↑, Log Papp ↓ 
hERG inhibition No influence ƒMF ↑, IC50 ↓ 
CyP 450 3A4 inhibition No influence ƒMF ↑, IC50 ↓ 
 
The relation of structural and physicochemical properties with ADME-Tox 
parameters is an extremely useful tool to aid in the selection of the compounds that seem 
more promising and also evaluating and orientating chemical modifications according to 
the effect that they will likely to have on pharmacokinetical and toxicological parameters 
[304]. To sum up, all these rules and trends described above are used with the intent of 
increasing the odds of developing candidates with a more drug-like character [147]. 
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CHAPTER 3 
Results and Discussion 
  
As referred and justified before, it was decided to search of more efficient XP13 
analogues focusing not only on the evaluation of the biological activity of analogues of 
XP13 synthesized, namely growth inhibition of tumor cell lines, but also on their 
physicochemical properties. Besides XP13 analogues, the prenylation of 1,2-
dihydroxyxanthone was also made since this strategy has shown to be a viable option 
for the search of new bioactive molecules (Chapter 2). The prenylated compounds 
obtained from this reaction followed the same treatment of XP13 analogues and their 
antitumor activity and physicochemical properties were also evaluated. 
This chapter will be divided in four sections to encompass the different parts of 
this approach: first, the syntheses of all the compounds explaining the underlying 
reasons that led to the choice of a specific synthetic route and the experimental data 
that allowed the structural unequivocal identification of each compound; second, the 
drug-like profiling of all the compounds using different physicochemical properties in 
order to predict their oral bioavailability; third, the evaluation of the growth inhibition of 
all the compounds in four tumor cell lines with the establishment of structure-activity 
relationship; fourth, assemble the data obtained from the three previous sections to 
select the most promising compounds taking in consideration the synthetic route, the 
drug-likeness and potency.  
Syntheses 
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3.1 Syntheses 
 
In this section it will be described the synthetic strategies used for the synthesis 
of XP13 analogues and also the compounds obtained from the prenylation of 1,2-
dihydroxyxanthone.   
 
Figure 3.1 XP13 (12-hydroxy-2,2-dimethyl-3,4-dihydropyrano[3,2-b]xanthen-6(2H)-
one). 
 
XP13 (Figure 3.1) is a xanthone with a fused 2,2-dimethyl-3,4-dihydropyran 
ring which was obtained as the sole product of the reaction between prenyl bromide 
with 3,4-dihydroxyxanthone under microwave heating and clay Montmorillonite K-10 
catalysis [1]. In order to evaluate the different structural features of XP13 responsible 
for the biological activity as well as to search for more potent and efficient compounds, 
the following structural features were considered: 
• presence or absence of either hydroxyl or methoxyl group on ring C 
(Figure 3.2; red); 
• position of the hydroxyl or methoxyl group on ring C; (Figure 3.2; 
green); 
• The presence of a double bond in position 3,4 of ring D (Figure 3.2; 
blue); 
• The orientation of the fused 2,2-dimethyl-3,4-dihydrobenzopyran – ring 
D (Figure 3.2; purple);  
• The presence of substituents on ring A (Figure 3.2; orange). 
The hydroxyl in position 12 of XP13 (Figure 3.1) has the possibility of 
interacting with a putative target by hydrogen bonding, where the oxygen act as 
hydrogen bond acceptor and the hydrogen as a hydrogen bond donor [2].  As a result, 
a change in the relative position of the hydroxyl group (C12 or C5), their removal or the 
introduction of methyl ether will allow taking some considerations regarding the 
influence of this group in the biological activity.  
XP13 has a 2,2-dimethyl-3,4-dihydropyran ring fused to 3,4-dihydroxyxanthone 
making it a linear tetracyclic molecule (Figure 3.1). XP13 is not totally planar and 
therefore, the introduction of a double bond between positions 3 and 4 of the 2,2-
dimethyldihydropyran ring has the possibility of turning the molecule more planar and 
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at the same time change the bonding possibilities with the putative receptor [2]. 
Besides, 2,2-dimethylpyran is a common moiety found in many natural products and 
not only has been considered to be a privileged structure [3-7], but also is frequently 
found in natural prenylated xanthones that have shown biological activity [8, 9]. 
Accordingly, the presence of either 2,2-dimethyl-3,4-dihydropyran or 2,2-dimethylpyran, 
and their orientation in the xanthone relatively to the xanthone will allow taking some 
considerations regarding the importance of the planarity and the geometry to the 
biological activity. 
Lastly, XP13 has no substituents on ring A (Figure 3.1) and consequently, 
there is the opportunity of introducing different functional groups on this ring to increase 
the interactions with the putative target and at the same time modify the 
physicochemical properties. 
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Figure 3.2 Target analogues of XP13 envisioned. 
 
The prenylation of simple mono and di-oxygenated xanthones has been used 
by CEQUIMED-UP with success for the search of new bioactive compounds [1, 10-13] 
and therefore the prenylation of 1,2-dihydroxyxanthone was also made and will be 
described. 
The section of synthesis will be sub-divided in 4 sub-sections according with the 
type of reactions and the target compounds involved 
Syntheses 
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3.1.1 Synthesis of XP13, XBp1, XBp2, XBp3, XP11, XP12, 
XP25 and XP26 
 
 
Figure 3.3 Compounds whose synthesis will be described section 3.1.1. 
 
In Figure 3.3 are represented the compounds whose synthesis will be described in 
this section. This section will be sub-divided according to the type of reaction. Section 
3.1.1.1 will refer the synthesis of XP13, XBp1, XP11 and XP12 which were synthesized 
by the prenylation clay-catalyzed of 3,4-dihydroxyxanthone (1), 3-hydroxy-4-
methoxyxanthone (2) and 1,3-dihydroxyxanthone (3) respectively. Section 3.1.1.2 will 
describe the synthesis of compounds XBp2 and XBP3 which were obtained by the 
cyclization of the appropriate 1’,1’-dimethylpropargyl ethers. Section 3.1.1.3 will describe 
the synthesis of compounds XP25 and XP26 obtained from the condensation of prenal 
with 1,3-dihydroxyxanthone (3). 
 
 
3.1.1.1 Synthesis of XP13, XBp1, XP11 and XP12 
 
Compounds XP11, XP12 and XP13 have already been obtained by our group by 
heating respectively 1,3-dihydroxyxanthone (3) and 3,4-dihydroxyxanthone (1) with prenyl 
bromide under microwave irradiation and clay Montmorillonite K-10 as catalyst [1, 10]. 
Besides the synthesis of XP11, XP12 and XP13 by this route and it was decided to apply 
this strategy for the synthesis of XBp1 (Figure 3.4) Therefore, the first step was the 
synthesis of 3,4-dihydroxyxanthone (1), 3-hydroxy-4-methoxyxanthone (2) and 1,3-
dihydroxyxanthone (3) (Figure 3.4).  
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Figure 3.4 Retrosynthetic plan for the synthesis of XP13, XBp1, XP11 and XP12. 
 
The 3,4-dihydroxyxanthone (1) and 3-hydroxy-4-methoxyxanthone (2) can be 
synthesized from 3,4-dimethoxyxanthone (4) by the removal of both O-methyl groups or 
by the selective O-demethylation of position 3 respectively (Figure 3.4). The synthetic 
route for the synthesis of 3,4-dimethoxyxanthone (4) has already been reported by our 
group [1, 14-16] and proceeds via benzophenone (Appendix I). The first step of this 
synthetic route is a Friedel-Crafts acylation between 2-methoxybenzoyl chloride and 1,2,3-
trimethoxyxanthone catalyzed by aluminum chloride and using the same procedure, 2-
hydroxy-2’,3,4-trimethoxybenzophenone (5) was obtained in 76 % yield (Figure 3.5). The 
next step is a base-catalyzed intramolecular nucleophilic aromatic substitution (SNAr) of 
the benzophenone 5 to give the 3,4-dimethoxyxanthone (4) (Figure 3.5) [1, 15, 17, 18]. 
This step was accomplished heating at reflux and with conventional heating a solution of 
benzophenone 5 in a mixture of methanol and water catalyzed by NaOH for 47 hours [1, 
15]. Since the time of reaction was very long, it was decided to use instead of 
conventional heating, microwaves as a source of heating. The use of microwaves in 
organic synthesis has shown to reduce drastically the reaction times and by-products, and 
increase the yields and selectivity [19-25]. Moreover, it has already been used with 
success for the intramolecular nucleophilic aromatic substitution of benzophenones to 
give xanthones in excellent yields and short reactions time [26-29]. Several temperatures 
and times of reaction were evaluated and the highest yields were obtained when 
benzophenone 5 was heated at 130 ºC in a closed vessel for 1 hour. The use of 
microwaves allowed to decrease significantly the time of reaction from 47 hours to 1 hour 
and obtain the 3,4-dimethoxyxanthone (4) with 77 % yield (Figure 3.5). Compounds 4 and 
5 were obtained as green and white solid respectively and were easily purified by 
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crystallization. The spectroscopic data of compounds 4 and 5 was in accordance with the 
literature [16, 30]. 
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Figure 3.5 Synthesis of 3,4-dimethoxyxanthone (4) via benzophenone. 
 
For the selective O-demethylation of polymethoxylated xanthones a search in the 
literature referred that nucleophilic bases could selective O-demethylate aryl methyl ethers 
in ortho or para position of a strong electron-withdrawing group [31-34]. 
 
Figure 3.6 3,4-Dimethoxyxanthone (4) and the representation of the resonance 
between the oxygen in position 3 and the carbonyl. 
 
In the case of 3,4-dimethoxyxanthone (4), the oxygen in position 3 is para to the 
carbonyl of the xanthone and as a result, the use of a base should be an excellent 
approach for the synthesis of 3-hydroxy-4-methoxyxanthone (Figure 3.6). Among the 
bases, the thiolates are one of the most frequently used, but they have a strong appalling 
smell that is hard to eliminate even after several purification procedures limiting its 
applicability [35]. Fortunately, during the last years, several methodologies were 
developed using odorless thiol reagents, such as 2-(diethylamino)ethanethiol [35], 1-
dodecanethiol [36] and 1-decanethiol [37].  
Other methodology reported in the literature described the selective O-
demethylation of aryl methyl ethers that were in resonance with an electron-withdrawing 
group using LiCl in DMF under microwave heating [38].  
Accordingly, it was decided to use LiCl/DMF and 2-(diethylamino)ethanethiol to the 
selective O-demethylation of 3,4-dimethoxyxanthone.  
In Figure 3.7 are represented the results obtained from the selective O-
demethylation of 3,4-dimethoxyxanthone (4) using the LiCl/DMF/Microwaves (method A) 
and 2-(diethylamino)ethanethiol (method B). The two methods shown to be effective since 
only one methyl ether was removed albeit the yields were moderate. The reaction using 
either the methodologies did not gave only one product since 3-hydroxy-4-
ŚĂƉƚĞƌϯ
ZĞƐƵůƚƐΘŝƐĐƵƐƐŝŽŶ
ϴϵ

methoxyxanthone (2) and 4-hydroxy-3-methoxyxanthone (6) were isolated, although 
method B (Figure 3.7; ratio 2/6 = 2.7) was more regioselective than method A (Figure 
3.7; ratio 2/6 = 1.25).  
The two isomers, 3-hydroxy-4-methoxyxanthone (2) and 4-hydroxy-3-
methoxyxanthone (6), were purified by silica gel flash chromatography and their 
spectroscopic data were in accordance with the literature [14]. 
 
Figure 3.7 Selective O-demethylation of 3,4-dimethoxyxanthone to give 3-hydroxy-4-
methoxyxanthone (2) and 4-hydroxy-3-methoxyxanthone (6). 
 
3,4-Dihydroxyxantone (Figure 3.8, 1) was also synthesized from 3,4-
dimethoxyxanthone (4) using the published procedure using AlCl3 has the O-
demethylating agent. This method led to 3,4-dihydroxyxanthone (1) with 78 % yield 
(Figure 3.8) [39, 40]. The compound 1 was purified by silica gel flash chromatography 
and the spectroscopic data were in accordance with the literature [14]. 
 
 
Figure 3.8 Synthesis of 3,4-dihydroxyxanthone (1) by O-demethylation of 3,4-
dimethoxyxanthone (4). 
 
The last building block that needed to be synthesized was 1,3-dihydroxyxanthone 
(3) which has been obtained by the Grover, Shah and Shah reaction [13, 41-44], Eaton’s 
reagent [45] or polyphosphoric acid [46]. It was decided to use the Eaton’s reagent since it 
is very useful when phloroglucinol is one of the reagents [45]. 1,3-Dihydroxyxanthone was 
obtained in one step by the condensation of salicylic acid with phloroglucinol with 62 % 
yield (Figure 3.9). The compound (3) was purified by silica gel flash chromatography and 
the spectroscopic data were in accordance with the literature [45, 47]. 
^ǇŶƚŚĞƐĞƐ
^ǇŶƚŚĞƐŝƐŽĨyWϭϯ͕yƉϭ͕yƉϮ͕yƉϯ͕yWϭϭ͕yWϭϮ͕yWϮϱĂŶĚyWϮϲ
ϵϬ

 
Figure 3.9 Synthesis of 1,3-dihydroxyxanthone (3) by the condensation of salicylic acid 
and phloroglucinol using the Eaton’s reagent (P2O5/CH3SO3H). 
 
The reaction of 3,4-dihydroxyxanthone (1), 3-hydroxy-4-methoxyxanthone (2) and 
1,3-dihydroxyxanthone (3) with prenyl bromide catalyzed by clay Montmorillonite K-10 and 
under microwave heating using the procedure developed by our group [10] led to the 
desired compounds in one step (Figure 3.10). XP13 was obtained with 21 % yield, XBp1 
with 12 % yield, and XP11 and XP12 with 27 % combined yield (Figure 3.10). The 
purification of these compounds was laborious and extensive chromatographic techniques 
had to be used which might help to explain the low yields attained. The compound XBp1 
was obtained in a lower yield than the others which can be explained by the presence of a 
methoxyl in position 4 of compound 2 which decreases the electron density of the 
aromatic ring and also creates steric hindrance during the formation of the 2,2-dimethyl-
3,4-dihydropyran ring.   
 
 
 
Figure 3.10 Synthesis of XP11, XP12, XP13 and XBp1 by a clay-catalyzed prenylation of 
1,3-dihydroxyxanthone (3), 3,4-dihydroxyxanthone (1) and 3-hydroxy-4-methoxyxanthone 
(2). 
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The structures of XP11, XP12 and XP13 were compared with CEQUIMED-UP 
samples [1, 13]. The structure of compound XBp1 was confirmed by 1H and 13C NMR 
(Table 3.1), IR and HRMS, and all the data are in accordance with the expected. 
Comparing with 3-hydroxy-4-methoxyxanthone (2), the 1H NMR spectrum of compound 
XBp1 showed five aromatic protons (įH 8.32, įH 7.86, įH 7.70, įH 7.57, įH 7.36) instead of 
the six protons in compound 2. The 2,2-dimethyl-3,4-dihydropyran ring was evidenced by 
1H NMR and 13C NMR spectra through the presence of two methylene groups (įH 2.64 td 
and įH 1.90 t; įc 32.3 and įc 22.1), two geminal methyl groups (įH 1.46 s, įc 32.3) and an 
oxygen bearing a quaternary carbon (įc 76.5). The presence of a methoxyl group was 
evidenced by 1H NMR and 13C NMR spectra through the presence of a methyl ether group 
(įH 4.00 s, įc 61.2). The IR spectrum of XBp1 did not shown any large stretching band of 
O-H which was present in XP13 and compound 2 and an increase in the number of C-H 
aliphatic stretching bands in XBp1 (2967 cm-1, 2936 cm-1 and 2829 cm-1) when compared 
with compound 2. The HRMS was in accordance with the molecular formula of compound 
XBp1 ([M+H]+ for C19H19O4). 
 
Table 3.1 1H NMR and 13C NMR for compound XBp1. Main HMBC connectivities 
represented in the structure above. 
1H NMR chemical shifta 13C NMR chemical shiftb 
H-3 1.90 (t, J = 6.8) C-2 76.5 
H-4 2.64 (td, J = 6.7, 0.9) C-3 32.3 
H-5 7.86 (t, J = 0.9) C-4 22.1 
H-7 8.32 (dd, J = 7.9, 1.6) C-4a 119.3 
H-8 7.36 (ddd, J = 7.9, 7.0, 1.1) C-5 121.2 
H-9 7.70 (ddd, J = 8.4, 7.0, 1.6) C-5a 115.2 
H-10 7.57 (dd, J= 8.4, 1.1) C-6 176.6 
H-1’a and H-1’b 1.46 (s) C-6a 121.5 
H-1’’ 4.00 (s) C-7 126.5 
 
 
C-8 123.6 
 
 
C-9 134.2 
 
 
C-10 118.0 
 
 
C-10a 156.2 
 
 
C-11a 149.1 
 
 
C-12 135.7 
 
 
C-12a 153.2 
 
 
C-1’a and C-1’b 27.0 
 
 
C1’’ 61.2 
aValues in ppm (įH) measured at 300.13 MHz J values (Hz) are shown in parentheses. The 1H chemical shifts 
were assigned by HSQC and HMBC. The 1H chemical shifts were measured in CDCl3. bValues in ppm (įC) 
measured at 75.47 MHz; the 13C chemical shifts were assigned by HSQC and HMBC; the 13C chemical shifts 
were measured in CDCl3.  
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3.1.1.2 Synthesis of XBp2 and XBp3 
 
The compounds XBp2 and XBp3 differ from XP13 by the presence of a double 
bond between carbons 3,4 (the fused ring is a 2,2-dimethylpyran instead of a 2,2-
dimethyl-3,4-dihydropyran), and in the case of XBp2, a methoxyl group instead of the 
hydroxyl in position 12 (Figure 3.4).  
 
 
Figure 3.11 Retrosynthetic plan for compounds XBp2 and XBp3. 
 
 The pyran moiety is commonly found fused to aromatic rings (generally referred as 
benzopyran or chromene moieties) and can be obtained by the thermal cyclization of the 
appropriate propargyl aryl ethers [48-54]. This strategy has been used for the synthesis of 
xanthones [55-60], azaxanthones [61] and acridones [62] with a fused 2,2-dimethylpyran 
moiety and it was envisioned that compounds XBp2 and XBp3 could also be obtained by 
this route. According to the retrosynthetic plan, the two compounds could be obtained in 
two steps needing as building blocks 3,4-dihydroxyxanthone (1) and 3-hydroxy-4-
methoxyxanthone (2) (Figure 3.11). The O-dimethylpropargylation step will not pose a 
problem for the synthesis of XBp2 since there is only one free hydroxyl in the 3-hydroxy-
4-methoxyxanthone (2). However, in the case of the synthesis of XBp3, there are two free 
hydroxyls in 3,4-dihydroxyxanthone (1) meaning that more than one product could be 
obtained from the O-dimethylpropargylation. Nevertheless, the hydroxyl in position 3 is in 
resonance with the xanthonic carbonyl meaning that it is more acidic than the hydroxyl in 
4, and considering that the nucleophile in the formation of the 1’,1’-dimethyl propargyl 
ether is the hydroxide (see below), the O-dimethylpropargylation will most likely take place 
at position 3. Moreover, after the formation of the 1,1-dimethylpropargyl ether, the steric 
hindrance caused by the two geminal methyl groups will decrease the likelihood of the 
introduction of another molecule in hydroxyl 4. Indeed, a monosubstitution of 3,4-
dihydroxyxanthone (1) has already been described [11, 15, 63]. 
The first step of this route is the synthesis of 1’,1’-dimethylpropargyl aryl ether 
which can be accomplished using different methodologies [51, 64-66]. The propargyl 
ethers are not only used for the synthesis of benzopyrans, but also in the synthesis of 
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ortho prenylated of phenols [3, 67] and 4-oxo-tricyclo[4.3.1.03.7]decan-8-en-2-one motif 
which is commonly found in many isolated Garcinia xanthones [8, 68-70]. Among all the 
possibilities, two methodologies are more commonly used: 
 
• CuI/KI/K2CO3 with 3-chloro-3-methyl-1-butyne [65, 66]; 
• CuCl2/DBU/acetonitrile with different propargylic reagents [64].  
 
The first methodology was chosen because is usually used for the introduction of 
1’,1’-dimethylpropargyl ethers in xanthones [44, 57, 60, 63, 71-75]. Therefore, applying 
the standard CuI/KI/K2CO3/3-chloro-3-methyl-1-butyne experimental conditions for the 
synthesis of the 1’,1’-dimethylpropargyl aryl ether of 3-hydroxy-4-methoxyxanthone (2) 
and milder conditions for 3,4-dihydroxyxanthone (1), led in the former to the desired 
product (Figure 3.12, compound 7) but not in the latter (Figure 3.12, method A). In the 
case of 3,4-dihydroxyxanthone, the only product obtained was a xanthone with a fused 
dihydro-dioxane moiety (9) resulting from the intramolecular cyclization of the 1’,1’-
dimethyl propargyl ether. This same result has been observed before being explained by 
an intramolecular reaction of the phenol in position 4 with a vinyl organocuprate 
intermediate [73]. The compound 8 was not obtained and it was decided to decrease the 
reactivity by changing the solvent to acetone [76] and the temperature to 40 ºC. After two 
hours most of the starting reagent was consumed and the main product was compound 8 
(Figure 3.12; method B). 
 
 
Figure 3.12 Synthesis of the 1’1-dimethylpropargyl ethers of 3-hydroxy-4-
methoxyxanthone (2) and 3,4-dihydroxyxanthone (1). 
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All the compounds were purified by silica gel flash chromatography and compound 
8 was hard to purify since the experimental procedure led to the decrease of the yield, 
probably due to the intramolecular cyclization to give compound 9. 
The structure of compounds 7 and 8 was confirmed by 1H NMR and IR. The 1,1-
dimethyl propargyl ether moiety could be evidenced in the 1H NMR spectrum by the 
presence of two geminal methyl groups (įH 1.78 s for compound 7 and įH 1.79 for 
compound 8) and an acetylenic proton (įH 2.67 s for compound 7 and įH 2,71 for 
compound 8). Moreover, the ŁC-H (3432 cm-1 for compound 7) and CŁC (2361 cm-1 for 
compound 8) stretching bands could also be observed in the IR spectra. The structure of 
compound 9 was evidenced by 1H NMR through the presence of a terminal vinylic 
methylene (įH 4.97 d and įH 4.67 d with a coupling constant of 2.5 Hz) and two geminal 
methyl groups (įH 1.58). 
The next step towards XBp2 and XBp3 (Figure 3.3) was the thermal cyclization of 
compound 7 and 8, respectively. The proposed mechanism for this reaction involves first 
a Claisen rearrangement to give an allene intermediate, which then enolizes and through 
a [1,5] sigmatropic hydrogen shift will give a diene. Finally, the diene undergoes an 
electrocyclization to benzopyran (Figure 3.13) [77, 78]. In the case of the propargyl aryl 
ethers with alkyl substituents in position 1’ (Figure 3.13; R = alkyl) especially dimethyl 
substituents, the cyclization occurs very smoothly, in high yields and low temperatures, 
due to the gem-dimethyl effect [51, 79]. It was described that the presence of the gem-
dimethyl group increased the rate of cyclization due to steric effects since they shift the 
relative proportion of rotamers in favor of the cyclization [51]. In addition, the two methyl 
groups could stabilize the allene intermediate [80] and favor the s-cis conformation of the 
diene in the electrocyclization step [81].  
 
 
 
 
Figure 3.13 Mechanism for the formation of the benzopyran from the O-1’,1’-
dimethylpropargyl aryl ether. 
 
In spite of the favorable features, the conditions used before for the cyclization of 
xanthone derivatives bearing a 1’,1’-dimethylpropargyl aryl ether [58] led to XBp2 with low 
yields and to compound 9 instead of XBp3 (Figure 3.14). The low yield obtained for 
compound XBp2 could be explained by the deleterious effect caused by the methoxyl in 
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position 4 since it could interfere with the gem-dimethyl effect reducing the relative 
proportion of the conformer favorable for the cyclization, which will lead to a decrease in 
the rate of the reaction. Moreover, if the rate if the reaction is slowed, there is an increase 
of the possibility of polymerization of the terminal alkyne leading to low yields [82]. In the 
case of the thermal cyclization of compound 8 the increase in temperature favored the 
intramolecular cyclization to give compound 9 instead. 
 
 
Figure 3.14 Thermal cyclization of compounds 7 and 8. 
As a result of the poor yields obtained from the cyclization of compound 7 to XBp2 
and compound 8 to XBp3, another approach was tested. During the last decade, several 
methodologies have been developed for the direct C-H functionalization of arenes and 
heteroarenes catalyzed by transition-metals [83-87]. Among the different strategies 
developed, the introduction of an alkenic moiety in aromatic rings through hydroarylation 
of alkynes catalyzed by a transition-metal has been one of the most fruitful areas being 
applied with success to several different substrates [88-93]. The hydroarylation of alkynes 
can be regarded as the formation of a C-C bond from the addition of both the aryl and 
hydrogen moieties of an aromatic compound across a triple bond to give an aromatic 
alkene. As a result, it is also commonly referred as arylation of alkynes or alkenylation of 
arenes [88]. The hydroarylation of alkynes can be catalyzed by several transition metals 
and among them, gold, platinum and palladium are the most commonly reported [88-93]. 
One of the areas where the hydroarylation of alkynes has been particularly useful is on 
the synthesis of benzo-fused heterocycles such as coumarins [94-105], benzopyrans [97, 
98, 105-111], quinolinones [94, 95] and dihydroquinolines [97, 98, 105-107, 109, 112].  
Regarding the benzopyran moiety, this scaffold has been obtained from an 
intramolecular alkyne hydroarylation of the appropriate propargyl aryl ether, catalyzed 
mainly by gold [105, 107-111] or platinum [97, 98, 106, 107, 110, 111] and as a result both 
catalysts were evaluated. In the case of the gold catalyst, it was decided to use a 
phosphine gold(I) bis-(trifluoromethanesulfonyl)imidate complex (Gagoz’s catalyst) [109], 
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since it does not need the use of a co-catalyst, it is air-stable and has shown to be the 
best catalyst in a series of transition-metal catalysts for the cyclization of a propargyl aryl 
ether [110, 111]. Moreover, it has been used for the cyclization of 1,1’-dimethylpropargyl 
aryl ethers to 2,2-dimethylbenzopyrans [108]. Two platinum catalysts have also been 
described for the cyclization of propargyl aryl ethers, namely PtCl2 and PtCl4 [97, 98, 106, 
107, 110, 111]. Among the two catalysts, it was decided to use PtCl4 given that it was 
described to be the best in the alkyne hydroarylation of propargyl ethers [97, 98], possibly 
due to the higher electrophilicity and solubility in organic solvents [98].  
The use of the two catalysts proved to be a better alternative than the thermal 
cyclization of compound 7 and XBp2 was obtained with 30 % for the gold catalyst (Figure 
3.15; method A.) and 57 % with the platinum catalyst (Figure 3.15; method B.). Since the 
platinum showed to be the best of the two catalysts and the temperature of the reaction 
was lower, it was applied for the cyclization of compound 8 leading to compound XBp3 
with 33 % yield as well as compounds 1 and 9 (Figure 3.15). Since compound 9 
alongside with XBp3 was again isolated, there is probably a competition between the 
nucleophilic attack of the aryl moiety and the phenol in position 4 on the 1’,1’-dimethyl 
propargyl ether. 
 
 
Figure 3.15 Transition-metal catalyzed hydroarylation of compounds 7 and 8 to XBp2 and 
XBp3 respectively. 
 
All the compounds were purified by silica gel flash chromatography and the 
structure of compounds XBp2 and XBp3 was confirmed by NMR (Table 3.2), IR and 
HRMS, and all the data are in accordance with the expected results. The 2,2-
dimethylpyran moiety was evidenced by 1H and 13C NMR through the presence of two 
olefinic groups (įH 5.75 d and įH 6.42 d; įc 131.2 and įc 121.6 for XBp2; įH 5.73 d and įH 
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6.47 d; įc 131.0 and įc 121.5 for XBp3), two geminal methyl groups (įH 1.55; įc 28.4 for 
XBp2; įH 1.55; įc 28.5 for XBp3) and an oxygen bearing a quaternary carbon (įc 78.1 for 
XBp2 and įc 76.5 for XBp3). In addition, XBp2 has a methoxyl group (įH 4.03; įc 61.5) 
and XBp3 a broad hydroxyl signal (įH 5.67) corresponding to the hydroxyl in position 12. 
Moreover, the IR showed the presence of a stretching band of O-H for compound XBp3 
(3247 cm-1) and the absence of this band for XBp2. The HRMS was in accordance with 
the molecular formula of compounds XBp2 ([M+H]+ C19H17O4) and XBp3 ([M+H]+ 
C18H15O4). 
 
Table 3.2 1H NMR and 13C NMR for compound XBp2 and XBp3. Main connectivities from 
HMBC for compound XBp2 in structure above. 
1H NMR chemical shifta 13C NMR chemical shiftb 
 XBp2c XBp3d  XBp2e XBp3f 
H-3 5.75 (d, J = 10.0) 5.73 (d, J = 10.0) C-2 78.1 78.7 
H-4 6.46 (d, J = 10.0) 6.47 (d, J = 10.0) C-3 131.2 131.0 
H-5 7.74 (s) 7.59 (s) C-4 121.6 121.5 
H-7 8.32 (dd, J = 8.0, 1.7) 8.32 (dd, J = 8.0, 1.7) C-4a 119.0 117.8 
H-8 7.37 (ddd, J = 8.0, 7.0, 0.9) 7.37 (ddd, J = 8.0, 7.1, 1.1) C-5 118.2 114.4 
H-9 7.71 (ddd, J = 8.5, 7.0, 1.7) 7.70 (ddd, J = 8.5, 7.1, 1.7) C-5a 116.1 116.1 
H-10 7.57 (dd, J= 8.5, 0.9) 7.56 (dd, J= 8.5, 1.1) C-6 176.3 176.4 
H-12 - 5.67 [broad, OH] C-6a 121.6 121.6 
H-1’a and 
H-1’b 1.55 (s) 1.55 (s) C-7 126.6 126.7 
H-1’’ 4.03 (s) - C-8 124.0 124.0 
 
 
 C-9 134.3 134.4 
 
  C-10 118.1 117.9 
 
  C-10a 156.0 155.9 
 
  C-11a 135.7 144.5 
 
  C-12 134.8 132.2 
 
  C-12a 151.5 145.5 
 
  C-1’a and C-1’b 28.4 28.5 
 
  C1’’ 61.5 - 
aValues in ppm (įH) measured at 300.13 MHz J values (Hz) are shown in parentheses, the 1H chemical shifts 
were measured in CDCl3. bValues in ppm (įC) measured at 75.47 MHz; the 13C chemical shifts were measured 
in CDCl3. cThe 1H chemical shifts were assigned by HSQC and HMBC.dThe 1H chemical shifts were assigned 
by comparison with the assignments established for XP13, XBp1 and XBp2. eThe 13C chemical shifts were 
assigned by HSQC and HMBC. dThe 13C chemical shifts were assigned by comparison with the assignments 
established for XP13, XBp1 and XBp2.
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3.1.1.3 Synthesis of XP25 and XP26 
 
 
The synthesis of compounds XP25 and XP26 have already been described by our 
group and was accomplished by the oxidation with DDQ of XP11 and XP12 respectively in 
moderate yields [12]. Since the yields obtained previously for the synthesis of XP11 and 
XP12 were low, it was decided to follow another route instead.  
Condensation of 1,3,7-trihydroxyxanthone with prenal can give regioselectively 
either osajaxanthone or nigrolineaxanthone (two xanthones with a fused 2,2-dimethypyran 
ring, one linear and other angular) depending on the experimental conditions used [113]. 
The heating of prenal and 1,3,7-trihydroxyxanthone led to nigrolineaxanthone and mixing 
the 1,3,7-trihydroxyxanthone in methanol catalyzed by Ca(OH)2 led to osajaxanthone. So, 
the use of 1,3-dihydroxyxanthone (3) instead of 1,3,7-trihydroxanthone could also give 
XP25 and XP26 regioselectively. Using the same experimental conditions that led to 
osajaxanthone or nigrolineaxanthone for the condensation of prenal with 1,3-
dihydroxyxanthone (2), compounds XP25 and XP26 were obtained in moderate yields but 
without regioselectivity (Figure 3.16). Nevertheless, this route can be an alternative for 
the synthesis of analogues XP25 and XP26.  
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Figure 3.16 Synthesis of XP25 and XP26 by the condensation of 1,3-dihydroxyxanthone 
(3) with prenal. 
 
 Compounds XP25 and XP26 were purified by silica gel flash chromatography and 
their structure was confirmed by comparing the IR and 1H NMR with authentic samples 
furnished from CEQUIMED-UP. 
 
 
 
Chapter 3 
Results & Discussion 
99 
 
3.1.2 Synthesis of compound 10 and XBp4 to XBp16 
 
 
Figure 3.17 Compounds whose synthesis will be described section 3.1.2. 
 
This section comprises compounds that differ at least from XP13 by the orientation 
of the fused ring and their structures can be seen in Figure 3.17. The compounds will be 
divided according to the synthetic route used.  
In section 3.1.2.1 will be described the synthesis of compounds XBp4, XBp5 and 
XBp6 which were obtained through the diaryl ether route (Appendix I). The synthesis of 
2,4-dimethoxyxanthone (10) will also be referred since it was used as a model for the 
development of the synthetic route used later for the synthesis of XBp4, XBp5 and XBp6.  
In section 3.1.2.2 will be described the synthesis of compounds XBp7, XBp8, 
XBp11, XBp12, XBp13 and XBp14 which were obtained through the benzophenone 
route (Appendix I). 
 Lastly, the synthesis of XBp9, XBp10, XBp15 and XBp16 will be described in 
section 3.1.2.3  
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3.1.2.1 Synthesis of XBp4, XBp5, XBp6 and 2,4-
dimethoxyxanthone (10) 
 
The compounds XBp4, XBp5 and XBp6 (Figure 3.17) differ from XP13, XBp1 and 
XBp2 by the orientation of the fused 2,2-dimethylpyran or 2,2-dimethyl-3,4-dihydropyran 
ring. In order to develop a route for the synthesis of these compounds, 2,4-
dimethoxyxanthone (10), which has a similar oxygenated pattern of substitution, was used 
as a template. The route developed for the synthesis of 2,4-dimethoxyxanthone (10) will 
then be applied for the synthesis of compounds XBp4, XBp5 and XBp6. 
 
3.1.2.1.1 Synthesis of 2,4-dimethoxyxanthone (10) 
 
 
Figure 3.18 Retrosynthetic plan for the synthesis of 2,4-dimethoxyxanthone (10). 
 
 One of the most commonly used routes for the synthesis of xanthones (Appendix I) 
is via diaryl ether through an Ullmann ether coupling [114-118] to form a C-O bond. 
According to the retrosynthetic plan (Figure 3.18), 2,4-dimethoxyxanthone (10) could be 
obtained via diaryl ether route by the coupling of 2,4-dimethoxyphenol and an o-
halobenzoic acid derivative. After the formation of the diaryl ether intermediate, the 
cyclization to xanthone could be easily accomplished through an intramolecular acylation 
(Figure 3.18) (Appendix I). 
 
 
Figure 3.19 Synthesis of 2,4-dimethoxyphenol and methyl 2-bromobenzoate which were 
used as building blocks for the synthesis of 2,4-dimethoxyxanthone (10). 
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According to the retrosynthetic plan, in order to synthesize the 2,4-
dimethoxyxanthone (10) it was needed an o-halobenzoic acid derivative and 2,4-
dimethoxyphenol (Figure 3.18). Regarding the o-halobenzoic acid, it was decided to use 
a 2-bromobenzoic acid derivative since the Ullmann ether coupling usually takes place in 
higher yields with iodine and bromine than with chlorine [119]. Since the ester is more 
easy to work with than the acid, the 2-bromobenzoic acid was esterefied to methyl 2-
bromobenzoate with 92 % yield (Figure 3.19) [120]. Regarding the 2,4-dimethoxyphenol, 
it was synthesized from 2,4-dimethoxybenzaldehyde by a Baeyer-Villiger-type oxidation 
with hydrogen peroxide and an acid catalyst with 94 % yield (Figure 3.19) [121].  
The Ullmann ether coupling applicability in the synthesis of xanthones, under 
standard conditions [115], is significantly restricted due to the harsh experimental 
conditions usually required [119, 122]. However, in the end of the last century new 
methodologies have emerged, particularly those using palladium [123-125] and aryl 
boronic acids [126, 127] as catalysts and substrate respectively which allowed the 
synthesis of diaryl ethers in milder conditions and higher yields. However, these 
methodologies have serious economical limitations since the palladium catalysts are 
significantly more expensive than copper catalysts, and the aryl boronic acids are also 
more expensive then the halo-aryl counterparts. On the other hand, during the last 
decade, several reports described improvements of the cross-coupling reactions 
catalyzed by copper for the formation of not only C-O bonds but also to C-N, C-C and C-S 
bonds in good yields and mild experimental conditions. These improvements were due to 
the use of different copper salts, additives (base and ligands) and microwave heating 
[128-132]. In the case of the Ullmann ether coupling, a work from Ma et al [133] described 
the synthesis of diaryl ether by the use of copper (I) iodide, N,N-dimethylglycine as ligand, 
which is used to increase the solubility of copper salts, and also cesium carbonate as 
base [133]. Consequently, it was decided to use these experimental conditions for the 
synthesis of the diaryl ether.  
 
Figure 3.20 Synthesis of 2,4-dimethoxyxanthone (10) via diaryl ether route. 
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The diaryl ether 11 was obtained from the Ullmann coupling with 10 % yield by the 
condensation of methyl 2-bromobenzoate and 2,4-dimethoxyphenol using the 
experimental developed by Ma et al [133] (Figure 3.20). The low yields obtained could be 
explained by steric hindrance [133]. The next step in our synthetic route was the 
hydrolysis of the ester to the respective acid 12 which was accomplished in 53 % yield by 
treating compound 11 with sodium hydroxide for 108 h (Figure 3.20) [134]. The last step 
was the cyclization of the diaryl ether 12 by an intramolecular acylation acid-catalyzed 
using acyl chloride and concentrated sulfuric acid leading to the 2,4-dimethoxyxanthone 
(10) in 29 % yield (Figure 3.20).  
 All the compounds were purified either by chemical extraction and column 
chromatography.  
 
The structure of methyl 2-bromobenzoate was confirmed by IR since its spectrum 
is available on commercial suppliers such as Sigma-Aldrich. The structure of 2,4-
dimethoxyphenol was confirmed by 1H NMR and IR. The structure of 2,4-dimethoxyphenol 
was evidenced by 1H NMR spectrum through the presence of 3 aromatic protons (įH 6.75 
d, įH 6.42 d and įH 6.31 dd) and 2 methyl signals (įH 3.79 s and įH 3.68 s) corresponding 
to the methoxyl groups. The presence of the hydroxyl of 2,4-dimethoxyphenol could be 
evidenced in the IR spectrum by a broad band at 3443 cm-1 corresponding to the O-H 
stretching. 
 The structure of the diaryl ether 11 was confirmed by 1H NMR and was evidenced 
through the presence of 7 aromatic protons (įH 7.86 dd, įH 7.34 ddd, įH 7.04 ddd, įH 6.92 
d, įH 6.72 dd, įH 6.57 d and įH 6.43 dd) and 3 methyl signals (įH 3.88 s, įH 3.81 s and įH 
3.78 s) corresponding to the two methoxyl groups and the ester. The structure of diaryl 
ether 12 could be evidenced through the comparison of its 1H NMR spectrum with the 
spectrum of compound 11. In this case, there was the presence of only 2 methyl signals 
(įH 3.85 s and įH 3.75 s) corresponding to the two methoxyl groups. In the IR spectrum, 
the OH from the carboxylic acid could be evidenced by the presence of a broad band at 
3418 cm-1 of the O-H stretching. 
 
2,4-Dimethoxyxanthone (10) structure was confirmed by NMR (Table 3.3), IR and 
HRMS and all the data is in accordance with the expected. The structure of 2,4-
dimethoxyxanthone was evidenced by 1H and 13C NMR spectra by the presence of 6 
aromatic protons (įH 8.34 dd, įH 7.72 ddd, įH 7.61 dd, įH 7.39 ddd, įH 7.25 d and įH 6.85 
ŚĂƉƚĞƌϯ
ZĞƐƵůƚƐΘŝƐĐƵƐƐŝŽŶ
ϭϬϯ

d) and two methoxyl groups (įH 4.01 s and įH 3.92 s). The HRMS was in accordance with 
molecular formula of 2,4-dimethoxyxanthone (10) ([M+H]+ C15H13O4). 
 
Table 3.3 1H NMR and 13C NMR for 2,4-dimethoxyxanthone (10). Main connectivities of 
the HMBC represented on the structure above. 
1H NMR chemical shifta 13C NMR chemical shiftb 
H-1 7.25 (d, J = 2.8) C-1 96.2 
H-3 6.85 (d, J = 2.8) C-2 155.8 
H-5 7.61 (dd, J= 8.5, 1.0) C-3 106.3 
H-6 7.72 (ddd, J = 8.5, 7.0, 1.7) C-4 149.6 
H-7 7.39 (ddd, J = 8.0, 7.0, 1.0) C-4a 142.0 
H-8 8.34 (dd, J = 8.0, 1.7) C-4b 155.8 
H-1’ 3.92 (s) C-5 118.2 
H-1’’ 4.01 (s) C-6 134.5 
 
 C-7 123.9 
 
 C-8 126.6 
 
 C-8a 121.2 
 
 C-9 176.9 
 
 C-1’ 55.9 
 
 C-1’’ 56.4 
aValues in ppm (įH) measured at 300.13 MHz J values (Hz) are shown in parentheses. The 1H chemical shifts 
were assigned by HSQC and HMBC. The 1H chemical shifts were measured in CDCl3. bValues in ppm (įC) 
measured at 75.47 MHz; the 13C chemical shifts were assigned by HSQC and HMBC; the 13C chemical shifts 
were measured in CDCl3.
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3.1.2.1.2 Synthesis of XBp4, XBp5 and XBp6 
 
 
 
Figure 3.21 Retrosynthetic plan for the synthesis of XBp4. 
 
The retrosynthetic plan established for the synthesis of 2,4-dimethoxyxanthone 
(10) was applied for compound XBp4 and is represented in Figure 3.21.  Accordingly, 
compound XBp4 could be synthesized via diaryl ether by the coupling of an o-halobenzoic 
acid derivative and 6-hydroxy-5-methoxy-2,2-dimethyl-2H-benzopyran (13).  
 
 
Figure 3.22 Retrosynthetic plan for the synthesis of compound 13. 
 
According to the retrosynthetic plan represented in Figure 3.22, compound 13 
could be obtained in three steps (Figure 3.22) since 2,4-dihydrobenzaldehyde and 2,4-
dihydroxyacetophenone are known to condense regioselectively with prenal to give a 2,2-
dimethylbenzopyran scaffold [135, 136]. After the synthesis of the 2,2-dimethylbenzopyran 
moiety 15 by the condensation of prenal with commercially available 2,4-
dihydroxybenzaldehyde, the O-methylation of this compound followed by a Baeyer-
Villiger-type oxidation could lead to compound 13. 
The synthesis of the 2,2-dimethylbenzopyran moiety from the condensation of 
prenal with 2,4-dihydroxybenzaldehyde and 2,4-dihydroxyacetophenone has been 
accomplished by several methodologies [113, 135-146].  
 
 
Figure 3.23 Synthesis of compound 13. 
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It was decided to use the second methodology which is catalyzed by calcium 
hydroxide and compound 15 was obtained with 50 % yield after 45 hours (Figure 3.23). 
The next step was the O-methylation of compound 15 which was accomplished with 
dimethyl sulfate leading to compound 14 in quantitative yield (Figure 3.23) [31]. The last 
step towards compound 13 was the oxidation of the benzaldehyde by a Baeyer-Villiger 
type oxidation which was accomplished in 94 % yield (Figure 3.23) [121]. 
All the compounds were purified by silica gel flash chromatography and the 
structure of compound 15 was evidenced by 1H NMR spectrum through the presence of 
the aldehyde proton (įH 9.66 s), a broad OH signal (įH 11.65), 2 aromatic signals (įH 7.29 
d and įH 6.44 d), two olefinic groups (įH 6.88 d and įH 5.61 d) and two geminal methyl 
groups (įH 1.46) referring the last two to the 2,2-dimethylpyran moiety. The structure of 
compound 14 was confirmed by comparison of its 1H NMR spectrum with compound 15 
since there was the presence of a methyl signal (įH 3.90) corresponding to the methoxyl 
group and all the other expected signals and the absence of a signal corresponding to the 
hydroxyl. The IR spectrum of compound 14 did not show also the presence of any broad 
O-H stretching band. The structure of compound 13 was evidenced by comparing its 1H 
NMR spectrum with the previous two which did not show an aldehyde proton, and instead 
a broad OH signal (įH 5.15). In the IR spectrum of compound 13 there was also the 
presence of a broad band at 3422 cm-1 corresponding to the O-H stretching band and also 
the absence of any carbonylic band. 
 
 
Figure 3.24 Synthesis of analogue XBp4. 
 
 The rational used for XBp4 was the same of that used for compound 10 but some 
modifications were introduced in order to increase the overall yield (Figure 3.24). The first 
change was the change of methyl 2-bromobenzoate to methyl 2-iodobenzoate (16), since 
Ma et al reported yields slightly higher with iodo-aryl derivatives [133]. The second change 
was in the hydroxide used for the hydrolysis of the ester to acid, and instead of the NaOH 
it was used LiOH in THF/methanol, a common method for the hydrolysis of esters [147]. 
Lastly, the change in the methodology used for the cyclization of the diaryl ether to 
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xanthone, and instead on acid catalyzed acylation it was decided to use an anionic 
acylation-equivalent using a directed remote metalation strategy [148].  
The methyl 2-iodobenzoate (16) was synthesized through a Fischer esterification 
from 2-iodobenzoic acid with 98 % yield (Figure 3.24). The Ullmann ether coupling 
between methyl 2-iodobenzoate (16) and compound 13 led to the diaryl ether 17 with 26 
% yield (Figure 3.24). The next step was the hydrolysis of the ester to acid with LiOH, 
which was accomplished with 98 % yield (Figure 3.24). In order to be able to cyclize the 
diaryl ether to xanthone by a directed remote metalation, the presence of a N,N-
dimethylamide [148] instead of an acid is advisable since the former is a stronger direct 
metalation group [149].  Therefore, the acid (18) was transformed into the respective N,N-
dimethylamide (19) in quantitative yield using TBTU as the coupling reagent (Figure 
3.24). The last step was the cyclization of the diaryl ether 19 to compound XBp4 which 
was accomplished with 91 % yield (Figure 3.24).   
 
 
 
Figure 3.25 Synthesis of compounds XBp5 and XBp6 from the hydrogenation and O-
demethylation of XBp4, respectively. 
 
 
 Compounds XBp5 and XBp6 were synthesized from XBp4 by hydrogenation of 
the double bond of the 2,2-dimethylpyran moiety and by O-demethylation, respectively. 
The hydrogenation of the double bond of compound XBp4 was accomplished using a 
Pd/C-triethylsilane(TES)/MeOH methodology [150] and compound XBp5 was obtained 
with 98 % yield (Figure 3.25). The O-demethylation of XBp4 was accomplished using 
BBr3 and compound XBp6 was obtained with 84 % yield (Figure 3.25).  
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All the compounds were purified by silica gel flash chromatography and 
crystallization. 
The structure of methyl 2-iodobenzoate (16) was confirmed by IR since its 
spectrum is available on commercial suppliers such as Sigma-Aldrich 
 The structure of the diaryl ether 17 was confirmed by 1H NMR and was evidenced 
through the presence of six aromatic protons (įH 7.87 dd, įH 7.36 ddd, įH 7.05 ddd, įH 
6.78 d, įH 6.75 d, and įH 6.54 d), two methyl signals (įH 3.90 s and įH 3.85 s) 
corresponding to the one methoxyl group and the ester, two olefinic goups (įH 6.63 d and 
įH 5.66 d) and two geminal methyl groups (įH 1.44) referring the last two to the 2,2-
dimethylpyran moiety. The structure of diaryl ether 18 was evidenced by the comparison 
of its 1H NMR spectrum with the spectrum of compound 17. In this case, there was the 
presence of only one methoxyl group (įH 3.74). Lastly, the structure of compound 19 was 
evidenced by the presence of two methylenic (įH 3.50 broad) and two methyl (įH 1.22 t 
and įH 1.11 t) signals corresponding to the N,N-dimethylamide group. 
The compounds XBp4, XBp5 and XBp6 structures were characterized by 1H and 
13C NMR (Table 3.4), IR and HRMS and all the data is in accordance with the expected 
for these molecules. The 2,2-dimethylpyran moiety in compounds XBp4 and XBp6 was 
evidenced by 1H and 13C NMR through the presence of two olefinic goups (įH 5.86 d and 
įH 6.71 d; įc 135.6 and įc 116.4 for XBp4; įH 5.77 d and įH 6.80 d; įc 132.9 and įc 116.3 
for XBp6), two geminal methyl groups (įH 1.40; įc 27.7 for XBp4; įH 1.36; įc 27.2 for 
XBp6) and an oxygen bearing a quaternary carbon (įc 76.2 for XBp4 and įc 75.4 for 
XBp6). The 2,2-dimethyl-3,4-dihydropyran moiety in compound XBp5 was evidenced by 
1H and 13C NMR spectra through the presence of two methylene groups (įH 2.93 t and įH 
1.86 t; įc 31.7 and įc 18.2), two geminal methyl groups (įH 1.36; įc 26.7) and an oxygen 
bearing a quaternary carbon (įc 74.3). In addition, XBp4 and XBp5 had a methyl singlet 
corresponding to the methoxyl group (įH 3.99; įc 62.3 for XBp4 and įH 4.07; įc 61.1 for 
XBp5). The HRMS was in accordance with the molecular formula of compounds XBp4 
([M+H]+ C19H17O4), XBp5 ([M+H]+ C19H19O4) and XBp6 ([M+H]+ C18H15O4). 
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Table 3.4 1H NMR and 13C NMR for compound XBp4, XBp5 and XBp6. Main 
connectivities from HMBC represented above. 
1H NMR chemical shifta 13C NMR chemical shiftb 
 XBp4c XBp5c XBp6d  XBp4e XBp5e XBp6f 
H-3  5.86 (d, J = 10.1) 
1.86 (t, J = 
6.8) 
5.77 (d, J = 
10.0) C-2 76.2 74.3 75.4 
H-4 6.71 (d, J = 10.1) 
2.93 (t, J = 
6.8) 
6.80 (d, J = 
10.0) C-3 135.6 31.7 132.9 
H-7 7.46 (d, J = 8.6) 
7.53 (dd, J 
= 8.4, 1.0) 
7.51 (dd, J = 
8.4, 0.9) C-4 116.4 18.2 116.3 
H-8 
7.64 (ddd, 
J = 8.6, 
7.1, 1.7) 
7.71 (ddd, 
J = 8.4, 
7.1, 1.7) 
7.63 (ddd, J 
= 8.4, 7.1, 
1.7) 
C-4a 121.6 123.6 115.3 
H-9 
7.29 (ddd, 
J = 8.0, 
7.1) 
7.36 (ddd, 
J = 8.0, 
7.1, 1.0) 
7.27 (ddd, J 
= 8.0, 7.1, 
0.9) 
C-5 143.6 146.0 141.1 
H-10 8.24 (dd, J 
= 8.0, 1.7) 
8.32 (dd, J 
= 8.0, 1.7) 
8.17 (dd, J = 
8.0, 1.7) C-5a 144.7 143.4 140.4 
H-12 7.39 (s) 7.49 (s) 7.03 (s)  C-6a 155.7 155.8 155.2 
H-1’a and 
H-1’b 1.40 (s) 1.36 (s) 1.36 (s) C-7 118.0 118.0 117.7 
H-1’’ 3.99 (s) 4.07 (s) - C-8 134.4 134.4 134.0 
 
   
C-9 123.8 123.6 123.2 
 
   
C-10 126.7 126.7 125.8 
 
 
 C-10a 121.3 121.2 120.6 
 
  C-11 176.4 176.8 175.8 
 
  C-11a 122.3 121.7 120.8 
 
  C-12 106.7 107.2 100.7 
 
  C-12a 148.9 150.6 148.6 
 
  C-1’a and C-1’b 27.7 26.7 27.2 
 
  C1’’ 62.3 61.1 - 
aValues in ppm (įH) measured at 300.13 MHz J values (Hz) are shown in parentheses; the 1H chemical shifts 
were assigned by HSQC and HMBC; bValues in ppm (įC) measured at 75.47 MHz; the 13C chemical shifts 
were assigned by HSQC and HMBC. cThe 1H chemical shifts were measured in CDCl3. dThe 1H chemical 
shifts were measured in DMSO-d6
. 
eThe 13C chemical shifts were measured in CDCl3. fThe 13C chemical shifts 
were measured in DMSO-d6. 
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3.1.2.2 Synthesis of XBp7, XBp8, XBp11, XBp12, XBp13 and 
XBp14 
 
Figure 3.26 Compounds that will be referred in this section. 
 
This section comprises compounds that differ from XP13 by the orientation of the 
fused the ring and also by the position of the hydroxyl or methoxyl on the xanthone ring 
(Figure 3.26).  
 Three retrosynthetic plans were envisioned for the synthesis of XBp7 (Figure 
3.27). The first approach leads to the synthesis of compound XBp7 through diaryl ether 
route and the second and third approach through benzophenone route [115-118] 
(Appendix I).  
 
Cy
clo
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S
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Figure 3.27 Retrosynthetic plan for compound XBp7. 
  
The three routes idealized (Figure 3.27) have several aspects that need to be 
taken into account. The first retrosynthetic plan describes the synthesis of xanthones via 
diaryl ether and contrary to the example of the previous section, the cycloacylation for the 
formation of the xanthone could occur at two places, namely positions 5 and 7 (Figure 
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3.28). This liability could be overcome by the use of an intramolecular anionic 
cycloacylation since in the presence of a direct metalation group (such as OCH3) in 
position 8, the cyclization could take place regioselectively to give XBp7 [134, 148] 
(Appendix I).  
 
 
Figure 3.28 Two possibilities for cycloacylation of the diaryl ether obtained from 
benzopyran A. 
 
In the second and third routes, the acylation reaction used for the synthesis of the 
benzophenone needs to take place at position 7 of the benzopyran B and C (Figure 3.27; 
positions highlighted in benzopyran B and C). The acylation can be accomplished 
regioselective in position 7 in the presence of two meta-disposed direct metalating groups, 
such as methoxyl groups, since they direct the formation of a lithiated intermediate in the 
position between them [151-157]. In the case of benzopyran B, there is the possibility of 
forming a lithiated intermediate in position 7, which will then act as a nucleophile and add 
to the appropriate carbonyl group leading in the end to the desired benzophenone 
(Appendix I). However, the cyclization of the benzophenone through an intramolecular 
nucleophilic aromatic substitution (SNAr) might lead to two products instead of only 
compound XBp7 (Figure 3.29) [115-118, 158]. Nevertheless, this can be seen as a 
positive aspect since from the same benzophenone, two xanthones are synthesized, 
being one of them an angular xanthone (XBp11) with a structure similar to acronycine, 
which is an extremely potent antitumor compound [159].  
 
Figure 3.29 Two possibilities for cyclization of the benzophenone obtained from 
benzopyran B. 
 
The lack of regioselectivity from the cyclization of the benzophenone obtained from 
benzopyran B could be overcome if benzopyran C is used instead and the protecting 
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group in position 6 behaves as the methoxyl group and orientates the lithiation to position 
7 (Figure 3.27). The methoxymethyl ether (a common protecting group for phenols [31])  
could be used in this case since it is known to be a good direct metalating group (Figure 
3.27; Pg = MOM) [149, 160-162]. However, there are examples in the literature referring 
the lithiation of 1-methoxy-3-(methoxymethoxy)benzene in both sides of the 
methoxymethyl ether group [162] and as a result the use of benzopyran C with 
methoxymethyl ether can also raise some questions regarding the regioselective 
synthesis of the benzophenone. 
 
 
Figure 3.30 Retrosynthetic plan for benzopyrans A, B and C. 
 
 In Figure 3.30 are represented the retrosynthetic plan for the synthesis of 
benzopyrans A, B and C. Benzopyrans A and C could be synthesized from vanillin and 
benzopyran B from 2,4-dimethoxybenzaldehyde (Figure 3.30). The benzopyran A could 
be obtained in three steps from vanillin by the synthesis of a 1’,1’-dimethylpropargyl aryl 
ether followed by thermal cyclization and a Baeyer-Villiger-type oxidation to give 
benzopyran A. This compound can then be O-protected with methoxymethyl ether to give 
the benzopyran C. The benzopyran B can be synthesized in three steps using the same 
strategy but, in this case, the first step is a Baeyer-Villiger-type oxidation to give 2,4-
dimethoxyphenol which is after O-1’,1’dimethylpropargylated and cyclized to give 
benzopyran B.  
Figure 3.31 Synthesis of 2,2-dimethylbenzopyrans A (24) and B (21). 
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In Figure 3.31 are represented the syntheses of benzopyran A (24) and 
benzopyran B (21). The formation of the 1’,1’-dimethylpropargyl ether with CuI/KI/K2CO3 
led to low yields in the synthesis of compound 20 (Figure 3.31). Consequently it was 
decided to use the methodology DBU/CuCl2 [64]. This methodology proved to be a better 
alternative then the CuI/KI/K2CO3 and compound 20 was obtained in higher yield with 3-
chloro-3-methyl-1-butyne and but-3-yn-2-yl 2,2,2-trifluoroacetate (Figure 3.31) The 
thermal cyclization of compound 20 led to benzopyran B (21) using either microwave or 
conventional heating in good yields (Figure 3.31). The benzopyran A (24) was obtained 
by the DBU/CuCl2 methodology followed by the Baeyer-Villiger-type oxidation but the 
yields were much lower than with benzopyran B (Figure 3.31). Consequently, the amount 
of benzopyran A was too low and benzopyran C was not synthesized. As a result, it was 
decided to use benzopyran B (21) as building block for the synthesis of analogue XBp7 
not only because of the higher yields but also due to the possibility of forming two 
xanthones from the same benzophenone.  
The compounds obtained were mostly purified by silica gel flash chromatography 
and compound 20 structure was confirmed by common spectroscopic methods. The O-
1’,1’-dimethylpropargylation of 2,4-dimethoxyphenol was evidenced by 1H NMR spectrum 
by the presence of two geminal methyl groups (įH 1.61 s) and one acetylenic proton (įH 
2.48 s), and also by the presence of two bands at 3273 cm-1 and 2354 cm-1 of the ŁC-H 
and CŁC stretching bands respectively in the IR spectrum. The formation of the 2,2-
dimethylbenzopyran of compound 21 from the thermal cyclization of compound 20 was 
evidenced by the presence of two olefinic groups (įH 6.27 d and įH 5.64 d), two geminal 
methyl groups (įH 1.46 s) and two aromatic protons (įH 6.40 d and įH 6.18 d with a 
coupling constant of 2.8 Hz). In the IR spectrum of compound 21 there was not the 
presence of any band regarding the alkynic stretching bands. The synthesis of compound 
23 from vanillin was evidenced in the 1H NMR spectrum by the presence of the aldehyde 
proton (įH 9.81 s), two aromatic protons (įH 7.32 d and įH 7.17 d with a coupling constant 
of 1.8 Hz), one methoxyl group (įH 3.93 s), two olefinic groups (įH 6.37 d and įH 5.70 d) 
and two geminal methyl groups (įH 1.53 s) corresponding the last two to the 2,2-
dimethylpyran fused ring. In the IR spectrum, the carbonyl could be evidenced by the 
presence of a strong band at 1649 cm-1 of the C=O stretching. The oxidation of the 
benzaldehyde to a phenol to give compound 24 was evidenced by the absence of any 
aldehyde proton in 1H NMR spectrum and C=O stretching band in the IR and the 
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presence of a broad band of the O-H stretching at 3389 cm-1 and a peak in the EIMS 
corresponding to molecular ion of 206 m/z. 
 
 
Figure 3.32 Protection of the hydroxyl of the methyl salicylate with methoxymethyl ether. 
 
The ortho lithiation to give benzophenone 26 (Figure 3.33) was carried out in THF 
and diethyl ether at 0 ºC with n-BuLi as the lithiating agent [149], and the building blocks 
were compound 21 and an O-protected salicylate ester (Appendix I). The ester used was 
methyl salicylate protected with methoxymethyl ether group since it is resistant to strong 
basic medium but can be easily hydrolyzed by in mild acidic medium [31]. The methyl 
salicylate protected with methoxymethyl was obtained under standard conditions with 82 
% yield [31] (Figure 3.33).  
 
In Figure 3.33 are represented the 2 synthetic steps that led to benzophenone 27. 
The ortho lithiation of benzopyran 21 led only to benzophenone 26 (Figure 3.33) and the 
THF (Figure 3.33; method B) showed to be a better solvent than diethyl ether (Figure 
3.33, method A) leading to a slightly higher yield of benzophenone 26 (Figure 3.33) 
possibly due to the higher reactivity of nBuLi in THF [149]. Albeit the yields were 
moderate, they are in line with what is commonly obtained for the ortho-lithiation reaction 
for this type of ortho metalating groups [149, 160, 161]. The O-deprotection was easily 
accomplished by the use of NbCl5 as Lewis acid to give benzophenone 27 (Figure 3.33) 
[163]. 
 
 
Figure 3.33 Synthesis of benzophenone 27. 
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The compounds were mostly purified by silica gel flash chromatography and the 
protection of the methyl salicylaldehyde with a methoxymethyl ether group was evidenced 
by the presence of methylene (įH 5.26 s) and methyl group (įH 3.52 s) and the absence of 
an O-H stretching band in the IR spectrum.
 
The structure of benzophenone 26 was confirmed by common spectroscopic 
techniques and was evidenced in 1H and 13C NMR spectra by the presence of 5 aromatic 
protons (įH 7.72 dd, įH 7.43 ddd, įH 7.12 d, įH 7.04 dd, įH 6.35 s), one carbonyl group (įc 
193.4), two methoxyl groups (įH 3.71 s, įH 3.66 s; įc 56.4, įc 61.1), one methyl įH (3.35 s, 
įc 56.5) and methylene (5.05 s, įc 94.7) of the methoxymethyl ether group, two olefinic 
groups (įH 5.69 d and įH 6.31 d; įc 132.1 and įc 122.3), two geminal methyl groups (įH 
1.52 s, įc 27.5 įH 1.46 s, įc 27.5) and an oxygen bearing a quaternary carbon (įc 76.1) 
corresponding the last three to the 2,2-dimethylpyran fused ring. The formation of the 
ketone linkage at the carbon 7 of the compound 21 to give benzophenone 26 (Figure 
3.33) could be confirmed by HSQC and HMBC by the correlation between the H-4 and 
carbon 5, and the correlation between H-5 with carbon 4 and 4a (Figure above Table 3.5). 
In the IR spectrum of benzophenone 26 was observed the presence of a strong C=O 
stretching band at 1661cm-1. The HRMS was in accordance with molecular formula of 
benzophenone 26 ([M+Na]+ C22H24NaO6). The O-deprotection of benzophenone 26 to give 
benzophenone 27 was evidenced in the 1H NMR spectrum by the absence of the 
methoxymethyl ether group and the presence of a hydroxyl group (įH 12.09 s), and in the 
IR spectrum by the presence of a broad O-H stretching band at 3415 cm-1. The HRMS 
was also in accordance with the molecular formula of benzophenone 27 ([M+Na]+ 
C20H20NaO5). 
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Table 3.5 1H NMR and 13C NMR for benzophenone 26. Main connectivities of the HMBC 
represented on the structure in the bottom of page 114. 
1H NMR chemical shifta 13C NMR chemical shiftb 
H-3 5.69 (d, J = 9.8) C-2 76.1 
H-4 6.31 (d, J = 9.8) C-3 132.1 
H-5 6.35 (s) C-4 122.3 
H-1’a and H-1’b 1.46 (s) C-4a 123.9 
H-3’’ 7.12 (d, J = 8.5) C-5 104.3 
H-4’’ 7.43 (ddd, J = 8.5, 7.0, 1.8) C-6 145.7 
H-5’’ 7.04 (dd, J = 7.7, 1.0) C-7 125.0 
H-6’’ 7.72 (dd, J = 7.7, 1.8) C-8 150.3 
H-1’’’ 3.71 (s) C-9 193.4 
H-1’’’’ 3.66 (s) C-1’a and C-1’b 27.5 
H-1’’’’’ 5.05 (s) C-1’’ 129.6 
H-2’’’’’ 3.35 (s) C-2’’ 156.2 
 
 C-3’’ 115.8 
 
 C-4’’ 133.6 
 
 C-5’’ 121.6 
 
 C-6’’ 131.5 
 
 C-1’’’ 56.4 
 
 C-1’’’’ 61.1 
 
 C-1’’’’’ 94.7 
 
 C-2’’’’’ 56.0 
aValues in ppm (įH) measured at 300.13 MHz J values (Hz) are shown in parentheses. The 1H chemical shifts 
were assigned by HSQC and HMBC. The 1H chemical shifts were measured in CDCl3. bValues in ppm (įC) 
measured at 75.47 MHz; the 13C chemical shifts were assigned by HSQC and HMBC; the 13C chemical shifts 
were measured in CDCl3.
 The last step in the synthetic pathway towards the xanthone is the cyclization of 
the benzophenone to xanthone through an intramolecular SNAr (Appendix I). The 
cyclization of benzophenone 27 was carried out with Cs2CO3 [164] and XBp11 was 
obtained in a much higher yield than XBp7 using either methanol or DMF as solvent (81 
% for XBp11 vs 8 % for XBp7) (Figure 3.34). 

 
Figure 3.34 Cyclization of the benzophenone 27 to compounds XBp7 and XBp11. 
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The higher ratio of XBp7 in relation with XBp11 could be explained by the 
inductive effect of neighbor oxygen (position 1) on methoxyl 8 which makes the adjacent 
carbon more prone to the nucleophilic attack from the phenoxide (Figure 3.34). Indeed, 
the SNAr has been described to occur in two steps: the first step is the attack of a 
nucleophile on the carbon bearing a leaving-group and the second is the elimination of the 
leaving-group [165]. Generally, the first step is the rate-determining step since the 
aromaticity is disrupted by the addition of the nucleophile, which in this case is the 
phenoxide anion, being mainly influence by the polar and steric effects. Since both leaving 
groups in benzophenone 27 are from the same size, the outcome of this reaction is mainly 
influenced by the polarization of the carbons. Considering that the carbon in position 8 is 
flanked by an oxygen in position 1, the inductive effect caused by this atom turn carbon 8 
more positively polarized, and consequently more prone to be attacked by the phenoxide.  
The analogue XBp7 and XBp11 were hydrogenated by the 
Pd/C/triethylsilane/methanol [150] to give analogues XBp8 and XBp12, respectively, in 
excellent yields (Figure 3.35). Compound XBp13 and XBp14 were synthesized from the 
O-demethylation of analogues XBp11 and XBp12 respectively in moderate to good yields 
(Figure 3.35).  
 
 
Figure 3.35 Synthesis of compounds XBp8, XBp12, XBp13 and XBp14. 
 
The compounds were mostly purified by silica gel flash chromatography and the 
structure of compounds XB7 and XBp11 were confirmed by common spectroscopy 
methodologies. The formation of the two compounds was evidenced by 1H NMR by the 
absence of hydroxyl group and one methoxyl group, the presence of 5 aromatic protons 
(įH 8.28 dd, įH 7.65 ddd, įH 7.38 dd, įH 7.32 ddd, įH 6.91 s for XBp7; įH 8.29 dd, įH 7.66 
ddd, įH 7.53 dd, įH 7.32 ddd, įH 6.38 s for XBp11), two olefinic groups (įH 5.95 d and įH 
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6.45 d; įc 136.5 and įc 121.5 for XBp7; įH 5.89 d and įH 6.38 d; įc 135.2 and įc 121.9 for 
XBp11), two geminal methyl groups (įH 1.52 s, įc 27.7  for XBp7; įH 1.46 s, įc 27.3 for 
XBp11) and an oxygen bearing a quaternary carbon (įc 76.5 for XBp7; įc 76.7 for XBp11) 
corresponding the last three to the 2,2-dimethylpyran fused ring. The IR spectrum of both 
compounds did not show the presence of any O-H stretching band. The HRMS was also 
in accordance with the molecular formula of XBp7 and XBp11 ([M+H]+ C19H17O4). The 
differentiation between the two isomers obtained from the cyclization of the 
benzophenone 27 was established based on 2-D NMR experiments namely, HSQC, 
HMBC and NOESY, and in the case of compound XBp11, its structure was elucidated by 
X-Ray crystallography as well (Figure 3.36). A NOE effect was observed between 
proton 5 and the methoxyl group which allowed the assignment of the structure XBp11 
(Figure 3.36).  
 
Figure 3.36 NOE correlation between proton in position 5 and the protons in the methoxyl 
group bond to carbon 6 of compound XBp11 and its crystallographic structure. 
 
 The structure of XBp8 obtained from the hydrogenation of the double bond of the 
2,2-dimethylpyran moiety of compound XBp7 was evidenced by the presence of two 
methylene groups (įH 1.89 t and įH 2.91 t; įc 32.2 and įc 23.4) in the 1H and 13C NMR 
spectra and molecular formula determined by the HRMS ([M+H]+ C19H19O4). In the case of 
compound XBp12 obtained from the hydrogenation of the double bond the 2,2-
dimethylbenzopyran of compound XBp11, the formation of the 2,2-dimethyl-3,4-
dihydrobenzopyran moiety was evidenced by the presence of two methylene groups (įH 
1.91 t and įH 2.88 t; įc 32.5 and įc 23.5) in the 1H and 13C NMR spectra and the molecular 
formula determined by HRMS ([M+H]+ C19H19O4). The O-demethylation of compounds 
XBp11 and XBp12 was evidenced in the 1H and 13C NMR by the absence of a methoxyl 
group and the presence of hydroxyl proton (įH 12.14 broad for XBp13; įH 12.00 broad for 
XBp14), and also by the presence of broad O-H stretching bands in the IR spectra of both 
compounds (3488 cm-1 for XBp13 and 3500 cm-1 for XBp14). The HRMS was in the 
accordance with the chemical formula of compounds XBp13 and XBp14 ([M+H]+ 
C18H15O4 for XBp13; [M+H]+ C18H17O4 for XBp14). 
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Table 3.6 1H NMR for compounds XBp7, XBp8, XBp11, XBp12, XBp13 and XBp14. 
Main connectivities of the HMBC represented on the structures above. 
 XBp7 Bp8 XBp11 XBp12 XBp13 XBp14 
H-3 5.95 (d, J = 9.8) 
1.89 (t, J = 
6.8) 
5.89 (d, J = 
9.8) 
1.91 (t, J = 
6.9) 
5.86 (d, J = 
9.8) 
1.92 (t, J = 
6.8) 
H-4 6.41 (d, J = 9.8) 
2.91 (t, J = 
6.8) 
6.38 (d, J = 
9.8) 
2.88 (t, J = 
6.9) 
6.31 (d, J = 
9.8) 
2.90 (t, J = 
6.8) 
H-5 6.91 (s) 7.00 (s) 6.47 (s) 6.50 (s) 6.42 (s) 6.56 (s) 
H-6 - - - - 12.14 [OH, s] 12.00 [OH, s] 
H-7 7.38 (dd, J 
= 8.5, 1.0) 
7.37 (dd, J 
= 8.5, 0.8) - - - - 
H-8 
7.65 (ddd, 
J = 8.5, 7.1, 
1.6) 
7.64 (ddd, 
J = 8.5, 7.0, 
1.7) 
8.29 (dd, J = 
8.0, 1.7) 
8.30 (dd, J = 
8.0, 1.7) 
8.19 (dd, J = 
8.0, 1.7) 
8.30 (dd, J = 
8.0, 1.7) 
H-9 
7.32 (ddd, 
J = 8.0, 7.1, 
1.0) 
7.31 (ddd, 
J = 8.0, 7.0, 
0.8) 
7.32 (ddd, J = 
8.0, 7.0, 1.0) 
7.33 (ddd, J = 
8.0, 6.9, 1.1) 
7.31 (ddd, J = 
8.0, 7.0, 1.0) 
7.40 (ddd, J = 
8.0, 7.1, 1.1) 
H-10 8.28 (dd, J 
= 8.0, 1.6) 
8.29 (dd, J 
= 8.0, 1.6) 
7.66 (ddd, J = 
8.5, 7.0, 1.7) 
7.65 (ddd, J = 
8.4, 6.9, 1.7) 
7.67 (ddd, J = 
8.5, 7.0, 1.7) 
7.76 (ddd, J = 
8.4, 7.1, 1.7) 
H-11 - - 7.53 (ddd, J = 8.5, 1.0) 
7.55 (ddd, J = 
8.4, 1.1) 
7.52 (ddd, J = 
8.5, 1.0) 
7.64 (ddd, J = 
8.4, 1.1) 
H-1’a and H-
1’b 1.52 (s) 1.42 (s) 1.46 (s) 1.46 (s) 1.46 (s) 1.46 (s) 
H-1’’ 4.02 (s) 3.99 (s) 3.97 (s) 3.97 (s) - - 
a.Values in ppm (įH) measured in CDCl3, at 300.13 MHz or 500.13 MHz. J values (Hz) are shown in 
parentheses; the 1H chemical shifts were assigned by HSQC and HMBC.  
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Table 3.7 13C NMR for XBp7, XBp8, XBp11, XBp12, XBp13 and XBp14. Main 
connectivities of the HMBC represented on the structure above. 
 XBp7 Bp8 XBp11 XBp12 XBp13 XBp14 
C-2 76.5 74.7 76.7 74.9 76.6 74.8 
C-3 136.5 32.2 135.2 32.5 136.2 32.5 
C-4 121.5 23.4 121.9 23.5 122.2 23.6 
C-4a 128.6 130.6 126.1 127.2 129.0 130.9 
C-5 109.7 112.3 102.6 105.3 106.6 109.0 
C-5a 151.3 149.7 - - - - 
C-6 - - 153.7 152.3 154.7 152.8 
C-6a 155.3 155.3 112.7 112.2 108.9 108.3 
C-7 117.2 117.2 176.4 176.7 181.9 182.1 
C-7a - - 122.9 122.9 120.6 120.6 
C-8 134.0 134.0 126.7 126.6 125.9 125.8 
C-9 123.5 123.3 123.8 123.1 124.0 124.0 
C-10 126.7 126.7 133.9 133.1 135.3 135.1 
C-10a 128.3 122.3 - - - - 
C-11 176.1 176.4 117.7 117.8 118.3 118.5 
C-11a 116.0 116.0 155.0 155.0 156.2 156.5 
C-12 147.1 147.6 - - - - 
C-12a 141.9 130.6 146.8 147.5 144.4 146.5 
C-12b - - 134.6 136.7 132.3 134.6 
C-1’a and C-1’b 27.7 26.8 27.3 26.4 27.4 26.6 
C1’’ 61.4 61.1 56.5 56.5 - - 
a.Values in ppm (įC) measured in CDCl3, at 75.47 MHz.or 125.77 MHz; the 13C chemical shifts were assigned 
by HSQC and HMBC. 
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3.1.2.3 Synthesis of XBp9, XBp10, XBp15 and XBp16 
 
The catalyzed PtCl4 cyclization of 1’,1’-dimethylpropargyl ethers was used for the 
synthesis of analogues of XP13 bearing a fused 2,2-dimethylbenzopyran moiety using 
simple oxygenated xanthones such as 1,2-dihydroxyxanthone (29),4-hydroxyxanthone 
(31) and 4-hydroxyxanthone (33) as building block (Figure 3.37). In the case of the 1,2-
dihydroxyxanthone, this strategy can lead to XBp9 which then can be hydrogenated to 
compound XBp10. (Figure 3.37). The cyclization of the 1’,1’-dimethylpropargyl ether 
derived from 4-hydroxyxanthone (30), might lead to caledinoxanthone B (XBp15) (Figure 
3.37), a xanthone which has been isolated Calophyllum caledonicum but whose biological 
activity has not been evaluated and has never been obtained by synthesis [166]. The 
cyclization of the 1’,1’-dimethylpropargyl ether derived from 2-hydroxyxanthone (32), 
might lead to two isomers bearing the 2,2-dimethylbenzopyran fused ring, one angular 
(XBp16) and other linear (Figure 3.37).  
 
 
Figure 3.37 Retrosynthetic plan for the synthesis of XBp10, XBp11, XBp15 and XBp16.  
 
 The first step of this strategy was the synthesis of the oxygenated xanthones, 
namely, 1,2-dihydroxyxanthone (29), 4-hydroxyxanthone (31) and 2-hydroxyxanthone 
(33). 
The 1,2-dihydroxyxanthone (29) was synthesized via diaryl ether route based on a 
procedure described by our group which used 3,4-dimethoxyphenol and methyl 2-
bromobenzoate as building blocks (Figure 3.38) [39, 134]. The diaryl ether was obtained 
by an Ullmann ether coupling using CuI, N,N-dimethylglycine and Cs2CO3 [133], which led 
ŚĂƉƚĞƌϯ
ZĞƐƵůƚƐΘŝƐĐƵƐƐŝŽŶ
ϭϮϭ

to a slight increase in the yield when compared with the previous published procedure (45 
% vs 41 %) [39, 134]. The 1,2-dimethoxyxanthone (36) was obtained by an intramolecular 
acylation through a directed remote metalation (Appendix I) [134] in 63 % yield (Figure 
3.38). The 1,2-dimethoxyxanthone (36) was later O-demethylated with BBr3 to give 1,2-
dihydroxyxanthone (29) with 94 % yield (Figure 3.38) [39]. The compounds were mostly 
purified by silica gel flash chromatography and crystallization, and spectroscopic data of 
the 1,2-dihydroxyxanthone (29) were in accordance with the literature [17]. 
 
 
Figure 3.38 Synthesis of 1,2-dihydroxyxanthone (29). 
 
The 4-hydroxyxanthone (31) and 2-hydroxyxanthone (33) were synthesized by the 
described procedure via diaryl ether and benzophenone route respectively (Figure 3.39) 
[16, 30, 167]. The compound were purified by column chromatography and the 
spectroscopic data obtained for these two compounds were in accordance with the 
literature [14, 30]. 
 
 
Figure 3.39 Synthesis of 4-hydroxyxanthone (31) and 2-hydroxyxanthone (33). 
 
The next step was the synthesis of the 1’,1’-dimethylpropargyl ethers (Figure 3.37) 
and since only one product could be obtained from the O-dimethylpropargylation of 4-
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hydroxyxanthone (31) and 2-hydroxyxanthone (33), the standard experimental procedure 
of CuI/KI/K2CO3 with 3-chloro-3-methyl-1-butyne in DMF [65, 66] was used leading to the 
two 1’1’-dimethyl propargyl ethers in moderate yields (Figure 3.40). On the other hand, 
the O-dimethylpropargylation of 1,2-dihydroxyxanthone (29) might lead to more than one 
compound due to the presence of two hydroxyls in position 1 and 2. However, the 
hydroxyl in position 1 is in an intramolecular hydrogen bond with the xanthonic ketone and 
consequently is less reactive then the hydroxyl in position 2 meaning that the main 
product might be probably the 1’,1’-dimethyl propargylic ether substitute at the hydroxyl of 
position 2 (28). Nevertheless, the temperature of the reaction was lowered to 50 ºC (75 ºC 
in the standard conditions) to reduce the likelihood of by-products, and the O-
dimethylpropargylation product at position 2 was obtained with low yield (10 %) (Figure 
3.40) since other two by-products from the cyclization of 1’,1’-dimethyl propargyl ether 
with the phenol were obtained (Figure 3.40; 39 and 40). In order to increase the yields, 
the temperature of reaction was lowered to 40 ºC and the solvent was changed to acetone 
leading to the desired compound (28) in 31 % yield (Figure 3.40).  
 
Figure 3.40 Synthesis of 4-hydroxyxanthone (31) and 2-hydroxyxanthone (33). 
 
The cyclization of compound 29 to analogue XBp9 was successfully accomplished 
with PtCl4 with 73 % yield, leading also to 1,2-dihydroxyxanthone (29) in 22 % yield 
(Figure 3.41). Contrary to the cyclization of compound 8 to XBp3 (Figure 3.15) where the 
product from the nucleophilic attack of the phenol into the alkyne was observed, in the 
cyclization of compound (28), the only product obtained was XBp9 meaning that possibly 
the intramolecular hydrogen bond of hydroxyl in position 1 with the xanthonic carbonyl 
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decreases the nucleophilicity of the phenol. The cyclization of the 1’,1’-dimethylpropargyl 
aryl ethers of 4-hydroxyxanthone (30) and 2-hydroxyxanthone (32) were accomplished in 
good yields to give respectively XBp15 and XBp16 (Figure 3.41). In the case of the 
cyclization of compound 32, an unexpected outcome was observed since only one isomer 
was obtained. Indeed, the literature does not refer any regioselectivity in the cyclization of 
propargyl aryl ethers catalyzed by PtCl4 [97, 98]. Therefore, the xanthonic carbonyl might 
coordinate with the platinum to give only compound XBp16.  
 
 
Figure 3.41 Synthesis of XBp9, XBp15 and XBp16. 
 
Lastly, XBp10 was obtained from the hydrogenation of analogue XBp9 by an 
Pd/C-TES-MeOH methodology in excellent yields (Figure 3.42) [150].  
 
 
Figure 3.42 Synthesis of XBp10 from the hydrogenation of compound XBp9. 
All compounds were either purified by silica gel flash chromatography, extraction 
or crystallization, being compound 28 hard to purify which might also help to explain the 
low yields obtained. 
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The structure of compounds 28, 30 and 32 obtained from the O-
dimethylpropargylation of 1,2-dihydroxyxanthone (29), 4-hydroxyxanthone (31) and 2-
hydroxyxathone (33) were characterized by common spectroscopic techniques and were 
in the accordance with the expected. The introduction of the 1’,1’-dimethylpropargyl ether 
in the three oxygenated xanthones was evidenced by the presence of one acetylenic 
proton (įH 2.57 s for compound 28; įH 2.56 s for compound 30; įH 2.64 s for compound 
32) and two geminal methyl groups (įH 1.72 s for compound 28; įH 1.78 s for compound 
30; įH 1.70 s for compound 32) in the 1H NMR spectra and in the IR spectra by the 
presence of H-CŁ and CŁC stretching bands (3241 cm-1 and 2324 cm-1 for compound 28; 
3266 cm-1 and 2334 cm-1 for compound 30; 3219 cm-1 and 2362 cm-1 for compound 32). 
The structure of the two by-products obtained in the first propargylation reaction of 1,2-
dihydroxyxanthone was evidenced by 1H NMR through the presence of a terminal vinylic 
methylene (įH 4.72 d and įH 4.52 d with a coupling constant of 2.3 Hz for compound 39; 
5.01 d and įH 4.61 d with a coupling constant of 2.3 Hz for compound 40) and two 
geminal methyl groups (įH 1.64 for compound 39; įH 1.64 compound 40). The two 
structures were not assigned since the 1H NMR spectra were very similar. 
The structure of XBp9, XBp15 and XBp16 obtained from the hydroarylation 
platinum-catalyzed of the appropriate 1’,1’,-dimethylpropargyl aryl ether were 
characterized by common spectroscopic techniques and the data was in accordance with 
what expected and in the case of XBp15 with the structure of caledonixanthone B [166]. 
In comparison with the 1H NMR spectrum of 1,2-dihydroxyxanthone (29), in the spectrum 
of compound XBp9 there are five aromatic protons (įH 8.28 dd, įH 7.72 ddd, įH 7.43 dd, 
įH 7.36 ddd, įH 6.65 s) instead of six aromatic protons in 1,2-dihydroxyxanthone (29) and 
one hydroxyl group (įH 12.26 broad). The presence of the 2,2-dimethylbenzopyran moiety 
was evidenced in the 1H and 13C NMR spectra by the two olefinic groups (įH 5.94 d and 
įH 6.40 d; įc 136.9 and įc 121.8), two geminal methyl groups (įH 1.54; įc 27.7) and an 
oxygen bearing a quaternary carbon (įc 76.4). In the IR spectrum of XBp9 there was the 
presence of a broad band at 3412 cm-1 corresponding to the O-H stretching and 2961, 
2914 and 2857 cm-1 corresponding to the C-H stretching. The HRMS was in accordance 
with molecular formula of XBp9 ([M+H]+ C18H15O4). In the 1H NMR spectrum of compound 
XBp15 and XBp16 the cyclization product was evidenced by the presence of six aromatic 
protons (įH 8.32 dd, įH 7.71 ddd, įH 7.61 dd, įH 7.37 ddd, įH 7.31 d, and įH 6.44 d for 
XBp15; įH 8.27 dd, įH 7.66 ddd, įH 7.41 dd, įH 7.32 ddd, įH 7.27 d, and įH 7.18 d for 
XBp16), two olefinic groups (įH 6.44 d, įH 5.82 d for XBp15; įH 8.09 d, įH 5.82 d for 
XBp16) and two geminal methyl groups (įH 1.57 for XBp15; įH 1.46 for XBp16) referring 
the last two to the 2,2-dimethylpyran moiety. The structure of the cyclization of compound 
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32 to XBp16 was assigned based on the coupling constant between the two aromatic 
protons (J = 9.2 Hz) in the aromatic ring bearing the 2,2-dimethylbenzopyran since the 
values were in accordance with an ortho coupling. The HRMS for XBp15 and XBp16 
were in accordance with molecular formula for these compounds ([M+H]+ C18H15O3 for 
XBp15; [M+H]+ C18H15O3 for XBp16). 
In the structure of compound XBp10 obtained from the hydrogenation of the 
double bond the 2,2-dimethylbenzopyran of compound XBp9, the formation of the 2,2-
dimethyl-3,4-dihydrobenzopyran moiety was evidenced by the presence of two methylene 
groups (įH 1.94 t and įH 2.90 t; įc 32.3 and įc 23.7) in the 1H and 13C NMR spectra and 
the molecular formula determined by HRMS ([M+H]+ C18H17O4). 
 
Table 3.8 1H NMR and 13C NMR for compound XBp9 and XBp10.  
1H NMR chemical shifta 13C NMR chemical shiftb 
 XBp9c XBp10c  XBp9d XBp10 
H-3 5.94 (d, J = 9.9) 1.94 (t, J = 6.8) C-2 76.4 74.7 
H-4 6.40 (d, J = 9.9) 2.90 (td, J = 6.8; 0.5) C-3 136.9 32.3 
H-5 6.65 (s) 6.70 (broad s) C-4 121.8 23.7 
H-7 7.43 (dd, J = 8.6, 0.9) 
7.44 (broad d, J = 
8.4) C-4a 129.1 131.3 
H-8 7.72 (ddd, J = 8.6, 7.2, 1.7) 
7.71 (ddd, J = 8.4, 
7.1, 1.7) C-5 103.2 105.4 
H-9 7.36 (ddd, J = 8.0, 7.1, 0.9) 
7.35 (ddd, J = 8.0, 
7.0, 1.0) C-5a 149.9 149.6 
H-10 8.28 (dd, J = 8.0, 1.7) 8.24 (dd, J = 8.0, 1.7) C-6a 156.3 156.3 
H-12 12.66 [OH, s] 12.77 [OH, s] C-7 117.7 117.7 
H-1’a and 
H-1’b 1.54 (s) 1.49 (s) C-8 135.2 135.2 
 
  
C-9 123.7 123.5 
 
 
 C-10 125.8 125.9 
 
  C-10a 120.1 119.9 
 
  C-11 182.0 182.5 
 
  C-11a 109.1 107.7 
 
  C-12 148.7 148.4 
 
  C-12a 135.0 137.4 
 
  C-1’a and C-1’b 27.7 26.7 
aValues in ppm (įH) measured at 300.13 MHz J values (Hz) are shown in parentheses, the 1H chemical shifts 
were measured in CDCl3. bValues in ppm (įC) measured at 75.47 MHz; the 13C chemical shifts were measured 
in CDCl3.cThe 1H chemical shifts were assigned by comparison with the assignments established for XBp7 
and XBp8. dThe 13C chemical shifts were assigned by comparison with the assignments established for XBp7 
and XBp8.  
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3.1.3 Synthesis of XBp17 to XBp33 
 
 
 
Figure 3.43 Analogues of XP13 synthesized bearing a substituent on ring A. 
 
 
In this section, compounds that differ mainly from XP13 by the presence of 
different substituents on ring A (Figure 3.2) will be presented. This section will be sub-
divided in two sections according to the orientation of the fused ring. In section 3.1.3.1, the 
synthesis of compounds bearing a different fused ring orientation than XP13, similar to 
compound XBp4 (Figure 3.17) will be discussed. In section 3.1.3.2, compounds that have 
the same fused ring orientation as XP13 will be discussed. 
 
 
3.1.3.1 Synthesis of XBp17 to XBp24 
 
 The same route used for the synthesis of XBp4 was not advisable for the 
synthesis of the desired compounds since there are few substituted 2-iodobenzoic acid 
derivatives commercially available. As a result, a different route needed to be established. 
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Figure 3.44 Retrosynthetic plan for the synthesis of analogues of XBp4 bearing 
substituents on ring A.  
 
The retrosynthetic plan for analogues of XBp4 bearing substituents on ring A was 
idealized based on the benzophenone route (Figure 3.29). According to the retrosynthetic 
plan, the compounds could be synthesized through the benzophenone route using as 
building blocks, a salicylaldehyde and a 2,2-dimethylbenzopyran 41. The benzophenone 
could be obtained through the directed ortho lithiation which could take place at positions 
7 or 8 (Figure 3.44, positions highlighted). In order to the reaction to be regioselective, 
position 7 must be more prone to suffer a directed ortho metalation than position 8.  
According to the literature, the directed ortho metalation is mainly influenced by 
two aspects:  
• the formation of a coordination complex between the metalating reagent 
and the directed metalation group of the aromatic ring. This phenomenon 
has been coined as “complexed-induced proximity effect” (CIPE) [168] and 
brings the reactive groups into proximity directing the deprotonation;  
• the electron-withdrawing strength of the directed ortho metalation group 
(via the inductive effect on the nearby protons) [149, 160]. The stronger the 
group, the higher acidity of the ortho-hydrogen of the direct metalation 
group. 
In the case of benzopyran 41, there is the present two methoxyl groups in an ortho 
disposition (Figure 3.44) and it has been described that this feature increased the rate of 
the directed ortho lithiation [155, 169, 170]. In fact, the presence of two adjacent methoxyl 
groups might favor the deprotonation either by increasing the acidity of the C–H bond by 
an inductive effect, or by increasing the ability of the ortho-methoxy group to coordinate 
with the metalating reagent through a conjugative effect [169]. In addition, the two 
adjacent methoxyl groups have the ability to deoligomerize the metalating reagent, usually 
alkylithium, making it more reactive towards ortho-metalations [155, 170]. In the case of 
1,2,4-trimethoxybenzene which has a similar oxygenated pattern of compound 41, after 
the lithiation of position 3 had been accomplished, the second position to be lithiated was 
position 6, not being observed any 5 substituted product [156].  
Accordingly, the 2,2-dimethylbenzopyran 41 will most likely be lithiated in  position 
7 due to the presence of two methoxyl groups in positions 5 and 6 (Figure 3.44). 
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Moreover, position 7 could be even more inclined to take part in the ortho lithiation since 
the oxygen in position 1 have two methyl groups in position 2, which can cause steric 
hindrance and interfere with the CIPE. Nevertheless, the lithiation of position 8 cannot be 
excluded and it is expected to occur but to a lesser extent in comparison with position 7. 
The first part of this strategy was the synthesis of compound 41 and the protection of the 
salicyaldehydes. 
 The compound 41 was easily synthesized by the O-methylation of compound 13 
using dimethyl sulfate as O-methylating reagent (Figure 3.45). Several substituted 
salicylaldehydes bearing different functionalities were protected with either methoxymethyl 
ether or benzyl ether (Figure 3.45).   
 
 
Figure 3.45 Synthesis of 2,2-dimethylbenzopyran 41 and protection of several 
salicyladehydes with methoxymethyl ether (47-51) or benzyl ether (52 and 53). 
  
Several experimental procedures varying the solvent, temperature and the ligand 
were evaluated and the ortho lithiation of compound 41 was accomplished with THF as 
solvent and TMEDA as ligand at 0ºC (Figure 3.46). The directed ortho lithiation of 
compound 41 took place at positions 7 and 8 and two diaryl methanol derivatives were 
obtained for each of the reactions in moderate to good yields (Figure 3.46). However, in 
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the GC-MS chromatogram of the most volatile samples, it was observed that one of the 
isomers was obtained in much higher yield than the other (average 1:10). On the other 
hand, the separation of the two isomers by common chromatographic techniques was not 
possible since they had a similar chromatographic behavior. Consequently, instead of 
using more exhaustive separation techniques, the two isomers were used as a mixture in 
the following reactions since in the cyclization step only one of the isomers would be able 
to cyclize to xanthone. 
 
 
 
Figure 3.46 Synthesis of diaryl methanol derivatives through the ortho lithiation of 
compound 41 followed by the nucleophilic addition to several protected salicyladehydes 
derivatives. 
 
 The next step is the oxidation of the diaryl methanol derivatives to benzophenone. 
This reaction can be accomplished using different oxidizing reagents [56, 139, 164, 171-
184] and iodoxybenzoic acid (IBX) was used since it does not need an inert atmosphere 
and the reaction could be carried out at room temperature [185, 186]. The 
benzophenones were synthesized in moderate to good yields as it can be depicted from 
Figure 3.47. 
 
 
Figure 3.47 Synthesis of benzophenones 71-86 by oxidation of the diaryl methanol 
derivatives with IBX in DMSO. 
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The following step was the removal of the protecting group which was 
accomplished using either NbCl5 for the compounds bearing methoxymethyl ether [163] or 
hydrogenated by the Pd/C-TES-MeOH methodology [150] for compounds bearing the 
benzyl protecting group (Figure 3.48). The latter methodology removed not only the 
benzyl group, but also hydrogenated the double bond of the 2,2-dimethylpyran moiety and 
the benzophenones were obtained in moderate yields (Figure 3.48). The removal of the 
methoxymethyl ether was accomplished in quantitative yield for majority of the 
benzophenones except for the benzophenones 75 and 83, and benzophenones 76 and 
84. In the case of hydrogenation, the yields were moderate and in the case of 
benzophenones 72 and 80, besides the two deprotected benzophenones, 
hydrodechlorinated compounds were isolated and since we were unable to purify this 
complex mixture, they were used in the next synthetic step. 
 
 
Figure 3.48 Removal of protecting groups from benzophenones 71-86 using either NbCl5 
or Pd/C-triethylsilane-methanol methodology. 
 
 During the last two steps, the pair of isomers maintained a similar chromatographic 
behavior and as a result they were used as a mixture in all the reactions. The first method 
used for the cyclization of the benzophenones to the xanthones used was cesium 
carbonate and DMF as solvent and led to XBp17, XBp19 and XBp20 with moderate 
yields (Figure 3.49). However, this methodology was unable to cyclize benzophenone 90 
to xanthone possibly due to the ionization of the hydroxyl in position R3, which may 
decrease the basicity of the hydroxyl ortho to the carbonyl, entering also in resonance with 
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the carbonyl, leading to a decrease in the ability of the carbonyl to participate in an 
intramolecular SNAr. Therefore, using microwaves instead of conventional heating led to 
XBp21, albeit in low yield (22%) (Figure 3.49). Since the cyclization took place in 15 
minutes, it was applied the microwave heating for the cyclization of the other four 
benzophenones and XBp18, XBp22, XBp23 and XBp24 were obtained with moderate 
yields (Figure 3.49). The xanthones obtained from the cyclization of the benzophenones 
had a different chromatographic behavior and were separated by silica gel flash 
chromatography.  
 
 
 
Figure 3.49 Cyclization of the benzophenones to xanthones. 
 
 
The structure of compound 41 was confirmed by common spectroscopic 
techniques and the data was in accordance with the expected. In comparison with the 1H 
NMR spectrum of compound 13, the spectrum of compound 41 evidenced the presence of 
two methoxyl groups (įH 3.84 s and įH 3.82 s), and the absence of the hydroxyl signal. In 
the IR spectrum, no O-H stretching band was observed. The protection of the 
salicylaldehydes was confirmed by 1H NMR and IR spectra. The structure of the 
diarylmethanol and benzophenone derivatives were not fully characterized since it was 
worked with a mixture of isomers.  
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Compounds XBp17 to XBp24 were characterized by common spectroscopic 
techniques and the data was in accordance with the expected. In the 1H and 13C NMR 
spectra, the presence of the 2,2-dimethylpyran fused ring in compounds XBp17, XBp19, 
XBp20, XBp21 and XBp22 was evidenced by the presence of two olefinic groups (Table 
3.9 “H-3”, “H-4” and Table 3.10 “C-3”, “C-4”for XBp17, XBp19, XBp20, XBp21 and 
XBp22), two geminal methyl groups (see Table 3.9 “H-1’a and H1’b” and Table 3.10 “C-
1’a and C-1’b” for XBp17, XBp19, XBp20, XBp21 and XBp22) and an oxygen bearing a 
quaternary carbon (Table 3.10 “C-2” for XBp17, XBp19, XBp20, XBp21 and XBp22). The 
2,2-dimethyl-3,4-dihydropyran of compounds XBp18, XBp23 and XBp24 was evidenced 
by the 1H and 13C NMR spectra through the presence of two methylene groups (Table 3.9 
“H-3”, “H-4” and table 3.10 “C-3”, “C-4” for XBp18, XBp23 and XBp24), two geminal 
methyl groups see Table 3.9 “H-1’a and H1’b” and Table 3.10 “C-1’a and C-1’b” for 
XBp18, XBp23 and XBp24) and an oxygen bearing a quaternary carbon (Table 3.10 “C-
2” for XBp18, XBp23 and XBp24). The presence of chlorine in compounds XBp17 and 
XBp18 was evidenced by the presence of 4 aromatic protons (įH 8.31 d, įH 7.69 dd, įH 
7.54 d and įH 7.48 s for XBp17; įH 8.28 d, įH 7.65 dd, įH 7.52 d and įH 7.48 s for XBp18) 
in the 1H NMR spectrum and through the molecular formula determined by HRMS ([M+H]+ 
C19H16ClO4 for XBp17 and [M+H]+ C19H18ClO4 for XBp18). The presence of methoxyl 
group in compound XBp19 was evidenced by the presence of 4 aromatic protons (įH 7.72 
d, įH 7.53 d, įH 7.52 s and įH 7.36 dd) and two methoxyl groups (įH 4.10 s and įH 3.97 s) 
in the 1H NMR spectrum and through the molecular formula determined by HRMS ([M+H]+ 
C20H19O5). The presence of methyl group in compound XBp20 was evidenced by the 
presence of 4 aromatic protons (įH 8.13 d, įH 7.56 d, įH 7.51 s and įH 7.48 d) and one 
methyl group (įH 2.51 s) in the 1H NMR spectrum) and through the molecular formula 
determined by HRMS ([M+H]+ C20H19O4). The presence of hydroxyl group in compound 
XBp21 was evidenced by the presence of 4 aromatic protons (įH 8.25 d, įH 7.44 s, įH 
7.27 dd, and įH 7.13 dd) in the 1H NMR spectrum, by the broad O-H stretching band in the 
IR spectrum at 3112 cm-1 and through the molecular formula determined by HRMS 
([M+H]+ C19H17O5). The presence of the N,N-diethyl group in compounds XBp22 and 
XBp23 was evidenced by the presence of 4 aromatic protons (įH 8.12 d, įH 7.46 s, įH 
6.71 dd and įH 6.59 d for XBp22; įH 8.12 d, įH 7.47 s, įH 6.69 dd and įH 6.54 d for 
XBp23), two methylene (įH 3.49 q for XBp22; įH 3.48 q for XBp23) and two methyl 
groups (įH 1.27 t for XBp22; įH 1.27 t for XBp23) and through the molecular formula 
determined by HRMS ([M+H]+ C23H26NO4 for XBp22 and [M+H]+ C23H28NO4 for XBp23). 
The presence of two methoxyl groups on ring A of compound XBp24 was evidenced by 
the presence of 3 aromatic protons (įH 7.65 s, įH 7.49 s and įH 6.96 s) and three 
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methoxyl group (įH 4.06, įH 4.03 s and įH 3.99 s) in the 1H NMR spectrum and through 
the molecular formula determined by HRMS ([M+H]+ C21H23O6). 
 
 
 
 
 
 
 
Table 3.9 1H NMR for compounds XBp17, XBp18, XBp19, XBp20. XBp21, XBp22, 
XBp23 and XBp24. 
 XBp17 XBp18  XBp19 XBp20 XBp21 XBp22 XBp23 XBp24 
H-3  5.99 (d, J 
= 10.8) 
1.89 (t, J 
= 6.8) 
5.98 (d, J 
= 10.0) 
5.97 (d, J 
= 10.1) 
5.93 (d, J 
= 9.9) 
5.89 (d, J 
= 10.2) 
1.85 (t, J 
= 6.9) 
1.86 (t, J 
= 6.8) 
H-4 6.82 (d, J 
= 10.8) 
2.95 (t, J 
= 6.8) 
6.83 (d, J 
= 10.0) 
6.83 (d, J 
= 10.1) 
6.78 (d, J 
= 9.9) 
6.77 (d, J 
= 10.2) 
2.92 (t, J 
= 6.9) 
2.92 (t, J 
= 6.8) 
H-7 7.54 (d, J 
= 8.8) 
7.52 (d, J 
= 8.9) 
7.53 (d, J 
= 9.2) 
7.48 (d, J 
= 8.4) 
7.27 (d, J 
= 2.3) 
6.59 (d, J 
= 2.4) 
6.54 (d, J 
= 2.5) 6.96 (s) 
H-8 
7.69 (dd, 
J = 8.8, 
2.6) 
7.65 (dd, 
J = 8.9, 
2.6) 
7.36 (dd, 
J = 9.2, 
3.1) 
7.56 (dd, 
J = 8.4, 
2.0) 
- - - - 
H-9 - - - - 
7.13 (dd, 
J = 8.7, 
2.3) 
6.71 (dd, 
J = 9.1, 
2.4) 
6.69 (dd, 
J = 9.5, 
2.1) 
- 
H-10 8.31 (d, J 
= 2.6) 
8.28 (d, J 
= 2.6) 
7.72 (d, J 
= 3.1) 
8.13 (d, J 
= 2.0) 
8.25 (d, J 
= 8.7) 
8.12 (d, J 
= 9.1) 
8.12 (d, J 
= 9.1) 7.65 (s) 
H-12 7.48 (s) 7.48 (s) 7.52 (s) 7.51 (s) 7.44 (s) 7.46 (s) 7.47 (s) 7.49 (s) 
H-1’a 
and H-
1’b 
1.51 (s) 1.40 (s) 1.52 (s) 1.51 (s) 1.47 (s) 1.47 (s) 1.37 (s) 1.37 (s) 
H-1’’ 4.09 (s) 4.09 (s) 4.10 (s) 4.10 (s) 4.06 (s) 4.05 (s) 4.05 (s) 4.06 (s) 
H-1’’’ - - 3.97 (s) 2.51 (s) - - - 4.03 (s) 
H-1’’’a 
and H-
1’’’b 
- - - - - 3.49 (q) 3.48 (q) - 
H-2’’’a 
and H-
2’’’b 
- - - - - 1.27 (t) 1.27 (t) - 
H-1’’’’ - - - - - - - 3.99 (s) 
a.Values in ppm (įH) measured in CDCl3, at 300.13 MHz or 400.21 MHz or 500.13 MHz, J values (Hz) are 
shown in parentheses; the 1H chemical shifts were assigned by comparison with the assignments established 
for either compound XBp4 or XBp5. 
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Table 3.10 13C NMR for XBp17, XBp18, XBp19, XBp20. XBp21, XBp22, XBp23 and 
XBp24.  
 XBp17 XBp18  XBp19 XBp20 XBp21 XBp22 XBp23 XBp24 
C-2 76.3 74.4 76.2 76.1 76.3 75.9 76.4 74.3 
C-3 135.8 31.5 135.5 135.5 135.5 134.7 31.8 31.8 
C-4 116.3 18.2 116.4 116.4 116.4 116.5 18.1 18.2 
C-4a 121.9 124.1 121.6 121.5 121.4 120.4 122.2 122.8 
C-5 143.6 146.0 143.6 143.6 143.6 143.3 145.6 145.9 
C-5a 144.6 143.2 144.8 144.7 144.8 144.4 143.2 143.9 
C-6a 154.1 154.0 155.9 154.0 157.3 158.3 158.3 155.2 
C-7 119.7 119.7 105.6 117.7 103.5 96.1 96.1 99.7 
C-8 134.5 134.4 124.7 135.7 161.4 152.4 152.6 152.1 
C-9 129.6 129.2 150.6 133.6 113.9 109.5 109.2 146.6 
C-10 125.9 125.9 119.4 125.9 128.7 128.1 128.1 105.4 
C-10a 121.9 121.2 121.7 120.9 116.9 111.1 110.8 114.2 
C-11 175.3 175.6 176.3 176.5 175.6 174.8 175.2 175.7 
C-11a 122.1 121.9 121.5 122.3 122.4 122.8 122.0 121.5 
C-12 106.7 107.2 106.7 106.7 106.9 106.9 107.4 107.1 
C-12a 149.3 150.9 148.8 148.8 149.1 148.5 150.0 150.5 
C-1’a 
and C-
1’b 
27.7 26.6 27.8 27.7 27.8 27.7 26.7 26.7 
C1’’ 62.3 61.1 62.2 62.2 62.4 62.3 61.1 61.1 
C1’’’a 
and 
C1’’’b 
- - 55.9 20.8 - 44.8 44.7 - 
C1’’’a 
and 
C1’’’b 
- - - - - 15.5 12.5 - 
C1’’’ - - - - - - - 56.5 and 
56.3 C1’’’’ - - - - - - - 
a.Values in ppm (įC) measured in CDCl3, at 75.47 MHz or 100.63 MHz; The 13C chemical shifts were assigned 
by comparison with the assignments established for either compound XBp4 or XBp5. 
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3.1.3.2 Synthesis of XBp25 to XBp33 
 
 
Figure 3.50 Analogues of XP13 synthesized differing mainly from this compound by the 
presence of substituents on ring A. 
 
This section will focus on the synthesis of analogues of XP13 that differ from this 
compound mainly by the presence of substituent(s) on ring A, maintaining the same 
orientation of the fused 2,2-dimethyl-3,4-dihydropyran and 2,2-dimethylpyran ring (Figure 
3.50).  
This section will be sub-divided in two according to the presence of a methoxyl or a 
hydroxyl in position 12 (Figure 3.50).  
  
3.1.3.2.1 Synthesis of XBp25 to XBp28 
 
 
Figure 3.51 Retrosynthetic plan for analogues of XP13 bearing a methoxyl in position 12. 
 
The synthetic route used for the synthesis of XBp7, XBp11 and XBp17 to XBp24 
could be employed here for the synthesis of the analogues of XP13 bearing a substituent 
on ring A and a methoxyl in position 12. The retrosynthetic plan that can be depicted on 
Figure 3.51 and the desired compounds can be synthesized from a protected 
salicylaldehyde and a 2,2-dimethylbenzopyran (103). The benzophenone can be obtained 
regioselectively since a directed ortho metalation will take place only in position 6 (Figure 
3.51). Moreover, the same salicylaldehydes employed before for the synthesis of 
compounds XBp17 to XBp24 could also be used here. 
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 The first part is the synthesis of the 2,2-dimethylbenzopyran 103 which was easily 
accomplished in two steps from 2,3-dimethoxyphenol through the cyclization of 1’,1’-
dimethylpropargyl aryl ether (Figure 3.52). Besides the salicyaldehydes protected with 
methoxymethyl ether referred in the previous section, the 3,4-dimethoxysalicylaldehyde 
was also protected with this same group with good yields (Figure 3.52). 
 
 
Figure 3.52 Synthesis of 2,2-dimethylbenzopyran 103 and protection of 3,4-
dimethoxysalicylaldehyde with methoxymethyl ether. 
 
The compounds were purified by silica gel flash chromatography and the structure 
of compound 104 obtained from the O-dimethylpropargylation of 2,3-dimethoxyphenol 
was characterized by common spectroscopic techniques, beingin the accordance with the 
expected. The introduction of the 1’,1’-dimethylpropargyl ether in the 2,3-dimethoxyphenol 
was evidenced in the 1H NMR spectrum by the presence of one acetylenic proton (įH 2.55 
s) and two geminal methyl groups (įH 1.68 s) and in the IR by the presence of H-CŁ and 
CŁC stretching bands (3298 cm-1 and 2338 cm-1) and also by the absence of a band 
corresponding to the O-H stretching. The cyclization of compound 104 to compound 103 
was evidenced in the 1H NMR spectrum by the presence of two aromatic protons (įH 6.69 
d and įH 6.42 d), two olefinic groups (įH 6.28 d and įH 5.52 d) and two geminal methyl 
groups (įH 1.48), referring the last two to the fused 2,2-dimethylpyran ring. 
 
 In spite of being described in the literature that the directed ortho lithiation of 1,2,3-
trimethoxybenzene was harder than the ortho lithiation of 1,2-dimethoxybenzene, 1,2,4-
trimethoxybenzene and 1,3-dimethoxybenzene, the reaction was doable and the reaction 
still took place [154, 156]. However, the directed ortho lithiation of compound 103 turned 
out to be more problematic than expected and success was only attained with compound 
105. However, the first reaction that led to the diarylmethanol derivates was very sluggish 
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and compound 106 was used impure in the next synthetic steps (Figure 3.53).  
Compound XBp25 was only purified in the last step, but the quantity isolated was too low.  
 
 
Figure 3.53 Synthesis of compound XBp25. 
 
The diarylmethanol derivatives and benzophenones that led to XBp25 were not 
fully characterized due to the lack of purity. Nevertheless, they were characterized by 
EIMS and were in accordance with the expected. Compound XBp25 which has been 
already isolated from Garcinia Porreta with the name porxanthone A [187], was evidenced 
in the 1H and 13C NMR spectra by the presence of 3 aromatic protons (įH 8.09 d, įH 7.75 
s, įH 7.04 d), three methoxyl groups (įH 4.15 s, įH 4.14 s, įH 4.11 s), by two olefinic 
groups (įH 5.78 d and įH 6.45 d; įc 131.0 and įc 121.6), two geminal methyl groups (įH 
1.59; įc 28.4) and an oxygen bearing a quaternary carbon (įc 78.0). The spectroscopic 
data was not in accordance with the published for porxanthone A, but since only one 
compound could be obtained from this route, the structure published is probably incorrect 
[187] 
 
The directed ortho lithiation was not favorable for substrate 103 and consequently 
another synthetic was idealized. The use of halogen/lithium exchange to form the lithiated 
intermediate had already been used with success for the synthesis of highly hindered 
benzophenones [139, 171, 172, 174-182]. Accordingly, if a bromine or iodine is introduced 
selectively in position 6 of compound 103, the halogen can be exchanged with lithium and 
the diarylmethanol could be obtained more cleanly and in better yield. However, the 
double bond of the 2,2-dimethylbenzopyran of compound 103 must be reduced since it 
susceptible to the bromination procedure.  
According to new route, the first step as the hydrogenation of the double bond 
which was accomplished using the Pd/C-TES-MeOH in excellent yield (Figure 3.54). The 
second step was the bromination of compound 109 which was made using NBS catalyzed 
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by ammonium acetate [188]. The bromination took place very smoothly, with high 
regioselectivity and in excellent yield (Figure 3.54). Moreover, 5-methylsalicyaldehyde 
was protected with benzyl group and used as building block (Figure 3.54). 
 
 
Figure 3.54 Synthesis of compound 110 by hydrogenation and bromination of compound 
103; protection of 5-methylsalicylaldehyde with benzyl group. 
 
All the compounds were purified by column chromatography and the structure of 
compound 109 obtained from the hydrogenation of the double bond of compound 103 was 
evidenced by 1H NMR spectrum by the presence of two methylene groups (įH 2.66 td and 
įH 1.71 t). The structure of compound 110 obtained from the bromination of compound 
109 was evidenced by 1H NMR spectrum by the presence of one aromatic proton (įH 7.01 
t), and the position of the bromine was assigned based on the allyl coupling (J = 1.0) 
between the aromatic proton and the methylene group of the 2,2-dimethyl-3,4-
dihydropyran ring closer to the aromatic ring. Moreover, the bromination was confirmed by 
the isotope ratio in the EIMS (302 (50, [M+2]+.) 300 (50, [M]+.)). The protection of the 5-
methylsalicylaldehyde was confirmed by 1H NMR and IR spectra. 
  
The halogen-lithium exchange proved to be a better alternative than the directed 
ortho lithiation and the diaryl methanol derivatives 112, 113 and 114 were obtained more 
cleanly and with better yields (Figure 3.55). The oxidation of the diaryl methanol derivates 
was carried out with IBX and the O-deprotection with either NbCl5 for the methoxymethyl 
ether and the Pd/C/triethylsilane/MeOH for the benzyl group and proceeded very smoothly 
to give the desired compounds (Figure 3.55). The cyclization of the benzophenones to 
xanthones was made by the use of K2CO3 in DMF with microwave heating the 
benzophenone with a hydroxyl in R3 (compound 160) was more problematic leading to low 
yields (Figure 3.55). 
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Figure 3.55 Synthesis of compounds XBp26, XBp27 and XBp28. 
 
The purification of all the compounds was mostly done by silica gel flash 
chromatography. 
 
The structure of the diarylmethanols obtained from the reaction between the 
salicylaldehydes and compound 110 were evidenced by the 1H NMR spectrum through 
the presence of two methylene groups (įH 2.68 td and įH 1.74 t for compound 112; įH 
2.60 td and įH 1.75 t for compound 113; įH 2.59 t and įH 1.75 t for compound 114) and 
two geminal methyl groups (įH 1.34 s and įH 1.32 s for compound 112; įH 1.37 s and įH 
1.34 s for compound 113; įH 1.37 s and įH 1.32 s for compound 114) corresponding to 
the 2,2-dimethyl-3,4-dihydropyran moiety, by the aromatic protons (įH 7.23 d, įH 6.78 d, 
įH 6.70 dd and įH 6.69 broad s for compound 112; įH 7.32-7.21 m 6H (one corresponding 
to the aromatic proton), įH 7.02 dd, įH 6.89 d and įH 6.59 s for compound 113; įH 7.04 s, 
įH 6.52 s and įH 6.59 s for compound 114), the benzyl proton (įH 6.25 d for compound 
112; įH 6.25 d for compound 113; įH 6.25 d for compound 114) and hydroxyl (įH 3.00 d 
for compound 112; įH 3.00 broad s for compound 113; įH 3.05 d for compound 114) 
corresponding to the dibenzylalcohol moiety and by the signals corresponding to the 
protecting groups (įH 5.19 d, įH 5.15 s, įH 5.12 d, įH 3.48 s and įH 3.35 s  for compound 
112; įH 7.32-7.21 m 6H (five correspond to the benzyl protecting group), įH 5.03 d and įH 
4.99 d for compound 113; įH 7.31-7-23 m 5H, įH 5.00 d, įH 4.96 d for compound 114). 
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The presence of the hydroxyl group was also evidenced by the IR spectrum by the 
presence of a broad band of the O-H stretching (3503 cm-1 for compound 112; 3474 cm-1 
for compound 113; 3518 cm-1 for compound 114). The oxidation of the diarylmethanol was 
confirmed by 1H NMR spectrum by the absence of the dibenzylic alcohol moiety and also 
by the presence of a strong C=O stretching band in the IR spectrum (1652 cm-1 for 
compound 115; 1649 cm-1 for compound 116; 1642 cm-1 for compound 117) as well as no 
O-H stretching band. The O-deprotection of the benzophenones was evidenced in the 1H 
NMR spectrum by the absence of any signal regarding the MOM group of benzophenone 
118 and benzyl group of benzophenones 119 and 120, as well as the presence of a 
hydroxyl group (įH 12.68 for compound 118; įH 12.02 for compound 119; įH 12.70 for 
compound 120). In the IR spectrum, a broad O-H stretching band was also observed 
(3328 cm-1 for compound 118; 3328 cm-1 for compound 119; 3473 cm-1 for compound 
120). 
 
The structure of XBp25, XBp26, XBp27 and XBp28 was confirmed by common 
spectroscopic techniques and were in accordance with the expected for these 
compounds. In comparison with the 1H NMR spectrum of benzophenones 118 to 120, the 
spectrum of XBp26, XBp27 and XBp28 did not shown any highly dishielded hydroxyl 
group and also a methoxyl group less. The substituents on ring A were also evidenced in 
the 1H NMR spectrum by the methyl group (įH 2.46 s) in XBp27 and two methoxyls of 
XBp28 (įH 4.00 s, įH 4.02 s and įH 4.00 s being one of them the methoxyl of position 12). 
In the IR spectrum of XBp26 it was observed a broad O-H stretching band at 3227 cm-
1
.The HRMS was in the accordance with the molecular formula of compounds XBp25, 
XBp26, XBp27 and XBp28 ([M+H]+ C21H21O6 for XBp25; [M+H]+ C19H19O5 for XBp26; 
[M+H]+ C20H21O4 for XBp27; [M+H]+ C21H23O6 for XBp28) 
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Table 3.11 1H NMR and 13C NMR for compounds XBp25, XBp26, XBp27 and XBp28.  
1H NMR chemical shifta 13C NMR chemical shiftb 
 
XBp25c XBp26d XBp27c XBp28c 
 
XBp25e XBp26f XBp27e XBp28e 
H-3 5.78 (d, J = 10.0) 
1.86 (t, J 
= 6.7) 
1.89 (t, J 
= 6.8) 
1.96 (t, J 
= 6.8) C-2 78.0 76.3 76.4 76.3 
H-4 6.49 (d, J = 10.0) 
2.64 (t, J 
= 6.7) 
2.92 (td, 
J = 6.7, 
1.0) 
2.94 (td, 
J = 6.8, 
1.0) 
C-3 131.0 31.5 32.4 32.5 
H-5 7.75 (s) 7.66 (s) 7.85 (t, J 
= 1.0) 
7.84 (t, J 
= 1.0) C-4 121.6 21.5 22.2 22.2 
H-7 8.09 (d, J = 9.0) 
7.99 (d, 
J = 8.5) 
8.09 (d, 
J = 2.1) 7.66 (s) C-4a 118.9 119.3 119.2 114.5 
H-8 7.04 (d, J = 9.0) 
6.87 (dd, 
J = 8.5, 
2.3) 
- - C-5 118.0 120.3 121.3 121.0 
H-9 - - 
7.50 (dd, 
J = 8.3, 
2.1) 
- C-5a 116.5 113.8 115.2 114.5 
H-10 - 6.85 (d, J= 2.3) 
7.46 (d, 
J= 8.3) 7.03 (s) C-6 175.8 174.1 176.7 175.6 
H-1’a 
and H-
1’b 
1.59 (s) 1.38 (s) 1.45 (s) 1.45 (s) C-6a 115.7 114.4 121.2 105.5 
H-1’’ 4.11 (s) 3.87 (s) 3.99 (s) 4.00 (s) C-7 120.0 127.8 125.9 119.2 
H-1’’’ 4.15 (s) - 2.46 (s) 4.02 (s) C-8 108.5 113.8 133.4 146.4 
H-1’’’’ 4.14 (s) - - 4.00 (s) C-9 150.8 163.7 135.5 152.4 
 
    C-10 136.6 102.2 117.8 100.0 
 
    
C-
10a 157.1 157.4 154.5 154.9 
 
    
C-
11a 150.3 147.8 149.2 149.0 
 
    C-12 135.8 135.2 135.7 135.7 
 
    
C-
12a 151.3 148.3 153.1 152.5 
 
    
C-1’a 
and 
C-
1’b 
28.4 26.6 27.0 27.0 
 
    C1’’ 61.5 60.7 61.2 61.3 
 
    C1’’’ 61.4 - 20.8 56.5 
and 
56.4      C1’’’’    
aValues in ppm (įH) measured at 400.21 MHz J values (Hz) are shown in parentheses; the 1H chemical shifts 
were assigned by comparison with assignments for XP13, XBp1 and XBp2; bValues in ppm (įC) measured at 
100.63 MHz; the 13C chemical shifts were assigned by by comparison with assignments for XP13, XBp1 and 
XBp2. cThe 1H chemical shifts were measured in CDCl3. dThe 1H chemical shifts were measured in DMSO-d6. 
eThe 13C chemical shifts were measured in CDCl3. fThe 13C chemical shifts were measured in DMSO-d6.
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3.1.3.2.2 Synthesis of XP13 and XBp29 to XBp33 
  
The synthesis of XP13 was described in section 3.1.1.1 and was obtained in one 
step by the prenylation under microwave heating and catalyzed by clay Montmorillonite-
K10 of 3,4-dihydroxyxanthone (1) with 21 % yield. However, If it is considered all the 
synthetic steps that lead to the 3,4-dihydroxyxanthone, XP13 is obtained in 4 steps with 
an overall yield of 9.6 %. Indeed, the last step reduced significantly the overall yield of this 
synthetic route (Figure 3.10). 
If analogues of XP13 with substituents on ring A are to be synthesized, the 
published route will most likely to be problematic not only due to the low yields of the last 
step but also by the influence that the putative substituents on ring A might have to the 
formation of the 2,2-dimethyl-3,4-dihydropyran. Accordingly, a new and more versatile 
route for the synthesis of xanthones had to be idealized for the synthesis of XP13 and 
analogues with substituents on ring A. 
 
Figure 3.56 Retrosynthetic plan for analogues of XP13 bearing substituents on ring A. 
 
Considering the route used for the synthesis of XBp26, XBp27 and XBp28, a 
similar retrosynthetic plan could be established (Figure 3.56). According to the idealized 
route, instead of 2,2-dimethylbenzopyran 110, a 2,2-dimethylbenzopyran with a more 
labile protecting group in position 8 could be used for the synthesis of XP13 and 
analogues bearing substituents on ring A (Figure 3.56) 
  
 
Figure 3.57 Retrosynthetic plan for the synthesis of a 2,2-dimethyldihydrobenzopyran for 
the synthesis of XP13 and analogues bearing substituents on ring A. 
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A similar strategy used for the synthesis of 2,2-dimethylbenzopyran 110 could be 
also applied using instead of 2,3-dimethoxyphenol, o-vanillin (Figure 3.57). According to 
the retrosynthetic plan idealized, an O-protecting group must be used that is resistant to 
the acidic conditions used in the Baeyer-Villiger-type oxidation, hydrogenation and 
bromination. The use of acidic conditions limit the number of protecting groups that could 
be used which includes the popular silyl, MOM and THP [31]. On the other hand, other 
groups such as benzyl are not resistant to the hydrogenation conditions and bromination. 
As a result, two type of protecting groups have to be used. In the Baeyer-Villiger the best 
option is the benzyl group that is removed during the hydrogenation and other group such 
as MOM or TBDMS is introduced for the bromination step. 
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Figure 3.58 Synthesis of compound 122. 
 
The O-benzylation of o-vanillin (121) was easily accomplished in quantitative yield 
using the published procedure [31] (Figure 3.58). The second step was more problematic 
and compound 122 was not obtained using the typical experimental conditions [121]. The 
literature refers that from a series of methoxylated benzaldehydes, the oxidation of 2,3-
dimethoxybenzaldehyde (similar to compound 122) was more difficult and the desired 
phenol was obtained in low yields (30 %), even with 63 hours of reaction which supports 
the unsuccessfulness of the reaction [121]. On the other hand, the use of boric 
acid/hydrogen peroxide in THF has been reported to improve the yields of the oxidation 
product of 2,3-dimethoxybenzaldehyde in shorter reaction times [189]. Using this 
procedure, compound 122 was synthesized after 56 hours of reaction in 54 % yield, being 
the benzyl ether stable under the experimental conditions.  
The structure of the compound 121 obtained from the O-benzylation of o-vanillin 
was characterized by common spectroscopic techniques and were in the accordance with 
the expected. The introduction of the benzyl group was evidenced by the presence of one 
methylene group (įH 5.18 s), one aldehyde proton (įH 10.23 s), one methoxyl group (įH 
3.94 s) and eight aromatic protons (įH 7.40-7.32 m 6H and įH 7.20-710 m 2H) in the 1H 
NMR spectrum and by the absence of any broad O-H stretching band in the IR spectrum. 
^ǇŶƚŚĞƐĞƐ
^ǇŶƚŚĞƐŝƐŽĨyƉϮϱƚŽyƉϯϯ
ϭϰϰ

The oxidation of compound 121 to compound 122 was evidenced in the 1H NMR spectrum 
by the absence of an aldehyde proton and presence of hydroxyl group (įH 5.03 broad), 
and in the IR spectrum by the presence of a broad O-H stretching band at 3507 cm-1. In 
spite of the relative success, an alternative synthetic pathway that could lead to the 
desired 2,2-dimethyldihydropyran with fewer steps and higher yields was sought. 
 
 
Figure 3.59 Alternative retrosynthetic plan for the synthesis of the desired 2,2-dimethyl-
3,4-dihydrobenzopyran. 
 
Several methodologies have reported a one step synthesis of 2,2-dimethyl-3,4-
dihydrobenzopyran by the reaction of an electron-rich phenol with a very reactive 1,1-
dimethylallyl cation generated in situ from several precursors namely, isoprene [190-201], 
prenyl alcohol [196], 2-methyl-3-buten-2-ol [196, 202-207], prenyl bromide [10, 208] and 
prenyl acetate [209]) through different acid catalysts. For that reason, it was expected that 
the 2,2-dimethyldihydrobenzopyran (123) could be obtained from 3-methoxycatechol 
which then just need to be O-protected and brominated to give the desired benzopyran 
(Figure 3.59).  
 
It was decided to use formic acid as the acid catalyst and 2-methyl-3-buten-2-ol as 
the 1,1-dimethylallyl cation precursor since they were used with fairly success for the 
synthesis of numerous 2,2-dimethyl-3,4-dihydrobenzopyrans from polyphenolic 
compounds [204, 206, 207]. In order to obtain mainly a monosubstituted product, special 
care must be given to the experimental procedure since the introduction of a dimethyl allyl 
cation in the aromatic ring increases the aryl nucleophilicity making it more prone to 
undergo a second addition reaction. Consequently, the 2-methyl-3-buten-2-ol should be 
added very slowly and be the limiting reagent [206].  If the reaction is stopped after the 
addition of the 2-methyl-3-buten-2-ol, large amounts of ortho-prenylated phenol might be 
obtained and as a result the reaction needs to be heated for at least one hour to 
guarantee that the 2,2-dimethyldihydrobenzopyran is formed [3, 67, 207].  
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Figure 3.60 Synthesis of compound 123 by the condensation of 3-methoxycatechol with 
2-methyl-3-buten-2-ol. 
 
The o-vanillin was oxidized to the 3-methoxycatechol with 91 % yield using a 
Baeyer-Villiger type oxidation (Figure 3.60). The 3-methoxycatechol was then allowed to 
react with 2-methyl-3-buten-2-ol under acid catalyst to give compound 123 with 36 % yield 
after 1 hour and half of reaction (Figure 3.60). 
 
 
Figure 3.61 Synthesis of the building block 127. 
 
The next two steps are the bromination and the O-protection of compound 123. In 
respect to the order of the reactions, it is better to do the bromination first since the 
experimental procedure of the bromination limits the type of protecting groups that could 
be used. Unfortunately, using the NBS/NH4OAc in acetonitrile protocol, two brominated 
isomers were obtained (124 and 125) (Figure 3.61). Since the bromination of aromatic 
compounds using NBS in acetonitrile as solvent has been described to follow a normal 
electrophilic aromatic substitution, it means that is mainly guided by electronic and steric 
factors [210]. As a result, if the phenol is protected first, the nucleophilicity of position 5 is 
decreased and the main product will likely be the desired compound (Figure 3.61). 
Among the different protecting groups it was decided to use tert-butyldimethylsilyl 
(TBDMS) ether as protecting group since it is stable not only under the bromination 
experimental procedure but also to the halogen-lithium exchange that will be done further 
ahead. Using the standard conditions [31, 211], compound 126 was obtained with 
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quantitative yield (Figure 3.61). The following step was the bromination and compound 
127 was obtained with high regioselectivity and in excellent yield (Figure 3.45). To sum 
up, the 2,2-dimethyl-3,4-dihydrobenzopyran 127 was synthesized in three steps with an 
overall yield of 35 % (the first step is not considered since 3-methoxycatechol is available 
commercially). 
All compounds were purified by silica gel flash chromatography and the structure 
of 3-methoxycatechol was confirmed by IR since its spectrum is available on commercial 
suppliers such as Sigma-Aldrich. The structure of compound 123 obtained from the 
reaction of the dimethyl allyl cation with 3-methoxycatechol was evidenced by 1H and 13C 
NMR spectra by the presence of two aromatic protons (įH 6.56 dt and įH 6.46 d), a 
methoxyl group (įH 3.87 s), two methylene groups (įH 2.74 td and įH 1.81 t), two geminal 
methyl groups (įH 1.38 s) and an oxygen bearing a quaternary carbon (įc 75.1) referring 
the last three to the 2,2-dimethyl-3,4-dihydrobenzopyran fused ring. In the IR spectrum of 
compound 123 it was also evidenced a broad O-H stretching band at 3461 cm-1 and 
several C-H bands (2969, 2944, 2922, 2852, and 2829 cm-1) The structure of compounds 
124 and 125 obtained from the bromination of compound 123 was evidenced by 1H NMR 
spectrum by the presence of one aromatic proton (įH 6.81 t for compound 124; įH 6.73 s 
for compound 125), and the structure of each isomer was assigned by the presence of an 
allylic coupling (J = 0.7) in one of the spectra corresponding to the structure of compound 
124. Moreover, the bromination was confirmed by the isotope ratio in the EIMS (288 (7, 
[M+2]+.) 286 (7, [M]+.) for compound 124; 288 (29, [M+2]+.) 286 (31, [M]+.) for compound 
125). The introduction of a TBDMS in compound 123 to give compound 126 was 
evidenced in 1H NMR spectrum by the presence of a tert-butyl group (įH 1.04 s) and two 
geminal methyl groups (įH 0.16 s), and also by the absence of an O-H stretching band in 
the IR spectrum. The bromination of compound 126 gave only one product and its 
structure was evidenced by 1H NMR spectrum by the presence of only one aromatic 
proton (įH 6.87 s). 
In order to be able to compare this route for the synthesis of XP13 with the 
published previously [1, 11], it was decided to synthesize XP13. According to the 
retrosynthetic plan established for the synthesis of analogues XBp26 to XBp28, the first 
step is a halogen-lithium exchange of the brominated 2,2-dimethylbehydrobenzopyran 
which will then behave as a nucleophile and add to the carbonyl of a protected 
salicylaldehyde (Figure 3.55). The secondary alcohol obtained from this reaction is 
oxidized to ketone, and then the O-deprotection and cyclization gives the xanthone 
(Figure 3.55). In order to decrease the number of synthetic steps, it was decided to use 
instead of a protected salicylaldehyde, a MOM-protected methyl salicylate.  
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The benzophenone 128 was synthesized in good yields (68 % yield) through a 
halogen lithium exchange between compounds 24 and 127 (Figure 3.62). The following 
step was the removal of the MOM group which was accomplished with NbCl5 leading to 
the expected benzophenone 129 (Figure 3.62) However, this was not the major product 
since the desilylated benzophenone 130 was obtained in 67 % yield possibly due to the 
acidity of NbCl5 that removed the TBDMS group (Figure 3.62). This result can be seen as 
an advantage since the removal of the silyl group means one step less in the route to 
XP13.  
 
Figure 3.62 Synthesis of benzophenones 129 and 130 that are intermediates in the 
synthesis of XP13. 
 
The next step towards the synthesis of XP13 was the cyclization of benzophenone 
130 which was accomplished in 15 minutes with cesium carbonate and microwave 
heating with 92 % yield (Figure 3.63). Though two more synthetic steps, this methodology 
gave XP13 with an overall yield of 14.5 % (6 steps), which is better than the previous one 
(9.6 % over 4 steps). Moreover, the final yield of XP13 could be higher since the protected 
benzophenone 129 was cyclized to XP13 in moderate yields (Figure 3.63). The 
cyclization of benzophenone 129 led also to an unexpected result since XBp1 was also 
obtained (Figure 3.63). 
 
Figure 3.63 Cyclization of benzophenones 129 and 130 to XP13. 
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All the compounds were purified by silica gel flash chromatography and the 
structure of benzophenone 128 obtained from the addition of the lithiated intermediate to 
the protected methyl salicylate was confirmed by common spectroscopic techniques and 
were in accordance with the expected. The 1H and 13C NMR spectra of benzophenone 
128 was evidenced the presence of 5 aromatic protons (įH 7.40 dd, įH 7.38 ddd, įH 7.14 
dd, įH 7.04 ddd and įH 7.00 s), one carbonyl carbon (įc 195.0), one methoxymethyl group 
(įH 5.05 s and įH 3.33 s), one methoxyl group (įH 3.51 s), the TBDMS group (įH 1.03 s 
9H and įH 0.17 s 6H), two methylene groups (įH 2.72 t and įH 1.78 t), two geminal methyl 
groups (įH 1.38 s) and an oxygen bearing a quaternary carbon (įc 75.6) referring the last 
three to the 2,2-dimethyl-3,4-dihydrobenzopyran fused ring. In the IR spectra it was also 
present a strong C=O stretching band at 1662 cm-1. The formation of the benzophenone 
129 and 130 was evidenced in the 1H NMR spectrum by the absence of any signal 
regarding the methoxyl methyl ether group and in the case of benzophenone 130, by the 
absence of the signals of the TBDMS group. In addition, the 1H NMR spectra of 
compound 129 evidenced the presence of one hydroxyl group (įH 12.27 s) and compound 
130 of two hydroxyl groups (įH 12.22 s and įH 5.62 broad). The IR of both compounds 
also showed the presence of a broad O-H stretching band. The products of the cyclization 
of benzophenones 129 and 130 were compared with samples of XP13 and XBp1.  
 
The new synthetic route is more versatile than the older and was applied for the 
synthesis of analogues of XP13 bearing substituents on ring A. Several salicylaldehydes 
were protected with benzyl group instead of the methoxymethyl ether group since it is 
cheaper than the former and its removal is easily made by hydrogenation. The 
salicylaldehydes chosen were 5-chloro, 5-methyl and 5-methoxylsalicylaldehyde, o-vanillin 
and 2,4-dihydroxybenzaldehyde (Figure 3.64) (the protection of 5-chloro, 5-methyl 
salicylaldehyde and o-vanillin had been described above).  
 
 
Figure 3.64 Protection of 5-methoxysalicyaldehyde (43) and 2,4-dihydroyxybenzaldehyde 
(45). 
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The first synthetic step was the coupling a lithiated intermediate of compound 127 
formed by halogen-lithium exchange with protected salicylaldehydes to give 
diarylmethanol derivatives. The reaction took place very smoothly for most of the case 
leading to the diarylmethanol derivatives obtained in good to excellent yields (Figure 
3.65). In the case of benzophenone 137, the purification was problematic and it was used 
in the next step impure. 
 
 
Figure 3.65 Synthesis of diarylmethanol derivatives 133-137 through the coupling of a 
lithiated intermediate generated from a halogen-lithium exchange with protected 
salicylaldehydes.   
  
The next step of the synthetic route was the synthesis of benzophenones through 
the oxidation of the secondary alcohols to ketone using IBX. Benzophenones 138 to 142 
were obtained in moderate yields (Figure 3.66).  
  
 
Figure 3.66 Synthesis of benzophenones 138-142 through the oxidation with IBX of the 
respective diarylmethanol derivatives. 
 
The next step in the synthetic approach towards the xanthone was the removal of 
the benzyl protecting group which was accomplished using the Pd/C/triethylsilane/MeOH 
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methodology in good to excellent yield for the great majority of the benzophenones 
(Figure 3.67). However, in the benzophenone 138, besides the unprotected compound, a 
hydrodechlorinated benzophenone was also obtained (the same structure of 
benzophenone 130; Figure 3.67). The benzophenone 130 and 143 had a similar 
chromatographic behavior and as a result were used directly in the next reaction. The 
hydrodehalogenation catalyzed by palladium on charcoal has been described previously 
[212-217], but as far as we now, there is not a report in the literature of 
hydrodechlorination using triethylsilane as a transfer hydrogenation catalyst. 
 
 
  
 
Figure 3.67 Removal of the benzyl group from the benzophenones by hydrogenation. 
 
The last step towards the synthesis of XP13 analogues with substituents on ring A 
was the cyclization of the benzophenones 143-147 to xanthones using an intramolecular 
SNAr. The cyclization of the benzophenones was accomplished using microwave heating 
at 140 ºC for 15 minutes and cesium carbonate in DMF. The experimental conditions, as 
shown previously in the cyclization of benzophenone 168 to XP13, lead to the cyclization 
of the xanthone and also remove the TBDMS protecting group. Therefore, the cyclization 
of all the benzophenones led to O-deprotected xanthones in good yields (Figure 3.68). In 
the cyclization of benzophenone 147, besides the xanthone, a benzophenone without the 
TBDMS (148) was also isolated (Figure 3.52). 
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Figure 3.68 Cyclization of the benzophenones to xanthone. 
 
 
 
The purification of all the compounds was mostly done by silica gel flash 
chromatography and in the case of compound 143 and benzophenone 137 an impure 
sample was used. 
 
 
The protection of salicylaldehydes was confirmed by 1H NMR and IR spectra and 
the structure of diarylmethanols 133-136 (diarylmethanol 137 was not pure) obtained from 
the reaction between the salicylaldehydes and compound 127 were evidenced by the 1H 
NMR spectra through the presence of two methylene groups (įH 2.61 t and įH 1.73 t for 
compound 133; įH 2.62 td and įH 1.73 t for compound 134; įH 2.65 t and įH 1.75 t for 
compound 135; įH 2.57 t and įH 1.69 t for compound 136) and two geminal methyl groups 
(įH 1.37 s and įH 1.33 s for compound 133; įH 1.37 s and įH 1.35 s for compound 134; įH 
1.39 s and įH 1.36 s for compound 135; įH 1.33 s and įH 1.31 s for compound 136) 
corresponding to the 2,2-dimethyl pyran moiety, by the aromatic protons (įH 7.43 d, įH 
7.32-7.16 m 6H (one correspond to the aromatic proton), įH 6.82 d and 6.41 s for 
compound 133; įH 7.42-7.18 m 6H (one correspond to the aromatic proton), įH 7.03 d, įH 
6.5 d and įH 6.48 s for compound 134, įH 7.34-7.25 m 4H (one correspond to the 
aromatic proton), įH 7.02 dd, įH 6.84 d and įH 6.51 s for compound 135; įH 7.38-7.17 m 
6H (one correspond to the aromatic proton), įH 7.06 d, įH 6.68 d and įH 6.41s for 
compound 136), the benzyl proton (įH 6.26 d for compound 133; įH 6.32 s for compound 
134, įH 6.34 s for compound 135, įH 6.25 broad s for compound 136) and hydroxyl (įH 
3.00 broad for compound 133; įH 2.91 broad d for compound 136) corresponding to the 
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dibenzylalcohol moiety, by the signals corresponding to the benzyl protecting group (įH 
7.32-7.16 m 6H (five of these protons correspond to the benzyl group), įH 5.05 d and įH 
4.99 d for compound 133; įH 7.42-7.18 m 6H (five correspond to the aromatic proton), įH 
5.02 d and įH 4.93 d for compound 134; įH 7.34-7.25 m 4H (one correspond to the 
aromatic proton), įH 7.23-7-20 m 2H, įH 5.07 d and įH 5.03 d for compound 135; įH 7.39-
7.17 m 6H (five of these protons correspond to the benzyl group), įH 5.01 d and įH 4.82 d 
for compound 136) and also by the presence of the TBDMS group (įH 1.04 s 9H, įH 0.18 
s 3H and įH 0.13 s 3H for compound 133; įH 1.05 s 9H, įH 0.20 s 3H and įH 0.18 s 3H for 
compound 134; įH 1.07 s 9H, įH 0.22 s 3H and įH 0.20 s 3H for compound 135; įH 1.06 s 
9H, įH 0.16 s 3H and įH 0.14 s 3H for compound 136). The presence of the hydroxyl 
group was also evidenced by the IR spectrum by the presence of a broad band of the O-H 
stretching (3445 cm-1 for compound 133; 3421 cm-1 for compound 134; 3439 cm-1 for 
compound 135; 3443 cm-1 for compound 136; 3374 cm-1 for compound 137). The 
oxidation of the diarylmethanols 133-137 to give benzophenones 138-142 was confirmed 
by 1H NMR spectra by the absence of the dibenzylic alcohol moiety and presence of a 
carbonyl group (įc 193.5 for compound 138; įc 194.5 for compound 139; įc 195.5 for 
compound 140; įc 195.0 for compound 141; įc 194.2 for compound 142) and also by the 
presence of a strong C=O stretching band in the IR spectrum (1637 cm-1 for compound 
138; 1640 cm-1 for compound 139; 1639 cm-1 for compound 140; 1658 cm-1 for compound 
141; 1638 cm-1 for compound 142) as well as no O-H stretching band. The O-deprotection 
of the benzophenones 138-142 was evidenced in the 1H NMR spectrum by the absence of 
any signal regarding the benzyl group, as well as the presence of a hydroxyl group in 
benzophenones 143-146 (įH 12.15 for compound 143; įH 11.90 for compound 144; įH 
12.07 for compound 145, įH 12.55 for compound 146) and two in benzophenone 147 (įH 
12.75 and įH 5.71). In the IR spectrum, a broad O-H stretching band was also observed 
(3434 cm-1 for compound 143; 3437 cm-1 for compound 144; 3438 cm-1 for compound 
145, 3454 cm-1 for compound 146, 3383 cm-1 for compound 147). The structure 
compound 130 obtained from the hydrodechlorinated of compound 138 was confirmed 
with a previous sample by NMR and IR.  
The structure of XBp29, XBp30, XBp31, XBp32 and XBp33 was confirmed by 
common spectroscopic techniques and were in accordance with the expected for these 
compounds. In comparison with the 1H NMR spectrum of benzophenones 143 to 147, the 
spectrum of XBp29, XBp30, XBp31, XBp32 and XBp33 (Tables 3.12 and 3.13) did not 
show any highly dishielded hydroxyl group, and instead, a less dishielded hydroxyl group 
of position 12 (įH 5.75 broad for XBp29; įH 8.12 broad for XBp30, įH 5.85 broad for 
XBp31, įH 6.03 broad for XBp32; įH 9.50 for XBp33) as well as the absence of signal 
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corresponding to one methoxyl group. The substituents on ring A could also evidenced in 
the 1H NMR spectrum of XBp29 by the presence of only four aromatic protons (įH 8.28 d, 
įH 7.67 t, įH 7.62 dd, įH 7.53 d (the second proton is from position 5)), by one methoxyl 
group in XBp30 and XBp32 (įH 3.91 s for XBp30, įH 4.03 s for XBp32), by a methyl 
group in XBp31 (įH 2.45 s) and by a hydroxyl group in XBp33 (įH 10.80 s). The HRMS 
was in the accordance with molecular formula of compounds XBp29, XBp30, XBp31, 
XBp32 and XBp33 ([M+H]+ C18H16ClO4 for XBp29; [M+H]+ C19H19O5 for XBp30; [M+H]+ 
C19H19O4 for XBp31; [M+H]+ C19H19O5 for XBp32, [M+H]+ C19H17O5 for XBp33). The 
structure of compound 149 was evidenced in the 1H NMR spectrum by the presence of 
three hydroxyls (įH 12.61 broad, įH 10.90 broad and įH 8.70 broad) and one methoxyl 
group (įH 3.61 s). The HRMS was also in accordance with molecular formula of this 
compound ([M+H]+ C19H21O6). 
 
Table 3.12 1H NMR for XBp29, XBp30, XBp31, XBp32 and XBp33.a. 
 XBp29b XBp30c XBp31b XBp32b XBp33d 
H-3  1.92 (t, J = 6.7) 1.91 (t, J = 6.7) 1.92 (t, J = 6.7) 1.92 (t, J = 6.7) 1.84 (t, J = 6.6) 
H-4 2.91 (td, J = 6.7, 1.0) 2.94 (t, J = 6.7) 
2.93 (td, J = 
6.7, 1.0) 
2.93 (td, J = 
6.7, 1.0) 2.87 (t, J = 6.6) 
H-5 7.67 (t, J = 1.0) 7.58 (s) 7.68 (t, J = 1.0) 7.67 (t, J = 1.0) 7.48 (s) 
H-7 8.28 (d, J = 2.6) 7.64 (d, J = 3.1) 8.11-8.10 (m) 7.88 (dd, J = 7.8, 1.8) 
8.02 (d, J = 
8.5.6) 
H-8 - - - 7.27 (t, J = 7.8) 6.87 (d, J = 8.5, 2.0) 
H-9 7.62 (dd, J = 8.4, 9.0) 
7.28 (dd, J = 
9.1, 3.1) 
7.48 (dd, J = 
8.7, 2.0) 
7.20 (dd, J = 
7.8, 1.8) 
10.80 [broad, 
OH] 
H-10 7.53 (d, J= 9.0) 7.52 (d, J= 9.1) 7.53 (dd, J= 8.7, 0.6) - 6.89 (d, J= 2.0) 
H-12 5.75 [broad, OH] 
8.12 [broad, 
OH] 
5.85 [broad, 
OH] 
6.03 [broad, 
OH] 
9.50 [broad, 
OH] 
H-1’a and b 1.45 (s) 1.45 (s) 1.43 (s) 1.44 (s) 1.38 (s) 
H-1’’ - 3.91 (s) 2.45 (s) 4.03 (s) - 
a.Values in ppm (įH) measured at 300.13 MHz. J values (Hz) are shown in parentheses; the 1H chemical shifts 
were assigned by comparison with assignments for XP13, XBp1 and XBp2͘ bThe 1H chemical shifts were 
measured in CDCl3. cThe 1H chemical shifts were measured in CDCl3:DMSO-d6 (10:1). dThe 1H chemical 
shifts were measured in DMSO-d6. 
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Table 3.13 13C NMR for XBp29, XBp30, XBp31, XBp32 and XBp33.a 
 XBp29b XBp30c XBp31b XBp32b XBp33d 
C-2 77.5 75.5 76.6 76.9 75.8 
C-3 32.5 31.7 32.6 32.6 31.9 
C-4 21.7 21.2 21.2 21.9 21.6 
C-4a 118.6 117.7 118.0 118.5 113.8 
C-5 117.1 115.1 117.0 117.6 118.4 
C-5a 115.0 113.7 115.4 115.1 113.5 
C-6 175.5 175.5 176.7 176.6 174.5 
C-6a 122.4 120.8 121.1 123.0 114.4 
C-7 126.0 118.5 126.0 116.7 127.9 
C-8 129.3 150.0 133.3 114.9 115.3 
C-9 134.3 123.0 135.5 122.4 163.4 
C-10 119.7 105.1 117.7 146.5 102.1 
C-10a 154.5 154.7 154.4 148.6 157.5 
C-11a 143.1 143.3 143.3 - 143.9 
C-12 132.5 132.3 132.3 132.8 133.1 
C-12a 146.6 146.5 146.1 146.4 147.2 
C-1’a and C-1’b 27.0 26.1 27.0 26.9 26.6 
C1’’ - 55.0 20.8 56.4 - 
a.Values in ppm (įC) measured at 75.47 MHz; the 13C were assigned by comparison with assignments for 
XP13, XBp1 and XBp2. bThe 13C chemical shifts were measured in CDCl3. cThe 13C chemical shifts were 
measured in CDCl3:DMSO-d6 (10:1). dThe 13C chemical shifts were measured in DMSO-d6. 
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3.1.4 Synthesis of XPr1 to XPr4 
 
 This section will refer to the prenylation of an oxygenated xanthone, namely 1,2-
dihydroxyxanthone (21).  
 
 
Figure 3.69 Prenylation of 1,2-dihydroxyanthone (21).  
 
The prenylation of 1,2-dihydroxyxanthone (21) (obtained using the procedure 
described in Figure 3.38) with prenyl bromide under basic catalysis and in acetone as 
solvent led to one mono-prenylated (compound XPr2) and two di-prenylated xanthones 
(compounds XPr1 and XPr3), being the XPr1 the compound obtained with higher yield 
(Figure 3.69; method A.). 
 
 
Figure 3.70 Retrosynthetic plan for the synthesis of XBp10 from XPr2.  
 
O-Prenylated aryl compounds had been described in the literature to follow a [1,3]-
sigmatropic rearrangement catalyzed by Montmorillonite KSF [218], Montmorillonite K-10 
[219-221] and Florisil [220, 222] to give ortho and para-prenyl phenols, which in the case 
of ortho prenyl phenols, prolonged heating with Montmorillonite KSF or K-10 led to the 
intramolecular cyclization to 2,2-dimethylbenzodihydropyran [218, 220, 221]. Accordingly, 
compound XPr2 could be used as a building block for the synthesis of XBp10 if it was 
allowed to heat for prolonged time in Montmorillonite KSF or K-10 (Figure 3.70). In order 
to achieve this goal, the XPr2 must be obtained with higher yields and as a result a new 
^ǇŶƚŚĞƐĞƐ
^ǇŶƚŚĞƐŝƐŽĨyWƌϭƚŽyWƌϰ
ϭϱϲ

prenylation reaction was made on 1,2-dihydroxyxanthone (21) but this time at room 
temperature and with an equimolar quantity of prenyl bromide. The milder conditions 
increased the yield of XPr2 and also led to another product, XPr4 (Figure 3.69, method 
B). 
 
 
Figure 3.71 Rearrangement of compound XPr2 clay-catalyzed. 
 
After obtaining XPr2, the next step was heating of XPr2 catalyzed by 
Montmorillonite K-10 for prolonged reaction time to obtain XBp10 in one step. However, 
the heating of XPr2 using microwaves with Montmorillonite K-10 at 115 ºC for 30 minutes 
did not lead to the XBp10 but instead to XPr4 and 1,2-dihydroxyxanthone (21) (Figure 
3.71). The synthesis of XPr4 from XPr2 mean that under this experimental conditions, the 
mechanism is probably not the [1,3]-sigmatropic rearrangement as it has been proposed 
by most groups [218-220], but possibly a mechanism involving the breakage of the O-
prenyl bond to give an dimethyl allyl cation followed by a normal electrophilic aromatic 
substitution. Nevertheless, this route has shown to be an interesting alternative route for 
the synthesis of XPr4 which was obtained in low yield previously (Figure 3.69). 
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Figure 3.72 Thermal rearrangement of XPr1. 
 
Compound XPr3 was obtained in low yield from the prenylation reaction (Figure 
3.69) and it was envisioned that this compound could also be obtained from para-Claisen 
rearrangement of compound XPr1. As a result, the heating of compound XPr1 in DMF at 
reflux gave compound XPr3 with 70 % yield alongside with compound XPr2 being the 
latter obtained with low yield (Figure 3.72). 
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All the compounds were purified by silica gel flash chromatography and the 
structures of compounds XPr1, XPr2, XPr3 and XPr4 were characterized by the common 
spectroscopic methodologies. In the case of the 1H NMR spectrum of compound XPr1, 
the presence of two prenyl moieties was evidenced by the presence of four methyl groups 
(įH 1.84 s 6H, įH 1.81 s 3H and įH 1.77 s 3H), two methylenic groups (įH 4.73 d and įH 
4.67 d) and two olefinic groups (įH 5.83 broad t and įH 5.57 broad t). The position of the 
two prenyl groups was evidenced by the presence of six aromatic protons (įH 8.35 dd, įH 
7.70 ddd, įH 7.44 d, įH 7.39 d, įH 7.37 ddd and įH 7.23 d) in the 1H NMR spectrum, and 
by the absence a broad O-H stretching band in the IR spectrum. In the case of the 1H 
NMR spectrum of compound XPr2, the presence of one prenyl moiety was evidenced by 
the presence of two geminal methyl groups (įH 1.84 s 3H and įH 1.79 s 3H), one 
methylenic group (įH 4.71 d) and by one olefinic group (įH 5.60 broad t). The position of 
the prenyl group was evidenced by the presence of six aromatic protons (įH 8.33 dd, įH 
7.79 ddd, įH 7.50 dd, įH 7.43 ddd, įH 7.38 d and įH 6.94 d) and one dishielded OH group 
(įH 12.86 d) in the 1H NMR spectrum, and by the presence of a broad O-H stretching 
band at 3441 cm-1 in the IR spectrum. The presence of two prenyl moieties in XPr3 was 
evidenced through the 1H NMR by the presence of four methyl groups (įH 1.86 s 3H, įH 
1.83 s 3H, įH 1.82 s 3H and įH 1.79 s 3H), two methylenic groups (įH 4.70 d and įH 3.59 
d) and two olefinic protons (įH 5.59 broad t and įH 5.38 broad t). The presence of one C-
prenyl was evidenced by the presence of five aromatic protons (įH 8.33 dd, įH 7.80 ddd, 
įH 7.54 d, įH 7.43 ddd and įH 7.26 s) and one dishielded OH group (įH 12.74 ppm) 
meaning that one must be bonded to carbon 3 or 4. However, since the thermal 
rearrangement of compound XPr1 led to the same compound (confirmed by NMR, IR and 
Mp) obtained from the prenylation of 1,2-dihydroxyxanthone (21), XPr3 must have the 
prenyl group bonded in carbon 4.  
 
 
 
Figure 3.73 Main connectivities found in the HMBC of compound XPr4. 
 
^ǇŶƚŚĞƐĞƐ
^ǇŶƚŚĞƐŝƐŽĨyWƌϭƚŽyWƌϰ
ϭϱϴ

In the 1H NMR spectrum of compound XPr4, the presence of one prenyl moiety 
was evidenced by the presence of two geminal methyl groups (įH 1.81 s 3H and įH 5.77 s 
3H), one methylenic group (įH 3.54 d) and by one olefinic proton (įH 5.33 broad t). 
Moreover, the presence of a C-prenyl was evidenced by the presence of five aromatic 
protons (įH 8.28 dd, įH 7.76 ddd, įH 7.51 dd, įH 7.39 ddd and įH 7.24 s) but the prenyl 
could be either bonded to carbon 3 or 4. The position of the C-prenyl was assigned based 
on the HMBC and HSQC of compound XPr4. The main connectivities of HMBC for 
compound XPr4 can be seen in Figure 3.73 and due to the correlation of the proton in 
position 3 with the carbons of positions 1, 2 and 4a, the prenyl could only be assigned to 
position 4. The HRMS was in the accordance with molecular formula of compounds XPr1, 
XPr2, XPr3 and XPr4 ([M+H]+ C23H25O4 for XPr1; [M+H]+ C18H17O4 for XPr2; [M+H]+ 
C23H25O4 for XPr3; [M+H]+ C18H17O4 for XPr4). 
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3.2 Drug-like Profiling 
 
The XP13 can be considered as a “hit” compound and it was used as the starting 
point and inspiration for the synthesis of analogues (chapter 3.1), which will then be 
evaluated not only in terms of their biological activity (chapter 3.3) but also on their drug-
like character. The objective is to obtain compounds with balanced activity and good 
ADME-Tox behavior. Moreover, the synthesized compounds can also serve as a tool 
since the results obtained can help to better understand the biological and 
physicochemical behavior of xanthones, as well as inform and predict what type of 
structural changes must be done in order to improve the pharmacokinetic behavior and 
prevent toxicological and safety issues. 
The pharmacokinetical and toxicological behavior can be related to several key 
structural and physicochemical properties being lipophilicity the most important [223-226]. 
Therefore it was decided to evaluate this property for all the synthesized compounds. Two 
membrane models were chosen: liposomes and micelles. It was decided to compare the 
two models and determine if the micelle-water could be used as an alternative to 
liposome-water model since is less laborious. The values obtained experimentally were 
also compared with the lipophilicity calculated using three computational programs. 
Besides the lipophilicity, the solubility and the plasma protein binding are also very 
important for the drug-like profiling of a compound and were evaluated for XP13 and some 
of its analogues. In addition to the experimental evaluation of different properties, the 
fulfillment of different set of rules by all the compounds was evaluated, enabling to realize 
the compounds that were not drug-like, and consequently, might not be available orally. In 
the end, the evaluation of all the structural and physicochemical properties allowed the 
prediction of the likelihood that XP13 and their analogues have of showing any 
pharmacokinetic and toxicological liabilities.  
 
3.2.1 Lipophilicity 
  
 The lipophilicity is a key physicochemical property influencing the 
pharmacokinetical and toxicological behavior of a compound [223-226]. The lipophilicity is 
commonly measured using a biphasic octanol-water system [227-229]. Albeit being 
spread among the scientific community, the octanol-water method fails to mimic the 
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membrane anisotropic media and encode some important interactions that take place 
between the solute and biomembranes [230]. Therefore, other models have been 
developed to take in consideration the anisotropic media found in membranes, being the 
liposome-water and IAM chromatographic the most well-known (Chapter 2) [230, 231]. 
Though liposome-water mimics to a better extent the biomembranes, liposomes are very 
laborious and as a result they are not commonly used in routine assays for the 
determination of lipophilicity. On the other hand, micelles are much easier to work with 
and if the same type interactions and with the same strength encoded in liposomes take 
place in micelles, the micelle-water model could become an important alternative to the 
liposome-water model for the determination of lipophilicity. Bearing this in mind, it was 
decided to determine the partition coefficient for a chemical library of analogues of XP13, 
oxygenated xanthones, benzophenones and prenylated xanthones using these two 
membrane models.  
This section will be divided in two parts: in the first part (3.2.1.1), the values 
obtained from the two membrane models will be compared between each other to 
evaluate the possibility of using micelles as an alternative to liposomes for the 
determination of lipophilicity, and later compared with the data obtained from three in silico 
programs commonly used for the calculation of Log P and Log D; in the second part 
(3.2.1.2), the chemical library of xanthones will be divided into different groups with similar 
structure to evaluate the influence that different functionalities have on the lipophilicity 
determined in micelles, liposomes and in silico. 
 
3.2.1.1 Comparison of lipophilicity values for all the data set 
  
The partition coefficient between liposomes and micelles was determined by 
derivative UV-Vis spectroscopy described in chapter 2. In Figure 3.74 is represented an 
illustrative experiment used for the determination of the partition coefficient in liposomes 
and micelles. As it can be depicted from the Figure 3.74, the second derivative increased 
significantly the resolution of the spectrum. Moreover, it can also be observed derivative 
isosbestic points that show the existence of an equilibrium between two states (solute 
interacting with the membrane/solute free in the aqueous phase) and the elimination of 
the residual background signal. The calculation of the partition coefficient was 
accomplished for the selected Ȝmax by plotting the derivative spectrophotometric data as a 
function of the lipid concentration. The data was fitted using the equation presented in 
chapter 2 with a non-linear regression method, being the partition coefficient one of the 
adjustable parameters. 
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Figure 3.74 Determination of the partition coefficient in micelles and liposomes for 
compound XBp12. 
 
The overall determination could be time consuming since spectra for different 
concentrations of lipid, with and without solute, need to be traced. In addition, there is also 
the need to calculate the second derivative for each spectrum. In order to make this 
methodology more expedite, a methodology developed by Magalhães et al [232] was 
developed and transposed for the determination of the partition coefficient of a solute 
between micelles and water, to liposomes and water. In this methodology a 96-well plate 
is used to allow a high throughput aided by an Excel calculator application developed for 
the determination of the partition coefficient by derivative spectroscopy. However, to 
increase the solubility of our compounds in water, DMSO needed to be added to each 
well, keeping to a maximum of 1 % since higher amounts could interfere with the partition 
between the two phases [227]. For compounds with either low solubility or low molar 
extinction, the spectra were traced in a more sensitive double-beam spectrophotometer. 
However, for few of the compounds, the solubility was too low and, even with the double-
beam spectrophotometer, the partition coefficient in liposomes was not evaluated due to 
the interference caused by light scattering. In the case of analogues XBp3, XBp22 and 
XBp25, we were not able to determine the partition coefficient due to the low quantity of 
compound obtained by synthesis. 
In Table 3.14 are represented all the partition coefficients determined 
experimentally for most of the analogues of XP13. Moreover, benzophenones 130 and 
148 containing a 2,2-dimethyl-3,4-dihydropyran fused ring, and a small chemical library of 
oxygenated xanthones from CEQUIMED-UP were evaluated. The oxygenated xanthones 
were 1-methoxyxanthone (149), 1-hydroxyxanthone (150), 2-methoxyxanthone (38), 2-
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hydroxyxanthone (33), 3-methoxyxanthone (151), 3-hydroxyxanthone (152), 4-
methoxyxanthone (37), 4-hydroxyxanthone (31), 1,2-dimethoxyxanthone (36), 1,2-
dihydroxyxanthone (29), 1,3-dihydroxyxanthone (3), 2,3-dihydroxyxanthone (153), 2,4-
dimethoxyxanthone (10), 3,4-dimethoxyxanthone (4), 3-hydroxy-4-methoxyxanthone (2), 
4-hydroxy-3-methoxyxanthone (6), 3,4-dihydroxyxanthone (1), 3,6-dihydroxyxanthone 
(154), 1,3-dihydroxy-2-methylxanthone (155).  
 
Table 3.14 Partition coefficients in liposomes-water and micelle-water for a chemical 
library of analogues of XP13, benzophenones, oxygenated and prenylated xanthones. 
Compound Log Kpliposomesa Log Kpmicellesa 
XP13 3.35 ± 0.02 3.28 ± 0.02 
XBp1 3.60 ± 0.08 3.59 ± 0.06 
XBp2 3.88 ± 0.09 3.83 ± 0.05 
XBp4 3.94 ± 0.09 4.07 ± 0.10 
XBp5 3.92 ± 0.04 3.88 ± 0.02 
XBp6 3.06 ± 0.16 3.29 ± 0.06 
XBp7 3.54 ± 0.01 3.76 ± 0.03 
XBp8 3.09 ± 0.18 3.58 ± 0.08 
XBp9 4.17 ± 0.06 4.15 ± 0.08 
XBp10 3.96 ± 0.03 3.88 ± 0.08 
XBp11 3.32 ± 0.12 3.33 ± 0.02 
XBp12 3.08 ± 0.06 3.46 ± 0.01 
XBp13 - 4.08 ± 0.04 
XBp14 - 4.28 ± 0.03 
XBp15 3.42 ± 0.02 3.50 ± 0.12 
XBp16 4.14 ± 0.08 4.10 ± 0.04 
XBp17 - 4.34 ± 0.04 
XBp18 4.48 ± 0.07 4.41 ± 0.03 
XBp19 - 4.21 ± 0.04 
XBp20 4.32 ± 0.06 4.29 ± 0.02 
XBp21 - 3.90 ± 0.06 
XBp23 4.62 ± 0.02 4.70 ± 0.04 
XBp24 3.88 ± 0.08 3.83 ± 0.1 
XBp26 3.43 ± 0.04 3.49 ± 0.06 
XBp27 4.02 ± 0.03 4.01 ± 0.06 
XBp28 - 3.88 ± 0.03 
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Table 3.14 (cont) 
Compound Log Kpliposomesa Log Kpmicellesa 
XBp29 - 4.39 ± 0.12 
XBp30 3.25 ± 0.08 3.35 ± 0.04 
XBp31 3.86 ± 0.08 3.92 ± 0.01 
XBp32 3.53 ± 0.04 3.58 ± 0.01 
XBp33 3.32 ± 0.10 3.76 ± 0.07 
XP25 - 4.27 ± 0.06 
XP11 - 4.32 ± 0.04 
XP26 - 4.06 ± 0.01 
XP12 - 4.02 ± 0.03 
XPr1 - 4.49 ± 0.03 
XPr2 - 3.91 ± 0.06 
XPr3 - 4.10 ± 0.05 
XPr4 - 4.62 ± 0.09 
1 2.48 ± 0.05 2.59 ± 0.04 
2 2.19 ± 0.08 2.65 ± 0.01 
3 3.49 ± 0.05 3.60 ± 0.01 
4 2.79 ± 0.02 2.94 ± 0.03 
6 2.61 ± 0.02 2.60 ± 0.01 
10 3.08 ± 0.06 3.41 ± 0.01 
29 3.44 ± 0.05 3.52 ± 0.03 
31 2.85 ± 0.05 2.87 ± 0.03 
33 3.26 ± 0.05 3.63 ± 0.01 
36 - 2.82 ± 0.01 
37 2.86 ± 0.02 2.90 ± 0.05 
38 3.30 ± 0.03 3.21 ± 0.01 
130 3.97 ± 0.03 3.73 ± 0.12 
148 3.44 ± 0.03 3.71 ± 0.11 
149 2.72 ± 0.04 2.78 ± 0.04 
150 3.40 ± 0.06 3.12 ± 0.02 
151 3.09 ± 0.01 3.31 ± 0.03 
152 2.90 ± 0.03 3.04 ± 0.01 
153 - 3.03 ± 0.02 
154 2.55 ± 0.02 2.95 ± 0.02 
155 3.85 ± 0.04 3.62 ± 0.05 
aMean of three independent measurements. 
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 In order to compare the liposome and micelle models used for the determination of 
the partition coefficient by second derivative, the Log Kp obtained from the liposome was 
ploted versus the Log Kp obtained from the micelle. A scatter plot was built with the 
values of Log Kp obtained for both models and it was observed a good linear correlation 
between them (Figure 3.75). The correlation equation is represented bellow wherein 95% 
confidence limits are in parentheses, n is the number of compounds, r2 the squared 
correlation coefficient, s the standard deviation, and F Fisher’s test. The slope of the 
correlation equation is near one, which means that there is not clear tendency for this 
class of compounds to increase the affinity for either of the membrane models with an 
increase of hydrophobicity. If the slope was higher or lower than one, we could suppose 
that with an increase in the hydrophobicity, the affinity was higher or lower for liposomes, 
respectively, than for micelles. On the other hand, since the y-intercept is slightly lower 
than zero (-0.3508), we suppose that it is probable that the sum of interactions taking 
place between these compounds and micelles is in general slightly higher than with 
liposomes since the Log Kp obtained with micelles is higher than with liposomes. 
However, our sample was limited to a class of xanthones with a strict range of Log Kp, 
and consequently we need to evaluate other families of compounds bearing other type of 
functionalities such as aldehydes, amines, amides, esters, carboxylic acid and alcohols to 
confirm the correlation between the two models. 
 
Log Kpliposomes = -0.3508(± 0.20319) + 1.075(± 0.0572)Log Kpmicelles 
n = 43; r2 = 0.90; s = 0.182; F = 352. 
 
 
Figure 3.75 Correlation between log Kpmicelles and log Kpliposomes. 
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The sample of compounds used consisted on neutral and ionizable molecules and 
the determination of the partition coefficient was made at pH 7.4, which means that for the 
ionizable compounds, depending on the pKa, a percentage of the compounds were in 
their ionized form. Bearing in mind what was referred in chapter 2 about the different 
interactions between liposome-water and octanol-water models and the possibility of 
electrostatic interactions with liposomes, it was decided to divide our sample into two 
groups, one with the ionizable compounds and other with the neutral compounds. The 
objective is to compare the two membrane models and observe if there is a better 
correlation for any of the groups, and in addition, by the slope and y-interception, if the 
interaction is of the same magnitude for both models. A good correlation between the two 
models was obtained for both neutral and ionizable compounds, being the correlation 
slightly better for the neutral compounds (Figure 3.76). The slope was similar for the two 
models being just slightly higher than one. In relation with the y-interception, the value for 
ionizable compounds was slightly lower than the value for neutral compounds. Therefore, 
the sum of interactions for ionized and neutral compounds with micelles is generally 
higher than with liposomes, but the difference is higher for ionizable molecules than for 
neutral molecules. Nevertheless, there is still a good correlation between the two 
membrane models meaning that the micelles could be used as an alternative for liposome 
models for the determination of lipophilicity for either ionized or neutral compounds, albeit 
more compounds need to be tested to assure the applicability of this model. 
 
 
Neutral compounds (A): 
Log Kpliposomes = -0.2847(± 0.28545) + 1.058(± 0.0788)Log Kpmicelles 
n = 20; r2 = 0.91; s = 0.16259; F = 181. 
 
 
Ionizable compounds (B): 
Log Kpliposomes = -0.4029(± 0.30467) + 1.089(± 0.0875)Log Kpmicelles 
n = 23; r2 = 0.88; s = 0.204; F = 157.   
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Figure 3.76 Correlation between liposomes and micelles for neutral (A) and ionizable (B) 
compounds.  
 
In order to evaluate the in silico lipophilicity of our compounds, it was decided to 
use three different computational programs: the ChemDraw/biobyte CLogP 
(ChemBioOffice 2010) which uses a fragmental method based on Hansch and Leo 
system; ALogPs (version 2.1) that uses topological descriptors; and ACDLogP (version 
6.0) which uses a fragmental approach based on atom and fragment contributions. The 
latter has also the possibility of predicting not only the Log P but also the Log D at 
different pHs, which is an important feature for compounds with ionizable functionalities. 
Moreover, since the partition coefficients in micelle-water and liposome-water were 
determined at pH 7.4, a comparison with the Log P and Log D
 
for ionizable compounds 
will be established. 
As referred previously, the determination of lipophilicity is commonly calculated 
from the partition of a solute between the biphasic system, octanol and water. However, 
this model has some limitations since it fails to mimic the anisotropic media of biological 
membranes which can be accomplished with membrane models. Nevertheless, all the 
membrane models need to be compared to the octanol-water model which is still the “gold 
standard” methodology. The octanol-water partition coefficient was not determined 
experimentally but was calculated using three different in silico programs. Moreover, since 
some of the molecules are ionizable, it was decided also to calculate the Log D for a pH of 
7.4 for those molecules. In Table 3.15 are compiled the Log P for all the compounds 
calculated using three different programs. The programs are created using different 
algorithms and as result, the values obtained in silico can differ between programs as it 
can be depicted from Table 3.15. 
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Table 3.15 Partition coefficients calculated in silico for a chemical library of analogues of 
XP13, benzophenones, oxygenated and prenylated xanthones. 
Compound CLogP ALogPs ACDLogP ACDLogD7.4 
XP13 4.33 4.09 3.90 3.86 
XBp1 4.70 4.07 4.53 - 
XBp2 4.60 3.92 4.29 - 
XBp4 4.59 3.92 4.55 - 
XBp5 4.70 4.08 4.76 - 
XBp6 4.23 4.18 4.93 4.77 
XBp7 4.59 3.92 4.71 - 
XBp8 4.70 4.15 4.95 - 
XBp9 5.13 4.15 5.47 4.61 
XBp10 5.23  4.14 5.37 5.09 
XBp11 4.59 3.91 4.25 - 
XBp12 4.70 4.13 4.49 - 
XBp13 5.12 4.13 4.99 4.80 
XBp14 5.23 4.06 4.89 4.76 
XBp15 4.56 4.11 4.41 - 
XBp16 4.56 4.11 5.01 - 
XBp17 5.31 4.47 5.34 - 
XBp18 5.42 4.71 5.55 - 
XBp19 4.54 3.85 4.92 - 
XBp20 5.09 4.19 5.01 - 
XBp21 4.16 3.19 3.99 3.51 
XBp23 5.98 5.09 6.08 6.08 
XBp24 4.27 4.11 4.74 - 
XBp26 4.26 3.81 3.97 3.45 
XBp27 5.20 4.12 4.99 - 
XBp28 4.27 4.11 4.52 - 
XBp29 5.05 4.64 4.70 4.64 
XBp30 4.27 3.90 4.07 4.04 
XBp31 4.82 4.22 4.36 4.34 
XBp32 4.27 3.90 3.47 3.42 
XBp33 3.74 3.95 3.34 2.84 
XP25 5.12 4.19 5.91 5.20 
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Table 3.15 (cont). 
Compound CLogP ALogPs ACDLogP ACDLogD7.4 
XP11 5.23 4.02 5.35 5.12 
XP26 5.12 4.15 5.65 5.08 
XP12 5.23 4.00 5.45 5.06 
XPr1 6.17 4.12 6.96 - 
XPr2 5.10 3.99 5.50 4.73 
XPr3 7.10 4.44 7.59 6.90 
XPr4 5.06 3.89 5.54 5.11 
1 2.23 2.83 2.02 1.71 
2 2.49 3.03 2.19 1.95 
3 3.06 2.82 3.12 2.54 
4 2.77 3.17 2.78 - 
6 2.49 3.07 2.15 2.08 
10 3.12 3.13 3.00 - 
29 3.06 2.84 3.45 2.94 
31 2.71 3.04 2.45 2.38 
33 2.71 3.03 3.04 3.04 
36 2.77 3.14 3.20 - 
37 3.08 3.15 2.96 - 
38 3.08 3.19 3.56 - 
130 4.32 4.00 4.49 4.18 
148 3.68 3.72 4.19 3.64 
149 3.08 3.14 3.12 - 
150 3.61 3.04 3.66 3.34 
151 3.08 3.19 3.31 - 
152 2.71 3.02 2.45 2.38 
153 2.23 2.86 2.62 2.25 
154 2.16 2.81 2.27 1.71 
155 3.46 3.03 3.58 3.23 
 
The correlation between the Log Kp determined experimentally and calculated in 
silico was poor as it can be depicted from the correlation equations bellow and the scatter 
plots (Figure 3.77). Nevertheless, the correlation was better for the CLogP and ACDLogP 
than for the ALogPs for both the membrane models. In general, from the slopes of the 
equations and y-intercept values, it can be observed that for compounds with low 
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lipophilicity, the Kp in micelles and liposomes is higher, and for highly lipophilic 
compounds the opposite is observed, meaning also that the amplitude of values 
calculated in silico is higher than the membrane models. Moreover, the slope for all the 
correlation equations is lower than one which means that an increase in a Log unit in the 
Log P calculated in silico, does not correspond to the same increment in the Log Kp 
determined in micelles or liposomes. Comparing the slopes and y-intercept for liposomes 
and micelles, the y-intercept is higher for micelles than for liposomes, which is 
understandable since a similar relationship was observed when the two models were 
correlated with each other (Figure 3.75). In the case of the slopes, it can be observed that 
it is higher in liposomes than in micelles indicating that an increment in a log unit of the 
values determined in silico corresponds to higher increase in the Log Kp determined in 
liposomes. Accordingly, if one of the in silico programs was used for the determination of 
the lipophilicity of this type of xanthones, the lipophilicity would probably be 
underestimated for the less lipophilic compounds and overestimated for the high lipophilic 
compounds. However, the compounds tested are limited to a family of compounds with 
some functional groups. Therefore, compounds with different scaffolds and functional 
groups need to be tested to prove that the same observation occurs with other families of 
compounds.  
 
Comparison of Log Kp determined in liposomes with in silico programs: 
 
Log Kpliposomes = 1.584(± 0.2036) + 0.4681(± 0.0518)CLogP 
n = 43; r2 = 0.67; s = 0.319; F = 87 
Log Kpliposomes = 0.8581(± 0.39093) + 0.39093(± 0.10506)ALogPs 
n = 43; r2 = 0.51; s = 0.391; F = 44 
Log Kpliposomes = 1.644(± 0.1840) + 0.4543(± 0.0432)ACDLogP 
n = 43; r2 = 0.70; s = 0.304; F = 100 
 
Comparison of Log Kp determined in micelles with in silico programs: 
 
Log Kpmicelles = 1.927(± 0.1493) + 0.4136(± 0.03439)CLogP 
n = 60; r2 = 0.71; s = 0.290; F = 145 
Log Kpmicelles = 0.9024(± 0.30772) + 0.7356(± 0.08104)ALogPs 
n = 60; r2 = 0.58; s = 0.348; F = 82 
Log Kpmicelles = 2.049(± 0.1381) + 0.3788(± 0.03117)ACDLogP 
n = 60; r2 = 0.71; s = 0.288; F = 148 
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Figure 3.77 Scatter plots and linear regressions for the correlation of the Log Kp 
determined in liposomes or micelles with three in silico programs. 
  
The Log P only refers to the partition of the compounds in its non-ionized form and 
for ionizable molecules, the partition of a solute between two phases is better expressed 
by the distribution coefficient since it takes in consideration the pH of the assay and the 
pKa of the solute. The ACDLabs program is able to calculate to Log D at different pHs and 
it was decided to compare the values obtained for the ionized compounds and the values 
determined experimentally with the Log D at pH 7.4. As it can be seen from the equations 
below, the correlation obtained for liposomes and micelles with Log D at pH 7.4 was poor, 
and it was approximately the same obtained for the ACDLogP (Figure 3.78). In the 
chemical library tested, most of the ionized compounds have a phenol group or a hindered 
aromatic amine which means that at pH 7.4, only a small proportion is in its ionized form. 
 
 
Log Kpliposomes = 1.908(± 0.2186) + 0.4261(± 0.06148)ACDLogD 
n = 23; r2 = 0.68; s = 0.329; F = 48 
Log Kpliposomes = 1.728(± 0.2166) + 0.4434(± 0.05675)ACDLogP 
n = 23; r2 = 0.69; s = 0.302; F = 61 
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Log Kpmicelles = 2.255(± 0.1691) + 0.3641(± 0.04169)ACDLogD 
n = 35; r2 = 0.69; s = 0.314; F = 76 
Log Kpmicelles = 2.195(± 0.1736) + 0.3502(± 0.03961)ACDLogP 
n = 35; r2 = 0.69; s = 0.312; F = 78 
 
 
 
Figure 3.78 Scatter plots and linear regressions for the correlation of the Log Kp 
determined in liposomes or micelles with ACDLogD at 7.4 and ACDLogP. 
 
 
3.2.1.2 Comparison between groups 
 
 In Tables 3.14 and 3.15, the partition coefficients determined experimentally and 
calculated using in silico models were compared either for the entire set of compounds or 
aggregated by their capability of being or not ionizable. As a result, no attention was 
addressed to the different families of scaffolds that compose the chemical library tested. In 
this section, the chemical library will be divided in two groups: xanthone analogues of 
XP13 and oxygenated xanthones.  
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3.2.1.2.1 Analogues of XP13 
 
 The chemical library of analogues of XP13 is comprised of xanthones bearing 2,2-
dimethyl-3,4-dihydropyran and 2,2-dimethylpyran fused rings and the Log Kp values 
obtained experimentally with the membrane models were for most of the compounds 
lower than the calculated in silico (Table 3.16). Comparing linear xanthones with similar 
pattern of substitution, differing only in the fused ring, the calculated Log P using the three 
in silico programs gave higher values for xanthones with a fused 2,2-dimethyl-3,4-
dihydropyran than for xanthones with a fused 2,2-dimethylpyran ring. On the other hand, 
for the Log Kp determined experimentally, it was observed that the order of higher or 
lower lipophilicity was case sensitive, albeit, for most of the cases, the xanthones with a 
2,2-dimethylpyran fused ring had higher lipophilicity (compounds XBp1 and XBp2; XBp4 
and XBp5; XBp7 and XBp8; XBp9 and XBp10). In the case of angular xanthones, the 
ALogPs and ACDLogP predicted higher Log P values for the xanthones with a 2,2-
dimethylpyran and the CLogP the opposite (compounds XBp11-14, XP26 and XP12). For 
the Log Kp determined experimentally, the order of lipophilicity varied greatly for each pair 
of compounds, and even between the two membrane models (compounds XBp11 and 
XBp12). The three dimensional structure of xanthones with a fused 2,2-dimethylpyran ring 
is slightly more planar when compared with the xanthones bearing a 2,2-dimethyl-3,4-
dihydropyran ring. Considering that liposomes and micelles are constituted by aggregates 
of amphiphilic molecules organized in an ordered way to form an anisotropic media, the 
increase in the planarity as well as the possibility that the double bond have of Van der 
Walls and hydrophobic interactions can help to explain the higher values obtained for the 
xanthones fused with a 2,2-dimethylpyran ring, especially for the linear analogues. In the 
angular xanthones, the interaction could be slightly different due to the three dimensional 
disposition of the four rings which could help to explain the differences observed for 
compounds XBp11 and XBp12 between the liposome and micelle models. Moreover, this 
fact would probably not be observed if an isotropic system such as octanol-water was 
used. As a matter of fact, the in silico programs use algorithms that take in consideration 
the Log P determined experimentally in octanol-water biphasic system and as a result, it 
can be proposed that for linear xanthones bearing a 2,2-dimethyl-3,4-dihydropyran fused 
ring might have a higher lipophilicity than the xanthones with a fused 2,2-dimethylpyran 
ring if the octanol-water model was used. Another interesting feature could be observed 
by the comparison of compounds XBp9, XBp10, XBp13, XP14, XP25, XP11, XP26 and 
XP12 with compounds XP13, XBp6, XBp7, XBp8, XBp11 and XBp12, since the latter 
have a hydroxyl ortho to the xanthonic carbonyl which led to an increase in the lipophilicity 
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of the compounds. This observation is in line with the values calculated in silico with the 
three programs and it was caused by the intramolecular hydrogen bond which takes place 
between the xanthonic carbonyl and the hydroxyl group in ortho position. Moreover, if it 
was considered linear xanthones differing between each other on the type and orientation 
of the pyran or dihydropyran fused-ring, and by the position of the hydroxyl or methoxyl 
group, the comparison between compounds XBp1 and XBp2 with XBp4 and XBp5, and 
compounds XBp9 and XBp10 with XP25 and XP11, it could be observed that when the 
methoxyl or hydroxyl and the oxygen of the pyran or dihydropyran ring are ortho to each 
other, the Log Kp is lower than the respective structural isomers bearing the two oxygens 
meta to each other. As it can be depicted from Table 3.16, only for the Log P calculated 
from ACD Log P program, the structural isomers gave different values of Log P being in 
accordance with the experimental data. The introduction of chlorine, methoxyl, methyl and 
N,N-diethyl groups on ring A led to an increase in the Log Kp as expected from the 
computational programs. However, an exception was observed for the introduction of two 
methoxyl groups (compound XBp24) which maintained a similar value of Log Kp. In the 
case of the hydroxyl, the outcome is more case-sensitive although a generally decrease in 
the Log Kp was observed, with the exception of the Log Kp in micelles of compound 
XBp33. 
 
Table 3.16 Partition coefficient for linear xanthones determined experimentally in 
membrane models, or calculated in silico. 
Structure 
Log 
Kpliposomes 
Log 
Kpmicelles 
CLogP ALogPs ACDLogP ACDLogD 
XP13  
3.35  3.28  4.33 4.09 3.90 3.86 
XBp1  
3.60 3.59  4.70 4.07 4.53 - 
XBp2  
3.88 3.83 4.60 3.92 4.29 - 
XBp4  
3.94 ± 0.09 
4.07 ± 
0.10 
4.59 3.92 4.55 - 
XBp5  
3.92 3.88  4.70 4.08 4.76 - 
XBp6  
3.06 3.29 4.23 4.18 4.93 4.77 
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Table 3.16 (cont). 
Structure 
Log 
Kpliposomes 
Log 
Kpmicelles 
CLogP ALogPs ACDLogP ACDLogD 
XBp7  
3.54 3.76 4.59 3.92 4.71 - 
XBp8  
3.09 3.58 4.70 4.15 4.95 - 
XBp9  
4.17 4.15  5.13 4.15 5.47 4.61 
XBp10  
3.96  3.88 5.23  4.14 5.37 5.09 
XBp11  
3.32 3.33 4.59 3.91 4.25 - 
XBp12  
3.08 3.46 4.70 4.13 4.49 - 
XBp13  
- 4.08 5.12 4.13 4.99 4.80 
XBp14  
- 4.28 5.23 4.06 4.89 4.76 
XBp15  
3.42 3.50  4.56 4.11 4.41 - 
XBp16  
4.14  4.10  4.56 4.11 5.01 - 
XBp17  
- 4.34  5.31 4.47 5.34 - 
XBp18  
4.48  4.41  5.42 4.71 5.55 - 
XBp19  
- 4.21  4.54 3.85 4.92 - 
XBp20   
4.32  4.29  5.09 4.19 5.01 - 
XBp21  
- 3.90 4.16 3.19 3.99 3.51 
XBp23  
4.62 4.70 5.98 5.09 6.08 6.08 
XBp24  
3.88 3.83  4.27 4.11 4.74 - 
XBp26  
3.43  3.49  4.26 3.81 3.97 3.45 
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Table 3.16 (cont). 
Structure 
Log 
Kpliposomes 
Log 
Kpmicelles 
CLogP ALogPs ACDLogP ACDLogD 
XBp27  
4.02  4.01 5.20 4.12 4.99 - 
XBp28  
- 3.88  4.27 4.11 4.52 - 
XBp29  
- 4.39 5.05 4.64 4.70 4.64 
XBp30  3.25 3.35 4.27 3.90 4.07 4.04 
XBp31  3.86 3.92 4.82 4.22 4.36 4.34 
XBp32  
3.53 3.58 4.27 3.90 3.47 3.42 
XBp33  3.32 3.76 3.74 3.95 3.34 2.84 
XP25  
- 4.27 5.12 4.19 5.91 5.20 
XP11  
- 4.32 5.23 4.02 5.35 5.12 
XP26  
- 4.06 5.12 4.15 5.65 5.08 
XP12  
- 4.02 5.23 4.00 5.45 5.06 
 
In the previous section it was discussed the possibility of using the micelle-water 
as an alternative to the liposome-water model since a good correlation for all the data set 
was observed. However, the data set was first analyzed globally and then particularized to 
either ionizable or non-ionizable compounds, and consequently, no attention was given to 
the structural features. As a result, the information obtained did not give an idea of 
whether the micelle-water correlates better with liposome-water models for the analogues 
of XP13 or oxygenated xanthones. Consequently, it was decided to compare all the Log 
Kp determined in micelles and liposomes for analogues of XP13 and a similar correlation 
to all the data set was obtained. However, it can be observed from the scatter plot the 
presence of three outliers which were placed near the line of 95 % prediction interval 
(Figure 3.79; (A)). The three outliers correspond to compounds XBp8, XBp11 and XBp33 
and refer to three examples where the two models did not correlate. In the case of 
compounds XBp8 and XBp11, similar features are observed such as a methoxyl in an 
ortho position to the carbonyl and a fused 2,2-dimethyl-3,4-dihydropyran ring. 
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Consequently, it was decided to remove the three points and a better correlation between 
the two models was obtained as it can be depicted from the correlation equations. 
Nevertheless, if the micelle-water is used as an alternative to the liposome-water model 
for the determination partition coefficient of linear xanthones, the values obtained for 
compounds bearing free hydroxyl groups, or a methoxyl ortho to the carbonyl should be 
confirmed with the liposome-water model. Moreover, since the y-intercept was slightly 
lower than zero, the Log Kp determined with the micelle-water model for analogues of 
XP13 will probably be slightly higher if compared with liposome-water model.   
 
(A) Log Kpliposomes = -0.5666(± 0.34031) + 1.129(± 0.0893)Log Kpmicelles 
n = 24; r2 = 0.87; s = 0.159; F = 160. 
(B) Log Kpliposomes = -0.254(± 0.1978) + 1.06(± 0.052)Log Kpmicelles 
n = 21; r2 = 0.95; s = 0.089; F = 423. 
             
 
Figure 3.79 Correlation between micelle-water and liposome-water for analogues of 
XP13. In (A) is all the data and in (B) the three outliers were removed. 
 
 The two membrane models were compared with three computational programs 
and the results are summarized in Table 3.17. The correlation between the different 
programs was worse than the observed for all the data set. Nevertheless, among three 
computational programs, CLogP gave the best correlation, especially in comparison with 
the values obtained from the Log Kp obtained in liposomes.    
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Table 3.17 Correlation between the Log Kp liposomes and Log Kp micelles with three 
computational programs for analogues of XP13.  
 CLogP ALogPs ACDLogP 
n r2 s F n r2 s F n r2 s F 
Log 
Kpliposomes 
20 0.65 0.263 36 20 0.38 0.349 13 20 0.41 0.342 14 
Log 
Kpmicelles 
27 0.57 0.243 35 27 0.26 0.318 10 27 0.45 0.276 22 
 
 
3.2.1.2.2 Oxygenated xanthones 
 
 
In the previous section, it was observed that for the majority of the analogues of 
XP13, the values of Kp determined experimentally were lower than the calculated in silico. 
In the case of simple oxygenated xanthones, there is not a clear trend, but it can be 
observed that for the majority of the ionizable compounds, the Log Kp in liposomes and 
micelles were slightly higher in comparison with the Log P calculated in silico (Table 
3.18). On the other hand, for methoxylated compounds, the values determined 
experimentally were lower or in line with the calculated in silico. The ionizable compounds 
are partially ionized in at pH 7.4 and since liposomes and micelles are made of 
amphiphilic molecules, the ionized compounds have the possibility of electrostatic and 
ionic interactions with the polar “head” group of the membranes which leads to an 
increase in the lipophilicity. Moreover, for ionizable compounds, the sum of interactions 
between the solutes and the two membrane models are not of the same strength, and in 
the presence of a hydroxyl in positions 1, 2 or 3, the partition in micelles was higher than 
the partition in liposomes (compounds 1, 2, 3, 33, 152 and 154). This fact was also 
observed for compound XBp33. As with the analogues of XP13, the presence of a 
hydroxyl ortho to the carbonyl increased to a deep extent the lipophilicity of the xanthones. 
For example, if it is considered the dihydroxyxanthones 1, 3, 29, and 153-155, the 
compounds with a hydroxyl ortho to the carbonyl have a higher lipophilicity when 
compared to other isomers.  
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Table 3.18 Partition coefficient for oxygenated xanthones determined experimentally in 
membrane models, or calculated in silico. 
Structure 
Log 
Kpliposomes 
Log 
Kpmicelles 
CLogP ALogPs ACDLogP ACDLogD 
1  
2.48 2.59 2.23 2.83 2.02 1.71 
2  
2.19 2.65 2.49 3.03 2.19 1.95 
3  3.49 3.60 3.06 2.82 3.12 2.54 
4  2.79 2.94 2.77 3.17 2.78 - 
6  
2.61 2.60 2.49 3.07 2.15 2.08 
10  
3.08 3.41 3.12 3.13 3.00 - 
29  3.44 3.52 3.06 2.84 3.45 2.94 
31  
2.85 2.87 2.71 3.04 2.45 2.38 
33  3.26 3.63 2.71 3.03 3.04 3.04 
36  - 2.82 2.77 3.14 3.20 - 
37  
2.86 2.90 3.08 3.15 2.96 - 
38  3.30 3.21 3.08 3.19 3.56 - 
149  2.72 2.78 3.08 3.14 3.12 - 
150  3.40 3.12 3.61 3.04 3.66 3.34 
151  3.09 3.31 3.08 3.19 3.31 - 
152  2.90 3.04 2.71 3.02 2.45 2.38 
153  - 3.03 2.23 2.86 2.62 2.25 
154  2.55 2.95 2.16 2.81 2.27 1.71 
155  3.85 3.62 3.46 3.03 3.58 3.23 
ŚĂƉƚĞƌϯ
ZĞƐƵůƚƐΘŝƐĐƵƐƐŝŽŶ
ϭϳϵ

 The correlation between the two membrane models has shown to be good for all 
the data set and better for the analogues of XP13. Therefore, it was decided also to 
evaluate the correlation of two membrane models for the oxygenated xanthones and in 
this case, a lower correlation was observed (Figure 3.80; (A)). As it was discussed above, 
the micelles models gave a higher lipophilicity than the liposomes for compounds with a 
hydroxyl in positions 1, 2 and/or 3. Consequently, it was decided to divide the oxygenated 
xanthones into two groups, one comprised of xanthones with a phenol in position 1, 2 
and/or 3, and another group with the remaining compounds. From the correlation 
equation, it can be observed a better correlation for the two groups, especially for the first 
group (Figure 3.80; (B) and (C)). However, the sample was made of few compounds and 
more compounds need to be tested to confirm the results obtained. 
 
 
(A) Log Kpliposomes = -0.2421(± 0.45709) + 1.042(± 0.1464)Log Kpmicelles 
n = 17; r2 = 0.76; s = 0.212; F = 51 
 
(B) Log Kpliposomes = -0.3328(± 0.46972) + 1.042(± 0.052)Log Kpmicelles 
n = 9; r2 = 0.85; s = 0.170; F = 48 
 
(C) Log Kpliposomes = 0.5651(± 0.43334) + 0.7898(± 0.14201)Log Kpmicelles 
n = 8; r2 = 0.81; s = 0.123; F = 32 
 
 
 
 
Figure 3.80 Correlation between the two membrane models for oxygenated xanthones. In 
(A) is the correlation for all the data set, (B) xanthones with a hydroxyl in position 1,2 
and/or 3, and (C) the remaining xanthones.  
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 In the previous section, it was observed that for analogues of XP13, the correlation 
between the two membrane models with the different computational programs was worse 
than for the whole data set. Nevertheless, the CLogP gave a better correlation than the 
other two programs especially for liposomes. In the case of oxygenated xanthones (Table 
3.19), the correlation was also worse than for the all data set, with the exception of the 
correlation between ACDLogP and the Log Kp determined in liposomes. 
 
Table 3.19 Correlation between the Log Kp liposomes and Log Kp micelles with three 
computational programs for oxygenated xanthones. 
 CLogP ALogPs ACDLogP 
n r2 s F n r2 s F n r2 s F 
Log Kpliposomes 17 0.58 0.277 23 17 0 - - 17 0.71 0.231 40 
Log Kpmicelles 19 0.26 0.299 7 19 0 - - 19 0.43 0.262 14 
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3.2.2 Solubility 
 
 
The solubility is one of the key physicochemical properties that is addressed in 
different stages of a drug discovery and development project, including in the early stages 
of drug discovery [233]. There is not a single value of solubility for each compound, but 
what is considered is the solubility of a compound in certain experimental conditions [227, 
234-238]. The experimental conditions are chosen taking in consideration the information 
desired from the solubility assays. For instance, the solubility assays in the early stages of 
the drug discovery, are usually determined at physiological pH or at the experimental 
conditions used in the bioassays, with the objective of having an insight of whether the 
more promising compounds have the possibility to continue in the drug discovery project 
or have to be halted due to lack of solubility. Moreover, the compound could also be 
falsely dismissed as inactive due to insolubilization in the bioassays. On the other hand, in 
the later stages, the objective is to evaluate the solubility in different biological matrices 
such as simulated gastric or intestinal fluids for example, to predict oral bioavailability 
[227, 233-237, 239-242].  
 The kinetic solubility assay is the preferred method of pharmaceutical industries for 
the determination of the solubility in an early stage of the drug discovery project [233, 
234]. Accordingly, the possibility of using automated high throughput equipment allows the 
determination of hundreds of compounds a day, with a minimum expense of sample 
solubilized in DMSO, making this method a very attractive approach. Since the chemical 
library is made of only a few dozens of compounds, the use of kinetic solubility is not 
justifiable and as a result the solubility was determined by a thermodynamic method. 
However, it was not determined the solubility for all the compounds synthesized since the 
amount of sample that needs to be spent for each assay is considerable, and the solubility 
was only determined for compounds XP13, XBp11, XBp13 and XBp29 to XBp33 (Table 
3.20). The determination of the solubility of compounds XBp29-33 alongside with XP13 
will allow studying the influence that chlorine, methoxyl, methyl and hydroxyl have on the 
solubility of XP13. The determination of the solubility of compounds XBp11 and XBp13 
will allow studying the influence that an intramolecular hydrogen bonding has on solubility. 
 The solubility was calculated by determining the amount of compound solubilized 
after a saturated solution have been stirred for 24 h at 37 ºC and pH 7.4, using HEPES as 
buffer. The standards for each compound were prepared using DMSO as co-solvent, with 
a concentration of 1% in the final solution (1% of DMSO was added to each sample as 
well). The determination of the concentration was made by UV-Vis, and since the 
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concentration was low for all the compounds, there was the need to prepare standards of 
low concentration. However, the UV-Vis spectrum for the samples and standards of low 
concentration was strongly influenced by the background noise which makes it hard to 
establish a standard calibration curve. Therefore, there was the need to use the second 
derivative to increase the resolution of the spectrum (Figure 3.81). 
 
 
 
   
 
 
 
 
 
 
 
 
  
Figure 3.81 Determination of the standard calibration curve using the second derivative of 
the UV-Vis absorption spectra. 
 
The values of solubility for all the compounds tested were low as it can be depicted 
from Table 3.20. From the structure-solubility relationship for compounds XP13 and 
XBp29-33, only for compound XBp33 it was observed an increase in the solubility when 
compared to XP13. The introduction of chlorine (XBp29), methyl (XBp31), and methoxyl 
(XBp30 and 32) had an adverse effect on the solubility. However, the presence of a 
methoxyl in position 10 (compound XBp33) have a less detrimental effect in the solubility 
when compared to a methoxyl in position 8 (compound XBp31). In the case of compound 
XBp13, which in comparison with compound XBp11 have a hydroxyl in an intramolecular 
hydrogen bonding with the xanthonic carbonyl, this structural feature led to the decrease 
in the solubility. This can be explained by the fact that an intramolecular hydrogen bond 
decreases the possibility of hydrogen bonds with water and consequently decreases the 
solubility in aqueous buffer.   
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Table 3.20 Solubility determined experimentally for compounds XP13, XBp11, XBp13 
and XBp29-33. 
Compound Experimental Solubilitya 
XP13         
0.40 ± 0.1 μM 
XBp11       
0.18 ± 0.02 μM 
XBp13        
< 0.1 μM 
XBp29      
< 0.1 μM 
XBp30  
< 0.1 μM 
XBp31    
< 0.1 μM 
XBp32        
0.23 ± 0.02 μM 
XBp33      
0.62 ± 0.1 μM 
aMean of three independent measurements. 
  
 
 
 The solubility for all the compounds synthesized was also predicted using 
ACDLogS program and different empirical models discussed in chapter 2. Comparing the 
solubility determined experimentally (XP13, XBp11, XBp13 and XBp29-XBp33) with the 
predicted by the different models, it can be observed from Table 3.21 that the GSE model 
gave the best results. The ACDLog S and the classification tree (considering the MW and 
the AP, the classification tree model gave “soluble” for all the compounds in the database) 
were the worst models since they predicted solubility values considerably higher than 
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determined experimentally. In the case of ESOL equation, the values calculated were 
between the Log S predicted by the GSE and ACDLog S (with the exception of compound 
XBp11). The ESOL and the GSE uses the Log P as a variable but the former uses MW, 
AP and RB as a surrogate of Mp [243]. Since GSE uses the experimental Mp and gave 
lower values than the ESOL, it can be speculated that the Mp predicted by the ESOL 
equation was lower than expected for compounds with a similar number of AP, RBs, MW 
and Log P. In the case of the Fsp3, the calculated values for all the compounds were in 
agreement with the low solubility determined experimentally as it can be depicted from 
examination of Tables 2.10 (Chapter 2) and 3.21. On the other hand, the correlation 
between the Fsp3 and the Mp of all the compounds synthesized was weak, especially for 
compounds with values of Fsp3 around 0.32 (Table 3.21). Therefore, it can be 
hypothesized that in average, compounds with similar values of Fsp3 have usually a lower 
Mp when compared to the values to XP13 and the analogues synthesized. 
In the case of the compounds whose solubility was not determined experimentally, 
the observation of the LogS calculated by the different predictive models allowed to take 
the conclusion that the solubility is very likely to be low for all the compounds synthesized. 
Considering the Log P and Mp observed from Table 3.21, generally compounds with 
lower Log P have higher Mp and compounds with low Mp have high Log P, which 
according to the GSE and ESOL leads to low solubility.  
The application of the different models allowed us to realize that the low solubility 
of XP13 and its analogues are caused mainly by the tridimensionality of these compounds 
and their lipophilicity. In the case of the tridimensionality, the xanthones synthesized are 
tetracyclic moieties (with the exception of compounds XPr1-4, that have prenyl groups) 
containing two aromatic rings which create a high degree of planarity and symmetry. In 
Chapter 2 it was referred that these characteristics lead to an increase in the Mp, 
contributing to a low solubility. If the compounds have a low lipophilicity and a high melting 
point, that would not have a high impact on the solubility. However, the lipophilicity of 
these compounds determined experimentally and calculated was higher than 3 leading to 
low solubility. When compared to XP13, compound XBp33 have an extra phenolic group 
and it would be logically expected that the introduction of this polar group would lead to a 
significant increase in solubility [244] due to a decrease of lipophilicity and the introduction 
of an acid functionality, which would be partially ionized at pH 7.4. However, it was 
observed only a slight increase in the solubility, much lower than expected [244]. This 
result can be explained by the increase in the crystal packing caused by the phenolic 
group which can be verified by the high melting point determined for compound XBp33.  
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Table 3.21 Prediction of solubility considering structural and physicochemical parameters.  
 
Lipophilicity ACD 
Log S 
pH = 7.4 
LogS 
Exp. 
Mpa 
(ºC) GSE
b
 Fsp3 AP MW ESOLb Log 
Kpliposomes 
Log 
Kpmicelles 
ACD 
LogP 
XP13 3.35 3.28 3.90 -4.22 -6.40 200.5 -5.41 0.28 0.54 296 -4.62 
XBp1 3.60 3.59 4.53 -5.32 - 173.5 -5.77 0.32 0.52 310 -5.08 
XBp2 3.88 3.83 4.29 -5.27 - 129.5 -5.09 0.21 0.52 308 -4.91 
XBp3 
- - 
4.00 -4.15 - 178.5 -5.29 0.17 0.54 294 -4.67 
XBp4 3.94 4.07 4.55 -5.46 - 124.5 -5.30 0.21 0.52 308 -5.08 
XBp5 3.92 3.88 4.76 -5.49 - 135.5 -5.62 0.32 0.52 310 -5.22 
XBp6 3.06 3.29 4.93 -4.93 - 245.5 -6.89 0.17 0.54 294 -5.25 
XBp7 3.54 3.76 4.71 -5.58 - 125 -5.46 0.21 0.52 308 -5.18 
XBp8 3.09 3.58 4.95 -5.63 - 132.5 -5.78 0.32 0.52 310 -5.34 
XBp9 4.17 4.15 5.47 -4.44 - 132 -6.29 0.17 0.54 294 -5.59 
XBp10 3.96 3.88 5.37 -4.90 - 172.5 -6.60 0.28 0.54 296 -5.54 
XBp11 3.32 3.33 4.25 -5.25 -6.74 164.5 -5.40 0.21 0.52 308 -4.89 
XBp12 3.08 3.46 4.49 -5.29 - 204.5 -6.04 0.32 0.52 310 -5.05 
XBp13 
- 4.08 4.99 -4.84 < -7 191.5 -6.41 0.17 0.54 294 -5.29 
XBp14 
- 4.28 4.89 -4.92 - 205.5 -6.45 0.28 0.54 296 -5.24 
XBp15 3.42 3.50 4.41 -5.16 - 183 -5.74 0.21 0.57 248 -4.66 
XBp16 4.14 4.10 5.01 -5.61 - 97 -5.48 0.21 0.57 248 -5.04 
XBp17 
- 4.34 5.34 -6.81 - 163.5 -6.09 0.32 0.50 343 -5.78 
XBp18 4.48 4.41 5.55 -6.84 - 167.5 -6.69 0.32 0.50 345 -5.92 
XBp19 
- 4.21 4.92 -5.79 - 174.5 -6.17 0.20 0.48 338 -5.46 
XBp20 4.32 4.29 5.01 -5.66 - 181.5 -6.33 0.20 0.50 322 -5.44 
XBp21 
- 3.90 3.99 - 4.14 - 193.5 -5.43 0.21 0.50 324 -4.81 
XBp22 
- - 
5.87 -6.02 - 57 -5.94 0.35 0.43 379 -6.26 
XBp23 4.62 4.70 6.08 -6.10 - 127 -6.85 0.43 0.43 381 -6.41 
XBp24 3.88 3.83 4.74 -5.88 - 216.5 -6.41 0.33 0.44 370 -5.51 
XBp25 
- - 
3.68 -5.23 - 174.5 -4.93 0.24 0.44 368 -4.83 
XBp26 3.43 3.49 3.97 -4.03 - 286.5 -6.34 0.32 0.50 326 -4.81 
XBp27 4.02 4.01 4.99 -5.52 - 101.5 -5.51 0.30 0.50 324 -5.44 
XBp28 
- 3.88 4.52 -5.72 - 228.5 -6.31 0.33 0.44 370 -5.37 
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Table 3.21 (cont). 
 Lipophilicity ACD 
Log S 
pH = 7.4 
LogS 
Exp. 
Mpa 
(ºC) GSE
b
 Fsp3 AP MW ESOLb 
 
Log 
Kpliposomes 
Log 
Kpmicelles 
ACD 
LogP 
XBp29 
- 4.39 4.70 -5.00 < -7 226 -6.46 0.28 0.52 331 -5.32 
XBp30 3.25 3.35 4.07 -4.56 < -7 200 -5.57 0.32 0.50 326 -4.87 
XBp31 3.86 3.92 4.36 -4.58 < -7 227.5 -6.14 0.32 0.52 310 -4.98 
XBp32 3.53 3.58 3.47 -4.18 < 6.64 207.5 -5.05 0.32 0.50 326 -4.49 
XBp33 3.32 3.76 3.34 -3.36 < 6.21 263 -5.47 0.28 0.52 312 -4.35 
XP25 
- 4.27 5.91 -4.85 - 166 -7.07 0.17 0.14 294 -5.53 
XP11 
- 4.32 5.35 -4.89 - 188.5 -6.74 0.28 0.54 296 -5.53 
XP26 
- 4.06 5.65 -4.85 - 172 -6.87 0.17 0.54 294 -5.71 
XP12 
- 4.02 5.45 -4.86 - 147.5 -6.43 0.28 0.54 296 -5.59 
XPr1 
- 4.49 6.96 -6.36 - 71 -7.17 0.26 0.44 364 -6.85 
XPr2 
- 3.91 5.50 -4.42 - 78.5 -5.79 0.17 0.54 296 -5.60 
XPr3 
- 4.10 7.59 -5.89 - 67 -7.76 0.26 0.44 364 -7.26 
XPr4 
- 4.62 5.54 -4.60 - 100.5 -6.05 0.17 0.54 296 -5.64 
aThe melting point correspond to the mean value of the interval. bThe Log P values used were the ACDLog P.  
(The meaning of the abbreviations is in the section “List of abbreviations and symbols”) 
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3.2.3 Plasma Protein Binding 
  
The binding extent of a drug to plasmatic proteins is directly related with the 
amount of free drug that is available to exert the pharmacological activity in in vivo 
studies. Therefore, the plasma protein binding (PPB) influences different areas such as 
the drug safety and efficacy, the metabolism and pharmacokinetic, the drug-drug 
interaction and also the penetration into the blood-brain barrier (chapter 2) [227, 245]. The 
in vitro PPB is usually expressed as the percentage of drug bound or unbound in the 
plasma or by the equilibrium dissociation constant Kd [227]. The high or low values 
obtained from the plasma protein binding must be seen with caution since they do not 
always correlate with the in vivo pharmacokinetic parameters and the living systems are 
dynamic processes influenced by many different aspects including the PPB [246]. 
Consequently, the PPB determined in vitro should be used in context with other properties 
[227, 246]. Nevertheless, highly lipophilic drugs are known to have high PPB contributing 
to a reduction in efficacy and drug efficiency [247, 248].  
 
 
 
 
Figure 3.82 Bovine Albumin intrinsic fluorescence emission spectra in the presence of 
increasing concentrations of XP13 and compounds XBp11, XBp13 and XBp29-33. 
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The fluorescence quenching caused by the interaction of eight of the compounds 
synthesized, namely XP13, XBp11, XBp13 and XBp29 to XBp33, with bovine serum 
albumin (BSA) can be depicted in Figure 3.82. The percentage of quenching is 
dependent on the concentration of the compound and albumin, and can be related 
through the binding dissociation constant (chapter 2). According to the data gathered on 
Table 3.22, the compound with the lower binding dissociation constant and consequently 
higher affinity to BSA was XBp13. Moreover, all the compounds had only one binding site. 
By comparing XBp13 with XBp11, the change of a methoxyl to a hydroxyl was associated 
with a significant increase in the affinity with the BSA. In the case of the analogues of 
XP13 that differ from this compound by the presence of a substituent on ring A (XBp29 to 
XBp33), it can be observed that the presence of a methyl or methoxyl in position 8 
(XBp30 and XBp31) is associated with a decrease and chlorine with an increase in the 
affinity to BSA. On the other hand, the presence of a hydroxyl in position 9 and methoxyl 
in position 10 respectively, is associated with an increase in the affinity to the BSA. From 
these results it can be observed the importance of the type and position of the 
substituents, not being directly related to the lipophilicity (see table at the end of the 
thesis). In the case of the Human Serum Albumin (HSA), it was only determined for three 
of the compounds and their results can be observed in Table 3.22. The XP13 and XBp29 
had a higher affinity for HSA than for BSA, with chlorine in position 9 having no relation 
with an increase in the affinity to HSA which was observed in BSA. On the other hand, 
XBp11 had a lower affinity to HSA than to BSA. The comparison between the two 
albumins for three of the compounds showed that the affinity of the xanthones between 
the two albumins may vary considerably, being influenced by the pattern of substitution. 
The ǻG for some of the compounds is represented in Table 3.22. and was calculated 
using the formula described in chapter 2 which takes in consideration the binding 
dissociation constant, the temperature of the assay (in Kelvin) and the gas constant. The 
values of ǻG varied from -8.61 Kcal.mol-1 for the compound with higher affinity (XBp13) to 
-6.58 Kcal.mol-1 for the compound with lower affinity (XBp29 in HSA). The negative values 
of ǻG indicate that the binding between the xanthones and the albumin is thermodynamic 
spontaneous.  
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Table 3.22 Binding dissociation constants calculated for some of the analogues of XP13 
synthesized. 
 
Human Seric Albumin (HSA)a Bovine Seric Albumin (BSA)a 
Kd (μM) Qmax r2 n ǻGb Kd (μM) Qmax r2 n ǻGb 

yWϭϯ 
1.48 ± 0.40 88 ± 5 0.975 1 -7.81 6.16 ± 0.25 112 ± 1 0.999 1 -6.98 

yƉϭϭ 
12.38 ± 1.68 112 ± 2 0.999 1 -6.58 5.31 ± 0.21 110 ± 1 0.998 1 -7.07 

yƉϭϯ 
- - - - - 0.38 ± 0.06 24 ± 1 0.993 1 -8.61 
yƉϮϵ 
1.50 ± 0.06 86 ± 3 0.971 1 -7.81 4.24 ± 0.32 102 ± 3 0.998 1 -7.20 
yƉϯϬ 
- - - - - 9.4 ± 0.84 107 ± 5 0.998 1 -6.74 
yƉϯϭ 
- - - - - 7.24 ± 0.25 114± 1 0.998 1 -6.89 
yƉϯϮ 
- - - - - 5.82 ± 0.40 113 ± 2 0.997 1 -7.02 
yƉϯϯ 
- - - - - 4.78 ± 0.23 111± 1 0.999 1 -7.13 
aMean of three independent assays. bThe Gibbs free energy is represent in Kcal.mol-1 and 
the temperature of the assay is 20 ºC. 
 
 The HSA is a heart-shaped protein that is constituted by 585 aminoacids being 
one of the aminoacids a tryptophan which is the main responsible for the fluorescence of 
HSA. The HSA has 7 different binding sites for fatty acids, but the drugs bind mainly to 
two binding sites located in the subdomains IIA and IIIA [249]. The tryptophan of HSA is in 
residue 234 which is in the subdomain IIA and through the use of the FRET theory, the 
distance r between the bound xanthones and the tryptophan residue was determined.  
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Figure 3.83 Overlap of the absorption spectrum of XP13 and the fluorescence emission 
spectra of HSA. 
 
The overlap of the UV absorption spectrum (Figure 3.83, in grey) of XP13 with the 
fluorescence emission spectra of HSA can be depicted from Figure 3.83, and its extent 
determines the extent of energy transferred (chapter 2). The values of the Förster 
parameters for XP13 and XBp9 are summarized in Table 3.23 and since the values of r 
are below 8 nm (chapter 2), it indicates that the energy transfer from the HSA to XP13 and 
XBp29 occurs with high probability [250, 251]. Considering that XP13 and XBp29 bind to 
one site of the albumin (Table 3.22) and that the tryptophan is located in the subdomain 
IIA, it can be proposed that this is the most probably the binding site for XP13 and XBp9 
[252]. 
 
Table 3.23 Förster parametersa for XP13 and XBp9. 
 Eb J (cm3.M−1) R0 (nm) rb(nm) 
XP13 0.71 ± 0.03 1.22 E-14 2.50 2.15 ± 0.03 
XBp29 0.68 ± 0.01 2.66 E-15 1.94 1.71 ± 0.01 
aMean of three independent assays. bFor the concentration of [XP13] = 10 µM and [XBp29] = 10 µM. 
 
 In Table 3.24 is presented the variation of the energy transfer (E) and the distance 
(r) in relation to the concentration of the each of the compounds and it can be observed 
that with an increase of the concentration there is an increase in the energy transfer and a 
decrease in the distance between the donor and the acceptor. The R0 is the characteristic 
distance where the FRET efficiency is 50 percent (chapter 2) and for distances lower than 
R0, FRET efficiency is close to maximal and for distances higher than R0, the efficiency 
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approaches zero. For distances close to R0, the FRET can be effectively used as a 
molecular ruler [253]. Considering the R0 for XP13 (2.50 nm) and XBp29 (1.94 nm), for 
concentrations of XP13 and XBp29 higher than 2,5 μM, the FRET efficiency is higher than 
50 %. 
 
Table 3.24 Variation of the energy transfer (E) and the distance (r) between the donor and 
the acceptor, in relation to the concentration of XP13 and XBp29. 
XP13 XBp29 
[XP13] μM E r (nm) [XBp29] μM E r (nm) 
1 0.40 ± 0.02 2.68 ± 0.03 0.5 0.16 ± 0.01 2.56 ± 0.03 
2.5 0.52 ± 0.07 2.47 ± 0.11 1 0.28 ± 0.02 2.27 ± 0.04 
5 0.60 ± 0.07 2.34 ± 0.11 2.5 0.61 ± 0.01 1.80 ± 0.01 
7.5 0.68 ± 0.05 2.21 ± 0.08 5 0.65 ± 0.003 1.75 ± 0.004 
10 0.71 ± 0.03 2.15 ± 0.05 7.5 0.68 ± 0.01 1.71 ± 0.01 
20 0.80 ± 0.03 1.98 ± 0.06 10 0.70 ± 0.003 1.69 ± 0.004 
30 0.85 ± 0.04 1.88 ± 0.09 15 0.73 ± 0.01 1.65 ± 0.01 
Mean of three independent assays 
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3.2.4 Drug-like profiling based on structural and 
physicochemical parameters determined experimentally 
and in silico 
   
A fast and easy way to roughly predict the oral bioavailability of a compound is 
through the compliance or non-compliance with the Lipinski “rule of five” and “Veber rules” 
(polar surface area and rotatable bonds). Since these rules were developed relating 
structural and physicochemical properties with the oral bioavailability of marketed oral 
drugs and candidates, the application of these rules can be used with the sole intention of 
predicting the general oral bioavailability. Other groups have investigated instead large in-
house and/or public databases with the objective of relating simple structural and 
physicochemical properties with one or more ADME-Tox parameters determined 
experimentally. The information gathered from these works can be used as a tool to 
orientate and prioritize candidates that have a better chance of becoming a drug, and 
inform the medicinal chemist about the likelihood that a specific structural modification will 
make to different ADME-Tox parameters. 
Accordingly, XP13 and the analogues as well as the prenylated xanthones 
synthesized were evaluated in terms of the general oral bioavailability by the compliance 
or non-compliance with “rule of five” and “Veber rules”. The analogues were also 
evaluated regarding the likelihood of specific ADME-Tox liabilities by examination of 
structural and physicochemical properties determined either experimentally or predicted 
using in silico models.  
 
3.2.4.1 Prediction of drug-likeness 
 
 Prediction of the drug-likeness of the XP13 synthesized analogues was evaluated 
through the Lipinski “rule of five” and “Veber rules”: 
 
• Molecular Weight (MW)  500 
• Log P  5 
• H-bond Donors (HBD)  5 
• H-bond acceptors (HBA)  10 
• Polar Surface Area (PSA)  140 A2 
• Rotatable bonds (RB) 10 
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Since the Log P in the Lipinski “rule of five” is referred as the calculated Log P 
octanol-water [254], besides the lipophilicity determined experimentally using two 
membrane models, it will be used Log P values determined by three in silico programs. 
The PSA was calculated through the tPSA using web-based “molinspiration” program 
[255]. 
 In Table 3.25 are gathered all the calculated and determined experimentally data 
regarding the different descriptors of the Lipinski “rule of five” and “Veber rules” for the 
compounds synthesized. In order to have a better understanding of the results obtained, 
any violation of the “rule of five” and “Veber rule” is highlighted in red. When the values 
were bellow the cut-off limits, the colors used were yellow or green depending if it was 
near the cut-off limits or not, respectively. As it can be depicted from Table 3.25, all the 
compounds have values considerably below the cut-off limits (green) with the exception of 
lipophilicity. In fact, for many of the compounds, especially for calculated Log P using 
CLog P and ACDLog P, values higher than 5 were observed corresponding to a violation 
of the Lipinski “rule of five”. On the other hand, the lipophilicity values determined 
experimentally with two membrane models were lower than the calculated in silico and 
none of the compounds violated the “Lipinski rule of five”. However, for ionizable 
compounds, the determination of the partition coefficient was made at pH = 7.4 which 
means that a part of the compound could be in the ionized form and consequently, the 
partition coefficient could be better represented as the Log D.  
The objective of this first part is to predict the overall drug-likeness of the 
compounds synthesized and therefore it was decided also to classify the compounds 
using red, yellow and green colors. For compounds with two determined Log P and/or Log 
Kp higher than 4 and two Log P and Log Kp values higher than 5, it was colored red to 
highlight possible pharmacokinetic problems these compounds might show due to high 
lipophilicity. Consequently, if any of these compounds show potent activity and is 
subjected to further chemical optimization, the introduction of polar substituents to 
decrease the lipophilicity is strongly advisable. In the case of compounds with calculated 
Log P higher than 4 and one Log Kp determined experimentally higher than 4 or one 
calculated Log P higher than 5, a yellow color was placed. These compounds might show 
some pharmacokinetic problems due to high lipophilicity and if any of the compounds is 
potent, the introduction of more lipophilic group can lead to violation of the Lipinski “rule of 
five”. In the case of the compounds colored green, those can be considered the most 
promising in terms of the oral bioavailability.  
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Table 3.25 Descriptors of XP13 and some of the analogues. 
(The meaning of the abbreviations is in the section “List of abbreviations and symbols”) 
 
MW 
Lipophilicity 
HBA HBD tPSA RB ABS Log 
Kpliposomes 
Log 
Kpmicelles 
CLogP ALogPs ACDLogP 
XP13 296 3.35  3.28  4.33 4.09 3.90 4 1 60 0 0.55 
XBp1 310 3.60 3.59 4.70 4.07 4.53 4 0 49 1 0.55 
XBp2 308 3.88 3.83 4.60 3.92 4.29 4 0 49 1 0.55 
XBp3 294 
- - 
4.22 4.19 4.00 4 1 60 0 0.55 
XBp4 308 3.94 4.07 4.59 3.92 4.55 4 0 49 1 0.55 
XBp5 310 3.92 3.88 4.70 4.08 4.76 4 0 49 1 0.55 
XBp6 294 3.06 3.29 4.23 4.18 4.93 4 1 60 0 0.55 
XBp7 308 3.54 3.76 4.59 3.92 4.71 4 0 49 1 0.55 
XBp8 310 3.09 3.58 4.70 4.15 4.95 4 0 49 1 0.55 
XBp9 294 4.17 4.15 5.13 4.15 5.47 4 1 60 0 0.17 
XBp10 296 3.96 3.88 5.23  4.14 5.37 4 1 60 0 0.55 
XBp11 308 3.32 3.33 4.59 3.91 4.25 4 0 49 1 0.55 
XBp12 310 3.08 3.46 4.70 4.13 4.49 4 0 49 1 0.55 
XBp13 294 
- 4.08 5.12 4.13 4.99 4 1 60 0 0.17 
XBp14 296 
- 4.28 5.23 4.06 4.89 4 1 60 0 0.55 
XBp15 248 3.42 3.50 4.56 4.11 4.41 3 0 39 0 0.55 
XBp16 248 4.14 4.10 4.56 4.11 5.01 3 0 39 0 0.55 
XBp17 343 
- 4.34 5.31 4.47 5.34 4 0 49 1 0.17 
XBp18 345 4.48 4.41 5.42 4.71 5.55 4 0 49 1 0.17 
XBp19 338 
- 4.21 4.54 3.85 4.92 5 0 58 2 0.55 
XBp20 322 4.32 4.29 5.09 4.19 5.01 4 0 49 1 0.17 
XBp21 324 
- 3.90 4.16 3.19 3.99 5 1 69 1 0.55 
XBp22 379 
- - 
5.88 4.83 5.87 5 0 52 4 0.17 
XBp23 381 4.62 4.70 5.98 5.09 6.08 5 0 52 4 0.17 
XBp24 370 3.88 3.83 4.27 4.11 4.74 6 0 67 3 0.55 
XBp25 368 
- - 
4.17 3.68 3.68 6 0 67 3 0.55 
XBp26 326 3.43 3.49 4.26 3.81 3.97 5 1 69 1 0.55 
XBp27 324 4.02 4.01 5.20 4.12 4.99 4 0 49 1 0.17 
XBp28 370 
- 3.88 4.27 4.11 4.52 6 0 67 3 0.55 
XBp29 331 
- 4.39 5.05 4.64 4.70 4 1 60 0 0.55 
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Table 3.25 (cont)  
 
MW 
Lipophilicity 
HBA HBD tPSA RB ABS 
 
Log 
Kpliposomes 
Log 
Kpmicelles 
CLogP ALogPs ACDLogP 
XBp30 326 3.25  3.35  4.27 3.90 4.07 5 1 69 1 0.55 
XBp31 310 3.86 3.92 4.82 4.22 4.36 4 1 60 0 0.55 
XBp32 326 3.53 3.58 4.27 3.90 3.47 5 1 69 1 0.55 
XBp33 312 3.32 3.76  3.74 3.95 3.34 5 2 80 0 0.55 
XP25 294 
- 4.27 5.12 4.19 5.91 4 1 60 0 0.17 
XP11 296 
- 4.32 5.23 4.02 5.35 4 1 60 0 0.17 
XP26 294 
- 4.06 5.12 4.15 5.65 4 1 60 0 0.17 
XP12 296 
- 4.02  5.23 4.00 5.45 4 1 60 0 0.17 
XPr1 364 
- 4.49  6.17 4.12 6.96 4 0 49 6 0.17 
XPr2 296 
- 3.91 5.10 3.99 5.50 4 1 60 3 0.55 
XPr3 364 
- 4.10 7.10 4.44 7.59 4 1 60 4 0.17 
XPr4 296 
- 4.62 5.06 3.89 5.54 4 2 71 2 0.55 
 
A Bioavailability Score (ABS) can be used as a complement to the Lipinski “rule of 
five” and “Veber rules” for the determination of the general drug-likeness of a compound 
[256]. The ABS  gives an idea about the probability that a compound has of possessing a 
bioavailability higher than 10 % in rat, taking in consideration the ionization state at pH 6.0 
(Chapter 2, Table 2.8) [256]. At pH 6.0, all the compounds can be considered as neutral, 
and according to the results expressed in Table 3.25, the ABS will be either 0.55 or 0.17 
depending if a compound pass or not the “rule of five”, respectively. A ABS of 0.55 can be 
regarded as, the compound has 55 % chance of possessing an oral bioavailability in rat 
higher than 10 %. 
 
3.2.4.2 Prediction of the likelihood of pharmacokinetic and toxicological 
liabilities 
 
 Pharmacokinetic and toxicological parameters can be related with structural and 
physicochemical properties, namely lipophilicity, molecular weight and ionization state 
(chapter 2, Table 2.9), and higher pharmacokinetic issues are raised for compounds with 
a molecular weight higher than 400 and cLog P higher than 4, being dependent also on 
the ionization state [223]. The analogues of XP13 synthesized are neutral molecules 
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(according to the authors of this work) and for neutral molecules, several ADME-Tox 
parameters might become a problem when the Log P is higher than 4 [223]. In fact, 
according to the GSK studies, with the exception of CNS penetration, hERG inhibition and 
inhibition of the Cyp P450 isozyme 1A2, there is an increased risk of having problems in 
all the other ADME-Tox parameters. Considering the compounds synthesized and that the 
cLog determined by computational programs gave for many of the compounds a Log P 
higher than 4, this means that those compounds might experience some ADME-Tox 
issues. For compounds with a calculated Log P lower than 4, pharmacokinetic problems 
might be observed as a result of an average solubility (Table 2.9). In fact, we have 
already observed low solubility for some of the compounds synthesized which is 
accordance with the qualitative risk prediction observed in Table 2.9. On the other hand, 
since the molecular weight is below 400 for all the compounds, there is the possibility of 
introducing polar functionalities which can decrease the Log P without affecting the 
likelihood of good ADME-Tox.  
 Other authors using a database of Pfizer pre-clinical candidates related the 
physicochemical properties and toxicity [257]. The two physicochemical properties that 
correlated with toxicity were the Log P and tPSA, and a higher probability of finding 
compounds with toxicity was observed for compounds with a Log P higher than 3 and a 
tPSA lower than 75 A2. Considering the tPSA and cLog P calculated for the compounds 
synthesized (Table 3.25), it can be observed that with the exception of compound XBp33, 
all compounds have a tPSA lower than 75 A2 and a cLog P higher than 3. Therefore, it is 
again advisable to introduce polar groups that do not affect the activity but increase the 
tPSA and decrease the cLog P in order to lower the likelihood of toxicological effects. 
A group from Astra Zeneca studied the relationship between permeability in Caco-
2 cell assay of and several structural and physicochemical parameters in an in-house 
chemical library [258]. It was observed a correlation between permeability and different 
structural parameters including Log D, MW, tPSA, HBD, HBA and RBs. Among the 
different parameters, the most discriminatory were Log D and MW and as a result, a 
relationship between these two properties and 50 % chance of permeability in Caco-2 
assay was proposed (Table 2.10). Considering the ACD Log D and also the Log Kp 
determined experimentally in the membrane assays for all the analogues of XP13 were 
higher than 3, and the molecular weight bellow 400, it might be expected that all the 
compounds fulfill the characteristics that allow them to have a 50 % chance of being 
highly permeable. 
A group of Pfizer found a relationship between permeability in Caco-2 cell, 
clearance (predicted by the microsome assay) with Log D and molecular weight [259]. 
ŚĂƉƚĞƌϯ
ZĞƐƵůƚƐΘŝƐĐƵƐƐŝŽŶ
ϭϵϳ

Plotting the compounds that had good permeability and clearance using Log D and MW 
as variables, led to the observation of a triangular area, called Golden Triangle, where the 
potential to find a compound with good permeability and clearance was higher (Chapter 2, 
Figure 2.18). Most of the analogues of XP13 have a MW bellow 350 and a Log Kp and 
Log D around 4 which mean that they have a good possibility of having a good 
permeability and clearance. However, there are some compounds with a MW higher than 
350 and also a Log Kp and Log D higher than 4 which means that for those compounds, 
bad permeability and clearance might be observed. 
  
3.2.4.3 Overview of the drug-likeness of the compounds synthesized 
 
The analysis of the structural and physicochemical properties of the compounds 
synthesized allowed us to raise some questions regarding possible pharmacokinetic 
issues these compounds might show. The first question concerns the oral bioavailability 
caused by lack of solubility since it was observed a low intrinsic solubility in a small 
sample of the chemical library synthesized, being afterwards extrapolated for all the other 
compounds. The second question concerns the high lipophilicity encountered for the 
majority of the compounds synthesized since a high lipophilicity is known to increase the 
likelihood of encountering pharmacokinetic and toxicological problems. However, other 
structural and physicochemical properties that are known to influence ADME-Tox 
parameters, such as MW, tPSA, HBD, HBA and RBs are significantly below the values 
considered to be problematic. Therefore, there is the opportunity of introducing polar 
groups to decrease the lipophilicity for the more hydrophobic compounds without affecting 
potency and reaching dangerous values in respect to other structural and 
physicochemical parameters. In addition to lipophilicity, the high percentage of aromatic 
carbons and high planarity has been also proposed to be responsible for the low solubility 
encountered and consequently, it is advisable to introduce more hybridized-sp3 carbons 
in order to decrease the planarity [260]. 
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3.3 Growth inhibition on four human tumor cell 
lines1 
 
 Previously published results had shown that XP13 presented potent 
antiproliferative and apoptotic activities in leukemia cell lines and it was proposed that 
XP13 might block the binding of anti-apoptotic Bcl-xL to pro-apoptotic Bad and Bim [1]. In 
addition, XP13 had previously also shown an enhancement in the anti-estrogenic effect of 
4-hydroxytamoxifen in an estrogen-dependent tumor cell line (MCF-7) [11]. These results 
prompted us to use XP13 as the building block for a multidimensional optimization in the 
search for more potent and promising compounds. The synthesis of all the analogues was 
described in the section 3.1 and the cell growth inhibition effect will be described below. 
The effect of the newly synthesized compounds in the tumor cell lines growth was 
evaluated using the Sulforhodamine B (SRB) assay in the following four cell lines, MCF-7 
(breast adenocarcinoma), NCI-H460 (non-small cell lung cancer), A375-C5 (melanoma) 
and HL-60 (acute myeloid leukemia). A drug-screening procedure adopted from the 
National Cancer Institute (NCI, USA) uses the protein-binding SRB to indirectly assess 
cell growth [261, 262]. In each cell line, a dose-response curve was established for each 
compound tested and the concentration that caused a cell growth inhibition of 50 % (GI50) 
was determined  [263].  
 The GI50 concentrations obtained for the 36 compounds in the different tumor cell 
lines are summarized in Table 3.26. In addition the GI50 determined with the SRB assay 
for compounds XP11, XP12, XP25 to XP26 which have been published elsewhere are 
also presented in Table 3.26 [1, 11-13]. Regarding the results obtained in the MCF-7 cell 
line the compounds which presented higher activity (i.e. GI50 < 30 μM) were: XBp15, 
XBp23 and XPr4. In the NCI-H460 cells, the most active compounds were XBp23 and 
XPr4 (GI50 < 20 μM). In the A375-C5 cell line, the compounds that had a stronger growth 
inhibitory effect (with a GI50 < 20 μM) were XBp15, XBp23, XBp31 and XPr4. Regarding 
the HL-60 cell line, the compounds XBp1, XBp4, XBp7, XBp11, XBp13, XBp15, XBp17, 
XBp21, XBp22, XBp23, XBp26, XBp27, XBp29, XBp31, XPr1 and XPr2 presented a 
GI50 below 20 μM, and from among them, compounds XBp1, XBp7, XBp11, XBp13, 
XBp15, XBp22, XBp26, XBp27, XBp29, XPr1 and XPr2 had GI50 below 10 μM. From 
these results, it was possible to observe that compounds XBp15, XBp23 and XPr4 had a 
broader range of activity, being active against all the tumor cell lines analyzed. From all 
the compounds tested, XBp15 presented the lowest GI50 (3.2 μM) in the HL-60 tumor cell 
line. 
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In general, the synthesized compounds were shown to be more active against the 
HL-60 tumor cell line, several with GI50 concentrations below 10 μM. Therefore, the HL-60 
cell line seems to be more sensitive to the effect of xanthones with a 2,2-dimethylpyran 
and a 2,2-dimethyl-3,4-dihydropyran fused ring. A possible explanation for this effect may 
involve a cellular target which is present in the cell line (HL-60) but not in the other cell 
lines analyzed in this study. 
 
Table 3.26 Growth Inhibitory activity of the synthesized analogues in MCF-7 (breast 
adenocarcinoma), NCI-H460 (non-small cell lung cancer), A375-C5 (melanoma) and HL-
60 (acute myeloid leukemia) cell lines expressed in μMa. 
 MCF-7 NCI-H460 A375-C5 HL-60 
XP13 39.7 ± 3.2 40.3 ± 3.3 28.9 ± 8.1 6-7b 
XBp1 >150 >150 >150 8.8 ± 5.9 
XBp2 >150 >150 >150 N.R. 
XBp4 N.R. N.R. N.R. 11.8 ± 3.8 
XBp5 45.1 ± 3.3 47.3 ± 6.0 42.5 ± 5.5 31.8 ± 6.1 
XBp6 107.9 ± 13.9 >150 >150 >70 
XBp7 N.R. 42.9 ± 16.1 47.4 ± 4.1 9.6 ± 3.2 
XBp8 N.R. >150 >150 37.6 ±  17.1 
XBp9 39.6 ± 0.6 31.7 ± 2.6 29.6 ±  4.7 38.9 ± 9.8 
XBp10 >150 >150 >150 26.1 ± 9.5 
XBp11 N.R N.R. 69.5 ±  5.9 9.6 ± 1.7 
XBp12 >100 N.R. >100 30.9 ± 10.8 
XBp13 N.R. N.R. >100 6.4 ± 0.3 
XBp14 >50 >50 >50 >50 
XBp15 13.3 ± 1.3 32.9 ± 7.1 6.2 ± 0.6 3.2 ± 0.7 
XBp16 50.9 ± 3.5 44.5 ± 1.4 37.9 ± 6.5 36.7 ± 3.3 
XBp17 >150 >150 >150 14.1 ± 1.4 
XBp18 >75 >75 >75 48.4 ± 7.5 
XBp19 >150 >150 >150 N.R. 
XBp20 >50 >50 >50 >50 
XBp21 36.9 ± 4.7 34.9 ± 1.8 27.1 ± 1.7 18.8 ± 4.7 
XBp22 34.3 ± 1.1 26.8 ± 1.6 21.9 ± 2.7 9.2 ± 4.9 
XBp23 14.5 ± 1.0 13.7 ± 0.47 19.6 ± 4.7 14.4 ± 3.7 
XBp24 >75 >75 >75 N.R. 
XBp25 >150 >150 >150 22.8 ± 8.0 
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Table 3.26 (cont) 
 MCF-7 NCI-H460 A375-C5 HL-60 
XBp26 >150 >150 >150 8.3 ± 2.7 
XBp27 31.8 ± 5.4 30.9 ± 3.6 29.7 ± 4.7 5.14 ± 1.8 
XBp28 >100 >100 >100 72.3 ± 4.3 
XBp29 >150 >150 >150 9.0 ± 1.1 
XBp30 >150 >150 >150 23.9 ± 3.5 
XBp31 >150 48.1 ± 13.6 17.6 ± 4.9 12.5 ± 3.2 
XBp32 N.R. 41.1 ± 8.6 68.0 ± 4.5 27.3 ± 5.6 
XBp33 82.5 ± 15.0 59.1 ± 14.1 40.7 ± 8.5 57.0 ± 6.8 
XP25c >150 >150 N.D. N.D. 
XP11d 88.6 ± 12.9 >160 N.D. N.D. 
XP26c >150 >150 N.D. N.D. 
XP12d >160 >160 N.D. N.D. 
XPr1 38.6 ± 7.2 37.9 ± 6.0 23.1 ± 4.1 5.1 ± 0.9 
XPr2 48.6 ± 7.6 24.2 ± 1.5 >150 5.5 ± 1.5 
XPr3 >150 >150 >80 21.6 ± 4.7 
XPr4 19.9 ± 5.1 18.1 ± 5.4 13.6 ± 2.2 39.0 ± 7.8 
The values presented refer to mean ± SE of at least three independent experiments. a.N.R.- non-reproducible; 
N.D-not determined. The maximum DMSO concentration used was 0.25 % for all compounds tested which did 
not interfere with cell growth (data not shown). Doxorubicin was used as a positive control (MCF-7 = 31 ± 2 
nM; NCI-H460 = 38 ± 2 nM; A375-C5 = 36 ± 3 nM; HL-60 = 64.4 ± 7 nM).bThe results were published 
elsewhere [1]and were detected with the Trypan blue exclusion assay (IC50). cThe results were published in 
[12]. dThe results were published in [13]. 
 
 Furthermore, when analyzing the dose-response curves of these compounds 
(Appendix II), it was possible to observe that some of the tested compounds were able to 
decrease the cellular protein content (after 48 hours of treatment) to values lower than 
those present at time zero (cell growth lower than zero). This was an indication that some 
of the compounds were inducing programmed cell dead (e.g. apoptosis). The compounds 
in which this was observed were the following: XBp9, XBp16, XBp21, XBp27 and XPr4 in 
the MCF-7; XBp7, XBp9, XBp16, XBp21, XBp27 and XPr4 in the NCI-H460; XBp9, 
XBp16, XBp21, XBp22, XBp27, XBp31, XBp33 and XPr4 in the A375-C9 cell line and; 
XBp7, XBp11, XBp21, XBp22, XBp30, XBp31, XBp32, XBp33, XPr1, XPr2, XPr3 and 
XPr4 in the HL-60 cell line.  
In the other cases, where a decrease in the cell growth was observed but without 
reaching values of cell growth below 0, it cannot be confirmed neither excluded that these 
compounds might be able to induce cell death. 
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In order to further confirm if these compounds may act by inducing apoptosis, 
other assays could be used as the TUNEL assay or the Annexin V/PI labeling followed by 
flow cytometry. Nonetheless, such analyses were not under the scope of this thesis. 
 
3.3.1 Structure-Activity Relationship 
 
The evaluation of the structure-activity relationship (SAR) allowed drawing some 
conclusions regarding structural features of the compounds associated with their effect in 
growth inhibition in the four human tumor cell lines.   
In order to better understand the influence of the different substituents in the 
growth inhibition of the four human tumor cell lines, the hydroxyl, methoxyl, chlorine and 
N,N-diethylamine were removed from the xanthones core and therefore three scaffolds 
with a fused 2,2-dimethylpyran or 2,2-dimethyl-3,4-dihydropyran were obtained (Figure 
3.84, scaffold A, B and C). 
 
Figure 3.84 Schematic representations of the three scaffolds without substituents in the 
xanthone ring. 
 
The SAR for the compounds with the scaffold A is summarized in Figure 3.85 in 
which the association between the type and position of functional groups and the effect on 
the growth inhibition of the four human tumor cell lines analyzed can be observed. The 
hydroxyl in position 12 is associated with a moderate inhibitory activity observed in all the 
four tumor cell lines studied. Nevertheless, in the HL-60 cell line, its exchange by a 
methoxyl allows to maintain the growth inhibitory activity of these compounds. On the 
other hand, if the position of the hydroxyl group changes from osition 12 to position 5, the 
growth inhibitory activity is no longer observed in the MCF-7 and NCI-H460 cell lines. 
Considering XP13, XBp1 and XBp2, some SAR associated with presence of different 
functionalities in positions 8, 9 and 10 can be drawn. Regarding position 8, the presence 
of chlorine or methoxyl group was associated with a loss of the cell growth inhibitory 
activity in the MCF-7 tumor cell line. Considering the other tumor cell lines tested, chlorine 
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was associated with a loss of the cell growth inhibitory effect in NCI-H460 and A375-C5 
cells and but not in the HL-60 cells. On the other hand, the methoxyl was associated with 
the loss of the cell growth inhibitory effect in the NCI-H460 and A375-C5 cells and a 
decrease in the HL-60 cells. The introduction of a methyl group in position 8 of XP13 led 
to the loss of cell growth inhibitory effect in the MCF-7 cells, a slight decrease in the NCI-
H460 and HL-60 cells, but increased growth inhibitory activity in the A375-C5 cells. On the 
other hand, the introduction of a methyl group in position 8 of XBp1 led to an increase on 
the growth inhibitory effect on the four tumor cell lines tested. Considering position 9, the 
hydroxyl was associated with a moderate growth inhibitory effect in three of the tumor cell 
lines studied, while in the HL-60 cells, its effect was dependent on the group present in 
position 12. For compounds with a methoxyl group in positions 8 and 9 or in positions 9 
and 10, no growth inhibitory activity was observed for the MCF-7, NCI-H460 and A375-C5 
cells, and moderate activity was observed for the HL-60 cells. The presence of a methoxyl 
in position 10 was associated with a decreased activity in three of the cell lines tested, 
namely, NCI-H460, A375-C5 and HL-60. 
 
O O
O
OH
Cl
CH3
OCH3
OH
OCH3
5
1210
9
8
MCF-7
O O
O
5
1210
9
8
O O
O
1210
9
8
A375-C5
O O
O
1210
9
8
HL-60
NCI-H460
OH
OCH3
OH
OH
OCH3
Cl
CH3
OCH3
OH
OCH3
OCH3
Cl
CH3
OCH3
OH
OCH3
OH
OCH3
OCH3
Cl
CH3
OCH3
OH
OCH3
OH
OCH3
OCH3
 
Figure 3.85 SAR in the different human tumor cell lines for the scaffold A. 
ŚĂƉƚĞƌϯ
ZĞƐƵůƚƐΘŝƐĐƵƐƐŝŽŶ
ϮϬϯ

 
 
 
 The evaluation of the SAR for compounds with the scaffold B allowed taking some 
considerations about the effect of the type and position of the substituents in the cell 
growth inhibitory effect on the four tumor cell lines tested (Figure 3.86). Comparing the 
growth inhibitory activity of compounds that differ between each other only by the 
presence or absence of a double bond in position 3-4, it was observed that the presence 
of the double bond is associated with an increase of growth inhibitory activity in all tumor 
cell lines tested. There were a few exceptions to this observation such as for compounds 
XBp23 and XBp24 (in MCF-7, NCI-H460, A375-C5 tumor cell lines) and for compounds 
XBp9 and XBp10 (HL-60 tumor cell line). Contrary to XP13, the presence of a hydroxyl in 
position 5 (position 12 of XP13) was associated with a decrease in the growth inhibitory 
activity of all the cell lines analyzed (XBp6) and the best results were obtained with a 
methoxyl group. In the case of position 12, the observed growth inhibitory activity was 
more dependent on the presence or absence of the double bond between positions 3 and 
4, than on the presence of a hydroxyl or methoxyl in position 12. Nevertheless, for 
compounds with the double bond, the methoxyl was associated with a more potent cell 
growth inhibitory activity. Considering compound XBp4, the introduction of a substituent in 
position 9 was not associated with an improvement in the growth inhibitory activity, albeit 
with chlorine, there was not an important decrease in the activity in the HL-60 tumor cell 
line. On the other hand, for analogues of XBp4 with different substituents in position 8, the 
introduction of a hydroxyl group (XBp21) was associated with a moderate activity in the 
four tumor cell lines, albeit in the HL-60, the GI50 was lower when compared to XBp4. The 
introduction of N,N-diethylamine group (XBp22) in position 8 of XBp4 was associated with 
moderate to good activity in the four tumor cell lines tested, which means that this group 
can be associated with an increase in the potency. Considering compound XBp5, it was 
observed for all the cell lines that the presence of a chlorine in positions 9 (XBp18) and 
two methoxyls (XBp24) in positions 8 and 9 were associated with a decrease in the 
growth inhibitory activity and the presence of a N,N-diethylamine group (XBp23) was 
associated with an increase on the growth inhibitory activity. 
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Figure 3.86 SAR in the different human tumor cell lines for the scaffold B. 
 
 
 
The SAR for the compounds synthesized bearing the scaffold C can be depicted in 
Figure 3.87. The presence of the double bond between position 3 and 4 was associated 
with a growth inhibitory activity. In fact, only compounds with this feature showed a potent 
activity. Regarding the introduction of a hydroxyl or methoxyl group in position 6, it was 
observed that the presence of those groups in this position associated with a decrease on 
the cell growth inhibitory in all tumor cell lines, although the effect was not relevant in the 
HL-60 cells. 
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Figure 3.87 SAR in the different human tumor cell lines for the scaffold C. 
 
 The SAR for compounds XPr1, XPr2, XPr3 and XPr4 allowed to take important 
considerations concerning the growth inhibitory activities associated with the presence of 
prenyl(s) group(s) in different positions of the 1,2-dihydroxyxanthone scaffold. The 
presence of two O-prenyls in positions 1 and 2 (XPr1), and an O-prenyl in position 2 
(XPr2) was associated with a moderate activity in the three of the tumor cell lines tested 
(MCF-7, NCI-H460 and A375-C5) and a good growth inhibitory activity in the HL-60 tumor 
cell line. In comparison with XPr2, the presence of a C-prenyl in position 4 of XPr3 was 
associated with a loss of growth inhibitory activity in three tumor cell lines tested, albeit 
having a moderate activity in the HL-60 tumor cell line. The presence of one prenyl group 
in C-4 was associated with a moderate to good growth inhibitory activity in the four tumor 
cell lines. To sum up, compounds bearing an O-prenyl in position 2 seemed to be more 
active against HL-60 cells and the compound bearing a C-prenyl in position 4 was 
associated with a lower selectivity in the four tumor cell lines tested.  
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3.4 Most promising compounds considering the 
drug-likeness and growth inhibitory activity 
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Figure 3.88 Schematic representation of the most potent compounds found based on 
their studied biological activity and general drug-likeness. 
 
 Figure 3.88 represents a schematic flowchart associating the growth inhibitory 
activity in the four tumor cell lines tested and the general drug-likeness for the most active 
compounds synthesized. The compounds can be mainly divided into two groups: i) those 
who exhibit selectivity to one of the four cell lines tested and ii) compounds with a growth 
inhibitory activity in more than one tumor cell line.  
Several of the compounds tested shown to be more selective to the HL-60 cells: 
XBp1, XBp4, XBp11, XBp13, XBp26, XBp27 and XBp29. Among them, the most 
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promising candidates can be considered to be XBp1, XBp11 and XBp26 since they were 
also associated with more favorable structural and physicochemical features for a good 
oral bioavailability. However, they will most likely show poor solubility due to the high 
planarity and symmetry typical of xanthones as previously referred in section 3.2.2. 
Therefore, future chemical modifications should focus on the increase of its solubility by 
the disruption of the planarity and/or by the introduction of polar/ionizable groups. The 
compound XBp4 was also associated with a good cell growth inhibitory activity in the HL-
60 tumor cell line but its selectivity was not established. Nevertheless, this compound can 
be considered as a promising compound for future studies. 
XP13 may be considered as belonging to the second group since it exhibited 
cytotoxicity in the HL-60 tumor cell line with an IC50 of 6-7 μM, previously detected with the 
Trypan blue exclusion assay [1] as well as a moderate cell growth inhibitory activity in the 
other three tumor cell lines. Considering the other compounds that had shown a growth 
inhibitory activity in more than one tumor cell line, the most promising were XBp7, XBp15, 
XBp21 and XBp31. Among them the most potent was XBp15. By comparison of the 
effect of this compound with compounds XBp11 and XBp13, the introduction of a 
methoxyl or hydroxyl in position 6 is not advisable since it associated with a decrease in 
the cell growth inhibitory activity, although increasing the selectivity to the HL-60 tumor 
cell line. The XBp7 and XBp31 were active in more than one tumor cell line but were 
more potent in the HL-60 tumor cell line. All these compounds have showed structural and 
physicochemical properties that were in conformity with good oral availability. Again, the 
structural features of the xanthone scaffold might lead to poor solubility. The other 
compounds, in particular compounds XPr1, XBp22, XBp23, XPr2 and XPr4 might show 
poor oral bioavailability due to high lipophilicity. 
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CHAPTER 4 
Conclusions and General Remarks 
 
 
 The objective of this work was to synthesize analogues of XP13 with antitumor 
activity and with better pharmacokinetic behavior. In order to complete this goal, several 
analogues of XP13 were synthesized using different approaches such as total synthesis 
via diaryl ether and benzophenone, by the cyclization of O-1’,1’-dimethylpropargyl 
xanthones and by the condensation of prenyl bromide with oxygenated xanthones 
catalyzed by clay Montmorillonite K-10. Moreover, a new synthetic route for the synthesis 
of XP13 was developed which allowed the synthesis of this compound in higher yields and 
greater versatility.  
The synthesis of 185 compounds was reported which include 38 xanthones with a 
fused 2,2-dimethylpyran or 2,2-dimethyl-3,4-dihydropyran ring (being 31 described for the 
first time), 4 prenylated xanthones and one dimethoxylated xanthone described for the 
first time. To obtain the desired compounds, different experimental techniques were used 
which include heterogeneous catalysis with Montmorillonite K-10 catalysis, microwave 
assisted organic synthesis, transition-metal catalysis with copper, platinum and gold, 
lithiations by halogen-lithium exchange and directed ortho and remote metalations, O-
protection/deprotection with four different protecting groups, nucleophilic substitutions 
(SN1 and SN2), hydrogenation by a catalytic transfer hydrogenation, Baeyer-Villiger type 
oxidations and IBX oxidation, nucleophilic and electrophilic aromatic substitutions, and 
thermal rearrangements. 
 The prediction of the pharmacokinetic profiler was made through the determination 
of structural and physicochemical properties, namely lipophilicity, solubility and binding to 
albumin. The lipophilicity was determined experimentally for sixty compounds (53 
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compounds synthesized in this wrok and 7 from the chemical library of CEQUIMED-UP) in 
membrane models, namely micelles and liposomes, and compared between each other 
and three computational programs. Micelles can be used for the determination of 
lipophilicity of xanthones in detriment of the more laborious method that uses liposomes, 
since a very good correlation was found. The comparison of the two membrane models 
with three computational programs showed that in general, for the more polar compounds, 
the Log P determined in silico was lower than the Log Kp determined with the two 
membrane models and for the more lipophilic compounds the opposite was found. The 
three used computational models were developed taking in consideration the Log P 
determined experimentally by the octanol-water model, and the poor correlation found 
between the membrane models and the three computational programs showing the 
limitations of this model to mimic the biological membranes, particularly for this class of 
compounds.  
 The solubility was determined experimentally by a thermodynamic assay for 8 
analogues of XP13 and predicted for all the prenylated and ring-fused xanthones using 
several empirical models. The solubility determined experimentally and predicted showed 
that all the compounds had a poor solubility being caused by high lipophilicity but mainly 
by the high planarity and symmetry of the xanthone scaffold and which can be linked to 
the high melting point found for all compounds.  
 The dissociation binding constant between 8 of the analogues of XP13 and 
albumin (human and bovine) was determined and it was observed that there was only one 
binding site for all the compounds. Moreover, it was found that the position of the 
substituents on the xanthone scaffold was not related to the increasing strength of the 
binding. Moreover, for XP13 and XBp29 it was determined that they probably bind to the 
subdomain IIA of HSA. 
 A preview of the drug-likeness of the compounds synthesized was made by the 
evaluation of different descriptors related to structural and physicochemical properties. 
The comparison of the observed results with published guidelines aided in the selection of 
the most promising compounds as well as the prediction possible ADME-Tox liabilities the 
synthesized compounds might show.  
 The evaluation of the biological activity was determined for 36 compounds by the 
growth inhibition on four human tumor cell lines, namely, MCF-7 (breast cancer), NCI-
H460 (NSCLC), A375-C5 (melanoma) and HL-60 (leukemia). Compounds more potent 
than XP13 were found, appearing some of them selective for the HL-60 tumor cell line. 
The SAR analysis of the compounds tested allowed taking some considerations about the 
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influence that the different substituents have on the growth inhibition of the different tumor 
cell lines tested. 
 The evaluation of the growth inhibitory activity in conjunction with the 
physicochemical parameters and evaluation of the drug-likeness allowed the selection of 
the most promising compounds for HL-60 tumor cell line and with a broader range of 
acitivity (Figure 4.1).  
 
 
Figure 4.1 Most promising compounds. 
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CHAPTER 5 
Experimental 
 
In this Chapter, it will only be referred the experimental procedures used for the 
synthesis of XP13 analogues, for the determination of physicochemical properties and 
growth inhibition of several tumor cell lines, described in chapter 3. 
 
5.1 Syntheses 
General Methods: 
Purifications of compounds were performed by column chromatography either by 
using Merck silica gel 60 (0.040-0.063 mm) (when it is referred flash chromatography) or 
using Merck silica gel 60 (0.2-0.5 mm) (when nothing is referred) and preparative thin 
layer chromatography (TLC) using Merck silica gel 60 (GF254) plates or GraceResolv® 
silica gel cartridges (5 g/25 mL). Reactions were monitored by TLC and/or GC-MS. MW 
reactions were performed using glassware setup for atmospheric-pressure reactions and 
also 12 mL, 50 mL, 100 or 270 mL closed glass reactors (internal reaction temperature 
measurement with a fiber-optic probe sensor) and were carried out using an Ethos 
MicroSYNTH 1600 Microwave Labstation from Milestone. Microwave reactions were also 
carried out on a CEM Discover BenchMate with 10-mL pressurized vials. Melting points 
were obtained in a Köfler microscope and are uncorrected. IR spectra were measured on 
an ATI Mattson Genesis series FTIR (software: WinFirst v. 2.10) spectrophotometer in 
KBr microplates (cm-1). 1H and 13C NMR spectra were taken in CDCl3 or DMSO-d6 at 
room temperature, on Bruker Avance 300 and 500 instruments and Bruker ARX-400. 
Chemical shifts are expressed in į (ppm) values relative to tetramethylsilane (TMS) as an 
internal reference. 1H NMR spectra were measured at 300.13 MHz, 400.21 MHz or 500.13 
MHz and assignment abbreviations are the following: singlet (s), doublet (d), triplet (t), 
quartet (q), quintet (qt), multiplet (m), doublet of doublets (dd), double doublet of doublets 
(ddd), doublet of triplets (dt) and triplet of doublets (td). 13C NMR spectra were measured 
at 75.47 MHz or 100.63 MHz or 125.77 MHz. 13C NMR assignments were made by 2D 
HSQC and HMBC experiments (long-range C, H coupling constants were optimized to 7 
and 1 Hz) or by comparison with the assignments of similar molecules. The EI-MS were 
recorded either in a Shimadzu GCMS-QP5000 or on a ThermoQuest Finnigan GC 2000 
series/GCQ plus. Elemental analysis results were determined in an Analizador Elemental 
CarloErba 1108 at C.A.C.T.I., Vigo, Spain. HRMS spectra were recorded as ESI 
(electrospray ionization) mode either on an APEXQe FT-ICRMS (Bruker Daltonics), 
equipped with a 7T actively shielded magnet or VG Autoespec MicroTOF FOCUS (Bruker 
^ǇŶƚŚĞƐĞƐ
ϮϮϲ

Daltonics) spectrometer at C.A.C.T.I.-University of Vigo, Spain. All the reagents were 
purchased from Sigma Aldrich or Acros and all the solvents were PA used without further 
purification. The anhydrous solvents were either purchased from Sigma-Aldrich or dried 
according to the published procedures [1]. The X-Ray was determined in a Gemine PX 
ultra equipped with a CuKĮ radiation (Ȝ= 1.54184 Å) and the structure was solved using 
SHELXS-97 and refined with SHELXL-97. 
 
5.1.1 Synthesis of XP11, XP12, XP13 and XBp1 
5.1.1.1 2-Hydroxy-2’,3,4-trimethoxybenzophenone (5): 
In an oven-dried two-necked round-bottom flask of 500 mL, was placed 2,3-
trimetoxybenzene (3.77 g/ 22.42 mmol) and 150 mL of ether anhydrous. The solution was 
placed on an ice bath and aluminum chloride anhydrous (8.9 g/67 mmol) was added 
cautiously. When no more gas evolved, the solution was placed under nitrogen 
atmosphere and 2-methoxybenzoyl chloride (3.33 mL/3.83 g/22.42 mmol) was added 
dropwise. The solution was allowed to warm to room temperature and was stirred for 22 
hours under nitrogen atmosphere. The solution was poured into a mixture of 100 g of 
crushed ice and 5 mL of concentrated HCl, and extracted with 3 x 100 mL of ethyl acetate. 
The organic phase was washed 3 x 100 mL of water, dried over anhydrous Na2SO4, 
filtered and the organic solvent evaporated. The solid obtained was first recrystallized first 
from acetone and second from ethyl acetate to give compound 5 as yellowish green solid 
(4.9 g/76 %).  
Mp: 115-116 ºC. IR ȣmax (cm-1) (KBr): 3437, 1599, 1497, 1450, 1424, 1343, 1284, 1172, 
1097, 979, 755. 1H NMR (300.13 MHz, CDCl3) į (ppm): 12.49 (s, OH), 7.47 (ddd, J = 8.0, 
7.9, 1.7), 7.27 (dd, J = 7.5, 1.7), 7.10 (d, J = 8.9), 7.06 (ddd, J = 7.9, 7.5, 0.6), 7.01 (dd, J 
= 8.0, 0.6), 6.40 (d, J = 8.9), 3.94 (s, OCH3), 3.92 (s, OCH3), 3.79 (s, OCH3). 13C NMR 
(75.47 MHz, CDCl3) į (ppm): 200.7, 158.7, 157.5, 156.4, 136.3, 131,6, 130.3, 128.7, 
127.9, 120.4, 115.7, 111.4, 102.7, 60.7, 56.1, 55.7. EIMS m/z (%): 290 (6, [M+2]+.), 289 
(30, [M+1]+.), 288 (60 [M]+.), 258 (14), 157 (100), 213 (8), 181 (14), 180 (58), 152 (44), 136 
(18), 135 (44), 78 (20), 77 (38), 51 (10). 
 
5.1.1.2 3,4-Dimethoxyxanthone (4): 
In a sealed reactor vessel (quartz 30 mL) for microwave synthesis was placed compound 
45 (1 g/3.45 mmol) and 15 mL of a mixture of methanol/water (2:1) with NaOH (45 mmol). 
The mixture was then heated at 130 ºC for 1 hour, and then allowed to cool to room 
temperature. The solid was filtered and washed with 100 mL of water. The solid was then 
crystallized from methanol to give compound 4 as a white solid (690 mg, 77 %). 
Mp: 153-154 ºC. IR ȣmax (cm-1) (KBr): 1659, 1604, 1508, 1438, 1332, 1288, 1224, 1091, 
1048, 975, 892, 752. 1H NMR (300.13 MHz, CDCl3) į (ppm): 8.33 (dd, J = 7.9, 1.7), 8.11 
(d, J = 9.0), 7.72 (ddd, J = 8.4, 7.1, 1.7), 7.58 (d, J = 8.2), 7.38 (dd, J = 7.1, 1.0), 7.03 (d, J 
= 9.0), 4.04 (s, OCH3), 4.02 (s, OCH3). 13C NMR (75.47 MHz, CDCl3) į (ppm): 176.6, 
157.5, 156.1, 150.6, 136.3, 134.5, 126.6, 123.9, 122.4, 121.3, 118.0, 116.7, 108.6, 61.6, 
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56.4. EIMS m/z (%): 258 (4, [M+2]+.), 257 (20, [M+1]+.), 256 (88 [M]+.), 241 (56), 213 (100), 
185 (82), 170 (50), 129 (46), 114 (72), 113 (46), 76 (18), 63 (24). 
5.1.1.3 3-Hydroxy-4-methoxyxanthone (2) and 4-hydroxy-3-
methoxyxanthone (6): 
Method A. O-demethylation with LiCl: 
In a 5 mL two-necked glass apparatus for microwave heating was placed compound 4 
(600 mg/2.34 mmol), LiCl (595 mg/14.04 mmol) and 5 mL of anhydrous DMF. The mixture 
was then heated at 155 ºC for 1h and 30 min using microwave heating. The mixture was 
allowed to cool to room temperature and 50 mL of HCl 0.1 M was added followed by an 
extraction with 3 x 50 mL of ethyl acetate. The organic phase was washed with 3 x 50 mL 
of water, dried over sodium sulfate anhydrous, filtered and the organic solvent 
evaporated. The crude product was then purified by silica gel flash chromatography (n-
hexane/ethyl acetate 7:3). Compound 2 (142 mg, 25 %) was recrystallized as white solid 
from chloroform/n-hexane and compound 6 (113,4 mg/ 20 %) as a white solid from 
methanol. 
Method B. O-demethylation with N,N-(diethylamine)ethanethiol HCl/NaOtBu: 
To an oven-dried 50 mL two-necked round-bottom flask equipped with a magnetic stirrer 
and under nitrogen atmosphere was added 2-(diethylamino)ethanethiol HCl (397 mg/2.34 
mmol) and 8 mL of DMF anhydrous. The flask was cooled in an ice bath and when the 
internal temperature was below 5 ºC, solid NaOtBu (450 mg/4.68 mmol) was added in one 
portion. After 5 minutes the ice bath was removed and it was allowed to warm to room 
temperature. After 15 minutes, a solution of 3,4-dimethoxyxanthone (4) (500 mg/1,95 
mmol) in 4 mL of DMF anhydrous was added. The mixture was heated at reflux for 2 
hours under nitrogen atmosphere. The mixture was allowed to cool to room temperature 
and then was placed in an ice bath. A solution of HCl 1 M was added to the mixture until 
pH 1 and 30 mL of water was added to the mixture. The mixture was extracted with 3 x 50 
mL of ethyl acetate. The organic phase was washed with 3 x 50 mL of water, dried over 
sodium sulfate anhydrous, filtered and the organic solvent evaporated. The crude product 
was purified by silica gel flash chromatography (petroleum ether (60-80º)/ethyl acetate 
7:3). Compound 2 was crystallized from chloroform/petroleum ether (60-80º) as white 
solid (221.4 mg/46 %) and compound 6 from methanol as a white solid (83 mg/17 %). 
Compound 2: Mp: 223-224 ºC. IR ȣmax (cm-1) (KBr): 3210, 1642, 1594, 1522, 1468, 1436, 
1336, 1262, 1226, 1066, 1034, 1016, 789, 745. 1H NMR (300.13 MHz, CDCl3) į (ppm): 
10.08 (s, OH), 8.35 (dd, J = 7.9, 1.7), 8.05 (d, J = 8.8), 7.73 (ddd, J = 8.4, 7.1, 1.7), 7.54 
(d, J = 8.4), 7.40 (ddd, J = 7.9, 7.1, 0.9), 7.03 (d, J = 8.8), 4.16 (s, OCH3). 13C NMR (75.47 
MHz, CDCl3) į (ppm): 175.8, 155.9, 155.5, 150.6, 134.2, 134.0, 126.0, 123.5, 121.7, 
121.0, 117.6, 115.1, 113.6, 61.0.  
Compound 6: Mp: 191-192 ºC. IR ȣmax (cm-1) (KBr): 3237, 1633, 1604, 1462, 1339, 1282, 
1224, 1085, 753. 1H NMR (300.13 MHz, CDCl3) į (ppm): 8.34 (dd, J = 8.0, 1.7), 7.93 (d, J 
= 8.9), 7.72 (ddd, J = 7.8, 7.1, 1.7), 7.58 (d, J = 7.8), 7.38 (ddd, J = 8.0, 7.1, 1.0), 7.00 (d, 
J = 8.9), 4.05 (s, OCH3). 13C NMR (75.47 MHz, CDCl3) į (ppm): 176.6, 156.1, 150.9, 
144.7, 134.6, 133.2, 126.7, 123.9, 121.5, 118.0, 118.0, 116.8, 107.4, 56.6. 
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5.1.1.4 3,4-Dihydroxyxanthone (1): 
In a two-necked round-bottom flask was placed 3,4-dimethoxyxanthone 4 (769 mg/3 
mmol) and 50 mL of anhydrous toluene. The mixture was placed at 0ºC and aluminum 
chloride (1.2 g/9 mmol) was added slowly. The mixture was heated for 2 hours under 
reflux. The mixture was allowed to cool to room temperature and poured over 150 g of 
crushed ice and 1 mL of concentrated HCl. The aqueous phase was extracted with 3 x 
100 mL of ethyl acetate. The organic phase was washed 3 x 150 mL of distilled water, 
dried over sodium sulfate anhydrous, filtered and the organic solvent evaporated. The 
crude product was purified by silica gel chromatography (chloroform/acetone 9:1). 3,4-
Dihydroxyxanthone (1) was crystallized from methanol as a pale yellow solid (534 mg/78 
%). 
Mp: > 330 ºC. IR ȣmax (cm-1) (KBr): 3517, 3108, 2827, 2800, 1635, 1603, 1582, 1556, 
1457, 1350, 1222, 1062, 991, 759, 686. 1H NMR (300.13 MHz, DMSO-d6) į (ppm): 8.16 
(dd, J = 7.9, 1.7), 7.84 (ddd, J = 8.1, 7.1, 1.7), 7.60 (d, J = 8.1), 7.57 (d, J = 8.8), 7.45 
(ddd, J = 7.9, 7.1, 0.7), 6.95 (d, J = 8.8). 
5.1.1.5 1,3-Dihydroxyanthone  (82): 
Phosphorus pentoxide (3 g) was added slowly to 20 mL of methanesulfonic acid and it 
was heated at 100 ºC until it solubilized completely. The phloroglucinol (1.55 g/9.57 mmol) 
and the salicylic acid (1.3 g/9.57 mmol) were then added to the solution and it was left 
stirring for 15 minutes at 100 ºC. The mixture was allowed to cool to room temperature 
and poured over 200 g of crushed ice. The solid formed was filtered and then purified by 
silica gel chromatography (chloroform). Compound 3 was crystallized from methanol as a 
yellow solid (1.34 g/62 %). 
IR: ȣmax (cm-1) (KBr): 3321, 1653, 1608, 1565, 1513, 1490, 1466, 1440, 1348, 1282, 1259, 
11218, 1158, 1074, 823, 759, 721. 
The data was in accordance with a sample of 1,3-dihydroxyxanthone kindly provided by 
CEQUIMED-UP. 
5.1.1.6 Reaction of compounds 1, 2 and 3 prenyl bromide with clay 
Montmorillonite K-10 under microwave heating: 
In a typical experiment: 
To a Teflon vessel for microwave heating with compound 43 (110 mg/ 0.46 mmol), 2 g of 
clay montmorillonite K-10 and approximately 10 mL of chloroform (just enough to wet the 
clay), was added prenyl bromide (0.92 mmol). The mixture was heated for 1 h and 15 min 
at 110 ºC under microwave heating. The mixture was allowed to cool to room temperature 
and the product was filtered and washed with chloroform, acetone and methanol. The 
organic solvents were reunited and evaporated. The crude product was then purified 
several times by silica gel flash chromatography (petroleum ether (60-80º)/ethyl acetate 
95:5 to 5:5). Compound XBp1 was recrystallized from chloroform and petroleum ether 
(60-80º) as a white solid (17 mg/12 %). 
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12-Methoxy-2,2-dimethyl-3,4-dihydropyrano[3,2-b]xanthen-6(2H)-one (XBp1; 12 %): Mp: 
173-174 ºC. IR ȣmax (cm-1) (KBr): 2967, 2936, 2829, 1655, 1609, 1443, 1326, 1114, 1077, 
748. 1H NMR (300.13 MHz, CDCl3) į (ppm): 8.32 (dd, J = 7.9, 1.6; H-C(7)); 7.86 (t, J = 
0.9; H-C(5)), 7.70 (ddd, J = 8.4, 7.0. 1.6; H-C(9)), 7.57 (dd, J = 8.4, 1.1; H-C(10)), 7.36 
(ddd, J = 7.9, 7.0, 1.1; H-C(8), 4.00 (s; H3CO-C(12)), 2.64 (td J = 6.8, 0.9; H2-C(4)), 1.90 
(t, J = 6.8; H2-C(3)), 1.46 (s; (CH3)2-C(2)). 13C NMR (75.47 MHz, CDCl3) į (ppm): 176.6 
(C6), 156.2 (C10a), 153.2 (C12a), 149.1 (C11a), 135.7 (C12), 134.2 (C9), 126.5 (C7), 
123.6 (C8), 121.5 (C6a), 121.2 (C5a), 119.3 (C4a), 118.0 (C10), 115.2 (C5a), 76.4 (C2), 
61.2 (C1’’), 32.3 (C3), 27.0 (C4), 22.1 (C1’a and C1’b). HRMS (ESI) m/z calcd for 
C19H19O4 [M+H]+: 311,12779; found: 311,12772. Elemental analysis: calcd for C19H18O4: 
C, 73.53, H 5.85, O, 20.62; found: C, 72,51, H, 6.06, O, 21.43. 
12-Hydroxy-2,2-dimethyl-3,4-dihydropyrano[3,2-b]xanthen-6(2H)-one (XP13; 21 %): Mp: 
199-202 ºC. IR ȣmax (cm-1) (KBr): 3315, 2867, 2924, 2851, 1653, 1611, 1455, 1370, 1253, 
1222, 1190, 1154, 1117, 757. 1H NMR (300.13 MHz, CDCl3): 8.33 (dd, J = 8.0, 1.6; H-
C(7)), 7.70 (ddd, J = 8.4, 7.1, 1.6; H-C(9)), 7.70 (s; H-C(5)), 7.58 (dd, J = 8.4, 1.0; H-
C10)), 7.35 (ddd, J = 8.0, 7.1, 1.0; H-C(8)), 5.74 (HO-C(12)); 2.93 (t, J = 6.7; H2-C(4)), 
1.92 (t, J = 6.7; H2-C(3)), 1.45 (s; (CH3)2-C(2)). 13C NMR (75.47 MHz, CDCl3): 176.7, 
156.1, 146.3, 143.2, 134.3, 132.4, 126.6, 123.6, 121.5, 118.2, 117.9, 117.0, 115.4, 76.5, 
32.6, 27.0, 21.7; EIMS m/z (%): 296 (98, [M]+.), 241 (100), 209 (28), 156 (15), 128 (15), 73 
(5). 
12-Hydroxy-2,2-dimethyl-3,4-dihydropyrano[3,2-b]xanthen-6(2H)-one (XP11; 15 %): IR: 
ȣmax (cm-1) (KBr): 3430, 2970,  2925,  2852, 1665, 1606,1565, 1472, 1429, 1329, 1293, 
1240, 1163, 1120, 1080,812, 747. 
6-hydroxy-3,3-dimethyl-2,3-dihydropyrano[2,3-c]xanthen-7(1H)-one (XP12; 12 %): IR: ȣmax 
(cm-1) (KBr): 3467, 2970,  2930, 2860, 1650, 1602, 1573, 1456, 1288, 1258, 1222, 1135, 
1083, 820, 750; 
The data obtained for XP11 and XP12 were in accordance with a sample provided by 
CEQUIMED-UP. 
 
5.1.2 Synthesis of XBp2 and XBp3 
5.1.2.1 Synthesis of the propargyl ethers of compounds 1 and 2:  
O-dimethylpropargylation of 3-hydroxy-4-methoxyxanthone (2) 
To a two-necked round-bottom flask was added compound 2 (120 mg/0.5 mmol), KI 
(168.5 mg/1 mmol), CuI (11.8 mg/0.062 mmol), K2CO3 (135.8 mg/1 mmol) and 5 mL of 
anhydrous DMF. 3-Chloro-3-methyl-1-butyne (430 μL/13.2 mmol) was then added and the 
mixture was heated under nitrogen atmosphere at 75 ºC for 8 hours. The solution was 
allowed to cool to room temperature and it was poured over crushed ice and 5 mL of HCl 
1 M. The aqueous phase was extracted with 3 x 50 mL of ethyl acetate. The organic layer 
was washed with 3 x 50 mL of distilled water, dried over sodium sulfate anhydrous, filtered 
and the organic solvent evaporated. The crude product was then purified by silica gel 
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flash chromatography (chloroform). It was obtained compound 7 has a white solid (126 
mg/83 %).  
4-Methoxy-3-((2-methylbut-3-yn-2-yl)oxy)xanthone (7). Mp: 121-123 ºC. IR ȣmax (cm-1) 
(KBr): 3432, 3249, 2984, 2934, 2836, 1655, 1602, 1498, 1464, 1448, 1424, 1332, 1278, 
1140, 1068, 1034, 743. 1H NMR (300.13 MHz, CDCl3) į (ppm): 8.33 (dd, J = 8.0, 1.7), 
8.04 (d, J = 9.1), 7.73 (ddd, J = 8.5, 7.0, 1.7), 7.62 (d, J = 9.1), 7.58 (d, J = 7.8), 7.39 (ddd, 
J = 8.0, 7.1, 1.0), 4.03 (s, OCH3), 2.67 (s, 1H), 1.78 (s, 6H). 13C NMR (75.47 MHz, CDCl3) 
į (ppm): 176.7, 156.2, 154.2, 150.8, 139.9, 134.5, 126.6, 124.0, 121.6, 121.0, 118.1, 
118.0, 116.8, 85.2, 74.9, 74.2, 61.5, 29.7. 
O-dimethylpropargylation of 3,4-dihydroxyxanthone (1) 
Method A: 
In an oven-dried two-necked round-bottom flask was placed 3,4-dihydroxyxanthone 1 
(320 mg/ 1.4 mmol), potassium carbonate (194 mg/1.4 mmol), potassium iodide (349 
mg/2.1 mmol) and copper iodide (40 mg/ 0.21 mmol). The flask was placed under nitrogen 
atmosphere and 20 mL of anhydrous dimethylformamide were added. The mixture was 
allowed to stir for 15 minutes and 3-chloro-3-methyl-1-butyne (270 mg/2.1 mmol) was 
added dropwise. The mixture was warmed at 50 ºC for 3 hours and then allowed to cool to 
room temperature. The crude product poured over 100 g of crushed ice and extracted 3 x 
100 mL of ethyl ether. The organic phase was washed with 2 x 100 mL of brine, dried over 
sodium sulfate anhydrous, filtered and the organic solvent evaporated. The extract was 
then purified by silica gel flash chromatography (n-hexane/ethyl acetate 9:1). Compound 9 
was isolated as a white solid (295 mg/72 %). 
Method B: 
In an oven-dried two round bottom necked flask was placed 3,4-dihydroxyxanthone 1 (100 
mg/ 0.44 mmol), potassium carbonate (91 mg/0.66 mmol), potassium iodide (109 
mg/0.66) mmol and copper iodide (13 mg/ 0.066 mmol). The flask was placed under 
nitrogen atmosphere and 20 mL of anhydrous acetone was added. The mixture was 
allowed to stir for 15 minutes and 3-chloro-3-methyl-1-butyne (45 mg/0.438 mmol) was 
added dropwise. The mixture was warmed at 40 ºC for 2 hours and then allowed to cool to 
room temperature. The crude product was filtered and the organic solvent evaporated. 
The extract was then purified by silica gel flash chromatography (n-hexane/ethyl acetate 
9:1). Compound 9 was isolated as a white solid (60 mg/ 47 %) and compound 8 as a 
white solid (39 mg/30 %).  
4-Hydroxy-3-((2-methylbut-3-yn-2-yl)oxy)xanthone (8). Mp: 168-169 ºC. IR ȣmax (cm-1) 
(KBr): 3254, 3152, 3114, 3071, 2992, 2934, 2361, 1639, 1604, 1577, 1455, 1344, 1277, 
1247, 1217, 1135, 1065, 1004, 760, 707, 677. 1H NMR (300.13 MHz, CDCl3) į (ppm): 
8.34 (dd, J = 8.0, 1.7), 7.86 (d, J = 8.9), 7.73 (ddd, J = 8.5, 7.0, 1.7), 7.60 (dd, J = 8.5, 
1.1), 7.55 (d, J = 8.9), 7.39 (ddd, J = 8.0, 7.0, 1.1), 5.89 (OH), 2.71 (s, 1H), 1.79 (s, 6H). 
EIMS m/z (%): 295 (2, [M+1]+.), 294 (8, [M]+.), 279 (56), 277 (5), 262 (5), 261 (9), 247 (6), 
233 (11), 223 (11), 209 (10), 208 (12), 205 (16), 191 (9), 165 (16), 152 (11), 146 (21), 141 
(12), 139 (15), 121 (36), 115 (39). 103 (14), 102 (23), 101 (11), 92 (26). 91 (26), 77 (100), 
76 (30), 75 (40), 74 (30), 65 (39), 64 (14), 63 (33), 53 (13), 51 (84).   
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3,3-dimethyl-2-methylene-2H-[1,4]dioxino[2,3-c]xanthen-7(3H)-one(9). Mp: 173-175 ºC. IR 
ȣmax (cm-1) (KBr): 3008, 2972, 2920, 1651, 1605, 1501, 1449, 1332, 1303, 1220, 1203, 
1165, 1060, 1032, 899, 861, 748, 677. 1H NMR (300.13 MHz, CDCl3) į (ppm): 8.32 (dd, J 
= 8.0, 1.7), 7.89 (d, J = 8.9), 7.70 (ddd, J = 8.5, 7.1, 1.7), 7.59 (dd, J = 8.5, 1.0), 7.37 (ddd, 
J = 8.0, 7.1, 1.0), 6.89 (d, J = 8.9), 4.97 (d, J = 2.5, 1H), 4.65 (d, J = 2.5, 1H), 1.58 (s, 6H). 
EIMS m/z (%): 295 (1, [M+1]+.), 294 (12, [M]+.), 279 (7), 251 (25), 229 (11), 228 (69), 223 
(7), 200 (19), 299 (11), 172 (21), 171 (31), 142 (6), 127 (6), 126 (14), 116 (12), 115 (53), 
114 (44), 113 (18), 105 (9), 92 (12), 89 (13). 88 (23), 87 (10), 77 (26), 76 (30), 75 (21), 74 
(19), 67 (74), 65 (100), 63 (39), 62 (24). 53 (35), 51 (53). HRMS (ESI) m/z calcd for 
C18H15O4 [M+H]+: 295.09649; found: 295.09787; m/z calcd for C18H14NaO4 [M+Na]+: 
317.07843, found: 317.07867. 
5.1.2.1 Cyclization of the propargyl ethers 7 and 8: 
Cyclization of compound 7: 
Thermal cyclization: 
A solution of 81 mg of compound 7 in 10 mL of anhydrous DMF was heated at 130 ºC 
under nitrogen atmosphere for 7 hours. The solution was allowed to cool to room 
temperature and the mixture was poured into 50 g of crushed ice and 1 mL of 
concentrated HCl. The aqueous phase was extracted with 3 x 50 mL of ethyl acetate. The 
organic phase was washed 3 x 50 mL of distilled water, dried over Na2SO4, filtered and 
the organic solvent evaporated. The crude product was purified by silica gel flash 
chromatography (petroleum ether (60-80º)/ethyl ether 7:3). The product was then further 
purified by preparative TLC to give compound XBp2 as a white solid (6.3 mg/8 %).  
Method A: hydroarylation of alkynes by Gagoz’s catalyst: 
In a two-necked flask was placed compound 7 (166.1 mg, 0.539 mmol) and (Ph3P)AuNTf2 
(4.2 mg, 2.695 μmol) (Gagoz’s catalyst). The two solids were placed under nitrogen 
atmosphere and 5 mL of anhydrous toluene was added. The mixture was stirred for 7 
hours at 85 ºC. The reaction mixture was allowed to cool to room temperature, filtered, 
and washed with acetone. The mixture was then concentrated under reduced pressure 
and the crude product was purified by silica gel flash chromatography (n-hexane/ethyl 
acetate 9:1 to 5:5). Compound XBp2 was obtained as a white crystalline solid (50.1 mg, 
30%). Compound 2 was also isolated (83 mg/ 50 %). 
Method B: hydroarylation of alkynes by PtCl4: 
In a two-necked round bottom flask was placed compound 7 (110 mg, 0.35 mmol), PtCl4 
(17.7 mg, 52.5 μmol, 15 mol %) and 15 mL dioxane. The mixture was stirred at r.t. for 11 h 
and then filtered. The solid was washed with diethyl ether and dichloromethane. The 
organic phases were reunited and concentrated under reduced pressure. The crude 
product was purified by silica gel flash chromatography (n-hexane/ diethyl ether 8:2). 
Compound XBp2 was obtained as a white crystalline solid (62.3 mg, 57 %). 
12-Methoxy-2,2-dimethylpyrano[3,2-b]xanthen-6(2H)-one (XBp2). Mp: 129-130 ºC. IR 
ȣmax (cm-1) (KBr): 3254, 2973, 2932, 1656, 1607, 1482, 1438, 1326, 1274, 1128, 1074, 
748. 1H NMR (300.13 MHz, CDCl3) į (ppm): 8.32 (dd, J = 8.0, 1.7; H-C(8)), 7.74 (s; H-
C(4)), 7.71 (ddd, J = 8.5, 7.0, 1.7; H-C(9)), 7.57 (dd, J = 8.5, 0.9; H-C(10), 7.37 (ddd, J = 
8.0, 7.0, 0.9; H-C(8)), 6.46 (d, J = 10.0; H-C(4)), 5.75 (d, J = 10.0; H-C(3)), 4.03 (s; H3CO-
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C(12)), 1.55 (s; (CH3)2-C(2)). 13C NMR (75.47 MHz, CDCl3) į (ppm): 176.3 (C6), 156.0 
(C10a), 151.5 (C12a), 135.7 (C11a), 134.3 (C9), 131.2 (C3), 126.6 (C7), 124.0 (C8), 
121.6 (C6a), 121.6 (C4), 119.0 (C4a), 118.2 (C5), 118.2 (C5), 116.1 (C5a), 78.1 (C2), 
61.5 (C1’’), 28.4 (C1’a and C1’b). HRMS (ESI) m/z calcd for C19H17O4 [M+H]+: 309.11214; 
found: 309.11204. Elemental analysis: calcd for C19H16O4: C, 74.01, H 5.23, O, 20.72; 
found: C, 73,41, H, 5.42, O, 21.16. 
Cyclization of compound 8: 
Thermal cyclization: 
In an oven-dried two round bottom necked flask was placed 3,4-dihydroxyxanthone 1 (150 
mg/ 0.657 mmol), potassium carbonate (136 mg/0.99 mmol), potassium iodide (164 
mg/0.99) mmol and copper iodide (19 mg/ 0.099 mmol). The flask was placed under 
nitrogen atmosphere and 20 mL of anhydrous acetone was added. The mixture was 
allowed to stir for 15 minutes and 3-chloro-3-methyl-1-butyne (81 mg/0.79 mmol) was 
added dropwise. The mixture was warmed at 40 ºC for 2 hours and then allowed to cool to 
room temperature. The crude product was filtered and the solvent evaporated. To the 
extract was added 10 mL of anhydrous DMF and the mixture was refluxed for one hour. 
The mixture was then allowed to cool to room temperature and poured over 100 g of 
crushed ice and extracted 3 x 100 mL of ethyl ether. The organic phase was washed with 
2 x 100 mL of brine, dried over sodium sulfate anhydrous, filtered and the organic solvent 
evaporated. The extract was then purified by silica gel flash chromatography (n-
hexane/ethyl acetate 9:1). Compound 9 was isolated as a white solid (275 mg/ 70 %). 
Hydroarylation of alkynes by PtCl4: 
To a solution of compound 8 (30 mg/0.102 mmol) in 2.5 mL of dioxane was added PtCl4 
(0.015 mmol/5 mg). The mixture was allowed to stir for 6 hours. The mixture was filtered 
and washed with the ethyl ether. The organic solvents were reunited and evaporated. The 
crude mixture was then purified by silica gel flash chromatography (n-hexane/ethyl 
acetate 9:1 to 7:3). Compound XBp3 was isolated as a light yellow solid (10 mg/ 33 %). 
Compound 9 (16 mg/53 %) and 3,4-dihydroxyxanthone (1) (2 mg/7 %) were also isolated. 
12-Hydroxy-2,2-dimethylpyrano[3,2-b]xanthen-6(2H)-one (XBp3). Mp: 178-179 ºC. IR ȣmax 
(cm-1) (KBr): 3247, 2955, 2915, 1843, 1638, 1600, 1449, 1346, 1272, 1208, 1135, 753. 1H 
NMR (300.13 MHz, CDCl3) į (ppm): 8.32 (dd, J = 8.0, 1.7; H-C(7)), 7.70 (ddd, J = 8.5, 7.1, 
1.7; H-C(9)), 7.59 (s; H-C(5)), 7.56 (dd, J = 8.5, 1.1; H-C(10)), 7.37 (ddd, J = 8.0, 7.1, 1.1; 
(H-C(8)), 6.47 (d, J = 10.0; H-C(4)), 5.75 (d, J = 10.0; H-C(5)), 5.67 (OH), 1.55 (s, C1’a 
and C1’b). 13C NMR (75.47 MHz, CDCl3) į (ppm): 176.4 (C6), 155.9 (C10a), 145.5 
(C12a), 144.5 (C11a), 134.4 (C9), 132.2 (C12), 131.0 (C3), 126.7 (C7), 124.0 (C8), 121.6 
(C6a), 121.5 (C4), 117.8 (C4a), 117.9 (C10), 117.8 (C4a), 116.1 (C5a), 114.4 (C5), 78.7 
(C2), 28.5 (C1’a and C1’’b). EIMS m/z (%): 294 (3, [M]+.), 280 (14), 279 (69), 243 (13), 
233 (18), 221 (11), 219 (13), 205 (34), 178 (11), 177 (11), 176 (14), 167 (11), 166 (11), 
165 (36), 152 (23), 151 (13), 139 (22), 121 (19), 115 (30), 111 (10), 105 (14), 102 (19), 92 
(16), 91 (29), 89 (31), 88 (27), 87 (20), 77 (84), 75 (60), 63 (89), 53 (22), 51 (100). HRMS 
(ESI) m/z calcd for C18H15O4 [M+H]+: 295.09649, found: 295.09584. 
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5.1.3 Synthesis of XP25 and XP26 
5.1.3.1 Condensation of prenal with compound 3 
Method A. 
Compound 3 (200 mg/0.88 mmol) was heated with prenal (848 μL/740 mg/8.8 mmol) at 
140 ºC for 14 h. The mixture was allowed to cool to room temperature and it was poured 
over 25 g of crushed ice and 0.5 mL of concentrated HCl. The aqueous phase was 
extracted with 3 x 25 mL of ethyl acetate. The organic phase was washed with 3 x 50 mL 
of distilled water, dried over sodium sulfate anhydrous, filtered and the organic solvent 
evaporated. The crude product was purified by silica gel flash chromatography 
(chloroform). Compounds XP25 (13 mg/5 %) and XP26 (16 mg/6 %) were obtained as 
yellow needles. 
Method B. 
To a solution of compound 3 (200 mg/0.88 mmol) and Ca(OH)2 (130.4 mg/ 1.76 mmol) in 
50 mL of methanol was added prenal (370 mg/4.4 mmol). The mixture was stirred for 66 
hours at room temperature. Methanol was evaporated and the crude product was 
partitioned between water and ethyl acetate. The aqueous phase was extracted 2 x 50 mL 
of ethyl acetate. The organic phase was washed 3 x 50 mL HCl 1 M, 3 x 50 mL of distilled 
water, dried over sodium sulfate anhydrous, filtered and the organic solvent evaporated. 
The crude product was purified by silica gel chromatography using Grace ResolvTM 5g/25 
mL cartridge (petroleum ether (60-80º)/ethyl acetate 9:1 to 5:5). Compound XP25 (61.2 
mg/24 %) and XP26 (10 mg/4 %) were purified as yellow needles.  
5-Hydroxy-2,2-dimethylpyrano[3,2-b]xanthen-6(2H)-one (XP25). IR ȣmax (cm-1) (KBr): 
3437, 2971, 2924, 1650, 1607, 1569, 1457, 1298, 1141, 1081, 832, 752;  
6-hydroxy-3,3-dimethylpyrano[2,3-c]xanthen-7(3H)-one (XP26). IR ȣmax (cm-1) (KBr): 3430, 
2968, 2920, 1646, 1605, 1566, 1451, 1384, 1296, 1138, 1078, 831, 749.  
The data were in accordance with two samples of compounds XP25 and XP26 kindly 
provided by CEQUIMED-UP. 
5.1.4 Synthesis of compounds 10, XBp4, XBp5 and XBp6 
5.1.4.1 2,4-dimethoxyxanthone (10): 
Methyl 2-bromobenzote: 
To a solution of 2-bromobenzoic acid (3 g/14.9 mmol) in 50 mL of methanol were added 
2.2 mL of sulfuric acid dropwise. The solution was refluxed for 24 hours. The mixture was 
allowed to cool to room temperature and most of the methanol was evaporated by rotary 
evaporator until approximately 5 mL of solution. The product was then partitioned between 
water and dichloromethane. The aqueous phase was extracted with 2 x 50 mL of 
dichloromethane. The organic layer was then washed with 3 x 100 mL of a saturated 
solution of bicarbonate, 3 x 100 mL of water, dried over sodium sulfate anhydrous, filtered 
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and the organic solvent evaporated. It was obtained the methyl 2-bromobenzoate as light 
yellow oil (2.94 g/ 1.37 mmol/ 92 %). 
IR ȣmax (cm-1) (KBr): 3442, 3063, 3018, 2944, 2834, 1727, 1582, 1426, 1287, 1246, 1121, 
1104, 1026, 952, 738, 453. 
2,4-Dimethoxyphenol: 
To a solution of 2,4-dimethoxybenzaldehyde (5.0 g/30 mmol), 5 mL of H2O2 30 % in 50 
mL of methanol, was added dropwise 0.5 mL of sulfuric acid. The mixture was stirred for 
20 hours at room temperature. Approximately 45 mL of methanol were evaporated by 
rotary evaporator and the solution was partitioned between dichloromethane and distilled 
water. The aqueous phase was extracted 3 x 50 mL of dichloromethane. The organic 
phase was washed with 3 x 50 mL of distilled water, dried over sodium sulfate anhydrous, 
filtered and the organic solvent evaporated. The crude product was purified by column 
chromatography (chloroform). 2,4-Dimethoxyphenol was obtained as light yellow oil (4.33 
g/ 94 %).  
IR ȣmax (cm-1) (KBr): 3443, 2997, 2939, 2835, 1610, 1512, 1461, 1433, 1374, 1299, 1263, 
1228, 1202, 1151, 1116, 1033, 918, 830, 792. 1H NMR (300.13 MHz, CDCl3) į (ppm): 
6.75 (d, J= 5.2), 6.42 (d, J = 1.7), 6.31 (dd, J = 5.2, 1.7), 3.79 (s, OCH3), 3.69 (s, OCH3). 
EIMS m/z (%): 156 (4, [M+2]+.), 155 (40, [M+1]+.), 154 (100 [M]+.), 140 (4), 139 (58), 112 
(4), 111 (90), 96 (22), 79 (10), 69 (10), 51 (20). 
Methyl 2-(2,4-dimethoxyphenoxy)benzoate (11): 
In a 500 mL oven-dried two-necked round-bottom flask was placed cesium carbonate 
(12.3 g/38 mmol), copper iodide (361.8 mg/1.9 mmol), 2,4-dimethoxyphenol (4.3 g/28 
mmol), methyl 2-bromobenzoate (5 g/23 mmol), N,N-dimethylglycine (796 mg/3.7 mmol) 
and 50 mL of anhydrous dioxane. The mixture was refluxed under nitrogen atmosphere 
for 24 hours. The product was allowed to cool to room temperature and was partitioned 
between distilled water and ethyl acetate. The aqueous phase was extracted with 3 x 100 
mL of ethyl acetate. The organic phase was washed 2 x 100 mL of brine, dried over 
sodium sulfate anhydrous, filtered and the organic solvent evaporated. The crude product 
was purified by silica gel flash chromatography (n-hexane/ethyl acetate 9:1). Compound 
11 was isolated as yellow solid (800 mg /10 %).   
Mp: 37-38 ºC. IR ȣmax (cm-1) (KBr): 2998, 2948, 2834, 1727, 1599, 1506, 1481, 1449, 
1300, 1254, 1226, 1205, 1156, 1081, 1034, 752. 1H NMR (300.13 MHz, CDCl3) į (ppm): 
7.86 (dd, J = 7.8, 1.8), 7.34 (ddd, J = 8.4, 7.6, 1.8), 7.04 (ddd, J = 7.8, 7.6, 1.0), 6.92 (d, J 
= 8.7), 6.72 (dd, J = 8.4, 1.0), 6.57 (d, J = 2.8), 6.43 (dd, J = 8.7, 2.8), 3.88 (s, OCH3), 3.81 
(s, OCH3), 3.78 (s, OCH3). 
2-(2,4-Dimethoxyphenoxy)benzoic acid (12): 
In a two-necked round-bottom flask was placed compound 11(780 mg/2.7 mmol) and 50 
mL of a mixture of THF/MeOH (1:1). It was then added 2 mL of a solution of NaOH 5N. 
The mixture was left stirring at room temperature for 108 hours. The mixture was 
concentrated to approximately 20 mL and it was added 15 mL of distilled water. The 
mixture was washed with 3 x 50 mL of dichloromethane. The aqueous phase was then 
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acidified with HCl 5 N until pH 2. The aqueous phase was then extracted with 3 x 100 mL 
of dichloromethane. The organic phase was washed with 2 x 100 mL of brine, dried over 
sodium sulfate anhydrous, filtered and the organic solvent evaporated. Compound 12 was 
isolated as a white solid (390 mg/53 %). 
Mp: 127-128 ºC. IR ȣmax (cm-1) (KBr): 3418, 3060, 2930, 2838, 1661, 1597, 1503, 1464, 
1307, 1218, 1074, 759. 1H NMR (300.13 MHz, CDCl3) į (ppm): 8.19 (dd, J = 7.8, 1.8), 
7.41 (ddd, J = 8.8, 7.0, 1.8), 7.15 (d, J = 8.7), 7.15 (ddd, J = 7.0, 1.0), 6.75 (dd, J = 8.7, 
1.0), 6.59 (d, J = 2.8), 6.52 (dd, J = 8.7, 2.8), 3.85 (s, OCH3), 3.75 (s, OCH3). HRMS (ESI) 
m/z calcd for C16H16NaO5 [M+Na]+: 311.08899, found: 311.08886. 
2,4-Dimethoxyxanthone (10): 
To a solution of compound 12 (300 mg/1.09 mmol) in 6 mL of acetyl chloride was added 6 
mL of concentrated H2SO4 dropwise. The mixture was allowed to react for 10 min at room 
temperature and then poured into crushed ice. The aqueous phase was extracted with 3 x 
50 mL of chloroform. The organic phase was washed with 3 x 50 mL of a solution of 
saturated NaHCO3, 2 x 100 mL of distilled water, dried over sodium sulfate anhydrous, 
filtered and the organic solvent evaporated. The crude product was purified by silica gel 
flash chromatography (chloroform). Compound 10 was crystallized from acetone as white 
needles (80 mg). 
Mp: 180-181 ºC. IR ȣmax (cm-1) (KBr): 3008, 2971, 2919, 1646, 1608, 1494, 1457, 1383, 
1316, 1204, 1145, 1041, 829, 749. 1H NMR (300.13 MHz, CDCl3) į (ppm): 8.35 (dd, J = 
8.0, 1.7; H-C(8)), 7.73 (ddd, J = 8.5, 7.0, 1.7; H-C(6)), 7.61 (dd, J = 8.5, 1.0; H-C(5)), 7.39 
(ddd, J = 8.5, 7.0. 1.7; H-C(7)), 7.28 (d, J = 2.8; H-C(1)), 6.87 (d, J = 2.8; H-C(3)), 4.01 (s, 
H3CO-C(4)), 3.92 (s, H3CO-C(2)). 13C NMR (75.47 MHz, CDCl3): 176.9 (C9), 155.8 (C4b), 
155.8 (C2), 149.6 (C4), 142.0 (C4a), 134.5 (C6), 126.6 (C8), 123.9 (C7), 122.6 (C9a), 
121.2 (C8a), 118.2 (C5), 106.3 (C3), 96.2 (C1), 56.4 (C1’’), 55.9 (C1’). EIMS m/z (%): 257 
(25, [M+1]+.), 256 (100 [M]+.), 241 (25), 227 (42), 213 (95), 185 (80), 170 (45), 155 (18), 
142 (30), 114 (56), 75 (35), 63 (45). HRMS (ESI) m/z calcd for C15H13O4 [M+H]+: 
257.08084; found: 257.08073. Elemental analysis: calcd for C15H12O4: C, 70.31, H 4.72, 
O, 24.97; found: C, 69.88, H, 4.58, O, 25.54. 
 
5.1.4.2 Synthesis of XBp4 
Synthesis of the building blocks 13 and 16 
6-Formyl-5-hydroxy-2,2-dimethyl-2H-benzopyran (15): 
In a two-necked round-bottom flask of 100 mL was placed 2,4-dihydroybenzaldehyde (3 
g/20.17 mmol), calcium hydroxide (1.543 g/20.8 mmol) and 150 mL of methanol. Then, 
prenal (9.135 g/108.6 mmol) was added dropwise. The mixture was allowed to stir at room 
temperature for 48 hours. The reaction was quenched with HCl 1M until pH 1-2. The 
methanol was evaporated and the aqueous phase was extracted with 3 x 150 mL of ethyl 
acetate. The organic phase was washed with 2 x 100 mL of brine, dried over sodium 
sulfate anhydrous, filtered and the organic solvent evaporated. The crude product was 
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purified by silica gel flash chromatography (n-hexane/ethyl acetate 9:1). Compound 15 
was crystallized from n-hexane/ethyl acetate 3:1 as a yellow solid (2.06 g/50 %). 
Mp: 68-69 ºC. IR ȣmax (cm-1) (KBr): 3464, 2967, 2922, 2857, 1628, 1484, 1330, 1294, 
1247, 1176, 1107, 1081, 748. 1H NMR (300.13 MHz, CDCl3) į (ppm): 11.65 (OH), 9.66 (s, 
CHO), 7.29 (d, J = 8.6), 6.88 (d, J = 10.0), 6.44 (d, J = 8.6), 5.61 (d, J = 10.0), 1.46 (s, 
6H). EIMS m/z (%): 205 (5, [M+1]+.), 204 (10 [M]+.), 190 (15), 189 (100), 187 (60), 159 
(12), 131 (12), 103 (10), 77 (12), 51 (6). HRMS (ESI) m/z calcd for C12H13O3 [M+H]+: 
205.08570, found: 205.08592. 
6-Formyl-5-methoxy-2,2-dimethyl-2H-benzopyran (14): 
In a two-necked round-bottom flask of 100 mL in nitrogen atmosphere was added 
potassium carbonate (2.43 g/17.6 mmol). Then, compound 15 (1.7976 g/ 8.8 mmol) 
solubilized in 20 mL of anhydrous acetone was added by syringe. Dimethyl sulfate 
(1.667/13.2 mmol) was added dropwise and the mixture was allowed to stir for 20 hours at 
room temperature and under nitrogen atmosphere. The reaction was quenched by the 
addition of 20 mL of distilled water and the acetone was evaporated. The aqueous phase 
was acidified with HCl 1N until pH 2-3 and extracted with 3 x 100 mL of ethyl acetate. The 
organic phase was washed with 2 x 50 mL of brine, dried over sodium sulfate anhydrous, 
filtered and the organic solvent evaporated. Compound 14 was obtained in quantitative 
yield as yellow oil. 
IR ȣmax (cm-1) (KBr): 2974, 2932, 2840, 2747, 1679, 1634, 1463, 1370, 1281, 1249, 1213, 
1158, 1110, 1068, 984, 736. 1H NMR (300.13 MHz, CDCl3) į (ppm): 10.18 (s, CHO), 7.66 
(d, J = 8.6), 6.65 (d, J = 8.6), 6.60 (dd, J = 9,9, 0.6), 5.70 (d, J = 9.9), 3.90 (s, OCH3), 1.47 
(s, 6H). EIMS m/z (%): 219 (5, [M+1]+.), 218 (10 [M]+.), 204 (18), 205 (100), 174 (10), 160 
(60), 133 (16), 105 (5), 91 (8), 78 (10), 51 (6). HRMS (ESI) m/z calcd for C13H15O3 [M+H]+: 
219.10177; found: 205.10157. 
6-Hydroxy-5-methoxy-2,2-dimethyl-2H-benzopyran (13): 
Compound 14 (1.0139 g/4.64 mmol) was solubilized in 20 mL of methanol and H2O2 (540 
μL of a solution of H2O2 30 % in water). Then, KHSO4 (94.7 mg/0.7 mmol) was added 
quickly and the solution was allowed to stir at room temperature for 8 hours. The reaction 
was quenched by the addition 10 mL of distilled water and the methanol evaporated. The 
aqueous phase was extracted with 3 x 20 mL of dichloromethane. The organic phase was 
washed with 2 x 50 mL of brine, dried over sodium sulfate anhydrous, filtered and the 
organic solvent evaporated. The crude product was purified by silica gel flash 
chromatography (n-hexane/ethyl acetate 9:1). Compound 13 was isolated as orange oil 
(898 mg/4.36 mmol/94 %).  
IR ȣmax (cm-1) (KBr): 3422, 3045, 2973, 2934, 2836, 1728, 1634, 1584, 1470, 1437, 1373, 
1295, 1260, 1215, 1152, 1114, 960, 811, 731. 1H NMR (300.13 MHz, CDCl3) į (ppm): 
6.72 (d, J = 8.6), 6.55 (d, J = 10), 6.50 (d, J = 8.6), 5.69 (d, J = 9.9), 5.15 (OH), 3.82 (s, 
OCH3), 1.41 (s, 6H). EIMS m/z (%): 208 (5, [M+2]+.), 207 (15, [M+1]+.), 206 (60 [M]+.), 191 
(100), 177 (50), 176 (30), 148 (18), 91 (10), 77 (5). HRMS (ESI) m/z calcd for C12H15O3 
[M+H]+: 207.10139; found: 207.10157. 
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Methyl 2-iodobenzoate (16): 
To a solution of 2-iodobenzoic acid (15 g/60 mmol) in 200 mL of methanol were added 8.8 
mL of sulfuric acid dropwise. The solution was refluxed for 16 hours. The mixture was 
allowed to cool to room temperature and most of the methanol was evaporated by rotary 
evaporator until approximately 20 mL of solution. The product was then partitioned 
between water and dichloromethane. The aqueous phase was extracted 2 x 150 mL of 
dichloromethane. The organic layer was then washed with 3 x 100 mL of saturated 
solution of bicarbonate, 3 x 100 mL of water, dried over sodium sulfate anhydrous, filtered 
and the organic solvent evaporated. Compound 16 was isolated as light yellow oil (15.4 g/ 
98 %). 
IR ȣmax (cm-1) (KBr): 3444, 3057, 2994, 2946, 2894, 2836, 1728, 1579 1459, 1428, 1290, 
1249, 1127, 1100, 1013, 738. 
Methyl 2-((5-methoxy-2,2-dimethyl-2H-benzopyran-6-yl)oxy)benzoate (17): 
In a two-necked round-bottom flask was added the methyl 2-iodobenzoate (16) (9.369 
g/35.76 mmol), CuI (1.7 g/ 8.94 mmol), cesium carbonate (19.4 g/59.6 mmol), N,N-
dimethylglycine (495.6 mg/3.576 mmol) and placed under nitrogen atmosphere. To this 
flask was added compound 13 (6.1 g/29.8 mmol) solubilized in 20 mL of anhydrous 
dioxane. The reaction was heated for 18 hours at 90 ºC and under nitrogen atmosphere. 
The reaction was allowed to cool to room temperature and filtered. The solid was washed 
several times with acetone and then the organic phase was concentrated. The mixture 
was partitioned between ethyl acetate and water. The aqueous phase was then extracted 
with 2 x 50 mL of ethyl acetate. The organic phase was washed 2 x 50 mL with brine, 
dried over sodium sulfate anhydrous, filtered and the organic solvent evaporated. The 
crude product was purified by silica gel flash chromatography (n-hexane/ethyl acetate 
(9:1)). Compound 17 was recrystallized from ethyl acetate/n-hexane 1:1 as a white solid 
(2.5655 g/ 26 %). 
Mp: 88-89 ºC. IR ȣmax (cm-1) (KBr): 3072, 2974, 2943, 2869, 2838, 1729, 1599, 1472, 
1369, 1298, 1250, 1218, 1075, 959, 751. 1H NMR (300.13 MHz, CDCl3) į (ppm): 7.87 (dd, 
J = 7.9, 1.8), 7.36 (ddd, J = 8.4, 7.5, 1.8), 7.05 (dd, J = 7.5, 0.8), 6.78 (d, J = 8.7), 6.75 (d, 
J = 8.4), 6.63 (d, J = 9.9), 6.54 (d, J = 8.8), 5.66 (d, J = 9.9), 3.90 (s, OCH3), 3.85 (s, 
OCH3), 1.44 (s, 6H). 13C NMR (75.47 MHz, CDCl3): 166.5, 157.8, 150.2, 147.2, 141.1, 
133.4, 131.6, 130.9, 121.7, 121.7, 120.5, 116.9, 116.0, 112.0, 75.9, 61.6, 52.1, 27.7; 
HRMS (ESI) m/z calcd for C19H17O4 [M-OCH3]+: 309.11214, found: 309.11203. 
2-((5-Methoxy-2,2-dimethyl-2H-benzopyran-6-yl)oxy)benzoic acid (18): 
In a two-necked round-bottom was placed compound 17 (129.6 mg/0.38 mmol) and 10 
mL of a solution of THF/methanol 1:1. Then 250 μL of a solution of LiOH 3N was added 
dropwise. The mixture was allowed to stir at room temperature. After 46 hours the solution 
was concentrated and partitioned between distilled water (50 mL) and dichloromethane 
(50 mL). The aqueous phase was then washed with 2 x 50 mL of dichloromethane. The 
aqueous phase was acidified with HCl 5% until pH 2-3 and extracted with 3 x 50 mL of 
dichloromethane. The organic phase was washed with 2 x 50 mL of brine, dried over 
sodium sulfate anhydrous, filtered and the organic solvent evaporated. Compound 18 was 
obtained as a white solid (121.7 mg/98 %). 
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Mp: 143-144 ºC. IR ȣmax (cm-1) (KBr): 3065, 2974, 2934, 2869, 2809, 2640, 2592, 2809, 
1684, 1565, 1464, 1250, 1233, 1060, 953, 772, 730. 1H NMR (300.13 MHz, CDCl3) į 
(ppm): 8.20 (dd, J = 7.9, 1.8), 7.45 (ddd, J = 8.4, 7.1, 1.8), 7.19 (ddd, J = 7.9,7.1,1.0), 6.79 
(d, J = 8.4), 6.92 (d, J = 8.8), 6.63-6.57 (m, 2H), 5,71 (d, J = 10.0), 3.74 (s, OCH3), 1.46 (s, 
6H). 13C NMR (75.47 MHz, CDCl3): 166.7, 158.0, 151.7, 147.7, 138.9, 134.9, 133.5, 
131.4, 123.0, 122.4, 117.8, 116.4, 115.5, 112.5, 76.3, 62.1, 27.7. HRMS (ESI) m/z calcd 
for C19H17O4 [M-OH]+: 309.11214, found: 309.11203. 
2-((5-Methoxy-2,2-dimethyl-2H-benzopyran-6-yl)oxy)-N,N-dimethylbenzamide (19): 
In a two-necked round-bottom flask was placed TBTU (2.44 g/7.6 mmol) and then 
compound 18 (2.48 g/7.6 mmol) solubilized in 250 mL of THF was added. Then 
triethylamine (1.538 g/15.2 mmol) was added dropwise and the mixture allowed to stir at 
room temperature for 15 minutes. Diethylamine (1.112 g/15.2 mmol) was then added and 
stirred overnight at room temperature. The mixture was concentrated and partitioned 
between ethyl acetate (250 mL) and water (250 mL). The aqueous phase was extracted 
with 2 x 250 mL of ethyl acetate. The organic phase was washed 2 x 150 mL of a 
saturated solution of NaHCO3, 2 x 150 mL with brine, dried over sodium sulfate 
anhydrous, filtered and the organic solvent evaporated. The crude product was purified by 
silica gel flash chromatography (n-hexane/ethyl acetate 7:3). Compound 19 was obtained 
as colorless oil in quantitative yield. 
IR ȣmax (cm-1) (KBr): 2974, 2931, 2870, 1633, 1470, 1432, 1370, 1293, 1255, 1217, 1113, 
1074, 960, 753. 1H NMR (300.13 MHz, CDCl3) į (ppm): 7.28 (dd, J = 7.4,1.7), 7.22 (ddd, J 
= 8.4, 7.6, 1.7), 7.03 (ddd, J = 7.6, 7.4, 0.8), 6.79 (d, J = 8.8), 6.67 (d, J = 8.4), 6.63 (d, J = 
10.0), 6.53 (d, J = 8.8), 5.66 (d, J = 10.0), 3.80 (s, OCH3), 3.50 (broad, 4H), 1.44 (s, 6H), 
1.22 (t, 3H, J = 7.1), 1.11 (t, 3H, J = 7.1). EIMS m/z (%): 382 (18, [M]+.), 366 (28), 295 
(35), 263 (100), 235 (45), 189 (25), 176 (34), 160 (32), 72 (38). HRMS (ESI) m/z calcd for 
C23H28NO4 [M+H]+: 382.20118; found: 382.20128. 
5-Methoxy-2,2-dimethylpyrano[2,3-b]xanthen-11(2H)-one (XBp4): 
In a three-necked round-bottom flask of 500 mL under nitrogen flow was placed 
compound 19 (2.555 g/6.7 mmol). Then 150 mL of anhydrous THF was added and the 
solution was placed in an ice bath. After 10 min, LDA (16.75 mmol of a solution 2M in 
THF) was added dropwise and allowed to stir for 15 minutes at 0ºC and then warm slowly 
to room temperature. After 1 hour the reaction was quenched by the addition of a 
saturated solution of NH4Cl. The mixture was partitioned between ethyl acetate (150 mL) 
and water (150 mL). The aqueous phase was extracted with 2 x 150 mL of ethyl acetate. 
The organic phase was washed with 2 x 50 mL of brine, dried over sodium sulfate 
anhydrous, filtered and the organic solvent evaporated. The crude product was purified by 
silica gel flash chromatography (n-hexane/ethyl acetate 9:1). Compound XBp4 was 
obtained as yellow solid (1.9 g/91 %).  
Mp: 124-125 ºC. IR ȣmax (cm-1) (KBr): 2975, 2935, 2841, 1652, 1605, 1472, 1426, 1315, 
1072, 961, 760. 1H NMR (300.13 MHz, CDCl3) į (ppm): 8.24 (dd, J = 8.0, 1.7; H-C(10)), 
7.64 (ddd, J = 8.6, 7.1, 1.7; H-C(8)), 7.46 (d, J = 8.6; H-C(7)), 7.39 (s; H-C(12)), 7.29 (dd, 
J = 8.0, 7.1; H-C(9)), 6.71 (d, J = 10.1; H-C(4)), 5.86 (d, J = 10.1; H-C(3)), 3.99 (s, H3CO-
C(5)), 1.40 (s, (CH3)2-C(2)). 13C NMR (75.47 MHz, CDCl3) į (ppm): 176.4 (C11), 155.7 
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(C6a), 148.9 (C12a), 144.7 (C5a), 143.6 (C5), 135.6 (C3), 134.4 (C8), 126.7 (C10), 123.8 
(C9), 122.3 (C11a), 121.6 (C4a), 121.6 (C4a), 121.3 (C10a), 118.0 (C7), 116.4 (C4), 
106.7 (C12), 76.2 (C2), 62.3 (C1’’), 27.7 (C1’a and C1’b). EIMS m/z (%): 308 (12, [M]+.), 
294 (12), 293 (55), 279 (16), 278 (100), 235 (40), 221 (30), 179 (30), 165 (90), 152 (15), 
77 (20). HRMS (ESI) m/z calcd for C19H17O4 [M+H]+: 309.11286; found: 309.11214. 
Elemental analysis: calcd for C19H16O4: C, 74.01, H 5.23, O, 20.76; found: C, 73.53, H, 
5.61, O, 20.86. 
5.1.4.3 Synthesis of XBp5: 
In a three-necked round-bottom flask was added Pd/C 10 % (10-20 % weight for mass) 
and placed under N2 atmosphere. Then, MeOH 40 mL and compound XBp4 (270 mg/0.87 
mmol) was added dropwise. To this mixture was added triethylsilane (8.7 mmol/ 1g) in a 
dropping-funnel with pressure-equalizer. The mixture was allowed to react for 15 minutes 
and then the crude product was filtered through cellite. The crude product was purified by 
silica gel flash chromatography (n-hexane/ethyl acetate 9:1). Compound XBp5 was 
obtained as a white solid (267 mg, 98%).  
5-Methoxy-2,2-dimethyl-3,4-dihydropyrano[2,3-b]xanthen-11(2H)-one (XBp5). Mp: 135-
136 ºC. IR ȣmax (cm-1) (KBr): 2983, 2936, 2840, 1658, 1473, 1441, 1312, 1074, 758. 1H 
NMR (300.13 MHz, CDCl3) į (ppm): 8.32 (dd, J = 8.0, 1.7; H-C(10)), 7.71 (ddd, J = 8.4, 
7.1, 1.7; H-C(8)), 7.53 (dd, J = 8.4, 1.0; H-C(7)), 7.49 (s, H-C(12)), 7.36 (ddd, J = 8.0, 7.1, 
1.0; H-C(9)), , 4.07 (s, H3CO-C(5)), 2.93 (t, J = 6.8; H2-C(4)), 1.86 (t, J = 6.8; H2-C(3)), 
1.37 (s, (CH3)2-C(2)). 13C NMR (75.47 MHz, CDCl3) į (ppm): 176.8 (C11), 155.8 (C6a), 
150.6 (C12a), 146.0 (C5), 134.4 (C8), 126.7 (C10), 123.6 (C9), 123.6 (C4a), 121.7 
(C11a), 121.2 (C10a), 118.0 (C7), 107.2 (C12), 74.3 (C2), 61.1 (C1’’), 31.7 (C3), 26.7 
(C1’a and C1’b), 18.2 (C4). EIMS m/z (%): 311 (12, [M+1]+.), 310 (30, [M]+.), 255 (96), 254 
(100), 225 (84), 211 (55), 197 (48), 169 (30), 141 (60), 128 (60), 115 (30), 77 (42), 51 
(38). HRMS (ESI) m/z calcd for C19H19O4 [M+H]+: 311.12779; found: 311.12767. Purity by 
GC-MS: 99.5 %. 
5.1.4.4 Synthesis of XBp6: 
In a two-necked round-bottom flask under nitrogen flow was placed compound XBp4 
(247.3 mg/0.8 mmol). Then 30 mL of anhydrous dichloromethane was added and the 
solution was placed in at -78 ºC. It was allowed to stay at 15 min and BBr3 (2 mmol of a 
solution 1M in dichloromethane) was added dropwise. The mixture was stirred for 1 hour 
at -78ºC and then allowed to warm slowly to room temperature. After reaching room 
temperature, the reaction was quenched by the addition of methanol. It was added 20 mL 
of water to the mixture and the organic solvent evaporated. The aqueous phase was 
extracted with 2 x 50 mL of dichloromethane. The organic phase was washed with 2 x 50 
mL of brine, dried over sodium sulfate anhydrous, filtered and the organic solvent 
evaporated. The crude product was purified by silica gel flash chromatography (n-
hexane/ethyl acetate 8:2). Compound XBp6 was obtained as yellow solid (198.1 mg/84 
%).  
5-Hydroxy-2,2-dimethylpyrano[2,3-b]xanthen-11(2H)-one (XBp6). Mp: 245-246 ºC. IR ȣmax 
(cm-1) (KBr): 2973, 2911, 2840, 1622, 1447, 754. 1H NMR (500.13 MHz, CDCl3) į (ppm): 
8.17 (dd, J = 8.0, 1.7, H-C(10)), 7.63 (ddd, J = 8.4, 7.1, 1.7, H-C(8)), 7.51 (dd, J = 8.4, 0.9; 
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H-C(7)), 7.27 (ddd, J = 8.0, 7.1, 0.9; H-C(9)), 7.03 (s; H-C(12)), 6.80 (d, J = 10.0; H-C(4)), 
5.77 (d, J = 10.0, H-C(3)), 1.36 (s, (CH3)2-C(2)). 13C NMR (75.47 MHz, CDCl3) į (ppm): 
175.9 (C11), 155.2 (C6a), 148.6 (C12a), 141.1 (C5), 140.4 (C5a), 134.0 (C8), 132.9 (C3), 
125.8 (C10), 123.2 (C9), 120.8 (C11a), 120.6 (C10a), 117.7 (C7), 116.4 (C4), 115.4 
(C4a), 100.7 (C12), 75.4 (C2), 27.2 (C1’a and C1’b). HRMS (ESI) m/z calcd for C18H15O4 
[M+H]+: 295.09653; found: 295.09649.  
5.1.5 Synthesis of XBp 7, XBp8, XBp11, XBp12, XBp13 
and XBp14 
5.1.5.1 Synthesis of building blocks 21, 24 and 25: 
2,4-Dimethoxyphenol: 
See section 5.1.4.1. 
2,4-Dimethoxy-1-(2-methylbut-3-yn-2-yloxy)benzene (20): 
Method A: 
In a two-necked round-bottom flask was added KI (9.03 g/50.44 mmol), CuI (122 
mg/0.05044 mmol), K2CO3 (8.85 g/64 mmol) and placed under nitrogen atmosphere. To 
the mixture was added a solution of 2,4-dimethoxyphenol (5 g/32 mmol) in 35 mL of 
anhydrous DMF. To the solution was added 3-chloro-3-methyl-1-butyne (5 g/48 mmol). 
The mixture was heated for 6 hours at 65 ºC and under nitrogen atmosphere. The mixture 
was allowed to cool to room temperature and it was partitioned between ethyl ether and a 
solution of NaOH 10 %. The organic phase was washed with 2 x 100 mL of a solution of 
NaOH 10%, 2 x 100 mL of brine, dried over sodium sulfate anhydrous, filtered and the 
organic solvent evaporated. The crude product was purified by silica gel flash 
chromatography (n-hexane/ethyl acetate 9:1). Compound 20 was obtained as yellowish oil 
(1.3909 g/20 %). 
Method B.  
In a two-necked round-bottom flask was placed 2,4-dimethoxyphenol (3 g/19 mmol) and 
CuCl2 anhydrous (2.5 mg/0.019 mmol). The mixture was placed under nitrogen 
atmosphere and 25 ml of anhydrous CH3CN was added. The mixture was cooled to 0 ºC 
on an ice bath and DBU (3.76 g/24.7 mmol) was added. 10 minutes after 3-chloro-3-
methyl-1-butyne (2.53 g/24.7 mmol) was added dropwise to the mixture. The mixture was 
allowed to stir at 0 ºC for 10 hours. The mixture was allowed to warm to room temperature 
and then partitioned between 50 mL of distilled water and 50 mL of diethyl ether. The 
aqueous solution was extracted with 2 x 50 mL of diethyl ether. The organic phase was 
washed with 2 x 50 mL of brine, dried over sodium sulfate anhydrous, filtered and the 
organic solvent evaporated. The crude product was purified by silica gel flash 
chromatography (n-hexane/ethyl acetate 95:5) obtaining compound 20 as yellowish oil 
(3.5792 g/86 %). 
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Method C. 
To a solution of 2-methyl-3-butyn-2-ol (2.49 g, 29.58 mmol) in 30 mL of anhydrous CH3CN 
under nitrogen and cooled in a salt ice-bath (-5°C) was added DBU (5.53 mL, 36.975 
mmol) followed by trifluoroacetic anhydride dropwise (4.2 mL, 29.58 mmol). The reaction 
mixture was slowly warmed to 0 ºC over 30 minutes. In another flask, 2,4-
dimethoxyphenol (3.42 g, 22.185 mmol) was dissolved in 30 mL of anhydrous CH3CN and 
placed under nitrogen at -10ºC. To this solution was added DBU (4.79 mL, 32.095 mmol) 
followed by CuCl2 anhydrous (3.3 mg, 0.02465 mmol, 0.1 mol%). To the latter reaction 
mixture was added dropwise via canulla the ice-cold solution of the freshly prepared but-
3-yn-2-yl 2,2,2-trifluoroacetate in CH3CN. The resulting reaction mixture was warmed to 0 
ºC and stirred for 5 hours. The mixture was warmed to room temperature and then 
partitioned between 50 mL of distilled water and 50 mL of diethyl ether. The aqueous 
solution was extracted with 2 x 50 mL of diethyl ether. The organic phase was washed 
with 2 x 50 mL of 5 % solution of HCl, with 2 x 50 mL of NaOH 1M and with 2 x 50 mL of 
brine. The organic phase was dried over sodium sulfate anhydrous, filtered and the 
organic solvent evaporated. The crude product was purified by silica gel flash 
chromatography (n-hexane/ ethyl acetate 8:2). Compound 20 was obtained as yellowish 
oil (2.973 g, 61 %). 
IR: ȣmax (cm-1) (KBr): 3273, 2981, 2928, 2826, 2354, 2325, 1598, 1497, 1453, 143, 1200, 
1148, 1127, 1030, 872. 1H NMR (300.13 MHz, CDCl3) į (ppm): 7.30 (d, J= 8.7), 6.48 (d, J 
= 2.8), 6.39 (dd, J = 8.7, 2.8), 3.79 (s, OCH3), 3.78 (s, OCH3), 2.48 (s, 1H), 1.61 (s, 6H). 
EIMS m/z (%): 222 (10, [M+2]+.), 221 (20, [M+1]+.),  220 (42 [M]+.), 205 (25), 189 (10), 155 
(15), 154 (100), 139 (40), 125 (30), 111 (30), 93 (15). HRMS (ESI) m/z calcd for C13H17O3 
[M+H]+: 221.11722; found: 221.11705. 
6,8-Dimethoxy-2,2-dimethyl-2H-benzopyran (21): 
Method D. 
In a two-necked round-bottom flask was placed compound 20 (700 mg/2.3 mmol) and 
then under nitrogen atmosphere. 15 mL of anhydrous DMF were added and the solution 
was stirred for 4 hours at 145 ºC. The mixture was allowed to cool to room temperature 
and poured over 50 g of crushed ice. The aqueous phase was extracted with 3 x 50 mL of 
diethyl ether. The organic phase was washed with 2 x 50 mL of brine, dried over sodium 
sulfate anhydrous, filtered and the organic solvent evaporated. The crude product was 
purified by silica gel flash chromatography (n-hexane/ethyl acetate 85:15) and compound 
21 was obtained as yellow oil (649mg/ 93%). 
Method E. 
In a Teflon vessel for microwave heating was placed a solution of compound 20 (2.973 g, 
0.0135 mol) in 10 mL of anhydrous DMF. The mixture was heated under microwave at 
150 ºC for 1 h. The mixture was allowed to cool to room temperature and then poured into 
50 g of crushed ice. The aqueous phase was extracted with 3 x50 mL of diethyl ether. The 
organic phase was washed with 2 x 50 mL of brine, dried over sodium sulfate anhydrous, 
filtered and the organic solvent evaporated. The crude product was purified by silica gel 
flash chromatography (n-hexane/ ethyl acetate 85:15). Compound 21 was obtained as 
yellow oil (2.350 g, 79 %). 
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IR ȣmax (cm-1) (KBr): 3033, 2967, 2930 2834, 1631, 1602, 1578, 1478, 1382, 1251, 1199, 
1151, 1085, 1047, 824. 1H NMR (300.13 MHz, CDCl3) į (ppm): 6.40 (d, J = 2.8), 6.27 (d, J 
= 9.8), 6.18 (d, J = 2.8), 5.64 (d, J = 9.8), 3.84 (s, OCH3), 3.76 (s, OCH3), 1.46 (s, 6H). 
EIMS m/z (%): 221 (10, [M+1]+.),  220 (24 [M]+.), 205 (100), 190 (20), 162 (20), 133 (22), 
119 (26), 115 (32), 91 (80). HRMS (ESI) m/z calcd for C13H17O3 [M+H]+: 221.11722; 
found: 221.11707. 
6-Formyl-8-methoxy-2,2-dimethyl-2H-benzopyran (23): 
To a solution of 2-methyl-3-butyn-2-ol (7.2 g, 90.62 mmol) in 100 mL of anhydrous CH3CN 
under nitrogen, cooled in a salt ice-bath (-5°C) was added DBU (17.6 mL, 118.2 mmol) 
followed by trifluoroacetic anhydride dropwise (12.6 mL, 90.62 mmol). The reaction 
mixture was slowly warmed to 0 ºC over 30 minutes. In another flask, vaniline (12 g, 78.8 
mmol) was solubilized in 100 mL of anhydrous CH3CN and placed under nitrogen at -5 ºC. 
To this solution was added DBU (15.3 mL, 15.59 mmol) followed by anhydrous CuCl2 
(10.49 mg, 0.078 mmol, 0.1 mol %). To the latter reaction mixture was added dropwise via 
canulla the ice-cold solution of the freshly prepared but-3-yn-2-yl 2,2,2-trifluoroacetate in 
CH3CN. The resulting reaction mixture was warmed to 0 ºC and stirred for 5 hours. The 
mixture was warmed to room temperature and concentrated to 100 mL. Then it was 
partitioned between 250 mL of distilled water and 250 mL of diethyl ether. The aqueous 
solution was extracted with 2 x 250 mL of diethyl ether. The organic phase was washed 
with 2 x 150 mL of a 5% solution of HCl, with 2 x 150 mL of NaOH 1M and with 2 x 150 
mL of brine. The organic phase was dried over sodium sulfate anhydrous, filtered and the 
organic solvent evaporated. The crude product of compound 22 was used in the next step 
without further purification. 
In a Teflon vessel for microwave heating was placed a solution of compound 22 (crude 
product of the last step) in 20 mL of anhydrous DMF. The mixture was heated under 
microwave heating for 50 min at 150 ºC. After cooling to room temperature, the mixture 
was poured into crushed ice (150 g) and extracted with 3 x 150 mL of diethyl ether. The 
organic phase was washed with 2 x 150 mL of brine, dried over sodium sulfate anhydrous, 
filtered and organic solvent evaporated. The crude product was purified by silica gel flash 
chromatography (n-hexane/ ethyl acetate 9:1). Compound 23 was obtained as colorless 
oil (4.1423 g, 24 % over two steps). 
IR ȣmax (cm-1) (KBr): 2975, 2932, 2841, 2809, 2747, 1649, 1644, 1579, 1467. 1386, 1297, 
1273, 1137, 1087, 725. 1H NMR (300.13 MHz, CDCl3) į (ppm): 9.81 (s, CHO), 7.32 (d, J = 
1.8), 7.17 (d, J = 1.8), 6.37 (d, J = 9.9), 5.70 (d, J = 9.9), 3.93 (s, OCH3), 1.53 (s, 6H). 
EIMS m/z (%): 218 (5, [M]+.), 204 (12), 203 (100), 188 (26), 160 (14), 129 (15), 115 (27), 
91 (26). 
6-Hydroxy-8-methoxy-2,2-dimethyl-2H-benzopyran (24): 
Compound 23 (4.06 g/18.6 mmol) was solubilized in 150 mL of methanol and H2O2 (2 mL 
of a solution of H2O2 30 % in water). Then, KHSO4 (378 mg/2.8 mmol) was added quickly 
and the solution was allowed to stir at room temperature for 21 hours. The reaction was 
quenched by the addition 50 mL of distilled water and the methanol was evaporated. The 
aqueous phase was extracted with 3 x 100 mL of ethyl acetate. The organic phase was 
washed with 2 x 50 mL of brine, dried over sodium sulfate anhydrous, filtered and the 
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organic solvent evaporated. The crude product was purified by silica gel flash 
chromatography (n-hexane/ethyl acetate 9:1). Compound 24 was crystallized from ethyl 
acetate/n-hexane (1:4) as white solid (2.97 g/77 %).  
Mp: 131-132 ºC. IR ȣmax (cm-1) (KBr): 3389, 3241, 2973, 2929, 2841, 1584, 1493, 1463, 
1308, 1256, 1207, 1156, 1087, 837, 805, 717. 1H NMR (300.13 MHz, CDCl3) į (ppm): 
6.36 (d, J = 2.8), 6.22 (d, J = 9.8), 6.13 (d, J= 2.8), 5.65 (d, J = 9.8), 3.83 (s, OCH3), 1.46 
(s, 6H). EIMS m/z (%): 207 (10, [M+1]+.), 206 (34, [M]+.), 191 (100), 176 (35), 148 (36), 
119 (8), 91 (20), 69 (14). 
Methyl 2-(methoxymethoxy)benzoate (25): 
In a two-necked round-bottom flask was placed sodium hydride (3.63 g/90.53 mmol of 
60% sodium hydride in mineral oil) and washed with anhydrous n-hexane. The flask was 
then placed under nitrogen atmosphere and on an ice-bath. Methyl salicylate (6.88 
g/45.26 mmol) was solubilized in 60 mL of anhydrous THF and added slowly to the flask 
containing the sodium hydride. The mixture was allowed to stir for 15 minutes and MOMCl 
(7.288 g/90.53 mmol) was added dropwise and the flask placed under reflux for 16 hours. 
The mixture was cooled to room temperature and poured over 100 g of crushed ice. The 
aqueous phase was extracted with 3 x150 mL of ethyl acetate. The organic phase was 
washed with 2 x 100 mL of brine, dried over sodium sulfate anhydrous, filtered and the 
organic solvent evaporated. The crude product was purified by silica gel flash 
chromatography (n-hexane/ethyl acetate 95:5). Compound 25 was obtained as colourless 
oil (8.1522 g/92 %).  
IR: ȣmax (cm-1) (KBr): 2991, 2947, 2903, 2825, 1725, 1596, 1485, 1449, 1432, 1296, 1249, 
1150, 1128, 1073, 984, 755. 1H NMR (300.13 MHz, CDCl3) į (ppm): 7.78 (dd, J = 7.8, 
1.8), 7.44 (ddd, J= 8.4, 7.5, 1.8), 7.20 (dd, J= 8.4, 0.9), 7.05 (ddd, J = 7.8, 7.5, 0.9), 5.26 
(s, 2H), 3.89 (s, OCH3), 3.52 (s, OCH3). EIMS m/z (%): 197 (16, [M]+.),  165 (100), 135 
(26), 92 (45), 63 (34). 
5.1.5.2 Synthesis of benzophenone 26: 
Method A. 
A solution of n-BuLi in hexanes (1.6 M, 1.725 mL, 2.706 mmol) was placed in a dropping 
funnel with pressure equalizing tube. This solution was then added dropwise over a 5 
minutes period, to a solution of compound 21 (541 mg, 2.46 mol) in 20 mL of anhydrous 
diethyl ether at 0ºC under nitrogen.  The reaction mixture was stirred for 30 minutes and 
then compound 25 (1.092 g, 5.5 mmol) dissolved in 15 mL of anhydrous diethyl ether was 
added dropwise, via canulla, at 0 ºC and under nitrogen. The reaction was allowed to 
reach room temperature slowly and then stir overnight. The reaction was quenched with a 
saturated solution of NH4Cl. The mixture was extracted with 3 x 50 mL of diethyl ether. 
The organic phase was washed with 2 x 50 ml of brine, dried over sodium sulfate 
anhydrous, filtered and the organic solvent evaporated. The crude product was purified by 
silica gel flash chromatography (n-hexane/ ethyl acetate 95:5). Compound 26 was 
obtained as orange oil (295 mg, 31 %). 
Method B. 
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A solution of n-BuLi in hexanes (1.6 M, 6.25 mL, 11 mmol) was placed in a dropping 
funnel with pressure equalizing tube. This solution was then added dropwise over a 5 
minutes period, to a solution of compound 21 (2.350 g, 0.01 mol) in 70 mL of anhydrous 
THF at 0ºC under nitrogen and stirred for 30 minutes. Then, compound 25 (3.9 g, 0.02 
mol) dissolved in 30 mL of anhydrous THF was added dropwise, via canulla, at 0 ºC under 
nitrogen. The reaction mixture was allowed to stir for 5 hours at 0 ºC. The reaction was 
quenched with a saturated solution of NH4Cl. The mixture was extracted with 3 x 100 mL 
of diethyl ether. The organic phase was washed with 2 x 50 ml of brine, dried over sodium 
sulfate anhydrous, filtered and the organic solvent evaporated. The crude product was 
purified by silica gel flash chromatography (n-hexane/ ethyl acetate 95:5). Compound 26 
was obtained as orange oil (1.716 g, 45%). 
(6,8-Dimethoxy-2,2-dimethyl-2H-benzopyran-7-yl)(2-(methoxymethoxy)phenyl) 
methanone (26). :IR ȣmax (cm-1) (KBr): 2971, 2934, 2833, 1661, 1596, 1568, 1455, 1417, 
1372, 1291, 1236, 1204, 1157, 1112, 1080, 980, 913, 756. 1H NMR (300.13 MHz, CDCl3) 
į (ppm): 7.72 (dd, J = 7.7, 1.8; H-C(6’’)), 7.43 (ddd, J = 8.5, 7.0, 1.8; H-C(4’’)), 7.12 (d, J = 
8.5; H-C(3’’)), 7.04 (dd, J = 7.7, 1.0; H-C(5’’)), 6.35 (s; H-C(5)), 6.31 (d, J = 9.8; H-C(4)), 
5.69 (d, J = 9.8; H-C(3)), 5.05 (s, H2-C(1’’’’’)), 3.71 (s, H3CO-C(6)), 3.66 (s, H3CO-C(8)), 
3.35 (s, H3-C(2’’’’’)), 1.46 (s, (CH3)2-C(2)). 13C NMR (75.47 MHz, CDCl3): 193.4 (C9), 
156.6 (C2’’), 150.3 (C8), 145.7 (C6), 139.4 (C8a), 133.6 (C4’’), 132.1 (C3), 131.5 (C6’’), 
129.6 (C1’’), 125.0 (C7), 123.9 (C4a), 122.3 (C4), 121.6 (C5’’), 115.8 (C3’’), 104.3 (C5), 
94.7 (C1’’’’’), 76.1 (C2), 61.1 (C1’’’’), 56.4 (C1’’’), 56.0 (C2’’’’’), 27.5 (C2’a and C2’b). 
HRMS (ESI) m/z calcd for C22H24NaO6 [M+Na]+: 407.14651; found: 407.14638. 
5.1.5.3 Synthesis of benzophenone 27: 
To a solution of compound 26 (152 mg, 0.396 mmol) in 10 mL of CH3CN at 0 ºC was 
added in one portion NbCl5 (107 mg, 0.396 mmol). The mixture was stirred at 0ºC for 10 
minutes and then allowed to warm to room temperature and let stirring for more 50 
minutes. After this time, the reaction mixture was quenched with saturated solution of 
NaHCO3. The mixture was extracted with 3 x 50 ml of ethyl acetate. The organic phase 
was washed with 2 x 50 ml of brine, dried over anhydrous sodium sulfate and organic 
solvent evaporated. Compound 27 was obtained as orange oil (131.9 mg/98 %). 
(6,8-Dimethoxy-2,2-dimethyl-2H-benzopyran-7-yl)(2-hydroxyphenyl)methanone (27). IR 
ȣmax (cm-1) (KBr): 3415, 3343, 2973, 2935, 1623, 1568, 1461, 1119, 1071, 1029, 916, 808, 
756. 1H NMR (300.13 MHz, CDCl3) į (ppm): 12.09 (s, OH), 7.45 (ddd, J = 8.5, 7.1, 1.7), 
7.34 (dd, J = 8.0, 1.7), 7.01 (dd, J = 8.4, 1.0), 6.79 (ddd, J = 8.2, 7.1, 1.0), 6.38 (s), 6.33 
(d, J = 9.8), 5.73 (d, J = 9.8), 3.79 (s, OCH3), 3.68 (s, OCH3), 1.48 (s, 6H). EIMS m/z (%): 
342 (1, [M+2]+), 325 (4), 309 (10),  294 (4), 279 (12), 253 (4), 207 (5), 206 (13), 205 (100), 
190 (7), 173 (8), 147 (11), 121 (16), 91 (14), 77 (17), 65 (17). HRMS (ESI) m/z calcd for 
C20H21O5 [M+H]+: 341.13835; found: 341.13816; m/z calcd for C20H20NaO5 [M+Na]+: 
363.12029; found: 363.12021. 
5.1.5.4 Synthesis of XBp7 and XBp11 
Method A. 
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To a solution of compound 27 (119 mg, 0.35 mmol) in 15 mL of DMF was added Cs2CO3 
(171 mg, 0.525 mmol). The mixture was stirred at 50ºC for 25 hours. The mixture was 
allowed to cool to room temperature and poured into crushed ice. The aqueous phase 
was then extracted with 3 x 50 mL of diethyl ether. The organic phase was washed with 2 
x 50 ml of brine, dried over anhydrous sodium sulfate, filtered and the organic solvent 
evaporated. The crude product was purified by silica gel flash chromatography (n-hexane/ 
ethyl acetate 8:2). Compound XBp11 was obtained as deep green solid (87.6 mg, 81%) 
and compound XBp7 as deep green oil (8.6 mg, 8%).  
Method B. 
In a closed vessel was placed a solution of compound 27 (330 mg, 0.97 mmol) in 15 mL 
of MeOH and it was added Cs2CO3 (475 mg, 1.457 mmol).  The mixture was stirred at 
80ºC for 96 hours and then allowed to cool to room temperature. The mixture was then 
partitioned between water and ethyl acetate. The aqueous phase was then extracted with 
2 x 50 mL of ethyl acetate. The organic phase was washed with 2 x 50 ml of brine, dried 
over sodium sulfate anhydrous, filtered and the organic solvent evaporated. The crude 
product was purified by silica gel flash chromatography (n-hexane/ethyl acetate 8:2). 
Compound XBp11 was obtained as deep green solid (184.1 mg, 62 %) and compound 
XBp7 as deep green oil (11.2 mg, 4 %). 
12-methoxy-2,2-dimethylpyrano[2,3-b]xanthen-11(2H)-one (XBp7). IR ȣmax (cm-1) (KBr): 
2958, 2923, 2853, 1653, 1614, 1463, 1429, 1111, 1083. 1H NMR (300.13 MHz, CDCl3) į 
(ppm): 8.28 (dd, J = 8.0, 1.6; H-C(10)), 7.65 (ddd, J = 8.5, 7.1, 1.6; H-C(8)), 7.38 (dd, J = 
8.4, 1.0; H-C(7)), 7.32 (ddd, J = 8.0, 7.1, 1.0; H-C(9)), 6.91 (s, H-C(5)), 6.41 (d, J = 9.8, H-
C(4)), 5.95 (d, J = 9.8; H-C(3)), 4.02 (s, H3CO-C(12)), 1.52 (s, (CH3)2-C(2)). 13C NMR 
(75.47 MHz, CDCl3) į (ppm): 176.1 (C11), 155.3 (C6a), 151.3 (C5a), 147.1 (C12), 141.9 
(C12a), 136.5 (C3), 134.0 (C8), 128.6 (C4a), 126.7 (C10), 123.5 (C9), 122.4 (C10a), 
121.5 (C4), 117.2 (C7), 116.0 (C11a), 109.7 (C5), 76.5 (C2), 61.4 (C1’’), 27.7 (C1’a and 
C1’b). EIMS m/z (%): 308 (10, [M]+), 293 (18), 276 (22), 265 (85), 349 (64), 221 (25), 191 
(35), 173 (65), 165 (100), 152 (24), 121 (30), 115 (50), 95 (25), 89 (40), 77 (65), 63 (50), 
51 (28). HRMS (ESI) m/z calcd for C19H17O4 [M+H]+: 309.11214, found: 309.11206. 
Elemental analysis: calcd for C19H16O4: C, 73.71, H 4.47, O, 21.82; found: C, 73.63, H, 
5.30, O, 21.07. Purity by GC-MS: 99 %. 
6-Methoxy-2,2-dimethylpyrano[3,2-c]xanthen-7(2H)-one (XBp11). Mp: 164-165 ºC. IR ȣmax 
(cm-1) (KBr): 2974, 2927, 1652, 1615, 1554, 1468, 1420, 1344, 1305, 1265, 1219, 1120, 
1077. 1H NMR (300.13 MHz, CDCl3) į (ppm): 8.29 (dd, J = 8.0, 1.7; H-C(8)), 7.66 (ddd, J 
= 8.5, 7.0, 1.7; H-C(10)), 7.53 (dd, J = 8.4, 1.0; H-C(11)), 7.32 (ddd, J = 7.9, 7.0, 1.0; H-
C(9)), 6.47 (s; H-C(5)), 6.38 (d, J = 9.8; H-C(4)), 5.89 (d, J = 9.8; H-C(3)), 3.97 (s, H3CO-
C(6)), 1.54 (s; (CH3)2-C(2)). 13C NMR (75.47 MHz, CDCl3) į (ppm): 176.4 (C7), 155.0 
(11a), 153.7 (C6), 146.8 (C12a), 135.2 (C3), 134.6 (C12b), 133.9 (C10), 126.7 (C8), 126.1 
(C4a), 123.8 (C9), 122.9 (C7a), 121.9 (C4), 117.7 (C11), 112.7 (C6a), 102.6 (C5), 76.7 
(C2), 56.5 (C1’’), 27.5 (C1’a and C1’b). EIMS m/z (%): 308 (20, [M]+), 294 (20), 293 (45), 
276 (52), 265 (45), 250(55), 249 (60), 221 (40), 205 (35), 178 (45), 165 (100), 152 (20), 
121 (55), 115 (35), 89 (20), 77 (45), 63 (40), 51 (45). HRMS (ESI) m/z calcd for C19H17O4 
[M+H]+: 309.11214, found: 309.11203. Elemental analysis: calcd for C19H16O4: C, 73.71, 
H 4.47, O, 21.82; found: C, 74.21, H, 5.22, O, 20.57. Purity by GC-MS: 99 %. 
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5.1.5.5 Synthesis of XBp8: 
In a three-necked round-bottom flask was added Pd/C 10 % (10-20 % weight for mass) 
and placed under N2 atmosphere. Then, compound XBp7 (28 mg/0.09 mmol) solubilized 
in 10 mL of MeOH was added dropwise. To this mixture was added triethylsilane (0.9 
mmol/104 mg) in a dropping-funnel with pressure-equalizing. The mixture was allowed to 
react for 10 minutes and then the crude product was filtered by cellite. The crude product 
was purified by Grace cartridge flash chromatography (n-hexane/ethyl acetate 8:2). 
Compound XBp8 was obtained as a green solid in quantitative yield.  
12-Methoxy-2,2-dimethyl-3,4-dihydropyrano[2,3-b]xanthen-11(2H)-one (XBp8). Mp: 132-
133 ºC. IR ȣmax (cm-1) (KBr): 2972, 2919, 2849, 1655. 1616, 1458, 1421, 1320, 1122, 
1078, 746. 1H NMR (300.13 MHz, CDCl3) į (ppm): 8.29 (dd, J = 8.0, 1.7; H-C(10)), 7.64 
(ddd, J = 8.5, 7.1, 1.7; H-C(8)), 7.37 (dd, J = 8.5, 0.8; H-C(7)), 7.31 (ddd, J = 8.0, 7.1, 0.8; 
H-C(9)), 7.00 (s, H-C(5)), 3.99 (s, H3CO-C(12)), 2.91 (t, J = 6.8, H2-C(4)), 1.89 (t, J = 6.8; 
H2-C(3)), 1.42 (s, (CH3)2-C(2)). 13C NMR (75.47 MHz, CDCl3) į (ppm): 176.4 (C11), 155.3 
(C6a), 149.7 (C5a), 147.6 (C12), 144.0 (C12a), 134.0 (C8), 130.6 (C4a), 126.7 (C10), 
123.3 (C9), 122.3 (C10a), 117.2 (C7), 116.0 (C11a), 112.3 (C5), 74.7 (C2), 61.1 (C1’’), 
32.2 (C3), 26.8 (C1’a and C1’b), 23.4 (C4). HRMS (ESI) m/z calcd for C19H19O4 [M+H]+: 
311.12779; found: 311.12769. Purity by GC-MS: 99.9 %. 
5.1.5.6 Synthesis of XBp12: 
In a three-necked round-bottom flask was added Pd/C 10 % (10-20 % weight for mass) 
and placed under N2 atmosphere. Then, MeOH 20 mL and compound XBp11 (166 
mg/0.54 mmol) was added dropwise. To this mixture was added triethylsilane (5.4 
mmol/627 mg) in a dropping-funnel with pressure-equalizing. The mixture was allowed to 
react for 10 minutes and then the crude product was filtered by cellite and washed 
repeatedly with methanot. The organic solvent was evaporated and the crude product was 
purified by Grace cartridge chromatography (n-hexane/ethyl acetate 8:2). Compound 
XBp12 was obtained as a light yellow solid (138 mg, 81 %).  
6-Methoxy-2,2-dimethyl-3,4-dihydropyrano[3,2-c]xanthen-7(2H)-one (XBp12). Mp: 204-
205 ºC. IR ȣmax (cm-1) (KBr): 2971, 2933, 2874, 2844, 1661, 1603, 1481, 1082, 749. 1H 
NMR (300.13 MHz, CDCl3) į (ppm): 8.30 (dd, J= 8.0, 1.7, H-C(8)), 7.65 (ddd, J = 8.4, 6.9, 
1.7; H-C(10)), 7.55 (dd, J= 8.4, 1.1; H-C(11)), 7.33 (ddd, J= 8.0, 6.9, 1.1; H-C(9)), 6.50 (s; 
H-C(5)), 3.95 (s, OCH3), 2.88 (t, J = 6.8; H2-C(4)), 1.91 (t, J = 6.8; H2-C(3)), 1.46 (s; 
(CH3)2-C(2)). 13C NMR (75.47 MHz, CDCl3) į (ppm): 176.6 (C7), 155.0 (C11a), 152.3 
(C6), 147.5 (C12a), 136.7 (C12b), 133.8 (C10), 127.2 (C4a), 126.6 (C8), 123.1 (C9), 
122.9 (C7a), 117.8 (C11), 112.2 (C6a), 105.1 (C5), 74.9 (C9), 56.5 (C1’’), 32.5 (C3), 26.4 
(C1’a and C1’b), 23.5 (C4). EIMS m/z (%): 308 (10, [M]+), 293 (18), 276 (22), 265 (85), 
349 (64), 221 (25), 191 (35), 173 (65), 165 (100), 152 (24), 121 (30), 115 (50), 95 (25), 89 
(40), 77 (65), 63 (50), 51 (28). HRMS (ESI) m/z calcd for C19H19O4 [M+H]+: 311.12779; 
found: 311.12769. Purity by GC-MS: 99.9 %. 
5.1.5.6 Synthesis of XBp13: 
To an oven-dried 50 mL two-necked round-bottom flask equipped with a magnetic stirrer 
and under nitrogen atmosphere was added N,N-2-(diethylamino)ethanethiol HCl (98.9 
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mg/0.584 mmol) and 5 mL of DMF anhydrous. The flask was cooled in an ice bath and 
when the internal temperature was below 5 ºC, solid NaOtBu (117.2 mg/1.22 mmol) was 
added in one portion. After 5 minutes the ice bath was removed and it was allowed to 
warm to room temperature. After 15 minutes, a solution of compound XBp11 (150 
mg/0.487 mmol) in 2 mL of DMF anhydrous was added. The mixture was heated at reflux 
for 30 minutes under nitrogen atmosphere. The mixture was allowed to cool to room 
temperature and then was placed in an ice bath. A solution of HCl 1 M was added to the 
mixture until pH 1 and 20 mL of water was added to the mixture. The mixture was 
extracted with 3 x 50 mL of diethyl ether. The organic phase was washed with 3 x 50 mL 
of brine, dried over sodium sulfate anhydrous, filtered and the organic solvent evaporated. 
The crude product was purified by silica gel flash chromatography (n-hexane/ethyl acetate 
9:1). Compound XBp13 was obtained as orange crystalline solid (102.8 mg/72 %). 
6-Hydroxy-2,2-dimethylpyrano[3,2-c]xanthen-7(2H)-one (XBp13). Mp: 191-192 ºC. IR ȣmax 
(cm-1) (KBr): 3488, 2970, 2919, 1648, 1606, 1464, 1356, 1272, 1214, 1110, 762. 1H NMR 
(500.13 MHz, CDCl3) į (ppm): 12.14 (OH), 8.19 (dd, J = 8.0, 1.7; H-C(8)), 7.67 (ddd, J = 
8.5, 7.0, 1.7; H-C(10)), 7.52 (dd, J = 8.5, 1.0; H-C(11)), 7.31 (ddd, J = 7.9, 7.0, 1.0; H-
C(9)), 6.42 (s; H-C(5)), 6.31 (d, J = 9.8; H-C(4)), 5.86 (d, J = 9.8; H-C(3)), 1.46 (s; (CH3)2-
C(2)). 13C NMR (75.47 MHz, CDCl3) į (ppm): 181.9 (C7), 156.2 (C11a), 154.7 (C6), 144.0 
(C12a), 136.2 (C3), 135.3 (C10), 132.3 (C12b), 129.0 (C4a), 125.9 (C8), 124.0 (C9), 
122.2 (C4), 120.6 (C7a), 118.3 (C11), 108.9 (C6a), 106.6 (C5), 76.6 (C2), 27.4 (C1’a and 
C1’b). HRMS (ESI) m/z calcd for C18H15O4 [M+H]+: 295.09649; found: 295.09614. 
5.1.5.7 Synthesis of XBp14: 
To an oven-dried 50 mL two-necked round-bottom flask equipped with a magnetic stirrer 
and under nitrogen atmosphere was added N,N-2-(diethylamino)ethanethiol HCl (35.6 
mg/0.193 mmol) and 3 mL of DMF anhydrous. The flask was cooled in an ice bath and 
when the internal temperature was below 5 ºC, solid NaOtBu (41.7 mg/0.43 mmol) was 
added in one portion. After 5 minutes the ice bath was removed and it was allowed to 
warm to room temperature. After 15 minutes, a solution of compound XBp11 (54 mg/0.16 
mmol) in 2 mL of DMF anhydrous was added. The mixture was heated at reflux for 2 
hours under nitrogen atmosphere. The mixture was allowed to cool to room temperature 
and then was placed in an ice bath. A solution of HCl 1 M was added to the mixture until 
pH 1 and 10 mL of water was added to the mixture. The mixture was extracted with 3 x 25 
mL of diethyl ether. The organic phase was washed with 3 x 25 mL of brine, dried over 
sodium sulfate anhydrous, filtered and the organic solvent evaporated. The crude product 
was purified by silica gel flash chromatography (n-hexane/ethyl acetate 9:1). Compound 
XBp14 was obtained as orange crystalline solid (21 mg/45 %). 
6-Methoxy-2,2-dimethyl-3,4-dihydropyrano[3,2-c]xanthen-7(2H)-one (XBp14). Mp: 205-
206 ºC. IR ȣmax (cm-1) (KBr): 3500, 2924, 2857, 1654, 1607, 1467, 1375, 1271, 751. 1H 
NMR (300.13 MHz, CDCl3) į (ppm): 12.00 (OH), 8.30 (dd, J = 8.0, 1.7; H-C(8)), 7.76 (ddd, 
J = 8.4, 7.1, 1.7; H-C(10)), 7.64 (dd, J = 8.4, 1.1; H-C(11)), 7.40 (ddd, J = 8.0, 7.1, 1.1; H-
C(9)), 6.56 (s; H-C(5)); 2.90 (d, J = 6.8; H2-C(4)), 1.92 (d, J = 6.8; H2-C(3)), 1.46 (s; 
(CH3)2-C(2)). 13C NMR (75.47 MHz, CDCl3) į (ppm): 182.1 (C7), 156.2 (C11a), 152.8 
(C6), 146.5 (C12a), 135.1 (C10), 134.6 (C12b), 130.9 (C4a), 125.8 (C8), 124.0 (C9), 
120.6 (C7a), 118.5 (C11), 109.0 (C5), 108.3 (C6a), 74.8 (C2), 32.5 (C3), 26.6 (C1’a and 
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C1’b), 23.6 (C4). HRMS (ESI) m/z calcd for C18H17O4 [M+H]+: 297.11214; found: 
297.11204. 
5.1.6 Synthesis of XBp 9, XBp10, XBp15 and XBp16 
5.1.6.1 Synthesis of 1,2-Dihydroxyxanthone (29), 4-hydroxyxanthone 
(31) and 2-hydroxyxanthone (33) 
1,2-dihydroxyxanthone (29): 
Methyl 2-bromobenzoate: 
See section 5.1.4.1. 
Methyl 2-(3,4-dimethoxyphenoxy)benzoate (34): 
In an oven-dried two-necked round-bottom flask was placed cesium carbonate (26 g/80 
mmol), copper iodide (1.12 g/5.8 mmol), 3,4-dimethoxyphenol (6.2 g/40 mmol), methyl 2-
bromobenzoate (16.5 g/77 mmol) and 120 mL of anhydrous pyridine. The mixture was 
refluxed under nitrogen atmosphere for 24 hours. The product was allowed to cool to 
room temperature and was filtered. The solid was washed firstly with 200 mL ethyl acetate 
and this was joined to the filtrated. The solid was then washed with 200 mL of chloroform. 
The two organic phases were washed with 3 x 250 mL of HCl 1 N, 3 x 150 mL of distilled 
water, dried over Na2SO4, filtered and organic the solvent evaporated. The two products 
were reunited and the crude product was purified by silica gel flash chromatography 
(petroleum ether (60-80º)/ethyl ether 8:2). Compound 34 was crystallized from ethyl ether 
and n-hexane as a white solid (5.182 g/45 %).  
Mp: 63-65 ºC. IR ȣmax (cm-1) (KBr): 3066, 2996, 2955, 2932, 2830, 1698, 1596, 1509, 
1477, 1438, 1299, 1221, 1121, 1027, 955, 855, 761. 1H NMR (300.13 MHz, CDCl3) į 
(ppm): 7.88 (dd, J = 7.7, 1.7), 7.42 (ddd, J = 8.4, 7.6, 1.7), 7.12 (ddd, J = 7.7, 7.6, 0.9), 
6.90 (dd, J = 8.4, 0.9), 6.80 (d, J = 8.7), 6.67 (d, J = 2.7), 6.50 (dd, J = 8.7, 2.7), 3.87 (s, 2 
x OCH3), 3.84 (s, OCH3). 13C NMR (75.47 MHz, CDCl3) į (ppm): 166.3, 157.3, 150.7, 
149.9, 145.4, 133.4, 131.7, 122.6, 122.2, 119.0, 111.7, 110.2, 104.2, 56.3, 56.0, 52.2. 
2-(3,4-Dimethoxyphenoxy)benzoic acid (35): 
In a two-necked round-bottom flask was placed compound 34 (5.123 g/17.788 mmol) and 
200 mL of a mixture of THF/MeOH (1:1). It was then added 7.5 mL of a solution of NaOH 
5N. The mixture was left stirring at room temperature for 72 hours. The mixture was 
concentrated to approximately 20 mL and it was added 15 mL of distilled water. The 
mixture was washed with 2 x 50 mL of dichloromethane. The aqueous phase was then 
acidified with 15 mL of HCl 3 N and extracted with 3 x 100 mL of dichloromethane. The 
organic phase was washed with 2 x 100 mL of brine, dried over sodium sulfate anhydrous, 
filtered and the organic solvent evaporated. Compound 35 was obtained as a white solid 
(4.4 g/ 91 %). 
Mp: 147-148 ºC. IR ȣmax (cm-1) (KBr): 3434, 3074, 2988, 2953, 2926, 2901, 2827, 2698, 
2641, 2597, 2556, 1687, 1663, 1596, 1571, 1508, 1438, 1408, 1312, 1264, 1218, 1114, 
952, 760. 1H NMR (300.13 MHz, CDCl3) į (ppm): 8.21 (dd, J = 7.9, 1.8), 7.47 (ddd, J = 
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8.6, 7.8, 1.8), 7.19 (ddd, J = 7.9, 7.8, 1.1), 6.90 (d, J = 8.4), 6.82 (d, J = 0.9,8.4), 6.70-6.69 
(m, 2H), 3.91 (s, OCH3), 3.87 (s, OCH3). 
1,2-Dimethoxyxanthone (36): 
In a three-necked round-bottom flask was added 150 mL of anhydrous THF and 
compound 35 (4.29 g/15.6 mmol). The mixture was cooled to -20 ºC in N2 atmosphere 
and LDA (4.19 g/39 mmol) was added slowly. The mixture was allowed to warm to room 
temperature and react for 3 hours. The reaction was quenched by the addition of HCl 10 
% dropwise until pH 2-3. The THF was evaporated the aqueous solution extracted with 3 
x 100 mL of dichloromethane. The organic phase was first washed 2 x 100 mL of 
saturated solution of hydrogenocarbonate and then with 2 x 100 mL of brine. The organic 
phase was dried over sodium sulfate anhydrous, filtered and the organic solvent 
evaporated. The crude product was crystallized from methanol to give 1,2-
dimethoxyxanthone (36) as yellow solid (2.56 g/ 63 %). The saturated solution of 
hydrogenocarbonate was acidified until pH 2-3 with HCl 5 N and extracted with 3 x 100 
mL of dichloromethane. The organic phase was washed 2 x 100 mL of brine, dried over 
sodium sulfate anhydrous, filtered and the organic solvent evaporated to give compound 
35 that did not reacted (984.6 mg/23 %). 
Mp: 131-132 ºC. IR ȣmax (cm-1) (KBr): 3076, 2962, 2928, 2830, 1660, 1602, 1464, 1434, 
1324, 1285, 1225, 1085, 1049, 969, 752. 1H NMR (300.13 MHz, CDCl3) į (ppm): 8.30 
(dd, J = 8.0, 1.7), 7.68 (ddd, J = 8.5, 7.0, 1.7), 7.41 (dd, J = 8.5, 0.8), 7.37 (d, J = 9.2), 
7.34 (ddd, J = 8.0, 7.0, 0.8), 7.25 (d, J = 9.2), 4.02 (s, OCH3), 3.94 (s, OCH3). EIMS m/z 
(%): 258 (4, [M+2]+.), 257 (10, [M+1]+.), 256 (20 [M]+.), 241 (56), 227 (62), 213 (100), 185 
(20), 155 (22), 139 (22), 128 (20), 92 (10), 74 (10). 
1,2-Dihydroxyxanthone (29): 
In a three-necked round-bottom flask of 500 mL under N2 was added compound 36 (2.539 
g/9.9 mmol) and 200 mL of dichloromethane anhydrous. The mixture was cooled to -78 ºC 
and BBr3 (1M in dichloromethane/ 4.96 mmol) was added dropwise. The mixture was 
allowed to warm to room temperature and quenched with methanol. It was added 50 mL 
of distilled water and all the methanol and dichloromethane evaporated. The aqueous 
phase was extracted with 3 x 100 mL of chloroform and the organic phase was washed 
with 2 x 100 mL of brine, dried over sodium sulfate anhydrous, filtered and the organic 
solvent evaporated. Compound 29 was obtained as a yellow solid (2.1247 g/94 %)  
Mp: 171-172 ºC. IR ȣmax (cm-1) (KBr): 3449, 3078, 1649, 1613, 1581, 1464, 1293, 1190, 
1048, 755. 1H NMR (300.13 MHz, CDCl3) į (ppm): 12.59 (OH), 8.27 (dd, J = 8.0, 1.7), 
7.76 (ddd, J = 8.6, 7.0, 1.7), 7.47 (dd, J = 8.6, 1.0), 7.39 (dd, J = 8.0, 7.0, 1.0), 7.34 (d, J = 
9.1), 6.92 (d, J = 9.1). 
4-Hydroxyxanthone (31) 
4-Methoxyxanthone (37) 
Sodium 2-chlorobenzoate (5.5 g/30 mmol) and sodium 2-methoxyphenoxide (7.0 
g/35mmol) were suspended in 100 mL of anhydrous dioxane. To this suspension, copper 
chloride and tris(2-(2-methoxyethoxy)ethyl)amine (TDA-1) were added and the mixture 
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refluxed under nitrogen atmosphere for 48 hours. The organic solvent was evaporated 
and the mixture poured into 150 mL of water. The solid formed was filtered and the filtrate 
acidified with HCl 10 %. The solution was extracted with 3 x 100 mL of ethyl acetate and 
subsequently washed 2 x 100 mL with water, dried over sodium sulfate anhydrous, filtered 
and the organic solvent evaporated. The product was then crystallized from ethyl acetate. 
This solid was dried for 48 hours at 100 ºC and used in the second step without further 
purification. In the second step, 20 mL of sulfuric acid were added dropwise to the solution 
of the solid obtained in the first step in 20 mL of acetyl chloride. The mixture was then 
stirred for 10 minutes at room temperature. The mixture was poured slowly into 250 g of 
crushed ice and extracted with 3 x 50 mL of chloroform. The organic phase was washed 
successively with 3 x 75 mL of a saturated solution of sodium hydrogen carbonate, 3 x 75 
mL of a solution of potassium hydroxide 10 % and 3 x 20 mL of water. The organic phase 
was dried over sodium sulfate anhydrous, filtered and the organic solvent evaporated. The 
solid was crystallized from methanol obtaining compound 37 as a white solid (800 
mg/12%). 
Mp: 175-176 ºC. IR ȣmax (cm-1) (KBr): 3137, 1659, 1600, 1496, 1468, 1334, 1280, 1232, 
1074, 749. 1H NMR (300.13 MHz, CDCl3) į (ppm): 8.28 (dd, J = 8.0, 1.6), 7.84 (dd, J = 
7.8, 1.8), 7.67 (ddd, J = 8.4, 7.0, 1.6), 7.54 (dd, J = 8.4,1.0), 7.32 (ddd, J = 8.0, 7.0, 1.0), 
7.22 (dd, J = 7.8, 7.7), 7.17 (dd, J = 7.7, 1.7), 3.97 (s, OCH3). 13C NMR (75.47 MHz, 
CDCl3) į (ppm): 177.2, 155.9, 148.6, 146.5, 134.8, 126.7, 124.1, 123.4, 122.2, 121.7, 
118.3, 117.6, 115.3, 56.4. EIMS m/z (%): 228 (2, [M+2]+.), 227 (16, [M+1]+.), 226 (100, 
[M]+.), 212 (8), 211 (48), 158 (14), 127 (12), 113 (7 
4-Hydroxyxanthone (31): 
In a two-necked round-bottom flask was placed 4-methoxyxanthone 37 (180 mg/0.796 
mmol) and 20 mL of anhydrous toluene. The mixture was placed at 0ºC and aluminum 
chloride (212 mg/1.59 mmol) was added slowly. The mixture was heated for 6 hours 
under reflux. The mixture was allowed to cool to room temperature and poured over 50 g 
of crushed ice and 0.5 mL of concentrated HCl. The aqueous phase was extracted with 3 
x 100 mL of ethyl acetate. The organic phase was washed 3 x 150 mL of NaOH 5 %, 
dried over sodium sulfate anhydrous, filtered and the organic solvent evaporated. 4-
hydroxyxanthone (31) was crystallized from methanol as a white solid (151 mg/90 %). 
Mp: 235-236 ºC. IR ȣmax (cm-1) (KBr): 3204, 1636, 1584, 1499, 1455, 1349, 1287, 1220, 
899, 750. 1H NMR (300.13 MHz, DMSO-d6) į (ppm): 10.56 (OH), 8.20 (dd, J = 8.0, 1.6), 
7.89 (ddd, J = 8.3, 7.1, 1.6), 7.70 (d, J = 8.3), 7.62 (dd, J = 7.8,1.7), 7.50 (dd, J = 7.1, 0.6), 
7.35 (dd, J = 7.9, 1.7), 7.28 (dd, J = 7.8, 7.9). 13C NMR (75.47 MHz, DMSO-d6) į (ppm): 
176.4, 155.5, 146.7, 145.3, 135.6, 126.1, 124.4, 124.2, 121.3, 121.0, 120.4, 118.4, 115.4. 
EIMS m/z (%): 214 (2, [M+2]+.), 213 (15, [M+1]+.), 212 (100 [M]+.), 211 (4), 184 (12), 155 
(4), 128 (7), 127 (6), 106 (4), 59 (16). 
2-Hydroxyxanthone (33): 
2-Methoxyxanthone (38) 
In a two-necked round-bottom flask of 1 L with f 2-methoxybenzoyl chloride (9.15 mL/68 
mmol) and 1.4-dimethoxybenzene (10 g/72 mmol) in 680 mL of ether anhydrous was 
added slowly aluminum chloride anhydrous (22.7 g/170 mmol) and allowed to stir at room 
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temperature for 70 hours. Then, the solution was concentrated by rotary evaporator and 
the product poured over 200 g of crushed ice. The solution was acidified with HCl 10 % 
until pH 3 and extracted with 3 x 100 mL of ethyl acetate. The organic layers were washed 
with 3 x 50 mL of water, dried over sodium sulfate anhydrous, filtered and the organic 
solvent evaporated. The crude product of this reaction was then dissolved in a mixture of 
170 mL of methanol, 120 mL of water and 35 g of NaOH, and stirred at 70 ºC for 24 
hours. The solution was allowed to cool to room temperature and placed in the fridge 
overnight. The solid formed was filtered and purified by silica gel column chromatography 
(petroleum ether (40-60º)/ethyl acetate). 2-Methoxyxanthone (38) was crystallized from 
methanol as a white solid (768 mg/5 %). 
Mp: 135-136 ºC. IR ȣmax (cm-1) (KBr): 1650, 1612, 1489, 1461, 1313, 1208, 1141, 1021, 
860, 754. 1H NMR (300.13 MHz, CDCl3) į (ppm): 8.35 (dd, J = 8.0, 1.7), 7.72 (ddd, J = 
8.3, 7.1, 1.7), 7.71 (d, J = 3.3), 7.50 (d, J = 8.3), 7.45 (d, J = 9.1), 7.40 (dd, J = 7.1, 1.1), 
7.34 (dd, J = 9.1, 3.3), 3.93 (s, OCH3). 13C NMR (75.47 MHz, CDCl3) į (ppm): 177.1, 
156.1, 155.9, 151.0, 134.6, 126.6, 124.9, 123.7, 122.1, 121.2, 119.4, 117.9, 105.7, 55.5. 
EIMS m/z (%): 228 (2, [M+2]+.), 227 (16, [M+1]+.), 226 (100, [M]+.), 225 (58), 211 (20), 197 
(42), 196 (18), 183 (15), 168 (12), 155 (33), 127 (19), 77 (5). 
2-Hydroxyxanthone (33): 
In a two-necked round-bottom flask was placed 2-methoxyxanthone 39 (180 mg/0.796 
mmol) and 20 mL of anhydrous toluene. The mixture was placed at 0ºC and aluminum 
chloride (212 mg/1.59 mmol) was added slowly. The mixture was heated for 6 hours 
under reflux. The mixture was allowed to cool to room temperature and poured over 50 g 
of crushed ice and 0.5 mL of concentrated HCl. The aqueous phase was extracted with 3 
x 100 mL of ethyl acetate. The organic phase was washed 3 x 150 mL of NaOH 5 %, 
dried over sodium sulfate anhydrous, filtered and the organic solvent evaporated. 2-
hydroxyxanthone (33) was crystallized from methanol as a pale yellow solid (155 mg/92 
%). 
Mp: 232 ºC. IR ȣmax (cm-1) (KBr): 3308, 1653,1616, 1594, 1478, 1459, 1337, 1300, 1233, 
1142, 748. 1H NMR (300.13 MHz, DMSO-d6) į (ppm): 10.01 (OH), 8.18 (dd, J = 8.0, 1.6), 
7.86 (ddd, J = 8.6, 7.2, 1.6), 7.64 (d, J = 8.6), 7.57 (d, J = 9.0), 7.48 (d, J = 3.0), 7.45 (dd, 
J = 8.0, 0.9), 7.33 (dd, J = 9.0, 3.0). 13C NMR (75.47 MHz, DMSO-d6) į (ppm): 175.9, 
155.6, 153.9, 149.2, 135.3, 125.5, 124.6, 124.0, 121.7, 120.4, 119.5, 118.2, 108.5. EIMS 
m/z (%): 214 (2, [M+2]+.), 213 (15, [M+1]+.), 212 (100 [M]+.), 184 (8), 155 (5), 128 (5), 127 
(6), 106 (4), 92 (4). 
 
5.1.6.2 Synthesis of the propargyl ethers of compounds 29, 31 and 33: 
1-Hydroxy-2-((2-methylbut-3-yn-2-yl)oxy)xanthone (28): 
Method A: 
In an oven-dried two round bottom necked flask was placed 1,2-dihydroxyxanthone 29 
(300 mg/ 1.31 mmol), potassium carbonate (181 mg/1.31 mmol), potassium iodide (328 
mg/1.97) mmol and copper iodide (38 mg/ 0.197 mmol). The flask was placed under N2 
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atmosphere and 20 mL of anhydrous DMF was added. The mixture was allowed to stir for 
15 minutes and 3-chloro-3-methyl-1-butyne (202 mg/1.97 mmol) was added dropwise. 
The mixture was warmed at 50 ºC for 1 hour and then allowed to cool to room 
temperature. The crude product poured over 100 g of crushed ice and extracted 3 x 100 
mL of ethyl ether. The organic phase was washed with 2 x 100 mL of brine, dried over 
sodium sulfate anhydrous, filtered and the organic solvent evaporated. The crude product 
was purified by silica gel flash chromatography (n-hexane/ethyl acetate 95:5). Compound 
28 was isolated as an orange solid (38 mg/ 10 %), compound 39 (181 mg/ 47 %) as an 
orange solid and also compound 40 (35 mg / 10 %) as an orange solid. 1,2-
Dihydroxyxanthone (29) was also recovered (90 mg/30 %). 
Method B: 
In an oven-dried two round bottom necked flask was placed 1,2-dihydroxyxanthone 29 
(250 mg/ 1.09 mmol), potassium carbonate (181 mg/1.31 mmol), potassium iodide (271 
mg/1.635) mmol and copper iodide (31 mg/ 0.163 mmol). The flask was placed under 
nitrogen atmosphere and 20 mL of anhydrous acetone was added. The mixture was 
allowed to stir for 15 minutes and 3-chloro-3-methyl-1-butyne (117 mg/1.314 mmol) was 
added dropwise. The mixture was warmed at 40 ºC for 12 hours and then allowed to cool 
to room temperature. The crude product was filtered and the organic solvent evaporated. 
The crude product was then purified by silica gel flash chromatography (n-hexane/ethyl 
acetate 95:5). Compound 28 was isolated as an orange solid (100 mg/ 31 %).  
1-Hydroxy-2-((2-methylbut-3-yn-2-yl)oxy)xanthone (28). Mp: 103-104 ºC. IR ȣmax (cm-1) 
(KBr): 3465, 3241, 2978, 2917, 2847, 2324, 1647, 1606, 1580, 1460, 1283, 1232, 1133, 
1053, 888, 760. 1H NMR (300.13 MHz, CDCl3) į (ppm): 12.81 (OH), 8.29 (dd, J = 8.0, 
1.7), 7.83 (d, J = 9.0), 7.76 (ddd, J = 8.3, 7.1, 1.7), 7.47 (d, J = 8.3), 7.40 (ddd, J = 8.0, 
7.1, 0.9), 6.90 (d, J = 9.0), 2.57 (s, 1H), 1.72 (s, 6H). EIMS m/z (%): 295 (2, [M+1]+.), 294 
(8, [M]+.), 279 (56), 277 (5), 262 (5), 261 (9), 247 (6), 233 (11), 223 (11), 209 (10), 208 
(12), 205 (16), 191 (9), 165 (16), 152 (11), 146 (21), 141 (12), 139 (15), 121 (36), 115 
(39). 103 (14), 102 (23), 101 (11), 92 (26). 91 (26), 77 (100), 76 (30), 75 (40), 74 (30), 65 
(39), 64 (14), 63 (33), 53 (13), 51 (84).   
3,3-dimethyl-2-methylene-2H-[1,4]dioxino[2,3-a]xanthen-12(3H)-one or 2,2-dimethyl-3-
methylene-2H-[1,4]dioxino[2,3-a]xanthen-12(3H)-one (39 or 40) 
Compound 39. Mp: 90-93 ºC. IR ȣmax (cm-1) (KBr): 2976, 2929, 2847, 1651, 1613, 1460, 
1299, 1231, 1198, 1161, 1043, 859, 801, 761. 1H NMR (300.13 MHz, CDCl3) į (ppm): 
8.28 (dd, J = 8.0, 1.6), 7.66 (ddd, J = 8.5, 7.0, 1.6), 7.40 (d, J = 8.5, 1.1), 7.33 (ddd, J = 
8.0, 7.0, 1.1), 7.31 (d, J = 9.0), 7.03 (d, J = 9.0), 4.72 (d, J = 2.3, 1H), 4.52 (d, J = 2.3, 1H), 
1.64 (s, 6H). EIMS m/z (%): 295 (2, [M+1]+.), 294 (9, [M]+.), 253 (27), 252 (12), 251 (45), 
237 (7), 229 (13), 228 (70), 225 (9), 209 (6), 200 (27), 199 (47), 182 (7), 142 (11), 126 
(11), 115 (35), 114 (24), 92 (12), 89 (10), 88 (16), 78 (19), 77 (100), 76 (19), 75 (14), 74 
(16), 67 (22), 65 (38), 63 (40), 62 (18), 53 (17), 51 (62). 
Compound 40. Mp: 116-119 ºC. IR ȣmax (cm-1) (KBr): 2955, 2923, 2849, 1653, 1615, 1592, 
1462, 1301, 1232, 1163, 1044, 862, 799, 761. 1H NMR (300.13 MHz, CDCl3) į (ppm): 
8.31 (dd, J = 8.0, 1.7), 7.67 (ddd, J = 8.5, 7.1, 1.7), 7.42 (d, J = 8.5), 7.35 (ddd, J = 8.0, 
7.1, 1.1), 7.24 (d, J = 9.0), 7.03 (d, J = 9.0), 5.01 (d, J = 2.3, 1H), 4.61 (d, J = 2.3, 1H), 
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1.64 (s, 6H). EIMS m/z (%): 295 (3, [M+1]+.), 294 (17, [M]+.), 279 (9), 253 (13), 251 (50), 
237 (12), 229 (16), 228 (90), 227 (10), 225 (26), 200 (28), 195 (54), 142 (11), 126 (12), 
115 (34), 114 (22), 113 (10), 92 (15), 89 (11), 88 (16), 78 (16), 77 (100), 75 (14), 74 (19), 
67 (31), 65 (44), 63 (40), 62 (23), 53 (20), 51 (69). 
 
4-((2-Methylbut-3-yn-2-yl)oxy)xanthone (30): 
In an oven-dried two round bottom necked flask was placed 4-hydroxyxanthone (31) (150 
mg/ 0.707 mmol), potassium carbonate (147 mg/1.06 mmol), potassium iodide (176 
mg/1.06 mmol) and copper iodide (20 mg/ 0.106 mmol). The flask was placed under 
nitrogen atmosphere and 15 mL of anhydrous DMF was added. The mixture was allowed 
to stir for 15 minutes and 3-chloro-3-methyl-1-butyne (145 mg/1.415 mmol) was added 
dropwise. The mixture was warmed at 75 ºC for 14 hours and then allowed to cool to room 
temperature. The crude product poured over 100 g of crushed ice and extracted 3 x 100 
mL of ethyl ether. The organic phase was washed with 2 x 100 mL of brine, dried over 
sodium sulfate anhydrous, filtered and the organic solvent evaporated. The crude product 
was purified by silica gel flash chromatography (n-hexane/ethyl acetate 9:1). Compound 
30 was isolated as a white solid (102 mg/52 %). 
4-((2-Methylbut-3-yn-2-yl)oxy)xanthone (30). Mp: 59-61 ºC. IR ȣmax (cm-1) (KBr): 3266, 
2980, 2919, 2866, 2334, 1649, 1590, 1560, 1479, 1457, 1434, 1329, 1216, 1123, 904, 
745, 626. 1H NMR (300.13 MHz, CDCl3) į (ppm): 8.34 (dd, J = 8.0, 1.70), 8.08 (dd, J = 
8.0, 1.6), 7.82 (dd, J = 8.0, 1.6), 7.73 (ddd, J = 8.5, 7.1, 1.7), 7.55 (d, J = 8.5), 7.39 (ddd, J 
= 8.0, 7.1, 1.1), 7.30 (t, J = 8.0), 2.56 (s, 1H), 1.78 (s, 6H). EIMS m/z (%): 278 (5, [M]+.), 
264 (20), 263 (100), 235 (10), 218 (10), 205 (19), 189 (18), 180 (19), 179 (25), 178 (57), 
165 (11), 152 (11), 115 (36), 89 (17), 77 (21), 76 (20), 75 (17), 74 (14), 63 (34), 62 (14), 
51 (33). 
2-((2-Methylbut-3-yn-2-yl)oxy)xanthone (32): 
In an oven-dried two round bottom necked flask was placed 2-hydroxyxanthone (33) (155 
mg/ 0.73 mmol), potassium carbonate (151 mg/1.1 mmol), potassium iodide (183 mg/1.1 
mmol) and copper iodide (21 mg/ 0.11 mmol). The flask was placed under nitrogen 
atmosphere and 15 mL of anhydrous DMF was added. The mixture was allowed to stir for 
15 minutes and 3-chloro-3-methyl-1-butyne (150 mg/1.46 mmol) was added dropwise. 
The mixture was warmed at 75 ºC for 24 hours and then allowed to cool to room 
temperature. The crude product poured over 100 g of crushed ice and extracted 3 x 100 
mL of ethyl ether. The organic phase was washed with 2 x 100 mL of brine, dried over 
anhydrous sodium sulfate, filtered and the solvent evaporated. The crude product was 
purified by silica gel flash chromatography (n-hexane/ethyl acetate 9:1). Compound 32 
was isolated as a white solid (80 mg/39 %). 
2-((2-Methylbut-3-yn-2-yl)oxy)xanthone (32). Mp: 103-105 ºC. IR ȣmax (cm-1) (KBr): 3219, 
2976, 2917, 2847, 2362, 1645, 1484, 1462, 1314, 1224, 1141, 899, 752. 1H NMR (300.13 
MHz, CDCl3) į (ppm): 8.34 (dd, J = 8.0, 1.7), 8.15 (d, J = 2.9), 7.72 (ddd, J = 8.6, 7.1, 
1.7), 7.57 (dd, J = 8.9, 2.9), 7.48 (dd, J = 8.6, 1.0), 7.44 (d, J = 8.9), 7.37 (ddd, J = 8.0, 
7.1, 1.0), 2.64 (s, 1H), 1.70 (s, 6H).  
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5.1.6.3 Synthesis of XBp9, XBp15 and XBp16 
12-Hydroxy-2,2-dimethylpyrano[2,3-b]xanthen-11(2H)-one (XBp9): 
To a solution of compound 28 (81 mg/0.275 mmol) in 2.5 mL of dioxane was added PtCl4 
(0.041 mmol/14 mg). The mixture was allowed to stir for 24 hours. The solution was 
filtered and the organic solvent evaporated. The crude product was purified by silica gel 
flash chromatography (n-hexane/ethyl acetate 95:5). Compound XBp9 was isolated as an 
orange solid (60 mg/ 73 %) and also 1,2-dihydroxyxanthone (29) (14 mg/22 %). 
12-Hydroxy-2,2-dimethylpyrano[2,3-b]xanthen-11(2H)-one (XBp9). Mp: 131-133 ºC. IR 
ȣmax (cm-1) (KBr): 3412, 2961, 2914, 2857, 1651, 1599, 1475, 1439, 1303, 1209, 1135, 
1072, 902, 788, 610. 1H NMR (300.13 MHz, CDCl3) į (ppm): 12.66 (OH), 8.29 (dd, J = 
8.0, 1.7; H-C(10)), 7.72 (ddd, J = 8.6, 7.2, 1.7; H-C(8)), 7.43 (dd, J = 8.6, 0.9; H-C(7)), 
7.36 (ddd, J = 8.0, 7.1, 0.9; H-C(9)), 6.65 (s, H-(5)), 6.40 (d, J = 9.9; H-C(4)), 5.94 (d, J = 
9.9; H-C(3)), 1.54 (s, (CH3)2-C(2)). 13C NMR (125.77 MHz, CDCl3) į (ppm): 182.0 (C11), 
156.3 (C6a), 149.9 (C5a), 148.7 (C12), 136.9 (C3), 135.2 (C8), 135.0 (C12a), 129.1 
(C4a), 125.8 (C10), 123.7 (C9), 121.8 (C4), 120.1 (C10a), 117.7 (C7), 76.4 (C2), 27.7 
(C1’a and C1’b). EIMS m/z (%): 294 (24, [M]+.), 280 (17), 279 (84), 262 (10), 213 (28), 205 
(48), 197 (20), 165 (42), 151 (32), 121 (44), 115 (42), 77 (100), 63 (67), 51 (83). HRMS 
(ESI) m/z calcd for C18H15O4 [M+H]+: 295.09649, found: 295.09704; m/z calcd for 
C18H14NaO4 [M+Na]+: 317.07843; found: 317.07825. 
2,2-Dimethylpyrano[3,2-c]xanthen-7(2H)-one (XBp15): 
To a solution of compound 30 (60 mg/0.216 mmol) in 2 mL of dioxane was added PtCl4 
(0.032 mmol/11 mg). The mixture was allowed to stir overnight. The solution was filtered 
and the solvent evaporated. The crude mixture was purified by silica gel flash 
chromatography (n-hexane/ethyl acetate 9:1). Compound XBp15 was isolated as yellow 
solid (45 mg/ 76 %) and also 4-hydroxyxanthone (31) as a white solid (7 mg/15 %). 
2,2-Dimethylpyrano[3,2-c]xanthen-7(2H)-one (XBp15). Mp: 182-184 ºC. IR ȣmax (cm-1) 
(KBr): 2967, 2918, 2880, 1639, 1597 1449, 1318, 1260, 1209, 1185, 1113, 1057, 905, 
761, 737, 680. 1H NMR (300.13 MHz, CDCl3) į (ppm): 8.32 (dd, J = 8.0, 1.6), 7.82 (d, J = 
8.1), 7.71 (ddd, J = 8.5, 8.0, 1.6), 7.61 (dd, J = 8.5, 1.1), 7.37 (ddd, J = 8.0, 6.9, 1.1), 7.01 
(d, J = 8.1), 6.44 (d, J = 9.8), 5.82 (d, J = 9.8), 1.57 (s, 6H). 13C NMR (125.77 MHz, CDCl3) 
į (ppm): 176.9, 156.1, 145.7, 141.3, 134.5, 133.5, 126.6, 126.0, 123.8, 122.4, 122.0, 
121.7, 121.3, 118.4, 117.6, 77.5, 27.9. EIMS m/z (%): 278 (5, [M]+.), 264 (20), 263 (100), 
235 (6), 205 (11), 189 (9), 179 (13), 178 (24), 152 (13), 131 (9), 115 (19), 103 (12), 89 
(20), 77 (21), 76 (25), 75 (21), 74 (19), 63 (35), 62 (15), 51 (36). HRMS (ESI) m/z calcd for 
C18H15O3 [M+H]+: 279.10157; found: 279.10257; m/z calcd for C18H14NaO4 [M+Na]+: 
301.08352; found: 308.08303. 
3,3-Dimethylpyrano[3,2-a]xanthen-12(3H)-one (XBp16): 
To a solution of compound 32 (60 mg/0.216 mmol) in 2 mL of dioxane was added PtCl4 
(0.032 mmol/11 mg). The mixture was allowed to stir overnight. The solution was filtered 
and the solvent evaporated. The crude product was purified by silica gel flash 
chromatography (n-hexane/ethyl acetate 9:1). Compound XBp16 was isolated as yellow 
solid (44 mg/ 75 %) and 2-hydroxyxanthone (33) as a pale yellow solid (7 mg/15 %). 
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3,3-Dimethylpyrano[3,2-a]xanthen-12(3H)-one (XBp16). Mp: 96-98 ºC. IR ȣmax (cm-1) 
(KBr): 3063, 2968, 2915, 2853, 1642, 1608, 1576, 1466, 1449, 1300, 1234, 1115, 911, 
824, 764, 749, 714. 1H NMR (300.13 MHz, CDCl3) į (ppm): 8.27 (dd, J = 8.0, 1.7), 8.09 (d, 
J = 10.2), 7.66 (ddd, J = 8.4, 7.1, 1.74), 7.41 (dd, J = 8.4, 1.1), 7.32 (ddd, J = 8.0, 7.1, 
1.1), 7.27 (d, J = 9.2), 7.18 (d, J = 9.2), 5.82 (d, J = 10.2), 1.46 (s, 6H). 13C NMR (125.77 
MHz, CDCl3) į (ppm): 179.1, 155.3, 151.9, 149.1, 134.3, 132.5, 126.6, 124.1, 123.4, 
122.2, 120.9, 120.0, 118.0, 117.4, 116.3, 75.4, 27.3. EIMS m/z (%): 278 (5, [M]+.), 264 
(18), 263 (100), 208 (10), 205 (17), 189 (11), 180 (30), 179 (13), 178 (25), 152 (20), 139 
(8), 115 (14), 115 (14), 103 (13), 89 (19), 88 (91), 87 (11), 77 (23), 76 (24), 75 (23), 74 
(21), 65 (51), 62 (22), 51 (34). HRMS (ESI) m/z calcd for C18H15O3 [M+H]+: 279.10157; 
found: 279.10227; m/z calcd for C18H14NaO3 [M+Na]+: 301.08352; found: 308.09484 
 
5.1.6.4 Synthesis of XBp10: 
In a two-necked round-bottom flask were placed compound XBp9 (25 mg/0.08 mmol) and 
5 mL of anhydrous methanol in nitrogen atmosphere. To the solution was added Pd/C 10 
% (15 % weight/4 mg) in one portion. Triethylsilane (0.136 mL, 0.8 mmol) was then added 
dropwise. The mixture was allowed to stir for 15 minutes. The product was filtered over 
celite and washed 3 times with methanol. The methanol was then evaporated and the 
crude product was purified by column chromatography (silica gel, n-hexane/ethyl acetate 
95:5). Compound XBp10 was isolated as light orange solid (23 mg/97 %). 
12-Hydroxy-2,2-dimethyl-3,4-dihydropyrano[2,3-b]xanthen-11(2H)-one (XBp10). Mp: 172-
173 ºC. IR ȣmax (cm-1) (KBr): 3443, 2972, 2917, 2858, 1650, 1602, 1478, 1444, 129, 1182, 
1073, 921, 774. 1H NMR (300.13 MHz, CDCl3) į (ppm): 12.77 (OH), 8.24 (dd, J = 8.0, 1.7; 
H-C(10)), 7.71 (ddd, J = 8.4, 7.1, 1.7; H-C(8)), 7.41 (broad d, J = 8.4; H-C(7)), 7.35 (ddd, J 
= 8.0, 7.1, 1.0; H-C(9)), 6.70 (broad s; H-C(5); 2.90 (td, J = 6.8, 0.5; H2-C(4)), 1.94 (t, J = 
6.8; H2-C(3)), 1.49 (s, (CH3)2-C(2)). 13C NMR (75.47 MHz, CDCl3) į (ppm): 182.4 (C11), 
156.3 (C6a), 149.6 (C5a), 148.4 (C12), 137.5 (C12a), 135.2 (C8), 131.3 (C4a), 125.9 
(C10), 123.5 (C9), 119.9 (C10a), 117.7 (C7), 107.7 (C11a), 105.4 (C5), 74.7 (C2), 32.3 
(C3), 26.7 (C1’a and C1’b), 23.7 (C4). EIMS m/z (%): 297 (2, [M+1]+.), 296 (100, [M]+.), 
281 (4), 267 (16), 253 (22), 240 (43), 212 (48), 184 (19), 156 (13), 141 (11),139 (20), 129 
(18), 128 (77), 115 (27), 102 (41), 92 (46), 77 (85), 76 (31), 75 (32), 74 (26), 65 (32), 6 
(22), 63 (100), 62 (39). HRMS (ESI) m/z calcd for C18H17O4 [M+H]+: 297.11214; found: 
297.11353; m/z calcd for C18H16NaO4 [M+Na]+: 319.09408; found: 319.09250. 
5.1.7 Synthesis of XBp17, XBp18, XBp19, XBp20, XBp21, 
XBp22, XBp23 and XBp24 
5.1.7.1 Synthesis of building blocks 41 and 47-53: 
5,6-Dimethoxy-2,2-dimethyl-2H-benzopyran (41): 
In a two necked round-bottom flask of 100 mL in nitrogen atmosphere was added 
potassium carbonate (10.6 g/76.8 mmol). Then, compound 13 (8 g/38.4 mmol) was 
solubilized in 100 mL of anhydrous acetone and added to the two necked round-bottom 
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flask. Dimethyl sulfate (7.26 g/57.6 mmol) was added dropwise and the mixture was 
allowed to stir for 20 hours at reflux and under nitrogen atmosphere. The reaction was 
quenched by the addition of 50 mL of distilled water and the acetone evaporated. The 
aqueous phase was acidified with HCl 1N until pH 2-3 and extracted with 3 x 200 mL of 
ethyl ether. The organic phase was washed with 2 x 100 mL of brine, dried over sodium 
sulfate anhydrous, filtered and the organic solvent evaporated. The crude product was 
purified by silica gel flash chromatography (n-hexane/ethyl acetate 95:5) obtaining 
compound 41 as light yellow oil (7.73 g/92 %). 
IR ȣmax (cm-1) (KBr): 2974, 2932, 2831, 1576, 1474, 1215, 1063, 797. 1H NMR (300.13 
MHz, CDCl3) į (ppm): 6.69 (d, J = 8.8), 6.65 (d, J = 9.9), 6.51 (d, J = 8.8), 5.66 (d, J = 
9.9), 3.84 (s, OCH3), 3.82 (s, OCH3), 1.41 (s, 6H). 13C NMR (75.47 MHz, CDCl3): 147.0, 
146.7, 131.4, 131.3, 117.1, 112.7, 112.6, 111.0, 75.4, 61.3, 55.5, 27.5. EIMS m/z (%): 221 
(22, [M+1]+.), 220 (65, [M]+.), 205 (100), 190 (34), 161 (34), 144 (9), 91 (14), 77 (5). 
Protected salicylaldehydes (47-53): 
Methoxymethyl ether protecting group: 
In a typical experiment: in a two-necked round-bottom flask was placed sodium hydride 
(333 mg/8.3 mmol of 60% sodium hydride in mineral oil) and rinsed with anhydrous n-
hexane. The flask was then placed under nitrogen atmosphere and on an ice-bath. 5-
Methylsalicyladehyde (44) (688mg/5 mmol) was solubilized in 20 mL of anhydrous THF 
and added slowly to the flask containing the sodium hydride. The mixture was allowed to 
stir for 15 minutes and MOMCl (803 mg/10 mmol) was added dropwise and the flask 
placed under reflux overnight. The mixture was cooled to room temperature and poured 
over 50 g of crushed ice. The aqueous phase was extracted with 3 x 50 mL of ethyl 
acetate. The organic phase was then washed with 2 x 50 mL of brine, dried over sodium 
sulfate anhydrous, filtered and the organic solvent evaporated. The crude product was 
purified by silica gel flash chromatography (n-hexane/ethyl acetate 9:1). Compound 49 
was obtained as colorless oil (791 mg/88 %). 
5-Chloro-2-(methoxymethoxy)benzaldehyde (47) as a colorless oil (88 %): IR ȣmax (cm-1) 
(KBr): 2922, 2852, 1667, 1628, 1472 1127, 866. 1H NMR (300.13 MHz, CDCl3) į (ppm): 
10.43 (s, CHO), 7.80 (d, J = 2.8), 7.47 (dd, J = 9.0, 2.8), 7.20 (d, J = 9.0), 5.29 (s, 2H), 
3.52 (s, OCH3). EIMS m/z (%): 202 (10, [M+2]+.), 200 (30, [M]+.), 170 (16), 169 (30), 155 
(35), 99 (16), 77 (30), 75 (82), 63 (100). 
5-Methoxy-2-(methoxymethoxy)benzaldehyde (48) as a colorless oil (78 %): IR ȣmax (cm-1) 
(KBr): 2927, 2879 1666, 1627, 1490. 813. 1H NMR (300.13 MHz, CDCl3) į (ppm): 10.47 
(s, CHO), 7.33 (d, J = 3.2), 7.18 (dd, J = 9.1), 7.11 (dd, J = 9.0, 3.2), 5.24 (s, 2H), 3.81 (s, 
OCH3), 3.52 (s, OCH3). EIMS m/z (%): 197 (18, [M+1]+.), 196 (100, [M]+.), 165 (52), 150 
(98), 120 (25), 95 (36), 65 (38), 63 (58). 
2-(Methoxymethoxy)-5-methylbenzaldehyde (49) colorless oil (88 %): IR ȣmax (cm-1) (KBr): 
2925, 2853, 2790, 2665, 1627, 1450, 1386, 666. 1H NMR (300.13 MHz, CDCl3) į (ppm): 
10.48 (s, CHO), 7.64 (d, J= 2.5), 7.34 (dd, J = 8.5, 2.5), 7.12 (d, J = 8.5), 5.27 (s, 2H), 
3.52 (s, OCH3), 2.32 (s, CH3). EIMS m/z (%): 181 (10, [M+1]+.), 180 (34, [M]+.), 151 (20), 
149 (45), 135 (100), 91 (44), 77 (55), 65 (25), 51 (56). 
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2,4-Bis(methoxymethoxy)benzaldehyde (50) as white solid (56%): MP: 44-45 ºC. IR ȣmax 
(cm-1) (KBr): 3003, 2989, 2959, 2904, 1679, 1601, 1255, 1155, 999, 921. 1H NMR (300.13 
MHz, CDCl3) į (ppm): 10.34 (s, CHO), 7.80 (d, J = 8.7), 6.83 (d, J = 2.2), 6.74 (dd, J = 
8.7, 2.2), 5.28 (s, 2H), 5.22 (s, 2H), 3.53 (s, OCH3), 3.49 (s, OCH3). EIMS m/z (%): 227 
(10, [M+1]+.), 226 (15, [M]+.), 181 (28), 165 (35), 151 (22), 136 (40), 77 (23), 63 (100). 
4-(Diethylamino)-2-(methoxymethoxy)benzaldehyde (51) as yellow oil (71 %): IR ȣmax (cm-
1) (KBr): 2916, 2770, 1667, 1598, 1267, 1267, 990, 798. 1H NMR (300.13 MHz, CDCl3) į 
(ppm): 10.17 (s, CHO), 7.74 (d, J= 9.4), 6.39-6.37 (m, 2H), 5.27 (s, 2H), 3.52 (s, OCH3), 
3.45-3.38 (m, 4H), 1.21 (t, J=7.1, 6H). EIMS m/z (%): 238 (10, [M+1]+.), 237 (25, [M]+.), 
222 (56), 192 (20), 178 (45), 176 (56), 162 (100), 148 (24), 134 (30), 122 (10), 77 (20), 65 
(20). 
Benzyl ether protecting group: 
In a typical experiment: in a two-necked round-bottom flask was placed 5-
chlorosalicylaldehyde (42) (1 g/ 6.4 mmol) and then it was added Cs2CO3 (3.13 g/9.6 
mmol), benzyl bromide (1.64 g/ 9.6 mmol) and 50 mL of acetone. The mixture was 
allowed to stir at room temperature overnight. The product was then filtrated and washed 
with acetone. The solvent was evaporated and the crude product purified by column 
chromatography (silica gel, n-hexane/ethyl acetate 95:5). Compound 94 was obtained as 
white solid (1.42 g/ 90 %). 
2-(Benzyloxy)-5-chlorobenzaldehyde (52) as white solid (90 %). Mp: 77-78 ºC. IR ȣmax 
(cm-1) (KBr): 2867, 2757, 1678, 1590, 1451, 1383, 1266, 1174, 1123, 1019, 819, 733, 676. 
1H NMR (300.13 MHz, CDCl3) į (ppm): 10.44 (s, CHO), 7.75 (d, J= 2.8), 7.43-7.3 (6H, m), 
6.97 (d, J = 8.7), 5.13 (s, 2H). EIMS m/z (%): 248 (0.4, [M+2]+.), 246 (1.5, [M]+.), 219 (2), 
218 (6), 217 (4), 155 (27), 156 (3), 155 (27), 99 (3), 92 (11), 91 (100), 75 (4), 74 (3), 73 
(6), 65 (34). 63 (16), 62 (6). 
2-(Benzyloxy)-4-(diethylamino)benzaldehyde (53) as yellow solid (65 %): Mp: 67-69 ºC.  
5.1.7.2 Synthesis of diarylmethanol derivatives 55-70: 
In a typical Experiment: in a two-necked round-bottom flask was placed compound 41 
(193 mg/0.87 mmol) solubilized in 5 mL of anhydrous THF and TMEDA (1.05 mmol, 121 
mg). The mixture was then placed at 0 ºC and nBuLi (1.6 M, 1.05 mmol) was added 
dropwise. The mixture was allowed to react for 30 min at 0 ºC. Then the benzaldehyde 47 
(176 mg/0.87 mmol) was added and allowed to react for 1h 30 min at 0 ºC and 6 hours at 
room temperature. The reaction was quenched with a saturated solution of ammonium 
chloride, extracted with 3 x 20 mL of ethyl acetate. The organic phase was washed 2 x 25 
mL of brine, dried over sodium sulfate anhydrous, filtered and the organic solvent 
evaporated. The crude product was then separated by silica gel flash chromatography (n-
hexane/ethyl acetate 8:2). Compounds 55 and 63 were obtained as yellow oil (137 mg/ 38 
%), although compound 97 was obtained in higher yield. The mixture was used in the next 
reaction without further purification. 
Combined yield for compounds 55 and 63 (yellow oil, 137 mg/38 %). (5-chloro-2-
(methoxymethoxy)phenyl)(5,6-dimethoxy-2,2-dimethyl-2H-benzopyran-7-yl)methanol (55): 
EIMS m/z (%): 422 (15, [M+2]+.), 420 (35, [M]+.), 407 (40), 405 (100), 373 (10), 345 (10), 
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329 (20), 327 (40), 312 (20), 297 (10), 205 (20), 155 (20). (5-chloro-2-
(methoxymethoxy)phenyl)(5,6-dimethoxy-2,2-dimethyl-2H-benzopyran-8-yl)methanol (63): 
EIMS m/z (%):422 (20, [M+2]+.), 420 (65, [M]+.), 407 (30), 405 (75), 373 (20), 359 (35), 345 
(50), 315 (25), 247 (20), 221 (65), 219 (55), 205 (100), 189 (30), 155 (62). 
Combined yield for compounds 56 and 64 (yellow oil, 1.48 g/ 40 %). Both isomers were 
separated from the starting materials by silica gel flash chromatography but were not 
characterized by GC-MS since they were not volatile. 
Combined yield for compounds 57 and 65 (yellow oil, 185 mg/41 %). (5,6-dimethoxy-2,2-
dimethyl-2H-benzopyran-7-yl)(5-methoxy-2-(methoxymethoxy)phenyl)methanol (57): 
EIMS m/z (%): 416 (15, [M]+.), 401 (20), 369 (15), 353 (15), 323 (100), 308 (20), 293 (15), 
205 (15), 151 (20). (5,6-dimethoxy-2,2-dimethyl-2H-benzopyran-8-yl)(5-methoxy-2-
(methoxymethoxy)phenyl)methanol (65): EIMS m/z (%): 417 (10, [M+1]+.), 416 (40, [M]+.), 
401 (25), 354 (70), 311 (100), 247 (40), 247 (35), 219 (95), 195 (35), 175 (30), 151 (70), 
137 (25). 
Combined yield for compounds 58 and 66 (yellow oil, 261 mg/45 %). (5,6-dimethoxy-2,2-
dimethyl-2H-benzopyran-7-yl)(2-(methoxymethoxy)-5-methylphenyl)methanol (58): EIMS 
m/z (%): 401 (10, [M+1]+.), 400 (40, [M]+.), 385 (90), 353 (30), 307 (100), 292 (25), 277 
(20), 205 (30), 135 (55). (5,6-dimethoxy-2,2-dimethyl-2H-benzopyran-8-yl)(2-
(methoxymethoxy)-5-methylphenyl)methanol (66): EIMS m/z (%): 401 (10, [M+1]+.), 400 
(50, [M]+.), 385 (45), 355 (10), 325 (20), 395 (20), 247 (35), 219 (30), 205 (100), 179, 135 
(65). 
Combined yield for compounds 59 and 67 (yellow oil, 1.03 g/68 %). (2,4-
bis(methoxymethoxy)phenyl)(5,6-dimethoxy-2,2-dimethyl-2H-benzopyran-7-yl)methanol 
(59): EIMS m/z (%): 447 (10, [M+1]+.), 446 (45, [M]+.), 432 (25), 431 (100), 399 (15), 353 
(35), 247 (50), 205 (25), 181 (20), 151 (20). (2,4-bis(methoxymethoxy)phenyl)(5,6-
dimethoxy-2,2-dimethyl-2H-benzopyran-8-yl)methanol (67): EIMS m/z (%): 446 (20, [M]+.), 
415 (25), 397 (40), 369 (20), 354 (30), 353 (100), 323 (30), 293 (35), 281 (20), 263 (80), 
247 (55), 207 (30), 165 (25). 
Combined yield for compounds 60 and 68 (yellow oil, 165 mg/33 %). Both isomers were 
separated from the starting materials by silica gel flash chromatography but were not 
characterized by GC-MS since they were not volatile. 
Combined yield for compounds 61 and 69 (yellow oil, 750 mg/16 %). Both isomers were 
separated from the starting materials by silica gel flash chromatography but were not 
characterized by GC-MS since they were not volatile. 
Combined yield for compounds 62 and 70 (yellow oil, 951 mg/50 %). Both isomers were 
separated from the starting materials by silica gel flash chromatography but were not 
characterized by GC-MS since they were not volatile. 
5.1.7.3 Synthesis of benzophenone derivatives 71-86: 
In a typical experiment: in a round-bottom flask were placed the two isomers, 55 and 63 
(46.2 mg/0.11 mmol) and 1 mL of DMSO. Then it was added IBX (37 mg/0.132 mmol). 
After 12 hours the reaction was quenched with the addition of a solution of Na2S2O3 10%, 
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saturated NaHCO3 and water. The aqueous phase was then extracted with 3 x 15 mL of 
ethyl acetate. The organic phase was washed with 2 x 25 mL of a 10% solution of 
Na2S2O3, 2 x 25 mL of a saturated solution of NaHCO3, dried over sodium sulfate 
anhydrous, filtered and the organic solvent evaporated. The crude product was purified by 
silica gel column chromatography (n-hexane/ethyl acetate 9:1) and both benzophenones 
(71 and 79) were obtained as yellow oil (33.6 mg/73 %). 
Combined yield for compounds 71 and 79 (yellow oil, 137 mg/73 %). (5-chloro-2-
(methoxymethoxy)phenyl)(5,6-dimethoxy-2,2-dimethyl-2H-benzopyran-7-yl)methanone 
(71): EIMS m/z (%): 420 (5, [M+2]+.), 418 (30, [M]+.), 405 (30), 403 (100), 387 (30), 373 
(5), 371 (30), 359 (40), 327 (40), 327 (40). (5-chloro-2-(methoxymethoxy)phenyl)(5,6-
dimethoxy-2,2-dimethyl-2H-benzopyran-8-yl)methanone (79): EIMS m/z (%): 420 (10, 
[M+2]+.), 418 (70, [M]+.), 405 (35), 403 (100), 373 (25), 345 (35), 343 (95), 315 (25), 219 
(50), 207 (40), 189 (30), 155 (70). 
Combined yield for compounds 72 and 80 (yellow oil, 1.13 g/ 91 %). Both isomers were 
separated by silica gel flash chromatography but were not characterized by GC-MS since 
they were not volatile. 
Combined yield for compounds 73 and 81 (yellow oil, 113 mg/86 %). (5,6-dimethoxy-2,2-
dimethyl-2H-benzopyran-7-yl)(5-methoxy-2-(methoxymethoxy)phenyl)methanone (73): 
EIMS m/z (%): 414 (15, [M]+.), 399 (40), 383 (50), 367 (95), 351 (100), 323 (50), 249 (30). 
(5,6-dimethoxy-2,2-dimethyl-2H-benzopyran-8-yl)(5-methoxy-2-
(methoxymethoxy)phenyl)methanone (81): EIMS m/z (%): 415 (10, [M+1]+.), 414 (55, 
[M]+.), 399 (60), 367 (35), 339 (100), 311 (30), 295 (35), 219 (40), 189 (35), 175 (60), 151 
(90). 
Combined yield for compounds 74 and 82 (yellow oil, 66 mg/87 %). (5,6-dimethoxy-2,2-
dimethyl-2H-benzopyran-7-yl)(2-(methoxymethoxy)-5-methylphenyl)methanone (74): 
EIMS m/z (%): 399 (5, [M+1]+.), 398 (40, [M]+.), 383 (100), 367 (60), 351 (50), 335 (55), 
307 (40). (5,6-dimethoxy-2,2-dimethyl-2H-benzopyran-8-yl)(2-(methoxymethoxy)-5-
methylphenyl)methanone (82): EIMS m/z (%): 399 (10, [M+1]+.), 398 (70, [M]+.), 383 (80), 
353 (20), 323 (100), 135 (65). 
Combined yield for compounds 75 and 83 (yellow oil, 870 mg/88 %). (2,4-
bis(methoxymethoxy)phenyl)(5,6-dimethoxy-2,2-dimethyl-2H-benzopyran-7-yl)methanone 
(75): EIMS m/z (%): 445 (10, [M+1]+.), 444 (45, [M]+.), 429 (100), 413 (40), 381 (50), 353 
(20), 309 (25), 249 (15). (2,4-bis(methoxymethoxy)phenyl)(5,6-dimethoxy-2,2-dimethyl-
2H-benzopyran-8-yl)methanone (83): EIMS m/z (%): 445 (5, [M+1]+.), 444 (30, [M]+.), 429 
(40), 400 (25), 385 (60), 369 (100), 341 (25), 205 (20). 
Combined yield for compounds 76 and 84 (yellow oil, 135 mg/ 74 %). Both isomers were 
separated by silica gel flash chromatography but were not characterized by GC-MS since 
they were not volatile. 
Combined yield for compounds 77 and 85 (yellow oil, 489 mg/ 59 %). Both isomers were 
separated silica gel flash chromatography but were not characterized by GC-MS since 
they were not volatile. 
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Combined yield for compounds 78 and 86 (yellow oil, 1.13 g/ 91 %). Both isomers were 
separated by silica gel flash chromatography but were not characterized by GC-MS since 
they were not volatile. 
5.1.7.4 Synthesis of benzophenone derivatives 87-102: 
Methoxymethyl ether removal: 
In a typical experiment: in a round-bottom flask was placed compounds 87 and 92 (80.6 
mg, 0.19 mmol) in 1.5 mL of CH3CN. The solution was placed at 0 ºC and NbCl5 (52 mg, 
0.19 mmol) was added in one portion. The mixture was stirred at 0ºC for 10 minutes and 
then allowed to warm to room temperature and let stirring for more 45 minutes. After this 
time, the reaction was quenched with saturated solution of NaHCO3. The mixture was 
extracted with 3 x 15 ml of ethyl acetate. The organic phase was washed with 2 x 100 ml 
of brine, dried over sodium sulfate anhydrous and the organic solvent evaporated. The 
mixture of the two isomers was obtained as yellow oil in quantitative yield and used in the 
next reaction without further purification. 
Compounds 87 and 92 as yellow oil in quantitative yield. (5-chloro-2-hydroxyphenyl)(5,6-
dimethoxy-2,2-dimethyl-2H-benzopyran-7-yl)methanone (87): EIMS m/z (%): 376 (5, 
[M+2]+.), 374 (30, [M]+.), 361 (40), 359 (100), 343  (40), 219 (20), 164 (25), 155 (30). (5-
chloro-2-hydroxyphenyl)(5,6-dimethoxy-2,2-dimethyl-2H-benzopyran-8-yl)methanone (92): 
EIMS m/z (%): 376 (5, [M+2]+.), 374 (30, [M]+.), 361 (40), 359 (100), 331 (20), 219 (20), 
205 (20), 155 (30). 
Compounds 88 and 93 as yellow oil in quantitative yield. (5,6-dimethoxy-2,2-dimethyl-2H-
benzopyran-7-yl)(2-hydroxy-5-methoxyphenyl)methanone (88): EIMS m/z (%): 370 (20, 
[M]+.), 355 (60), 339 (100), 309 (25), 205 (20), 162 (20). (5,6-dimethoxy-2,2-dimethyl-2H-
benzopyran-8-yl)(2-hydroxy-5-methoxyphenyl)methanone (93): EIMS m/z (%): 371 (10, 
[M+1]+.), 370 (40, [M]+.), 355 (100), 327 (20), 295 (15), 205 (20), 151 (40). 
Compounds 89 and 94 as yellow oil in quantitative yield. (5,6-dimethoxy-2,2-dimethyl-2H-
benzopyran-7-yl)(2-hydroxy-5-methylphenyl)methanone (89): EIMS m/z (%): 354 (25, 
[M]+.), 339 (90), 323 (100), 293 (40), 154 (60), 135 (50). (5,6-dimethoxy-2,2-dimethyl-2H-
benzopyran-8-yl)(2-hydroxy-5-methylphenyl)methanone (94): EIMS m/z (%): 354 (35, 
[M]+.), 339 (100), 281 (30), 205 (20), 135 (40). 
Combined yield for compounds 90 and 95 (yellow oil, 76 mg/85 %). (2,4-
dihydroxyphenyl)(5,6-dimethoxy-2,2-dimethyl-2H-benzopyran-7-yl)methanone (90): EIMS 
m/z (%): 357 (5, [M+1]+.), 356 (30, [M]+.), 341 (100), 325 (70), 295 (20), 205 (25), 176 (20), 
155 (30), 137 (50). (2,4-dihydroxyphenyl)(5,6-dimethoxy-2,2-dimethyl-2H-benzopyran-8-
yl)methanone (95): EIMS m/z (%): 357 (5, [M+1]+.), 356 (40, [M]+.), 341 (100), 313 (20), 
281 (30), 207 (40), 137 (60). 
Combined yield for compounds 91 and 96 (yellow oil, 60 mg/ 56 %). Both isomers were 
separated by silica gel flash chromatography but were not characterized by GC-MS since 
they were not volatile. 
Benzyl ether removal and hydrogenation of the double bond of the 2,2-dimethylpyran 
moiety: 
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In a typical experiment: in a two-necked round-bottom flask were placed compounds 78 
and 86 (575 mg/1.14 mmol) and 25 mL of anhydrous methanol in nitrogen atmosphere. 
To the solution was added Pd/C 10 % (15 % weight/86 mg) in one portion. Triethylsilane 
(2.7 mL, 17.1 mmol) was then added dropwise. The mixture was allowed to stir for 15 
minutes. The product was filtered over celite and washed 3 times with methanol. The 
methanol was then evaporated and the crude product was purified by silica gel column 
chromatography (n-hexane/ethyl acetate 9:1). Compounds 99 and 102 were isolated as 
yellowish oil (380 mg/83 %). 
Combined yield for compounds 97 and 100 (yellow oil, 400 mg of impure mixture). From 
the GC-MS chromatogram we observed not only the desired compounds but also 
hydrodechlorinated products which we were not able to isolate. 
Combined yield for compounds 98 and 101 (yellow oil, 250 mg/ 69 %). Compounds 
decomposed with the conditions used in the GC-MS. 
Combined yield for compounds 99 and 102 (yellow oil, 380 mg/83 %). (5,6-dimethoxy-2,2-
dimethyl-3,4-dihydrobenzopyran-7-yl)(2-hydroxy-4,5-dimethoxyphenyl)methanone (99): 
EIMS m/z (%): 403 (1, [M+1]+.), 402 (4, [M]+.), 372 (20), 371 (100), 315 (7), 303 (4), 301 
(5), 287 (5), 222 (3), 207 (5), 180 (9), 166 (5), 151 (4), 125 (4), 69 (5), 53 (3). (5,6-
dimethoxy-2,2-dimethyl-3,4-dihydrobenzopyran-8-yl)(2-hydroxy-4,5-
dimethoxyphenyl)methanone (102): EIMS m/z (%): 403 (2, [M+1]+.), 402 (8, [M]+.), 221 (6), 
207 (8), 182 (10), 181 (100), 125 (6), 110 (3), 95 (3). 
5.1.7.5 Synthesis of analogues XBp17 to XBp24: 
With conventional heating: 
In a typical experiment: In a two-necked round-bottom flask was placed a solution of 
compound 87 and 92 (68 mg, 0.18 mmol) in 1 mL of DMF and then it was added Cs2CO3 
(88 mg, 0.27 mmol).  The mixture was stirred at 50ºC for 21 hours. The mixture was 
allowed to cool to room temperature and poured into crushed ice. The aqueous phase 
was then extracted with 3 x 50 mL of diethyl ether. The organic phase was washed with 2 
x 50 ml of brine, dried over sodium sulfate anhydrous, filtered and the organic solvent 
evaporated. The crude product was purified by silica gel flash chromatography (n-
hexane/ethyl acetate 95:5). Compound XBp17 was obtained as yellow solid (35 mg, 65 
%) and compound 92 (7.1 mg) was also isolated. 
9-Chloro-5-methoxy-2,2-dimethylpyrano[2,3-b]xanthen-11(2H)-one (XBp17) yellowish 
solid (35 mg/65 %). Mp: 163-164 ºC. IR ȣmax (cm-1) (KBr):2954, 2913, 2846, 1644, 1603, 
1478, 1435, 1256, 1116, 1079, 1017, 806, 699. 1H NMR (300.13 MHz, CDCl3) į (ppm): 
8.31 (d, J = 2.6; H-C(10)), 7.69 (dd, J = 8.8, 2.6; (H-C(8)), 7.54 (d, J = 8.8; H-C(7)), 7.48 
(s, H-C(12)), 6.82 (d, J = 10.8, H-C(4)), 5.99 (d, J = 10.8; H-C(3)), 4.09 (s; H3CO-C(5)), 
1.51 (s, (CH3)2-C(2)). 13C NMR (75.47 MHz, CDCl3): 175.3 (C11), 154.1 (C6a), 149.3 
(C12a), 144.6 (C5a), 143.6 (C5), 135.8 (C3), 134.5 (C8), 129.6 (C9), 126.0 (C10), 122.1 
(C11a), 121.9 (C10a), 121.9 (C4a), 119.7 (C7), 116.3 (C4), 106.7 (C12), 76.3 (C2), 62.3 
(C1’’), 27.8 (C1’a and C1’b). EIMS m/z (%): 344 (10, [M+2]+.), 342 (70, [M]+.), 329 (35), 
327 (100), 314 (10), 312 (40), 156 (20). HRMS (ESI) m/z calcd for C19H16ClO4 [M+H]+: 
343.07316; found: 343.07304. Compound 92 (7.1 mg). 
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5,9-Dimethoxy-2,2-dimethylpyrano[2,3-b]xanthen-11(2H)-one (XBp19) yellow solid (46 
mg/51 %). Mp: 174-175 ºC. IR ȣmax (cm-1) (KBr): 2978, 2943, 2845, 1642, 1617, 1488, 
1444, 1202, 1127, 783. 1H NMR (300.13 MHz, CDCl3) į (ppm): 7.72 (d, J = 3.1; H-C(10)), 
7.53 (d, J = 9.2; H-C(7)), 7.52 (s; H-C(12)), 7.36 (dd, J = 9.2, 3.1; H-C(8)), 6.83 (d, J = 
10.0; H-C(4)), 5.98 (d, J = 10.0; H-C(3)), 4.10 (s, H3CO-C(5)), 3.97 (s H3CO-C(9)), 1.52 (s; 
(CH3)2-C(2)). 13C NMR (75.47 MHz, CDCl3): 176.3 (C11), 155.9 (C6a), 150.7 (C9), 148.8 
(C12a), 144.8 (C5a), 143.6 (C5), 135.6 (C3), 124.7 (C8), 121.7 (C10a), 121.5 (C11a), 
121.4 (C4a), 119.4 (C10), 116.4 (C4), 106.5 (C12), 105.6 (C7), 76.2 (C2), 62.2 (C1’’), 55.9 
(C1’’’), 27.7 (C1’a and C1’b). EIMS m/z (%): 338 (30, [M]+.), 323 (100), 308 (40), 161 (20). 
HRMS (ESI) m/z calcd for C20H19O5 [M+H]+: 339.12270, found: 339.12259. Compound 93 
(5 mg). 
5-Methoxy-2,2,9-trimethylpyrano[2,3-b]xanthen-11(2H)-one (XBp20) yellowish solid (85 
mg/72 %). Mp: 181-182 ºC. IR ȣmax (cm-1) (KBr): 2973, 2924, 1642, 1616, 1484, 1437, 
1305, 1119. 1H NMR (300.13 MHz, CDCl3) į (ppm): 8.13 (d, J = 2.0; H-C(10)), 7.56 (dd, J 
= 8.4, 2.0; H-C(8)), 7.51 (s; H-C(12)), 7.48 (d, J = 8.4; H-C(7)), 6.83 (d, J = 10.1; H-C(4)), 
5.97 (d, J = 10.1; H-C(3)), 3.98 (s, H3CO-C(5)), 2.38 (s, H3C-C(9)), 1.39 (s, (CH3)2-C(2)). 
13C NMR (75.47 MHz, CDCl3): 176.5 (C11), 154.0 (C6a), 148.8 (C12a), 144.7 (C5a), 
143.6 (C5), 135.7 (C8), 135.5 (C3), 133.6 (C9), 125.9 (C10), 122.2 (C11a), 121.4 (C4a), 
120.9 (C10a), 117.7 (C7), 116.4 (C4), 106.7 (C12), 76.1 (C2), 62.2 (C1’’), 27.7 (C1’a and 
C1’b), 20.8 (C1’’’). EIMS m/z (%): 323 (5, [M+1]+.), 322 (70, [M]+.), 308 (20), 307 (100), 
292 (40), 153 (20). HRMS (ESI) m/z calcd for C20H19O4 [M+H]+: 323.12779, found: 
323.12768. Compound 94 (4.8 mg). 
With microwave heating: 
In a typical experiment: To a solution of compounds 90 and 95 (210 mg, 0.11 mmol) in 1.5 
mL of DMF was added K2CO3 (163 mg, 1.18 mmol).  The mixture was irradiated with 
microwave (200 W max) for 15 minutes at 140 ºC. The mixture was allowed to cool to 
room temperature and poured into crushed ice. The aqueous phase was then extracted 
with 3 x 30 mL of diethyl ether. The organic phase was washed with 2 x 30 ml of brine, 
dried over sodium sulfate anhydrous, filtered and the organic solvent evaporated. The 
crude product was purified by silica gel flash chromatography (n-hexane/ ethyl acetate 
8:2). Compound XBp21 was obtained as light yellow solid (87 mg, 22 %). 
8-Hydroxy-5-methoxy-2,2-dimethylpyrano[2,3-b]xanthen-11(2H)-one (XBp21) as a light 
yellow solid (87 mg/22 %). Mp: 193-194 ºC. IR ȣmax (cm-1) (KBr): 3112, 2975, 2936, 2845, 
1609, 1435, 1234, 1101, 1005, 846, 780. 1H NMR (400.21 MHz, CDCl3) į (ppm): 8.25 (d, 
J = 8.7; H-C(10)), 7.44 (s; H-C(12)), 7.27 (d, J = 2.3; H-C(7)), 7.13 (dd, J = 8.7, 2.3; H-
C(9)), 6.78 (d, J = 9.9; H-C(4)), 5.93 (d, J = 9.9; H-C(3)), 4.06 (s; H3CO-C(5)), 1.47 (s; 
(CH3)2-C(2)). 13C NMR (100.63 MHz, CDCl3) į (ppm): 175.6 (C11), 161.4 (C8), 157.3 
(C6a), 149.1 (C12a), 143.6 (C5), 135.5 (C3), 128.7 (C10), 122.4 (C11a), 121.4 (C4a), 
116.9 (C10a), 116.4 (C4), 113.9 (C9), 106.9 (C12), 103.5 (C7), 76.3 (C2), 62.4 (C1’’), 27.8 
(C1’a and C1’b). HRMS (ESI) m/z calcd for C19H17O5 [M+H]+: 325.10705; found: 
325.10695.  
8-(Diethylamino)-5-methoxy-2,2-dimethylpyrano[2,3-b]xanthen-11(2H)-one (XBp22) as a 
yellowish solid (20 mg/44 %). MP: 56-58 ºC. IR ȣmax (cm-1) (KBr): 2967, 2929, 2868, 1640, 
1607, 1435, 114, 1073, 813. 1H NMR (300.13 MHz, CDCl3) į (ppm): 8.12 (d, J = 9.1; H-
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C(10)), 7.46 (s; H-C(12)), 6.77 (d, J = 10.2; H-C(4)), 6.71 (dd, J = 9.1, 2.4; H-C9)), 6.59 (d, 
J = 2.4; H-C(7)), 5.89 (d, J = 10.2; H-C(3)), 4.05 (s, H3CO-C(5)), 3.49 (q, J = 7.1; H2-
C(1’’’a and 1’’’b)), 1.47 (s; (CH3)2-C(2)), 1.27 (t, J = 7.1; H3-C(2’’’a and 2’’’b)). 13C NMR 
(75.47 MHz, CDCl3): 174.8 (C11), 158.4 (C6a), 152.4 (C8), 148.5 (C12a), 144.4 (C5a), 
143.3 (C5), 134.7 (C3), 128.1 (C10), 122.8 (C11a), 120.4 (C4a), 116.6 (C4), 111.1 
(C10a), 109.5 (C9), 106.9 (C12), 96.1 (C7), 75.9 (C2), 62.3 (C1’’), 44.8 (C1’’’a and C1’’’b), 
27.6 (C1’a and C1’b), 12.5 (C2’’’a and C2’’’b). HRMS (ESI) m/z calcd for C23H26NO4 
[M+H]+: 380.18563; found: 380.18546. 
9-Chloro-5-methoxy-2,2-dimethyl-3,4-dihydropyrano[2,3-b]xanthen-11(2H)-one (XBp18) 
as a white solid (105 mg/37 %). Mp: 167-168 ºC. IR ȣmax (cm-1) (KBr): 2976, 2933, 1841, 
1658, 1615, 1466, 1432, 1120, 1075, 942, 821. 1H NMR (300.13 MHz, CDCl3) į (ppm): 
8.28 (d, J = 2.6; H-C(10)), 7.65 (dd, J = 8.9, 2.6; H-C(8)), 7.52 (d, J = 8.9; H-C(7)), 7.48 (s; 
H-C(12)), 4.09 (s; H3CO-C(5)), 2.95 (t, J = 6.8; H2-C(4)), 1.89 (t, J = 6.8; H2-C(3)), 1.40 (s; 
(CH3)2-C(2)). 13C NMR (75.47 MHz, CDCl3): 175.6 (C11), 154.0 (C6a), 150.9 (C12a), 
146.9 (C5), 143.2 (C5a), 134.4 (C8), 129.2 (C9), 125.9 (C10), 124.1 (C4a), 121.9 (C11a), 
121.2 (C10a), 119.7 (C7), 107.2 (C12), 74.4 (C2), 61.1 (C1’’), 31.5 (C3), 26.6 (C1’a and 
C1’b), 18.2 (C4). EIMS m/z (%): 346 (2, [M+2]+.), 345 (9, [M+1]+.), 344 (16, [M]+.), 290 (24), 
289 (51), 288 (50), 259 (34), 231 (36), 217 (51), 168 (57), 161 (29), 139 (52), 126 (84), 77 
(33), 75 (58), 74 (41), 63 (100), 51 (61). HRMS (ESI) m/z calcd for C19H18ClO4 [M+H]+: 
345.08881, found: 345.08865.  
8-(Diethylamino)-5-methoxy-2,2-dimethyl-3,4-dihydropyrano[2,3-b]xanthen-11(2H)-one 
(XBp23) as a light yellow solid (100 mg/48 %). Mp: 126-128 ºC. IR ȣmax (cm-1) (KBr): 
2067, 2921, 2876, 1644, 1609, 1438, 1343, 1098, 773. 1H NMR (300.13 MHz, CDCl3) į 
(ppm): 8.12 (d, J = 9.1; H-C(10)), 7.47 (s; H-C12)), 6.69 (dd, J = 9.1, 2.5; H-C(9)), 6.54 (d, 
J = 2.5; H-C(7)), 4.05 (s; H3CO-C(5)), 3.48 (q, J = 7.1; H2-C(1’’’a and 1’’’b)), 2.92 (t, J = 
6.9; H2-C(4)), 1.85 (t, J = 6.9; H2-C(3)), 1.37 (s; (CH3)2-C(2)), 1.27 (d, J = 7.1; H3-C(2’’’a 
and 2’’’b)). 13C NMR (75.47 MHz, CDCl3): 175.2 (C11), 158.3 (C6a), 152.6 (C8), 150.0 
(C12a), 145.6 (C5), 143.3 (C5a), 128.1 (C10), 122.1 (C4a), 122.0 (C11a), 110.8 (C10a), 
109.2 (C9), 107.4 (C12), 96.1 (C7), 74.0 (C2), 61.1 (C1’’), 44.7 (C1’’’a and C1’’’b), 31.8 
(C3), 26.7 (C1’a and C1’b), 18.1 (C4), 12.5 (C2’’’a and C2’’’b). HRMS (ESI) m/z calcd for 
C23H28NO4 [M+H]+: 382.20128; found: 382.20109. 
5,8,9-Trimethoxy-2,2-dimethyl-3,4-dihydropyrano[2,3-b]xanthen-11(2H)-one (XBp24) as a 
light yellow solid (130 mg/46 %). Mp: 216-217 ºC. IR ȣmax (cm-1) (KBr): 2979, 2933, 2830, 
1642, 1615, 1479, 1447, 1432, 1270, 1097, 1004, 779. 1H NMR (400.21 MHz, CDCl3) į 
(ppm): 7.65 (s; H-C(10)), 7.49 (s; H-C(12)), 6.96 (s; H-C(7)), 4.06 (s, H3CO-C(5)), 4.03 (s, 
H3CO-C(8)), 3.99 (s, H3CO-C(9)), 2.92 (t, J = 6.8; H2-C(4)), 1.86 (t, J = 6.8; H2-C(3)), 1.37 
(s, (CH3)2-C(2)). 13C NMR (100.63 MHz, CDCl3) į (ppm): 175.7 (C11), 155.2 (C6a), 152.1 
(C8), 150.5 (C12a), 146.6 (C9), 145.9 (C5), 143.4 (C5a), 122.8 (C4a), 121.5 (C11a), 
114.3 (C10a), 107.1 (C12), 105.4 (C10), 99.7 (C7), 74.3 (C2), 61.1 (C1’’), 56.5 and 56.3 
(C1’’’ and C1’’’’), 31.8 (C3), 26.7 (C1’a and C1’b), 18.2 (C4). EIMS m/z (%): 371 (25, 
[M+1]+.), 370 (100, [M]+.), 355 (8), 316 (11), 316 (62), 314 (50), 299 (8), 286 (8), 285 (26), 
271 (16), 257 (10), 243 (10), 207 (7), 170 (11). HRMS (ESI) m/z calcd for C21H23O6 
[M+H]+: 371.14891; found: 371.14872.  
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5.1.8 Synthesis of compounds XBp25, XBp26, XBp27 and 
XBp28 
5.1.8.1 Synthesis of the building blocks 103 and 105: 
2,4-Dimethoxy-1-((2-methylbut-3-yn-2-yl)oxy)benzene (104): 
To a solution of 2-methyl-3-butyn-2-ol (4.71 g, 56 mmol) in 100 mL of anhydrous CH3CN 
under nitrogen, cooled in a salt ice-bath (-5°C) was added DBU (11.11 mL, 73 mmol) 
followed by trifluoroacetic anhydride dropwise (7.79 mL, 56 mmol). The reaction mixture 
was slowly warmed to 0 ºC over 30 minutes. In another flask, 2,3-dimethoxyphenol (7.5 g, 
48.6 mmol) was dissolved in 100 mL of anhydrous CH3CN and placed under nitrogen at -5 
ºC. To this solution was added DBU (9.62 mL, 63.2 mmol) followed by anhydrous CuCl2 
(6.5 mg, 0.0486 mmol, 0.1 mol %). To the latter reaction mixture was added dropwise via 
canulla the ice-cold solution of the freshly prepared 1,1-dimethyl-2-propynyl 
trifluoroacetate in CH3CN. The resulting reaction mixture was warmed to 0 ºC and stirred 
for 7 hours. The mixture was warmed to room temperature and concentrated to 100 mL. 
Then it was partitioned between 250 mL of distilled water and 250 mL of diethyl ether. The 
aqueous phase was extracted with 2 x 250 mL of diethyl ether. The organic phase was 
washed with 2 x 150 mL of a 5 % of solution of HCl, with 2 x 150 mL of a solution of 
NaOH 1M and with 1 x 150 mL of brine. The organic phase was dried over anhydrous 
sodium sulfate and the organic solvent evaporated. The crude product was purified by 
silica gel flash chromatography (n-hexane/ethyl acetate 9:1). Compound 104 was 
obtained as colorless oil (6.2151g/58 %). 
2,4-Dimethoxy-1-((2-methylbut-3-yn-2-yl)oxy)benzene (104). IR ȣmax (cm-1) (KBr): 3298, 
3266, 2987, 2936, 2834, 2338, 2323, 1590, 1475, 1090, 740, 653. 1H NMR (300.13 MHz, 
CDCl3) į (ppm): 7.13 (dd, J = 8.3, 1.4), 6.98 (t, J = 8.2), 6.67 (d, J= 8.3, 1.4), 3.86 (s, 
OCH3), 3.85 (s, OCH3), 2.55 (s, 1H), 1.68 (s, 6H). EIMS m/z (%): 221 (8, [M+1]+.), 220 (19, 
[M]+.), 189 (15), 154 (100), 139 (50), 95 (21), 93 (32). 
7,8-Dimethoxy-2,2-dimethyl-2H-benzopyran (103): 
In a closed vessel was placed a solution of compound 105 (6.19 g/28.1 mmol) in 
anhydrous DMF (20 mL). The mixture was heated 145 ºC for 4 hours. After cooling to 
room temperature, the mixture was poured into 150 g of crushed ice and extracted with 3 
x 150 mL of diethyl ether. The organic phase was washed with 2 x150 mL of brine, dried 
over sodium sulfate anhydrous, filtered and the organic solvent evaporated. The crude 
product was purified by silica gel flash chromatography (n-hexane/ ethyl acetate 95:5). 
Compound 145 was obtained as colorless oil (4.1113 g, 66 %). 
7,8-Dimethoxy-2,2-dimethyl-2H-benzopyran (103). IR ȣmax (cm-1) (KBr): 2973, 2934, 2933, 
1605, 1496, 1455, 1098, 797, 646. 1H NMR (300.13 MHz, CDCl3) į (ppm): 6.69 (d, J = 
8.4), 6.42 (d, J = 8.4), 6.28 (d, J = 9.8), 5.52 (d, J= 9.8), 3.87 (s, OCH3), 3.85 (s, OCH3), 
1.48 (s, 6H). 13C NMR (75.47 MHz, CDCl3): 153.5, 146.5, 137.5, 128.5, 122.1, 120.8, 
116.3, 103.8, 76.4, 60.9, 56.0, 27.9. EIMS m/z (%): 221 (6, [M+1]+.), 220 (19, [M]+.), 205 
(100), 190 (21), 161 (38), 144 (19), 91 (11). 
3,4-Dimethoxy-2-(methoxymethoxy)benzaldehyde (105): 
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in a two-necked round-bottom flask was placed sodium hydride (312 mg/7.8 mmol of 60% 
sodium hydride in mineral oil) and rinsed with anhydrous n-hexane. The flask was then 
placed under nitrogen atmosphere and on an ice-bath. 3,4-Dimethyoxybenzaldehyde (716 
mg/3.9 mmol) was solubilized in 20 mL of anhydrous THF and added slowly to the flask 
containing the sodium hydride. The mixture was allowed to stir for 15 minutes and MOMCl 
(626 mg/7.9 mmol) was added dropwise and the flask placed under reflux overnight. The 
mixture was cooled to room temperature and poured over 50 g of crushed ice. The 
aqueous phase was extracted with 3 x 50 mL of ethyl acetate. The organic phase was 
then washed with 2 x 50 mL of brine, dried over sodium sulfate anhydrous, filtered and the 
organic solvent evaporated. The crude product was purified by silica gel flash 
chromatography (n-hexane/ethyl acetate 9:1). Compound 147 was obtained as white solid 
(726 mg/82 %).  
3,4-Dimethoxy-2-(methoxymethoxy)benzaldehyde (105). Mp: 56-57 ºC. IR ȣmax (cm-1) 
(KBr): 2987, 2932, 2846, 1679, 1590, 1290, 1068, 973, 807, 778. 1H NMR (300.13 MHz, 
CDCl3) į (ppm): 10.30 (s, CHO), 7.64 (d, J = 8.8), 6.79 (d, J = 8.8), 5.28 (s, 2H), 3.94 (s, 
OCH3), 3.86 (s, OCH3), 3.57 (s, OCH3). EIMS m/z (%): 227 (25, [M+1]+.), 226 (25, [M]+.), 
197 (28), 195 (32), 180 (96), 166 (100), 152 (96), 123 (45), 95 (32). 77 (34), 51 (30). 
 
5.1.8.2 Synthesis of XBp25: 
 (7,8-Dimethoxy-2,2-dimethyl-2H-benzopyran-6-yl)(3,4-dimethoxy-2-
(methoxymethoxy)phenyl)methanol (106): 
In a two-necked round-bottom flask was placed compound 103 (300 mg/1.63 mmol) 
solubilized in 5 mL of anhydrous THF and TMEDA (190 mg, 1.05 mmol). The mixture was 
then placed at 0 ºC and nBuLi (1.6 M, 1.63 mmol) was added dropwise. The mixture was 
allowed to react for 30 min at 0 ºC. Then the benzaldehyde 105 (308 mg/1.36 mmol) was 
added and allowed to react for 1h 30 min at 0 ºC and 6 hours at room temperature. The 
reaction was quenched by a saturated solution of NH4Cl, extracted with 3 x 20 mL of ethyl 
acetate. The organic phase was washed 2 x 25 mL of brine, dried over sodium sulfate 
anhydrous, filtered and the organic solvent evaporated. The crude product was purified by 
flash chromatography (n-hexane/ethyl acetate 8:2). We were unable to purify compound 
106 and it was obtained 156 mg of impure yellow oil. 
EIMS m/z (%): 446 (15, [M]+.), 431 (20), 401 (15), 353 (100), 249 (25), 233 (20). 
(7,8-Dimethoxy-2,2-dimethyl-2H-benzopyran-6-yl)(3,4-dimethoxy-2-
(methoxymethoxy)phenyl)methanone (107): 
In a round-bottom flask was placed an impure solution of compound 106 (150 mg) in 1 mL 
of DMSO. Then it was added IBX (98 mg/0.35 mmol). After 12 hours the reaction was 
quenched with the addition of a solution of Na2S2O3 10%, saturated NaHCO3 and water. 
The aqueous phase was then extracted with 3 x 25 mL of ethyl acetate. The organic 
phase was washed with 2 x 25 mL of a 10% solution of Na2S2O3, 2 x 25 mL of a saturated 
solution of NaHCO3, dried over sodium sulfate anhydrous, filtered and the organic solvent 
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evaporated. The crude product was purified by silica gel column chromatography (n-
hexane/ethyl acetate 8:2) and 63 mg of impure benzophenone 107 was isolated. 
EIMS m/z (%): 444 (10, [M]+.), 429 (20), 413 (95), 383 (30), 353 (20), 249 (100). 
(7,8-Dimethoxy-2,2-dimethyl-2H-benzopyran-6-yl)(2-hydroxy-3,4-
dimethoxyphenyl)methanone (108): 
In a round-bottom flask was placed benzophenone 107 (55 mg impure) in 1.5 mL of 
CH3CN. The solution was placed at 0 ºC and NbCl5 (33.5 mg, 0.12 mmol) was added in 
one portion. The mixture was stirred at 0ºC for 10 minutes and then allowed to warm to 
room temperature and let stirring for more 45 minutes. After this time, the reaction was 
quenched with saturated solution of NaHCO3. The mixture was extracted with 3 x 15 ml of 
ethyl acetate. The organic phase was washed with 2 x 100 ml of brine, dried over sodium 
sulfate anhydrous and the organic solvent evaporated. Compound 108 was used in the 
next reaction without further purification. 
EIMS m/z (%): 400 (15, [M]+.), 385 (70), 369 (100), 339 (40), 205 (80). 
9,10,12-Trimethoxy-2,2-dimethylpyrano[3,2-b]xanthen-6(2H)-one (XBp25): 
In a two-necked round-bottom flask was placed a solution of compound 108 (impure 
mixture of the previous reaction) in 1 mL of DMF and then it was added Cs2CO3 (58 mg, 
0.18 mmol).  The mixture was stirred at 50ºC for 16 hours. The mixture was allowed to 
cool to room temperature and poured into crushed ice. The aqueous phase was then 
extracted with 3 x 50 mL of diethyl ether. The organic phase was washed with 2 x 50 ml of 
brine, dried over sodium sulfate anhydrous, filtered and the organic solvent evaporated. 
The crude product was purified by silica gel flash chromatography (n-hexane/ethyl acetate 
8:2). Compound 30 was obtained as light yellow solid (10 mg). 
9,10,12-Trimethoxy-2,2-dimethylpyrano[3,2-b]xanthen-6(2H)-one (XBp25). Mp: 174-175 
ºC. IR ȣmax (cm-1) (KBr): 2971, 2936, 2911, 1644, 1605, 1436, 1277, 1128, 776. 1H NMR 
(300.13 MHz, CDCl3): 8.09 (d, J = 9.0; H-C(7)), 7.75 (s; H-C(5)), 7.04 (d, J = 9.0; H-C(8)), 
6.49 (d, J = 10.0; H-C(4)), 5.78 (d, J = 10.0; H-C(3)), 4.14 (s; H3OC-C(10)), 4.11 (s; H3OC-
C(12)), 4.05 (s, H3OC-C(9)), 1.59 (s, (CH3)2-C(2)). 13C NMR (125.8 MHz, CDCl3): 175.8 
(C6), 157.1 (C10a), 151.3 (C12a), 150.8 (C9), 150.3 (C11a), 136.6 (C10), 135.8 (C12), 
131.0 (C3), 121.6 (C4), 120.0 (C7), 118.9 (C4a), 118.0 (C5), 116.5 (C5a), 115.7 (C6a), 
108.5 (C8), 78.0 (C2), 61.5 (C1’’), 61.4 (C1’’’), 56.4 (C1’’’’), 28.4 (C1’a and C1’b). EIMS 
m/z (%): 368 (30, [M]+.), 353 (100), 323 (20), 207 (25). HRMS (ESI) m/z calcd for C21H21O6 
[M+H]+: 369.13326; found: 369.13316.  
5.1.8.3 Synthesis of the building blocks 110 and 111: 
7,8-Dimethoxy-2,2-dimethyl-3,4-dihydropyran (109):  
In a two-necked round-bottom flask was placed compound 103 (2.65 g/12 mmol) and 2 
mL of anhydrous methanol in nitrogen atmosphere. To the solution was added Pd/C 10 % 
(15 % weight/395 mg) in one portion. Triethylsilane (19.2 mL, 120 mmol) was then added 
dropwise. The mixture was allowed to stir for 15 minutes. The product was filtered over 
celite and washed 3 times with methanol. The methanol was evaporated and the crude 
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product was purified by silica gel column chromatography (n-hexane/ethyl acetate 9:1). 
Compound 109 was isolated as yellowish oil (2.65 g/99 %). 
7,8-Dimethoxy-2,2-dimethyl-3,4-dihydropyran (109). IR ȣmax (cm-1) (KBr): 2975, 2932, 
2833, 1609, 1496, 1457, 1293, 1153, 1100, 1058, 955, 788. 1H NMR (400.21 MHz, 
CDCl3) į (ppm): 6.67 (dt, J = 8.3, 0.9), 6.37 (d, J = 8.3), 3.75 (s, 2 x OCH3), 2.66 (td, J = 
6.7, 0.9, 2H), 1.71 (t, J= 6.7, 2H), 1.30 (s, 6H). EIMS m/z (%): 222 (6, [M]+.), 167 (100), 
151 (17), 106 (12). 
6-Bromo-7,8-dimethoxy-2,2-dimethyl-3,4-dihydrobenzopyran (110): 
In a two-necked round-bottom flask was placed compound 109 (2.6 g/11.7 mmol), NBS 
(2.19 g/12.28 mmol), NH4OAc (90 mg/1.17 mmol) and 100 mL of CH3CN. The mixture 
was allowed to stir for 20 minutes at room temperature and then the CH3CN was 
evaporated. The crude product was partitioned between water and ethyl acetate. The 
aqueous phase was then extracted 2 x 250 mL of ethyl acetate. The organic phase was 
washed 2 x 250 mL with brine, dried over sodium sulfate anhydrous, filtered and the 
organic solvent evaporated. The crude product was purified by silica gel column 
chromatography (n-hexane/ethyl acetate 95:5). Compound 110 was isolated as colorless 
oil (3.4 g/96 %). 
6-Bromo-7,8-dimethoxy-2,2-dimethyl-3,4-dihydrobenzopyran (110). IR ȣmax (cm-1) (KBr): 
2975, 2933, 1461, 1419, 1339, 1205, 1097, 1050, 851. 1H NMR (400.21 MHz, CDCl3) į 
(ppm): 7.01 (t, J = 1.0), 3.89 (s, OCH3), 3.87 (s, OCH3), 2.74 (td, J = 6.7, 1.0, 2H), 1.80 (t, 
J= 6.7, 2H), 1.39 (s, 6H). EIMS m/z (%): 302 (50, [M+2]+.) 300 (50, [M]+.), 247 (95), 245 
(100), 231 (17), 229 (19). 
2-(Benzyloxy)-5-methylsalicylaldehyde (111): 
In a two-necked round-bottom flask was placed 5-methylsalicylaldehyde (44) (1 g/ 7.3 
mmol) and then it was added Cs2CO3 (3.59 g/11 mmol), benzyl bromide (1.88 g/ 11 mmol) 
and 50 mL of acetone. The mixture was allowed to stir at room temperature overnight. 
The product was then filtrated and washed with acetone. The solvent was evaporated and 
the crude product purified by silica gel column chromatography (n-hexane/ethyl acetate 
95:5). Compound 111 was obtained as white solid (1.5 g/ 93%). 
2-(Benzyloxy)-5-methylsalicylaldehyde (111). Mp: 55-56 ºC. IR ȣmax (cm-1) (KBr): 2919, 
2864, 2760, 1677, 1606, 1490, 1453, 1381, 1280, 1244, 1154, 1110, 1025, 817, 733, 721, 
686, 647. 1H NMR (300.13 MHz, CDCl3) į (ppm): 10.52 (s, CHO), 7.67 (d, J= 2.7), 7.43-
7.28 (m, 6H), 6.92 (d, J = 8.5), 5.12 (s, 2H), 2.28 (s, 3H). EIMS m/z (%): 226 (2.5, [M]+.), 
198 (4), 197 (7), 135 (9), 92 (8), 91 (100), 65 (14), 51 (4). 
5.1.8.4 Synthesis of XBp26, XBp27 and XBp28: 
Synthesis of diarylmethanol derivatives 112-114: 
In a typical Experiment: in a two-necked round-bottom flask was placed compound 110 
(800 mg/2.7 mmol) solubilized in 25 mL of anhydrous THF. The mixture was then placed 
at -78 ºC and nBuLi (1.6 M, 3.24 mmol) was added dropwise. The mixture was allowed to 
react for 15 min at -78 ºC. Then the benzaldehyde 54 (882 mg/3.24 mmol) solubilized in 
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anhydrous THF was added dropwise and allowed to react for 1 hour and 30 mintutes at -
78 ºC and slowly warm to room temperature (about 6h). The reaction was quenched by 
addition of a saturated solution of NH4Cl. The aqueous phase was extracted with 3 x 50 
mL of ethyl acetate. The organic phase was washed 2 x 50 mL of brine, dried over sodium 
sulfate anhydrous, filtered and the oraganic solvent evaporated. The crude product was 
then purified by silica gel flash chromatography (n-hexane/ethyl acetate 8:2). Compound 
114 was obtained (652 mg/48 %) as yellow oil. 
(2,4-Bis(methoxymethoxy)phenyl)(7,8-dimethoxy-2,2-dimethyl-3,4-dihydrobenzopyran-6-
yl)methanol (112) as a yellow oil (460 mg/38%). IR ȣmax (cm-1) (KBr): 3503, 3447, 2971, 
2934, 2829, 1606, 1464, 1153, 1106, 1072, 1010, 923. 1H NMR (400.21 MHz, CDCl3) į 
(ppm): 7.23 (d, J = 8.5), 6.78 (d, J = 2.3), 6.70 (dd, J = 8.5, 2.3), 6.69 (broad s), 6.25 (d, J 
= 3.7, 1H), 5.19 (d, J = 6.7, 1H), 5.15 (s, 2H), 5.12 (d, J = 6.7, 1H) 3.83 (s, OCH3), 3.78 (s, 
OCH3), 3.48 (s, OCH3), 3.35 (s, OCH3), 3.00 (d, J = 3.7, OH), 2.68 (td, J = 6.9, 2.0, 2H), 
1.74 (t, J = 6.9, 2H), 1.34 (s, 3H), 1.32 (s, 3H). 
(2-(Benzyloxy)-5-methylphenyl)(7,8-dimethoxy-2,2-dimethyl-3,4-dihydrobenzopyran-6-
yl)methanol (113) as a yellow oil (730 mg/58 %). IR ȣmax (cm-1) (KBr): 3474, 3442, 2975, 
2931, 2860, 1494, 1463, 1343, 1241, 1106, 736. 1H NMR (400.21 MHz, CDCl3) į (ppm): 
7.32-7.21 (m, 6H), 7.02 (dd, J = 8.3, 2.1), 6.81 (d, J = 8.3), 6.59 (s), 6.25 (broad s), 5.03 
(d, J = 11.4, 1H), 4.99 (d, 1H, J = 11.4), 3.82 (s, OCH3), 3.67 (s, OCH3), 3.00 (broad s, 
OH), 2.60 (t, J = 6.8, 2H), 2.30 (s, CH3), 1.75 (t, J = 6.7, 2H), 1.37 (s, 3H),1.34 (s, 3H). 
(2-(Benzyloxy)-4,5-dimethoxyphenyl)(7,8-dimethoxy-2,2-dimethyl-3,4-dihydrobenzopyran-
6-yl)methanol (114) as a yellow oil (652 mg/48 %). IR ȣmax (cm-1) (KBr): 3518, 3493, 2965, 
2926, 2832, 1537, 1504, 1457, 1337, 1202, 1104, 1019, 876. 1H NMR (400.21 MHz, 
CDCl3) į (ppm): 7.31-7.23 (m, 5H), 7.04 (s), 6.57 (s), 6.52 (s), 6.25 (d, J = 3.9, 1H), 5.00 
(d, 1H, J = 11.5), 4.96 (d, 1H, J = 11.5), 3.85 (s, OCH3), 3.84 (s, OCH3), 3.83 (s, OCH3), 
3.71 (s, OCH3), 3.05 (d, J = 3.9, OH), 2.59 (t, J = 6.8, 2H), 1.75 (t, J = 6.8, 2H), 1.37 (s, 
3H),1.34 (s, 3H). 
Synthesis of benzophenone derivatives 115-117: 
In a typical experiment: in a round-bottom flask was placed compound 112 (450 mg/1.0 
mmol) and 10 mL of DMSO. Then it was added IBX (420 mg/1.5 mmol). After 12 hours 
the reaction was quenched with the addition of a 10% solution of Na2S2O3, a saturated 
solution of NaHCO3 and distilled water. The aqueous phase was then extracted with 3 x 
50 mL of ethyl acetate. The organic phase was washed with 2 x 50 mL of a 10% solution 
of Na2S2O3, 2 x 50 mL of a saturated solution of NaHCO3, dried over sodium sulfate 
anhydrous, filtered and the organic solvent evaporated. The crude product was purified by 
silica gel flash chromatography (n-hexane/ethyl acetate 8:2) and compound 157 was 
isolated as yellow oil (380 mg/85 %). 
(2,4-Bis(methoxymethoxy)phenyl)(7,8-dimethoxy-2,2-dimethyl-3,4-dihydrobenzopyran-6-
yl)methanone (115) as a yellow oil (380 mg/85 %). IR ȣmax (cm-1) (KBr): 2973, 2935, 2830, 
1652, 1601, 1464, 1343, 1308, 1156, 1116, 1075, 1000, 923, 848, 793. 1H NMR (400.21 
MHz, CDCl3) į (ppm): 7.44 (d, J = 8.5), 7.06 (s), 6.80 (d, J = 2.3), 6.72 (dd, J = 8.5, 1.4), 
5.20 (s, 2H), 5.03 (s, 2H), 3.82 (s, OCH3), 3.62 (s, OCH3), 3.49 (s, OCH3), 3.32 (s, OCH3), 
2.75 (t, J = 6.9, 2H), 1.82 (t, J = 6.9, 2H), 1.40 (s, 6H). EIMS m/z (%): 447 (3, [M+1]+.), 446 
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(10, [M]+.), 416 (25), 415 (100), 385 (38), 383 (19), 359 (12), 315 (31), 249 (12), 235 (18), 
211 (26), 193 (14), 179 (12), 69 (10). 
(2-(Benzyloxy)-5-methylphenyl)(7,8-dimethoxy-2,2-dimethyl-3,4-dihydrobenzopyran-6-
yl)methanone (116) as a yellow solid (460 mg/66 %). Mp: 114-115 ºC. IR ȣmax (cm-1) 
(KBr): 2975, 2924, 2865, 1649, 1604, 1498, 1459, 1340, 1247, 1149, 1108, 1026, 987, 
804, 734. 1H NMR (400.21 MHz, CDCl3) į (ppm): 7.33 (d, J = 2.3), 7.22-7.18 (m, 4H), 7.14 
(s), 7.01-6.98 (m, 2H), 6.87 (d, J = 8.3), 4.94 (s, 2H), 3.71 (s, OCH3), 3.52 (s, OCH3), 2.73 
(t, J = 6.7, 2H), 2.83 (s, CH3), 1.81 (t, J = 6.7, 2H), 1.39 (s, 6H). 
(2-(Benzyloxy)-4,5-dimethoxyphenyl)(7,8-dimethoxy-2,2-dimethyl-3,4-dihydrobenzopyran-
6-yl)methanone (117) as a yellow solid (580 mg/96 %). Mp: 128-129 ºC. IR ȣmax (cm-1) 
(KBr): 2973, 2930, 2843, 1642, 1604, 1513, 1450, 1404, 1341, 1276, 1210, 1111, 1026 
732. 1H NMR (400.21 MHz, CDCl3) į (ppm): 7.23-7.20 (m, 4H), 7.03 (s), 6.97-6.95 (m, 
2H), 6.55 (s), 4.90 (s, 2H), 3.92 (s, OCH3), 3.90 (s, OCH3), 3.69 (s, OCH3), 3.60 (s, OCH3), 
2.72 (t, J = 6.7, 2H), 1.79 (t, J = 6.7, 2H), 1.38 (s, 6H). 
Synthesis of benzophenones 118-120: 
Methoxymethyl ether removal: 
To a solution of compounds 115 (227 mg, 0.51 mmol) in 5 mL of CH3CN at 0 ºC was 
added in one portion NbCl5 (138 mg, 0.19 mmol). The mixture was stirred at 0ºC for 10 
minutes and then allowed to warm to room temperature and let stirring for more 45 
minutes and the reaction mixture was quenched with a saturated solution of NaHCO3. The 
mixture was extracted with 3 x 25 ml of ethyl acetate. The organic phase was washed with 
2 x 50 ml of brine, dried over sodium sulfate anhydrous, filtered and the organic solvent 
evaporated. Compound 118 was obtained as yellow oil (172 mg/94 %) and used in the 
next reaction without further purification 
(2,4-Dihydroxyphenyl)(7,8-dimethoxy-2,2-dimethyl-3,4-dihydrobenzopyran-6-
yl)methanone (118). IR ȣmax (cm-1) (KBr): 3328, 2975, 2932, 2857, 1606, 1460, 1353, 
1239, 1114, 989, 799. 1H NMR (400.21 MHz, CDCl3) į (ppm): 12.68 (OH), 7.34 (d, J = 
8.8), 6.78 (s), 6.41 (d, J = 2.5), 6.30 (dd, J = 8.8, 2.5), 3.88 (s, OCH3), 3.79 (s, OCH3), 
2.75 (t, J = 6.7, 2H), 1.83 (t, J = 6.7, 2H), 1.41 (s, 6H). EIMS m/z (%): 345 (5, [M]+.), 328 
(21), 327 (100), 303 (7), 272 (10), 271 (52), 192 (26), 151 (4), 137 (42), 123 (6), 115 (5), 
107 (5), 107 (5), 91 (6), 81 (13), 79 (6), 77 (7), 69 (11), 53 (10). 
Benzyl ether removal: 
In a typical experiment: in a two-necked round-bottom flask were placed compound 117 
(344 mg/0.68 mmol) and 25 mL of anhydrous methanol/ THF (1:1) in nitrogen 
atmosphere. To the solution was added Pd/C 10 % (15 % weight/52 mg) in one portion. 
Triethylsilane (1.1 mL, 6.8 mmol) was then added dropwise. The mixture was allowed to 
stir for 15 minutes. The product was filtered over celite and washed 3 times with methanol. 
The methanol was then evaporated and the crude product was purified by silica gel 
column chromatography (n-hexane/ethyl acetate 8:2). Compound 120 was isolated as 
yellowish oil (180 mg/67 %). 
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(7,8-Dimethoxy-2,2-dimethyl-3,4-dihydrobenzopyran-6-yl)(2-hydroxy-5-
methylphenyl)methanone (119) as yellow oil (110 mg/77 %). IR ȣmax (cm-1) (KBr): 3328, 
2976, 2934, 1629, 1601, 1474, 1349, 1110, 1072, 989, 828, 767, 670. 1H NMR (400.21 
MHz, CDCl3) į (ppm): 12.02 (OH), 7.28 (dd, J = 8.4, 2.3), 7.21 (d, J = 2.3), 6.93 (d, J = 
8.4), 6.80 (t, J = 0.8), 3.88 (s, OCH3), 3.79 (s, OCH3), 2.77 (td, J = 6.7, 0.8, 2H), 2.23 (s, 
CH3), 1.85 (t, J = 6.7, 2H), 1.43 (s, 6H). EIMS m/z (%): 357 (12, [M+1]+.), 356 (1, [M]+.), 
355 (2), 325 (16), 270 (20), 269 (100), 226 (8), 222 (10), 193 (47), 168 (11), 167 (63), 165 
(10), 135 (20), 115 (10), 91 (11), 79 (11), 77 (31), 51 (11). 
(7,8-Dimethoxy-2,2-dimethyl-3,4-dihydrobenzopyran-6-yl)(2-hydroxy-4,5-
dimethoxyphenyl)methanone (120) as yellow oil (180 mg/67 %). IR ȣmax (cm-1) (KBr): 
3473, 2974, 2936, 2857, 1619, 1505, 1461, 1350, 1268, 1203, 1153, 1110, 1071, 829. 1H 
NMR (400.21 MHz, CDCl3) į (ppm): 12.70 (OH), 6.86 (s), 6.83 (s), 6.51 (s) 3.94 (s, 
OCH3), 3.88 (s, OCH3), 3.79 (s, OCH3), 3.70 (s, OCH3), 2.77 (t, J = 6.7, 2H), 1.84 (t, J = 
6.7, 2H), 1.42 (s, 6H). EIMS m/z (%): 402 (12, [M]+.), 372 (28), 371 (79), 355 (6), 315 (30), 
281 (19), 222 (41), 209 (10), 208 (14), 207 (68), 193 (10), 191 (11), 181 (17), 168 (10), 
167 (100), 166 (13), 165 (11), 147 (11), 133 (10), 96 (11), 73(22). 
Synthesis of XBp26, XBp27 and XBp28: 
In a typical experiment: To a solution of compound 119 (186 mg, 0.52 mmol) in 3 mL of 
DMF was added K2CO3 (142 mg, 1.03 mmol).  The mixture was irradiated with microwave 
(200 W max) for 15 minutes at 140 ºC. The mixture was allowed to cool to room 
temperature and poured into crushed ice. The aqueous phase was then extracted with 3 x 
50 mL of diethyl ether. The organic phase was washed with 2 x 50 ml of brine, dried over 
sodium sulfate anhydrous, filtered and the organic solvent evaporated. The crude product 
was purified by silica gel flash chromatography (n-hexane/ ethyl acetate 8:2). Compound 
XBp27 was obtained as light yellow solid (160 mg, 95 %). 
9-Hydroxy-12-methoxy-2,2-dimethyl-3,4-dihydropyrano[3,2-b]xanthen-6(2H)-one (XBp26) 
as a white solid (64 mg/42 %). Mp: 286-287 ºC. IR ȣmax (cm-1) (KBr): 3227, 2973, 2940, 
2840, 1646, 1611, 1574, 1444, 1349, 1202, 1116. 1H NMR (400.21 MHz, DMSO-d6) į 
(ppm): 7.99 (d, J = 8.5; H-C(7)), 7.66 (s; H-C(5)), 6.87 (dd, J = 8.5, 2.3; H-C(8)), 6.85 (d, J 
= 2.3; H-C(10)), 3.87 (s; H3CO-C(12)), 2.89 (t, J = 6.7; H2-C(4)), 1.86 (t, J = 6.7; H2-C(3)), 
1.38 (s; (CH3)2-C(2)). 13C NMR (100.63 MHz, DMSO-d6) į (ppm): 174.1 (C6), 163.7 (C9), 
157.5 (C10a), 148.3 (C12a), 147.8 (C11a), 135.2 (C12), 127.8 (C7), 120.3 (C5), 119.3 
(C4a), 114.4 (C6a), 113.8 (C8), 113.8 (C6a), 102.2 (C10), 76.3 (C2), 60.7 (C1’’), 31.5 
(C3), 26.7 (C1’a and C1b), 21.5 (C4). HRMS (ESI) m/z calcd for C19H19O5 [M+H]+: 
327.12270; found: 327.12258.   
12-Methoxy-2,2,8-trimethyl-3,4-dihydropyrano[3,2-b]xanthen-6(2H)-one (XBp27) as a 
yellowish solid (160 mg/95 %). Mp: 101-102 ºC. IR ȣmax (cm-1) (KBr): 2972, 2926, 2846, 
1655, 1609, 1480, 1446, 1312, 1117, 1083, 781. 1H NMR (400.21 MHz, CDCl3) į (ppm): 
8.09 (d, J = 2.1; H-C(7)), 7.85 (t, J = 1.0; H-C(5)), 7.50 (dd, J = 8.3, 2.1; H-C(9)), 7.46 (d, J 
= 8.3; H-C(10)), 3.99 (s; H3CO-C(12)), 2.93 (td, J = 6.8, 1.0; H2-C(4)), 2.46 (s; H3C-C(8)), 
1.89 (t, J = 6.8; H2-C(3)), 1.45 (s, (CH3)2-C(2)). 13C NMR (100.63 MHz, CDCl3) į (ppm): 
176.7 (C6), 154.5 (C10a), 153.1 (C11a), 149.2 (C11a), 135.7 (C12), 135.5 (C9), 133.4 
(C8), 125.9 (C7), 121.3 (C5), 121.2 (C6a), 119.2 (C4a), 117.8 (C10), 115.2 (C5a), 76.4 
(C2), 61.2 (C1’’), 32.4 (C3), 27.0 (C1’a and C1’b), 22.2 (C4), 20.8 (C1’’’). EIMS m/z (%): 
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325 (10, [M+1]+.), 324 (47, [M]+.), 307 (4), 293 (4), 270 (18), 269 (100), 268 (25), 267 (15), 
239 (9), 197 (6), 141 (5), 115 (10), 91 (4), 77 (4). HRMS (ESI) m/z calcd for C20H21O4 
[M+H]+: 325.14344; found: 325.14330.  
8,9,12-Trimethoxy-2,2-dimethyl-3,4-dihydropyrano[3,2-b]xanthen-6(2H)-one (XBp28) as a 
yellowish solid (140 mg/83 %). MP: 228-229 ºC. IR ȣmax (cm-1) (KBr): 2968, 2928, 2832, 
1644, 1613, 1483, 1432, 1309, 1274, 1202, 1148, 1202, 1148, 1089, 1103, 784. 1H NMR 
(400.21 MHz, CDCl3) į (ppm): 7.84 (t, J= 1.0; H-C(5)), 7.66 (s; H-C(7)), 7.03 (s; H-C(10)), 
4.02 (s, H3CO-C(9)), 4.00 (s, 2 x H3CO-C(12) and C(8)), 2.94 (td, J = 6.8, 1.0; H2-C(4)), 
1.96 (t, J = 6.8; H2-C(3)), 1.45 (s; (CH3)2-C(2)). 13C NMR (100.63 MHz, CDCl3) į (ppm): 
175.6 (C6), 154.9 (C10a), 152.5 (C12a), 152.4 (C9), 149.0 (C11a), 146.4 (C8), 135.7 
(C12), 121.0 (C5), 119.2 (C7), 115.0 (C4), 114.5 (C5a), 105.5 (C6a), 100.0 (C10), 76.3 
(C2), 61.2 (C1’’), 56.5 (C1’’’), 56.4 (C1’’’’), 32.5 (C3), 27.0 (C1’a and C1’b), 22.2 (C4). 
EIMS m/z (%): 371 (14, [M+1]+.), 370 (57, [M]+.), 355 (12), 316 (20), 315 (100), 314 (28), 
313 (9), 300 (9), 299 (7), 285 (9), 170 (5). HRMS (ESI) m/z calcd for C21H23O6 [M+H]+: 
371.14891; found: 371.14872.  
5.1.9 Synthesis of XP13 and XBp29, XBp30, XBp31, 
XBp32 and XBp33 
5.1.9.1 Synthesis of the building block 121 and 127: 
2-(Benzyloxy)-3-methoxybenzaldehyde (121): 
In a round-bottom flask was placed o-vanillin (1.5 g/ 9.3 mmol) was placed in a round-
bottom flask and then it was added K2CO3 (1.92 g/14 mmol), benzyl bromide (2.37 g/ 14 
mmol) and 50 mL of acetone. The mixture was allowed to stir at reflux for 2 h. The product 
was then filtrated and washed with acetone. The solvent was evaporated and the crude 
product purified by silica gel column chromatography (n-hexane/ethyl acetate 95:5). 
Compound 121 was obtained as light yellow oil that solidified upon standing in quantitative 
yield. 
2-(Benzyloxy)-3-methoxybenzaldehyde (121). IR ȣmax (cm-1) (KBr): 3086, 3060, 2959, 
2938, 1896, 1874, 2837, 1690, 1582, 1479, 1454, 1439, 1367, 1309, 1268, 1248, 1217, 
1184, 100, 1060, 963, 909, 780, 752, 696. 1H NMR (300.13 MHz, CDCl3) į (ppm): 10.23 
(s, CHO), 7.40-7.32 (6H, m), 7.20-710 (2H, m), 5.18 (s, 2H), 3.94 (s, OCH3). EIMS m/z 
(%): 242 (3, [M]+.), 214 (8), 213 (25), 181 (5), 151 (8), 122 (6), 92 (11), 91 (100), 77 (4), 65 
(39), 63 (10), 51 (16). 
2-(Benzyloxy)-3-methoxyphenol (122): 
To a three necked round-bottom flask with boric acid (1.27/20.7 mmol), 50 mL of 
anhydrous THF and 1.02 mL of H2O2 30 % was added 0.4 mL of H2SO4. The mixture was 
allowed to stir for 30 minutes and compound 121 (1 g, 4.1 mmol) solubilized in 20 mL of 
anhydrous THF was added dropwise. The mixture was stirred at r. t. for 54 hours. The 
solution was filtered and washed with diethyl ether. The organic phase was then washed 
with 3 x 100 mL of a saturated solution of NaHCO3, with 2 x 100 mL of brine, dried over 
sodium sulfate anhydrous, filtered and the organic solvent evaporated. The crude product 
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was purified by silica gel flash chromatography (n-hexane/ ethyl acetate 95:5) and 
compound 122 was isolated as white oil (416 mg, 54 %).  
2-(Benzyloxy)-3-methoxyphenol (122). IR ȣmax (cm-1) (KBr): 3507, 3060, 3032, 3008, 
2957, 2942, 2894, 2838, 1596, 1496, 1478, 1309, 1219, 1172, 1089, 973, 775, 750, 732, 
699. 1H NMR (300.13 MHz, CDCl3): 7.49-7.36 (5H, m), 6.94 (t, J = 8.3), 6.57 (dd, J = 8.3, 
1.3), 6.51 (dd, J = 8.3, 1.3), 5.63 (b, OH), 5.08 (s, 2H), 3.91 (s, OCH3). 13C NMR (75.47 
MHz, CDCl3) į (ppm): 152.5, 149.7, 137.2, 134.4, 128.7, 128.5, 124.2, 108.0, 104.0, 75.4, 
55.9. EIMS m/z (%): 230 (1, [M]+.), 181 (1), 92 (10), 91 (100), 89 (2), 65 (26), 63 (4), 53 
(2), 51 (7). 
3-Methoxycatechol: 
o-Vanillin (25 g/164 mmol) was solubilized in 600 mL of methanol and 22 mL of H2O2 30 
% was added. Then, KHSO4 (3.3 g/24.6 mmol) was added quickly and the solution was 
allowed to stir at room temperature for 48 hours. The reaction was quenched by the 
addition 200 mL of distilled water and the methanol evaporated. The aqueous phase was 
extracted with 3 x 300 mL of diethyl ether. The organic phase was washed with 2 x 250 
mL of brine, dried over sodium sulfate anhydrous, filtered and the organic solvent 
evaporated. The crude product was purified by silica gel flash chromatography 
(dichloromethane) obtaining 3-methoxycatechol as an orange oil (20.96 g/91 %) 
IR ȣmax (cm-1) (KBr): 3426, 2936, 1621, 1503, 1478, 1350, 1290, 1245, 1205, 1080, 765, 
714. EIMS m/z (%): 141 (2, [M+1]+.), 140 (24, [M]+.), 125 (23), 110 (7), 107 (3), 97 (87), 79 
(10), 77 (2), 68 (8), 65 (13), 63 (10), 53 (33), 52 (8), 51 (100). 
7-methoxy-2,2-dimethyl-3,4-dihydrobenzopyran-8-ol (123): 
In a two necked round-bottom flask was placed 3-methoxycatechol (1.5 g/10.7 mmol) and 
40 mL of an 80 % formic acid solution. The solution was heated to 80 ºC and then 2-
methyl-3-buten-2-ol was added dropwise (461 mg/5.35 mmol/ 560 μL) (over 10 minutes). 
The mixture was allowed to react for 1 hour and 30 min and then cooled to room 
temperature. The solution was poured over 100 mL of distilled water and neutralized with 
a saturated solution of NaHCO3 until pH 7-8. The aqueous phase was extracted with 3 x 
100 mL of diethyl ether. The organic phase was washed with 2 x 100 mL of brine, dried 
over sodium sulfate anhydrous, filtered and the organic solvent evaporated. The crude 
product was purified by silica gel flash chromatography (n-hexane/ethyl acetate 9:1) and 
compound 123 was isolated as light orange oil (398 mg/36 %). 
7-methoxy-2,2-dimethyl-3,4-dihydrobenzopyran-8-ol (123). IR ȣmax (cm-1) (KBr): 3461, 
2969, 2944, 2922, 2852, 2829, 1618, 1503, 1489, 1445, 1345, 1291, 1247, 1196, 1149, 
1111, 1083, 962, 779, 642. 1H NMR (300.13 MHz, CDCl3): 6.56 (dt, J = 8.7, 0.9), 6.46 (d, 
J = 8.7), 3.87 (s, OCH3), 2.74 (td, J = 6.7, 0.9, 2H), 1.81 (t, J = 6.7, 2 H), 1.38 (6H, s). 13C 
NMR (75.47 MHz, CDCl3) į (ppm): 145.3, 141.6, 134.1, 118.7, 114.5, 103.8, 75.1, 56.3, 
32.9, 26.8, 21.7. EIMS m/z (%): 209 (17, [M+1]+.), 208 (100 [M]+.), 193 (7), 161 (15), 154 
(8), 153 (84), 152 (17), 147 (5), 143 (8), 138 (8), 134 (10), 115 (10). 106 (16), 105 (27), 91 
(11), 78 (10), 77 (26), 76 (23), 65 (17), 63 (9), 53 (11), 51 (18). 
6-Bromo-7-methoxy-2,2-dimethyl-3,4-dihydrobenzopyran-8-ol (124) and 5-bromo-7-
methoxy-2,2-dimethyl-3,4-dihydrobenzopyran-8-ol (125): 
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In a two-necked round-bottom flask was placed compound 123 (100 mg/0.48 mmol), NBS 
(90 mg/0.504 mmol), NH4OAc (4 mg/0.048 mmol) and 3 mL of CH3CN. The mixture was 
allowed to stir for 15 minutes at room temperature. The solution was partitioned between 
water and ethyl acetate. The aqueous phase was then extracted 2 x 25 mL of ethyl 
acetate. The organic phase was washed 2 x 25 mL with brine, dried over sodium sulfate 
anhydrous, filtered and the organic solvent evaporated. The crude product was purified by 
silica gel flash chromatography (n-hexane/ethyl acetate 9:1). Compound 124 (35.5 mg/26 
%) and compound 125 (77 mg/ 56 %) were isolated as light yellow oils that crystallize 
upon standing. 
6-Bromo-7-methoxy-2,2-dimethyl-3,4-dihydrobenzopyran-8-ol (124). Mp: 69-70 ºC. IR ȣmax 
(cm-1) (KBr): 3455, 2960, 2922, 1556, 1449, 1415, 1310, 1248, 1186, 1107, 1018, 979, 
845, 452. 1H NMR (300.13 MHz, CDCl3): 6.81 (t, J = 0.7), 5.50 (b, OH), 3.89 (s, OCH3), 
2.72 (td, J = 6.7, 0.7, 2H), 1.83 (t, J = 6.7, 2H), 1.36 (s, 6H). EIMS m/z (%): 289 (1, 
[M+3]+.), 288 (7, [M+2]+.), 287 (1, [M+1]+.), 286 (7, [M]+.), 234 (17), 233 (17), 232 (32), 231 
(20), 230 (33), 207 (12), 192 (14), 186 (18), 184 (18), 109 (12), 105 (16), 91 (22), 79 (33), 
78 (17), 77 (59), 66 (11), 65 (40), 64 (6), 63 (18), 55 (10), 52 (14), 51 (100). 
5-bromo-7-methoxy-2,2-dimethyl-3,4-dihydrobenzopyran-8-ol (125). Mp: 70-72 ºC. IR ȣmax 
(cm-1) (KBr): 3412, 2961, 2916, 1850, 1823, 1606, 1483, 1436, 1341, 1244, 1211, 1148, 
1109, 1033, 783, 463. 1H-NMR (300 MHz, CDCl3): 6.73 (s), 5.50 (b, OH), 3.86 (s, OCH3), 
2.68 (t, J = 6.8, 2H), 1.83 (t, J = 6.7, 2H), 1.36 (6H, s). EIMS m/z (%): 289 (6, [M+3]+.), 288 
(29, [M+2]+.), 287 (7, [M+1]+.), 286 (31, [M]+.), 233(16), 232 (10), 231 (18), 230 (9), 208 
(16), 207 (100), 206 (62), 192 (15), 191 (25), 186 (24), 184 (24), 178 (10), 175 (19), 129 
(11), 105 (13), 91 (14), 79 (12), 78 (10), 77 (38), 65 (19), 63 (21), 52 (10), 51 (65). 
tert-Butyl((7-methoxy-2,2-dimethyl-3,4-dihydrobenzopyran-8-yl)oxy)dimethylsilane (126): 
In a two necked round-bottom flask of 100 mL was added compound 123 (500 mg/2.4 
mmol), imidazole (408.5 mg/6 mmol), and TBDMSCl (435 mg/2.9 mmol). The mixture was 
placed under nitrogen atmosphere and 5 mL of DMF anhydrous was added. The solution 
was allowed to react at 35 ºC for 5h. The solution was allowed to cool to room 
temperature and poured over 100 mL of distilled water and extracted with 3 x 50 mL of 
diethyl ether. The organic phase was washed with 2 x 50 mL of brine, dried over 
anhydrous sodium sulfate, filtered and the solvent evaporated. The crude product was 
purified by silica gel flash chromatography (n-hexane/ethyl acetate 95:5) and compound 
126 was isolated as colorless oil in quantitative oil.  
tert-Butyl((7-methoxy-2,2-dimethyl-3,4-dihydrobenzopyran-8-yl)oxy)dimethylsilane (126). 
IR ȣmax (cm-1) (KBr): 2965, 2922, 2890, 2847, 1493, 1454, 1289, 1242, 1148, 1097, 1051, 
865, 826, 773. 1H NMR (300.13 MHz, CDCl3): 6.60 (d, J = 8.4), 6.41 (d, J = 8.4), 3.76 (s, 
OCH3), 2.72 (t, J = 6.7, 2H), 1.76 (t, J = 6.7, 2H), 1.34 (s, 6H), 1.04 (s, 9H), 0.16 (s, 6H). 
13C NMR (75.47 MHz, CDCl3) į (ppm): 150.0, 146.2, 133.7, 120.5, 114.6, 103.9, 74.1, 
55.9, 32.9, 29.9, 25.9, 22.1, 18.7. EIMS m/z (%): 322 (3, [M]+.), 265 (10), 251 (2), 210 
(17), 109 (100), 194 (16), 179 (2), 166 (7), 151 (3), 91 (2), 89 (3), 75 (6), 73 (3), 59 (2). 
((6-Bromo-7-methoxy-2,2-dimethyl-3,4-dihydro-8-yl)oxy)(tert-butyl)dimethylsilane (127): 
In a two-necked round-bottom flask was placed compound 126 (8.9 g/27.6 mmol), 
NH4OAc (212 mg/2.76 mmol) and 200 mL of CH3CN.  The flask was placed at 0 ºC and 
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then NBS (5.16 g/28.9 mmol) was added in one portion. The mixture was allowed to stir 
for 15 minutes and warm to room temperature. The solution was partitioned between 
water and ethyl acetate. The aqueous phase was then extracted 2 x 250 mL of ethyl 
acetate. The organic phase was washed 2 x 250 mL with brine, dried over sodium sulfate 
anhydrous, filtered and the organic solvent evaporated. The crude product was purified by 
silica gel flash chromatography (n-hexane/ethyl acetate 99:1). Compound 127 was 
obtained as orange oil that solidified upon standing (10.68 g/ 96 %). 
((6-Bromo-7-methoxy-2,2-dimethyl-3,4-dihydro-8-yl)oxy)(tert-butyl)dimethylsilane (127). 
Mp: 41-43 ºC. IR ȣmax (cm-1) (KBr): 2971, 2925, 2889, 2851, 1462, 1441, 1338, 1249, 
1197, 1119, 1092, 1040, 996, 870, 831, 777. 1H NMR (300.13 MHz, CDCl3): 6.87 (s), 3.77 
(s, OCH3), 2.71 (t, J = 6.7, 2H), 1.75 (t, J = 6.7, 2H), 1.35 (s, 6H), 1.05 (s, 9H), 0.18 (s, 
6H). 13C NMR (75.47 MHz, CDCl3) į (ppm): 147.4, 146.0, 139.0, 124.2, 118.6, 106.6, 
74.8, 60.2, 32.6, 26.8, 25.8, 22.1, 18.6. EIMS m/z (%): 402 (1, [M+2]+.), 401 (0.5, [M+1]+.), 
400 (1, [M]+.), 346 (3), 345 (16), 344 (3), 343 (15), 290 (15), 289 (16), 288 (15), 287 (84), 
174 (22), 272 (21), 265 (21), 264 (100), 250 (5), 249 (23), 218 (9), 209 (10), 206 (19), 193 
(36), 180 (11), 179 (23), 166 (23), 165 (83), 137 (34), 135 (11), 109 (19), 91 (16), 89 (17), 
83 (17), 78 (10), 77 (16), 76 (5), 75 (56), 73 (45), 59 (17), 51 (13). 
5.1.9.2 Synthesis of XP13 by a new methodology: 
(8-((tert-Butyldimethylsilyl)oxy)-7-methoxy-2,2-dimethyl-3,4-dihydrobenzopyran-6-yl)(2-
(methoxymethoxy)phenyl)methanone (128): 
In an oven-dried three-necked round-bottom flask was placed compound 127 (1.5 g/3.74 
mmol) and it was solubilized in 50 mL of anhydrous THF. The mixture was then placed at 
-78 ºC and nBuLi (1.6 M, 5.6 mmol) was added dropwise. The mixture was allowed to 
react for 15 min at -78 ºC. Then the methyl 2-methoxymethylether-salicylate (66) (1.5 
g/7.5 mmol) solubilized in anhydrous THF at -78 ºC was added dropwise and allowed to 
react for 15 min at -78 ºC and slowly warm to room temperature. The reaction was 
quenched by the addition of a saturated solution of NH4Cl, extracted with 3 x 100 mL of 
ethyl acetate. The organic phase was washed 2 x 100 mL of brine, dried over sodium 
sulfate anhydrous, filtered and the organic solvent evaporated. The crude product was 
purified by silica gel flash chromatography (n-hexane/ethyl acetate 8:2).Compound 128 
was obtained as a white solid (1.25 g/68 %). 
Mp: 83-84 ºC. IR ȣmax (cm-1) (KBr): 2963, 2925, 2852, 1662, 1595, 1465, 1349, 1252, 
1232, 1201, 1150, 1116, 1099, 1074, 994, 834, 770. 1H NMR (300.13 MHz, CDCl3) į 
(ppm): 7.40 (dd, J = 8.0, 1.7), 7.38 (ddd, J = 8.8, 7.5, 1.7), 7.14 (dd, J = 0.8, 8.8), 7.04 
(ddd, J = 8.0, 7.5, 0.8), 7.00 (s), 5.05 (s, 2H), 3.51 (s, OCH3), 3.33 (s, OCH3), 2.72 (t, J = 
6.6, 2H), 1.78 (t, J = 6.6, 2H), 1.38 (s, 6H), 1.03 (s, 9H), 0.17 (s, 6H). 13C NMR (75.47 
MHz, CDCl3) į (ppm): 195.0, 155.1, 150.4, 150.4, 137.8, 131.4, 129.3, 125.5, 123.8, 
121.6, 121.3, 116.6, 114.9, 95.0, 75.6, 60.8, 55.9, 32.7, 26.9, 25.8, 22.1, 18.6. EIMS m/z 
(%): 486 (1, [M]+.), 384 (3), 383 (9), 373 (2), 341 (2), 310 (4), 309 (17), 298 (10), 297 (34), 
277 (12), 264 (21), 263 (100), 253 (15), 245 (12), 239 (6), 223 (16), 207 (9), 193 (6), 176 
(6), 165 (20), 121 (18), 75 (23), 73 (10), 59 (4). 
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(8-((tert-Butyldimethylsilyl)oxy)-7-methoxy-2,2-dimethyl-3,4-dihydrobenzopyran-6-yl)(2-
hydroxyphenyl)methanone (129)  and (8-hydroxy-7-methoxy-2,2-dimethyl-3,4-
dihydrobenzopyran-6-yl)(2-hydroxyphenyl)methanone (130): 
To a solution of compound 128 (1.12 g, 2.3 mmol) in 30 mL of CH3CN at 0 ºC was added 
in one portion NbCl5 (684 mg, 2.53 mmol). The mixture was stirred at 0ºC for 10 minutes 
and then allowed to warm to room temperature and let stirring for more 45 minutes. The 
reaction was quenched by the addition of a saturated solution of NaHCO3. The mixture 
was extracted with 3 x 100 ml of ethyl acetate. The organic phase was washed with 2 x 
100 ml of brine, dried over sodium sulfate anhydrous, filtered and the organic solvent 
evaporated. The crude product was purified by silica gel flash chromatography (n-
hexane/ethyl acetate 95:5). Compound 129 (390 mg/33 %) was isolated as colorless oil 
and compound 130 (498 mg/67 %) as a white solid 
Compound 129. IR ȣmax (cm-1) (KBr): 3443, 2970, 2925, 2851, 1622, 1460, 1354, 1236, 
1203, 1147, 1114, 1071, 830, 753. 1H NMR (300.13 MHz, CDCl3) į (ppm): 12.27 (OH), 
7.48-7.43 (m, 2H), 7.02 (dd, J = 8.8, 1.2), 6.81 (dd, J = 8.2, 1.1), 6.69 (s), 3.69 (s, OCH3), 
2.75 (t, J = 6.7, 2H), 1.80 (t, J = 6.7, 2H), 1.40 (s, 6H), 1.04 (s, 9H), 0.20 (s, 6H). EIMS 
m/z (%): 443 (1, [M]+.), 385 (1), 330 (5), 329 (21), 298 (11), 265 (6), 210 (7), 209 (45), 195 
(7), 194 (7), 122 (9), 121 (100), 89 (4), 75 (17), 65 (6), 59 (4). 
Compound 130. Mp: 173-174 ºC. IR ȣmax (cm-1) (KBr): 3352, 2965, 2928, 2896, 2927, 
1616, 1450, 1357, 1334, 1263, 1232, 1200, 1150, 1112, 1087, 983, 853, 759, 732, 655. 
1H NMR (300.13 MHz, CDCl3) į (ppm): 12.22 (OH), 7.52-7.45 (m, 2H), 7.02 (dd, J = 8.5, 
1.8), 6.84 (ddd, J = 8.1, 7.0,1.1), 6.65 (t, J = 0.7), 5.62 (broad, OH), 3.79 (s, OCH3), 2.77 
(td, J = 6.7, 0.7, 2H), 1.87 (t, J = 6.7, 2H), 1.43 (s, 6H). 13C NMR (75.47 MHz, CDCl3) į 
(ppm): 201.2, 162.8, 144.4, 143.0, 137.7, 136.3, 134.1, 123.9, 120.2, 119.9, 118.6, 117.9, 
116.4, 76.3, 61.7, 32.6, 26.9, 21.7. EIMS m/z (%): 329 (0.5, [M]+.), 298 (3), 297 (14), 254 
(3), 242 (19), 241 (99), 229 (6), 212 (7), 185 (11), 180 (9), 179 (78), 153 (18), 129 (12), 
128 (21), 121 (54), 115 (24), 105 (10), 93 (18), 92 (14), 91 (26), 79 (27), 78 (14), 77 (51), 
75 (10), 65 (14), 64 (100), 63 (40), 53 (31), 52 (13), 51 (54). HRMS (ESI) m/z calcd for 
C19H21O5 [M+H]+: 329.13835; found: 329.13787; m/z calcd for C19H20NaO5 [M+Na]+: 
351.12029; found: 351.11901. 
Synthesis of XP13 by cyclization of benzophenones 129 and 130: 
Cyclization of benzophenone 129: 
To a solution of compound 129 (340 mg, 1.2 mmol) in DMF (5 mL) was added Cs2CO3 
(375 mg, 1.15 mmol).  The mixture was irradiated with microwaves for 15 minutes at 140 
ºC. The mixture was allowed to cool to room temperature and poured into crushed ice. 
The aqueous phase was then extracted with 3 x 100 mL of diethyl ether. The organic 
phase was washed with 2 x 30 ml of brine, dried over sodium sulfate anhydrous, filtered 
and the organic solvent evaporated. The curde product was purified by silica gel flash 
chromatography (n-hexane/ ethyl acetate 7:3) and XP13 was obtained as light yellow solid 
(83 mg, 36 %) and XBp1 as a white solid (99 mg/32 %). 
Cyclization of benzophenone 130: 
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To a solution of compound 130 (396 mg, 1.2 mmol) in DMF (5 mL) was added Cs2CO3 
(982 mg, 3.01 mmol).  The mixture was irradiated with microwaves for 15 minutes at 140 
ºC. The mixture was allowed to cool to room temperature and poured into crushed ice. 
The aqueous phase was then extracted with 3 x 100 mL of diethyl ether. The organic 
phase was washed with 2 x 30 ml of brine, dried over sodium sulfate anhydrous, filtered 
and the organic solvent evaporated. The crude product was purified by silica gel flash 
chromatography (n-hexane/ ethyl acetate 7:3) and XP13 was obtained as light yellow solid 
(330 mg, 92 %). 
The spectroscopic data for both compounds was in accordance with the samples 
previously synthesized. 
5.1.9.3 Synthesis of the building block 131 and 132: 
In a typical experiment: in a two-necked round-bottom flask was placed 5-
methoxysalicylaldehyde 43 (1 g/ 6.5 mmol) was placed in a round-bottom flask and then it 
was added K2CO3 (1.36 g/9.8 mmol), benzyl bromide (1.67 g/9.8 mmol) and 50 mL of 
acetone. The mixture was allowed to stir at reflux overnight. The product was then filtrated 
and washed with acetone. The solvent was evaporated and the crude product was 
purified by silica gel flash chromatography (n-hexane/ethyl acetate 95:5) and compound 
131 was obtained as white solid in quantitative yield. 
2-(Benzyloxy)-5-methoxybenzaldehyde (131) as a white solid in quantitative yield. Mp: 45-
47 ºC. IR ȣmax (cm-1) (KBr): 2915, 2849, 1669, 1481, 1443, 1410, 1372, 1260, 1197, 1143, 
1025, 1006, 719, 677, 540. 1H NMR (300.13 MHz, CDCl3) į (ppm): 10.50 (s, CHO), 7.42-
7.33 (m, 5H), 7.31 (d, J = 3.1), 7.09 (dd, J = 9.1, 3.1), 6.98 (d, J = 9.1), 5.11 (s, 2H), 3.76 
(s, OCH3). EIMS m/z (%): 242 (0.8, [M]+.), 214 (2), 213 (2), 151 (2), 150 (2), 95 (2), 92 
(10), 91 (100), 89 (2), 77 (1), 65 (28), 53 (3), 52 (3), 51 (40). 
2,4-Bis(benzyloxy)benzaldehyde (132) as a light yellow solid in quantitative yield. Mp: 75-
77 ºC. IR ȣmax (cm-1) (KBr): 2949, 2925, 2846, 1664, 1601, 1452, 1381, 1324, 1178, 1094, 
1008, 827, 721, 691. 1H NMR (300.13 MHz, CDCl3) į (ppm): 10.38 (s, CHO), 7.84 (d, J = 
8.6), 7.42-7.35 (10H, m), 6.63 (dd, J = 8.6, 2.2), 6.59 (d, J = 2.2), 5.13 (s, 2H), 5.10 (s, 
2H). EIMS m/z (%): 318 (0.5, [M]+.), 298 (0.7), 199 (6), 181 (3), 92 (9), 91 (100), 65 (29), 
63 (6), 51 (3). 
 
5.1.9.4 Synthesis of XBp29, XBp30, XBp31, XBp32 and XBp33: 
Synthesis of diarylmethanol derivatives 133-137: 
In a typical experiment: in an oven-dried three-necked round-bottom flask was placed 
compound 127 (1.5 g/3.74 mmol) and it was solubilized in 50 mL of anhydrous THF. The 
mixture was then placed at -78 ºC and nBuLi (1.6 M, 5.6 mmol) was added dropwise. The 
mixture was allowed to react for 15 min at -78 ºC. Then the 2-benzyloxy-5-
chlorosalicylaldehyde (52) (1.38 g/5.6 mmol) solubilized in anhydrous THF was added 
dropwise and allowed to react for 15 min at -78 ºC and slowly warm to room temperature. 
The reaction was quenched by a saturated solution of NH4Cl, extracted with 3 x 100 mL of 
ethyl acetate. The organic phase was washed 2 x 100 mL of brine, dried over sodium 
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sulfate anhydrous, filtered and the organic solvent evaporated. The crude product was 
then purified by silica gel flash chromatography (n-hexane/ethyl acetate 8:2) and 
compound 175 was obtained as light yellow oil (1.62 g/76 %). 
(2-(Benzyloxy)-5-chlorophenyl)(8-((tert-butyldimethylsilyl)oxy)-7-methoxy-2,2-dimethyl-3,4-
dihydrobenzopyran-6-yl)methanol (133) as a yellow oil (1.62 g/76 %). IR ȣmax (cm-1) (KBr): 
3445, 2969, 2927, 2892, 2952, 1575, 1461, 1351, 1245, 1102, 1073, 1024, 1004, 944, 
832, 780, 732, 694. 1H NMR (300.13 MHz, CDCl3) į (ppm): 7.43 (d, J = 8.7), 7.32-7.29 
(m, 3H), 7.21-7.16 (m, 3H), 6.82 (d, J = 8.7), 6.41 (s), 6.26 (s), 5.05 (d, J = 11.8, 1H), 4.99 
(d, J = 11.8, 1H), 3.57 (s, OCH3), 2.61 (t, J = 6.8, 2H), 1.73 (t, J = 6.8, 2H), 1.37 (s, 
3H),1.33 (s, 3H), 1.04 (s, 9 H), 0.18 (s, 3H), 0.13 (s, 3H). EIMS m/z (%): 198 (1), 196 (3), 
167 (1), 141 (2), 92 (10), 91 (100), 89 (3), 77 (3), 75 (2), 65 (22), 63 (5), 51 (4). 
(2-(Benzyloxy)-5-methoxyphenyl)(8-((tert-butyldimethylsilyl)oxy)-7-methoxy-2,2-dimethyl-
3,4-dihydrobenzopyran-6-yl)methanol (134) as a colorless oil (1.9 g/98 %). IR ȣmax (cm-1) 
(KBr): 3421, 2928, 2901, 2853, 1585, 1495, 1463, 1352, 1246, 1207, 1155, 1103, 1075, 
1041, 834, 781, 734, 694. 1H NMR (300.13 MHz, CDCl3) į (ppm): 7.42-7.18 (m, 6H), 7.03 
(d, J = 2.7), 6.85 (d, J = 8.7), 6.48 (s), 6.32 (s), 5.02 (d, J = 10.7, 1H), 4.93 (d, J = 11.3, 
1H), 3.79 (s, OCH3), 3.76 (s, OCH3), 2.62 (t, J = 6.8, 2H), 1.73 (t, J = 6.8, 2H), 1.37 (s, 
3H),1.35 (s, 3H), 1.05 (s, 9 H), 0.20 (s, 3H), 0.18 (s, 3H). EIMS m/z (%): 299 (1.5), 283 
(1.3), 214 (2), 193 (13), 192 (92), 191 (3), 177 (2), 163 (19), 138 (8), 137 (76), 136 (17), 
121 (10), 110 (7), 107 (7), 92 (10), 91 (100), 71 (13), 65 (41), 53 (6), 51 (13). 
(2-(Benzyloxy)-5-methylphenyl)(8-((tert-butyldimethylsilyl)oxy)-7-methoxy-2,2-dimethyl-
3,4-dihydrobenzopyran-6-yl)methanol (135) as a colorless oil (1.91g/93 %). IR ȣmax (cm-1) 
(KBr): 3439, 2969, 2926, 2894, 1606, 1495, 1462, 1351, 1244, 1209, 1102, 1074, 1024, 
1004, 832, 779, 693. 1H NMR (300.13 MHz, CDCl3) į (ppm): 7.34-7.25 (m, 4H), 7.23-7.20 
(m, 2H), 7.02 (d, J = 2.1), 6.84 (d, J = 8.4), 6.52 (s), 6.34 (s), 5.07 (d, J = 11.7, 1H), 5.03 
(d, J = 11.7, 1H), 3.60 (s, OCH3), 2.65 (t, J = 6.8, 2H), 2.31 (s, CH3), 1.75 (t, J = 6.8, 2H), 
1.39 (s, 3H),1.36 (s, 3H), 1.07 (s, 9 H), 0.22 (s, 3H), 0.20 (s, 3H). EIMS m/z (%): 199 (0.7), 
176 (3), 175 (1), 147 (5), 135 (2), 121 (8), 119 (1), 115 (1), 92 (10), 91 (100), 79 (3), 65 
(22), 51 (6). 
(2-(Benzyloxy)-3-methoxyphenyl)(8-((tert-butyldimethylsilyl)oxy)-7-methoxy-2,2-dimethyl-
3,4-dihydrobenzopyran-6-yl)methanol (136) as a yellow oil (1.9 g/90 %). IR ȣmax (cm-1) 
(KBr): 3443, 2967, 2928, 2894, 2851, 1578, 1469, 1351, 1261, 1205, 1102, 1077, 1025, 
1003, 986, 832, 78, 745, 693. 1H NMR (300.13 MHz, CDCl3) į (ppm): 7.39-7.17 (m, 6H), 
7.06 (d, J = 8.0), 6.68 (d, J = 8.4), 6.41 (s), 6.25 (broad s), 5.01 (d, J = 10.7, 1H), 4.82 (d, 
J = 10.7, 1H), 3.89 (s, OCH3), 3.49 (s, OCH3), 2.91 (broad d, J = 4.1, OH), 2.57 (t, J = 6.8, 
2H), 1.69 (t, J = 6.8, 2H), 1.33 (s, 3H),1.31 (s, 3H), 1.02 (s, 9 H), 0.16 (s, 3H), 0.14 (s, 3H). 
EIMS m/z (%): 283 (1.2), 214 (1.4), 193 (6), 192 (49), 163 (19), 150 (5), 145 (5), 137 (55), 
131 (20), 124 (8), 121 (5), 103 (18), 92 (10), 91 (100), 79 (5), 78 (4), 77 (11), 65 (40), 51 
(12). 
(2,4-Bis(benzyloxy)phenyl)(8-((tert-butyldimethylsilyl)oxy)-7-methoxy-2,2-dimethyl-3,4-
dihydrobenzopyran-6-yl)methanol (137) as a light green oil (2.2 g).  
Synthesis of benzophenone derivatives 138-142: 
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In a typical experiment: in a round-bottom flask were placed compound 133 (1.5 g/2.6 
mmol) and 20 mL of DMSO. Then it was added IBX (1.1 g/3.9 mmol). After 24 hours the 
reaction was quenched by the addition of a 10% solution of Na2S2O3, a saturated solution 
of NaHCO3 and distilled water. The aqueous phase was then extracted with 3 x 150 mL of 
ethyl acetate. The organic phase was washed with a 2 x 100 mL solution of Na2S2O3 10%, 
2 x 100 mL of a saturated solution of NaHCO3, dried over sodium sulfate anhydrous, 
filtered and the organic solvent evaporated. The crude product was purified by silica gel 
flash chromatography (n-hexane/ethyl acetate 95:5) and compound 138 was recrystallized 
from ethyl acetate/n-hexane as white solid (1.04 g/70 %). 
(2-(Benzyloxy)-5-chlorophenyl)(8-((tert-butyldimethylsilyl)oxy)-7-methoxy-2,2-dimethyl-3,4-
dihydrobenzopyran-6-yl)methanone (138) as a white solid (1.04 g/70 %). Mp: 123-125 ºC. 
IR ȣmax (cm-1) (KBr): 2948, 2925, 2880, 2877, 1637, 1590, 1544, 1453, 1342, 1301, 1239, 
1206, 1137, 1101, 1077, 1016, 989, 963, 872, 825, 772, 728, 688, 458. 1H NMR (300.13 
MHz, CDCl3) į (ppm): 7.42 (d, J = 2.6), 7.33 (dd, J = 8.8, 2.6), 7.24-7.20 (m, 3H), 7.07 (s), 
7.07-7.04 (m, 2H), 6.88 (d, J = 8.8), 4.98 (s, 2H), 3.42 (s, OCH3), 2.76 (t, J = 6.7, 2H), 1.80 
(t, J = 6.7, 2H), 1.38 (s, 6H) 1.00 (s, 9 H), 0.08 (s, 6H). 13C NMR (75.47 MHz, CDCl3) į 
(ppm): 193.5, 155.1, 150.9, 150.5, 137.7, 136.3, 133.4, 130.9, 129.0, 128.2, 127.6, 126.5, 
125.6, 125.1, 123.8, 116.9, 113.7, 75.6, 70.3, 60.8, 32.7, 27.0, 25.7, 22.1, 18.6. EIMS m/z 
(%): 355 (1), 333 (2), 331 (4), 300 (4), 299 (19), 263 (7), 245 (3), 225 (4), 223 (4), 209 (6), 
207 (4), 155 (12), 105 (33), 92 (9), 91 (100), 77 (6), 75 (14), 73 (19), 65 (17), 59 (4), 51 
(7). 
(2-(Benzyloxy)-5-methoxyphenyl)(8-((tert-butyldimethylsilyl)oxy)-7-methoxy-2,2-dimethyl-
3,4-dihydrobenzopyran-6-yl)methanone (139) as a white solid (1.14 g/60 %). Mp: 69-70 
ºC. IR ȣmax (cm-1) (KBr): 2956, 2930, 2891, 2853, 1640, 1599, 1496, 1462, 1416, 1350, 
1305, 1245, 1218, 1106, 1080, 1048, 996, 909, 835, 779, 733, 464. 1H NMR (300.13 MHz, 
CDCl3) į (ppm): 7.25-7.18 (m, 3H), 7.06-7.05 (m, 2H), 7.03 (d, J = 2.9), 7.01 (s), 6.93 (dd, 
J = 8.9, 2.9), 6.87 (d, J = 8.9), 4.91 (s, 2H), 3.79 (s, OCH3), 3.46 (s, OCH3), 2.72 (t, J = 
6.7, 2H), 1.77 (t, J = 6.7, 2H), 1.36 (s, 6H), 0.99 (s, 9 H), 0.08 (s, 6H). 13C NMR (75.47 
MHz, CDCl3) į (ppm): 194.9, 153.5, 150.8, 150.4, 150.4, 137.7, 137.0, 132.7, 128.1, 
127.4, 126.6, 125.8, 123.9, 117.2, 116.6, 114.3, 114.2, 75.5, 70.9, 60.9, 55.8, 32.7, 29.7, 
27.0, 25.8, 22.1, 18.6. EIMS m/z (%): 448 (0.11), 431 (0.7), 399 (1), 355 (1), 339 (1), 327 
(7), 300 (4), 299 (9), 277 (23), 263 (19), 255 (12), 241 (8), 225 (9), 219 (10), 209 (19), 207 
(12), 151 (84), 121 (4), 105 (21), 92 (9), 91 (100), 75 (23), 73 (26), 65 (22), 59 (7), 51 (12). 
(2-(Benzyloxy)-5-methylphenyl)(8-((tert-butyldimethylsilyl)oxy)-7-methoxy-2,2-dimethyl-
3,4-dihydrobenzopyran-6-yl)methanone (140) as a white solid (1.14 g/64 %). Mp: 110-111 
ºC. IR ȣmax (cm-1) (KBr): 2950, 2926, 2886, 2849, 1639, 1599, 1550, 1495, 1451, 1346, 
1304, 1243, 1145, 1104, 1084, 1026, 992, 832, 799, 774, 731, 462. 1H NMR (300,13 MHz, 
CDCl3) į (ppm): 7.29 (d, J = 2.2), 7.23-7.17 (m, 4H), 7.07-7.04 (m, 2H), 7.02 (s), 6.84 (d, J 
= 8.4), 4.96 (s, 2H), 3.44 (s, OCH3), 2.74 (t, J = 6.7, 2H), 2.31 (s, CH3), 1.79 (t, J = 6.7, 
2H), 1.38 (s, 6H) 1.00 (s, 9 H), 0.09 (s, 6H). 13C NMR (75.47 MHz, CDCl3) į (ppm): 195.5, 
154.6, 150.2, 150.2,  137.7, 137.0, 132.1, 131.6, 130.1, 129.8, 128.1, 127.3, 126.5, 126.1, 
123.7, 112.5, 75.4, 70.1, 60.8, 32.8, 27.9, 25.8, 22.1, 20.4, 18.6. EIMS m/z (%): 432 (0.1), 
431 (0.6), 413 (0.7), 357 (0.8), 343 (0.8), 327 (7), 315 (2), 299 (20), 291 (4), 278 (6), 277 
(26), 263 (25), 255 (13), 209 (9), 152 (10), 151 (100), 105 (22), 92 (9), 91 (92), 75 (14), 73 
(15), 65 (18), 51 (6). 
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(2-(Benzyloxy)-3-methoxyphenyl)(8-((tert-butyldimethylsilyl)oxy)-7-methoxy-2,2-dimethyl-
3,4-dihydrobenzopyran-6-yl)methanone (141) as a colorless oil (1.37 g/71 %). IR ȣmax (cm-
1) (KBr): 2972, 2929, 2892, 2854, 1658, 1594, 1578, 1562, 1469, 1349, 1312, 1259, 1210, 
1116, 1064, 992, 907, 835, 780, 749, 695. 1H NMR (300.13 MHz, CDCl3) į (ppm): 7.25-
7.23 (m, 5H), 7.11 (dd, J = 8.2, 7.3), 7.03 (dd, J = 8.2, 1.9), 7.00 (dd, J = 7.3,1.9), 6.92 (s), 
4,93 (s, 2H), 3.89 (s, OCH3), 3.54 (s, OCH3), 2.67 (t, J = 6.6, 2H), 1.76 (t, J = 6.6, 2H), 
1.37 (s, 6H), 1.01 (s, 9 H), 0.13 (s, 6H). 13C NMR (75.47 MHz, CDCl3) į (ppm): 195.0, 
152.8, 150.6, 150.6, 145.9, 137.6, 128.1, 128.0, 127.5, 127.0, 125.2, 124.7, 123.7, 120.9, 
116.5, 114.3, 75.6, 75.5, 60.8, 56.1, 32.7, 27.0, 25.8, 22.1, 18.6. EIMS m/z (%): 547 (0.1), 
490 (0.2), 415 (0.12), 397 (0.6), 383 (0.2), 355 (1), 339 (2), 329 (1), 327 (1), 312 (5), 311 
(14), 299 (16), 277 (16), 263 (21), 239 (7), 225 (10), 203 (16), 136 (9), 135 (100), 105 
(30), 92 (8), 91 (90), 77 (5), 75 (11), 65 (15), 51(3). 
(2,4-Bis(benzyloxy)phenyl)(8-((tert-butyldimethylsilyl)oxy)-7-methoxy-2,2-dimethyl-3,4-
dihydrobenzopyran-6-yl)methanone (142) as a colorless oil (1.4 g). IR ȣmax (cm-1) (KBr): 
2966, 2923, 2883, 2849, 1638, 1595, 1567, 1494, 1459, 1419, 1347, 1305, 1250, 1202, 
1171, 1112, 1076, 1021, 860, 829. 1H NMR (300.13 MHz, CDCl3) į (ppm): 7.53 (d, J = 
8.5), 7.45-7.34 (m, 5H), 7.23-7.18 (m, 3H), 7.04-7.01 (m, 2H), 6.96 (s), 6.60 (dd, J = 8.5, 
2.2), 6.56 (d, J = 8.5), 5.09 (s, 2H), 4.94 (s, 2H), 3.44 (s, OCH3), 2.73 (t, J = 6.6, 2H), 1.77 
(t, J = 6.6, 2H), 1.36 (s, 6H), 0.98 (s, 9 H), 0.06 (s, 6H). 13C NMR (75.47 MHz, CDCl3) į 
(ppm): 194.2, 162.3, 158.9, 149.8, 149.7, 136.6, 136.4, 132.1, 128.7, 128.2, 127.7, 127.4, 
127.0, 126.5, 124.7, 123.1, 116.6, 105.5, 100.4, 75.3, 70.2, 69.9, 61.0, 32.8, 29.7, 27.0, 
25.8, 22.8, 18.6. EIMS m/z (%): 429 (0.8), 413 (0.5), 369 (0.33), 357 (0.7), 355 (2), 327 
(11), 299 (20), 271 (5), 267 (7), 263 (19), 253 (9), 241 (13), 227 (10), 225 (20), 219 (12), 
211 (16), 209 (11), 207 (29), 193 (11), 151 (69), 105 (20), 92 (9), 91 (100), 75 (16), 73 
(31), 65 (15), 51 (14),   
Synthesis of benzophenone derivatives 143-147: 
In a typical experiment: in a two-necked round-bottom flask were placed compound 138 
(750 mg/1.32 mmol) and 40 mL of anhydrous methanol/THF 3:1 in nitrogen atmosphere. 
To the solution was added Pd/C 10 % (15 % weight/112.5 mg) in one portion. 
Triethylsilane (2.1 mL, 10.32 mmol) was then added dropwise. The mixture was allowed 
to stir for 15 minutes. The product was filtered over celite and washed 3 times with 
methanol. The methanol was evaporated and the crude product was purified by silica gel 
flash chromatography (n-hexane/ethyl acetate 95:5). The mixture of compound 143 and 
130 was isolated as yellowish oil (564 mg). A small fraction of this mixture was purified by 
preparative thin layer chromatography and a small amount of compound 143 and 
compound 130 was isolated. 
Mixture of compounds 143 and 130 as yellow oil (564 mg). (8-((tert-butyldimethylsilyl)oxy)-
7-methoxy-2,2-dimethyl-3,4-dihydrobenzopyran-6-yl)(5-chloro-2-
hydroxyphenyl)methanone (143) as a green solid. Mp: 107-109 ºC. IR ȣmax (cm-1) (KBr): 
3434, 2943, 2879, 2840, 1614, 1582, 1452, 1346, 1238, 1183, 1102, 1062, 978, 890, 820, 
769, 745, 454. 1H NMR (300.13 MHz, CDCl3) į (ppm): 12.15 (OH), 7.43 (d, J = 2.8), 7.39 
(dd, J = 8.9, 2.8), 6.97 (d, J = 8.9), 6.72 (s), 3.64 (s, OCH3), 2.72 (t, J = 6.7, 2H), 1.80 (t, J 
= 6.7, 2H), 1.41 (s, 6H), 1.04 (s, 9 H), 0.22 (s, 6H). EIMS m/z (%): 477 (0.6, [M]+.], 421 
(0.6), 419 (0.7), 393 (0.4), 366 (2), 365 (9), 364 (4), 363 (20), 347 (2), 334 (6), 333 (8), 
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332 (15), 266 (17), 265 (81), 210 (17), 209 (100), 195 (12), 194 (15), 167 (7), 166 (12), 
157 (17), 155 (58), 99 (10), 75 (48), 73 (37), 59 (17), 53 (4), 51 (5). 
(8-((tert-Butyldimethylsilyl)oxy)-7-methoxy-2,2-dimethyl-3,4-dihydrobenzopyran-6-yl)(2-
hydroxy-5-methoxyphenyl)methanone (144) light yellow solid (816 mg/89 %). Mp: 74-75 
ºC. IR ȣmax (cm-1) (KBr): 3437, 2970, 2939, 2893, 2849, 1628, 1591, 1462, 1416, 1355, 
1328, 1294, 1195, 1150, 1110, 1068, 1036, 828, 780, 741, 657. 1H NMR (300.13 MHz, 
CDCl3) į (ppm): 11.90 (OH), 7.10 (dd, J = 9.1, 3.0), 6.96 (d, J = 9.1), 6.94 (d, J = 3.0), 
6.71 (s), 3.67 (s, OCH3), 3.66 (s, OCH3), 2.75 (t, J = 6.7, 2H), 1.80 (t, J = 6.7, 2H), 1.40 (s, 
6H), 1.05 (s, 9 H), 0.20 (s, 6H). EIMS m/z (%): 473 (0.5, [M]+.], 415 (0.6), 360 (3), 359 
(12), 329 (4), 328 (9), 327 (5), 299 (2), 292 (3), 265 (2), 250 (7), 239 (2), 221 (2), 210 (6), 
209 (28), 195 (5), 194 (5), 179 (4), 165 (3), 152 (10), 151 (100), 135 (2), 95 (4), 89 (3), 77 
(2), 75 (10), 73 (4), 65 (3), 59 (3), 51 (2). 
(8-((tert-Butyldimethylsilyl)oxy)-7-methoxy-2,2-dimethyl-3,4-dihydrobenzopyran-6-yl)(2-
hydroxy-5-methylphenyl)methanone (145) as a white oil (900 mg/quantitative). IR ȣmax 
(cm-1) (KBr): 3438, 2971, 2947, 2926, 2886, 2852, 1628, 1596, 1462, 1356, 1245, 1206, 
1184, 1150, 1103, 1071, 910, 828, 778, 668. 1H NMR (300.13 MHz, CDCl3) į (ppm): 
12.07 (OH), 7.29-7.22 (2H, m), 6.92 (d, J = 8.4), 6.70 (s), 3.62 (s, OCH3), 2.76 (t, J = 6.7, 
2H), 2.20 (s, CH3), 1.81 (t, J = 6.7, 2H), 1.40 (s, 6H), 1.04 (s, 9 H), 0.21 (s, 6H). EIMS m/z 
(%): 457 (1, [M]+.], 399 (1), 344 (3), 345 (13), 313 (4), 312 (9), 311 (5), 291 (3), 283 (3), 
250 (4), 210 (5), 209 (28), 195 (6), 194 (5), 179 (3), 165 (3), 136 (10), 135 (100), 91 (2), 
77 (8), 75 (10), 59 (2), 54 (2). 
(8-((tert-Butyldimethylsilyl)oxy)-7-methoxy-2,2-dimethyl-3,4-dihydrobenzopyran-6-yl)(2-
hydroxy-3-methoxyphenyl)methanone (146) as a yellow solid (717 mg/85 %). Mp: 138-
139 ºC. IR ȣmax (cm-1) (KBr): 3454, 2967, 2918, 2878, 2843, 1617, 1599, 1447, 1348, 
1249, 1106, 1084, 1050, 982, 896, 825, 774, 746, 728. 1H NMR (300.13 MHz, CDCl3) į 
(ppm): 12.55 (OH), 7.07 (dd, J = 8.1, 1.3), 7.05 (dd, J = 8.1, 1.3), 6.76 (t, J = 8.1), 6.69 (s), 
3.93 (s, OCH3), 3.67 (s, OCH3), 2.74 (t, J = 6.7, 2H), 1.80 (t, J = 6.7, 2H), 1.40 (s, 6H), 
1.04 (s, 9 H), 0.19 (s, 6H). EIMS m/z (%): 473 (0.8, [M]+.], 415 (0.9), 360 (3), 359 (13), 329 
(2), 328 (4), 327 (3), 313 (2), 299 (2), 291 (3), 285 (2), 250 (10), 209 (14), 195 (5), 179 (4), 
152 (10), 151 (100), 77 (4), 75 (10), 73 (4), 65 (3), 59 (2), 51 (12). 
(8-((tert-Butyldimethylsilyl)oxy)-7-methoxy-2,2-dimethyl-3,4-dihydrobenzopyran-6-yl)(2,4-
dihydroxyphenyl)methanone (147) as a yellow oil (850 mg/quantitative). IR ȣmax (cm-1) 
(KBr): 3383, 2968, 2925, 2851, 1622, 1594, 1459, 1360, 1296, 1242, 1207, 1113, 1071, 
985, 830, 779, 625. 1H NMR (300.13 MHz, CDCl3) į (ppm): 12.75 (OH), 7.35 (d, J = 8.8), 
6.66 (s), 6.40 (d, J = 2.5), 6.28 (dd, J = 8.8, 2.5), 5.71 (OH), 3.66 (s, OCH3), 2.74 (t, J = 
6.7, 2H), 1.79 (t, J = 6.7, 2H), 1.39 (s, 6H), 1.03 (s, 9 H), 0.20 (s, 6H). 
Synthesis of XBp29, XBp30, XBp31, XBp32 and XBp33: 
To a solution of a mixture 143 and 130 (530 mg) in DMF (10 mL) was added Cs2CO3 (543 
mg, 1.67 mmol).  The mixture was irradiated with microwaves for 15 minutes at 140 ºC. 
The mixture was allowed to cool to room temperature and poured into crushed ice. The 
aqueous phase was then extracted with 3 x 100 mL of diethyl ether. The organic phase 
was washed with 2 x 50 mL of brine, dried over sodium sulfate anhydrous, filtered and the 
organic solvent evaporated. The crude product was purified by silica gel flash 
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chromatography (n-hexane/ ethyl acetate 8:1). Compound XBp29 was recrystallized 
obtained as yellow solid (210 mg), and XP13 as a light yellow solid (40 mg). 
8-Chloro-12-hydroxy-2,2-dimethyl-3,4-dihydropyrano[3,2-b]xanthen-6(2H)-one (XBp29) as 
a yellow solid (210 mg). Mp: 225-227 ºC. IR ȣmax (cm-1) (KBr): 3322, 2973, 2937, 2854, 
1636, 1614, 1471, 1353, 1259, 1239, 1214, 1185, 1157, 1124, 1073, 981, 887, 808, 645. 
1H NMR (300.13 MHz, CDCl3) į (ppm): 8.28 (d, J = 2.6; H-C(7)), 7.67 (t, J = 1.0; H-C(5)), 
7.62 (dd, J = 9.0, 2.6; H-C(9)), 7.53 (d, J = 9.0; H-C(10)), 5.75 (HO-C(12)), 2.91 (td, J = 
6.7, 1.0; H2-C(3)), 1.92 (t, J = 6.7; H2-C(3)), 1.45 (s; (CH3)2-C(2)). 13C NMR (75.47 MHz, 
CDCl3) į (ppm): 175.5 (C6), 154.5 (C10a), 146.6 (C12a), 143.1 (C11a), 134.3 (C9), 132.5 
(C12), 129.3 (C8), 126.0 (C7), 122.4 (C6a), 119.7 (C10), 118.6 (C4a), 117.1 (C5), 115.0 
(C5a), 77.5 (C2), 32.5 (C3), 27.0 (C1’a and C1’b), 21.7 (C4). EIMS m/z (%): 331 (3, 
[M+1]+.), 330 (5, [M]+.), 287 (6), 276 (9), 275 (23), 275 (23), 274 (18), 220 (12), 219 (26), 
218 (24), 217 (22), 202 (13), 192 (18), 191 (12), 190 (48), 184 (22), 173 (12), 165 (10),164 
(21), 163 (17), 162 (62), 155 (47), 139 (25), 128 (53), 127 (67), 126 (44), 99 (20), 92 (16), 
91 (18), 87 (15), 77 (42), 75 (77), 74 (45), 65 (1), 63 )10), 62 (44), 53 (34), 51 (78). HRMS 
(ESI) m/z calcd for C18H16ClO4 [M+H]+: 331.07316; found: 331.07271; m/z calcd for 
C18H16NaClO4 [M+Na]+: 353.05511; found: 353.05410. 
12-Hydroxy-8-methoxy-2,2-dimethyl-3,4-dihydropyrano[3,2-b]xanthen-6(2H)-one (XBp30) 
as a white solid (478 mg/ 89 %). Mp: decomp. IR ȣmax (cm-1) (KBr): 3232, 2975, 2931, 
2841, 1647, 1613, 1591, 1490, 1467, 1438, 1370, 1253, 1208, 1122, 1075, 1029, 787. 1H 
NMR (300.13 MHz, CDCl3:DMSO-d6 (10:1)) į (ppm): 8.12 (broad; HO-C(12)), 7.64 (d, J = 
3.1; H-C(7)), 7.58 (s; H-C(5)), 7.52 (d, J = 9.1; H-C(10)), 7.28 (dd, J = 9.1, 3.1; H-C(9)), 
3.91 (s, H3CO-C(8)), 2.94 (t, J = 6.7; H2-C(4)), 1.91 (t, J = 6.7; H2-C(3)), 1.45 (s; (CH3)2-
C(2)). 13C NMR (75.47 MHz, CDCl3:DMSO-d6 (10:1)): 175.5 (C6), 154.7 (C10a), 150.0 
(C8), 146.4 (C12a), 143.3 (C11a), 132.3 (C12), 123.0 (C9), 120.8 (C6a), 118.5 (C7), 
117.7 (C4a); 115.1 (C5), 113.7 (C5a) 105.1 (C10), 75.5 (C2), 55.9 (C1’’), 31.7 (C3), 26.1 
(C1’a and C1’), 21.2 (C4). EIMS m/z (%): 327 (5, [M+1]+.), 326 (10, [M]+.), 272 (30), 271 
(93), 270 (100), 267 (12), 255 (11), 254 (8), 242 (12), 228 (18), 215 (12), 214 (15), 171 
(12), 115 (12), 77 (11), 63 (27), 62 (20), 53 (13), 51 (9). HRMS (ESI) m/z calcd for 
C19H19O5 [M+H]+: 327.12270; found: 327.12371; m/z calcd for C19H18NaO5 [M+Na]+: 
349.10464; found: 349.10323.  
12-Hydroxy-2,2,8-trimethyl-3,4-dihydropyrano[3,2-b]xanthen-6(2H)-one (XBp31) as a 
white solid (385 mg/65 %). Mp: 227-228 ºC. IR ȣmax (cm-1) (KBr): 3239, 2981, 2934, 2856, 
1652, 1616, 1490, 1465, 1421, 1365, 1252, 1220, 1197, 1153, 1131, 1096, 1073, 1021, 
813, 783, 660. 1H NMR (300.13 MHz, CDCl3) į (ppm): 8.11-8.10 (m, 1H; H-C(7)), 7.68 (t, 
J = 1.0; H-C(5)), 7.49 (dd, J = 8.7, 2.0; H-C(9)), 7.46 (dd, J = 8.7, 0.6; H-C(10)), 5.85 
(broad; HO-C(12)), 2.91 (td, J = 6.7, 1.0; H2-C(4)), 2.45 (s, H3C-C(8)), 1.91 (t, J = 6.7; H2-
C(3)), 1.43 (s; (CH3)2-C(2)). 13C NMR (75.47 MHz, CDCl3): 176.7 (C6); 154.4 (C10a), 
146.1 (C12a), 143.3 (C11a), 135.5 (C9), 133.3 (C8), 132.3 (C12), 126.0 (C7), 121.1 
(C6a), 118.0 (C4a), 117.7 (C10), 117.0 (C5), 115.4 (C5a), 76.6 (C2), 32.6 (C3), 27.0 (C1’a 
and C1’b), 21.2 (C4), 20.8 (C1’’). EIMS m/z (%): 311 (3, [M+1]+.), 310 (8, [M]+.), 295 (3), 
277 (5), 267 (12), 256 (16), 255 (100), 254 (74), 227 (9), 199 (25), 198 (24), 197 (15), 170 
(37), 153 (12), 143 (11), 142 (33), 141 (32), 135 (12), 128 (26), 115 (35), 91 (14), 89 (14), 
77 (28), 65 (10), 63 (25), 53 (7), 51 (30).  HRMS (ESI) m/z calcd for C19H19O4 [M+H]+: 
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311.12779; found: 311.12851; m/z calcd for C19H18NaO4 [M+Na]+: 333.10973, found: 
333.10805.  
12-Hydroxy-10-methoxy-2,2-dimethyl-3,4-dihydropyrano[3,2-b]xanthen-6(2H)-one 
(XBp32) as a light yellow solid (387 mg/83 %). Mp: 207-208 ºC. IR ȣmax (cm-1) (KBr): 
3308, 3271, 2976, 2931, 2843, 1650, 1597, 1473, 1445, 1372, 1265, 1223, 1197, 1118, 
1069, 937, 755. 1H NMR (300.13 MHz, CDCl3) į (ppm): 7.88 (dd, J = 7.8, 1.8; H-C(7)), 
7.67 (t, J = 1.0; H-C(5)), 7.27 (t, J = 7.8; H-C(8)), 7.20 (dd, J = 7.8, 1.8; H-C(9)), 6.03 
(broad; HO-C(12)), 4.03 (s; H3O-C(10)), 2.93 (td, J = 1.0, 6.7; H2-C(2)), 1.92 (t, J = 6.7; 
H2-C(3)), 1.44 (s; (CH3)2-C(2)). 13C NMR (75.47 MHz, CDCl3): 176.6 (C6); 148.6. (C10a), 
146.5 (C10), 146.4 (C12a), 132.8 (C12), 123.0 (C6a), 122.4 (C9), 118.5 (C4a), 117.6 
(C5), 116.7 (C7), 115.1 (C5a), 114.9 (C8), 76.9 (C2), 56.4 (C1’’), 32.6 (C3), 26.9 (C1’a 
and C1’b), 21.6 (C4). EIMS m/z (%): 327 (11, [M+1]+.), 326 (11, [M]+.), 311 (4), 309 (5), 
297 (4), 283 (6), 282 (8), 271 (50), 270 (33), 256 (11), 251 (2), 250 (2), 240 (5), 228 (8), 
214 (24), 200 (28),  199 (28), 185 (33), 184 (13), 172 (14), 171 (22), 168 (10), 158 (13), 
157 (25), 156 (18), 155 (13), 151 (26), 144 (31), 143 (11), 141 (12), 135 (17), 129 (17), 
128 (37), 121 (12), 116 (24), 115 (100), 91 (17), 89 (21), 77 (40), 75 (22), 65 (18), 63 (59), 
62 (24), 53 (24), 51 (64). HRMS (ESI) m/z calcd for C19H19O5 [M+H]+: 327.12270; found: 
327.12325; m/z calcd for C19H18NaO5 [M+Na]+: 349.10464; found: 349.10362.  
9,12-Dihydroxy-2,2-dimethyl-3,4-dihydropyrano[3,2-b]xanthen-6(2H)-one (XBp33) as a 
white solid (407 mg/71 %). Mp: 262-264 ºC. IR ȣmax (cm-1) (KBr): 3334, 3288, 3241, 2972, 
2925, 2845, 1645, 1611, 1588, 1457, 1266, 1324, 1256, 1217, 1192, 1162, 1118, 1017, 
850, 699. 1H NMR (300.13 MHz, CDCl3) į (ppm): 10.80 (broad; HO-C(9)), 9.50 (broad; 
HO-C(12)), 8.02 (d, J = 8.5; H-C(7)), 7.42 (s; H-C(5)), 6.89 (d, J = 2.0; H-C(10)), 6.87 (dd, 
J = 8.5, 2.0; H-C(8)), 2.87 (t, J = 6.6; H2-C(4)), 1.84 (t, J = 6.6; H2-C(3)), 1.38 (s; (CH3)2-
C(2)). 13C NMR (75.47 MHz, CDCl3) į (ppm): 174.5 (C6), 163.4 (C9), 147.2 (C12a), 143.9 
(C11a), 133.1 (C12), 127.9 (C7), 118.4 (C5), 115.3 (C8), 114.4 (C6a), 113.8 (4a), 113.5 
(5a), 102.1 (C10), 75.8 (C2), 31.9 (C3), 26.6 (C1’a and C1’b), 21.6 (C4). HRMS (ESI) m/z 
calcd for C19H17O5 [M+H]+: 313.10705; found: 313.10696. 
(2,4-dihydroxyphenyl)(8-hydroxy-7-methoxy-2,2-dimethyl-3,4-dihydrobenzopyran-6-
yl)methanone (149) as a white solid (125 mg, 20 %). Mp: 220-222 ºC. IR ȣmax (cm-1) 
(KBr): 3378, 3283, 2971, 2930, 2895, 2849, 1630, 1583, 1492, 1371, 1313, 1295, 1251, 
1201, 1154, 1090, 1054, 983, 948, 786, 623. 1H NMR (300.13 MHz, CDCl3) į (ppm): 
12.61 (OH), 10.90 (broad, OH), 8.70 (broad, OH), 7.23 (d, J = 8.6), 6.51 (s), 6.33 (dd, J = 
2.3, 8.6), 6.30 (d, J = 2.3), 3.61 (s, OCH3), 2.60 (t, J = 6.6, 2H), 1.77 (t, J = 6.6, 2H), 1.33 
(s, 6H). HRMS (ESI) m/z calcd for C19H21O6 [M+H]+: 345.13326; found: 345.13402; m/z 
calcd for C19H20NaO6 [M+Na]+: 367.11521; found: 36.11345. 
5.1.10 Synthesis of XPr1, XPr2, XPr3 and XPr4 
5.1.10.1 Prenylation of 1,2-dihydroxyxanthone with prenyl bromide and 
potassium carbonate: 
Method A. 
In a two round-bottom flask of 250 mL were placed 1,2-dihydroxyxanthone (21) (400 mg/ 
1.75 mmol) and K2CO3 (315 mg/2.28 mmol) and then under nitrogen atmosphere. 50 mL 
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of anhydrous acetone was added and then prenyl bromide (402 mg/312 μL/2.7 mmol) 
dropwise. The mixture was heated at reflux for 3 hours. The mixture was allowed to cool 
to room temperature and filtered. The residue was washed with acetone and the organic 
solvent evaporated. The crude product was purified by silica gel flash chromatography (n-
hexane/ethyl acetate 95:5). Compound XPr1 was isolated as yellow solid (365 mg/58 %), 
compound XPr2 as yellow solid (117 mg/23 %) and compound XPr3 as yellow solid (66 
mg/10 %). 
Method B. 
In a two necked round-bottom flask of 250 mL was placed 1,2-dihydroxyxanthone (29) 
(400 mg/ 1.75 mmol) and K2CO3 (315 mg/2.28 mmol) and then under nitrogen 
atmosphere. 50 mL of anhydrous acetone was added and then prenyl bromide (261 
mg/202 μL/1.75 mmol) dropwise. The mixture was stirred at room temperature for 8 hours. 
The mixture was filtered and the residue was washed with acetone and then the organic 
solvent evaporated. The crude product was purified by silica gel flash chromatography (n-
hexane/ethyl acetate 95:5). Compound XPr1 was isolated as yellow solid (35 mg/5 %), 
compound XPr2 as yellow solid (200 mg/39 %), compound XPr3 as yellow solid (10 mg/2 
%) and compound XPr4 as orange solid (74 mg/14%). 1,2-Dihydroxyxanthone (70) was 
also recovered (158 mg).  
1,2-Bis((3-methylbut-2-en-1-yl)oxy)-9H-xanthen-9-one (XPr1). Mp: 70-72 ºC. IR ȣmax (cm-
1) (KBr): 2967, 2915, 2878, 1659, 1610, 1462, 1281, 1043, 945, 803, 755. 1H NMR 
(300.13 MHz, CDCl3) į (ppm): 8.35 (dd, J = 8.0, 1.6), 7.70 (ddd, J = 8.5, 7.1, 1.6), 7.44 (d, 
J = 8.5), 7.39 (d, J = 9.1), 7.37 (ddd, J = 8.0, 7.1, 1.0), 7.23 (d, J = 9.1), 5.83 (broad t, J = 
7.2, 1H), 5.57 (broad t, J = 6.8, 1H), 4.73 (d, J = 7.2, 2H); 4.67 (d, J = 6.8, 2H), 1.84 (s, 
6H), 1.81 (s, 3H) 1.77 (s, 3H). 13C NMR (125.8 MHz, CDCl3) į (ppm): 176.6, 155.3, 151.7, 
149.9, 148.6, 138.2, 138.1, 134.2, 126.8, 123.4, 123.3, 122.2, 120.7, 120.0, 117.6, 117.3, 
112.9, 70.7, 67.5, 25.8, 25.7, 18.2, 18.0. HRMS (ESI) m/z calcd for C23H25O4 [M+H]+: 
365.17474; found: 365.17504; m/z calcd for C23H24NaO4 [M+Na]+: 387.15668; found: 
387.15688. 
1-Hydroxy-2-((3-methylbut-2-en-1-yl)oxy)-9H-xanthen-9-one (XPr2). Mp: 78-79 ºC. IR ȣmax 
(cm-1) (KBr): 3441, 2917, 2851, 1648, 1611, 1580, 1469, 1370, 1278, 1236, 1044, 754. 1H 
NMR (300.13 MHz, CDCl3) į (ppm): 12.86 (OH), 8.33 (dd, J = 8.0, 1.7), 7.79 (ddd, J = 8.5, 
7.1, 1.7), 7.50 (dd, J = 8.5, 1.0), 7.43 (ddd, J = 8.0, 7.1, 1.7), 7.38 (d, J = 9.0), 6.94 (d, J = 
9.0), 5.60 (t, J = 6.8, 1H), 4.71 (d, J = 6.8, 2H), 1.84 (s, 3H), 1.79 (s, 3H). 13C NMR (125.8 
MHz, CDCl3) į (ppm): 182.9, 156.4, 151.6, 150.3, 141.6, 138.4, 135.6, 126.0, 123.83, 
123.77, 120.0, 119.8, 117.9, 109.3, 105.6, 67.1, 25.8, 18.2. HRMS (ESI) m/z calcd for 
C18H17O4 [M+H]+: 297.11214; found: 297.11256; m/z calcd for C18H16NaO4 [M+Na]+: 
319.09408, found: 319.09328. 
1-Hydroxy-4-(3-methylbut-2-en-1-yl)-2-((3-methylbut-2-en-1-yl)oxy)-9H-xanthen-9-one 
(XPr3). Mp: 66-68 ºC. IR ȣmax (cm-1) (KBr): 3422, 2967, 2922, 2852, 1643, 1611, 1586, 
1467, 1222, 986, 757. 1H NMR (300.13 MHz, CDCl3) į (ppm): 12.75 (OH), 8.33 (dd, J = 
8.0, 1.6), 7.80 (ddd, J = 8.5, 7.1, 1.6), 7.54 (d, J = 8.5), 7.43 (ddd, J = 8.0, 7.1, 1.0), 7.26 
(s), 5.59 (broad t, J = 6.9, 1H), 5.38 (broad t, J = 7.5, 1H), 4.70 (d, J = 6.9, 2H); 3.59 (d, J 
= 7.5, 2H), 1.86 (s, 3H), 1.83 (d, J = 0.9, 3H), 1.82 (d, J = 1.1, 3H), 1.79 (s, 3H). 13C NMR 
(125.8 MHz, CDCl3) į (ppm): 183.1, 156.3, 149.6, 147.5, 141.1, 138.2, 135.4, 133.4, 
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126.0, 124.8, 123.7, 121.7, 120.1, 120.0, 118.3, 117.9, 109.3, 67.2, 27.6, 25.8 (x 2 C), 
18.2, 17.9. HRMS (ESI) m/z calcd for C23H25O4 [M+H]+: 365.17474; found: 365.17417; m/z 
calcd for C23H24NaO4 [M+Na]+: 387.15668, found: 387.15493. 
1,2-Dihydroxy-4-(3-methylbut-2-en-1-yl)-9H-xanthen-9-one (XPr4). Mp: 100-101 ºC. IR 
ȣmax (cm-1) (KBr): 3415, 2954, 2922, 2852, 1648, 1618, 1593, 1476, 1299, 1185, 1112, 
751. 1H NMR (300.13 MHz, CDCl3) į (ppm): 12.47 (HO-C(1)), 8.28 (dd, J = 8.0, 1.7; H-
C(8)), 7.76 (ddd, J = 8.4, 7.1, 1.7; H-C(6)), 7.51 (dd, J = 8.4, 0.9; H-C(5)), 7.39 (ddd, J = 
8.0, 7.1, 1.7; H-C(7)), 7.24 (s; H-C(3)), 5.33 (broad t, J = 7.1; H-C(2’)), 3.54 (d, J = 7.1, H2-
(C1’)), 1.81 (s; H3-C(4’a or 4’b)), 1.77 (d, J = 0.9; H3-C(4’a or 4’b)). 13C NMR (125.8 MHz, 
CDCl3) į (ppm): 182.8 (C9), 156.5 (C10a), 146.6 (C4a), 144.5 (C1), 138.7 (C2), 135.4 
(C6), 133.6 (C3’), 125.8 (C8), 123.8 (C7), 123.2 (C3), 121.4 (C2’), 119.9 (C8a), 119.4 
(C4), 118.0 (C5), 117.8 (C9a), 27.6 (C1’), 15.8 (C4’a or C4’b), 17.9 (C4’a or C4’b)er. 
HRMS (ESI) m/z calcd for C18H17O4 [M+H]+: 297.11214; found: 297.11152. 
5.1.10.2 Montmorillonite K-10 catalyzed rearrangement of compound 
XPr2: 
In a closed vessel of 50 mL for microwave heating was placed compound XPr2 (60 
mg/0.202 mmol), montmorillonite K-10 (1.2 g) and 10 mL of CHCl3. The vessel was closed 
and the mixture was heated for 30 minutes at 115 ºC. The vessel was allowed to cool to 
room temperature and the clay was filtered and washed with chloroform, acetone and 
methanol. The organic solvents were reunited and the organic solvent evaporated. The 
crude product was purified by silica gel flash chromatography (n-hexane/ethyl 
acetate/formic acid 95:5:0.1). Compounds 21 (22 mg/48 %) and XPr4 (30 mg/50 %) were 
isolated 
5.1.10.3 Thermal rearrangement of compound XPr1: 
In a two necked round-bottom flask of 50 mL was placed compound XPr1 (50 mg/0.16 
mmol) and 5 mL of anhydrous DMF. The mixture was heated at reflux for 3 hours under 
nitrogen atmosphere. The mixture was allowed to cool to room temperature and poured 
over 50 g or crushed ice. The aqueous phase was extracted with 3 x 50 mL of diethyl 
ether. The organic phase was then washed with 2 x 50 mL of brine, dried over sodium 
sulfate anhydrous, filtered and the organic solvent evaporated. The crude product was 
purified by silica gel flash chromatography (n-hexane/ethyl acetate 95:5). Compound XPr2 
(6 mg/ 15%) and XPr3 (35 mg/ 70 %) were isolated. 
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5.2 Drug-like Profiling 
  
The Drug-Like Profiling was evaluated by the determination of the lipophilicity, 
solubility and plasma protein binding. 
5.2.1 Lipophilicity 
5.2.1.1 Partition coefficient (Kp) determination: 
 
5.2.1.1.1 Materials 
  
The egg yolk phosphatidylcholine (EPC), HEPES, DMSO and NaCl were acquired from 
Sigma-Aldrich, the hexadecylphosphocoline (HDPC) from Cayman chemicals and the 
water used was double-deionised with conductivity less than 0.1 μS cm-1. The 96-well 
plate reader used was a Synergy HT from Bio-Tek Instruments and the double beam 
spectrophotometer was a JASCO V660. The extrusion device used was a Lipex® 
Extruder manufactured from Northern Lipids and the filters were acquired from Whatman. 
The determination of the UV-spectrum was made either in a flat-bottomed 96-well UV-
plates acquired from BD Biosciences or fused quartz cuvettes of 1.4 mL from Hellma.  
 
5.2.1.1.2 Liposome preparation 
  
Liposomes were prepared by evaporation to dryness with a nitrogen stream of an EPC 
solution prepared with chloroform/methanol (9/1). The resulting dried lipid film was 
dispersed with a buffer (HEPES: 10 mmol.L–1, I = 0.1 mol.L–1 with NaCl, pH 7.4) and the 
mixture was vortex mixed to give multilamellar liposomes (MLVs).  The MLVs  were  
extruded  10  times  through  polycarbonate filters  with  a  pore  diameter  of  100 nm  to  
form  large  unilamellar vesicles  (LUVs) . 
  
5.2.1.1.3 Micelle preparation 
 
Micelles solutions were prepared by dissolution of hexadecylphosphocholine (HDPC) in 
buffer (HEPES: 10 mmol.L–1, I=0.1 mol.L–1 with NaCl, pH 7.4) and mixed by vortex.  
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5.2.1.1.4 Determination of the concentration of compound used in the assay 
 
From a stock solution (usually 20 mM) of each compound in DMSO, several intermediate 
solutions were prepared in DMSO with a concentration of 4 mM, 2 mM, 1 mM, 500 μM, 
200 μM and 100 μM. 15 μL of each intermediate solution were added to 1485 μL of 
HEPES buffer to a give solution with a final concentration of 40 μM, 20 μM, 10 μM, 5 μM, 
2 μM and 1 μM, being DMSO 1% of total volume. Each solution was prepared in triplicate 
and transferred to a 96-well plate and an UV spectrum was traced for each sample. A 
calibration curve was established and a concentration in the linear zone was chosen for 
the determination of the partition coefficient.   
 
5.2.1.1.5 General procedure for Kp determination 
The procedure used was adapted from the literature [2] and was the following: 
 
• 3 μL of compound solubilized in DMSO (concentration established before in 
5.2.1.1.4) was added to each well; 
• Increasing volumes of liposome or micelles were added to each well and the final 
concentration for 300 μL were 0 (only buffer), 50, 100, 200, 300, 400, 500, 600, 
700, 800, 900 and 1000 μM. In the end, for the same concentration of xanthone, 
increasing concentrations of lipid were prepared; 
• HEPES buffer was added to make up 300 μL of final volume; 
• A blank was used for each concentration of lipid containing 1 % of DMSO; 
• The plate was incubated at 37 ± 0.1 °C for 30 minutes and then the spectrum was 
traced from 240 nm to 600 nm.  
 
For poorly soluble compounds, the solutions were prepared with the same concentration 
but in eppendorf (1.5 mL) instead.  Each solution was mixed by vortex and incubated for 
30 min. The spectrum ranging from 240-600 nm was traced individually in a double-beam 
spectrophotometer for each sample at 37 ºC.  
The compound concentration used in the determination of the Kp varied from 2.5 μM for 
the most poorly soluble compounds to 20 μM for the most soluble. 
 
Partition coefficient (Kp) was calculated by adjusting experimental data through a 
nonlinear regression of Levenberg-Marquardt in where the adjustable parameter was Kp. 
The program was available free of charge in the supplementary information from [2].The 
correlation between the different models was calculated using Analize-it® for excel. 
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5.2.2 Solubility 
5.2.2.1 Materials 
  
The HEPES, DMSO and NaCl were acquired from Sigma-Aldrich and the water used was 
double-deionised with conductivity less than 0.1 μS cm-1. The double beam 
spectrophotometer was a JASCO V660. The solutions were filtered through a 0.1 μm filter 
from Millipore. The UV/Vis spectrum was traced with fused quartz cuvettes of 1.4 mL from 
Hellma.  
 
5.2.2.2 Standard calibration curve determination 
 
The standard calibration curve for each compound was prepared using a stock solution of 
20 mM in DMSO. The final solutions for each standard were prepared containing 15 μL of 
DMSO and 1485 μL of buffer. An UV/Spectrum ranging from 240 to 500 nm was traced for 
each standard and a calibration curve was established using the second derivative. The 
concentrations of the standards ranged from 0.1 to 20 μM. 
 
5.2.2.3 Solubility procedure 
  
To 2 mL of an HEPES beffer (10 mmol.L–1, I=0.1 mol.L–1 with NaCl, pH 7.4) was added 
each compound until a saturated solution was obtained. The suspension of each 
compound (in triplicate) was agitated at 37 ºC for 24 hours. Each sample was filtered 
through a 0.1 μm filter and 1.485 μL of each filtrate was added to another eppendorf 
containing 15 μL of DMSO. The UV/Vis spectrum was traced in a double-beam 
spectrophotometer and the concentration was determined according to the standard 
calibration curve for each compound. 
 
 
 
 
 
 
 
 
 
ŚĂƉƚĞƌϱ
ǆƉĞƌŝŵĞŶƚĂů
Ϯϴϵ

5.2.3 Plasma Protein Binding 
5.2.3.1 Materials 
  
The human serum albumin (HSA), bovine serum albumin (BSA), Na2HPO4, KH2PO4, 
DMSO and NaCl were acquired from Sigma-Aldrich and the water used was double-
deionised with conductivity less than 0.1 μS cm-1. The double beam spectrophotometer 
was a JASCO V660 and the fluorimeter was a Perkin-Elmer LS. The UV/Vis spectrum and 
fluorescence were traced with fused quartz cuvettes of 1.4 mL from Hellma.  
 
5.2.3.2 Plasma Protein Binding Procedure 
 
A stock solution of HSA and BSA was prepared in deionized water with 6 μM and also a 
stock solution of each compound in DMSO (20 mM). From the sock solution of each 
compound, intermediates solutions in DMSO were prepared with concentration ranging 
from 0.25 mM to 40 mM. To an eppendorf was added 500 μL of the stock solution of 
albumin, 985 μL of phosphate buffer (I=0.1 mol.L–1 with NaCl, pH 7.4) and 15 μL of each 
intermediate solutions.  A solution was also prepared containing 500 μL of deionized 
water, 985 μL of phosphate buffer and 15 μL of an intermediate solution. Each solution 
was prepared in triplicate. 
An UV/Vis spectrum for each solution was traced in a double-beam spectrophotometer 
ranging from 240 to 500 nm. An excitation (emission 330 nm) and emission (280 nm) 
fluorescence spectrum was also traced for each sample. 
All the data treatment for the determination of the dissociation constant was made in 
EXCEL (Office 2007) and OriginLab (version 8.5.1). 
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5.3 Growth inhibition on four human tumor cell lines 
  
5.3.1 Cell lines 
 
The adherent cell lines MCF-7 (breast adenocarcinoma, ECACC, UK), NCI-H460 (non-
small cell lung cancer, a kind gift from NCI, Bethesda, USA), A375-C5 (melanoma, 
ECACC, UK) and the suspension cell line HL-60 (acute myelocid leukemia) were routinely 
maintained in RPMI-1640 (with Glutamax, Lonza), supplement with 5% heat inactivated 
fetal bovine serum (FBS, PAA) at 37 ºC in a humidified incubator with 5% CO2. Cell 
number and viability were routinely determined with Trypan blue (Sigma). All the 
experiments were performed with cells in exponential growth and presenting more than 
90% viability.  
 
5.3.2 Sulforhodamine B (SRB) assay 
 
Cells were plated into 96-well tissue culture plates at appropriate densities (MCF-7 and 
NCI-H460 at 5 x 103 cells/well, A375-C5 at 7.5 x 103 cells/well and HL-60 cells at 1 x 104 
cells/well) and incubated for 24 hours. Cells were then treated with serial dilutions of the 
different compounds (ranging from 0 to 150 μM). Following 48 h of incubation, the effect of 
the compounds in the growth of the different cell lines was analyzed with the SRB assay, 
as adopted by the Nacional Cancer Institute (NCI, USA) [3-6]. Briefly, following incubation, 
cells were fixed in situ with ice cold trichloroacetic acid (at 10 % for adherent cells and at 
16.7 % for the cells growing in suspension). Following SRB staining, plates were whashed 
with 1 % acetic acid, the bound dye was then solubilized with 10 mM Tris Base and 
absorbance was measured at 510 nm in a microplate reader (Biotek Instruments Inc, 
Synergy XS, Winooski, USA). The GI50 values for the compounds synthesized 
(concentration resulting in 50% inhibition of cell growth) were calculated from the plotted 
results. Doxorubicin was used as a positive control. The effect of the vehicle solvent on 
the growth of these cell lines was evaluated in preliminary experiments, by exposing 
untreated control cells to the maximum concentration of DMSO used in each assay 
(0.25%). 
 
5.3.3 Statistical Analysis 
 
All experimental data are presented as means ± SEM from at least three independent 
experiments.  
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Abstract 
Xanthones belong to a class of O-heterocycles which are known for their great variety of 
biological/pharmacological activities. The xanthone scaffold can be considered as a privileged structure and 
for that reason it is an excellent starting point for, through different synthetic pathways, to achieve new 
bioactive molecules. 
This review intends not only to make a literature survey about the synthesis of xanthones, but also to 
organize the most important and common syntheses that have been published from 2005 to 2012 in an 
integrative way. Among the new methodologies we highlight the synthesis of xanthones via benzyne, 
palladium-catalyzed, domino type reactions and imidazolidenyl carbene-catalyzed reactions.  
In the first three sections is given an overview concerning the classic methodologies focusing recent 
developments; the fourth section orders the different methodologies described for the synthesis of xanthones 
starting from chromen-4-ones. As far as our knowledge, this is the first time that a review systematizes the 
synthesis of xanthones based on chromen-4-ones. The fifth section refers a miscellaneous of methodologies 
that do not fit in any of the previous but nevertheless are useful. The last section is devoted to molecular 
modifications that can be done directly from the xanthone scaffold. 
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Main text: 
Introduction 
Natural Products have always been a source of inspiration in the drug discovery which can be depicted 
by the current number of drugs available in the market and in clinical trials that were isolated or based on 
natural products [1-10]. Xanthones are a class of natural products which have been gathering much attention 
due to their interesting biological activities [11-22]. They are capable of interacting with several different 
receptors being an interesting starting point for the discovery of new potential drug candidates. In addition, 
most of these compounds exhibit fluorescence which can be an advantage since they can be used as 
fluorescence probes. Xanthone family comprises O-heterocycles with a dibenzo-Ȗ-pyrone scaffold (Figure 1) 
and can be found in higher plants, fungi and lichens [23, 24]. Many xanthones with different patterns of 
substitution have been isolated leading to a great variety of compounds. In spite of this, the biosynthetic 
pathway only allows the presence of certain groups in specific positions of the xanthone scaffold. Therefore, 
the use of total synthesis could access structures that otherwise could not be reached if it was used the natural 
product as a launching platform for molecular modification. Moreover, the synthetic methods could be a way 
of getting biological interesting compounds in higher quantities which frequently is a drawback in natural 
products chemistry.  

Figure 1. Xanthone scaffold 
The synthesis of xanthones has been reviewed in the past [25-31]. However, the recent published 
reviews regarding xanthones have either focused mainly on the biological activities and synthetic approaches 
for a very specific class of derivatives [11-22], or referred the synthesis of xanthones very briefly in 
heterocycles book sections [32-36]. Therefore, no recently published review addressed the new synthetic 
methodologies that emerged in the past seven years. Consequently, an update can be extremely useful and 
opportune. In addition to the new methodologies that will be described in detail, previous-2005 
methodologies will only be referred very briefly, focusing mainly on recent examples. However, some of 
those methodologies will be looked more deeply when significant improvements have been reported. 
This review is divided in 6 sections (Scheme 1). The first section refers to the synthesis of xanthones 
in one step starting from two building blocks adequately functionalized. In this section, special care will be 
turned to the new methodologies via benzyne and annulations catalyzed by palladium. The two following 
sections concern two classical routes commonly described for the synthesis of xanthones, via benzophenone 
and diaryl ether routes, which lead generally to the xanthone scaffold in two steps. Therefore, each of these 
two sections is sub-divided; firstly the different options on how to obtain the benzophenone or the diaryl 
ether and secondly the respective cyclization methodologies to give the xanthone derivative. In addition, 
special attention will be given to improvements reported for these two approaches and also recent examples 
of their applicability. The fourth section deals with the synthesis of xanthones starting from chromen-4-ones. 
This strategy is not frequently used but is a very important approach since it can lead to xanthones with 
complex patterns of substitution. The fifth chapter describes less common strategies which can be a viable 
alternative to the classical methodologies. The last section refers to the molecular modifications directly in 
the xanthone core.   
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Scheme 1. Schematic representation of the different sections of the review. 
1. Synthesis of xanthones in one step 
There are three distinct approaches for the synthesis of xanthones in one step by condensation of two 
building blocks (Scheme 2). The oldest and well-known route 1.1, condensates salicylic acids or salicylic 
esters with polyphenolic compounds, catalyzed by a strong acid to give the xanthone scaffold. Several acid 
catalysts have been used and among them, the most successful and commonly used is zinc 
chloride/phosphoryl chloride, which was named Grover, Shah and Shah reaction [25-28, 37]. The second 
route 1.2, which was described for the first time in 2005, uses also salicylate esters but instead of a 
polyphenolic compound, is used an aryne intermediate [38, 39]. Later, it was reported that the reaction of an 
aryne intermediate with salicylaldehydes [40] or o-halobenzoic acids [41] leads also to the xanthone scaffold. 
The route 1.3, which was described in 2009, uses palladium as catalyst to promote an annulation between 
salicylaldehyde and 1,2-dibromoarene derivatives [42]. 
 
Scheme 2. Synthesis of xanthones in one step by reaction between two building blocks. 
1.1 Condensation of a salicylic acid or salicylic ester with a phenol derivative (Scheme 2; 1.1) 
The first synthesis of a xanthone was reported by Michael-Kostanecki and was successfully 
accomplished when a mixture of a polyphenol and different salicylic acids were heated in the presence of  a 
dehydrating agent such as acetic anhydride [43, 44]. Later, it was found that heating these same starting 
materials with zinc chloride/phosphoryl chloride (Grover, Shah and Shah reaction) [37], zinc chloride 
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(Nencki reaction) [45], polyphosphoric acid (PPA) [46] and phosphorous pentoxide/methanesulfonic acid 
(Eaton’s reagent) [47] the xanthone scaffold could also be synthesized and in better yields and shorter 
reaction times (Scheme 3). Moreover, there are few examples where no acid catalyst was needed when 
salicylate esters and a polyphenol were heated together in diphenyl ether [48]. These methodologies are still 
very useful for the synthesis of simple oxygenated xanthones since the reagents in general are cheap and 
accessible, and also the yields are reasonable. The most common methodology is undoubtedly the Grover, 
Shah and Shah but there are some limitations since this reaction proceeds via a benzophenone intermediate 
which must have one hydroxyl in the 6 or 6’ position, besides two hydroxyls in the position 2 and 2’ (Scheme 
3). If that does not occur, an additional cyclization of the benzophenone intermediate is needed in order to 
obtain the xanthone [37]. The Nencki reaction is not so commonly used since the temperature necessary for 
the reaction to take place is high (§ 160 ºC) and very often leads to undesirable O-demethylations [49]. In the 
case of PPA, normally it does not lead to high yields and even with the aid of microwave heating the yields 
do not improve significantly [50] (See Table 1). The use of Eaton’s reagent is limited to phloroglucinol as 
polyphenol since with resorcinol and pyrogallol it did not work [47]. In Table 1 are gathered recent examples 
of the described methodologies used for the synthesis of xanthones in one step (for more detailed information 
see classical methodologies in [26-28]). 
 
Scheme 3. Synthesis of xanthones by reaction of a salicylic acid derivative with an adequate polyphenolic 
compound.  
Table 1. Recent examples (2005-2012) of xanthones synthesized in one step by condensation of polyphenolic 
compounds and salicylic acids. 
Salicylic derivative Polyphenol Reagents Xanthone 
% Yield/  
[Reference] 
Salicylic acid 2-Methylphloroglucinol  ZnCl2, POCl3, 70 ºC, 3h 
2-Methyl-1,3-
dihydroxixanthone 32/ [51]
a
 
Salicylic acid Phloroglucinol ZnCl2, POCl3, 70 ºC, 3h 1,3-Dihydroxyxanthone 53/ [51]a 
Salicylic acid Phloroglucinol ZnCl2, POCl3 1,3-Dihydroxyxanthone 93-95/ [52]a 
2-Hydroxy-3-
methoxybenzoic acid Phloroglucinol ZnCl2, POCl3 
1,3-Dihydroxy-5-
methoxyxanthone 93-95/ [52]
a
 
Salicylic acid Phloroglucinol ZnCl2, POCl3, 65 ºC, 2h 1,3-Dihydroxyxanthone 52/ [53]a 
Salicylic acid Phloroglucinol ZnCl2, POCl3 1,3-Dihydroxyxanthone 38/ [54]a 
2,3,4-
Trihydroxybenzoic 
acid 
Phloroglucinol ZnCl2, POCl3, 70 ºC, 3h 
1,3,5,6-
Tetrahydroxyxanthone 
52 and 45/ 
[55, 56]a 
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2-Hydroxy-1-
naphthalenecarboxylic  
acid 
Phloroglucinol ZnCl2, POCl3, 65 ºC, 4h 
9,11-Dihydroxy-12H-
benzo[Į]xanthone 23/ [57] 
2-Hydroxy-1-
naphthalenecarboxylic  
acid 
3,5- 
Dimethoxyaniline 
ZnCl2, POCl3, 65 ºC, 1.5 
h 
11-Amino-9-methoxy-12H-
benzo[Į]xanthen-12-one 23/ [57] 
Salicylic acid Phloroglucinol ZnCl2, POCl3, 70 ºC, 3 h 1,3-Dihydroxyxanthone 43/[58]a 
Salicylic acid Resorcinol ZnCl2, 200ºC/5 min – 180 ºC/4 h 1-Hydroxyxanthone 48/ [59]
a
 
Salicylic acid Resorcinol PPA, 80-140 ºC, MW, 2-5 min 1-Hydroxyxanthone 29/ [50]
a
 
Salicylic acid Phloroglucinol PPA, 80-140 ºC, MW, 2-5 min 1,3-Dihydroxyxanthone 35/ [50]
a
 
2,6-Dihydroxybenzoic 
acid Resorcinol 
PPA, 80-140 ºC, MW, 2-
5 min 
1,8-Dihydroxyxanthone and 
1,6-Dihydroxyxanthone 
4 and 19/ 
[50]a 
2,6-Dihydroxybenzoic 
acid Phloroglucinol 
PPA, 80-140 ºC, MW, 2-
5 min 1,3,8-Trihydroxyxanthone 31/ [50]
a
 
2,4-Dihydroxybenzoic 
acid Phloroglucinol 
PPA, 80-140 ºC, MW, 2-
5 min 1,3,6-Trihydroxyxanthone 25/ [50]
a
 
2,5-Dihydroxybenzoic 
acid Phloroglucinol 
PPA, 80-140 ºC, MW, 2-
5 min 1,3,7-Trihydroxyxanthone 21/ [50]
a
 
2,4,6-
Trihydroxybenzoic 
acid 
Phloroglucinol PPA, 80-140 ºC, MW, 2-5 min 
1,3,6,8-
Tetrahydroxyxanthone 17/ [50]
a
 
2-Hydroxy-3-
methylbenzoic acid Phloroglucinol 
P2O5, CH3SO3H, 80 ºC, 
20 min 
1,3-Dihydroxy-5-
methylxanthone 96/ [60] 
2-Hydroxy-4-
methylbenzoic acid Phloroglucinol 
P2O5, CH3SO3H, 80 ºC, 
20 min 
1,3-Dihydroxy-6-
methylxanthone 95/ [60] 
2-Hydroxy-5-
methylbenzoic acid Phloroglucinol 
P2O5, CH3SO3H, 80 ºC, 
20 min 
1,3-Dihydroxy-7-
methylxanthone 91/ [60] 
2,5-Dihydroxy-4-
methoxybenzoic acid Phloroglucinol 
P2O5, CH3SO3H, 80 ºC, 
40 min 
7-Mesyloxy-6-methoxy-1,3-
dihydroxyxanthone 40/ [61]
a
 
a.Reference cited in the text. 
 In addition to these classical methodologies, a recent work described the synthesis of 
polyoxygenated xanthones in one step catalyzed by other acid catalysts, namely AlCl3, TiCl4 and SnCl2 [62]. 
The polyoxygenated xanthones were obtained in 50 seconds by the neat reaction of salicylic acids with 
polyphenolic compounds catalyzed by either AlCl3, TiCl4, SnCl2 or ZnCl2 under microwave heating. The 
yields were moderate to good for all the examples and the best results were obtained with SnCl2. This 
reaction was also applied for the synthesis of thioxanthones [62]. 
1.2 Synthesis of xanthones by condensation of either a salicylic ester, a salicylaldehyde or o-
fluorobenzoic acid with an aryne intermediate (Scheme 2; 1.2) 
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Scheme 4. Proposed mechanism for the synthesis of xanthones via benzyne. 
R. Larock group (2005) referred for the first time the synthesis in one step of xanthones using 
salicylates (methyl or benzyl) and trimethylsilylaryl triflates as building blocks [38]. The trimethylsilylaryl 
triflates in the presence of cesium fluoride lead to an extremely reactive aryne which through a tandem 
intermolecular nucleophilic coupling with the salicylate and intramolecular electrophilic cyclization give the 
xanthone (Scheme 4. A). The key intermediate seems to be the carbanion generated from the intermolecular 
coupling of the aryne and the phenol. This intermediate can follow two courses: it can undergo an 
electrophilic cyclization to give the xanthone or be protonated to give a diaryl ether. Therefore, the choice of 
solvent showed to be crucial for the course of the reaction and the use of tetrahydrofuran (THF) gave the 
xanthone with high regioselectivity. The scope and limitations of the reaction were further investigated and 
showed to accept both electron-donating and electron-withdrawing functionalities on the salicylate ring 
(Scheme 5; Table 2; entries 1-11). In the case of the salicylate ester, the phenyl salicylate worked better than 
the methyl salicylate (Scheme 5; Table 2; entries 1 and 12). On the other hand, the aryne ring appeared to be 
more vulnerable to substituents and higher temperatures were needed in order to obtain the desired products 
(Scheme 5; Table 2; entries 13-17) [38, 39]. This reaction was also used for the synthesis of thioxanthones 
[38, 39], benzoxanthones [38, 39], acridones [38, 39, 63, 64] and acridines [63, 65]. In 2010, the R. Larock 
group described an extension to this methodology and xanthones were also obtained from the reaction o-
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halobenzoic acids with aryne intermediates. However, the coupling of an aryne and o-halobenzoic acid does 
not produced a diaryl ether intermediate. Instead, the reaction proceeds through a benzophenone intermediate 
which then suffers an intramolecular nucleophilic aromatic substitution to give the xanthone (Scheme 4. B) 
[41]. The scope of this reaction was not thoroughly investigated since only two xanthones were synthesized 
(Scheme 5; Table 2; entries 18 and 19). This methodology was also employed for the synthesis of one 
azaxanthone [41]. In 2009, K. Okuma group reported an expansion of this reaction when synthesized 
xanthones from the condensation of an aryne intermediate with salicylaldehydes [40]. However, for these 
substrates, the reaction is not regioselective and the intermediate could give either a xanthone or a xanthene. 
This lack of selectivity is due to the fact that the reaction proceeds via a 9-hydroxyxanthene intermediate 
which suffers desproportionation to give both compounds (Scheme 4. C). Because of this fact, the yield 
obtained for the xanthones was only moderate. On the other hand, the reaction seemed to proceed well with 
both electron-withdrawing and electron-donating substituted salicylaldehydes (Scheme 5; Table 2; entries 20-
24). Moreover, if a base (K2CO3) was used, the reaction stopped at the intermediate xanthol which could be 
further oxidized to xanthone. The K. Okuma group reported another unexpected extension to the 
methodology and obtained the xanthone by the reaction of an trimethylsilylaryl triflate with N,N-
dimethylformamide (DMF), N-formylmorpholine and dimethylthioformamide [66]. However, the xanthone 
was not the desired product and was considered as a side-product. It was proposed that the xanthone was 
synthesized in view of the fact that when the aryne intermediate reacts with DMF, or N-formylmorpholine or 
N,N-dimethylthioformamide, it gives a salicylaldehyde which can react with a second molecule of the aryne 
and follow the same path explained previously (Scheme 4, C). Although all these methodologies seem very 
promising, there is a serious limitation due to only a few commercially available trimethylsilylarylaryl 
triflates.  
 
Scheme 5. Synthesis of xanthones by coupling of salicylic acids, or salicylate esters, or salicyladehydes with 
trimethylsilylaryl triflates.  
Table 2. Xanthones synthesized by coupling of salicylic acids, or salicylate esters or salicylaldehydes with 
(trimethylsilyl)aryl triflates. 
Entry X Y R1 R2 Experimental conditions Xanthone (s) % Yield 
1a OMe OH H H CsF, THF, 65 ºC, 24 h Xanthone 75 
2a OMe OH 3-OMe H CsF, THF, 65 ºC, 24 h 4-Methoxyxanthone 59 
3a OMe OH 4-OMe H CsF, THF, 90 ºC, 24 h 3-Methoxyxanthone 62 
4a OMe OH 5-OMe H CsF, THF, 65 ºC, 24 h 2-Methoxyxanthone 69 
5a OMe OH 6-OMe H CsF, THF, 65 ºC, 24 h 1-Methoxyxanthone 35 
6a OMe OH 5-COMe H CsF, THF, 65 ºC, 24 h 2-Acetylxanthone 58 
7a OMe OH 5-F H CsF, THF, 65 ºC, 24 h 2-Fluoroxanthone 83 
8a OMe OH 5-Br H CsF, THF, 65 ºC, 24 h 2-Bromoxanthone 75 
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a.The references for these entries are cited in the text with numbers 38 and 39. b.The product obtained was the 2-phenoxyxanthone instead 
hydroxyxanthone. c.Combined yield (1:1). dThe reference for these entries is cited in the text with number 41. e.The references for these entrie
cited in the text with number 40. f.Besides the xanthone, equivalent substituted xanthenes were obtained. 
1.3 Synthesis of xanthones by a palladium-catalyzed annulation of 1,2-dibromoarenes and 
salicylaldehydes (Scheme 2; 1.3) 
In 2009, a route for the synthesis of xanthones in one-step using salicylaldehyde and 1,2-
dibromobenzene derivatives as building blocks was described (Scheme 6) [42]. This reaction seems to 
proceed via palladium-catalyzed annulation and several xanthones were synthesized in moderate yields 
ranging from 33 to 63 % (Table 3). The methyl and methoxyl groups were both well-tolerated on 
salicylaldehyde derivatives (Table 3; entries 2-5, 8-11) but stronger electron-donating groups (EDGs) such as 
diethylamino group led to a decrease in the yield (Table 3; entry 6). The 1,2-dibromobenzene could bear a 
methyl group but two methoxyl substituents led to a significant decrease in the yields (Table 3; entry 12 and 
13). In addition, the Pd-catalyzed annulation was used for the synthesis of a benzoxanthone when 2-hydroxy-
1-naphthaldehyde was used instead of salicylaldehyde. As in the previous section, the lack of 1,2-
dibromoarenes commercially available can limit the applicability of this synthetic route. 
Scheme 6. Synthesis of xanthones by palladium-catalyzed annulations. 
Table 3. Xanthones synthesized by palladium-catalyzed annulations of salicyladehydes with 1,2-
dibromoarene 
9a OMe OH 5-Ph H CsF, THF, 65 ºC, 24 h 2-Phenylxanthone 64 
10a OMe OH 5-Me H CsF, THF, 65 ºC, 24 h 2-Methylxanthone 71 
11a,b OMe OH 5-OH H CsF, THF, 65 ºC, 24 h 2-Phenoxyxanthone 52 
12a OPh OH H H CsF, THF, 65 ºC, 24 h Xanthone 81 
13a OMe OH H 3-OMe CsF, THF, 90 ºC, 24 h 1-Methoxyxanthone 62 
14a OMe OH H 4-OMe, 5-OMe CsF, THF, 90 ºC, 24 h 2,3-Dimethoxyxanthone 57 
15a OMe OH H 4 –Me, 5 – Me CsF, THF, 90 ºC, 24 h 2,3-Dimethylxanthone 51 
16a OMe OH H 4-Me CsF, THF, 90 ºC, 24 h 
2-Methylxanthone 
3-Methylxanthone 
59c 
17a OMe OH H [ ȕ ]-2,3-dihydro-1H-indene CsF, THF, 90 ºC, 24 h 
1,2,3,5-
Tetrahydrocyclopenta[ȕ
]xanthone 
45 
18d OH F H H CsF, THF, 125 ºC, 24 h Xanthone 80 
19d OH F H 3-OMe CsF, THF, 125 ºC, 24 h 1-Methoxyxanthone 71 
20e,f H OH H H CsF, MeCN, r.t, 15 h Xanthone 46 
21e,f H OH 4-OMe H CsF, MeCN, r.t, 15 h 3-Methoxyxanthone 47 
22e,f H OH 4-Me H CsF, MeCN, r.t, 15 h 3-Methylxanthone 46 
23e,f H OH 4-t-Bu H CsF, MeCN, r.t, 15 h 3-(t-Bu)-xanthone 26 
24e,f H OH 2-Cl H CsF, MeCN, r.t, 15 h 1-Chloro-xanthone 42 
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Entry R1 R2 Xanthone(s) % Yield 
1 H H Xanthone 61 
2 5-Me H 2-Methylxanthone 54 
3 3-Me H 4-Methylxanthone 56 
4 4-OMe H 3-Methoxyxanthone 53 
5 3-OMe H 4-Methoxyxanthone 52 
6 4-NEt2 H 3-(Diethylamino)-xanthone 38 
7 H 4-Me 
2-Methylxanthone  
3-Methylxanthone 
56a 
8 5-Me 4-Me 
2,7-Dimethylxanthone 
2,6-Dimethylxanthone 
61a 
9 3-Me 4-Me 
2,5-Dimethylxanthone 
3,5-Dimethylxanthone 
60a 
10 4-OMe 4-Me 
6-Methoxy-2-methylxanthone 
3-Methoxy-6-methylxanthone 
59a 
11 3-OMe 4-Me 
5-Methoxy-2-methylxanthone 
5-Methoxy-3-methylxanthone 
63a 
12 H 3-OMe, 4-OMe 2,3-Dimethoxyxanthone 36 
13 3-Me 3-OMe, 4-OMe 2,3-Dimethoxy-5-methylxanthone 33 
a.Combined yield in 1:1 isomeric ratio. 
2. Synthesis of xanthones via benzophenone route (Scheme 1; 2.1 and 2.2) 
In order to overcome the limitations of one-step methodologies and to improve yields, several multi-
step approaches have been developed. Among them, the benzophenone route is undeniably the most used due 
to the high yields normally obtained [25]. This route involves two steps: the synthesis of benzophenones 
(Scheme 7; 2.1) and subsequent cyclization (Scheme 7; 2.2). Other methodologies referring the synthesis of 
xanthones via benzophenone can be seen in [25, 67-73]. In addition, more information regarding the 
synthesis of benzophenones is described in [74]. 
 
Scheme 7. Several alternatives for the synthesis of xanthones through benzophenone route. 
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2.1 Synthesis of the benzophenones 
2.1.1 Electrophilic Aromatic Substitution 
 
Scheme 8. Synthesis of benzophenones through electrophilic aromatic substitution 
Friedel-Crafts acylation is the most common methodology employed for the synthesis of 
benzophenones through electrophilic aromatic substitution. The reaction takes place between an acyl chloride 
and a phenol (Scheme 8; R3 = H)  or protected phenol derivative (Scheme 8; R3 = alkyl), usually catalyzed by 
aluminum chloride (Scheme 8) [75, 76]. The benzophenone derivative is generally obtained in good yields 
and in some cases selective O-demethylation is observed (for more detailed information about this 
methodology applied for the synthesis of xanthones see [25-27]). On the other hand, the Friedel-Crafts 
acylation suffers from significant limitations since it normally lacks regioselectivity because both ortho and 
para positions can be acylated. In addition, many functional groups are sensitive to the strong acid conditions 
which can restrict its applicability. In spite of this, it is still used frequently nowadays as a route to xanthones 
(in Scheme 9/Table 4 are described recent examples).  

Scheme 9. Synthesis of the benzophenone through a Friedel-Crafts acylation. 
Table 4. Recent examples of benzophenones synthesized by Friedel-Crafts acylation. 
X Y R1 R2 R3 Experimental Conditions Benzophenone 
% Yield/ 
[Reference] 
OMe Cla 6-OMe 2-OMe, 3-OMe Me AlCl3, Et2O, 12 h, r.t 
 
86/ [77]b 
F Cla H 2-OH, 3-OH H AlCl3, CH2Cl2, CHCl3, rt, 17 h 
 
Not 
isolated/ 
[78]b 
I OH H 4-Me H Graphite, MsOH, 3-4 h, 120 ºC 
 
42/ [79, 
80]b 
Br OH H 4-Me H Graphite, MsOH, 3-4 h, 120 ºC 
 
47/ [79, 
80]b 
Cl OH H 4-Me H Graphite, MsOH, 3-4 h, 120 ºC 
31/ [79]b 
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I OH H 3-Me, 4-Me H Graphite, MsOH, 3-4 h, 120 ºC 
 
42/ [79, 
80]b 
Br OH H 3-Me, 4-Me H Graphite, MsOH, 3-4 h, 120 ºC 
 
49/ [80]b 
Cl OH H 3-Me, 4-Me H Graphite, MsOH, 3-4 h, 120 ºC 
 
47/ [79]b 
Br OH 4-Me 4-Me H Graphite, MsOH, 3-4 h, 120 ºC 
30/ [79, 
80]b 
I OH 5-F 4-Me H Graphite, MsOH, 3-4 h, 120 ºC 
31/ [79, 
80]b 
I OH 5-F 3-Me, 4-Me H Graphite, MsOH, 3-4 h, 120 ºC 

50/ [79, 
80]b 
Br OH 4-Cl 3-Me, 4-Me H Graphite, MsOH, 3-4 h, 120 ºC 
46/ [79, 
80]b 
Br Cla H 2-OMe, 3-OMe Me AlCl3, CH2Cl2, reflux, 4 h 

53/ [79, 
80]b 
OMe Cl 4-OMe, 5-OMe 3-OMe, 5-OMe Me AlCl3, Et2O, 48 h, r.t 

72/ [81] 
OMe Cl H 2-OMe, 3-OMe Me AlCl3, Et2O, 22 h, r.t 
85/ [59, 
82]b 
F Cl H 2-OH, 3-OH H AlCl3, CH2Cl2, CHCl3, rt, 12 h 
 
45/ [83] 
F Cl H 
2-OH, 3-OH,  
5-Me 
H AlCl3, CH2Cl2, CHCl3, rt, 1.5 h, then 6 h 60 ºC 

Not 
isolated/ 
[84]b 
a.The acyl chloride was prepared before the Friedel-Crafts acylation; b.Reference cited in the text. 
In 2006 it was reported the synthesis of several benzophenones by an acylation of phenols using 
BCl3 as the Lewis acid and microwaves as the source of energy (Scheme 10; Table 5) [85]. The 
benzophenones were obtained in 30 min at 140 ºC in moderate to good yields. In spite of being 
regioselective, these reactions were limited to 3-methyl and 3-methoxyphenol, but only for the latter, good 
yields were obtained. For the acyl derivatives, both electron-withdrawing and electron-donating 
functionalities were well-tolerated. The benzophenones with the appropriate pattern of substitution were 
cyclized to xanthones. 
 
Scheme 10. Synthesis of benzophenones through a boron trichloride mediated acylation of phenols. 
Table 5. Benzophenones synthesized by ortho acylation of phenols using BCl3 as Lewis’ acid. 
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Entry R1 % Yield 
1 H 65 
2 4-Br 58 
3 5-Cl 69 
4 5-I 68 
5 5-CF3 64 
 
As it was explained in the section 1.1, the Grover, Shah and Shah Method only give xanthones in 
one step if the benzophenone intermediate has at least three hydroxyls in position 2, 2’, 6 or 6’ (Scheme 3). If 
that does not occur, a benzophenone is obtained that needs to be cyclized to the xanthonic derivative. As a 
matter of fact, one recent example referred the synthesis of a benzophenone by the reaction of the methyl 
ester of o-anisic acid with pyrogallol using the Grover, Shah and Shah conditions (Scheme 11; A). The 
benzophenone was obtained in 78 % yield and it was later cyclized to give 3,4-dihydroxyxanthone [84]. 
Another recent example used the Eaton’s reagent (P2O5/CH3SO3H) to give a benzophenone through the 
reaction of methyl 3-fluoro-2,4-dimethoxybenzoate with 2-fluoro-1,3-dimethoxybenzene (Scheme 11; B). 
The benzophenone was then selectively O-demethylated with BCl3 and cyclized to give the 3,6-dimethoxy-
4,5-difluoroxanthone [86].  
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Scheme 11. Synthesis of benzophenones using Grover, Shah and Shah methodology (A) and Eaton’s reagent 
(B). 
In an attempt to introduce a gem-difluoromethylene moiety through a Friedel-Crafts-type alkylation 
of bromodifluoro(phenylsulfanyl)methane into electron-rich aromatic chemical substrate, namely 
polymethoxylated benzenes, several benzophenones and thioesters were obtained instead [87]. Moreover, 
benzophenones and thioesteres could be obtained regioselectively by varying solely the experimental 
conditions. Therefore, in the presence of an excess of bromodifluoro(phenylsulfanyl)methane (Scheme 12, 
A), thioesters were the main product and, in some examples, the only product isolated. On the other hand, the 
use of an excess of polymethoxylated benzenes and prolonged reaction times led to a symmetrical 
benzophenone (Scheme 12, B) through a dimerization reaction. In addition, with the appropriate 
experimental conditions, two different polymethoxylated benzenes could be used to give instead of the 
dimerization product, unsymmetrical benzophenones. It was proposed that the first step of the reaction is 
related to the formation of a stabilized carbocationic intermediate generated from the reaction of the 
bromodifluoro(phenylsulfanyl)methane with a Lewis acid. The carbocationic intermediate then suffers a 
Friedel-Crafts-type alkylation leading to an adduct which reacts again with the Lewis acid to give another 
carbocationic intermediate. This carbocationic intermediate is critical to the outcome of the reaction since it 
can be hydrolyzed to give a thioester or reacts with another aromatic ring to give, after hydrolysis, a 
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benzophenone. These benzophenones with the appropriate pattern of substitution were selectively O-
demethylated and cyclized to xanthones [87]. 
 
Scheme 12. Synthesis of benzophenones by a Friedel-Crafts-type alkylation between 
bromodifluoro(phenylsulfanyl)methane and several electron rich aromatic compounds. 
2.1.2 Addition of an aryllithium to a carbonyl group 

Scheme 13. Synthesis of benzophenones in one (A) or two steps (B) by the nucleophilic addition of an 
aryllithium to a carbonyl group.  
Another well-known strategy to synthesize benzophenones is by the 1,2-nucleophilic addition of an 
aryllithium intermediate to a carbonyl group. This route begins always with the formation of a strong 
aryllithium nucleophile by a directed ortho lithiation or halogen/lithium exchange (Scheme 13) [88]. The 
aryllithium then reacts with a carbonyl group and the benzophenone is obtained in one or two steps 
depending on the nature of the carbonyl group. If an ester [89, 90] or an acyl chloride [91] is used, the 
benzophenone is obtained in one step by a nucleophilic acyl substitution (Scheme 13; A.). However, if the 
aryllithium reacts instead with a benzaldehyde, the 1,2-nucleophilic addition of the aryllithium to the 
carbonyl of the benzaldehyde leads to a secondary alcohol which needs a second oxidation step [92] (Scheme 
13; B.). Albeit one extra oxidation, the benzaldehyde is more commonly used than the ester or the acyl 
chloride since it does not have the same limitations the latter have. For example, in the case of the ester, a 
tertiary alcohol can be synthesized instead of the benzophenone since the carbonyl of the benzophenone 
obtained by the 1,2-nucleophilic carbonylic addition of an aryllithium is more electrophilic than the ester 
group, and therefore, a second molecule of aryllithium can be added to the benzophenone. In order to avoid 
this, it should be used a highly hindered aryllithium intermediate or special care should be given to the 
experimental conditions [88]. The acyl chloride does not have the same limitation of the ester since the 
carbonyl group of an acyl chloride is more electrophilic than the carbonyl group of the benzophenone. On the 
other hand, it is not very stable and needs to be prepared just before the reaction. The advantage of these 
methodologies lies in the fact that highly substituted benzophenones can be synthesized in a regioselective 
way leading to highly substituted xanthones. It must be noted that the yields are usually not very high and 
several protection/deprotection steps are needed. Moreover, several functional groups are sensitive to the 
strong bases used in this route. Considering that highly substituted benzophenones can be synthesized, this 
methodology was a crucial step in the total synthesis of natural xanthones and benzophenones (recent 
examples for the synthesis of xanthones [89, 93-95] are represented in Figure 2).  
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Figure 2. Recent examples of natural xanthones synthesized by total synthesis using the 1,2-nucleophilic 
addition of an aryllithium to a carbonyl as a crucial step. 
2.1.3 Addition of an arene C-H to nitrile, catalyzed by palladium 
 
Scheme 14. Synthesis of benzophenones by a palladium-catalyzed addition of an arene C-H to nitriles 
Richard Larock group described in 2006 the synthesis of several benzophenones by a palladium-
catalyzed reaction [96]. The arene C-H addition to nitriles leads to ketimines that, for the great majority of 
the examples, is hydrolyzed to benzophenone during the work-up (Scheme 14). However, ketimines are 
isolated with highly substituted arenes (R1), such as 1,3,5-trimethylbenzene, needing more drastic 
hydrolyzing conditions to give benzophenones. The scope and limitations of the reaction were evaluated and 
it was observed that the reaction took place in higher yields when electron-poor benzonitriles (R2) and 
electron-rich arenes (R1) were used. In addition, when more than one product could be obtained from the 
arene C-H addition to nitriles, the reaction was only regioselective for phenolic derivatives leading only to 
the acylation product ortho-to the hydroxyl. However, 4-methoxyphenol was an exception and no 
benzophenone was obtained possibily due to oligomerization reaction. The lack of regioselectivity observed 
in toluene or anisole could be overcome by the use of arylboronic acids since the substitution occurred only 
in the position of the boronic acid. Afterwards, the suitable benzophenones were cyclized to xanthones 
(Scheme 15; Table 6). 
 
Scheme 15. Synthesis of benzophenones through a palladium-catalyzed addition of an arene C-H to nitriles 
that were afterwards cyclized to xanthones. 
Table 6. Benzophenones synthesized trough a palladium-catalyzed addition of an arene C-H to nitriles which 
were then cyclized to xanthones. 
R1 R2 % Yield 
Mea OMe 82 
H Me 52 
H i-Pr 55 
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H t-Bu 61 
H Cl 42 
aThe methyl group was selectively removed with AlCl3 before the cyclization of the benzophenone to 
xanthone. 
2.1.4 Nucleophilic aroylation catalyzed by imidazolidenyl carbene 
The electrophilic aromatic substitution used for the synthesis of benzophenones (section 2.1.1) 
needed one electron-poor and one electron-rich aryl derivatives to be successful. With imidazolidenyl 
carbene as catalyst, benzophenones can be obtained from two electron-deficient building blocks. Therefore, 
this is a very appealing approach since it enables the introduction of aroyl groups in usually considered 
inaccessible positions by normal Friedel-Crafts acylation reactions. Several nitro-halobenzophenones were 
synthesized by nucleophilic aroylation of 3,4-difluoronitrobenzene or 2,4,5-trifluoronitrobenzene, with 
fluorobenzaldehyde or chlorobenzaldehyde derivatives catalyzed by a N-heterocyclic carbene generated in 
situ from 1,3-dimethylimidazolium iodide [97, 98] (Scheme 16, Table 7). The yields of the reaction were 
generally high except for the 2,6-disubstituted benzaldehydes possibly caused by steric hindrance around the 
formyl group by the two substituents (Table 7, entries 4 and 6). In some cases, besides the benzophenone, a 
diketone was also isolated since the nitro group behaved as a leaving group. The cyclization of these 2-2’-
dihalobenzophenones, led to xanthones or acridones depending on the reaction conditions.  This 
methodology was also applied for the total synthesis of atroviridin [98] (Figure 3). 
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Scheme 16. Synthesis of benzophenones by a nucleophilic aroylation catalyzed by imidazolidenyl carbene. 
Table 7. Benzophenones synthesized through a nucleophilic aroylation imidazolidenyl carbene-catalyzed. 
Entry X R1 R2 Yield (%) Benzophenone 
Yield (%) 
Diketone 
1a F H H 70 1 
2a F 4-F H 63 8 
3a F 5-F H 63 8 
4a F 6-F H 35 2 
5a Cl H H 64 7 
6a F 6-Cl H 27 - 
7b F 5-OMe F 76 - 
a.The reference for these entries is cited in the text with number 97; b.The reference for this entry is cited in 
the text with number 98. 
 
 
ŚĂƉƚĞƌϲ
ƉƉĞŶĚŝǆ
ϯϭϭ

Figure 3. Atroviridin synthesized via benzophenone using a nucleophilic aroylation catalyzed by 
imidazolidenyl carbene. 
2.1.5 Photoacylation 
The photoacylation can be a viable alternative to the classical Friedel-Crafts acylation, and therefore 
can also be applied for the synthesis of xanthones through benzophenone route. As a matter of fact, the 
photoacylation of 2,6-dimethoxybenzaldehyde with p-quinone led to a benzophenone that, after cyclization 
and O-demethylation, led to euxanthone [99] (Scheme 17). This methodology was also applied for the 
synthesis of benzoxanthones [99]. 
 
Scheme 17. Synthesis of euxanthone through a photoacylation step. 
 
2.2 Benzophenone Cyclization 
In order to obtain the xanthone scaffold from a benzophenone, positions 2 and 2’ must be connected 
by an ether bridge, and therefore the presence of at least one hydroxyl in either of those positions is essential 
(Scheme 18; X). In addition to the hydroxyl in one of the rings, the functionality present on the other ring can 
be numerous (Scheme 18; Y) and, in fact, it is the nature of this functionality that will influence the 
cyclization strategy to be used. There are three well-known strategies that use a nucleophilic aromatic 
substitution (SNAr)  [100], a nucleophilic displacement [101, 102] and an oxidative coupling [101] to form 
the ether bond. The first approach is undoubtedly the preferred strategy and during the last seven years has 
seen some improvements which will be described in detail below (Scheme 18; 2.2.1). The second strategy is 
seldom used [26, 27] and no reports of its use have been described in this period (it is not described here). 
The oxidative coupling is not used as frequently as the nucleophilic aromatic substitution but still has its 
utility (2.2.2) (Scheme 18; 2.2.2). Besides these three classical strategies, other two approaches can be 
followed. The copper-catalyzed intramolecular O-arylation (Scheme 18; 2.2.3), and the conjugate addition 
after oxidation of hydroquinone-benzophenones derivatives to quinones (Scheme 18; 2.2.4).  
 
Scheme 18. Synthesis of xanthones by cyclization of benzophenones. 
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2.2.1 Intramolecular nucleophilic aromatic substitution 
 
Scheme 19. Synthesis of xanthones by an intramolecular nucleophilic aromatic substitution. 
The intramolecular SNAr is the method of cyclization more commonly followed for the cyclization 
of benzophenones to xanthones. In the presence of a hydroxyl in position 2 and a functional group that can 
behave as leaving group in position 2’, an intramolecular SNAr can very easily take place. The SNAr is known 
to occur in two steps being the first-step the attack of the nucleophile to the carbon of the aromatic ring 
bearing the leaving group and the second-step the expelling of the leaving group (Scheme 19). The 
nucleophilic attack in the first-step of SNAr with moderate nucleophiles is the rate-determining step and is 
mainly influence by electrostatic interactions. Considering this fact, the relative leaving-group ability is 
largely influenced by the size and electronegativity of the functional group and so it has the following order: 
F- > -OR > Cl- > Br-> I- [103, 104]. However, there are some exceptions like the benzophenones, where the 
order of the relative leaving-group ability can be altered. The SNAr for benzophenones is entropically favored 
since it is intramolecular and therefore the energy of the transition state is lowered significantly. If the 
transition state is lowered to a similar energy state of the second-step, the elimination can become the rate-
determining step. However, in the second-step, the relative leaving-group ability is mainly influenced by the 
bong energy between the aromatic carbon and the leaving-group and the rate changes to: Br- < Cl- < F- < -OR 
[103, 104].  
 
Scheme 20. Different outcome of the reaction by variation of the solvent. 
Table 8. Conditions used for the cyclization of the benzophenone to xanthone. 
Entry X R Solvent Temperature (ºC) A/B 
1 F Me MeOH 85 100:0 
2 F iPr DMF 50 100:0 
3 F Me MeOH 85 100:0 
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4 F iPr DMF rt. 100:0 
5 Cl Me MeOH 80 1:11 
6 Cl Me H2O 100 1:8.6 
7 Cl Me Formamide 80 1:7.7 
8 Cl Me THF 80 1:8.5 
9 Cl Me DMF 45 1.7:1 
10 Cl Me DMPU 50 2.8:1 
11 Cl iPr MeOH 100 1:8 
12 Cl iPr Formamide 80-90 1:3.4 
13 Cl iPr THF 80 1:5.5 
14 Cl iPr DMF 50 10:1 
15 Cl iPr DMPU 50 20:1 
 
Bearing in mind that the transition-state for the two steps of the SNAr for benzophenones can be 
similar in energy, a solvent-effect was evaluated on the cyclization of benzophenones to xanthones with two 
types of leaving groups: halogens and alkoxides (Scheme 20; Table 8) [94]. In order to accomplish this, 
several benzophenones with a halogen (fluorine or chlorine) in position 2, an ether (methoxyl or isopropoxyl) 
in position 6 and a hydroxyl group in position 2’ were synthesized (Scheme 20). It was described that no 
matter the nature of the solvent, fluoride was always the best leaving group (Table 8; entries 1-4). However, 
for chloride, a solvent effect on the ratio of the products was observed (Table 8; entries 5-15). Moreover, this 
effect was more pronounced for isopropyl (Table 8; entries 11-15) than for methyl ether (Table 8; entries 5-
14). It was explained that in the presence of dipolar aprotic solvents, such as DMF, the nucleophilicity of the 
phenoxide is increased, and therefore the transition state for the first step is lowered in energy. Since the 
bonding energy between the aromatic carbon and the chlorine is lower than the bonding energy between the 
aromatic carbon and the alkoxyl group, if the decrease in energy of the first step is significant, the second-
step can become the rate-determining step, and consequently, the chloride becomes a better leaving group 
than the alkoxide. On the other hand, when the solvent polarity increases, the nucleophilicity of the 
phenoxide decreases and also the leaving group becomes better solvated. This will make the first-step the 
rate-determining step and so, the alkoxide becomes the best leaving group. The solvent-effect was applied for 
the regioselective cyclization of a benzophenone which was then used as building block in the total synthesis 
of FD-594 aglycon (Figure 1; Scheme 21; A).  
 
Scheme 21. Synthesis of xanthone core used for the synthesis of FD-594 aglycon. 
During the last seven years some improvements have been described for the intramolecular SNAr of 
benzophenones. For instance, the use of microwaves as heating source has shown to be a viable alternative to 
conventional heating since xanthones were obtained in higher yields and in shorter reaction times [77, 85, 
105, 106]. This is an interesting improvement since for the great majority of the SNAr, the time of reaction is 
long, leading to many undesired secondary products [76]. Another improvement in the intramolecular SNAr 
was the use of fluoride as leaving group (Scheme 19; X) since it generally leads to high yields and in short 
times of reaction [78, 85, 96]. Moreover, a green methodology was developed for the cyclization of 
benzophenones with bromide and iodide as leaving groups [79]. Finally, cesium carbonate has shown to be a 
good alternative to the commonly used sodium hydroxide and sodium carbonate [85, 94]. 
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In the intramolecular SNAr of benzophenones we have described so far, all the benzophenones had a 
hydroxyl in position 2 (Scheme 19). However, that is not an indispensable feature since it was described the 
synthesis of xanthones from the cyclization of 2,2’-difluorobenzophenones derivatives using two sequential 
SNAr. The first SNAr is intermolecular and occurs between the benzophenone and hydroxide anion to give a 
2’-hydroxy-2-fluorobenzophenone derivative. This derivative is not isolated and can suffer an intramolecular 
SNAr to give the xanthone scaffold in one pot synthesis (Scheme 22) [97, 107]. The cyclization was 
successfully accomplished with 2,2’-difluorobenzophenones derivatives (Table 9; entries 1-4 and 6-16), but 
when one of the fluorines in position 2 or 2’ was replaced by chlorine, the yields decreased significantly and 
the compound obtained in higher yield was 2’-chloro-2-hydroxy-4-nitrobenzophenone (Table 9; entry 5) 
[97]. This methodology was also applied for the synthesis of acridones [97, 107] and thioxanthones [107]. 
 
Scheme 22. Cyclization of benzophenones to xanthones by sequential SNAr, the first intermolecular and the 
second intramolecular. 
Table 9. Xanthones obtained by the cyclization of benzophenones by two sequential SNAr. 
Entry X R1 R2 R3 R4 R5 Experimental Conditions Xanthone 
% 
Yield 
1a F H H H H NO2 
10 % NaOH aq, 1,4 
dioxane, reflux, 12 h 
 
65 
2a F F H H H NO2 
10 % NaOH aq, 1,4 
dioxane, reflux, 12 h 
 
30 
3a F H F H H NO2 
10 % NaOH aq, 1,4 
dioxane, reflux, 12 h 
 
33 
4a F H H F H NO2 
10 % NaOH aq, 1,4 
dioxane, reflux, 12 h 
 
35 
5a,b Cl H H H H NO2 
10 % NaOH aq, 1,4 
dioxane, reflux, 12 h 
 
12 
6a Cl H H F H NO2 
10 % NaOH aq, 1,4 
dioxane, reflux, 12 h 
 
62 
7c F F F H F F KOH, H2O, 200 ºC, 3 h 

99 
8c F NH2 F H F F 
KOH, DMSO/H2O, 150 
ºC, 12 h 
80 
9c F NMe2 F H F NMe2 
KOH, DMSO/H2O, 150 
ºC, 12 h 
85 
10c F Net2 F H F Net2 
KOH, DMSO/H2O, 170 
ºC, 12 h 
85 
11c F Net2 F H F F 
KOH, DMSO/H2O, 150 
ºC, 12 h 
95 
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12c F NHiPr F H F NHiPr KOH, DMSO/H2O, 150 
ºC, 16 h 
92 
13c F NHtBu F H F NHtBu KOH, DMSO/H2O, 150 
ºC, 12 h 
90 
14c F Piperidyl F H F Piperidyl KOH, DMSO/H2O, 170 
ºC, 12 h 
92 
15c F Piperidyl F H F F KOH, DMSO/H2O, 150 
ºC, 12 h 

95 
16c F Morpholyl F H F Morpholyl KOH, DMSO/H2O, 170 
ºC, 12 h 
83 
a.The reference for these entries is cited in the text with number 97; b.2’-chloro-2-hydroxy-4-nitrobenzophenone was isolated as majo
product. c.The reference for these entries is cited in the text with number 107. 
2.2.2 Oxidative coupling 
The oxidative coupling is not as commonly used as the intramolecular SNAr but is still a valuable 
tool for the cyclization of polyoxygenated benzophenones bearing at least one hydroxyl in position 2 and one 
hydroxyl or methoxyl in position 3’. Therefore, it useful for the cyclization 2-hydroxybenzophenones 
derivatives that do not have a leaving group in positions 2’ or 6’. The benzophenone oxidative coupling can 
follow two paths: the p-coupling, which corresponds always to the major product, or o-coupling, which is 
occasionally observed. (Scheme 23) (for more detailed information regarding this methodology see [26, 27]). 
 
Scheme 23. Two possibilities for the oxidative coupling of 2-hydroxybenzophenones. 
A new methodology by the group of Charles de Koning was developed for the intramolecular 
cyclization of 2-hydroxy-2’,5’-dimethoxybenzophenones using ceric ammonium nitrate (CAN) as oxidant 
(Scheme 24) [90, 108]. This methodology led to xanthones from moderate to excellent yields (Table 10; 
entries 1-4), but for most of the examples, besides the xanthone, a dienone was also isolated. 
Scheme 24. Synthesis of xanthones CAN-mediated. 
Table 10. Xanthones synthesized by the oxidation of benzophenones using CAN as oxidant.  
Entry R1 R2 Xanthone Yield (%) Dienone Yield (%) 
1a H H 74 15 
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2a OMe H 91 - 
3a H Cl 63 17 
4a,b OMe Cl 21 29 
5c H Br 0 45 
6c,d OMe Br 0 18 
a.The reference for these entries is cited in the text with number 90;b.Another secondary product was isolated 
in 9 % yield; c.The reference for these entries is cited in the text with number 108; d.Another secondary 
product was isolated in 22 % yield. 
Examples of this situation occurred with cyclization of 2-hydroxy-2’-5’dimethoxybenzophenone 
derivatives with CAN (Scheme 24; Table 10). However, the group of Charles de Koning envisioned that the 
dienone could be converted by heating into the xanthone through an intermediate Michael acceptor. 
Therefore, the heating of three dienones in dimethoxyethane (DME) for 10 minutes at 150 ºC using 
microwaves led to the desired xanthones. On the other hand, the yields were only moderate (Scheme 25; 
Table 11) ranging from 10 to 50 % [108]. 
 
Scheme 25. Synthesis of xanthones from dienones.  
Table 11. Xanthones synthesized from dienones.  
Entry R1 R2 Xanthone Yield (%) 
1 H H 50 
2 H Br 10 
3 OMe Br 33 
 
2.2.3 Copper-catalyzed intramolecular O-arylation 
 In several of the examples presented in section 2.2.1 for the cyclization of 2-hydroxybenzophenone 
derivatives used halogens as leaving groups in the intramolecular SNAr. In addition, it was discussed that the 
best yields were attained with fluorine and chlorine since they were smaller and more electronegative than 
bromine and iodine. In spite of bromine and iodine being able to behave as leaving groups in SNAr, the ether 
linkage can be formed by an Ullmann ether coupling copper-catalyzed instead. Therefore, a methodology for 
the cyclization of 2-hydroxy-2’-halobenzophenones using an intramolecular copper catalyzed Ullmann was 
developed. The methodology was considered a “green” alternative for the cyclization of benzophenones, 
since it was carried out in water, the catalyst was recycled and it was also amenable to scale-up  [80] 
(Scheme 26). The scope and limitations of the reaction were studied and the reaction occurred only with 2’-
halo-2-hydroxybenzophenones that have a bromine or iodine in position 2’ (Table 12; entries 2-10). If the 
halogen was chlorine, no xanthone was obtained (Table 12; entry 1). On the other hand, whatever the 
substituents in the 2’-halo-2-hydroxybenzophenones scaffold, good to excellent yields were obtained (Table 
12; entries 2-6 and 10). The exception was observed for 2’-halo-2-hydroxybenzophenone with an extra 
halogen such as fluorine and chlorine (Table 12; entries 7-9).  
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Scheme 26. Benzophenone cyclization by an intramolecular O-arylation copper catalyzed. 
Table 12. Xanthones synthesized using an intramolecular O-arylation copper catalyzed. 
Entry X R1 R2 Xanthone % Yield 
1 Cl 5-Me H - - 
2 Br 5-Me H 2-Methylxanthone 90 
3 I 5-Me H 2-Methylxanthone 95 
4 Br 4-Me, 5-Me H 2,3-Dimethylxanthone 84 
5 I 4-Me, 5-Me H 2,3-Dimethylxanthone 73 
6 Br 2-OMe, 3-OMe H 3,4-Dimethoxyxanthone 70 
7 I 5-Me 5’-F 2-Fluoro-7-methylxanthone 69 
8 I 4-Me, 5-Me 5’-F 2-Fluoro-6,7-dimethylxanthone 54 
9 Br 4-Me, 5-Me 4’-Cl 6-Chloro-2,3-dimethylxanthone 66 
10 Br 5-Me 4’-Me 2,6-Dimethylxanthone 79 
 
2.2.4 Oxidation of 2,5-dihydroxybenzophenone derivatives followed by an intramolecular conjugate addition 
 In sections 2.2.1 and 2.2.3, the described syntheses of xanthones were accomplished at the cost of 
one functional group since in the intramolecular SNAr and intramolecular Ullmann-ether synthesis, one group 
had to behave as leaving-group. However, in the presence of a benzophenone with a hydroquinonic moiety in 
positions 2 and 5, and a protected or free hydroxyl in position 2’, no group needs to be eliminated and 
xanthones with the hydroquinonic moiety can be synthesized (Scheme 27). The first step of this strategy is 
the oxidation of the hydroquinone moiety of the benzophenone into quinone. If R3 is a hydrogen, the 
benzophenone cyclize spontaneously through an intramolecular conjugate addition. In the case of protected 
phenols (R3 = protecting group), as soon as the protecting group is removed, the cyclization takes place. The 
conjugate addition can lead to either a xanthone or to a dihydroxanthone adduct, being the latter easily 
oxidized to xanthone [98, 109-111] (Scheme 27). This methodology was a crucial step in the total synthesis 
of atroviridin (Figure 3).  
 
Scheme 27. Strategy for the synthesis of xanthones from 2,5,2’-trihydroxybenzophenone derivatives by an 
oxidation followed by an intramolecular conjugate addition. 
 
3. Synthesis of xanthone via diaryl ether route (Scheme 1; 3.1 and 3.2) 
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The last classical and well-known synthetic strategy for the synthesis of xanthones uses a diaryl 
ether as the key intermediate. When compared with the two classical methodologies described previously 
(section 1.1 and 2.1.1-2.2.1), the yields are usually lower [25], but, nevertheless, this is a still valuable route 
for the synthesis of xanthonic derivatives as it can be depicted by the current number of articles  published in 
the last seven years using this approach (see Table 13). In the synthesis of xanthones via diaryl ether, the 
ether linkage between two aromatic rings is the first synthetic step and then this intermediate is cyclized to 
give the xanthone (Scheme 28). Therefore, this section will be subdivided: the first sub-section (3.1) will 
address the different strategies for the synthesis of diaryl ethers; and in the second sub-section (3.2) the 
several strategies applied for the cyclization to xanthones will be discussed. 
 
Scheme 28. Synthesis of xanthones through diaryl ether route. 
3.1 Diaryl ether synthesis 
The preferred approach for the synthesis of diaryl ethers uses as building blocks an aryl halide and a 
phenol (3.1.1). This is undoubtedly the most important approach but other alternatives have been developed 
over the years. Since these methodologies had been reviewed and /or are seldom used they will not be 
discussed herein [25, 112, 113]. An exception will be made to the conjugate substitution of salicylate 
derivatives with a 1,4-halobenzoquinones (3.1.2) since this is an essential approach for the synthesis of 
biologically significant xanthones bearing a hydroquinonic moiety. In addition to these two approaches, 
during the last seven years a new methodology was reported for the synthesis of diaryl ethers by a formal [3 
+ 3] cyclocondensation, which led later to highly hindered xanthones with an interesting pattern of 
substitution (3.1.3).  
3.1.1 Coupling between an aryl halide and a phenol 
As it was stated above, the coupling between aryl halides and phenol derivatives is the most 
commonly used approach for the synthesis of xanthones through diaryl ether route. The great majority of the 
examples described in the literature used a copper-catalyzed Ullmann-ether synthesis for the formation of an 
ether bond [114]. However, the Ullmann ether synthesis has serious limitations since the yields are rarely 
high and the experimental conditions are reasonably harsh due to the high temperatures, the stoichiometric 
amounts of copper salts and the long reaction times needed [115]. Nevertheless, it is still frequently used 
since the lack of selectivity that is found in other methodologies, such as the Friedel-Crafts acylation, is not 
observed here. The coupling between the phenol and the aryl halide occurs exclusively at a specific position 
of the aromatic ring and therefore only one product is obtained (in Scheme 29 and Table 13 are represented 
recent examples of the synthesis of xanthones using this methodology). During the last decade, the Ullmann-
ether coupling has seen significant improvements, and diaryl ethers have been obtained in high yields and 
milder experimental conditions [116-119]. Albeit, none of the articles published in the past seven years 
applied any of those improvements. However, it is expected that in a near future these improvements will 
start to be more broadly applied and will therefore be used for the synthesis of xanthones, increasing the 
yields and allowing also the presence of a greater variety of functional groups.   
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Scheme 29. Synthesis of diaryl ether synthesis by an Ullmann reaction. 
Table 13. Recent examples of the diaryl ethers synthesized by an Ullmann reaction between an aryl halide 
and a phenol.  
Y X R1 R2 Experimental conditions % Yield Refs 
COOH Cl 4-OMe, 5-OMe 3-Cl K2CO3, Cu, CuI, nitrobenzene, 170 ºC, 8 h 41 [120]a 
COOH I 3-NO2, 4-Me 2-MeCOOH 
1 equiv of aqueous KOH, 20 °C, 5 min, dry 
well, then phenol, TDA-1, CuCl, p-dioxane, 
reflux, 16 h; 
46 [121]a 
COOH I 3-Me, 4-NO2 2-MeCOOH 
1 equiv of aqueous KOH, 20 °C, 5 min, dry 
well, then phenol, TDA-1, CuCl, p-dioxane, 
reflux, 16 h; 
51 [121]a 
COOH Cl H 2-Me, 3-Me Cu, CuI, K2CO3, 190-200 ºC, 2 h 45 [122] 
COOEt I H 4-NHAc K2CO3 , KI, Cu, dry DMF, 110 ºC, 12 h 84 [123]a 
NO2 Cl 4-Cl 2-COOEt K2CO3 ,  Cu2O,  DMF,  110 ºC,  8 h; 64b 
[124, 
125]a 
NO2 Cl 4-Cl, 6-NHAc 2-COOEt K2CO3, CuO, dry pyridine, reflux, 36 h 47c [126]a 
COOH Br 4-COOH H Cu, CuI, pyridine, DBU, DMF, reflux, 2h 93 [127, 128]a 
COOH I H H Cu, CuI, pyridine, DBU, DMF, reflux, 2h 93 [128]a 
COOH Br 4-COOH 4-Cl Cu, CuI, pyridine, DBU, DMF, reflux, 2h 91 [128]a 
COOH Br 4-COOH 4-F Cu, CuI, pyridine, DBU, DMF, reflux, 2h 81 [128]a 
COOH I H 4-MeCOOH Cs2CO3, CuCl, TDA-1, dioxane, reflux, 20 h 
Not 
isolat
ed 
[129] 
COOH I H 3-MeCOOH Cs2CO3, CuCl, TDA-1, dioxane, reflux, 20 h 
Not 
isolat
ed 
[129] 
COOH I H 2-MeCOOH Cs2CO3, CuCl, TDA-1, dioxane, reflux, 20 h 
Not 
isolat
ed 
[129] 
COOH I H 4-Me Cs2CO3, CuCl, TDA-1, dioxane, reflux, 20 h 
Not 
isolat
ed 
[129] 
COOH I H 2-Me Cs2CO3, CuCl, TDA-1, dioxane, reflux, 20 h 
Not 
isolat
ed 
[129] 
COOH C 4-NO2 3-F K2CO3, Cu, DMF, 130 ºC, 12 h 
Not 
isolat
ed 
[130]a 
a.Reference cited in the text. b.Besides the desired compound, an isomer was isolated (ethyl  2-(3-chloro-4-
nitrophenyloxy)benzoate) in 23 % yield. c.Besides the desired compound, an isomer was isolated (ethyl  2-(3-
acetylamino-5-chloro-4-nitrophenyloxy)benzoate) in 8 % yield. 
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In spite of not being as common as the copper-catalyzed Ullmann ether coupling, the intermolecular 
SNAr is a viable alternative for the synthesis of diaryl ethers from aryl halides and phenols. The SNAr has 
already been discussed in detail in section 2.2.1, but applied to the cyclization of benzophenones. In those 
examples, the SNAr was extremely useful and xanthones were obtained in high yields. In comparison with the 
intramolecular SNAr, the intermolecular equivalent is not as entropically favored, and therefore is not so 
prone to occur. Therefore, only with very electron-poor fluoro-aryl derivatives, especially those bearing a 
nitro group, the reaction takes place smoothly and in high yields (Scheme 30). As a result, this methodology 
is particularly useful in the synthesis of xanthones bearing a strong electron-withdrawing group (EWG) such 
as nitro [131-133]. 
 
Scheme 30. Synthesis of diaryl ether by an intermolecular SNAr. 
 
3.1.2 Conjugate substitution reaction of a phenol to a 1,4-halobenzoquinone 
An excellent approach for the synthesis of 1,4-dihydroxyxanthone or 1,4-dimethoxyxanthone 
derivatives uses a similar approach that was used for the intramolecular cyclization of benzophenones to 
xanthones (2.2.4). However, in this case there is not an intramolecular conjugate addition, but instead an 
intermolecular conjugate substitution reaction. The reaction occurs in two steps, being the first the 
nucleophilic addition of a phenoxide generated from a methyl salicylate derivative to 1,4-halobenzoquinone 
derivative followed by the elimination of the halogen to give a phenoxybenzoquinone (Scheme 31). The 
phenoxybenzoquinones can then be O-methylated [134] or reduced [135, 136] or reduced followed by O-
methylation [137] to give the respective diaryl ethers.  
 
Scheme 31. Synthesis of diaryl ethers by conjugate substitution of methyl salicylates with 1,4-
halobenzoquinone derivatives. 
3.1.3 Synthesis of 2-aryloxybenzoates by a formal [3+3] cyclocondensation  
In comparison with the other methodologies described for the synthesis of diaryl ethers, the formal 
[3+3] cyclocondensation assembles two arene moieties by a C-C coupling [138]. This is especially useful 
when a hindered diarylether is wanted. The reaction takes place by a formal [3+3] cyclocondensation of 3-
aryloxy-1-silyloxy-1,3-butadienes with 3-silyloxy-2-en-1-ones in the presence of TiCl4 (Scheme 32). The 
yields were moderate but, nevertheless, several methyl and ethyl 2-aryloxybenzoates with different 
substituents in both rings were synthesized (Table 14).  
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Scheme 32. Synthesis of diaryl ethers by a formal [3+3] cyclocondensation. 
Table 14. Diaryl ethers synthesized by a formal [3+3] cyclocondensation that led later to xanthones. 
R1 R2 R3 R4 % Yield 
H Et Me H 63 
H Et Me Me 44 
H Et Ph H 47 
Me Me Me Me 56 
Me Me Ph H 22 
Cl Me Me Me 47 
 
3.2 Cyclization of the diaryl ether 
 In order to obtain xanthones from diaryl ethers, a carbonyl bridge between the two aryl rings must 
be formed. The cyclization strategy is highly dependable on the functionality in position 2 (Scheme 33) and 
in the presence of a carboxylic acid derivative (Y = COOR), two approaches can be followed: an acid-
catalyzed intramolecular electrophilic cycloacylation (3.2.1), which is the most common methodology; and 
an anionic Friedel-Crafts equivalent (3.2.2).  If no substituent is present in position 2, an intermolecular 
acylation occurs to introduce a carbonyl group in this position and then an intramolecular cyclization can take 
place to give the xanthone (3.2.3) or a Palladium-catalyzed reaction can be applied (3.2.4). In addition, in the 
last seven years, three approaches were described for the cyclization of diaryl ethers bearing an aldehyde in 
position 2. In one of the methodologies, the aldehyde is converted into an imine and then by an aryl to 
imidoyl palladium migration, xanthones were synthesized (3.2.4). On the other two methodologies, there is 
no need of a pre-activating step, and through a Rhodium-catalyzed intramolecular cross-dehydrogenative 
coupling (3.2.5) or an iron-DDQ methodology the xanthone can be obtained (3.2.6). 
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Scheme 33. Strategies for the cyclization of diaryl ethers to xanthones. 
3.2.1 Intramolecular electrophilic cycloacylation 
In sections 1.1.1 and 2.1.1, several methodologies for the synthesis of xanthones and benzophenones 
using electrophilic aromatic acylations have been presented. In those examples, the intermolecular reactions 
took place between an electron-poor and an electron-rich aryl derivative leading to either a xanthone or a 
benzophenone in generally moderate to good yields. In diaryl ether derivatives bearing an acid derivative in 
position two, the reaction is intramolecular and therefore entropically favored which can help to justify the 
high yields usually obtained for both electron-rich (Scheme 34; R2 = EDG) and electron-poor (Scheme 34, R2 
= EWG) diaryl ethers derivatives. The same reagents employed in sections 1.1.1 and 2.1.1 such as Eaton’s 
Reagent [139, 140] and polyphosphoric acid [120, 124, 125, 141, 142] have been used for the cyclization of 
diaryl ether, albeit those are not the most commonly applied methodologies [28], since sulfuric acid [121, 
122, 127, 143, 144] and sulfuric acid/acetyl chloride [126, 145, 146] are used more frequently.  
In a classical Friedel-Crafts reaction, an acylation reaction occurs between an acyl chloride and an 
aromatic derivative catalyzed by aluminum chloride. Therefore, in order to use a Friedel-Crafts acylation for 
the cyclization of diaryl ethers, an acyl chloride must be present in position 2. However, the acyl chlorides 
are very reactive and probably would not be stable to the diaryl ether synthetic step. In view of this fact, the 
cyclization of xanthones can only be done in two steps: the synthesis of the acyl chloride from the carboxylic 
acid followed by the Friedel-Crafts acylation (Scheme 34). In spite of the extra step, the intramolecular 
Friedel-Crafts acylation can be a viable alternative for the synthesis of xanthones [139]. All the 
methodologies we have described so far use over-stoichiometric amounts of acid catalyst and are obviously 
not environmental-friendly. Therefore, a greener methodology would be undeniably a better approach and the 
use of heterogeneous catalysis has shown to be a viable alternative. The use of Nafion-H [147], heteropoly 
acids [148] and Yb(OTf3)/TfOH [149] was reported to be a practical methodology leading to xanthones in 
good to excellent yields. The intramolecular electrophilic acylation is a classical methodology for the 
cyclization of diaryl ethers and more detailed information can be found in previous reviews [25, 27, 28]. 
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Scheme 34. Intramolecular electrophilic cycloacylation. 
3.2.2 Intramolecular anionic Friedel-Crafts acylation equivalent 
 The most common approach for the cyclization of diaryl ethers to xanthones is through an 
intramolecular electrophilic acylation as discussed in section 3.2.1. However, that methodology has some 
weaknesses since no acid-labile group is allowed, and in some examples, more than one product can be 
obtained because the cyclization could occur at either 2’ or 6’ positions (Scheme 35) [25]. Especially in those 
cases, an anionic Fridel-Crafts acylation equivalent can be extremely useful. The intramolecular cyclization 
by an anionic Friedel-Crafts acylation equivalent occurs in two steps: in the first step a non-isolated 
aryllithium nucleophile is formed by a directed remote metalation using a strong non-nucleophilic base, such 
as lithium diisopropylamide (LDA); and in the second step the 1,2-nucleophilic addition of the aryllithium to 
the carbonyl in position 2 occurs. Therefore, in order to this reaction to take place, there is the need of direct 
metalation groups (DMGs). The carboxylic acid derivative, especial amide derivatives, in position 2 and the 
ether bond between positions 1and 1’ are two DMGs that direct the metalation to positions 2’ or 6’. 
Moreover, in the presence of another DMG in position 3’, the cyclization is regioselective and occurs only in 
position 2’ or 6’ leading to only one product (Scheme 35). This approach was used for the regioselective 
synthesis of methyl, chloro and methoxyxanthones [150, 151]. 
 
Scheme 35. Regioselectivity in the directed-ortho metalation of diaryl ether 2-carboxamide and diaryl ether 
2-carboxilic acid. 
3.2.3 Intermolecular acylation of diaryl ether 
The last two sections (3.2.1 and 3.2.2) focused on the synthesis of xanthones from diaryl ethers 
bearing a carboxylic acid derivative in positions 2 or 2’. However, that is not a mandatory feature for the 
synthesis of xanthones since several methodologies have been developed over the years for the synthesis of 
xanthones from diaryl ethers with no substituents in positions 2 or 2’. Therefore, in order to obtain xanthones 
from 2,2’-unsubstituted diaryl ethers derivatives, a carbonyl must be selectively introduced in positions 2 or 
2’ by intermolecular acylation reactions. The acylation reactions will be divided in two, types, taking in 
consideration the chemical behavior of the diaryl ether: electrophile (Scheme 36) or nucleophile (Scheme 37)   
When the diaryl ether is behaving as an electrophile, there are two main approaches for the synthesis 
of xanthones from 2,2’-unsubstituted diaryl ethers (Scheme 36). One of the approaches leads to xanthones in 
one step by the reaction of oxalyl chloride with aluminum chloride in carbon disulfide (Scheme 36; A.) 
[152]. The other one leads to xanthones in two steps, being the first step the synthesis of 9-
chloromethylenexanthene derivatives by the reaction of the diaryl ether derivatives with chloroacetyl chloride 
and aluminum chloride (Scheme 36; B.); and the second step the oxidation of the 9-chloromethylenexanthene 
derivatives to xanthones (Scheme 36; C.). Many oxidizing agents have been described to be capable of 
oxidizing 9-chloromethylenexanthene derivatives to xanthones, such as potassium permanganate [153, 154], 
mCPBA [155], chromic acid [155], singlet oxygen [155] or magnesium/THF followed by air-oxidation [156]. 
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One crucial aspect to take in consideration with these two approaches is that the most electrophilic aryl ring 
of the diaryl ether needs to be protected in position 4 in order to avoid para acylation products. 
 
Scheme 36. Cyclization of diaryl ether by an intermolecular electrophilic aromatic substitution. 
In section 3.2.2, an anionic Friedel-Crafts equivalent for the cyclization of diaryl ethers to xanthones 
have been described. The crucial feature of that approach was the selective synthesis of an aryllithium in 
position 2’ or 6’ coordinated by the DMGs present in positions 2, 1’ and/or 3’. In the absence of any DMG 
besides ether linkage, an aryllithium intermediate can also be selectively synthesized by a directed ortho 
lithiation in position 2 or 2’ of the diaryl ether by the reaction with a stronger base than LDA, such as n-
butyllithium. Once the aryllithium is synthesized, this extremely reactive intermediate can behave as a 
nucleophile and by quenching the reaction with either carbon dioxide or dimethylcarbamyl chloride, 2-
carboxilic acid and 2-carboxamide diaryl ethers can obtained respectively (Scheme 37). The 2-substituted 
diaryl ethers can then be easily cyclized using any of the methodologies described in section 3.2.1 and 3.2.2 
[155, 157]. In the presence of harsh experimental conditions, a 2-2’dilithiated diaryl ether can be obtained 
and quenching the reaction with carbon dioxide, a xanthone can be obtained in one step [158] (Scheme 37).   
 
Scheme 37. Synthesis of xanthones using a directed ortho metalation strategy. 
3.2.4 Aryl to imidoyl palladium migration and an oxidative double C-H functionalization/carbonylation 
catalyzed by palladium 
Most of the strategies reported so far for the cyclization of diaryl ethers to xanthones are based on 
building blocks bearing a carboxylic acid derivative in position 2 (Sections 3.2.1, 3.2.2 and 3.2.3). In 2007, a 
methodology described the cyclization of diaryl ethers to xanthones bearing instead of a carboxylic acid 
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derivative, a formyl group (Scheme 38) [133]. The xanthones were synthesized in two steps since the formyl 
need to be activated by the reaction with 2-iodoaniline to give an imine. The 2-iodoimine diaryl ether 
derivatives then led easily to the xanthone by an aroyl to imidoyl palladium migration through a seven-
membered ring intermediate to afford six-membered ring heterocycles. The scope and limitations of the 
reaction were studied for diaryl ethers bearing substituents in both aromatic rings (Scheme 38; R1, R2, R3; 
Table 15). Xanthones were obtained in good yields for most of the examples, except for diaryl ethers with an 
EWG in either of the rings (Table 15, entries 4,5 and 11). It was proposed that the intramolecular arylation 
proceeds through an aromatic electrophilic substitution, which means that in the presence of an EWG in 
either of the two aryl rings, the cyclization is disfavored. This methodology was also employed in the 
synthesis of acridones and fluorenones [133]. 
 
Scheme 38. Cyclization of 2-(aryloxy)benzaldehydes to xanthones in two steps. 
Table 15. Xanthones synthesized by an aryl to imidoyl palladium migration. 
Entry R1 R2 R3 % Yield 
1 H H H 72 
2 Me H H 80 
3 OMe H H 77 
4 CF3 H H 56 
5 NO2 H H 38 
6 H OMe H 77 
7 H Cl H 73 
8 H i-Pr H 56 
9 H Ph H 63 
10 H t-Bu H 61 
11 H CO2Me H 10 
12 H Me OMe 79 
 
 In section 3.2.3, the different alternatives for the synthesis of xanthones from diaryl ethers with no 
substituent in position 2 or 2’ were described. In all cases presented, the experimental conditions were harsh 
and generally, the xanthones were obtained in more than one step. An alternative methodology for the 
cyclization of 2,2’-unsubstituted diaryl ethers to xanthones can be accomplished through an oxidative double 
C-H functionalization/carbonylation catalyzed by palladium (Scheme 39; Table 16) [159]. The choice of 
palladium proved to be crucial for the success of the reaction and the best yields were obtained with 
Pd(OAc)2, K2S2O3 in TFA at 50 ºC and under 1 atm of CO. The scope and limitations of the reaction were 
evaluated and excellent yields were obtained only when methyl and/or tert-butyl were present in both 
aromatic rings (Table 16, entries 1, 2, 6, 15 and 16). Moreover, for all the other examples bearing EDG 
and/or EWG in one or both aromatic rings, xanthones were obtained in moderate yields (Table 16, entries 3-
5, 7-14 and 17-19). In the case of an unsubstituted diaryl ether (Table 16, entry 20), low yields were obtained 
[159].  
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Scheme 39. Synthesis of xanthones by a double C-H carbonylation of diaryl ether catalyzed by palladium. 
Table 16. Xanthones synthesized by a double C-H carbonylation of diaryl ether catalyzed by palladium. 
Entry R1 R2 R3 R4 R5 R6 R7 % Yield 
1 Me H H H H Me H 96 
2 tBu H H H H tBu H 92 
3 OMe H H H H OMe H 50 
4 Br H H H H Br H 65 
5 H C4H4 C4H4 H H 41 
6 Me H H H H tBu H 82 
7 Me H H H H OMe H 71 
8 Me H H H H CF3 H 56 
9 Me H H H H CO2Et H 51 
10 Me H H H H COMe H 58 
11 Me H H H H F H 76 
12 Me H H H H Cl H 63 
13 Me H H H H Br H 70 
14 Me H H C4H4 H H 70 
15 Me H H H Me H Me 89 
16 Me H H Me Me H Me 71 
17 H H H H H Me H 52 
18 H H H H H OMe H 46 
19 H H H H H F H 34 
20 H H H H H H H 27 
 
3.2.5 Cross-dehydrogenative coupling rhodium-catalyzed 
The cyclization of diaryl ethers to xanthones bearing a formyl group in position 2 can be 
accomplished through a cross-dehydrogenative coupling catalyzed by rhodium [160]. In comparison with the 
previous method (section 3.2.4), the aldehyde group did not need a pre-activating step and the reaction 
tolerated diverse substituent groups, bearing both EDG and EWG (Scheme 40; Table 17, entries 2-27). 
However, for most cases, the yields were higher with EDGs than with EWGs. In the presence of substituents 
in position 2’ (Scheme 40; R5), the yields were also lower possibly due to steric effect caused by the 
substituent group in this position (Table 17, entries 3, 5, 19, 21 and 24). When more than one product of 
cyclization could be obtained from the cross-dehydrogenative coupling reaction (Table 17, entries 6, 7 and 
10), only in 2-(m-trifluoromethylphenoxy) benzaldehyde the reaction was regioselective (Table 17, entry 10). 
Disubstituted ethers were also cyclized through cross-dehydrogenative coupling leading to a structure with a 
double xanthonic scaffold (Table 17, entry 25). 
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Scheme 40. Intramolecular cyclization of diaryl ethers by a cross-dehydrogenative coupling rhodium-
catalyzed. 
Table 17. Xanthones synthesized by the cross-dehydrogenative coupling rhodium-catalyzed of diaryl ethers 
bearing a formyl group in position 2. 
Entry R1 R2 R3 R4 R5 % Yield 
1 H H H H H 93 
2 H H Cl H H 49 
3 H H H H Cl 42 
4 H Cl H Cl H 39 
5 H H Cl H Cl 25 
6a H Cl H H H 49 
7b H Br H H H 66 
8 H H Br H H 70 
9 H H F H H 77 
10c H H H CF3 H 50 
11 H H COPh H H 53 
12 H H Pyrrolyl H H 80 
13 H H CN H H 23 
14 H H NHAc H H 46 
15 H H CO2Et H H 32 
16 H H OMe H H 82 
17 H OMe H OMe H 81 
18 H H Me H H 80 
19 H H Me H Me 63 
20 H H t-Bu H H 91 
21 H H H H t-Bu 36 
22 H H H H Ph 53 
23 H H H C4H4 36 
24 H C4H4 H OMe 39 
25d H H 2’-benzaldehyde H H 43 
26 CF3 H H H H 78 
27 H H OH H H 34 
a.Besides 1-chloroxanthone, 3-chloroxanthone was also obtained in 2:1 mixture; b.Besides 1-bromoxanthone, 
3-bromoxanthone was also obtained in 1:1 mixture; c.Only 3-trifluoromethyl-xanthone was obtained; d.Only 
chromeno[2,3-b]xanthene-7,14-dione was obtained. 
3.2.6 Synthesis of xanthones through an iron-DDQ catalyzed cyclization of 2-formyl diaryl ethers  
ƉƉĞŶĚŝǆϭ
ZŽƵƚĞƚŽyĂŶƚŚŽŶĞƐ͗ŶhƉĚĂƚĞŽŶƚŚĞ^ǇŶƚŚĞƚŝĐƉƉƌŽĂĐŚĞƐ
ϯϮϴ

 The palladium and rhodium have shown to be excellent catalysts for the cyclization of diaryl ethers 
with a formyl group in position 2 or 2’ to xanthones (sections 3.2.4 and 3.2.5). However, these types of 
catalysts are very expensive which can be considered as a disadvantage. On the other hand, the iron catalysts 
are cheap, non-toxic and easy to synthesize. Indeed, the FeCl3 was employed with success for the cyclization 
of diaryl ethers bearing a formyl group on position 2 and 2’ of the diaryl ether (Scheme 41) [161], turning it 
into an excellent alternative to palladium and rhodium catalysts for the cyclization of 2-formyl diaryl ethers. 
The reaction of cyclization of 2-formyldiaryl ethers catalyzed by FeCl3 without the addition of the DDQ 
leads to a xanthone and a xanthene. Therefore, it was proposed that the reaction proceeds through a xanthol 
intermediate which suffers desproportionation to give a xanthone and xanthone. This limitation could be 
overcome by the addition of DDQ which oxidize the xanthol intermediate leading directly to the xanthone in 
good to excellent yields. The scope and limitations of the reaction were studied and good to excellent yields 
were obtained for most of the examples (Scheme 41; Table 18, entries 1-3 and 6-9) with the exception of 
substituted diaryl ethers with chlorine in the ring that do not have the formyl group (Scheme 41; Table 18, 
entries 4 and 5). This reaction was also applied for the synthesis of thioxanthones [161]. 
 
Scheme 41. Synthesis of xanthones by the cyclization of 2-formyl diaryl ethers catalyzed by iron-DDQ. 
Table 18. Xanthones synthesized by the cyclization of 2-formyl diaryl ethers catalyzed by iron-DDQ 
Entry R1 R2 R3 R4 % Yield 
1 H H OMe H 94 
2 H H Me H 94 
3 H H H H 85 
4 H H Cl H 71 
5 H Cl Cl H 40 
6 Cl H H H 93 
7 Cl H OMe H 95 
8 Cl H Cl H 86 
9 H H C4H4 95 
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4 Synthesis of xanthones via chromen-4-one derivatives (Scheme 1; 4) 
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Scheme 42. Examples of xanthones synthesized using chromen-4-one as building block. 
All the strategies for the synthesis of xanthones described until now used as building blocks two aryl 
derivatives, and the xanthonic scaffold was obtained through the formation of an ether and ketone linkage. 
However, other strategy can be followed using instead a chromen-4-one as building block.  This approach is 
not as common as the previous but has the advantage of allowing the synthesis of xanthones bearing a 
complex pattern of substitution as it can be depicted from several examples of xanthones synthesized by this 
route represented in Scheme 42. In chromen-4-ones, the ketone and the ether linkage are already formed, but 
an aromatic ring attached to the side of the Į,ȕ-unsaturated carbonyl system is absent. In fact, the Į,ȕ-
unsaturated carbonyl system is extremely important since it increases significantly the reactivity of the 
chromen-4-ones. Depending on the substitutents in positions 2 and 3 of the chromen-4-ones, different 
reactions can be used for the synthesis of xanthones, such as Michael-initiated heteroannulations, pericyclic 
and photochemical. Therefore, this section will be sub-divided in 4 since xanthones were obtained using 
either unsubstituted (4.1) or 2-substituted (4.2) or 3-substituted (4.3) or 2,3-disubstituted (4.4) chromen-4-
ones (Scheme 42). Each sub-section will also be sub-divided by type of reaction.  
4.1 Synthesis of xanthones from unsubstituted chromen-4-one 
 
 
Scheme 43. Synthesis of xanthones using unsubstituted chromen-4-one as building block. 
Unsubstituted chromen-4-ones are seldom used as building block for the synthesis of xanthones. 
One rare example used a sulfone annulation reaction between chromen-4-one and 
(phenylsulfony1)isobenzofuranone to give a benzoxanthone regiospecifically. The chromen-4-one acted as a 
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Michael acceptor in the condensation reaction. The objective of this methodology was to synthesize the 
antiprotozoal agent bikaverin [162](Scheme 43).  
4.2 Synthesis of xanthones from 3-substituted chromen-4-one 
 The 3-substituted chromen-4-one is often used as building block for the synthesis of xanthones. The 
presence of a Į,ȕ-unsaturated carbonyl system increases the chromen-4-one reactivity allowing it to take part 
in pericyclic reactions (4.2.1), Michael-addition heteroannulations (4.2.2) and photochemical reactions 
(4.2.3). Moreover, in the last seven years, a methodology described the synthesis of xanthones from 3-
substituted chromen-4-ones employing organocatalysis (4.2.4). 
4.2.1 Cycloaddition 
The unsubstituted chromen-4-ones are not prone enough to enter in a Diels-Alder cycloaddition 
reaction. However, the introduction of adequate substituents in position 3 of the chromen-4-one enables it to 
behave either as dienophile (4.2.1.1), as diene (4.2.1.2) or both (4.2.1.3).   
4.2.1.1 Chromen-4-one as a 2 ʌ component 
The Į,ȕ-unsaturated carbonyl system of the chromen-4-one cannot participate as a dienophile in a 
Diels-Alder cycloaddition. However, the presence of an EWG in position 3 of the chromen-4-one, enhances 
greatly the dienophilicity of the Į,ȕ-unsaturated carbonyl system, enabling it to behave as a diene in a Diels-
Alder cycloaddition. This fact can be demonstrated from the next two examples (Schemes 44 and 45).  
The heating of 3-(4-chlorophenylsulfinyl)-4H-1-chromen-4-one with extremely reactive 
Danieshefsky’s diene, gave an adduct that eliminated methanol and 4-chlorobenzenesulfonic acid to give 3-
hydroxyxanthone in 50 % yield [163] (Scheme 44). 
 
Scheme 44. Synthesis of 3-hyroxyxanthone by a cycloaddition-elimination reaction between 3-(4-
chlorophenylsulfinyl)-4H-1-benzopyran-4-one and Danieshefsky’s diene. 
Several benzoxanthones were synthesized in two steps from the reaction of 3-formyl-chromen-4-
ones with ortho-benzoquinodimethanes formed in situ by thermal extrusion of sulfur dioxide. The reaction of 
the ortho-benzoquinodimethanes with the 3-formyl-chromen-4-ones gave two benzo-[b]-tetrahidroxanthones 
diastereoisomers which were later easily oxidized to benzoxanthones in almost quantitative yields using 
DMSO/I2 procedure (Scheme 45; Table 19) [164, 165].  
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Scheme 45. Synthesis of benzoxanthones in two steps by the reaction of a 3-formyl-chromen-4-one 
derivative with ortho-benzoquinodimethanes. 
Table 19. Benzoxanthones synthesized in two steps by from the reaction of 3-formyl-chromen-4-one 
derivatives with ortho-benzoquinodimethanes. 
R1 R2 R3 R4 R5 R6 R7 R8 Benzo-[b]-tetrahidroxanthones Diastereoisomers % Yielda Benzoxanthones % Yield 
H H H H H H H H 95 98 
H Me H H H H H H 94 97 
H Cl H H H H H H 94 94 
H Br H H H H H H 96 96 
H Br H Br H H H H 91 94 
H H OMe H H H H H 85 88 
OMe H H H H H H H 90.5 91 
OH H H H H H H H 80.5 91 
H NO2 H H H H H H 35.5 92 
H H H H OMe H H OMe 90 94 
H Me H H OMe H H OMe 92 93 
H Cl H H OMe H H OMe 92 89 
H H H H OMe Br Br OMe 93 92 
H Me H H OMe Br Br OMe 88 94 
H Cl H H OMe Br Br OMe 89 91 
aCombined yield of diasteromic mixture. 
4.2.1.2 Chromen-4-one as a 4ʌ component 
The 3-substituted chromen-4-one can also behave as a diene in Diels-Alder cycloaddition reactions, 
but in order to achieve this, chromen-4-ones need a viny EDG placed in position 3. (Z)-3-Styrylchromen-4-
ones gather all the requirements and its reaction with N-methylmaleimide and 2-(2-nitrovinyl)thiophen under 
microwave heating led to xanthones in two and one steps respectively [166].The Diels-Alder reaction of (Z)-
3-styrylchromones with N-methylmaleimide led to the cycloadducts 4-aryl-1,3-di-oxo-3a,4,11a,11b-
tetrahydropyrrolo[3,4-c]xanthones which were then esily oxidized to 4-aryl-1,3-dioxopyrrolo[3,4-
c]xanthones with DDQ (Scheme 46. A). On the other hand, the (Z)-3-styrylchromones and 2-(2-
nitrovinyl)thiophen led directly to 2-aryl-3-(2-thienyl)xanthones, since the cycloadduct obtained from the 
Diels-Alder reaction eliminated spontaneously HNO2 to give xanthones (Scheme 46. B). 
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Scheme 46. Synthesis of xanthones from a Diels-Alder cycloaddition of (Z)-3-styrylchromen-4-one 
derivatives with N-methylmaleimide and 2-(2-nitrovinyl)thiophen. 
In the last example described for the synthesis of xanthones, 3-styrylchromen-4-ones acted as an 
electron-rich diene in a classical Diels-Alder cycloaddition reaction. However, a vinyl EWG could also be 
present in position 3, since the chromen-4-one could also act as a diene in an inverse-electron-demand 
Diels−Alder (IEDDA) cycloaddition reaction. Therefore, the heating of 3-substituted chromen-4-ones, 
bearing a vinyl EWG in position 3, with either 1-(2,2-dimethoxyvinyl)pyrrolidine and tetramethoxy-ethene 
led in one and two steps to 4-methoxyxanthones and 3,4-dimethoxyxanthone bearing different functionalities 
in position 2, respectively (Scheme 47; Table 20 and 21) [167]. 4-Methoxyxanthone derivatives were 
obtained in moderate to excellent yields in one step by the heating of 3-vinylchromen-4-ones with a freshly 
generated 1-(2,2-dimethoxyvinyl)pyrrolidine (Scheme 47; A.; Table 20; entries 1-9). In spite of the 
possibility of a Michael/Mannich reaction, the authors proposed that it is likely that the reaction proceeds 
through an asynchronous IEDDA cycloaddition between the 3-vinylchromen-4-one and the enamine, 
followed by the fast elimination of methanol and pyrrolidine to give xanthones. Several 3-vinyl chromen-4-
ones bearing different EWG were studied and the yields showed a slight increment with the strength of the 
EWG and a slight decrease with its steric hindrance (Table 20; entries 1-9). The method applicability was 
broadened by the synthesis of 3,4-dimethoxyxanthone derivatives through the reaction of 3-vinylchromen-4-
ones with tetramethoxy-ethene (Scheme 47; B.). However, the tetramethoxy-ethene turned out to be a more 
reluctant partner since xanthones were obtained in two steps and in generally lower yields (Table 21). It was 
proposed that the lower polarity and higher steric hindrance was responsible for its reaction unwillingness. 
The reaction of the 3-vinyl chromen-4-ones with tetramethoxy-ethene occurred only when the two reactants 
were heated without solvent, or with high-boiling point solvents (Table 21). The reaction of the chromen-4-
ones with tetramethoxy-ethene did not lead directly to the xanthones but to an intermediate instead. This 
intermediate was a result of the methanol 1,2-elimination followed by either a [1,5] H shift or an acid base-
catalyzed tautomerism of the cycloadduct formed by the IEDDA cycloaddition reaction between the two 
reactants. The intermediate was later easily converted to the xanthone by the use of a Lewis acid (Scheme 47; 
B.). The scope of the reaction was investigated and moderate to excellent yields were obtained for most of 
the examples (Table 21; entries 1-6). In addition, higher yields were obtained in the presence of high-boiling 
solvent (Table 21; entries 1-6). On the other hand, lower yields were observed for less electron-withdrawing 
substituents (Table 21; entries 7-9). 
 
Scheme 47. Synthesis of xanthones by an inverse-electro-demand Diels-Alder (IEDDA). 
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Table 20. 4-Methoxyxanthones bearing an EWG in position 2 synthesized from an IEDDA cycloaddition 
between an electron-deficient 3-substitutent chromen-4-ones and 1-(2,2-dimethoxyvinyl)pyrrolidine. 
Entry EWG % Yield  
1 CONEt2 50 
2 CO2Et 71 
3 COPh 85 
4 COMe 90 
5 SO2Ph 70 
6 CN 84 
7 p-C6H4NO2 70 
8 C6H5 51 
9 p-C6H4OMe 39 
 
Table 21. 3,4-Methoxyxanthones bearing an EWG in position 2 synthesized in two steps from an IEDDA 
cycloaddition between an electron-deficient 3-substitutent chromen-4-ones and tetramethoxy-ethene. 
Entry EWG No solvent/ % Yield  C2H2Cl4/ % Yield 
1 CONEt2 28 40 
2 CO2Et 36 70 
3 COPh 84 90 
4 COMe 62 98 
5 SO2Ph 29 18 
6 CN 27 38 
7 p-C6H4NO2 25 trace 
8 C6H5 trace 6 
9 p-C6H4OMe 0 0 
 
4.2.1.3 Chromene as 2ʌ and 4ʌ component 
In the absence of strong dienophiles, the 2-vinylchromen-4-ones could act as both a dienophile and a 
diene in a Diels-Alder cycloaddition. This potentiality was used for the total synthesis of vinaxanthone 
(Scheme 48) obtained from the dimerization of the appropriate chromen-4-one. In order to achieve the 
desired compound, several solvents, temperatures and reaction times were investigated and the best results 
were obtained when the a solution of the chromen-4-ones in toluene was heated with 4.0 equiv. of 2,6-di-t-
butyl-4-methylphenol (DTBMP) in a sealed tube with air at 200 ºC for 24 hours. It was suggested that it is 
not DTBMP but its quinone, the responsible for the aromatization of the adduct resulted from the Diels-Alder 
cycloaddition [168].  
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Scheme 48. Synthesis of vinaxanthone using a Diels–Alder cycloaddition to connect two molecules of 
chromen-4-one. 
4.2.2 Michael-initiated heteroannulation reactions 
As it was stated at the beginning of the fourth section (4.2.1.1), the presence of an Į,ȕ-unsaturated 
carbonyl system increases significantly the reactivity of the chromen-4-ones. In addition, the introduction of 
the appropriate functionality in position 3 can increase even more the reactivity of chromen-4-ones allowing 
them to participate, for instance, in Diels-Alder reactions (Section 4.2.1). Therefore, with the appropriate 
substitutent in position 3, the chromen-4-ones could also be involved on other type of reactions such as 
domino processes. During the last seven years, several methodologies were described using 3-(1-
alkynyl)chromen-4-ones as  building blocks for the synthesis of highly substituted xanthones bearing a 
complex pattern of substitution (Scheme 49). 3-(1-Alkynyl)chromen-4-ones are extremely interesting from 
the chemical point of view since they have an Į,ȕ-unsaturated ketone skeleton conjugated with a triple bond. 
This moiety allows 3-(1-alkynyl)chromen-4-ones to participate as electrophiles in Michael-initiated 
heteroannulation reactions with different nucleophiles (Scheme 49), such as 1,3-dicarbonyl derivatives 
(Scheme 50), acetonitrile derivatives (Scheme 52) and even self-condensation (Scheme 51), which through 
domino processes lead to highly substituted xanthones.  
 
Scheme 49. Synthesis of xanthones using as starting point 3-(1-alkynyl)chromen-4-ones. 
The reaction of 3-(1-alkynyl)chromen-4-ones with 1,3-dicarbonyl derivatives led to xanthones in 
one step and in moderate to excellent yields by a domino process of Michael addition-
elimination/cyclization/1,2-addition/elimination reactions (Scheme 50; Table 22). The scope of this reaction 
was studied for the chromen-4-one (Scheme 50; R1 and R2; Table 22; entries 7-10), the acetylene moiety 
(Scheme 50; R3; Table 22; entries 1-6) and the 1,3-dicarbonyl derivative (Scheme 50; R4 and R5; Table 22; 
entries 11-17). In the case of the chromen-4-one moiety, if the substituent is an EWG longer reaction time is 
needed when compared with an EDG group. In regard to the acetylenic moiety, excellent yields were 
obtained in the presence of an aromatic ring, especially when it has an EDG in the para position (Table 22; 
entries 1-3). However, if the substituent was an aliphatic chain, the yields decreased slightly and for highly 
hindered groups, such as iPr, no product was isolated (Table 22; entries 4-6). In respect to the 1,3-dicarbonyl 
moiety, no restrictions were observed and xanthones were obtained in 65-82 % yield (Table 22; entries 1 and 
11-17)[169]. 
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Scheme 50. Synthesis of xanthones by reaction of 3-alkynylchromen-4-ones with 1,3-dicarbonyl compounds. 
Table 22. Xanthones synthesized by the reaction of 3-akynylchromen-4-ones with 1,3-dicarbonyl derivatives. 
Entry R1 R2 R3 R4 R5 %Yield 
1 H H (p-OMe)Ph OMea OMe 90 
2 H H Ph OMea OMe 76 
3 H H (p-CF3)Ph OMea OMe 68 
4 H H C3H6CN OMea OMe 60 
5 H H n-pentyl OMea OMe 55 
6 H H (Me)3Sib OMea OMe 65 
7 Cl H Ph OMea OMe 80 
8 NO2 H Ph OMea OMe 81 
9 OMe H Ph OMea OMe 80 
10 H OTHP (p-OMe)Ph OMea OMe 84 
11 H H (p-OMe)Ph Me OMe 82 
12 H H (p-OMe)Ph i-Pr OMe 80 
13 H H (p-OMe)Ph Ph OMe 65 
14 H H (p-OMe)Ph Bn OMe 60 
15 H H (p-OMe)Ph Me Me 75 
16 H H (p-OMe)Ph Ph Me 69 
17 H H (p-OMe)Ph Cyclic 1,3-diketone 75 
aThe methoxyl was eliminated and the xanthone have an OH in this position; b.trimethylsilyl was removed 
under basic conditions. 
The 3-(1-alkynyl)chromen-4-ones when heated at high temperatures in THF using DBU as base 
self-condensated to give 2-alkynylxanthones and 2-salicyloylxanthones (Scheme 51). It was proposed that 
the self-condensation reaction proceeds through a base-catalyzed domino process of Michael 
additions/cyclizations/desalicyloylation reaction. The scope and limitations of the reaction were studied and 
the best results were obtained when R3 was an aryl group (Table 23; entries 1-3 and 8-12). In the presence 
on an alkyl group in the alkynyl moiety, the yields decreased significantly, especially for bulky groups 
(Table 23; entry 6). Moreover, for a few of the alkylic acetylene derivatives, besides the 2-alkynylxanthones, 
2-salicyloylxanthones were also obtained (Table 23; entries 5 and 6) [170].  
 
Scheme 51. Synthesis of 2-alkynylxanthones (A) and 2-salicyloylxanthones by self-condensation of 3-(1-
alkynyl)chromen-4-ones. 
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Table 23. 2-Alkynylxanthones (A) and 2-salicyloylxanthones (B) synthesized by self-condensation of 3-(1-
alkynyl)chromen-4-ones. 
Entry R1 R2 R3 A (% Yield) B (%Yield) 
1 H H Ph 89 - 
2 H H (p-OMe)Ph 86 - 
3 H H (p-CF3)Ph 67 - 
4 H H C3H6CN 83 - 
5 H H n-pentyl 61 - 
6 H H i-Pr 38 27 
7 H H (Me)3Sib 48 25 
8 Me H Ph 68 - 
9 Cl H Ph 75 - 
10 NO2 H Ph 60 - 
11 OMe H Ph 73 - 
12 H OTHP Ph 80 - 
a.trimethylsilyl was removed. 
The reactivity of 3-(1-alkynyl)chromen-4-ones was further studied by their reaction with several 
acetonitrile derivatives. In this reaction, 3-aminoxanthone derivatives were obtained in good to excellent 
yields (Scheme 52) through a domino process of Michael addition/cyclization/1,2-addition. The scope of the 
reaction was studied and 3-aminoxanthones were obtained in good to excellent yields for the great majority 
of the examples (Table 24), with the exception of chromen-4-ones bearing a bulky group in the alkynyl 
moiety (Table 24, entry 11) and a strong EWG in the aromatic ring (Table 24, entry 15) [171]. 
 
Scheme 52. Synthesis of xanthones by reaction of 3-(1-alkynyl)chromen-4-ones with acetonitrile derivatives. 
Table 24. Xanthones synthesized by the reaction of 3-(1-alkynyl)chromen-4-ones with acetonitrile 
derivatives. 
Entry R1 R2 R3 R4 %Yield 
1 H H Ph Ph 90 
2 H H Ph (m-Br)Ph 95 
3 H H Ph (p-NO2)Ph 87 
4 H H Ph (p-OMe)Ph 69 
5 H H Ph CONH2 86 
6 H H Ph CN 88 
7 H H (p-CF3)Ph (m-Br)Ph 90 
8 H H (p-OMe)Ph (m-Br)Ph 86 
9 H H C3H6CN (m-Br)Ph 83 
10 H H n-pentyl (m-Br)Ph 92 
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11 H H i-Pr (m-Br)Ph 65 
12 Me H Ph (m-Br)Ph 96 
13 OMe H Ph (m-Br)Ph 92 
14 Cl H Ph (m-Br)Ph 94 
15 NO2 H Ph (m-Br)Ph 66 
 
4.2.3 Photochemical reaction 
Xanthones are not commonly obtained from photochemical reactions of 3-substituted chromen-4-
ones. However, one methodology described the synthesis of a benzoxanthone from the irradiation of a 3-
aroyl-chromen-4-one with UV light. It was proposed that the first step of the reaction is a photoenolization, 
which leads to either a thermal or photochemical cyclization to give a tetrahydrobenzoxanthone adduct. The 
synthesized adduct is not isolated and is quickly oxidized to give the benzoxanthone (Scheme 53) [172]. 
 
Scheme 53. Synthesis of a benzoxanthone by photochemical reaction. 
4.2.4 Organocatalysis 
In section 4.2.1.1, the synthesis of xanthones in two steps from a Diels-Alder reaction of 3-
formylchromen-4-ones with ortho-benzoquinodimethanes was presented. In that reaction, the 3-formyl 
chromen-4-ones behaved as dienophiles in the cycloaddition reaction. In 2011, a new methodology described 
the synthesis of xanthones from the reaction of 3-formylchromen-4-ones with acetylenedicarboxylates 
catalyzed by DMAP or 4-picoline, increasing as a result the range of reactions 3-formylchromen-4-ones 
could participate to give xanthones [173]. The organocatalyzed reaction led to xanthones in moderate to good 
yields, but was limited to 3-formylchromen-4-ones with EWGs (Scheme 54; R1 and R2; Table 25). In the 
presence of EDG, the organocatalytic reaction led instead to benzophenones if catalyzed by DMAP or to 
pyrano[4,3-c]chromones if catalyzed by 4-picoline. 
 
Scheme 54. Synthesis of xanthones by the reaction of 3-formylchromen-4-ones with acetylenedicarboxylate 
derivatives catalyzed by DMAP or 4-picoline.  
Table 25. Xanthones synthesized by the reaction of 3-formylchromen-4-ones with acetylenedicarboxylate 
derivatives organocatalyzed by DMAP or 4-picoline. 
R1 R2 R3 Catalyst % Yield 
Br Br Me 4-picoline 64 
NO2 H Me 4-picoline 59 
NO2 H Et 4-picoline 61 
Br Br Me DMAP 58 
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NO2 H Me DMAP 53 
NO2 H Et DMAP 55 
Cl H Me DMAP 9 
 
4.3 Synthesis of xanthones from 2-substituted chromen-4-one 
 There are few examples in the literature concerning the synthesis of xanthones using 2-substituted 
chromen-4-ones as building blocks. However, in the presence of appropriate functionalities, xanthone can be 
obtained from either cycloaddition reactions (4.3.1) or photochemical reactions (4.3.2).  
4.3.1 Cycloaddition  
In section 4.2.1.2, several approaches for the synthesis of xanthones through cycloaddition reactions 
using 3-vinylchromen-4-ones as building blocks were described. The chromen-4-ones were able to 
participate in cycloaddition reactions as a diene since the vinyl group in position 3 and the double bond of the 
chromen-4-one created a 4 ʌ component which enables it to participate in either a Diels-Alder or an IEDDA 
reaction. The ability to participate in a Diels-Alder or IEDDA depended on the chemical nature of the vinylic 
group. If the vinyl group was bonded to an EDG, it became electron-rich, and consequently, prone to 
participate in a normal Diels-Alder cycloaddition. On the other hand, if the group attached to the vinyl group 
was electron-withdrawing, the vinyl group became electron-poor, and the 3-vinylchromen-4-ones were prone 
to participate in an IEDDA instead. Therefore, if a vinyl group is present in position 2, a similar behavior is 
expected. Indeed, it has been described the synthesis of xanthones through Diels-Alder and IEDDA using 2-
vinyl chromen-4-ones as building blocks. Accordingly, 2-(2-dimethyl-aminovinyl)-chromen-4-ones which 
have an electron-rich vinylic group in position 2, were successfully employed in the synthesis of xanthones 
by Diels-Alder cycloaddition reactions with N-phenylmaleimide and 3-substituted chromen-4-ones (Schemes 
55, 56 and 57). In addition, 2-(2-dimethyl-aminovinyl)-chromen-4-ones can also participate in other 
cycloaddition reactions as a 2 ʌ component as in the case of the reaction with dimethyl 
acetylenedicarboxylate (Scheme 55 and 59) [174, 175]. As with 3-vinylchromen-4-ones, the presence of an 
electron-poor vinyl group in position 2, enables the chromen-4-one to participate as diene in an IEDDA. As a 
result, the reaction of electron-poor 2-vinylchromen-4-ones with enamines generated in situ from a catalytic 
amount of pyrrolidine with acetone, or butan-2-one, or propanal or butanal, gave 1-methyl, 1,2-methyl, 2-
methyl and 2-ethyl substituted xanthones respectively (Scheme 58)  [176]. 
 
Scheme 55. Synthesis of xanthones by cycloaddition reactions of 2-(2-dimethyl-aminovinyl)-chromen-4-one 
with N-phenylmaleimide, 3-substituted chromen-4-ones and dimethyl acetylenedicarboxylate. 
4.3.1.1 Chromen-4-one as a 4 ʌ component 
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The Diels-Alder cycloaddition reaction of 2-(2-dimethyl-aminovinyl)-chromen-4-ones with N-
phenylmaleimide led to xanthones in one step and in moderate yields (Scheme 56; Table 26). The reaction 
proceeds through the Diels-Alder cycloadducts which are not isolated and readily eliminate dimethylamine 
and aromatize to give the xanthone scaffold (Scheme 56). However, the reaction was successful only for 
DMF since in toluene no xanthones were obtained. It was suggested that the diene system of the chromen-4-
one remains in an s-trans conformation in a non-polar solvent, such as toluene, and in DMF it assumes 
mainly the s-cis conformation which allowed it to react with the dienophile [174, 175].  
 
Scheme 56. Synthesis of xanthones by Diels-Alder cycloaddition reaction between 2-(2-dimethyl-
aminovinyl)-chromen-4-one and N-phenylmaleimide. 
Table 26. Xanthones synthesized by a Diels-Alder cycloaddition reaction between 2-(2-dimethyl-
aminovinyl)-chromen-4-one and N-phenylmaleimide. 
R1 % (Yield) 
H 35-40 
Me 35-40 
Cl 42 
 
In section 4.2.1.1, several examples showed the use of 3-substituted chromen-4-ones as dienophiles 
in Diels-Alder reactions. One common feature was the presence of an EWG in position 3, since it increased 
the dienophilicity of the double bond. Therefore, 3-substituted chromen-4-ones are a viable substrate for a 
Diels-Alder reaction with 2-vinyl-chromen-4-ones. As a result, several 2-salicyloylxanthone derivatives were 
obtained from the reaction of 3-formyl and 3-carboxilic acid chromen-4-ones with 2-(2-dimethyl-
aminovinyl)-chromen-4-ones (Scheme 57; Table 27). Besides the expected Diels-Alder cycloaddition, it was 
proposed that the reaction could also follow a Michael-initiated heteroannulation reaction. Few xanthones 
were synthesized by this method but it was observed that with 3-formylchromen-4-ones, both formylated and 
deformylated xanthones were obtained (Table 27; entries 1-3). On the other hand, with chromen-4-one 
bearing a carboxylic acid in position 3, only the decarboxylated xanthone was obtained (Table 27; entries 4-
6) [174, 175].   
 
Scheme 57. Synthesis of xanthones by reaction of 2-(2-dimethyl-aminovinyl)-chromen-4-ones with 3-formyl 
and 4-carboxilic chromen-4-ones. 
Table 27. 2-Salicyloylxanthones synthesized by the reaction of 2-(2-dimethyl-aminovinyl)-chromen-4-ones 
with 3-formyl and 3-carboxilic chromen-4-ones. 
Entry R1 X A (% Yield) B (%Yield) 
1 H CHO 5 20 
2 Me CHO 4 15 
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3 Cl CHO 6 18 
4 H COOH 40 - 
5 Me COOH 35 - 
6 Cl COOH 37 - 
 
As stated above, electron-poor 2-vinylchromen-4-ones could behave as dienes in an IEDDA 
cycloaddition reaction to give xanthones. Therefore, the reaction of 2-vinylchromen-4-ones with enamines 
generated in situ from the reaction of a catalytic amount of pyrrolidine with acetone, or butan-2-one, or 
propanal or butanal reacting led to 1-methyl, 1,2-methyl, 2-methyl and 2-ethyl substituted xanthones 
respectively (Scheme 58; Table 28). For most of the examples, xanthones are obtained in one step with 
exception enamines generated from butan-2-one. In this case, a tetrahydroxanthone bearing a methylidene 
group is isolated and then it is easily converted to 1,2-dimethylxanthone by treatment with a strong acid 
(Table 28; entry 11). In addition, the enamine generated from butan-2-one also led to 2-ethylxanthone 
derivatives but as side products [176].  
 
Scheme 58. Synthesis of xanthones by an IEDDA cycloaddition reaction between 2-vinylchromen-4-ones 
and enamines. 
Table 28. Xanthones synthesized by an IEDDA cycloaddition reaction of 2-vinylchromen-4-ones with 
enamines. 
Entry R1 R2 R3 R4 R5 R6 R7 % Yield 
1 H H H H Ph H Me 76 
2 H H H H 2-thienyl H Me 70 
3 H H H H 2-furyl H Me 56 
4 H Me Me H Ph H Me 75 
5 H Cl H H 2-OMe-Ph H Me 63 
6 H Cl H H 2,4-Cl2-Ph H Me 58 
7 H Cl H Cl Ph H Me 57 
8 OMe H H H Ph H Me 59 
9 H OMe H H Ph H Me 63 
10 H H H H H H Me 58 
11 H H H H Ph Me Me (55)89a 
12 H H H H Ph Me H 12 
13 H H H H 2-thienyl Et H 15 
aSynthesis of the xanthone in two steps; the 1-methylidene-2-methyltetrahydroxanthone adduct is oxidized to 
xanthone by treatment with strong acid. 
4.3.1.2 Chromen-4-one as a 2 ʌ component in a [2 + 2] cycloaddition 
ŚĂƉƚĞƌϲ
ƉƉĞŶĚŝǆ
ϯϰϭ

The 2-(2-dimethyl-aminovinyl)-chromen-4-ones are expected to react through a Diels-Alder 
cycloaddition with dimethyl acetylenedicarboxylate (R2 = COOMe), dibenzoylacetylene (R2 = COPh) and 
ethyl propiolate (R2 = COOEt; R1 = H). However, xanthones were obtained in moderate yields not from a 
Diels-Alder cycloaddition but from a [2 + 2] cycloaddition between the enamine of the chromen-4-one and 
the alkyne (Scheme 59, Table 29). It was proposed that the enamine behaves as unconjugated and undergoes 
a [2 + 2] cycloaddition with alkyne to give cyclobutene adduct. The cyclobutene adduct then opens, 
electrocyclizes and eliminates dimethylamine to give xanthones [174, 175]. 
 
Scheme 59. Synthesis of xanthones by reaction of 2-(2-dimethyl-aminovinyl)-chromen-4-ones with dimethyl 
acetylenedicarboxylate (R2 = R3 = COOMe), dibenzoylacetylene (R2 = R3 =COPh) and ethyl propiolate (R2 = 
COOEt; R1 = H) 
Table 29. 2,3-Disubstituted xanthones synthesized by the reaction of 2-(2-dimethyl-aminovinyl)-chromen-4-
ones with dimethyl acetylenedicarboxylate (R2 = R3 = COOMe), dibenzoylacetylene (R2 = R3 = COPh) and 
ethyl propiolate (R2 = COOEt; R1 = H) 
Entry R1 R2 R3 % Yield 
1 H COOMe COOMe 40 
2 Me COOMe COOMe 37 
3 Cl COOMe COOMe 38 
4 H COPh COPh 38 
5 Me COPh COPh 32 
6 Cl COPh COPh 26 
7 H COOEt H 35 
8 Me COOEt H 28 
9 Cl COOEt H 26 
 
4.3.2 Photochemical reactions 
Photochemical reactions have shown to be useful in the cyclization of 3-aroyl-chromen-4-one to a 
benzoxanthone (section 4.2.3). In addition to that reaction, a photochemical oxidation was also used for the 
synthesis of benzo[a]xanthones by the photooxidation of a solution (E)-2-styryl-4H-1-benzopyran-4-ones in 
CHCl3 at daylight for several days (Scheme 60). It was proposed that the reaction proceeds through an E to Z 
photoisomerization which then follows an electrocyclic oxidative ring closure to give the benzoxanthone. 
The photooxidation led to several benzo[a]xanthones bearing chlorine, methyl and ethyl substituents in 
moderate yields (Table 30) [177]. 
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Scheme 60. Synthesis of benzoxanthones from photochemical reactions of (E)-2-styrylchromen-4-ones. 
  Table 30. Benzoxanthones synthesized from photochemical reactions of (E)-2-styrylchromen-4-ones. 
R1 R2 % (Yield) 
H H 40 
Me H 56 
Me Cl 52 
Et Cl 50 
 
4.4 Synthesis of xanthones from 2 and 3 disubstituted chromen-4-one 
 The 2 and 3 substituted chromen-4-ones have shown to be suitable building blocks for the synthesis 
of highly substituted xanthones (Section 4.2 and 4.3). Therefore, 2,3-disubstituted chromen-4-ones should 
also be excellent starting points for the synthesis of xanthones and several methodologies used 2,3-
disubstituted chromen-4-ones as building blocks. Most of the strategies described in the literature use 
Michael-initiated heteroannulations reactions (4.4.3), but pericyclic reactions (4.4.1 and 4.4.2), 
photochemical reactions (4.4.4) and Vilsmeier-Hack reactions (4.4.5) were also applied for the synthesis of 
xanthones. 
4.4.1 Cycloaddition 
In section 4.3.1.2 it was described the synthesis of xanthones from a [2 + 2] cycloaddition of 2-(2-
dimethylaminovinyl)-chromen-4-ones with several alkynes (Scheme 59, Table 29). This methodology can 
also be applied for the synthesis of xanthones from  2-(2-dimethylaminovinyl)-chromen-4-ones, bearing 
either an acetyl or a benzoyl in position 3, as building blocks (Scheme 61)  [175]. The scope of the reaction 
was investigated and two and one xanthones were obtained in moderate yields from the heating of 3-acetyl-2-
(2-dimethyl-aminoviny)chromen-4-one derivatives with dimethyl acetylenedicarboxylate and ethyl 
propiolate, respectively (Table 31, entries 1-3, 7 and 8). The observed outcome of the reaction could be 
explained by the two synthetic pathways that a non-isolable intermediate could follow: the intermediate could 
either eliminate an acetyl group to give compound B. or eliminate a hydroxyl to give 1-methylxanthone 
derivatives (A.). On the other hand, the heating of 3-benzoyl-2-(2-dimethyl-aminovinyl)-chromen-4-ones 
with dibenzoylacetylene led only to the deacetylated product in moderate yields (Table 31, entries 4-6). 
Scheme 61. Synthesis of xanthones by reaction of 3-benzoyl-2-(2-dimethyl-aminovinyl)-chromen-4-ones (R2 
= Ph) with dibenzoylacetylene (R3=R4=COPh) and 3-acetyl-2-(2-dimethyl-aminoviny)chromen-4-ones 
(R2=Me) with dimethyl acetylenedicarboxylate (R3=R4=COOMe) and ethyl propiolate (R3=COOEt, R4=H). 
Table 31. Xanthones synthesized by the reaction of 3-benzoyl-2-(2-dimethyl-aminovinyl)-chromen-4-ones 
(R2 = Ph) with dibenzoylacetylene (R3=R4=COPh) and 3-acetyl-2-(2-dimethyl-aminoviny)chromen-4-ones 
(R2=Me) with dimethyl acetylenedicarboxylate (R3=R4=COOMe) and ethyl propiolate (R3=COOEt, R4=H). 
Entry R1 R2 R3 R4 A. (% Yield) B. (% Yield) 
1 H Me COOMe COOMe 38 9 
2 Me Me COOMe COOMe 36 10 
3 Cl Me COOMe COOMe 42 15 
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4 H Ph COPh COPh 42 - 
5 Me Ph COPh COPh 45 - 
6 Cl Ph COPh COPh 46 - 
7 H Me COOEt H - 10 
8 Me Me COOEt H - 7 
 
4.4.3 Electrocyclization 
Two new routes for the synthesis of 2,3-diarylxanthones in one and two steps from either (E)-3-
bromo-2-styrylchromen-4-ones (Scheme 62, A.) or (E)-2-methyl-3-styrylchromen-4-ones (Scheme 62, B.) 
have been described respectively [178-180]. The (E)-3-bromo-2-styrylchromen-4-ones building blocks 
(Scheme 62, A.) could be easily synthesized using two approaches: by an aldol condensation between 2-
bromo-3-methylchromen-4-ones and benzaldehydes or through a Baker–Venkataraman rearrangement of 2-
acetylphenyl cinnamates followed by a one-pot bromination/cyclization reaction. The Heck coupling between 
(E)-3-bromo-2-styrylchromen-4-ones and styrene derivatives led directly to 2,3-diarylxanthones in one step, 
since the (E,E)-2,3-distyrylchromen-4-ones obtained from the coupling reaction were not isolated and 
suffered a spontaneous electrocyclization followed by aromatization to give 2,3-diarylxanthones (Scheme 62, 
A). Regarding (E)-2-methyl-3-styrylchromen-4-ones building blocks, they were easily obtained by the Heck 
reaction of 2-bromo-3-methylchromen-4-ones and styrenes (Scheme 62, B.). The 2,3-diarylxanthones were 
obtained in two steps since the base-catalyzed aldol condensation of (E)-2-methyl-3-styrylchromen-4-ones 
with a benzaldehyde derivative led to isolable (E,E)-2,3-distyrylchromen-4-ones, which after heating 
produced the xanthones (Scheme 62, B.).  
 
Scheme 62. Synthesis of 2,3-diarylxanthones. 
The 3-acetyl-2-(2-dimethylaminovinyl)-chromen-4-ones were used for the synthesis of xanthones 
from a [2 + 2] cycloaddition with alkynes (Scheme 61). In addition, they could also be used as building 
blocks for the synthesis of 1-hydroxyxanthone derivates since they could suffer an intramolecular cyclization 
[175]. The 1-hydroxyxanthone derivatives were obtained when 3-acetyl-2-(2-dimethylaminovinyl)-chromen-
4-ones were heated in the presence of a strong base, such as sodium methoxide. It was proposed that the 
sodium methoxide catalyses the formation of the enolate of the acetyl group present in position 3, which then 
suffers an intramolecular electrocyclization to give non-isolable cycloadduct. The dimethylamine is then 
eliminated from the cycloadduct and after aromatization, 1-hydroxyxanthone derivatives were obtained 
(Scheme 63). 
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Scheme 63. Synthesis of xanthones by electrocyclization 3-acetyl-2-(2-dimethylaminovinyl)-chromen-4-one 
base-catalyzed. 
4.4.3 Michael-initiated heteroannulation reactions 
In section 4.2.2 it was described the synthesis of several xanthones through Michael-initiated 
heteroannulation reactions between 3-(1-alkynyl)chromen-4-ones and different nucleophiles (Scheme 49). 
One of the examples described the synthesis of xanthones from the self-condensation of 3-(1-
alkynyl)chromen-4-ones (Scheme 51). Therefore, it was envisioned that 2-methyl-3-(1-alkynyl)chromen-4-
ones could also self-condensate or react with 3-(1-alkynyl)chromen-4-ones to give a chromen-4-one linked  
to a xanthone at position 3 (Scheme 64). Consequently, the heating of either 2-methyl-3-(1-alkynyl)chromen-
4-ones or these in the presence of 3-(1-alkynyl)chromen-4-ones led to the expected xanthones. It was 
proposed that the reaction involves domino processes of Michael additions/cyclizations between two 
chromen-4-ones molecules. The scope of the reaction was studied and it was observed that self-condensation 
occurred whatever the chemical nature of the substituent in R1 and R4 (Table 32, entries 9 to 13). In the case 
of the acetylenic moiety (R2 and R3), the reaction proceed smoothly and in good yields for both aromatic and 
alkylic chains (Table 32, entries 1-6 and 8) with the exception of sterically hindered groups such as tert-butyl 
(Table 32; entry 7). The reaction of 2-methyl-3-(1-alkynyl)chromen-4-ones with 3-(1-alkynyl)chromen-4-
ones led to xanthones in good yields for all the examples studied (Table 32, entries 14-21) [181].  
 
Scheme 64. Synthesis of xanthones by the self-condensation of 2-methyl-3-(1-alkynyl)chromen-4-ones or the 
reaction between 2-methyl-3-(1-alkynyl)chromen-4-ones and 3-(1-alkynyl)chromen-4-ones. 
Table 32. Xanthones synthesized by the self-condensation of 2-methyl-3-(1-alkynyl)chromen-4-ones or the 
reaction between 2-methyl-3-(1-alkynyl)chromen-4-ones and 3-(1-alkynyl)chromen-4-ones. 
Entry R1 R2 R3 R4 R5 %Yield 
1 H Ph Ph H Me 90 
2 H (p-OMe)Ph (p-OMe)Ph H Me 85 
3 H (p-CF3)Ph (p-CF3)Ph H Me 79 
4 H (p-Me)Ph (p-Me)Ph H Me 82 
5 H C3H6CN C3H6CN H Me 70 
6 H n-pentyl n-pentyl H Me 65 
7 H t-Bu t-Bu H Me 14 
8 H (Me)3Sia (Me)3Sia H Me 63 
9 Me Ph Ph Me Me 78 
10 OMe Ph Ph OMe Me 80 
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11 Br Ph Ph Br Me 74 
12 Cl Ph Ph Cl Me 77 
13 NO2 Ph Ph NO2 Me 75 
14 H Ph Ph H H 71 
15 H Ph (p-OMe)Ph H H 68 
16 H Ph (p-CF3)Ph H H 75 
17 H (p-OMe)Ph Ph H H 65 
18 H (p-CF3)Ph Ph H H 63 
19 H C3H6CN Ph H H 76 
20 OMe Ph Ph H H 75 
21 NO2 Ph Ph H H 78 
a.trimethylsilyl was removed. 
In section 4.2.2 it was reported several reactions between 3-(1-alkynyl)chromen-4-ones and 2-(3-
bromophenyl)acetonitrile which led to several aminoxanthones (Scheme 52,  Table 22, entries 2 and 7-15). 
Besides the 3-substituted chromen-4-ones, it was also studied the reaction of 2-methyl-3-(1-
alkynyl)chromen-4-ones with acetonitriles and two aminoxanthones were obtained (Scheme 65) [171]. The 
reaction seemed to involve also a domino process of Michael addition/cyclization/1,2-addition. Two 
aminoxanthones were obtained in good yields using microwave heating and t-BuOK as base (Scheme 65). 
 
Scheme 65. Synthesis of 3-aminoxanthones by the reaction of 2-methyl-3-(1-alkynyl)chromen-4-ones with 
2-vinylchromen-4-ones- 
In Scheme 64, the reactivity of 2-methyl-3-(1-alkynyl)chromen-4-ones towards a self-condensation 
reaction or to 3-(1-alkynyl)chromen-4-ones was described. In addition, 2-methyl-3-(1-alkynyl)chromen-4-
ones could also react with other chromen-4-ones such as 3-vinylchromen-4-ones to give a complex chromen-
4-one-fused scaffold. As a result, the reaction between the two chromen-4-ones led to benzo[a]xanthones 
with an interesting pattern of substitution (Scheme 66). The reaction involves a sequential Michael 
addition/cyclization/1,2-addition/elimination. The scope of the reaction was studied and it was verified that 
the acetylenic moiety could bear both aromatic and non-bulky groups (Table 33, entries 1 to 6). However, the 
use of a bulky acetylenic is not allowed since the expected product was not obtained (Table 33, entry 7). 
Regarding substituents in the chromen-4-ones (R1), substrates that had an EWG led to xanthones in higher 
yields than chromen-4-ones with EDGs (Table 33, entries 8 to 12). Moreover, several 2-vinyl chromen-4-
ones with different EWGs were studied (R3) and higher yields were obtained when less sterically hindered 
groups, such as CN and COMe, were used (Table 33, entries 13 to 18) [182]. 
Scheme 66. Synthesis of benzo[a]xanthones by Michael-initiated heteroannulations between 2-methyl-3-(1-
alkynyl)chromen-4-one and 3-vinylchromen-4-ones. 
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Table 33. Benzo[a]xanthones synthesized by Michael-initiated heteroannulations between 2-methyl-3-(1-
alkynyl)chromen-4-one and 3-vinylchromen-4-ones. 
Entry R1 R2 R3 %Yield 
1 H Ph COOEta 71 
2 H (p-OMe)Ph COOEta 61 
3 H (p-CF3)Ph COOEta 70 
4 H (p-Me)Ph COOEta 55 
5 H C3H6CN COOEta 54 
6 H n-pentyl COOEta 61 
7 H t-Bu COOEta - 
8 Me Ph COOEta 67 
9 OMe Ph COOEta 56 
10 Br Ph COOEta 65 
11 Cl Ph COOEta 75 
12 NO2 Ph COOEta 83 
13 H Ph CNb 64 
14 H Ph COMec 75 
15 H Ph Bzd 46 
16 H Ph (p-OMe)Bze 55 
17 H Ph (p- NO2)Bzf 20 
18 H Ph (p-Br)Bzg 50 
aEthanol was eliminated and the substituent is OH. bNitrile group was transformed into amino. cThe carbonyl 
group was eliminated and the substituent is methyl. dThe carbonyl group was eliminated and the substituent 
is phenyl. eThe carbonyl group was eliminated and the substituent is (p-OMe)Ph. fThe carbonyl group was 
eliminated and the substituent is (p-NO2)Ph. gThe carbonyl group was eliminated and the substituent is (p-
Br)Ph. 
The 3-vinylchromen-4-ones have shown to be a good partner for domino reactions with 3-(1-
alkynyl)chromen-4-ones leading to benzo[a]xanthones (Scheme 66) and their reactivity with other chromen-
4-ones such as 2-methyl-3-acetylchromen-4-ones was studied (Scheme 67). The reaction between the two 
chromen-4-ones led to several benzo[a]xanthones and it was proposed that a domino process of Michael 
addition reactions, eliminations, isomerizations and cyclizations could explain the outcome [183]. The scope 
of the reaction was studied and several 2-vinylchromen-4-ones bearing different EWGs (R) reacted with 2-
methyl-3-acetylchromen-4-one (Table 34). The presence of a phenyl ring as the substituent gave better yields 
than methyl group (Table 34, entry 1). In addition, phenyl rings substituted with EWGs (Table 34, 5-8) gave 
better yields than phenyl rings with strong EDGs (Table 34, entries 2 and 3). 
 
Scheme 67. Synthesis of benzo[a]xanthones by the reaction of 2-methyl-3-acetylchromen-4-one with 2-
vinylchromen-4-ones 
Table 34. Benzo[a]xanthones synthesized by the reaction of 2-methyl-3-acetylchromen-4-one with 2-
vinylchromen-4-ones. 
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Entry R % (Yield) 
1 Me 65 
2 (p-OMe)Ph 70 
3 (p-NEt2)Ph 67 
4 (p-Me)Ph 82 
5 (p-CF3)Ph 90 
6 (p-F)Ph 92 
7 (p-Br)Ph 80 
8 (p-NO2)Ph 93 
 
In addition to the self-condensation observed for 3-alkynyl-chromen-4-ones derivatives, 2-
salicyloylxanthone derivatives have also been obtained from the self-condensation of 3-acetylchromen-4-one 
(Scheme 68, R1=Me and R2=H) [184], 3-acetyl-2-methylchromen-4-one (Scheme 68, R1=Me and R2=Me)  
and 3-formyl-2-methylchromen-4-one (Scheme 68, R1=H and R2=Me)  [185]. These reactions were 
explained by a domino process of Michael-initiated ring closure followed by elimination reactions. 
 
Scheme 68. 2-Salicyloylxanthones synthesized by the dimerization of chromen-4-one 
In section 4.1, an example described the synthesis of a benzoxanthone through the condensation of 
an unsubstituted chromen-4-one with a (phenylsulfony1)isobenzofuranone. However, if the 
phenylsulfonylisofuranone group is attached to positions 2 and 3 of the chromen-4-one instead, a 
condensation between the chromen-4-one derivative and a Michael-acceptor can be used for the synthesis of 
xanthones. As a matter of fact, several xanthones were synthesized in good yields by the reaction of 
benzopyranonephatalides with different Michael-acceptors (Scheme 69) [186]. This is an useful approach for 
the regiospecific synthesis of linear and angular polycyclic aromatic systems containing a hydroquinonic 
xanthone fragment. 
 
Scheme 69. Synthesis of xanthones by the condensation of benzopyranonephatalide with several Michael 
acceptors. 
4.4.4 Photochemical Reactions 
 A similar strategy used for the synthesis of 2,3-diaryl xanthones from (E)-3-bromo-2-styrylchromen-
4-ones (Scheme 62) was followed for the synthesis of 5-arylbenzo[c]xanthones from (E)-styrylflavones 
(Scheme 70) [187]. In order to obtain the benzo[c]xanthone, the synthetic strategy involved in obtaining (E)-
styrylflavones which were synthesized in two steps and in moderate yields from 3-aryl-1-(2-
hydroxyphenyl)propan-1,3-diones as building blocks. The first synthetic step was the cyclization and 
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bromination of 3-aryl-1-(2-hydroxyphenyl)propan-1,3-diones to give 3-bromoflavones. Several reagents 
were employed and the best results were obtained with phenyltrimethylammonium tribromide (PTT). The 
second step was the coupling of 3-bromoflavones with styryl derivatives by a Heck reaction using microwave 
heating. In comparison with the Heck reaction of (E)-3-bromo-2-styrylchromen-4-one with styrenes (Scheme 
62) [178-180], no electrocyclization was observed and instead, the expected (E)-styrylflavones derivatives 
were isolated. The (E)-styrylflavones derivatives were then cyclized to benzo[c]xanthone and success was 
only attained for photoinduced reactions. Moreover the best yields were obtained using the UV radiation of 
high pressure mercury UV lamp and microwaves in 1,2,4-trichlorobenzene (TCB) and iodine. It was 
proposed that the UV light induces the electrocyclization of (E)-styrylflavones and the rearomatization of the 
cycloadduct leads to the benzo[c]xanthone. However, in the presence of a strong-EWG (Scheme 70, R1 = 
NO2), besides the expected benzo[c]xanthone, a compound with a hydroxyl in position 6 was also isolated by 
the reaction with a singlet oxygen. 
 
Scheme 70. Synthesis of 5-arylbenzo[c]xanthones through a photoinduced electrocyclization and oxidation 
of (E)-3-styrylflavones. 
4.4.5 Vilsmeier-Hack reaction 
3-Acetyl-2-(2-dimethyl-aminoviny)chromen-4-ones and 3-formyl-2-methylchromen-4-one have 
already been used as building blocks for the synthesis of xanthones. Besides cycloaddition reactions and self-
condensation reactions, 3-acetyl-2-(2-dimethyl-aminoviny)chromen-4-ones and 3-formyl-2-methylchromen-
4-one can also participate in a Vilsmeir-Hack reaction to give 4-formyl-1-hydroxyxanthone and 1-chloro-2-
formylxanthone in 40 % and 41 % yield respectively (Scheme 71) [185]. 
 
Scheme 71. Synthesis of xanthones by the reaction of 3-acetyl-2-(2-dimethylaminovinyl)-chromen-4-one and 
3-acetyl-2-methylchromen-4-one with DMF/POCl3 (Vilsmeier-Hack reaction). 
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5. Other methodologies (Scheme 1; 5) 
Most of the xanthones described in the literature were obtained using one the strategies described in 
the previous sections. However, xanthones can also be obtained using other less common methodologies, 
which should be referred since they could be an important alternative to the other “classical” approaches. To 
summarize, xanthones have been obtained from cycloaddition reactions (5.1.1) and oxidation of 
dehydroxanthones (5.1.2), from 2-hydroxychalcones (5.2), from the benzannulation of 1,2-adducts derived 
from cyclobutenediones (5.3), from a photochemical reaction of  2-benzylidene-1-tetralones (5.4), by an 
enzymatic synthesis (5.5), by the oxidation of xanthenes (5.6) and from acyl-radical reaction of 
phenoxybenzoquinones (5.7). 
5.1 Synthesis of xanthones from dehydroxanthone derivatives 
5.1.1. By a [4 + 2] cycloaddition reaction 
The reaction of 3,4-dehydroxanthones with dimethyl acetylenedicarboxylate led to methyl 3,4-
dicarboxilate xanthones (Scheme 72). The reaction proceeds through an initial [4 + 2] cycloaddition which 
through a subsequent retro Diels-Alder, gives the xanthone [188]. 
 
Scheme 72. Synthesis of 3,4-dicarboxilate xanthones by the reaction of 3,4-dehydroxanthones with dimethyl 
acetylenedicarboxylate 
5.1.2 Synthesis of xanthones by aromatization of dehydroxanthones  
The xanthone scaffold can also be obtained from the aromatization of dehydroxanthone derivatives 
(Scheme 73). Several catalysts have been employed and  xanthones were obtained with palladium on 
charcoal [189], sulfur [190], quinones [124, 125, 166], MnO2 [191] and pyrrolidine [192]. 
 
Scheme 73. Oxidation of dehydroxanthones to xanthones. 
5.2 Synthesis of xanthones from 2-hydroxychalcones 
In the synthesis of 3-aryl-2-napthyl-2-hydroxyphenyl ketones, several benzoxanthones were 
obtained as by-products during the oxidation step (Scheme 74). The first synthetic step towards 3-aryl-2-
napthyl-2-hydroxyphenyl ketones was the synthesis of 3-aryl-1,2,3,4-tetrahydro-2-naphthyl-2-hydroxyphenyl 
ketones cycloadducts as a result of the Diels-Alder reaction of 2-hydroxychalcones with ortho-
benzoquinodimethane. The cycloadduct was then oxidized with DDQ under microwave irradiation to give 3-
aryl-2-napthyl-2-hydroxyphenyl ketones. However, several benzoxanthones were also obtained as by-
products during the oxidation step, but only when microwave irradiation was employed [193]. 
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Scheme 74. Synthesis of benzoxanthones as by-products from the oxidation of 3-aryl-1,2,3,4-tetrahydro-2-
naphthyl 2-hydroxyphenyl ketones with DDQ and microwave heating. 
5.3 Synthesis of xanthones by benzannulation of 1,2-adducts derived from cyclobutenediones 
The addition of different lithiated derivatives to cyclobutenediones have shown to be very 
productive route of obtaining highly substituted xanthones. The crucial characteristic of this route is the 
benzannulation of the product resulted from the nucleophilic addition of lithiated derivative to the 
cyclobutenediones giving highly substituted aromatic rings, that, with the appropriate substituents, can be 
transformed into xanthones. Three different cyclobutenediones have been used with success: dithiane 
benzopyrone-fused cyclobutenediones (Scheme 75), 3-(o-anisoyl)-4-substituted cyclobutenedieones and their 
dithianyl derivatives (Scheme 76), and dimethoxy squarate (Scheme 77). 
Highly-substituted xanthones were obtained from the nucleophilic addition of different alkenyl, aryl 
and heteroaryl lithiates to dithiane benzopyrone-fused cyclobutenediones (Scheme 75) [194]. The 
nucleophilic addition of the different lithiated derivatives took place exclusively at the carbonyl opposite to 
the bulky dithiane moiety and gave the dithiated-protected xanthones in moderate to excellent yields. The 
dithiane products were then deprotected by a standard HgCl2 protocol to give the xanthones. 
 
Scheme 75. Synthesis of xanthones by nucleophilic addition of alky, heteroaryl lithiates to a dithiane-
protected benzopyrone-fused cyclobutenediones. 
 The reaction of benzannulation of 1,2-adducts derived from 3-(o-anisoyl)-4-substituted 
cyclobutenedieones and their dithianyl derivatives with different lithiates led to the synthesis of xanthones 
through benzophenone route (Scheme 76) [195]. The reaction of the lithiates with 3-(o-anisoyl)-4-substituted 
cyclobutenediones led directly to the 2-hydroxy-2’-methoxybenzophenone that underwent an intramolecular 
SNAr to give the xanthone. On the other hand, the benzophenones obtained from the nucleophilic addition of 
lithiates to protected 3-(o-anisoyl)-4-substituted cyclobutenediones, need an extra-step of deprotection, since 
the product obtained from the benzannulation still had the dithiane protecting group. The benzophenone was 
later cyclized to xanthones through an intramolecular SNAr. This approach is very interesting for the 
synthesis of angular-fused xanthones. 
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Scheme 76. Synthesis of xanthones by a benzannulation of 1,2-adducts derived from 3-(o-anisoyl)-4-
substituted cyclobutenediones and their dithianyl derivatives with lithiates. 
The use of benzannulations of 1,2-adducts derived from the addition of lithiates to 
cyclobutenediones have shown to be a viable alternative for the synthesis of xanthones bearing interesting 
patterns of substitution (Scheme 75 and 76). This same approach was used with success for the synthesis of 
several 1,4-dioxygenated xanthones in 6 and 7 steps (Scheme 77) [196]. The first step concerns the protection 
of salicylaldehydes with p-methoxybenzyl ether (PMB), which were then ethynylated with ethynyl 
magnesium to give propargylic alcohols. The addition of 2.2 equivalents of nBuLi led to the dilithiated 
derivatives of the propargylic ether which then added to dimethoxy squarate to give a 1,2-adducts. The 
thermal rearrangement of the 1,2-adducts led to quinones by a Moore cyclization. The removal of PMB 
protecting group with TFA led to the xanthone via cyclization by an intramolecular conjugate addition which 
had already been referred in section 2.2.4 (Scheme 27). The cyclization produced the xanthone directly only 
when R was H, 3-OMe, 5-OMe, 5-Cl and 4-Cl. For the other substituents, spirocyclic ketones were obtained 
which were easily transformed into xanthones by the reaction with potassium carbonate in acetone. 
 
 
Scheme 77. Multistep synthesis of 1,4-dioxygenated xanthones through benzannulations of 1,2-adducts 
derived from cyclobutenodiones. 
 
5.4 Synthesis of benzoxanthones by ultraviolet radiation-mediated domino reactions 
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Benzoxanthones were synthesized from 2-benzylidene-1-tetralone derivatives by ultraviolet 
radiation-mediated domino reactions (Scheme 78) [197]. It was proposed that the overall transformation 
presumably proceeds through a domino process of cis-trans isomerisation, oxa-6ʌ electrocyclization, singlet 
oxygen ene reaction, dehydration, and aromatization. The scope and limitations of this photoinduced 
oxidative cyclization were studied and it was observed that substituents on the phenyl group of the tetralone 
moiety had no effect on the yield of the reaction (Scheme 78, R3) [197]. On the other hand, substituents in the 
para and meta positions of the benzylidene (Scheme 78, R1 and R2) moiety influenced greatly the reaction 
since neither strong EWG (NO2) nor EDG (OMe) were tolerated. 
 
Scheme 78. Synthesis of benzoxanthones by ultraviolet radiation-mediated tandem reaction 2-benzylidene-1-
tetralones. 
5.5 Enzymatic synthesis of benzoxanthones 
In a completely different approach, Ma et al reported the synthesis of a novel benzoxanthone by 
enzymatic synthesis using a fungal PolyKetide Synthase (PKS). The fungal PKS4 can be found in Gibberella 
fujikuroi and is involved in the biosynthesis of the anticancer fungal polyketide bikaverin. The enzyme was 
expressed in Escherichia coli and reconstituted in vitro. The PKS was able to synthesize a benzoxanthone 
using malonyl Co-A as substrate and was able to maintain near complete length control during the elongation 
step to form the polyketide [198] (Scheme 79).  
 
Scheme 79. Enzimatic synthesis of a benzoxanthone 
5.6 Synthesis of xanthones by oxidation of xanthenes 
The xanthene scaffold can be used as a building block for the synthesis of xanthones. Several 
methodologies have been described for the oxidation of xanthenes to xanthones (Scheme 80) such as N-
hydroxyphthalimide/acetaldehyde/O2 [199], Ru-Co-Al-CO3 hidrotalcite [200], chromium [47, 201], (tert-
butylperoxy)iodanes [202], potassium permanganate [203-206], dimethyldioxirane [207], selenium [208, 
209] and DDQ [61].  
 
Scheme 80. Synthesis of xanthones by oxidation of xanthenes. 
5.7 Synthesis of xanthones by acyl radical cyclizations 
ŚĂƉƚĞƌϲ
ƉƉĞŶĚŝǆ
ϯϱϯ

In section 3.1.2 (Scheme 31), a strategy for synthesis of the diaryl ethers through conjugate 
substitution of methyl salicylates with 1,4-halobenzoquinones was described. That methodology has shown 
to be very useful for the synthesis of 1,4-dioxygenated xanthones and Kraus et al envisioned that 
salicylaldehydes could also be used instead of methyl salicylates. However, in this case, the 
phenoxybenzoquinone obtained after the conjugate substitution can generate an acyl radical which possibly 
can undergo an intramolecular cyclization to lead directly to xanthones (Scheme 81). Therefore, the first step 
of the synthetic pathway was to obtain the phenoxy benzoquinone. Unfortunately, the conjugate substitution 
of salicylaldehydes did not lead to the desired compound, but the corresponding acetal did (Scheme 81, A. 
The acetal was easily hydrolyzed giving the desired phenoxybenzoquinone (Scheme 81, B). The treatment of 
the phenoxybenzoquinone with NBS and a catalytic amount of AIBN produced xanthone D. However, this 
compound was not stable and so it was hydrogenated directly after the acyl radical reaction to give the 
xanthone derivative F (Scheme 81). Since the yield obtained in these two steps was very low (15 % over the 
two steps), a different strategy was envisioned. Instead of hydrogenating xanthone F, it was decided to reduce 
xanthone D using zinc chloride. The reduction was successful but instead of the xanthone, a benzophenone E 
was obtained which was easily cyclized to give the xanthone F (Scheme 81) [210]. 
 
Scheme 81. Synthesis of xanthones by acyl radical cyclizations. 
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6. Substitutions at the xanthone core (Scheme 1; 6) 
As it was highlighted in the introduction, xanthones are an extremely important building block from 
the biological point of view since it can be considered a privileged structure. Therefore, one very common 
strategy applied in medicinal chemistry is to synthesize xanthones bearing small functionalities, and later, by 
molecular modification, more complex xanthones are obtained and evaluated for their biological activities. 
Consequently, the introduction of small functionalities in the cheap and commercially available unsubstituted 
xanthone could be a logical alternative as building block. However, that strategy is rarely followed since the 
electron-withdrawing effect the carbonyl has over the two aromatic rings decrease drastically the 
nucleophilicy of the xanthone towards electrophiles. Nevertheless, several small functionalities, such as nitro 
[211-213], formyl [201, 214], acetyl [215], halogens [213, 216, 217] and sulfones [81], have been introduced 
by the reaction with strong electrophiles. In addition, xanthones cannot participate in ortho-lithiation or 
halogen-lithium exchange reactions since the carbonyl is not stable in these experimental conditions. To 
summarize, the carbonyl of the xanthone influences greatly the chemical reactivity of the xanthone. 
Therefore, one way to overcome this limitation and increase either the nucleophilicity or the stability of the 
xanthone is to convert the carbonyl group into other functionality, and after the introduction of the desired 
functional group, to replace the carbonyl group. As a matter of fact, two strategies have been applied in 
xanthones to overcome this limitation: the protection of the carbonyl group, and the reduction of the 
xanthone into the respective xanthene. The protection of the carbonyl was not easily made but success was 
attained through a ketal which was obtained in two steps from the reaction of the xanthone with sulfonyl 
chloride to give 9,9-dichloroxanthene followed by the reaction with sodium methoxide [218-220]. The 
protected xanthone could then generate strong lithiated nucleophiles by the reaction with strong bases, and 
consequently, methyl, N,N-diethyl amide, iodide and trimethylsilane functionalities were introduced 
regioselectively (Scheme 82). Moreover, regioselectivity was dependent on the experimental conditions used 
[213, 220]. As it was shown in section 5.6, there are several reagents that can be employed for the oxidation 
of xanthenes to xanthones. Therefore, instead of introducing a ketal group, the xanthone can be reduced into 
a xanthene and after the introduction of the desired functionality, the xanthene can be oxidized back to 
xanthone. This approach was used with success for the synthesis of mangiferin, isomangiferin and 
homomangiferin [61]. 
 
Scheme 82. Introduction of methyl, N,N-diethyl amide, iodide and trimethylsilane functionalities in the 
protected xanthone scaffold by ortho-lithiation. 
Although some small groups may be introduced directly in the xanthone scaffold as described 
above, the most commonly used strategy in medicinal chemistry is undoubtedly the synthesis of xanthones 
bearing small reactive functionalities, which by molecular modification lead to more complex xanthones. 
Several functional groups have been used [25], but herein we describe only the molecular modifications 
reported in the last 7 years (2005-2012) (Scheme 83). 
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Scheme 83. Schematic representation of different functional groups introduced by molecular modification of 
substituted xanthones. 
Hydroxyl xanthones are certainly the most versatile building blocks being used for later molecular 
modification as it can be depicted from Scheme 83. The reaction of hydroxyxanthones with different alkyl 
halides allowed the introduction of several groups, such as aminoalkoxyl [221-224], aminoisopropanoloxyl 
[221-223, 225], benzylmethylaminoalkoxyl [86], aryloxyl [50, 226, 227], oxime [228], butyraldehyde [55], 
methoxyl [120, 229-231], n-alkanoxyl [54, 59, 121, 227, 231-233], haloisopropanoloxyl [52], prenyloxyl [51, 
82, 234, 235], geranyloxyl [234], farnesyloxyl [234], solanesyloxyl [234], allyloxyl [77, 78, 84, 229], 
dimethylpropargyloxyl [55, 58, 78, 84, 230, 236]. In addition, some of the xanthone derivatives obtained 
from the molecular modification were intermediates in the synthesis of fused ring xanthones. For instance, 
allyloxyl and dimethylpropargyloxyl xanthone derivatives are common intermediates in the synthesis of 
caged xanthones [55, 58, 77, 78, 84] (4-oxa-tricyclo[4.3.1.0]dec-8-en-2-one scaffold) and psorospermin 
derivatives [229, 236]. Moreover, the propargyloxyl derivatives were also used for the synthesis of 
6’,6’dimethylpyranoxanthones [230]. On the other hand, the prenyloxyl and bromopropanyloxyl derivatives 
were intermediates in the synthesis of 6’,6’-dimethyldihydropyranoxanthones [51], dihydrofuranoxanthones 
[235] and dihydropyranoxanthones [232]. The hydroxyl group was also transformed into an ester group [50, 
53, 60, 89, 231, 234]. The xanthones are generally not assembled with an amino group. Usually 
aminoxanthones are obtained from the reduction of the nitro group [121, 123, 126, 130, 132, 232]. The amino 
group was used for the synthesis of azides [121, 130], acetamides [125, 132] and urea [132]. The carboxyl 
group was used for the synthesis of amides [127, 128, 221, 223, 237]. The methyl group, after bromination, 
was used for the synthesis of aminoalkyl [221, 223], carbaldehydes [60] and methylhydroxyl [238].  
The indicated molecular modifications above did not correspond to the inclusion of substituents 
directly in the carbons of the xanthone scaffold. However, some of the small groups can be converted into 
leaving groups and then the substitutions occur directly in the xanthonic core. As a result, several 
hydroxyxanthones were converted into the respective triflates and tosylates for the introduction of borate 
derivatives [106, 239], alkynes [240], and aminoalkyl chains [124, 230]. The halogens were also used for 
introduction of hydroxyl [120], aminoalkyl [124-126, 130, 139], vinyl ester [39], furan [39] and phenyl [213] 
substituents. 
7. Conclusion 
This review intended to give an overview about the most important and recent approaches that were 
developed for the synthesis of xanthones. As it was depicted from the first three sections, the classical routes 
are particularly useful approach for the synthesis of xanthones and are still used frequently nowadays. In 
addition, several improvements were described using for instance new catalysts, microwave irradiation and 
heterogeneous catalysis allowing the synthesis of xanthones in high yields, mild experimental conditions and 
short reaction times. Moreover, during the last seven years, several methodologies described the synthesis of 
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xanthones in one step through the reaction aryne intermediates with different substrates. Regarding chromen-
4-ones as building blocks for the synthesis of xanthones, it was shown that substituted and unsubstituted 
chromen-4-ones can lead to highly complex xanthone derivatives through for example pericyclic reactions, 
domino reactions and photochemical. Therefore, it must be highlighted that chromen-4-ones have a great 
potential as building blocks for the synthesis of xanthones.  
In comparison with the previous reviews, one feature stands out which is the significant number of 
methodologies describing the synthesis of xanthones using transition-metal catalysts, organocatalysts and 
domino reactions. Therefore, it is expected that this review could be an inspiration for the use of these 
methodologies in the future, namely for xanthones using chromen-4-ones as building blocks. To conclude, all 
the approaches described, create an extremely vast and versatile set of tools for the synthesis of xanthones, 
which can increase the importance of this scaffold as a privileged structure in the search of new bioactive 
molecules. 
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Dose-Response curves in the SRB assay 
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Drug-Like Properties Biological Activity 
MW 
Lipophilicity 
HBA HBD tPSA RB ABS 
Solubility 
MCF-7 
NCI-
H460 
A375-
C5 
HL-60 Log 
Kpliposomes 
Log 
Kpmicelles 
CLogP ALogPs 
ACD 
LogP 
ACD 
LogD 
Log S 
Exp. 
ACD 
Log S Mp 
GSE Fsp3 AP ESOL 
O O
O
OH
 
XP13 296 3.35 ± 0.02 
3.28 ± 
0.02 
4.33 4.09 3.90 3.86 4 1 60 0 0.55 -6.40 -4.22 200.5 -5.41 0.28 0.54 -4.62 
39.7 ± 
3.2 
40.3 ± 
3.3 
28.9 ± 
8.1 
6-7 
 
XBp1 310 3.60 ± 0.08 
3.59 ± 
0.06 
4.70 4.07 4.53 - 4 0 49 1 0.55 - -5.32 173.5 -5.77 0.32 0.52 -5.08 >150 >150 >150 
8.8 ± 
5.9 
 
XBp2 308 3.88 ± 0.09 
3.83 ± 
0.05 
4.60 3.92 4.29 - 4 0 49 1 0.55 - -5.27 129.5 -5.09 0.21 0.52 -4.91 >150 >150 >150 N.R. 
 
XBp3 294 - - 4.22 4.19 4.00 3.77 4 1 60 0 0.55 - -4.15 178.5 -5.29 0.17 0.54 -4.67 - - - - 
 
XBp4 308 3.94 ± 0.09 
4.07 ± 
0.10 
4.59 3.92 4.55 - 4 0 49 1 0.55 - -5.46 124.5 -5.30 0.21 0.52 -5.08 N.R. N.R. N.R. 
11.8 ± 
3.8 
 
XBp5 310 3.92 ± 0.04 
3.88 ± 
0.02 
4.70 4.08 4.76 - 4 0 49 1 0.55 - -5.49 135.5 -5.62 0.32 0.52 -5.22 
45.1 ± 
3.3 
47.3 ± 
6.0 
42.5 ± 
5.5 
31.8 ± 
6.1 
 
XBp6 294 3.06 ± 0.16 
3.29 ± 
0.06 
4.23 4.18 4.93 4.77 4 1 60 0 0.55 - -4.93 245.5 -6.89 0.17 0.54 -5.25 
107.9 ± 
13.9 
>150 >150 >70 
 
XBp7 308 3.54 ± 0.01 
3.76 ± 
0.03 
4.59 3.92 4.71 - 4 0 49 1 0.55 - -5.58 125 -5.46 0.21 0.52 -5.18 N.R. 
42.9 ± 
16.1 
47.4 ± 
4.1 
9.6 ± 
3.2 
 
XBp8 310 3.09 ± 0.18 
3.58 ± 
0.08 
4.70 4.15 4.95 - 4 0 49 1 0.55 - -5.63 132.5 -5.78 0.32 0.52 -5.34 N.R. >150 >150 
37.6 ±  
17.1 
 
XBp9 294 4.17 ± 0.06 
4.15 ± 
0.08 
5.13 4.15 5.47 4.61 4 1 60 0 0.17 - -4.44 132 -6.29 0.17 0.54 -5.59 
39.6 ± 
0.6 
31.7 ± 
2.6 
29.6 ±  
4.7 
38.9 ± 
9.8 
 
XBp10 296 3.96 ± 0.03 
3.88 ± 
0.08 
5.23 4.14 5.37 5.09 4 1 60 0 0.55 - -4.90 172.5 -6.60 0.28 0.54 -5.54 >150 >150 >150 
26.1 ± 
9.5 
 
XBp11 308 3.32 ± 0.12 
3.33 ± 
0.02 
4.59 3.91 4.25 - 4 0 49 1 0.55 -6.74 -5.25 164.5 -5.40 0.21 0.52 -4.89 N.R N.R. 
69.5 ±  
5.9 
9.6 ± 
1.7 
 
XBp12 310 3.08 ± 0.06 
3.46 ± 
0.01 
4.70 4.13 4.49 - 4 0 49 1 0.55 - -5.29 204.5 -6.04 0.32 0.52 -5.05 >100 N.R. >100 
30.9 ± 
10.8 
 
XBp13 294 - 
4.08 ± 
0.04 
5.12 4.13 4.99 4.80 4 1 60 0 0.17 < -7 -4.84 191.5 -6.41 0.17 0.54 -5.29 N.R. N.R. >100 
6.4 ± 
0.3 
 
XBp14 296 - 
4.28 ± 
0.03 
5.23 4.06 4.89 4.76 4 1 60 0 0.55 - -4.92 205.5 -6.45 0.28 0.54 -5.24 >50 >50 >50 >50 
 
  
Drug-Like Properties Biological Activity 
MW 
Lipophilicity 
HBA HBD tPSA RB ABS 
Solubility 
MCF-7 
NCI-
H460 
A375-
C5 
HL-60 Log 
Kpliposomes 
Log 
Kpmicelles 
CLog 
P 
ALogPs 
ACD 
LogP 
ACD 
LogD 
Log S 
Exp. 
ACD 
Log S Mp 
GSE Fsp3 AP ESOL 
 
XBp15 248 3.42 ± 0.02 
3.50 ± 
0.12 
4.56 4.11 4.41 - 3 0 39 0 0.55 - -5.16 183 -5.74 0.21 0.57 -4.66 
13.3 ± 
1.3 
32.9 ± 
7.1 
6.2 ± 
0.6 
3.2 ± 
0.7 
 
XBp16 248 4.14 ± 0.08 
4.10 ± 
0.04 
4.56 4.11 5.01 - 3 0 39 0 0.55 - -5.61 97 -5.48 0.21 0.57 -5.04 
50.9 ± 
3.5 
44.5 ± 
1.4 
37.9 ± 
6.5 
36.7 ± 
3.3 
 
XBp17 343 - 
4.34 ± 
0.04 
5.31 4.47 5.34 - 4 0 49 1 0.17 - -6.81 125 -6.09 0.32 0.50 -5.78 >150 >150 >150 
14.1 ± 
1.4 
 
XBp18 345 4.48 ± 0.07 4.41 ± 0.03 5.42 4.71 5.55 - 4 0 49 1 0.17 - -6.84 163.5 -6.69 0.32 0.50 -5.92 >75 >75 >75 
48.4 ± 
7.5 
 
XBp19 338 - 
4.21 ± 
0.04 
4.54 3.85 4.92 - 5 0 58 2 0.55 - -5.79 174.5 -6.17 0.20 0.48 -5.46 >150 >150 >150 N.R. 
 
XBp20 322 4.32 ± 0.06 
4.29 ± 
0.02 
5.09 4.19 5.01 - 4 0 49 1 0.17 - -5.66 181.5 -6.33 0.20 0.50 -5.44 >50 >50 >50 >50 
 
XBp21 324 - 
3.90 ± 
0.06 
4.16 3.19 3.99 3.51 5 1 69 1 0.55 - - 4.14 193.5 -5.43 0.21 0.50 -4.81 
36.9 ± 
4.7 
34.9 ± 
1.8 
27.1 ± 
1.7 
18.8 ± 
4.7 
 
XBp22 379 - - 5.88 4.83 5.87 5.87 5 0 52 4 0.17 - -6.02 57 -5.94 0.35 0.43 -6.26 
34.3 ± 
1.1 
26.8 ± 
1.6 
21.9 ± 
2.7 
9.2 ± 
4.9 
 
XBp23 381 4.62 ± 0.02 
4.70 ± 
0.04 
5.98 5.09 6.08 6.08 5 0 52 4 0.17 - -6.10 127 -6.85 0.43 0.43 -6.41 
14.5 ± 
1.0 
13.7 ± 
0.47 
19.6 ± 
4.7 
14.4 ± 
3.7 
 
XBp24 370 3.88 ± 0.08 
3.83 ± 
0.1 
4.27 4.11 4.74 3.45 6 0 67 3 0.55 - -5.88 216.5 -6.41 0.33 0.44 -5.51 >75 >75 >75 N.R. 
 
XBp25 368 - - 4.17 3.68 3.68 - 6 0 67 3 0.55 - -5.23 174.5 -4.93 0.24 0.44 -4.83 >150 >150 >150 
22.8 ± 
8.0 
 
XBp26 326 3.43 ± 0.04 
3.49 ± 
0.06 
4.26 3.81 3.97 3.45 5 1 69 1 0.55 - -4.03 286.5 -6.34 0.32 0.50 -4.81 >150 >150 >150 
8.3 ± 
2.7 
 
XBp27 324 4.02 ± 0.03 
4.01 ± 
0.06 
5.20 4.12 4.99 - 4 0 49 1 0.17 - -5.52 101.5 -5.51 0.30 0.50 -5.44 
31.8 ± 
5.4 
30.9 ± 
3.6 
29.7 ± 
4.7 
5.14 ± 
1.8 
 
XBp28 370 - 
3.88 ± 
0.03 
4.27 4.11 4.52 - 6 0 67 3 0.55 - -5.72 228.5 -6.31 0.33 0.44 -5.37 >100 >100 >100 
72.3 ± 
4.3 
 
XBp29 331 - 
4.39 ± 
0.12 
5.05 4.64 4.70 4.64 4 1 60 0 0.55 < -7 -5.00 226 -6.46 0.28 0.52 -5.32 >150 >150 >150 
9.0 ± 
1.1 
  
 
 
Drug-Like Properties Biological Activity 
MW 
Lipophilicity 
HBA HBD tPSA RB ABS 
Solubility 
MCF-7 
NCI-
H460 
A375-
C5 
HL-60 Log 
Kpliposomes 
Log 
Kpmicelles 
CLog 
P 
ALogPs 
ACD 
LogP 
ACD 
LogD 
Log S 
Exp. 
ACD 
Log S Mp 
GSE Fsp3 AP ESOL 
 
XBp30 326 3.25 ± 0.08 
3.35 ± 
0.04 
4.27 3.90 4.07 4.04 5 1 69 1 0.55 < -7 -4.56 200 -5.57 0.32 0.50 -4.87 >150 >150 >150 
23.9 ± 
3.5 
O O
O
OH
H3C
 
XBp31 310 3.86 ± 0.08 
3.92 ± 
0.01 
4.82 4.22 4.36 4.34 4 1 60 0 0.55 < -7 -4.58 227.5 -6.14 0.32 0.52 -4.98 >150 
48.1 ± 
13.6 
17.6 ± 
4.9 
12.5 ± 
3.2 
 
XBp32 326 3.53 ± 0.04 
3.58 ± 
0.01 
4.27 3.90 3.47 3.42 5 1 69 1 0.55 < 6.64 -4.18 207.5 -5.05 0.32 0.50 -4.49 N.R. 
41.1 ± 
8.6 
68.0 ± 
4.5 
27.3 ± 
5.6 
 
XBp33 312 3.32 ± 0.10 
3.76 ± 
0.07 
3.74 3.95 3.34 2.84 5 2 80 0 0.55 < 6.21 -3.36 263 -5.47 0.28 0.52 -4.35 
82.5 ± 
15.0 
59.1 ± 
14.1 
40.7 ± 
8.5 
57.0 ± 
6.8 
 
XP25 294 - 
4.27 ± 
0.06 
5.12 4.19 5.91 5.20 4 1 60 0 0.17 - -4.85 166 -7.07 0.17 0.14 -5.53 >150 >150 N.D. N.D. 
 
XP11 296 - 
4.32 ± 
0.04 
5.23 4.02 5.35 5.12 4 1 60 0 0.17 - -4.89 188.5 -6.74 0.28 0.54 -5.53 
88.6 ± 
12.9 
>160 N.D. N.D. 
 
XP26 294 - 
4.06 ± 
0.01 
5.12 4.15 5.65 5.08 4 1 60 0 0.17 - -4.85 172 -6.87 0.17 0.54 -5.71 >150 >150 N.D. N.D. 
 
XP11 296 - 
4.02 ± 
0.03 
5.23 4.00 5.45 5.06 4 1 60 0 0.17 - -4.86 147.5 -6.43 0.28 0.54 -5.59 >160 >160 N.D. N.D. 
 
XPr1 364 - 
4.49 ± 
0.03 
6.17 4.12 6.96 - 4 0 49 6 0.17 - -6.36 71 -7.17 0.26 0.44 -6.85 
38.6 ± 
7.2 
37.9 ± 
6.0 
23.1 ± 
4.1 
5.1 ± 
0.9 
 
XPr2 296 - 
3.91 ± 
0.06 
5.10 3.99 5.50 4.73 4 1 60 3 0.55 - -4.42 78.5 -5.79 0.17 0.54 -5.60 
48.6 ± 
7.6 
24.2 ± 
1.5 
>150 
5.5 ± 
1.5 
 
XPr3 364 - 
4.10 ± 
0.05 
7.10 4.44 7.59 6.90 4 1 60 4 0.17 - -5.89 67 -7.76 0.26 0.44 -7.26 >150 >150 >80 
21.6 ± 
4.7 
 
XPr4 296 - 
4.62 ± 
0.09 
5.06 3.89 5.54 5.11 4 2 71 2 0.55 - -4.60 100.5 -6.05 0.17 0.54 -5.64 
19.9 ± 
5.1 
18.1 ± 
5.4 
13.6 ± 
2.2 
39.0 ± 
7.8 
 
